<SEC-DOCUMENT>0000950170-23-006807.txt : 20230309
<SEC-HEADER>0000950170-23-006807.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309060202
ACCESSION NUMBER:		0000950170-23-006807
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galecto, Inc.
		CENTRAL INDEX KEY:			0001800315
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				371957007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39655
		FILM NUMBER:		23718062

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		45-70-70-52-10

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galecto Inc.
		DATE OF NAME CHANGE:	20200116
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>glto-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-08T13:45:18.7300+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:glto="http://galecto.com/20221231" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_c97e5a12-2637-4649-b0b9-ad9ec1e147a3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_63bad519-8d42-4588-8c64-dc3b578e5db5" name="us-gaap:LeaseExpirationDate1" contextRef="C_f9b208c9-11e0-43f5-9a13-0c029853484f" format="ixt:datemonthdayyearen">February 29,2024</ix:nonNumeric><ix:nonNumeric id="F_d29c6159-b3c6-43bd-8e35-677bf4164550" name="us-gaap:LeaseExpirationDate1" contextRef="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e" format="ixt:datemonthdayyearen">August 31, 2025</ix:nonNumeric><ix:nonNumeric id="F_707da240-abd0-4f6e-a72b-cfce036aa3ae" name="dei:CurrentFiscalYearEndDate" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb">--12-31</ix:nonNumeric><ix:nonFraction id="F_63d7ab59-43c4-4301-ae5c-263a48395952" name="us-gaap:PreferredStockValue" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_a8a21157-12a4-455d-8c10-d3493597fa16" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_b321da6e-9abd-4c83-b727-c755898fb0a5">P7Y</ix:nonNumeric><ix:nonNumeric id="F_0f88c296-6264-4042-8714-841aed812bb6" name="glto:DebtSecuritiesAvailableForSalesTypeExtensibleList" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a">us-gaap:CorporateDebtSecuritiesMember</ix:nonNumeric><ix:nonNumeric id="F_9ab22cc5-86e7-43b0-9814-29ed771a3b70" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_163c3014-e0f2-4cb5-a85c-2be49b326607" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0</ix:nonFraction><ix:nonNumeric id="F_a45c38bf-025d-4c16-a12b-c4a73e7af421" name="dei:DocumentFiscalPeriodFocus" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb">FY</ix:nonNumeric><ix:nonFraction id="F_7ab5c9a0-ad7e-4429-bd8a-27616dd14ffc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_44cda3a6-b017-451a-b0b6-7cab4805cade" name="glto:DebtSecuritiesAvailableForSalesTypeExtensibleList" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb">us-gaap:CorporateDebtSecuritiesMember</ix:nonNumeric><ix:nonNumeric id="F_39cd0535-b15b-47f4-8148-6db41c88544a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_3e2888de-d4a3-488c-aaae-ba1b2eadce87">P5Y</ix:nonNumeric><ix:nonNumeric id="F_3cbffc48-b954-4828-9d21-d46a15257703" name="us-gaap:LeaseExpirationDate1" contextRef="C_6bb29e1b-fe16-4cff-8393-88bae5954f84" format="ixt:datemonthdayyearen">May 31, 2023</ix:nonNumeric><ix:nonNumeric id="F_b8865681-fb3c-46b3-8f81-199888594bde" name="us-gaap:LeaseExpirationDate1" contextRef="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8" format="ixt:datemonthdayyearen">January 31, 2025</ix:nonNumeric><ix:nonFraction id="F_10c9ded1-f15d-437e-8e57-1eaa49edc1c9" name="us-gaap:CommonStockValue" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9426828b-8ce6-4136-9592-73b208402ab8" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_0c600085-f026-40c1-bda9-1000262a6429" name="us-gaap:CommonStockValue" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e1741f4a-98e5-4588-8510-d2daf22196c3" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0</ix:nonFraction><ix:nonNumeric id="F_a4ca3aef-639a-4ed8-ada7-89dde4d411d6" name="dei:EntityCentralIndexKey" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb">0001800315</ix:nonNumeric><ix:nonNumeric id="F_5407b56e-40d4-49ec-bb45-36fa98160e23" name="dei:AmendmentFlag" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb">false</ix:nonNumeric><ix:nonFraction id="F_9b9e6261-7f93-4be0-8e18-13b33f088337" name="us-gaap:PreferredStockValue" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="glto-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_c3ec0dd0-9fe6-42b3-b80d-334a822298e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b98f82b2-780e-4b62-9d74-6429370aa2d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30e1cab4-655e-4ed1-bfb8-3bd1c2074e24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b62815c-330f-4ecf-a0ae-127533136899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd6ff40d-6e4b-4542-b39b-9a47a5dc2935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4935191f-2911-40cc-83d3-1839e14b12c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4336373f-aca3-4ad2-b03c-279e75f3a53f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentyThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f2ccad7-282a-4f1b-bf36-002446285a34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfb03bcf-2388-41ae-925e-205c6106a3e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f74559e7-8f45-4159-a81f-b42a765ec89e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06554741-f66b-460a-9c53-5b5182d21b98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e70f639f-dec9-4e39-81e2-2e7b8c9db28e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d11ae7c-daf5-4cf4-9476-65d6996dfc53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f86986df-0846-4157-a5eb-a6c794351048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95336a64-c52f-4870-b189-b6f50eb63e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b896ceee-0f19-4736-be33-4c8a2a1b182f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e4e962b-0c7f-427f-b8d8-253f1dfe01e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a891281-b4a3-4bf6-89c4-3d7d6ec73b43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad36967d-c20c-4021-8d2a-690baad2b403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5660b0e7-05a2-4c92-a655-1dd591e67b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c0c025b-fcd6-4855-aa25-24dcd9c881c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_803e51c6-3b20-4c08-ab3e-92d3c19e9bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_beca966d-84f3-4639-bf46-46255ba1cc93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_446278fa-fce1-4cd4-b15e-1085d37b326c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c901782-4d88-468a-8b30-6a41c7e1f8ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a066ec17-6b16-4df9-a0d7-0630872d95c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63f1cd8-2964-4478-ba13-1aca8bfd1025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_741ac39e-ead2-496d-9277-da672f7a8e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da11831e-2def-422d-b9ba-135e9cc96547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68b96280-106d-4c4f-9050-7768f44a1658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76a1124d-1bc4-461a-9175-009a2d8648c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d93c29f-7701-4844-9f33-6bb356fa3531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f463f6f-54e1-43b8-b676-b1ff83a8e7b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_349093ed-5db6-4bb4-9588-93a0cf9b007d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_333a7d4a-b385-4327-8cb4-b33035085d6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5653da56-b435-4ded-887e-78f37a343b93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_298727fd-7dd4-400e-978d-2395c0ad7b94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfe5cd33-6411-4f7a-8986-194fe9cbf159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fed39e7-58c4-4ac9-ab3d-13d15fe315f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c6a862c-3e11-4d68-aa36-13ca8e140e89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6c185ed-a9aa-4137-a7f1-09443c4dd1f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b321da6e-9abd-4c83-b727-c755898fb0a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:StevenageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">glto:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35bc5886-d1e6-4ce7-bdf0-d68aa785f64f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5778128-4ddb-4ebe-97f8-350950f780c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a7732d2-f6dc-4da5-b07c-d4c3c940cae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_578a6731-4436-4656-baa1-0e8306439eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e2888de-d4a3-488c-aaae-ba1b2eadce87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bd75575-ee9b-4149-8e99-700c763cf2a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fd6f295-aa8c-4dd2-a215-0f6504345d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e2554ff-8b5a-4c27-b47d-d3a252e0b453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c5077bc-7856-49b1-b161-185d27434c17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6af6e762-621d-4e84-b2aa-92985a786e0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">glto:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97be5459-8e1d-4a9f-a3fe-24a288c0d7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glto:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0f9c207-2ba8-436a-9aa4-8eea6b502e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bb29e1b-fe16-4cff-8393-88bae5954f84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:GothenburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5e23dbf-7189-4f00-9cce-e1174083d383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26d85074-1442-4534-bfb5-878f1c5c9abc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glto:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9b208c9-11e0-43f5-9a13-0c029853484f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:LondonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83df5a70-5b7d-414e-98bc-028cfe3931af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dca04f3b-68dd-41e8-a315-ab386139707c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00b3ce82-ee23-4fad-a96c-75e32b50f767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:CopenhagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad845729-af55-4659-b3e7-c758123fc0b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e287338-bbea-4c9b-90ce-f4b9c66624f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e754f68-08d0-4938-98da-48e6218005eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84f94529-71c5-4ff9-b7c7-bebbc7bcaa33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8b87670-6319-4b49-9747-781911421762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa9917ab-7682-4151-a140-fba905b103eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38c70869-4934-4789-a4e2-402a3062df02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001800315</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>glto:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a" fromRefs="F_70ef8177-77d4-42db-8858-2e00b6e505a0 F_ad5aa444-009d-4bdb-94c2-4a078a241d56 F_5b8848ed-0da8-4574-8bb9-2db7a244814f F_06dee806-a64a-4d84-8dcd-905db2003c0c"></ix:relationship></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf63fc32-9e22-408c-bb2f-5f03a27e67d9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.002%;"></td>
    <td style="width:95.998%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_1a3a687e-f767-4623-b8cf-8fd0b92bc4a9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08a6e39f-e8b2-4c33-9717-cccbf2fc2005" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ff069c8-b070-4747-89cb-dc0356af07fb" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.002%;"></td>
    <td style="width:95.998%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_ca3ad775-ab92-4b12-8196-4bc8d63c6a17" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number: </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_953afe47-29cd-49e9-8f71-6614d68d099c" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:21.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3de62753-c629-44a5-8210-6c290288fee8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:21.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GALECTO, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c6fcd16c-b6bc-41ad-88d4-1addebe3525c" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f983c271-417e-49eb-831c-accec163f7c4" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37-1957007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:28.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ole Maaloes Vej 3</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DK-2200 Copenhagen N</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denmark</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></p><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe782ae6-973f-4b39-a4ae-8f2a0d3cfb98" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75 State Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df635d12-688c-4306-a0c6-58833ec9574b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1fadb46f-0bf8-4226-a17e-7a9a4ce566f7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99d7d578-9efd-40c3-b86c-c966e1806938" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7678fac3-f4a0-4d42-8883-03b56582e8f0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02109</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1695959c-7d76-48a8-a0bc-360f39ccd906" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+45</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3fb2eb62-b8ea-4ae5-b4e1-6d91a64b4b04" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70 70 52 10</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.012%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:18.997%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9102cfc6-72d6-44aa-a1c4-b516d4f50452" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b926260c-8d12-48ff-801e-7395f9d85d77" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GLTO</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25568a94-1b31-4c46-937d-9f9afae16710" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_27235aea-5a86-4b9b-9ff0-39fe1ba737a8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_03a55891-04fa-43e9-a99e-34f4ca675ccb" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3708a931-899d-440c-891a-fb9c14cbe755" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_752687b3-5253-474f-8e89-1e96a0fb66b9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.905%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:55.839%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ba0145c-a763-44e1-81af-8293a1eb1d2a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_a81cd068-24f3-4780-ad1f-1835a5fd4d53" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_902f2c67-bf4b-49c2-989b-509dd5f61980" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_e51b3787-0d57-4504-a051-d3aa07e65752" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_78af297e-269f-454e-bdaf-c69496b62740" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_412597bc-1e47-4f2b-9f63-83b8f7dd9ac6" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on June 30, 2022, was $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6164ffdf-1cc7-4bc0-8767-1eecf5cbb29b" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 6, 2023 was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5550d6a9-9553-4f57-93c7-db5abc5cdfb5" contextRef="C_741ac39e-ead2-496d-9277-da672f7a8e05" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,673,474</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_426c4f9a-62b1-4d37-8173-1d64157ea6c9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120 days of the end of the registrant&#x2019;s fiscal year ended December 31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.093%;"></td>
    <td style="width:82.824%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disc_foreign_juris_ins"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disc_foreign_juris_ins"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Material Risks Associated with Our Business</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is highly dependent on the success of our product candidates GB0139, GB1211 and GB2064, as well as any other product candidates that we advance into the clinic. All of our product candidates may require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we continue to encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The design or execution of our ongoing and future clinical trials may not support marketing approval or commercialization.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain U.S. Food and Drug Administration, or FDA, approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, or U.S., which would limit our ability to realize their full market potential.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely and expect to continue to rely on third parties to conduct certain aspects of our ongoing and future preclinical studies and clinical trials, including investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our common stock is delisted from The Nasdaq Global Select Market, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div></div>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The material and other risks summarized above should be read together with the text of the full risk factors below and in the other information set forth in this Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adversely affected. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, including &#x201c;Business&#x201d; in Item 1, &#x201c;Risk Factors&#x201d; in Item 1A and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in Item 7 includes &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are &#x201c;forward-looking statements&#x201d; for purposes of this Annual Report on Form 10-K. In some cases, you can identify forward-looking statements by terminology such as &#x201c;may,&#x201d; &#x201c;could,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;intend,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;project,&#x201d; &#x201c;continue,&#x201d; &#x201c;potential,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;goal,&#x201d; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding:</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success, cost and timing of our product development activities and planned initiation and completion of clinical trials of our most advanced product candidate, GB0139, and our other current fibrosis and oncology product candidates, including GB2064 and GB1211, and any future product candidates; </span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to raise additional funding;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain regulatory approval for our current or future product candidates that we may identify or develop;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to ensure adequate supply of our current or future product candidates;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain third-party relationships necessary to conduct our business;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our heavy dependence upon the success of our research to generate and advance additional product candidates;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish an adequate safety or efficacy profile for our current or future product candidates that we may pursue;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the implementation of our strategic plans for our business, our current or future product candidates we may develop and our technology;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate and degree of market acceptance and clinical utility for our current or future product candidates we may develop;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates about the size of our market opportunity;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain and establish collaborations;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance and liquidity;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage our potential growth;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments relating to our competitors and our industry, including the impact of government regulation;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to retain the continued service of our key professionals and consultants and to identify, hire and retain additional qualified professionals;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain adequate internal controls over financial reporting;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effects of global economic uncertainty and financial market volatility caused by economic effects of rising inflation and interest rates, the COVID-19 pandemic, geopolitical instability, changes in international trade relationships and conflicts, such as the ongoing conflict between Russia and Ukraine, on any of the foregoing or other aspects of our business or operations; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part II, Item 1A - &#x201c;Risk Factors&#x201d; below and for the reasons described elsewhere in this Annual Report on Form 10-K. Any forward-looking statement in this Annual Report on Form 10-K reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates, and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except where the context otherwise requires, in this Annual Report on Form 10-K, &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;Galecto,&#x201d; and the &#x201c;Company&#x201d; refer to Galecto, Inc. and, where appropriate, its consolidated subsidiaries.</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks</span></p>
  <p style="margin-left:3.333%;text-indent:9.379%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have applied for various trademarks that we use in connection with the operation of our business. This Annual Report on Form 10-K includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service marks, and trade names included in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the &#174; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. Our strategy is to focus on diseases without disease-modifying treatment options and where there is a high unmet medical need. We are concentrating on the development of a new class of medicines: small molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, that target underlying biology for the treatment of multi-factorial diseases like cancer and fibrotic diseases. Galectin proteins, and especially galectin-3, are highly expressed in many cancers, where they promote cancer progression, and fibrotic diseases, where they reduce organ function. The collagen cross-linking enzyme LOXL2 builds the backbone of fibrotic tissue by cross-linking collagen and elastin molecules and has been linked to cancer growth, metastasis and fibrosis. Our product candidates are designed to modulate multiple disease pathways simultaneously by inhibiting the master drivers of the cancer and fibrotic cascades. We believe our galectin and LOXL2 product candidates are distinct from the current generation of anti-cancer and anti-fibrotic agents and have the potential to significantly improve patient outcomes for these complex diseases.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the second half of 2022, we reported Phase 2 trial data for two of our product candidates. In September 2022, we announced data from a planned intermediate assessment from our Phase 2a trial of GB2064 for myelofibrosis, which we refer to as the MYLOX-1 trial, where four out of five evaluable myelofibrosis patients who received GB2064 monotherapy experienced a &#x2265; 1-grade reduction in collagen fibrosis of the bone marrow. We believe that this level of reduction in collagen fibrosis has not been shown in any other clinical trial and is an improvement suggesting that GB2064 could impact the progression of the disease and be disease-modifying. In the fourth quarter of 2022, we announced topline results from our Phase 1b/2a trial of GB1211 in patients with decompensated liver cirrhosis, which we refer to as the GULLIVER-2 trial, that showed statistically significant reductions in liver enzymes after 12 weeks of treatment and statistically significant reductions in biomarkers of inflammation and apoptosis, which are processes that are believed to be central to severe liver disease. We believe that this is the first study in a population of Child-Pugh Class B decompensated cirrhosis patients of non-viral etiology to show changes in a series of liver parameters that are potentially clinically meaningful. We currently have three ongoing Phase 2 clinical trials for GB0139, GB2064 and GB1211.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced product candidate, GB0139, is an inhaled small molecule inhibitor of galectin-3, one of the key regulators of fibrosis that controls the pro-fibrotic activity of TGF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Overexpression of galectin-3 is ubiquitous in fibrotic tissue, including in fibrotic lung tissue, and is linked to both disease severity and disease progression, as well as acute exacerbations of idiopathic pulmonary fibrosis, or IPF. We are initially developing GB0139 for the treatment of IPF, a life-threatening progressive fibrotic disease of the lung. IPF affects approximately 100,000 people in the United States, but limited treatment options have been associated with significant side effects, leading to poor therapeutic adherence or dose reduction. In our clinical trials completed to date, we found orally-inhaled GB0139 to be generally well-tolerated and it inhibited galectin-3 in the lungs in a dose-dependent manner. We also observed that GB0139 decreased systemic levels of a range of plasma biomarkers, such as YKL-40 and platelet-derived growth factor, or PDGF, that have been linked to mortality, disease severity and/or progression in IPF. We are currently conducting a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b trial investigating the safety and efficacy of GB0139 in patients with IPF, which we refer to as the GALACTIC-1 trial. We completed enrollment during the second quarter of 2022 and expect topline results to be available in mid-2023.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB2064 is a selective oral small molecule inhibitor of LOXL2 that we are initially developing for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow. Myelofibrosis is one of several types of cancer and multiple fibrotic diseases in which expression of LOXL2 is significantly increased. Unlike current treatment options for myelofibrosis, we believe that GB2064 has the potential to be a disease-modifying therapy as it is designed to have a direct impact on the fibrotic process and slow the progression of the disease. We are currently conducting a Phase 2a MYLOX-1 trial examining GB2064 in myelofibrosis and, in the third quarter of 2022, we announced results from a planned intermediate assessment of the first five patients who had completed at least six months of treatment with GB2064. Four of the five patients experienced a &#x2265; 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and potentially be disease modifying. All four patients who experienced a &#x2265; 1-grade reduction in collagen fibrosis also showed stable hematological parameters (hemoglobin, white blood cell count, and thrombocytes) and stable spleen volume over the six month treatment period, and none required</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transfusion. We expect topline results from the MYLOX-1 trial to be available by the end of 2023 and are beginning to plan for the next steps in clinical development, which we expect could include combining GB2064 with another myelofibrosis treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB1211 is a selective oral small molecule inhibitor of galectin-3 and is chemically distinct from GB0139. We believe GB1211 has the potential to treat multiple types of fibrosis and oncology indications. Within the field of fibrotic diseases, our initial target indication for GB1211 is liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure and for which there are limited treatment options and no FDA-approved disease modifying therapeutics available. In the fourth quarter of 2022, we announced topline results from the Phase 1b/2a GULLIVER-2 trial of GB1211 in severe liver cirrhosis classified as Child-Pugh B, which is also referred to as decompensated liver cirrhosis. Topline results showed statistically significant reductions in ALT (p&lt;0.0005), AST (p&lt;0.005) and GGT (p&lt;0.05), with encouraging reductions for ALP (p&lt;0.09), after 12 weeks of treatment, and included reductions in galectin-3 (p&lt;0.05) and CK-18 (M65) (p&lt;0.002), which are markers of inflammation and of apoptosis. These processes are believed to be central to the ongoing disease progression in liver cirrhosis. Bilirubin, albumin, international normalized ratio (INR) and other biochemical measurements remained stable. ALT reductions were observed after seven days of treatment and the liver enzyme levels continued to decrease over the 12 weeks of treatment. These liver enzyme levels remained decreased compared to baseline two weeks after the study&#x2019;s conclusion, suggesting durable effects and a decrease in liver inflammation. GB1211 generally exhibited a favorable tolerability profile. The consistency of the changes and the progressive improvement observed in this trial lead us to believe that a broader study in patients with compensated and/or decompensated cirrhosis could show wider effects, providing a potential regulatory path as the first FDA-approved therapy for liver cirrhosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB1211 is also being studied in oncology, where inhibition of galectin-3 has the potential to both directly reduce tumor growth as well as increase the immune mediated eradication of tumors, and is believed to increase T-cell recruitment and activation in the tumor microenvironment. We believe that high galectin-3 expression may be one of the important reasons why many patients experience checkpoint inhibitor resistance, and that the inhibition of galectin-3 could lead to an increase in the efficacy of checkpoint inhibitors in cancer patients with high galectin-3 expression. We presented preclinical data at the 2022 American Society of Clinical Oncology Annual Meeting that showed that GB1211 reversed a galectin-3 induced blockage of the checkpoint inhibitors atezolizumab and pembrolizumab, and exhibited synergistic effects with these checkpoint inhibitors. Our initial target indication for GB1211 in oncology is non-small cell lung cancer, or NSCLC, a cancer indication with high unmet medical need. In the fourth quarter of 2021, we announced that we had entered into a clinical trial supply agreement with F. Hoffmann-La Roche Ltd, or Roche, for our Phase 2a trial of GB1211 in combination with atezolizumab, marketed by Roche as Tecentriq&#174;, a programmed death-ligand 1 (PD-L1) checkpoint inhibitor for the first-line treatment of NSCLC, which we refer to as the GALLANT-1 trial. We initiated Part A of this trial, an open-label study to select the dose of GB1211 to be used with atezolizumab, in the second quarter of 2022. We expect to release interim safety data from this part of the GALLANT-1 trial in the second quarter of 2023. Part B of this trial is designed to evaluate the safety and tumor shrinkage (based on RECIST criteria) of the combination of the selected dose of GB1211 and atezolizumab and we expect topline results to be available in the first half of 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we expanded our focus on additional oncology indications and entered into an agreement with Providence Portland Medical Center&#x2019;s Earle A. Chiles Research Institute (EACRI) to evaluate the safety and efficacy of GB1211 in combination with pembrolizumab, marketed by Merck as Keytruda&#174;. This planned, randomized, double-blind placebo controlled, investigator-initiated Phase 2 trial is expected to evaluate whether the addition of GB1211 increases the response rate of pembrolizumab in metastatic melanoma and head and neck squamous cell carcinoma (HNSCC) patients. This trial is expected to begin in the second half of 2023 and topline results could be reported as early as 2025.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Clinical Stage Drug Development Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own global development and commercialization rights to all of the product candidates in our pipeline. The chart below summarizes key information about our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_0.jpg" alt="img108642122_0.jpg" style="width:627px;height:388px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 1. Galecto Clinical Pipeline</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also progressing several preclinical assets targeting galectin-3 and other galectin proteins that have been associated with disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB0139 (Idiopathic Pulmonary Fibrosis, IPF) &#x2013; GALACTIC-1 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced product candidate, GB0139, is an inhaled small molecule inhibitor of galectin-3 that is designed to be administered via a generic dry powder inhaler. GB0139 is designed to target galectin-3, one of the key regulators of fibrosis that controls the pro-fibrotic activity of TGF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The overexpression of galectin-3 is ubiquitous in fibrotic tissue, including in fibrotic lung tissue, and is linked to both disease severity and disease progression, as well as acute exacerbations of IPF. We are currently developing GB0139 for the treatment of IPF, a life-threatening progressive fibrotic disease of the lung, but we plan to further develop GB0139 with the goal of treating other severe lung diseases driven by galectin-3. While there are currently two approved therapies for the treatment of lung fibrosis, they have been shown to only have a modest impact on slowing the progression of the disease and have not conclusively shown an impact on survival. Both therapies have been associated with significant tolerability type of side effects leading to poor therapeutic adherence and dose reductions. There are no therapeutics approved that specifically target galectin-3. GB0139 for the treatment of IPF has been granted Orphan Drug Designation by both U.S. and European regulatory authorities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our clinical, preclinical and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> testing to date, we have demonstrated that GB0139 can directly target galectin-3 in the lungs and markedly lowers the systemic plasma levels of biomarkers of fibrosis in IPF patients. In our Phase 1/2a trial in both healthy volunteers and IPF patients, GB0139 was generally well-tolerated, showed consistent and tight pharmacokinetics measured as plasma levels of the compound, and showed target engagement with the inhibition of galectin-3 in the lungs of IPF patients in a dose-dependent manner. Our clinical trials completed to date have found that orally inhaled GB0139 also decreased systemic levels of a range of plasma biomarkers, such as the glycoprotein YKL-40 and PDGF, that have been linked to mortality, disease severity and/or progression in IPF.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galectin-3 overexpression has been associated with increased severity and poor prognosis in a number of viral infections, including COVID-19. In addition, viral infections are associated with the onset of acute exacerbations of IPF. in 2021, GB0139 was investigated in a Phase 2a trial as part of the University of Edinburgh&#x2019;s rapid experimental program for COVID-19 respiratory failure, which we refer to as the DEFINE trial. The trial met its primary endpoint with results showing that inhaled GB0139 had an acceptable tolerability profile when used in combination with standard of care (dexamethasone, remdesivir and anticoagulant therapy) in hospitalized patients with COVID-19 pneumonia requiring oxygen therapy.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite being breathless and requiring oxygen, patients receiving GB0139 plus standard of care were able to inhale and achieve consistent exposure of GB0139 and required significantly less oxygen when compared to patients receiving standard of care alone. The 10mg dose of GB0139, dosed twice a day for 2 days and subsequently once a day for up to 14 days, which was higher than the current 3mg dose being used in the GALACTIC-1 trial, was generally well-tolerated and no treatment-related serious adverse events were reported. Furthermore, inhaled GB0139 led to a significant reduction of galectin-3 levels in patients with COVID-19 compared to standard of care, demonstrating target engagement, and showed reduced plasma levels of other key biomarkers associated with severe disease and a poor prognosis, including key cytokines CXCL10, IL-6, IL-10 and TNF&#x3b1; and markers of fibrosis, YKL-40 and PAI-1. The study showed that galectin-3 inhibition may be a way to reduce virally induced systemic inflammation and other hallmarks of severe viral disease.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting the GALACTIC-1 trial, a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b trial investigating the safety and efficacy of GB0139 in patients with IPF. The primary endpoint of the trial is to assess the annual rate of decline in forced vital capacity, or FVC, over 52 weeks, which is the regulatory endpoint identified for IPF therapy approval. Reduction in the decline of FVC is the endpoint that was accepted by the FDA for the approval of both nintedanib, marketed as Ofev&#174; by Boehringer Ingelheim, and pirfenidone, marketed as Esbriet&#174; by Roche/Genentech, which are the only current therapeutic treatments for IPF. In March 2021, we were notified by the trial&#x2019;s data safety monitoring board, or the DSMB, who had access to unblinded safety and efficacy data, to discontinue dosing of GB0139 in patients who were also receiving nintedanib or pirfenidone, and in patients receiving the monotherapy GB0139 10mg dose. The DSMB&#x2019;s determination was based on an identification of an imbalance in the serious adverse events across the study groups, but not an imbalance between the groups in mortality. During the second quarter of 2021, we amended the study protocol to reflect these changes, and in July 2021 we resumed recruitment of patients for the GALACTIC-1 trial. The study has completed enrollment of the 144 patients provided for in the amended study protocol, and all of these patients have received or are receiving either the 3mg dose of GB0139 or placebo. We expect topline results to be available in mid-2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB2064 (Myelofibrosis) &#x2013; MYLOX-1 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing GB2064, a selective oral small molecule inhibitor of LOXL2. In contrast to previous attempts to inhibit LOXL2 with a monoclonal antibody, such as simtuzumab, GB2064 is designed to inhibit the enzymatic center of the LOXL2 molecule to a much higher degree and shut down collagen cross-linking more effectively. Our initial focus is developing GB2064 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow. This indication allows us to take and examine serial bone marrow biopsies where we can study GB2064&#x2019;s potential impact on bone marrow collagen. Myelofibrosis is one of several types of cancer and multiple fibrotic diseases in which expression of LOXL2 is significantly increased. Myelofibrosis is a disease with significant morbidity and mortality that affects between 16,000 and 18,500 patients in the United States. The current standard of care for myelofibrosis consists of inhibitors of the JAK2 protein kinase, which alleviate the disease symptoms through inhibition of cell proliferation but do not directly target or reduce the fibrosis of the bone marrow. As a result, a significant unmet need remains. We believe that GB2064 has the potential to be a disease-modifying therapy, as it is designed to have a direct impact on the fibrotic process and slow the progression of the disease, as opposed merely to treating symptoms, such as splenomegaly.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In preclinical studies, GB2064 showed activity in multiple models of fibrosis including lung, liver and kidney fibrosis. GB2064 has successfully completed a Phase 1 trial in 78 healthy volunteers, in which orally-administered GB2064 led to dose-dependent inhibition of LOXL2 in serum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the third quarter of 2021, we initiated the Phase 2a MYLOX-1 trial examining GB2064 for the treatment of myelofibrosis. The primary endpoint of this trial is safety and secondary endpoints include measurements of drug levels in the bone marrow and grade of fibrosis, improvement of anemia and/or thrombocytopenia and assessment of spleen and liver size. During the third quarter of 2022, we announced data from a planned intermediate assessment. As part of this assessment, we evaluated results from the first five patients who had completed at least six months of treatment with GB2064 and who had repeated valid bone marrow biopsies. In the intermediate assessment, four out of five evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a &#x2265; 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and potentially be disease modifying. We believe that this &#x2265; 1-grade reduction in collagen fibrosis has not been shown in any other clinical trial, signaling both an opportunity in myelofibrosis and, more generally, a wider opportunity for LOXL2 inhibition in other cancers and fibrotic diseases. All four patients who experienced a &#x2265; 1-grade reduction in fibrosis score also showed stable hematological parameters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(hemoglobin, white blood cell count, and thrombocytes) and stable spleen volume over the six month treatment period, and none required transfusion. As of the date of the planned intermediate assessment, sixteen patients in the MYLOX-1 trial had been dosed with GB2064, of which eight patients had completed or continued to receive treatment and eight patients had either discontinued treatment as a result of an adverse event or disease progression. The most commonly observed treatment-related adverse events were gastrointestinal in nature and were manageable in most patients with standard therapy. In the five patients who completed at least six months of treatment with GB2064 and valid bone marrow biopsies, there were no treatment-related serious adverse events, while in the entire trial population, the only possibly treatment-related serious adverse event was a case of fall.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data from the intermediate assessment of the MYLOX-1 trial suggest that the LOXL2 mechanism may be a way to reduce fibrosis, which we believe has not been shown with any FDA-approved therapy. We continue to enroll patients in the MYLOX-1 trial and expect topline results from the MYLOX-1 trial to be available by the end of 2023. Because the MYLOX-1 trial has already exceeded the pre-defined target of a &#x2265; 1 grade reduction in collagen fibrosis in at least three patients, we may determine to enroll fewer patients than the sixteen evaluable patients provided for in the protocol. Given that we have already shown bone marrow collagen reduction and a manageable clinical tolerability profile, we are beginning to plan for next steps in clinical development, which we expect could include combining GB2064 with another myelofibrosis treatment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data from the intermediate assessment of the MYLOX-1 trial and the published literature on the LOXL2 mechanism suggest that LOXL2 inhibition may also be important in other solid and liquid tumor types as well as in fibrotic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB1211 (Liver Cirrhosis and Oncology Indications) &#x2013; GULLIVER-2 and GALLANT-1 Trials</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB1211 is a selective oral small molecule inhibitor of galectin-3 and is chemically distinct from GB0139. We believe GB1211 has the potential to treat multiple types of fibrosis and oncology indications. GB1211 demonstrated antifibrotic activity and an anticancer effect in multiple preclinical models and was evaluated in a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and showed dose-dependent pharmacokinetics.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liver Cirrhosis</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial target indication for GB1211 in fibrosis is liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure and for which there are limited treatment options. While the historical view was that established fibrosis is very difficult to impact, our preclinical data suggest that galectin-3 inhibition could reduce established fibrosis and the disease processes that drive the disease progression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the fourth quarter of 2022, at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting&#174; 2022, we announced topline results from our Phase 1b/2a GULLIVER-2 trial of GB1211 that is focused on safety and effect on liver function and fibrosis biomarkers in patients with decompensated liver cirrhosis. These topline results showed statistically significant reductions in ALT (p&lt;0.0005), AST (p&lt;0.005) and GGT (p&lt;0.05), with encouraging reductions for ALP (p&lt;0.09), after 12 weeks of treatment. Patients treated with GB1211 also demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 (p&lt;0.05) and CK-18 (M65) (p&lt;0.002). Bilirubin, albumin, international normalized ratio (INR) and other biochemical measurements remained stable. These findings suggest that GB1211 provided liver cell protection and improved liver status, further supporting clinical development in severe liver disease. Liver enzyme (ALT, AST and GGT) reductions were observed after seven days of treatment and continued to decrease over the 12 weeks of treatment. These liver enzyme levels remained decreased compared to baseline two weeks after the study&#x2019;s conclusion, suggesting durable effects and a decrease in liver inflammation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB1211 exhibited a favorable tolerability profile in patients with decompensated liver cirrhosis in the GULLIVER-2 trial. Five of 15 patients on GB1211 and four of 15 patients on placebo reported nine and eight treatment-emergent adverse events (TEAEs), respectively. Three serious </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TEAEs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> consistent with severe liver disease were observed in one patient (2 after cessation of active therapy) on GB1211 and were deemed to be unrelated to GB1211.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consistency of the reductions in liver enzymes shown in this severe form of liver cirrhosis, the progressive improvement we observed over 12 weeks and the favorable safety profile observed in the GULLIVER-2 trial lead us to believe that a broader study in patients with compensated and/or decompensated cirrhosis could show broader clinical activity, providing a potential regulatory path to approval as the first FDA-approved therapy in liver cirrhosis. We may also consider further development of GB1211 in hepatocellular cancer, which often occurs in patients with cirrhosis of any etiology, where a product that is administered orally and has a favorable tolerability profile could offer significant advantages over current treatment options.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Oncology Indications</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial target indication for GB1211 in oncology is NSCLC, a cancer indication with a high unmet medical need despite recent medical progress with checkpoint inhibitor therapies. Many tumors overexpress galectin-3, which mechanistically is linked to several cancer promoting mechanisms, including those linked to programmed cell death receptor 1 (PD-1) or its ligand, PD-L1 resistance and chemotherapy resistance, and may ultimately lead to worse clinical outcomes. Galectin-3 inhibition has the potential to both directly reduce tumor growth as well as increase the immune mediated eradication of tumors and is believed to increase T-cell recruitment and activation in the tumor microenvironment. We believe that inhibiting galectin-3 could lead to an increase in the efficacy of checkpoint inhibitors in cancer patients, and especially those with galectin-3 expression. In an animal model, we observed that oral administration of our galectin-3 inhibitors reduced human and mouse lung adenocarcinoma growth and blocked metastasis. Treatment with one of our galectin-3 inhibitors also potentiated the activity of a PD-L1 immune checkpoint inhibitor. The mechanisms at work include checkpoint inhibitor-type mechanisms (inhibition of TGF-&#x3b2; signaling, LAG-3, T-cell receptor, interferon gamma) and mechanisms potentially enhancing PD-1/PD-L1 activity, as evidenced by preclinical data that we recently presented at the 2022 American Society of Clinical Oncology Annual Meeting showing that GB1211 reversed a galectin-3 induced blockage of the checkpoint inhibitors atezolizumab and pembrolizumab and exhibited synergistic effects with these checkpoint inhibitors. Furthermore, in the clinic, a retrospective study showed that patients with high tumor staining for galectin-3 were resistant to treatment with pembrolizumab, an anti-PD-1 antibody approved for the treatment of NSCLC, and, by contrast, patients with low galectin-3 had a good response to pembrolizumab and a reduction in tumor volume. Recent clinical data has shown clinical activity when using a LAG-3 inhibitor in combination with a PD-1 inhibitor. We believe galectin-3 is a principal activator of LAG-3 and mediates LAG-3 effects, and in preclinical studies we have shown that GB1211 can block galectin-3 binding to LAG-3, in addition to other galectin-3 cancer promoting mechanisms. Thus, galectin-3 could be a biomarker for anti-PD-1/PD-L1 resistance and, therefore, also be a marker for patients who may benefit from galectin-3 inhibition, which could enable a biomarker-based therapy. We believe the emerging data of galectin-3 as a checkpoint inhibitor resistance mechanism supports a key role for our oral galectin-3 inhibitor candidates in cancer therapy.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2021, we announced that we had entered into a clinical trial supply agreement with Roche for our Phase 2a GALLANT-1 trial of GB1211 in combination with atezolizumab, a PD-L1 checkpoint inhibitor, for the treatment of first-line NSCLC. This randomized, double blind, placebo-controlled trial is examining the effect of GB1211 and atezolizumab on tumor shrinkage based on RECIST criteria, as well as secondary endpoint measures such as overall survival, progression-free survival and others. We also plan to analyze how plasma galectin-3 levels and tumor galectin-3 correlate with tumor response. We initiated Part A of this trial, an open-label study to select the dose of GB1211 to be used with atezolizumab, in the second quarter of 2022. In the first 6 patients who received 200mg twice daily in combination with atezolizumab, we observed two serious adverse events of autoimmune-type skin rashes (showing perivascular lymphocytic infiltrates), which were determined by the principal investigator to be related to the administration of atezolizumab. The reactions were similar to those observed with atezolizumab and described in the label. Both reactions responded to therapy with oral glucocorticosteroids and were clinically manageable. In accordance with the protocol, we reduced the GB1211 dose to 100mg twice daily for the second patient cohort. Recruitment in this cohort is currently ongoing. Interestingly, inflammatory and perivascular lymphocytic infiltrates were observed in both skin reactions, and could signal an exaggerated immune activation, something often observed with checkpoint inhibitor therapy and associated with improved clinical outcomes. Because a central aspect of the mechanism of action for GB1211 in combination with a checkpoint inhibitor is to remove galectin-3 from the lymphocytes and the tumor cells, and thereby increase lymphocyte-based tumor killing, we believe this could also be a positive signal of enhanced lymphocyte activation. We expect to release interim safety data from this part of the GALLANT-1 trial in the second quarter of 2023. Part B of this trial is designed to evaluate the safety and tumor shrinkage (based on RECIST criteria) of the combination of the selected dose of GB1211 and atezolizumab and we expect topline results to be available in the first half of 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we expanded our focus on additional oncology indications and entered into an agreement with Providence Portland Medical Center&#x2019;s EACRI to evaluate the safety and efficacy of GB1211 in combination with pembrolizumab in an investigator-initiated trial in metastatic melanoma and HNSCC patients. Galecto has committed to supply GB1211 for this Phase 2 trial. The randomized, double-blind placebo controlled, investigator-initiated Phase 2 trial is expected to evaluate whether the addition of GB1211 increases the response rate of pembrolizumab in metastatic melanoma and HNSCC patients. The study is designed to evaluate GB1211 in combination with the standard therapeutic dose of pembrolizumab in patients with unresectable or metastatic melanoma or recurrent or metastatic HNSCC progressing during or after platinum-containing chemotherapy. In addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relevant to galectin-3 biology and checkpoint inhibition. This trial is expected to begin in the second half of 2023 and topline results could be reported as early as 2025.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organizational Background</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are built upon more than a decade of research into galectin, fibrosis and cancer modulators and were founded by leading researchers on the galectin family of proteins, including one of the discoverers of the galectin family of proteins, the first chemist to develop selective galectin inhibitors based on the x-ray crystal structure of galectin-3, and the discoverer of galectin-3&#x2019;s role in fibrosis and cancer. We believe we were the first company to apply click-chemistry in the galectin field and the first to synthesize highly potent small molecule inhibitors of galectin-3. Our founders, executives and employees have significant experience that provides unique insights into the targets that underlie the biological process of fibrosis, cancer and other related disease. We leverage this expertise, as well as established relationships with outside consultants and universities, to achieve cost-effective and efficient drug development. We have developed from a university spin-out, with only one part-time employee at inception in December 2011, to a company with three product candidates in Phase 2 clinical development and several preclinical molecules with differentiated specificity advancing towards the clinic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to become a leader in developing and commercializing therapeutics that directly target the biological processes at the heart of fibrotic diseases and cancer. Our strategy is focused on the following key components:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficient advancement of GB0139 in IPF through clinical development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are currently conducting a Phase 2b trial of GB0139 in patients with IPF, with topline data expected in mid-2023. IPF is an orphan disease that is therapeutically underserved, and we believe that GB0139 may have the ability to become the first true disease-modifying therapy. Assuming positive results from the Phase 2b trial, we intend to expeditiously initiate a Phase 3 trial program in IPF.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further develop GB1211 for the treatment of liver disease. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There remains a significant need for disease-modifying therapies that postpone or replace liver transplantation in late-stage liver cirrhosis patients. In the fourth quarter of 2022, we announced topline results from our Phase 1b/2a GULLIVER-2 trial in patients with decompensated liver cirrhosis showing statistically significant reductions in ALT (p&lt;0.0005), AST (p&lt;0.005) and GGT (p&lt;0.05), with encouraging reductions for ALP (p&lt;0.09), after 12 weeks of treatment. These findings suggest that GB1211 provided liver cell protection and improved liver status, further supporting clinical development in severe liver disease. The consistency of the changes and the progressive improvement, together with the favorable safety profile, observed in this trial lead us to believe that a broader study in patients with compensated and/or decompensated cirrhosis could show wider effects, providing a potential regulatory path as the first FDA-approved therapy for liver cirrhosis. Our next step in the development of GB1211 for the treatment of liver cirrhosis and other liver diseases is to conduct a Phase 2b trial, subject to obtaining additional financing or collaborating with a third party. We may also consider further development of GB1211 in hepatocellular cancer, which often occurs in patients with cirrhosis of any etiology, where a product that is administered orally and has a favorable tolerability profile could offer significant advantages over current treatment options.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Build on our understanding of the galectin-3 target to develop our pipeline of oncology product candidates.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Galectin-3 has been identified as the guardian of the tumor microenvironment, driving cancer growth and allowing tumor cells to escape the immune mediated attack through the activation of a number of central tumor-promoting mechanisms such as LAG-3, TGF-&#x3b2;, VEGF and K-Ras. Galectin-3 inhibition has the potential to both directly reduce tumor growth and increase the immune-mediated eradication of tumors. Galectin-3 inhibition is believed to increase T-cell recruitment and activation in the tumor microenvironment, as well as increase the efficacy of checkpoint inhibitors in cancer patients with high galectin-3 expression. We are collaborating with (i) Roche in the examination of GB1211 combined with atezolizumab for the first-line treatment of NSCLC and (ii) Providence Portland Medical Center in the examination of GB1211 with pembrolizumab for the treatment of melanoma and HNSCC. However, we also believe that GB1211 has the potential to treat many other forms of cancer and we plan to conduct additional oncology trails in the future, subject to obtaining additional financing or collaborating with a third party.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leverage our understanding of the LOXL2 pathway to advance GB2064 through a Phase 2 trial in myelofibrosis and continue evaluating GB2064 in subsequent indications. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting a Phase 2 trial of GB2064, our lead product candidate targeting LOXL2, in myelofibrosis. In the third quarter of 2022, we announced that of the first five patients who had completed at least six months of treatment with GB2064 and had a valid bone marrow biopsy at baseline and at 6 months in our Phase 2a MYLOX-1 trial, four experienced a &#x2265; 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and potentially be disease modifying. The data from the planned intermediate assessment of the MYLOX-1 trial suggest that the LOXL2 mechanism may be a way to reduce bone marrow fibrosis, which we believe has not been shown with any FDA-approved therapy. We continue to enroll patients in the MYLOX-1 trial and expect topline results from the MYLOX-1 trial to be available by the end of 2023. Because the MYLOX-1 trial has already exceeded the pre-defined target of a &#x2265; 1 grade reduction in collagen fibrosis in at least three patients, we may determine to enroll fewer patients than the sixteen evaluable patients provided for in the protocol. We are also beginning to plan for next steps in clinical development, which we expect could include combining GB2064 with another myelofibrosis treatment. The data from the intermediate assessment and the published literature on the LOXL2 mechanism suggest that LOXL2 inhibition may also be important in other solid and liquid tumor types as well as in fibrotic diseases.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to build a patient-focused company targeting fibrosis and cancer.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In building a patient-focused company to address the needs of patients with fibrotic diseases and cancer, we are working with clinicians, patient advocacy groups, medical centers of excellence and medical key opinion leaders to better understand unmet medical needs, to expeditiously develop and provide better treatments to patients, and to increase awareness of these diseases. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand our fibrosis and cancer portfolio by opportunistically advancing our research and development efforts beyond our current expertise in the galectin and LOXL2 pathways. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to expand our leadership as a company dedicated to developing therapies that directly target the biological processes at the heart of fibrotic diseases and cancer by developing product candidates against other targets involved in the regulation, formation, or maintenance of fibrosis or cancer. We also intend to selectively pursue business development opportunities to expand our current product portfolio, which may include product candidates targeting fibrosis or cancer that work through mechanisms that we believe are complimentary to, or independent of, galectins or LOXL2. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximize the commercial value of our product candidates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have retained worldwide development and commercial rights to all of our product candidates. We intend to commercialize any products in our portfolio for which we receive regulatory approvals in certain rare indications in the United States and the EU with a limited and targeted commercial team. We also intend to retain the flexibility to evaluate strategic collaborations and to seek partners to commercialize our products in other geographies and for our products in highly prevalent indications such as NSCLC, which require significant investment to build a commercial infrastructure. We have built an extensive wholly-owned patent portfolio around our fibrosis and oncology pipeline. We intend to continue to seek additional patent protection as we develop additional novel fibrosis and oncology candidates using our existing galectin and LOXL2 experience.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galectin-3 and LOXL2 Mediated Fibrosis and Cancer Background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing small molecule inhibitors focusing on galectin-3 and LOXL2 that target key common cellular and molecular biological processes that drive fibrosis and cancer and have shown antifibrotic and anticancer activity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. High levels of galectin-3 and LOXL2 are linked to worse clinical outcomes in both fibrosis and many types of cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fibrosis is the development of abnormal fibrous connective tissue in response to injury, damage or dysfunctional gene regulation. This fibrous connective tissue consists of elongated proteins such as collagen and elastin fibers that provide support to surrounding key functional cells in all tissue and all organs. Production and break-down of collagen is tightly regulated to preserve optimal organ function. The deposition of excess collagen and the formation of fibrosis can cause remodeling of surrounding healthy tissue and the loss of normal organ or tissue function. Fibrotic disease can affect tissues throughout the body including the lungs, liver, heart, kidneys and vascular system. Fibrosis typically progresses slowly and can ultimately lead to organ failure and death. Fibrosis is also a hallmark of solid tumors, with up to 20 percent of cancers associated with chronic inflammation-linked fibrosis. It has been estimated that fibrosis contributes to up to 45 percent of all deaths in the developed world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The currently approved therapeutic treatments for IPF are associated with significant side effects leading to significant discontinuation rates with median time on treatment only between 7.5 and 8.9 months, and they have not been linked to improvements in overall survival. Scientific literature supports the understanding that there are common biological mechanisms that drive fibrosis that are distinct from those regulating inflammation. It is these mechanisms that we are targeting with our proprietary product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both LOXL2 and galectin-3 have been shown to also play central roles in cancer progression and the formation of fibrosis associated with the tumor and in the tumor microenvironment (TME). These effects help tumors grow, metastasize and evade anticancer treatments. Hence, by inhibiting LOXL2 and galectin-3, it may be possible to reduce tumor growth, enhance the effect of anticancer treatments and hence reduce disease progression and potentially improve survival.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_1.jpg" alt="img108642122_1.jpg" style="width:522px;height:269px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 2. Overlapping biology in fibrosis and cancer through galectin-3 and LOXL2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Galectin-3</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galectin-3 is a lectin central to the development of fibrotic disease across multiple tissue types and is part of a pre-innate galectin immune defense developmentally conserved for over 500 million years, which steers local inflammation and when chronically activated, drives the development of fibrosis via several pathways and several cell inflammatory cell types and fibrocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is very little expression of galectin-3 in healthy tissues, but galectin-3 is overexpressed, sometimes profoundly, in damaged or inflamed tissues. Galectin-3 drives fibrosis by activating multiple pathways involved in tissue injury and repair. The presence of excess galectin-3 triggers the fibrotic process by converting quiescent fibroblast cells into activated cells called myofibroblasts. This triggering effect takes place when galectin-3 stimulates the signaling of growth factor receptors such as TGF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a master regulator of cell growth, immune regulation and fibrosis. Myofibroblasts are harmful in the context of fibrosis, since they secrete excess collagen and elastin, and as such are the key cellular drivers of fibrosis. Furthermore, galectin-3 reduces apoptosis, or programmed cell death, of inflammatory cells called neutrophils, allowing these cells to persist and potentially cause further damage and abnormal repair in fibrotic tissue. Finally, galectin-3 also promotes the activation of macrophages, resulting in increased fibrosis as well as further galectin-3 expression, which leads to a feed-forward cycle that can accelerate the fibrotic process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The galectin-3 mediated fibrosis is central to IPF and to several cancer types. The galectin-3 inhibitors inhibit the carbohydrate recognition domain stopping the attachment of galectin-3 to sugar moieties on cell surfaces receptors, and therefore stops its activation of key molecules like the receptors for TGF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and VEGF. Given its central role in fibrosis, there are FDA- and EU-cleared diagnostics for the detection of galectin-3 used for assessing the prognosis of patients diagnosed with chronic heart failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_2.jpg" alt="img108642122_2.jpg" style="width:376px;height:288px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 3. Multiple roles of galectin-3 in fibrosis</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interestingly, studies have shown that galectin-3 is not expressed during the first trimester of pregnancy and intra-uterine surgery during this time period leaves no scars. The inability of first trimester fetuses to scar further demonstrates that fibrotic tissue cannot develop if galectin-3 is missing or blocked. Preclinical studies have also shown that mice deficient in galectin-3 exhibit decreased fibrosis in models of liver, kidney, and lung disease. Furthermore, inhibition of galectin-3 has been shown to slow the development of lung, liver and cardiac fibrosis in preclinical models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In patients with IPF, elevated galectin-3 is found in the fibrotic patches in the lung, in bronchoalveolar lavage, or BAL, fluid and in plasma. In longitudinal studies, elevated galectin-3 has been associated with a greater decline in lung function. Patients with liver cirrhosis have highly elevated galectin-3 levels in biopsies of their liver nodules. Elevated galectin-3 is also found in serum of patients with fibrosis related to diseases characterized by fibrosis such as cancer, cardiac disease and renal disease. The level of galectin-3 expression in fibrotic tissue both spatially and temporally correlates with the degree of fibrosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite galectin-3&#x2019;s proximity to and involvement in fibrosis disease pathology, no approved drugs specifically target galectin-3. However, there are FDA- and EU-cleared diagnostics for the detection of galectin-3 in plasma to assess the prognosis of patients diagnosed with chronic heart failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galectin-3 is widely expressed in several cell types such as macrophages, fibroblasts, activated T-lymphocytes and epithelial cells and is highly expressed in high fatality cancers such as NSCLC. In NSCLC, particularly in adenocarcinoma, increased galectin-3 expression in tumors, lymph nodes and serum correlate with metastases and is a negative prognostic indicator. The galectin-3 genetic polymorphism rs4652 associated with impaired galectin-3 secretion has been linked to increased survival and response to chemotherapy in NSCLC. Galectin-3 drives fibrosis and blocking fibrosis around cancers may improve responses to immunotherapy and chemotherapy, as well as reduce angiogenesis and metastasis. Galectin-3 can directly enhance cell proliferation, apoptosis resistance and metastatic potential, as well as lung cancer stemness. It is also an important constituent of the tumor microenvironment acting on endothelial cells to promote angiogenesis and blocking galectin-3 inhibits angiogenesis. Ras mutations are the most common oncogenic driver mutation in human cancers and Ras mutations are dependent galectin-3 to drive oncogenic signaling. Thus, galectin-3 inhibitors could be effective in blocking oncogenic signaling in human tumors with Ras mutations, such as NSCLC, colorectal cancer and pancreatic cancer. Furthermore, many studies have revealed the inhibitory effects of galectin-3 on activated cytotoxic T lymphocytes (CTLs), and we have shown in preclinical trials that it is essential for M2 macrophage differentiation. In a recent study it was shown that patients with high levels of galectin-3 expression in NSCLC tumors did not respond to anti-PD-1 treatment, whereas patients with lower levels of galectin-3 expression did respond to the treatment. Similar data was also seen in melanoma patients, suggesting that the inhibition of galectin-3 may be broadly applicable in a number of cancers and indicating a central role of galectin-3 in the tumor defense mechanisms. Recent clinical data has shown clinical activity using a LAG-3 inhibitor in combination with a PD-1 inhibitor. Galectin-3 is a principal activator of LAG-3 and mediates LAG-3 effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_3.jpg" alt="img108642122_3.jpg" style="width:591px;height:323px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 4. Increased levels of tumor galectin-3 significantly drives the hallmarks of cancer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LOXL2</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lysyl oxidases are a family of enzymes that are secreted from the cell. Once outside the cell membrane, these enzymes help create and strengthen connective tissue by catalyzing the crosslinking of proteins such as collagen and elastin in the extracellular matrix, which is essential for normal tissue function, but can become fibrotic and lead to organ dysfunction in the diseased state. There are five members of the LOX family in humans, LOX and LOXL1 through LOXL4. Each of these family members is believed to play a specific role in the formation and maintenance of the extracellular matrix. Any therapy that is not sufficiently specific to LOXL2 (i.e., that also interacts with other members of the LOX family) is at risk for creating toxicity. Mice deficient in the gene for LOX, for example, die soon after birth as a result of defects in the formation of the cardiovascular and respiratory systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have chosen to target only the LOXL2 enzyme because it plays a key role in the development of fibrosis. In fibrotic diseases such as lung, liver, and kidney fibrosis, increased levels of LOXL2 are observed. The level of LOXL2 expression correlates with the degree of liver fibrosis, with the highest levels of LOXL2 being found in cirrhosis and in decompensated liver disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_4.jpg" alt="img108642122_4.jpg" style="width:462px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 5. LOXL2 expression correlates with degree of liver damage in patients with chronic hepatitis B</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LOXL2 is also increased in cancer-related fibrosis across a wide range of cancers, including breast, colon, and pancreatic cancers. The presence of LOXL2 is a negative prognostic for survival in pancreatic cancer with patients with tumors expressing LOXL2 having an overall survival of approximately half of those with LOXL2 negative tumors. LOXL2 is significantly upregulated in mesenchymal stromal cells, which are bone marrow cells that support hematopoietic stem cell differentiation, isolated from patients with myelofibrosis compared to healthy adults. The levels of other LOX family members do not significantly change between healthy and diseased mesenchymal stromal cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_5.jpg" alt="img108642122_5.jpg" style="width:440px;height:273px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 6. LOXL2 is highly overexpressed in myelofibrosis stromal cells (expression level in myeloid biopsies from myelofibrosis patients relative to expression in healthy individuals)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical experience with drugs specifically targeting LOXL2 has been limited. Simtuzumab, an antibody targeting LOXL2 that is administered by a subcutaneous or intravenous injection, has been evaluated in a number of clinical trials, including a Phase 2b trial in patients with myelofibrosis. These trials failed to show a positive effect on the reduction of fibrosis and further development of simtuzumab was discontinued due to lack of efficacy. Simtuzumab binds to LOXL2 without fully inhibiting its catalytic activity. This activity is, we believe, the critical feature of LOXL2 that needs to be blocked in order to achieve maximal antifibrotic activity. We believe that the LOXL2 target has not been fully explored. There is evidence that small molecule inhibitors with high penetration through fibrotic tissue that directly inhibit the catalytic activity of LOXL2 and which have the ability to penetrate deeper into fibrotic tissue than a large molecule antibody may show greater activity as antifibrotic agents, given that small molecules can more readily bind to the catalytic site of an enzyme deep in fibrotic tissue. GB2064 is designed to inhibit the enzymatic center to a much higher degree than simtuzumab and shut down collagen cross-linking more effectively. Inhibitors that preferentially target LOXL2 over other LOX family members may avoid triggering adverse events due to the ubiquitous and important roles that lysyl oxidases have in maintaining tissue structure throughout the body.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Clinical Product Candidate Portfolio</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB0139 for the Treatment of IPF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 is an inhaled small molecule inhibitor of galectin-3 that we are developing for the treatment of IPF. GB0139 has been tested in toxicological studies and observed to have a favorable tolerability profile in chronic toxicity studies. The molecule is delivered via oral inhalation utilizing a dry powder inhaler, a standard capsule-based inhaler that has been previously approved by the FDA for use in the delivery of other compounds. GB0139 for the treatment of IPF has been granted orphan drug designation by both U.S. and European regulatory authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IPF Background and Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPF is a rare life-threatening disease characterized by progressive fibrosis of the lungs leading to their deterioration and destruction. The most common symptoms of IPF are shortness of breath and a dry persistent cough, and a decreasing ability to perform normal daily activities. Over time, as a result of the unrelenting progress of the disease, breathing difficulties increase and lack of oxygen to tissues triggers weight loss, aching muscles, chronic fatigue, generally deteriorating health and can ultimately lead to death, often within 2 to 5 years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPF is a rare disease affecting approximately 100,000 people in the United States and occurs primarily in persons between the ages of 50 and 70. Between 30,000 and 40,000 new cases are diagnosed in the United States each year. The exact cause of IPF is not known, but a family history of the disease and environmental exposure to toxins, such as smoking, are known to increase the likelihood of developing the disease. Some patients with IPF develop other serious lung conditions such as lung cancer, pulmonary embolisms, pneumonia and pulmonary hypertension. Patients with IPF generally have a poor prognosis with a mean survival between two to five years depending on the stage of diagnosis and the rate of lung deterioration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatments for IPF and Their Limitations</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some IPF patients with mild or moderate symptoms are treated with either nintedanib, marketed as Ofev&#174; by Boehringer Ingelheim, or pirfenidone, marketed as Esbriet&#174; by Roche/Genentech. These drugs have been shown to slow progression of decrease in lung function associated with IPF and deterioration of pulmonary function, but neither drug has been associated with improvements in overall survival, and both have been associated with significant side effects. Over 60 percent of patients dosed with nintedanib have diarrhea and 14 percent experience elevated levels of liver enzymes. Thirty percent of patients treated with pirfenidone have skin rash, and nine percent experience photosensitivity, both of which can lead to dose reductions or discontinuations. Both agents have some efficacy in patients with more advanced disease, but high rates of discontinuations due to adverse events in these patients limit their use. The median time on treatment for currently approved therapies is only between 7.5 and 8.9 months, and these treatments have not been linked to improvements in overall survival. A survey of 290 physicians published by a third party in 2017 found that over half of IPF patients are not being treated with either agent for multiple reasons, including physicians not having sufficient confidence in clinical benefit and concerns about safety. A retrospective cohort analysis of prescription records conducted by researchers at the Mayo Clinic and presented in 2019 found that the adoption of pirfenidone and nintedanib by IPF patients was approximately ten percent for each therapy, supporting the earlier observation that the majority of IPF patients are not actively being treated. Despite this, total worldwide sales of pirfenidone and nintedanib combined were approximately $3.7 billion and $3.5 billion in 2021 and 2020, respectively.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the poor prognosis and the lack of therapies that impact survival, patients diagnosed with IPF are routinely referred for lung transplantations and it is generally recommended that all patients without contraindications for surgery be added to transplant lists. IPF patients represent the majority of all lung transplantations. However, the survival rate of IPF patients following transplant is lower than that observed for other diseases due to their advanced age and associated comorbidities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution - GB0139</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing GB0139 for inhaled delivery to target the IPF disease site directly in the periphery of the lung while limiting potential systemic toxicity. GB0139 is differentiated from current IPF therapies because it is designed to directly target galectin-3. By inhibiting the carbohydrate binding domain of galectin-3, GB0139 is designed to prevent the binding of galectin-3 to cell surface receptors, and hence reduce the profibrotic activity of galectin-3. GB0139 has been generally well-tolerated in clinical trials we have completed to date both in healthy adults and in IPF patients. In both populations, dosing with GB0139 resulted in highly consistent drug exposure and led to reductions in galectin-3 levels in macrophages isolated by BAL in the IPF patients. In our Phase 2a clinical trial, local therapy in the lungs of IPF patients with GB0139 also led to markedly decreased systemic levels of plasma biomarkers, such as YKL-40 and PDGF, that have been linked to mortality, severity and/or progression in IPF. While we are currently developing GB0139 for the treatment of IPF, we also plan to further develop GB0139 with the goal of treating other severe lung diseases driven by galectin-3.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 has also been investigated in a Phase 2a DEFINE trial as part of the University of Edinburgh&#x2019;s rapid experimental program for COVID-19 respiratory failure. We believe that GB0139&#x2019;s mechanism of action suggests it may have potential to prevent infection with COVID-19, as well as treat cytokine release syndrome, one of the major complications of the infection that can cause long-term damage in the lungs. This DEFINE trial included 41 hospitalized patients with COVID-19 infection who did not require mechanical ventilation, of which 20 were randomized to the GB0139 plus standard of care (dexamethasone, remdesivir and anticoagulant therapy) arm. The trial met its primary endpoint with results showing that inhaled GB0139 had an acceptable tolerability profile when used in combination with standard of care in hospitalized patients with COVID-19 pneumonia.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite being breathless and requiring oxygen, patients receiving GB0139 plus standard of care were able to inhale and achieve consistent exposure of GB0139. The 10mg dose of GB0139, dosed twice a day for 2 days and subsequently once a day for up to 14 days, which was higher than the current 3mg dose being used in the ongoing GALACTIC-1 trial, was generally well-tolerated and no treatment-related serious adverse events were reported. Furthermore, inhaled GB0139 led to a significant reduction of galectin-3 levels in patients with COVID-19 compared to standard of care (dexamethasone, remdesivir and anticoagulant therapy), demonstrating target engagement and reduced plasma levels of other key biomarkers associated with severe disease and a poor prognosis, including YKL-40, PAI-1, CXCL10, IL-6, IL-10 and TNF&#x3b1;. Patients receiving GB0139 also showed improved inflammation and coagulation biomarkers, including CXCL10, thrombocytes and reduced D-dimers, as well as improved biomarkers of liver function and tissue damage.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 pneumonitis is very fibrotic and, in some cases, can lead to &#x201c;long COVID&#x201d; lung fibrosis. COVID-19 patients treated with GB0139 showed a reduction in the processes and biomarkers of acute and chronic fibrosis. These results represent additional evidence of the positive impact of galectin-3 inhibition in severe lung disease, strengthening our confidence in the potential safety and tolerability profile of GB0139 in patients with compromised lung function and indicating potential activity in virus-induced acute lung injury. Viral infection and features of acute lung injury are associated with acute exacerbations of IPF, a major cause of rapid decline in lung function and death. The results from this study aligned with our findings in our IPF clinical trials and reaffirms the potential efficacy of GB0139 in IPF our ongoing Phase 2b GALACTIC-1 trial and also the potential to reduce acute exacerbations. We plan to continue to explore co-development opportunities with GB0139 for the treatment of COVID-19 and other severe viral lung diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data from our completed clinical trials to date on GB0139 in IPF patients demonstrated that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High exposure of GB0139 can be delivered to the target tissue with low systemic exposure; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inhalation dosing of IPF patients is feasible and results in highly reproducible drug levels; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 was generally well-tolerated, including daily dosing; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 leads to dose-dependent decreases in galectin-3 levels; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 leads to decreases in multiple fibrosis biomarkers that are present in the diseased lung tissue and measured in plasma, including YKL-40 and PDGF, which is consistent with GB0139 having direct antifibrotic activity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing Phase 2b Clinical Trial &#x2013; GALACTIC-1 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2019, we initiated the GALACTIC-1 trial, a 52-week randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b trial investigating the safety and efficacy of GB0139 in patients with IPF. The primary endpoint is the annual rate of decline in FVC at one year. FVC is a common test that measures the total amount of air that a person can expel from the lungs. A decline in FVC is an indirect measure of worsening fibrosis and increased lung stiffness and has become the most commonly accepted measure of disease progression in IPF. Patients with IPF lose FVC at a higher rate than normal leading to invalidity and, ultimately, to death. Therefore, a reduction in decline of FVC is the endpoint that was accepted by the FDA for the approval of both pirfenidone and nintedanib, the two current therapeutic treatments for IPF.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the clinical Phase 1b/2a study, both the 3 and the 10mg dose were shown to reach the periphery of the lung at high concentrations and to reduce the extracellular levels of galectin-3 on alveolar macrophages harvested from the lung of IPF patients. In the current clinical trial design for the GALACTIC-1 trial, patients are receiving an inhaled daily dose of 3mg of GB0139 or placebo for one year. In March 2021, the DSMB, who had access to unblinded interim safety and efficacy data, recommended that we discontinue dosing of GB0139 in patients on nintedanib or pirfenidone, and in patients receiving the 10mg dose. The DSMB&#x2019;s determination was based on an identification of an imbalance in the serious adverse events across the study groups, but not an imbalance between the groups in mortality. During the second quarter of 2021, we amended the study protocol to reflect these changes, and in July 2021, we resumed recruitment of patients for the GALACTIC-1 trial with the 3mg dose. Since July 2021, the DSMB has reviewed the unblinded safety data multiple times and has not communicated to us any safety signals or recommended any changes in the protocol. As with the initial study design, the annual rate of decline in FVC will be assessed as the primary endpoint using baseline FVC and several FVC measurements during the year to establish the rate of decline, and to compare that measure between patients on active treatment versus placebo. Secondary endpoints include the absolute decline in FVC; time to first hospitalization related to IPF, including acute IPF exacerbation; overall survival; and patient outcome measures such as 6-minute walk test distance and quality of life as determined by standard instruments. All patients will continue receiving their blinded treatments for up to two years until the last patient completes one year of dosing enabling the generation of extended safety and efficacy data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_6.jpg" alt="img108642122_6.jpg" style="width:609px;height:210px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 7. Ongoing GALACTIC-1 trial design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below shows an overview of the interim blinded safety data in the study. As the data has not been fully cleaned, since the study is ongoing, this table should not be seen as the final and definitive adverse event table, but is included here to provide an impression of the character of the serious adverse events that have been reported in the study as treatment emergent (i.e. starting after the onset of dosing of the experimental drug inhalations). Since the table represents a blend of patients on placebo, the 3mg dose of GB0139 and the 10mg dose of GB0139, including those taking concomitant nintedanib and pirfenidone, no firm conclusion can be made that these reported serious treatment emergent adverse events are related to GB0139 and conversely neither that they are unrelated to the GB0139 therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_7.jpg" alt="img108642122_7.jpg" style="width:695px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 8. GALACTIC-1 Interim blinded safety data as of March 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Phase 1/2a Clinical Trial - Phase 2a Part in IPF Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have conducted a randomized placebo-controlled Phase 1/2a multi-dose trial of GB0139 in the United Kingdom, or U.K., with the Phase 2a part conducted in 24 IPF patients. Patients in this part received 0.3, 3, or 10mg of GB0139 or placebo control by inhalation once daily for 14 days. All patients completed the 14-day dosing and BAL samples were obtained for all patients before dosing and at the conclusion of dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB0139 was generally well-tolerated in these patients with no serious drug-related adverse events, and there were no discontinuations in the trial. There were four incidents of mild adverse events (fever, upper respiratory tract infection, abnormal taste in mouth and dry throat) that were deemed possibly or probably drug related.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the presence of lung damage from IPF in patients entering this trial, inhalation of GB0139 resulted in highly reproducible drug levels (see Figure 9 below, which shows very tight standard deviation intervals) that were very consistent between patients and demonstrated higher systemic uptake of GB0139 than in healthy adult males in the Phase 1 part of the trial. This indicates that IPF patients are able to receive an inhaled drug to the peripheral parts of their lungs, which is the site of disease. Although observed at very low plasma concentrations, the higher plasma levels of GB0139 observed in the IPF patients is probably due to a loss of alveolar barrier integrity with increased epithelial permeability, which is present in the fibrotic lung.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_8.jpg" alt="img108642122_8.jpg" style="width:515px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 9. Consistent exposure of GB0139 among IPF patients in Phase 2a trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also observed dose-dependent increases in GB0139 levels in alveolar macrophages obtained from the BAL fluid, confirming drug exposure in situ in the lung. There was a significant correlation between plasma levels of GB0139 and levels in the macrophages in BAL fluid (Pearson correlation coefficient 0.89 with p&lt;0.0001). However, inhaled dosing of GB0139 resulted in drug levels that were between 567 and 1,930 times higher in alveolar macrophages than in plasma at two hours post-dose on day 14. This large difference in drug levels between plasma and alveolar lung macrophages supports our approach of delivering GB0139 through inhalation to maximize the exposure of the target lung tissue to the drug, while minimizing systemic exposure, which we believe will improve patient safety and tolerability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dosing with GB0139 led to dose-dependent decreases in galectin-3 levels on the cell surface of macrophages harvested from the BAL fluid, providing further evidence that GB0139 was able to reach the target tissue and significantly reduce the levels of the galectin-3 target protein attached to macrophages. These cells play an active part in the pathobiology in IPF.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_9.jpg" alt="img108642122_9.jpg" style="width:381px;height:290px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 10. GB0139 led to dose-dependent decrease of galectin-3 in alveolar macrophages</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of IPF patients with GB0139 resulted in decreases in serum levels of a broad panel of biomarkers associated with fibrosis and progression of IPF, as well as decreases in levels of galectin-3. The clear reduction in the serum levels of several fibrosis biomarkers may suggest that treatment with GB0139 had a measurable effect on the parenchymal disease process in the lungs. We believe no other IPF therapeutic has presented data of similar type and magnitude. These include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">YKL-40, an inflammation-related glycoprotein, the levels of which have been used to predict survival in IPF patients; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAI-1, or plasminogen activator inhibitor type -1, a regulator of tissue homeostasis and wound repair that is elevated in fibrosis; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PDGF-BB, or platelet-derived growth factor, a stimulator of fibroblast growth; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CCL-18, or CC Chemokine Ligand 18, a small protein derived from alveolar macrophages that acts as a chemo-attractant and is negatively correlated to pulmonary function tests in IPF patients.</span></div></div>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="margin-left:9.067%;text-indent:-3.805%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:0.782%;"></td>
    <td style="width:97.655%;"></td>
    <td style="width:0.782%;"></td>
    <td style="width:0.782%;"></td>
   </tr>
   <tr style="height:8.65pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:110.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_10.jpg" alt="img108642122_10.jpg" style="width:677px;height:414px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 11. Inhaled GB0139 led to significant reduction in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">serum</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> levels of a panel of fibrosis biomarkers and correlation between reduction of the plasma biomarkers and the alveolar macrophage surface galectin-3 levels</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The observation that these fibrosis-related biomarkers in plasma are concertedly and markedly reduced upon dosing IPF patients with GB0139 supports the key role of galectin-3 in IPF and the potential of GB0139 to generate antifibrotic activity in these patients. The levels of galectin-3 in alveolar macrophages directly correlate with the levels of serum biomarkers of fibrosis, including YKL-40, which has been shown to have prognostic significance in IPF. Four highly relevant disease biomarkers, PDGF, MCP-1, PAI-1 and YKL-40, have been shown to have prognostic significance in IPF and have a well described relationship with myofibroblast activity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In our completed Phase 2a clinical trial, these biomarkers were reduced from baseline in several dose groups compared to placebo and may offer a less invasive measure of pharmacodynamic effects going forward. In a post-hoc analysis of the ASCEND trial and the two CAPACITY trials, which were the three phase 3 clinical trials used for the approval of pirfenidone, YKL-40 was prognostic for progression in the test cohort. However, there was no association between pirfenidone treatment and the longitudinal concentration of any biomarker. In another study comparing treatment na&#xef;ve IPF patients with those on antifibrotic treatment (pirfenidone or nintedanib), CA-125, CXCL13, MMP7, YKL-40 and OPN predicted differential transplant free survival in treated patients, but at higher thresholds than treatment na&#xef;ve individuals. There is therefore substantial evidence that several biomarkers are related to disease severity and prognosis, several of which were significantly reduced in plasma of IPF patients after 2 weeks of treatment with inhaled GB0139. The biomarker data suggested a low degree of dose response between the 3mg dose and the 10mg dose. Following the recommendation of the DSMB in March 2021 and the subsequent amendment of the GALACTIC-1 trial protocol, the GALACTIC-1 trial is now evaluating the 3mg dose of GB0139, as compared to placebo, over 52 weeks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Phase 1/2a Clinical Trial - Phase 1 Part in Healthy Adult Males</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Phase 1 part of our Phase 1/2a clinical trial conducted in the U.K., we conducted a single ascending dose escalation study in 36 healthy adult males investigating six doses of GB0139 ranging from 0.15mg to 50mg. Inhaled GB0139 was generally well-tolerated in this trial with a half-life of 7 hours, and we observed predictable and well-characterized pharmacokinetics. No drug-related severe adverse events were reported, and other adverse events were mild in severity, and all resolved without intervention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB2064 for the Treatment of Myelofibrosis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are leveraging our knowledge of mechanisms underlying fibrosis and other related diseases to develop product candidates for indications beyond lung fibrosis and targeting pathways that are complementary to galectin-3. We are currently developing GB2064, a selective oral LOXL2 inhibitor, for the treatment of myelofibrosis. The LOXL2 mechanism may also be important in other solid and liquid tumor types as well as fibrotic diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Myelofibrosis Disease Background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Myelofibrosis is one of a number of progressive blood cancers known as myeloproliferative neoplasms and is associated with significantly reduced quality of life and shortened survival. In myelofibrosis, the bone marrow produces fewer blood cells, which leads to multiple negative impacts, including thrombocytopenia, or greater incidence of low platelet counts; anemia, or low red blood cell counts; and an increased need for red-blood-cell transfusions. When bone-marrow based production of blood cells is significantly reduced, myelofibrosis patients also suffer from enlarged spleens due to overabundance of blood-forming stem cells. Myelofibrosis is considered to be a chronic leukemia which, in a subset of patients, can transform into an acute form of leukemia. Median overall survival is approximately 2.25 to 11.25 years. Transformation to acute leukemia is the most common cause of death from myelofibrosis, followed by cardiovascular complications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Myelofibrosis affects between 16,000 and 18,500 patients in the United States with significant morbidity and mortality. Although the precise cause of myelofibrosis remains unknown, overactive Janus-associated kinase, or JAK, pathway signaling is present in all patients with the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatments for Myelofibrosis and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The only currently approved specific therapeutic treatments for myelofibrosis are inhibitors of JAK2, consisting of ruxolitinib marketed as JAKAFI&#174; by Incyte in the United States and JAKAVI&#174; by Novartis outside of the United States and fedratinib, marketed as Inrebic&#174; by Celgene/BMS. These kinase inhibitors provide symptomatic benefit, but only modest reductions in bone marrow fibrosis. In patients dosed for four or more years with ruxolitinib, for example, only one-third of patients showed reductions in fibrosis. Additionally, 60% of patients on ruxolitinib become transfusion dependent, versus 38% of patients in the placebo group. 16.8% of patients treated with ruxolitinib and 0.7% of patients treated with placebo developed newly occurring or worsening Grade 1 elevations in cholesterol. The incidence of Grade 2 cholesterol elevations was 0.6% for ruxolitinib with no Grade 3 or 4 cholesterol elevations. Despite this, total worldwide sales of ruxolitinib and fedratinib combined were approximately $3.7 billion and $3.3 billion in 2021 and 2020, respectively.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The only curative treatment for myelofibrosis is an allogeneic hematopoietic stem cell transplant, or HSCT. However, HSCT in myelofibrosis patients is a procedure associated with a high treatment-related mortality rate. Even when HSCT is restricted to the subpopulation of patients who are deemed healthy enough to withstand the treatment, there is a one-year treatment-related mortality rate of between 12 percent and 25 percent. Due to the only modest reductions in fibrosis demonstrated by JAK inhibitors and the high mortality rate associated with HSCT, we believe that significant unmet need remains for new therapeutic options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution - GB2064</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have chosen to pursue myelofibrosis as our first indication for GB2064 due to the upregulation of the LOXL2 in a number of fibrotic diseases, including myelofibrosis, the drug activity seen in preclinical data, the rapid rate of progression of the disease, and the relative ease of following disease progression through serum samples and bone marrow biopsies. In preclinical models, GB2064 is approximately 400-fold more selective for human LOXL2 over other human LOX enzymes. GB2064 has shown activity in a number of preclinical models of fibrosis; has demonstrated good pharmacokinetics; and was generally well-tolerated in a Phase 1 trial in healthy adults. While the current standard of care for myelofibrosis consists of inhibitors of the JAK2 protein kinase, which only alleviate the disease symptoms through inhibition of cell proliferation but do not directly target fibrosis, we believe that GB2064 has the potential to be a disease-modifying therapy because it is designed to have a direct impact on the fibrotic process and slow the progression of the disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Ongoing Clinical Trial &#x2013; MYLOX-1 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the third quarter of 2021, we initiated the Phase 2a MYLOX-1 trial examining GB2064 for the treatment of myelofibrosis. The primary endpoint of this trial is safety and secondary endpoints include measurements of drug levels in the bone marrow and grade of fibrosis, improvement of anemia and/or thrombocytopenia and assessment of spleen and liver size.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_11.jpg" alt="img108642122_11.jpg" style="width:615px;height:123px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 12. MYLOX-1 trial design</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the third quarter of 2022, we announced data from a planned intermediate assessment. As part of this assessment, we evaluated results from the first five patients who had completed at least six months of treatment with GB2064 and who had repeated bone marrow biopsies. In the intermediate assessment, four out of five evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a &#x2265; 1-grade reduction in collagen fibrosis of the bone marrow (see Figure 13 below), an improvement suggesting that GB2064 could impact the progression of the disease and potentially be disease modifying. All four patients who experienced a &#x2265; 1-grade reduction in fibrosis score also showed stable hematological parameters (hemoglobin, white blood cell count, and thrombocytes) and stable spleen volume over the six month treatment period, and none required transfusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img108642122_12.jpg" alt="img108642122_12.jpg" style="width:624px;height:323px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 13. Phase 2a MYLOX-1 trial intermediate assessment - collagen fibrosis grade</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the date of the planned intermediate assessment, sixteen patients in the MYLOX-1 trial had been dosed with GB2064, of which eight patients had completed or continued to receive treatment and eight patients had either discontinued treatment as a result of an adverse event or disease progression. The most commonly observed treatment-related adverse events were gastrointestinal in nature and were manageable in most patients with standard therapy. In the five patients who completed at least six months of treatment with GB2064, there were no treatment-related serious adverse events, while in the entire trial population, the only possibly treatment-related serious adverse event was a case of fall.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data from the intermediate assessment of the MYLOX-1 trial suggest that the LOXL2 mechanism may be a way to reduce fibrosis, which we believe has not been shown with any FDA-approved therapy. We continue to enroll patients in the MYLOX-1 trial and expect topline results from the MYLOX-1 trial to be available by the end of 2023. Because the MYLOX-1 trial has already exceeded the pre-defined target of a &#x2265; 1 grade reduction in collagen fibrosis in at least three patients, we may determine to enroll fewer patients than the sixteen evaluable patients provided for in the protocol. Given that we have already</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shown bone marrow collagen reduction and a manageable clinical tolerability profile, we are beginning to plan for next steps in clinical development, which we expect could include combining GB2064 with another myelofibrosis treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Phase 1 Clinical Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a Phase 1 single ascending dose and multiple ascending dose trial of GB2064 in 78 healthy volunteers. Volunteers received single doses of 150, 450, 1000, 2000 or 2500mg of GB2064 or daily doses of 150, 750, 2000mg or placebo for seven days. Dose-dependent increases in serum levels of GB2064 were observed, and using a proprietary assay, we determined that our oral selective inhibitor GB2064 led to dose-dependent inhibition of LOXL2 in serum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No serious adverse events were reported, and the reported adverse events included nausea, headache, and dizziness that were mild in severity and frequency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In preclinical studies, GB2064 showed activity in multiple models of fibrosis including lung, liver and kidney fibrosis. In a bleomycin-induced model of lung fibrosis, treatment of mice with bleomycin leads to lung fibrosis. Prophylactic dosing of GB2064 led to a significant reduction in fibrosis development in this model. Where fibrosis had already developed, therapeutic dosing of GB2064 led to reductions in further fibrosis development.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LOXL2 is highly expressed in other fibrotic diseases such as renal fibrotic disease. The mouse Col4A3 model of kidney disease is based on a genetic mutation that is found in patients with Alport Syndrome, a rare disease characterized by fibrosis that leads to progressive loss of kidney function among other symptoms such as progressive loss of hearing and retinopathy. LOXL2 expression is significantly elevated in both the kidney cortex and glomeruli in this mouse model. In preclinical studies, treatment of Col4A3 mice with GB2064 has demonstrated an ability to prevent glomerular sclerosis and a scarring of the blood filtering vessels in the kidney and resulted in lower fibrosis scores in the kidney.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB1211 for the Treatment of Fibrosis and Cancer</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe GB1211, a selective oral galectin-3 inhibitor, has the potential to treat multiple types of fibrosis and oncology indications. We are developing GB1211 initially for the treatment of liver cirrhosis, a disease with no regulatory approved treatments except for symptomatic therapy or liver transplant and NSCLC, a disease with high mortality and few treatment options. We may also consider developing GB1211 for other cancers and fibrotic diseases and, in October 2022, we expanded our focus on additional oncology indications and entered into an agreement with Providence Portland Medical Center&#x2019;s EACRI to evaluate the safety and efficacy of GB1211 in combination with pembrolizumab for the treatment of metastatic melanoma and HNSCC in an investigator-initiated trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liver Cirrhosis Background</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fibrous tissue accumulation is seen in the liver as a result of continued liver injury driven by a different stimulus or the autoimmune processes. The process of chronic inflammation leads to a progressive accumulation of extracellular matrix, or a scar tissue. Although different chronic liver diseases are characterized by distinct patterns of fibrosis deposition, the development of cirrhosis represents a common outcome and leading to similar clinical consequences, and ultimately liver related death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cirrhosis is defined histologically as a diffuse process in which the normal anatomical lobules are gradually replaced by architecturally abnormal nodules separated by fibrous tissue. Different histological scoring systems have been defined to describe the stages of transformation from lack of fibrosis through formation of a portal, periportal and bridging fibrosis to cirrhosis. Our preclinical data suggests that inhibition of galectin-3 may counter established liver cirrhosis and could therefore become one of the first disease-modifying agents for liver cirrhosis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatments for Liver Cirrhosis and Their Limitations</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are no FDA approved drugs for liver cirrhosis. In general, therapeutic interventions are limited to supportive care relating to complications caused by the liver not functioning, and, in advanced cases, liver transplantation. As such, this is an area of high unmet medical need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Galectin-3 in Liver Cirrhosis</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial target indication for GB1211 in fibrosis is liver cirrhosis. While the historical view was that established fibrosis is very difficult to impact, our preclinical data suggest that galectin-3 inhibition could reduce established fibrosis and the disease processes that drive the disease progression. Galectin-3 is a central regulator of chronic inflammation and fibrogenesis. Although not present in normal hepatocytes, galectin-3 expression is markedly increased in cirrhotic human liver secondary to a wide range of etiologies including viral-induced liver disease (Hepatitis B and C), NASH, autoimmune, copper or iron overload, primary biliary cirrhosis and alcohol-induced liver disease. Galectin-3 levels are highest in the F3/F4 fibrotic stages compared to F0/F1 and may arise by the impaired hepatic removal and/or by higher hepatic synthesis of galectin-3. Systemic galectin-3 is also increased in alcoholic liver disease and negatively correlates with liver function and Child-Pugh score.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In rodent models, galectin-3 expression is increased temporally in areas of bridging fibrosis and at the periphery of the hepatocyte nodules in the liver following CCl</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> administration. Galectin-3 is also increased in other models of liver fibrosis including thioacetamide-induced and nutritionally deficient, dietary models of hepatocellular and biliary injury in mice. In models of primary biliary cirrhosis, galectin-3 may mediate injury in these models via activation of the inflammasome and IL33/sT2 pathways. Global genetic deletion of galectin-3 results in reduced fibrosis in several models of toxin-induced, dietary- and surgically induced liver fibrosis in mice. These data suggest that galectin-3 up-regulation within the liver is a basic response to liver injury, irrespective of the initiating agent or disease process. As a result, we believe galectin-3 inhibitors have the potential to be a therapy for NASH or liver cirrhosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most advanced clinical studies investigating the blockade of galectin-3 in liver fibrosis have used modified pectins such as belapectin. However, these large complex carbohydrates demonstrate low affinity for the galectin-3 carbohydrate recognition domain (CRD, 11) and with human PK data showing levels of systemic drug at orders of magnitude lower than K</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, this predicts a low chance of any meaningful target engagement in a clinic setting.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed small molecule orally active galectin-3 inhibitors, including GB1211, which demonstrate high (nM) affinity for human galectin-3 and good systemic exposure. GB1211 has been shown to reduce CCl</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-induced liver fibrosis and fibrotic gene expression in mice. In the fourth quarter of 2022, we announced topline results from our Phase 1b/2a GULLIVER-2 trial of GB1211 in patients with decompensated liver cirrhosis that showed statistically significant reductions in liver enzymes after 12 weeks of treatment. We believe that this is the first study in a population of Child-Pugh Class B decompensated cirrhosis patients of non-viral etiology showing changes in a series of liver parameters that are potentially clinically meaningful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NSCLC Background</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lung cancer is the most common fatal malignancy in the developed world accounting for approximately 1.7 million deaths per year worldwide. In the United States in 2021, it is estimated that there were approximately 236,000 new cases of lung cancer and approximately 132,000 deaths from lung cancer. NSCLC is believed to account for about 85% of all lung cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatments for NSCLC and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NSCLCs are relatively insensitive to available treatments, which include surgery, irradiation and cytochemical therapy. With the advent of immunotherapy, a new understanding of the interplay between the immune system and cancer has evolved, and it is now increasingly understood that cancer can avoid immune detection and immune killing by a series of mechanisms. The readiness of the immune cells that can detect and kill cancer (including T-cells), the tumor micro-environment, or TME, in which they work, and cancer cell characteristics determine whether or not the immune system will be successful in killing cancer cells. A certain class of immune stimulation therapies have been developed and approved for treating lung cancer. The class is called checkpoint inhibitors, as these are compounds that specifically target and inhibit cell surface molecules, so-called &#x201c;checkpoints&#x201d;, that inhibit the activity of the immune system. The most well characterized class, the anti-PD-1 antibodies, have been shown to reduce mortality and increase progression free survival. However, even though these have been introduced in the clinic, mortality from lung cancer remains very high, as only approximately 30% of patients respond to anti-PD-1/PD-L1 therapies and approximately 20% of the patients treated with anti-PD-1/PD-L1 therapy show significant adverse lung effects, including inflammation and fibrosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of the reasons that anti-PD-1/PD-L1 medicines are believed to only show limited efficacy is that factors in the tumor micro-environment reduce T-cell entry and induce T-cell anergy, which leads to reduced T-cell mediated toxicity. We believe one of these TME factors is high levels of galectin-3 in the tumor micro-environment. Galectin-3 has been shown to reduce T-cell entry and activity through binding to cells surface proteins, such as LAG3, PD-1 and the T-cell receptor. Further, galectin-3 disrupts the IFN&#x3b3; gradient in the tumor, which in turn reduces T-cell chemotaxis. In addition, galectin-3 polarizes the tumor associated macrophage, which also reduce T-cell activation. Hence, blockade of galectin-3 may lead to increased T-cell number and activity in the tumor, though inhibition of these many factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the wide tumor and metastasis promoting actions of galectin-3, we believe that our compounds targeting galectin-3 could counter many of the detrimental effects of galectin-3 and may be suitable as single agents or in combination with other checkpoint inhibitors, chemotherapy or chemo-irradiation therapies. Based on the favorable tolerability profile of our compounds observed to date, we believe our galectin-3 inhibitor therapies could be suitable for many clinical situations. In addition to galectin-3 inhibitors, we are progressing galectin-1 and galectin-9 inhibitors which may be useful in certain types of cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Galectin-3 in NSCLC</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galectin-3 inhibition has the potential to both increase T-cell function as a single agent as well as to increase the efficacy of checkpoint inhibitors for NSCLC. In an animal model, we observed that oral administration of our galectin-3 inhibitors reduced human and mouse lung adenocarcinoma growth and blocked metastasis. Treatment with one of our galectin-3 inhibitors also potentiated the effects of a PD-L1 immune checkpoint inhibitor. The mechanisms at work include checkpoint inhibitor-type mechanisms (inhibition of TGF-&#x3b2; signaling, LAG-3, T-cell receptor, interferon gamma) and mechanisms potentially enhancing PD-1/PD-L1 activity, as evidenced by preclinical data that we recently presented at the 2022 American Society of Clinical Oncology Annual Meeting showing that GB1211 reversed a galectin-3 induced blockage of the checkpoint inhibitors atezolizumab and pembrolizumab and exhibited synergistic effects with these checkpoint inhibitors. Furthermore, in the clinic, a retrospective study showed that patients with high tumor staining for galectin-3 were resistant to treatment with pembrolizumab, an anti-PD-1 antibody approved for the treatment of NSCLC, and, by contrast, patients with low galectin-3 had a good response to pembrolizumab and a reduction in tumor volume (see Figure 14 below). Similar data was also seen in melanoma patients, suggesting that the inhibition of galectin-3 may be broadly applicable in a number of cancers and indicating a central role of galectin-3 in the tumor defense mechanisms. Galectin-3 could be a biomarker for anti-PD-1/PD-L1 resistance and, therefore, for patients who may benefit from galectin-3 inhibition. While we will not screen for high galectin-3 in the currently planned GALLANT-1 trial, we do intend to use galectin-3 immunohistochemistry staining in NSCLC to select patients with high galectin-3 levels in the tumor tissue, who may respond to the combination of an anti-PD-1/PD-L1 therapy and our galectin-3 inhibitor GB1211. Because we also measure circulating levels of galectin-3, this may also prove suitable for patient selection. Galectin-3 is an FDA approved biomarker for fibrotic heart disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_13.jpg" alt="img108642122_13.jpg" style="width:610px;height:284px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 14. High galectin-3 expression in 34 patients with NSCLC strongly correlated with tumor resistance to pembrolizumab</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution &#x2013; GB1211</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe GB1211 has the potential to treat multiple types of fibrosis and oncology indications. We have demonstrated anticancer and fibrosis activity of GB1211 in several preclinical models and have completed a Phase 1 trial in 78 healthy volunteers, where GB1211 showed good pharmacokinetics and was generally well-tolerated. Additionally, GB1211 has shown anticancer effects in preclinical models, specifically in NSCLC tumors high in galectin-3 and resistant to anti-PD-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effect of GB1211 was evaluated in a mouse model of carbon-tetrachloride-induced liver fibrosis. In two separate studies, fibrosis was induced in mice, which were then given either GB1211 or placebo. Mice dosed with 10mg/kg GB1211 twice a day had significantly lower levels of liver fibrosis compared to mice given placebo as detected by histological staining of liver sections with a collagen-specific dye, picrosirius red. This reduction in fibrosis was observed in the absence of changes in liver weight or body weight. These findings were consistent when compared with a standard measurement of collagen content using levels of hydroxyproline, a major component of collagen</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Phase 1 Clinical Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a Phase 1 single ascending dose and multiple ascending dose trial of GB1211 in 78 healthy volunteers in the U.K. GB1211 was generally well-tolerated with no drug-related serious adverse events at any doses up to the maximum dose tested of 400mg.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Phase 1b/2a Clinical Trial in Liver Cirrhosis &#x2013; GULLIVER-2 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the fourth quarter of 2022, at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting&#174; 2022, we announced topline results from our Phase 1b/2a GULLIVER-2 trial of GB1211 that is focused on safety and effect on liver function and fibrosis biomarkers in patients with decompensated liver cirrhosis. These topline results showed statistically significant reductions in ALT (p&lt;0.0005), AST (p&lt;0.005) and GGT (p&lt;0.05), with encouraging reductions for ALP (p&lt;0.09), after 12 weeks of treatment. Patients treated with GB1211 also demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 (p&lt;0.05) and CK-18 (M65) (p&lt;0.002). Bilirubin, albumin, international normalized ratio (INR) and other biochemical measurements remained stable. These findings suggest that GB1211 provided liver cell protection and improved liver status, further supporting clinical development in severe liver disease. Liver enzyme (ALT, AST and GGT) reductions were observed after seven days of treatment and continued to decrease over the 12 weeks of treatment. These liver enzyme levels remained decreased compared to baseline two weeks after the study&#x2019;s conclusion, suggesting durable effects and a decrease in liver inflammation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img108642122_14.jpg" alt="img108642122_14.jpg" style="width:600px;height:322px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 15. Topline Phase 1b/2a GULLIVER-2 liver-related biochemistry results</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GB1211 exhibited a favorable tolerability profile in patients with decompensated liver cirrhosis in the GULLIVER-2 trial. Five of 15 patients on GB1211 and four of 15 patients on placebo reported nine and eight treatment-emergent adverse events (TEAEs), respectively. Three serious </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TEAEs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> consistent with severe liver disease were observed in one patient (2 after cessation of active therapy) on GB1211 and were deemed to be unrelated to GB1211.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consistency of the reductions in liver enzymes shown in this severe form of liver cirrhosis, the progressive improvement we observed over 12 weeks and the favorable safety profile observed in the GULLIVER-2 trial lead us to believe that a broader study in patients with compensated and/or decompensated cirrhosis could show broader clinical activity, providing a potential regulatory path to approval as the first FDA-approved therapy in liver cirrhosis.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2a Clinical Trial in NSCLC &#x2013; GALLANT-1 Trial</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2021, we announced that we had entered into a clinical trial supply agreement with Roche for our Phase 2a GALLANT-1 trial of GB1211 in combination with atezolizumab, a PD-L1 checkpoint inhibitor, for the treatment of first-line NSCLC. This randomized, double blind, placebo-controlled trial is examining the effect of GB1211 and atezolizumab on tumor shrinkage based on RECIST criteria, as well as secondary endpoint measures such as overall survival, progression-free survival and others. We also plan to analyze how plasma galectin-3 levels and tumor galectin-3 correlate with tumor response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img108642122_15.jpg" alt="img108642122_15.jpg" style="width:521px;height:216px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 16. GALLANT-1 trial design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated Part A of this trial, an open-label study to select the dose of GB1211 to be used with atezolizumab, in the second quarter of 2022. In the first 6 patients who received 200mg twice daily in combination with atezolizumab, we observed two serious adverse events of autoimmune-type skin rashes (showing perivascular lymphocytic infiltrates), which were determined by the principal investigator to be related to the administration of atezolizumab. The reactions were similar to those observed with atezolizumab and described in the label. Both reactions responded to therapy with oral glucocorticosteroids and were clinically manageable. In accordance with the protocol, we reduced the GB1211 dose to 100mg twice daily for the second patient cohort. Recruitment in this cohort is currently ongoing. Interestingly, inflammatory and perivascular lymphocytic infiltrates were observed in both skin reactions, and could signal an exaggerated immune activation, something often observed with checkpoint inhibitor therapy and associated with improved clinical outcomes. Because a central aspect of the mechanism of action for GB1211 in combination with a checkpoint inhibitor is to remove galectin-3 from the lymphocytes and the tumor cells, and thereby increase lymphocyte-based tumor killing, we believe this could also be a positive signal of enhanced lymphocyte activation. We expect to release interim safety data from this part of the GALLANT-1 trial in the second quarter of 2023. Part B of this trial is designed to evaluate the safety and tumor shrinkage (based on RECIST criteria) of the combination of the selected dose of GB1211 and atezolizumab and we expect topline results to be available in the first half of 2024.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 Investigator-Initiated Trial in Metastatic Melanoma and HNSCC</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we expanded our focus on additional oncology indications and entered into an agreement with Providence Portland Medical Center&#x2019;s EACRI to evaluate the safety and efficacy of GB1211 in combination with pembrolizumab in an investigator-initiated trial in metastatic melanoma and HNSCC patients. Galecto has committed to supply GB1211 for this Phase 2 trial. The randomized, double-blind placebo controlled, investigator-initiated Phase 2 trial is expected to evaluate whether the addition of GB1211 increases the response rate of pembrolizumab in metastatic melanoma and HNSCC patients. The study is designed to evaluate GB1211 in combination with the standard therapeutic dose of pembrolizumab in patients with unresectable or metastatic melanoma or recurrent or metastatic HNSCC progressing during or after platinum-containing chemotherapy. In addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin-3 biology and checkpoint inhibition. This trial is expected to begin in the second half of 2023 and topline results could be reported as early as 2025.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our management team, clinical capabilities, research and development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including biotechnology and biopharmaceutical companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a large number of large biotechnology and biopharmaceutical companies that are currently pursuing the development of products for the treatment of fibrosis and cancer, and smaller number of companies seeking to develop treatments for liver cirrhosis. Companies that we are aware of that are targeting the treatment of fibrotic and related diseases include large companies with significant financial resources such as Pharmaxis Ltd, Biogen, Inc., AbbVie Inc., Gilead Sciences, Inc., Pliant Therapeutics, Inc., Galectin Therapeutics, Inc., FibroGen, Inc., Liminal BioSciences, Inc., Galapagos NV, Bristol Myers Squibb Co., Madrigal Pharmaceuticals, Inc., Inventiva, Akero Therapeutics, Inc., Boehringer Ingelheim, Roche/Genentech and Novartis AG. However, we know of no other companies currently in clinical development with an inhaled or orally available small molecule inhibitor of galectin-3 or an orally available small molecule inhibitor of LOXL2 for myelofibrosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or regulatory approval from comparable foreign regulatory authorities for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of our product candidates are likely to be efficacy, safety, cost, and convenience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our owned patents and patent applications relate to our fibrosis-inhibiting compounds and include patents and patent applications directed to new compositions of matter and to methods of treating lung, kidney and liver disorders. As we continue to develop our product candidates, we intend to seek additional patent protection in the United States, EU and in other key commercial markets worldwide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB0139</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we owned five patent families that included eight issued U.S. patents, three pending U.S. patent applications, as well as issued and pending foreign counterpart patents and patent applications, relating to our product candidate, GB0139. These patent families include U.S. Patent No. 9,243,021, which is directed to composition of matter of and methods of treatment using compound GB0139; and U.S. Patent Nos. 10,307,403 and 10,369,136, which are directed to composition of matter of and methods of treatment using a polymorphic form of compound GB0139. U.S. Patent No. 9,243,021 is expected to expire in 2033, and U.S. Patent Nos. 10,307,403 and 10,369,136 are expected to expire in 2036, absent any patent term extension. The other issued U.S. patents are expected to expire between 2029 and 2036, absent any patent term extension. If we continue to pursue patent protection, and if any patents issue based on our pending applications, we expect such patents to expire between 2033 and 2040, absent any patent term adjustment and patent term extension in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB1211</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we owned three patent families that included three issued U.S. patents, three pending U.S. patent application, as well as pending foreign counterpart patent applications, relating to our product candidate, GB1211. One patent family includes U.S. Patent No. 10,526,360, U.S. Patent No.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,774,102 and U.S. Patent No.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,377,464, which are directed to composition of matter of D-galactopyranose compounds of which compound GB1211 is a species. The issued U.S. patents are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expected to expire in 2036, absent any patent term extension. If we continue to pursue patent protection, and if any patents issue based on our pending applications, we expect such patents to expire in 2036, absent any patent term extension in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our other patent families include two pending U.S. patent applications and pending foreign counterpart patent applications. If we continue to pursue patent protection, and if any patents issue based on our pending applications, we expect such patents, if issued, to expire in 2040, absent any patent term adjustment and patent term extension in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GB2064</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we owned three patent families that included five issued U.S. patents, two pending U.S. patent applications, as well as issued and pending foreign counterpart patent and patent applications, relating to our product candidate, GB2064. These patent families include U.S. Patent Nos. 10,150,732, 10,570,094 and 11,072,585, which are directed to composition of matter of and methods of treatment using compound GB2064. These issued U.S. patents are expected to expire in 2036, absent any patent term extension. The third issued patents, U.S. Patent Nos. 10,774,069 and 11,459,309, are directed to crystalline forms of GB2064. These patents are expected to expire in 2037, absent any patent term extension. If we continue to pursue patent protection, and if any patents issue based on our pending applications, we expect such patents to expire between 2036 and 2037, absent any patent term adjustment and patent term extension in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of the risks associated with our intellectual property, see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Government Regulation of Drug Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also regulates biological products under the FDCA and the Public Health Service Act, or PHSA. If we advance clinical development of a biologic candidate in the future, these development activities will be subject to additional regulatory requirements specific to biologics. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending New Drug Applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#x2019;s good laboratory practice, or GLP, regulations;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval of the protocol and related documentation by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed drug product for each indication;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an NDA, including payment of application user fees;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A determination by the FDA within 60 days of its receipt of an NDA to accept the marketing application for review;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of an FDA advisory committee review, if applicable;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of FDA audits of clinical trial sites that generated the data in support of the NDA to assure compliance with GCPs and the integrity of the clinical data; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and animal studies to assess potential safety and efficacy. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to commencing an initial clinical trial in humans with a product candidate in the United States, an IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND application. An IND application is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may or may not result in the FDA allowing clinical trials to initiate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators, generally physicians not employed by or under the control of the trial sponsor, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND application. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it is initiated at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB also must review and approve the informed consent form and other clinical trial documentation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as required can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH&#x2019;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the NIH and FDA signaled the government&#x2019;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1: The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2: The investigational product is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3: The investigational product is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a DSMB or safety review committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access to certain data from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA Submission and Marketing Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of preclinical studies and clinical trials, together with detailed information relating to the product candidate&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product candidate for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. The FDA will initially review an NDA for completeness before it accepts it for &#x201c;filing.&#x201d; Under the FDA&#x2019;s procedures, the agency has 60 days from its receipt of the NDA to determine whether the application will be accepted for filing based on the agency&#x2019;s threshold determination that the application is sufficiently complete to permit substantive review. Under the Prescription Drug User Fee Act, or PDUFA, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; in which to complete its initial review of a standard NDA for a new molecular entity, and six months from the filing date of a new molecular entity NDA with priority review. Accordingly, this review process typically takes 12 months and eight months, respectively from the date the NDA is submitted to the FDA. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#x2019;s continued safety, quality and purity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer an application for a novel drug or a drug that presents difficult questions of safety or efficacy to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also may require the submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug. A REMS may include one or more elements, including medication guides, physician communication plans, patient package insert and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter generally describes all of the deficiencies that the FDA has identified in the NDA and contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product candidate with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product is entitled to orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in certain limited circumstances. If a product candidate designated as an orphan drug ultimately receives marketing approval for an indication broader than what it was designated for, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan drug has exclusivity. Orphan drug designation entitles sponsors to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Priority Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients earlier than under standard FDA development and review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing application before the sponsor submits the complete application, as well as priority review, discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. A product may also be eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review and to shorten the FDA&#x2019;s goal for taking action on an NDA for a new molecular entity from ten months to six months from the date of filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product may also be eligible for accelerated approval if it treats a serious or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of accelerated approval, the FDA may require that a sponsor perform adequate and well-controlled post-marketing confirmatory trials with due diligence and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Under FDORA, the FDA also has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials for products considered for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Fast Track designation, Breakthrough Therapy designation and Priority Review designation do not change the standards for approval but may expedite the development or review process. Drugs granted accelerated approval also must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain follow-on applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, for a generic version of the drug or a 505(b)(2) NDA for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such a follow-on application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of market exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity period covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving follow-on applications that do not reference the protected clinical data. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods or listed patents. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations which require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. </span><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or withdrawal of product approvals; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted by a sponsor and any third parties acting on behalf of a sponsor only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval. Arrangements with third-party payors, healthcare providers and physicians, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The AKS has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts have found that if &#x201c;one purpose&#x201d; of remuneration is to induce referrals, the AKS is violated. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA. On November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications to the federal Anti-Kickback Statute. Under the final rule, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, this rule will have on our business;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal civil and criminal false claims laws, including the FCA, which can be enforced by private citizens through &#x201c;qui tam&#x201d; or &#x201c;whistleblower&#x201d; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Pharmaceutical and other healthcare companies have been, and continue to be, prosecuted under these laws, among other things, for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, off-label, and thus generally non-reimbursable, uses. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. Similar to the AKS, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Like the AKS, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS, under the Open Payments Program, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), to certain non-physician providers such as physician assistants and nurse practitioners, and to teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a pharmaceutical manufacturer&#x2019;s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#x2019;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if we become subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer&#x2019;s ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state and federal health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The CCPA went into effect into effect on January 1, 2020, and the California State Attorney General has submitted various versions of final regulations. Since July 1, 2020, the California State Attorney General has had the authority to commence enforcement actions against violators. Further, a California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020 and entered into force on January 1, 2023. The CPRA creates additional obligations with respect to processing and storing personal information. We will continue to monitor developments related to the CPRA and anticipate additional costs and expenses associated with CPRA compliance. Other U.S. states also are considering omnibus privacy legislation (with one additional law already passed in Colorado, Connecticut, Utah and Virginia) and industry organizations regularly adopt and advocate for new standards in these areas. While the CCPA, as modified by the CPRA contain an exception for certain activities involving PHI under HIPAA, we cannot yet determine the impact the CCPA, CPRA or other such future laws, regulations and standards may have on our business, as these laws either do not yet apply to us or are not yet in effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions, under state and federal law or other obligations. We may become or are already subject to data privacy laws in other countries, including the EU General Data Protection Regulation, or EU GDPR, in Europe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the GDPR and similar processing of personal data regarding individuals in the U.K. is subject to the U.K. General Data Protection Regulation, or U.K. GDPR, and the U.K. Data Protection Act 2018. In this Annual Report on Form 10-K, GDPR refers to both the EU GDPR and the U.K. GDPR, unless specified otherwise. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA/U.K., including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million (&#163;17.5 million) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current and Future Healthcare Reform Legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes to the health care system. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In particular, in 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current and Future Healthcare Reform Legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes to the health care system. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In particular, in 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. Subsequent legislation extended the 2% reduction which remains in effect through 2030. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On&#x202f;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022, or the IRA, includes provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000, impose new manufacturer financial liability on certain drugs covered under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs (&#x201c;SCODs&#x201d;). The court ruled this change was not an &#x201c;adjustment&#x201d; which was within the Secretary&#x2019;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#x2019;s decision and found that the changes were within the Secretary&#x2019;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. Plaintiffs-appellees filed a petition for a writ of certiorari at the Supreme Court on February 10, 2021 and the petition was granted on July 2, 2021. On June 15, 2022, the Supreme Court unanimously reversed the Court of Appeals&#x2019; decision, holding that HHS&#x2019;s 2018 and 2019 reimbursement rates for 340B hospitals were contrary to the statute and unlawful. We continue to review developments impacting the 340B program.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legislative and regulatory proposals and enactment of laws, at the foreign federal and state levels, directed at containing or lowering the cost of healthcare, will continue into the future. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to set a price that we believe is fair for our products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of capital. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulation Outside the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. The cost of establishing a regulatory compliance system for numerous varying jurisdictions can be very significant. Although many of the issues discussed above with respect to the United States apply similarly in the context of the EU and in other jurisdictions, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial authorization application, or CTA, must be submitted for each clinical protocol to each country&#x2019;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance with a country&#x2019;s requirements, the clinical trial may proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements and processes governing the conduct of clinical trials vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP, the applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain regulatory approval of an investigational medicinal product under EU regulatory systems, we must submit a marketing authorization application. The content of the NDA filed in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development, the conduct of clinical trials, manufacturing, distribution, marketing approval, product licensing, pricing and reimbursement vary from country to country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Countries that are part of the EU, as well as countries outside of the EU, have their own governing bodies, requirements, and processes with respect to the approval of drug products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, to the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Authorization Procedures in the EU</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EEA (comprised of the EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or one of the national authorization procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Centralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, following the opining of the EMA&#x2019;s Committee for Medicinal Products for Human Use, or CHMP, the EC issues a single marketing authorization valid across the EEA. The centralized procedure is compulsory for human medicines derived from biotechnology processes or advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), products that contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other immune dysfunctions, viral diseases, and officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, or is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. Under the centralized procedure, the maximum timeframe for the evaluation of a marketing authorization application, or MAA, by the EMA is 210 days, excluding &#x201c;clock stops&#x201d;, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, and which can add materially to the timeframe. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now that the U.K. (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the U.K. medicines regulator, may rely on a decision taken by the EC on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">National authorization procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Decentralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EEA country of medicinal products that have not yet been authorized in any EEA country and that do not fall within the mandatory scope of the centralized procedure. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mutual recognition procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;In the mutual recognition procedure, a medicine is first authorized in one EEA member state, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EEA countries in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, new products for therapeutic indications that are authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the EEA are similar in principle to those in the United States. In the EEA, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a &#x201c;similar medicinal product&#x201d; for the same indication. A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if (i) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder of the authorized orphan product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As in the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022. The transitory provisions of the new Regulation provide that, by January 31, 2025, all ongoing clinical trials must have transitioned to the new Regulation. The new Regulation overhauls the system of approvals for clinical trials in the EU. Specifically, it is directly applicable in all Member States (meaning that no national implementing legislation in each Member State is required), and aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the new Regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all Member States of the European Union, or EU Member States, in which an application for authorization of a clinical trial has been submitted (Concerned Member States) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Concerned Member State. Strict deadlines have been established for the assessment of clinical trial applications.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should we utilize third-party distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the U.K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.K. formally left the EU (commonly referred to as &#x201c;Brexit&#x201d;) on January 31, 2020, and the EU and the U.K. have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of U.K. and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework continues to apply in Northern Ireland). Except in respect of the new EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore largely aligns with EU regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#x2019;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and E.U. pharmaceutical legislation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successful commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. In the United States, government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on its investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a drug product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any product for which we obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each Part D prescription drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly eligible entities (with the exception of children&#x2019;s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As the required 340B discount is determined based on average manufacturer price, or AMP, and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by HHS, the Agency for Healthcare Research and Quality and the NIH, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our product candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#x2019;s drug could adversely affect the sales of our product candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 45 full-time employees, including six who hold M.D. degrees and 14 who hold Ph.D. degrees. Most of our employees work from our offices in Denmark, Sweden, the U.K. and the United States. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be strong.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With our science and knowledge at the center of our business, we have a team of knowledgeable and highly skilled employees who are crucial to the success of our business. As we strive to be an employer of choice and maintain the strength of our workforce, we consistently assess the current business environment and labor market to refine our compensation and benefits programs and other resources available to our employees. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We believe that a compensation program with both short-term and long-term awards provides fair and competitive compensation and aligns employee and stockholder interests, including incentivizing business performance and integrating compensation with our overall business plans and strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are committed to investing in the development of our people and creating an environment where diverse perspectives and backgrounds are encouraged and supported. We host weekly company-wide sessions where ideas are discussed, feedback on corporate initiatives is received, scientific breakthroughs are shared, and other corporate updates are provided. Our people&#x2019;s voices are central to identifying how we, as an organization, can strengthen the organization further and maintain high retention. In 2022, we initiated a bi-annual employee satisfaction survey throughout the organization, showing strong engagement scores throughout 2022. Our future focus is to maintain and grow employee satisfaction by working systematically based on the feedback received from our team.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diversity, equality, and inclusion are fundamental pillars of our culture, and have been since Galecto was founded in 2011. We believe that an equitable and inclusive environment with diverse teams creates higher engagement, better solutions, and higher productivity, and is crucial to our efforts to attract and retain key employees and improve the business. The composition of our organization accounts for more than 15 different nationalities and our workforce is 53% male and 47% female. Among our leadership team, 62.5% are male and 37.5% are female.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Internet address is www.galecto.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy, and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. Information on our website is not part of this Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC's Interactive Data Electronic Applications system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K and in the section entitled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses since our inception and have financed our operations principally through equity and debt financing. We continue to incur significant research and development and other expenses related to our ongoing operations. For the years ended December 31, 2022 and 2021, we reported a net loss of $61.6 million and $51.8 million, respectively. As of December 31, 2022, we had an accumulated deficit of $217.7 million. We have devoted substantially all of our resources and efforts to research and development, and we expect that it will be several years, if ever, before we generate revenue from product sales. Even if we receive marketing approval for and commercialize one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to develop and market additional potential product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant losses for the foreseeable future, and we anticipate that our expenses will increase substantially if, and as, we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance our most advanced product candidate, GB0139, our other current fibrosis and oncology product candidates and any future product candidates through clinical development, and, if successful, later-stage clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance our preclinical development programs into clinical development; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience delays or interruptions to preclinical studies, clinical trials, our receipt of services from our third-party service providers on whom we rely, or our supply chain, including delays and economic uncertainty in various global markets caused by geopolitical instability and conflict and economic challenges caused by the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialize GB0139, our other current fibrosis and oncology product candidates and any future product candidates, if approved; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase the amount of research and development activities to discover and develop product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical development, quality control, scientific and management personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts, general and administrative functions and our operations as a public company; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">invest in or in-license other technologies or product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing biotechnology and biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our planned and ongoing clinical trials of GB0139, GB2064 and GB1211 and any future product candidates that we may develop, seek regulatory approvals for any of our product candidates and to launch and commercialize any products for which we receive regulatory approval. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had $66.1 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and in any event, we will require additional capital in order to complete clinical development of any of our current programs. Changes in economic conditions, including rising inflation and interest rates, lower consumer confidence, volatile equity capital markets and lower market prices for our securities, ongoing supply chain disruptions and geopolitical instability may adversely affect our business, our future capital requirements and our ability to finance our future cash needs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates, including GB0139, GB2064, GB1211 and any our other product candidates we develop in the future; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical development plans we establish for these product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of, and development requirements for, other product candidates that we develop; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timelines of our clinical trials and the overall costs to finish the clinical trials due to geopolitical instability and conflict and economic challenges caused by the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates, and the terms of such arrangements;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are able to enter into and maintain collaboration agreements, including the terms of and timing of payments under any such agreements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, or technologies;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing clinical, technological and market developments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of completion of commercial-scale outsourced manufacturing activities;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in economic conditions, including rising inflation and interest rates, lower consumer confidence and volatile equity capital markets; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of continuing to operate as a public company. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, if at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. Volatility in equity capital markets may adversely affect the market price of our equity securities, which may materially and adversely affect our ability to fund our business through public or private sales of equity securities. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility and economic uncertainty in various global markets resulting from geopolitical instability and conflict and economic challenges caused by the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The amount of our future losses is uncertain and our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract, hire and retain qualified personnel; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenditures that we will or may incur to develop additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for our product candidates should they receive approval, which may vary significantly; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general market conditions or extraordinary external events, such as increased economic uncertainty in the United States and abroad or the economic challenges caused by the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the changing and volatile U.S. and global economic environments; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company with a limited operating history. We were founded as Galecto Biotech AB, a Swedish operating company, in 2011 and incorporated in Delaware as Galecto, Inc. in October 2019, have no products approved for commercial sale and have not generated any revenue. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product candidates. Our approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. In addition, our product candidates, including GB0139, for the treatment of IPF, GB1211 for the treatment of various oncology indications and liver cirrhosis, and GB2064 for the treatment of myelofibrosis, are in the early stages of clinical development. These three programs will require substantial additional development and clinical research time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We have not yet demonstrated the ability to progress any product candidate through later-stage clinical trials leading to successful marketing authorization. We may be unable to obtain regulatory approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, achieve market access, and acceptance with insurers and health care providers, or conduct sales and marketing activities necessary for successful product commercialization. Investment in biotechnology and biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biotechnology and biopharmaceutical companies in rapidly evolving fields. Consequently, we have no meaningful history of operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of our product candidates, GB0139, GB1211, GB2064, as well as any other product candidates that we advance into the clinic. All of our product candidates may require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We are very early in our development efforts, and our product candidates, including GB0139, are in early clinical development. Because GB0139 is our most advanced product candidate, if GB0139 encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would be significantly harmed. We have completed a placebo-controlled Phase 2a multi-dose trial of GB0139 in 24 IPF patients. We are currently conducting a Phase 2b placebo-controlled clinical trial of GB0139 in IPF patients and we expect to release topline results in mid-2023. The primary endpoint of the trial is to assess annual rate of decline in forced vital capacity, or FVC, after one year of dosing. Reduction in decline of FVC is the primary endpoint that was accepted by the FDA for the approval of both of the currently approved treatments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for IPF. For future clinical trials of GB0139, including a Phase 3 clinical trial or trials, the design, duration, and scope of such clinical trials will be decided upon after further discussions with FDA or the EMA, as applicable. As a result, we are unable to predict with certainty the estimated timing or scope of future clinical trials of GB0139 we may conduct.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before we can generate any revenue from sales of our most advanced product candidate, GB0139, or any of our other fibrosis or oncology product candidates, we must undergo additional preclinical and clinical development, regulatory review and approval in one or more jurisdictions. In addition, if one or more of our product candidates are approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the financial resources to continue development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience setbacks that could delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or inconclusive results from our preclinical studies or clinical trials or positive results from the clinical trials of others for product candidates similar to ours leading to their approval, and evolving to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product-related side effects experienced by patients or subjects in our clinical trials or by individuals using drugs or therapeutics that we, DSMBs, institutional review board, or IRBs, the FDA, other regulators or others view as relevant to the development of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials, including our clinical endpoints; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in enrolling subjects in clinical trials, including due to geopolitical instability and conflict in Eastern Europe and the economic challenges caused by the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high drop-out rates of subjects from clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than anticipated clinical trial costs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to compete with other therapies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">poor efficacy of our product candidates during clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trial results taking longer than anticipated; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trials being subjected to fraud or data capture failure or other technical mishaps leading to the invalidation of our trials in whole or in part; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our trials not supporting application for conditional approval in the EU; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical development generally or with respect to our technology in particular; or </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">varying interpretations of data by the FDA and similar foreign regulatory agencies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach for FDA approval of a new drug is dispositive data from two well-controlled, Phase 3 clinical trials of the relevant drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, in our earlier clinical trials, we did not identify any imbalance in the serious adverse events across study groups, in contrast to what was reported to us in March 2021 by the DSMB in our ongoing Phase 2b trial of GB0139. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biotechnology and biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as therapeutic products, and there can be no assurance that any of our future clinical trials will ultimately be successful or support further clinical development of GB0139 or any of our other fibrosis or oncology product candidates. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical studies or clinical trials may show the product candidates to be less effective than expected (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to receive the necessary regulatory approvals; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make a product candidate uneconomical; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, several of our past, planned and ongoing clinical trials utilize an &#x201c;open-label&#x201d; trial design, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may also be subject to a &#x201c;patient bias&#x201d; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the standards that the FDA and comparable foreign regulatory authorities use when regulating our product candidates require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Although we are initially focusing our efforts on development of small molecule drug products, we may in the future pursue development of biological products, which could make us subject to additional regulatory requirements. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations. Examples of such regulations include future legislation or administrative action, or changes in FDA policy during the period of product development and FDA regulatory review. We cannot predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. The FDA may also require a panel of experts, referred to as an advisory committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the advisory committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting clinical trials in foreign countries, as well as in the United States. If we continue to seek to conduct clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval from foreign regulatory agencies may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successful completion of clinical trials is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or inconclusive results, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies or trials or abandon some or all of our product development programs, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of GB0139 or any of our other fibrosis or oncology product candidates in development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience delays in initiating or completing clinical trials. We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that could delay or prevent our ability to receive marketing approval for, or to commercialize, GB0139</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or any of our other fibrosis or oncology product candidates in development, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with respect to dosing levels administered in our planned and ongoing clinical trials, which may delay or prevent us from initiating or continuing our clinical trials with our originally intended trial design; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">due to the impact of economic challenges caused by the COVID-19 pandemic and uncertainty in various global markets caused by geopolitical instability, we may experience delays or interruptions to our manufacturing supply chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with third-party service providers on whom we rely; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional delays and interruptions to our clinical trials could extend the duration of the trials and increase the overall costs to finish the trials as our fixed costs are not substantially reduced during delays; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may elect to, or regulators, IRBs, DSMBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not have the financial resources available to complete our planned and ongoing clinical trials, or the cost of clinical trials of any product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs will increase if we experience additional delays in clinical testing or in obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. In addition, we may voluntarily redesign or otherwise modify our plans with respect to an ongoing or planned clinical trial, and changing the design of a clinical trial can be expensive and time consuming. If we do not achieve our product development goals in the time frames we announce and expect, the approval and commercialization of our product candidates may be delayed or prevented entirely. Significant clinical trial modifications or delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any changes or delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a placebo-controlled Phase 2a multi-dose trial of GB0139 in 24 IPF patients and, with the exception of a number of minor reported adverse events (fever, upper respiratory tract infection, abnormal taste in mouth, dry throat), GB0139 was observed to be generally well-tolerated in these patients with no serious drug-related adverse events. We are currently conducting a double-blind placebo-controlled Phase 2b trial of GB0139. In March 2021, the DSMB for this trial recommended that, based upon a safety analysis of the data, the company discontinue dosing and enrolling patients in the 10mg arm along with patients in the 3mg arm who are receiving combination treatment with the currently approved treatments of IPF, nintedanib and pirfenidone. The DSMB informed the company, based on unblinded safety and efficacy data, that there was an imbalance in the serious adverse events across the study groups, but not an imbalance between the groups in mortality.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are designed to inhibit galectin-3 or LOXL2, and we believe such inhibition can play a key role in regulating fibrosis and cancer. However, our products are still in the testing phase. If significant adverse events or other side effects are observed in any of our ongoing or future clinical trials, including of GB0139 for the treatment of IPF, GB02064 for the treatment of myelofibrosis or GB1211 for the treatment of liver cirrhosis and NSCLC, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to reduce the dosage amount of our intended product candidate or abandon the trials or our development efforts altogether. For instance, in the dose selection phase of our Phase 2a GALLANT-1 trial for the first-line treatment of NSCLC, we observed two serious adverse events of autoimmune-type skin rashes (showing perivascular lymphocytic infiltrates), which were determined by the principal investigator to be related to the administration of atezolizumab. The reactions were similar to those observed with atezolizumab and described in the label, however, in accordance with the protocol, we reduced the GB1211 dose to 100mg twice daily for the second patient cohort. Some potential therapeutics developed in the biotechnology and biopharmaceutical industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we continue to encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of completion of our clinical studies depends in part on the speed at which we can recruit patients to participate in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">testing our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From 2020 to 2022, the COVID-19 pandemic caused delays in certain of our studies, including (i) a delay in recruitment for our ongoing Phase 2b trial of GB0139 in IPF patients, which has resulted in certain trial protocol amendments and increased costs and (ii) a delay in the initiation and recruitment of our planned and ongoing clinical trials of GB1211 and GB2064. We may continue to experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints and the process for identifying patients; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness or availability of patients to participate in our trials (including due to fears of contracting COVID-19 and other highly infectious or contagious diseases) or known or perceived risks associated with our product candidates;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of competing commercially available therapies and other competing product candidates&#x2019; clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient informed consents; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we are initially developing GB0139 for the treatment of IPF, which is an orphan indication. In the United States, IPF is estimated to affect approximately 100,000 patients in the United States alone. As a result, we may encounter difficulties enrolling subjects in our clinical trials of GB0139 due, in part, to the small size of this patient population. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Certain of our clinical trials may also involve invasive procedures, such as bone marrow biopsies in our MYLOX-1 trial, which may lead some patients to drop out of trials to avoid these follow-up procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics and political and social conditions. For example, the COVID-19 pandemic and military action and civil and political unrest in regions where we have operations have affected certain of our clinical trial sites as they have not been allowed to enroll or recruit patients and other sites have not been able to receive patient visits, which resulted in the need to amend our protocol for our GALACTIC-1 trial in IPF. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in our trials or are subject to isolation or shelter-in-place restrictions, they may drop out of our trials, miss scheduled doses or follow-up visits, or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if our trial results are otherwise disputed due to the effects of the COVID-19 pandemic or actions taken to mitigate its spread and other restrictions resulting from political instability and conflict, the integrity of data from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could cause us to reprioritize our clinical trials and use of funds for such trials, prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The design or execution of our ongoing and future clinical trials may not support marketing approval or commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The design or execution of a clinical trial can determine whether its results will support marketing approval and successful commercialization, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. Additionally, in some instances, there can be significant variability in safety or efficacy results between different trials with the same product candidate due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we conduct will demonstrate consistent or adequate efficacy and safety to obtain marketing approval to market our product candidates, or commercial acceptance thereafter. For example, we have designed our product candidates to be selective, but they may not be selective enough to achieve the desired safety or efficacy to gain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for any of our product candidates. Our product candidates may not be approved even if they achieve their primary endpoints in future Phase 3 clinical trials or registrational trials. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. In addition, any of these regulatory authorities may change the requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical trial. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to develop certain of our product candidates and potentially other product candidates in combination with other therapies, which exposes us to additional risks.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to develop certain of our product candidates and likely other future product candidates in combination with one or more other approved or unapproved therapies to treat cancer or other diseases. For example, in the fourth quarter of 2021, we announced that we had entered into a clinical trial supply agreement with Roche for our planned Phase 2a trial of GB1211 in combination with atezolizumab, a PD-L1 checkpoint inhibitor, for the first-line treatment of NSCLC. For instance, in the dose selection phase of our Phase 2a GALLANT-1 trial for the first-line treatment of NSCLC, we observed two serious adverse events of autoimmune-type skin rashes (showing perivascular lymphocytic infiltrates), which were determined by the principal investigator to be related to the administration of atezolizumab. The reactions were similar to those observed with atezolizumab and described in the label. Both reactions responded to therapy with oral glucocorticosteroids and were clinically manageable. In accordance with the protocol, we reduced the GB1211 dose to 100mg twice daily for the second patient cohort. Recruitment in this cohort is currently ongoing. Interestingly, inflammatory and perivascular lymphocytic infiltrates were observed in both skin reactions, and could signal an exaggerated immune activation, something often observed with checkpoint inhibitor therapy and associated with improved clinical outcomes. Because a central aspect of the mechanism of action for GB1211 in combination with a checkpoint inhibitor is to remove galectin-3 from the lymphocytes and the tumor cells, and thereby increase lymphocyte based tumor killing, we believe this could be a positive signal of enhanced lymphocyte activation. Although we may be able to observe activity of our product candidates as a monotherapy, it may be difficult to observe activity of our product candidates when administered with approved agents or investigational products. For example, based on an interim review of unblinded safety and efficacy data by a DSMB, the addition of GB0139 to nintedanib or pirfenidone was determined to potentially give rise to side effects that were not anticipated based on preclinical studies or early clinical studies in which GB0139 was given as a monotherapy, and, as a result, we modified our ongoing Phase 2b clinical for GB0139 to remove combination therapy. Such discoveries may lead to discontinuations of certain dosing groups and the modification or termination of our clinical trials. We are unable to predict how the results of our combination therapy trial cohorts could affect the prospects for securing marketing approval of GB0139 or commercial acceptance thereafter.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may choose to evaluate our current product candidates or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our current product candidates or any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities do not approve these other products or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the products we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have obtained orphan drug designation for GB0139; however, we may be unable to maintain this designation or obtain orphan drug designation for our other fibrosis or oncology product candidates, and we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business strategy, we sought and have received orphan drug designation from the FDA and the EC for treatment of IPF for GB0139; however, we may not be able to maintain this status. We may also seek orphan drug designation for future product candidates, and we may be unsuccessful in obtaining this designation. Regulatory authorities in some jurisdictions, including the United States and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, or the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, in Europe, the EC grants orphan drug designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan drug designation application. Orphan drug designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug or biologic no longer meets the criteria for orphan drug designation or if the drug or biologic is sufficiently profitable such that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even though we have obtained orphan drug designation for GB0139, and even if we are able to obtain orphan drug exclusivity for a future product candidate, that exclusivity may not effectively protect the relevant product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label for the orphan disease. Even after an orphan drug is approved, the FDA may subsequently approve another product for the same condition if the FDA concludes that the latter product is not the same product or is clinically superior to the protected orphan drug because it is shown to be safer or more effective or makes a major contribution to patient care. The FDA may reevaluate its regulations and policies under the Orphan Drug Act. We do not know if, when, or how the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the orphan indication for which it was designated. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we have obtained orphan drug designation for GB0139, we may not be able to maintain such designations; and while we may seek orphan drug designation for applicable indications for any future product candidates, we may never receive such designations. Even though we have received such designations for GB0139, and may receive further such designations in the future, there is no guarantee that we will enjoy the benefits of those designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Breakthrough Therapy designation and Fast Track designation by the FDA, neither of which has been obtained, even if granted for any of our current or future product candidates, may not lead to a faster development or regulatory review process, and such designations do not increase the likelihood that any of our product candidates will receive marketing approval in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to evaluate regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our product candidates, although we cannot be certain that our product candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant designations. Potential expedited development pathways that we could pursue include breakthrough therapy and Fast Track designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Breakthrough Therapy designation is intended to expedite the development and review of product candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a product candidate as a breakthrough therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast Track designation is designed for product candidates intended for the treatment of a serious or life-threatening disease or condition, where nonclinical or clinical data demonstrate the potential to address an unmet medical need for this disease or condition. The designation of a product candidate as Fast Track provides potential benefits that include more opportunities for frequent interaction and communication with FDA during product development and eligibility for rolling review and priority review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we believe a particular product candidate is eligible for Breakthrough Therapy or Fast Track designation, we cannot assure you that the FDA would decide to grant such a designation in response to our written requests. Breakthrough Therapy designation and Fast Track designation do not change the standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the Breakthrough Therapy designation or Fast Track designation. Thus, even if we do receive Breakthrough Therapy or Fast Track designation for any of our product candidates, we may not experience a faster development process, review or marketing approval compared to conventional FDA procedures. The FDA may withdraw Breakthrough Therapy or Fast Track designation if it believes that the product no longer meets the qualifying criteria. Our business may be harmed if we are unable to avail ourselves of these or any other expedited development and regulatory pathways.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently conduct and may in the future conduct clinical trials for our product candidates outside the United States. The FDA, EMA or comparable foreign regulatory authorities may not accept data from such trials, and doing so subjects us to the risk that clinical development of our product candidates may be adversely affected by changes in local and regional political and economic conditions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our ongoing clinical trials are enrolling or will seek to enroll some or all patients outside of the United States. The acceptance of trial data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any comparable regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, we are seeking to enroll and have enrolled patients in our clinical trials in Ukraine, Russia and other Eastern European countries. Any escalation of political tensions, economic instability, military activity or civil hostilities in this region could disrupt or delay such trials, or adversely affect the timeliness of such trials. In connection with this geopolitical instability , the United States and other countries have imposed sanctions against Russia. Our ability to conduct these trials is dependent upon whether or not our involvement in such projects is restricted under U.S. or EU sanctions laws and the extent to which any of our current or prospective operations may become subject to those laws. Those laws may change from time to time, and any expansion of sanctions against Russia could hinder our ability to conduct such trials, which would result in the need for alternative trial sites, which would be costly and time-consuming and delay the clinical development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, various aspects of the development program, such as manufacturing methods and the product&#x2019;s formulation, may be altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. These changes carry the risk that they will not achieve their intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of our current clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there are risks associated with process development and large-scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that our third-party manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. Additionally, if we advance a biological candidate into IND-enabling studies, the manufacturing processes for biological products are more complex and expensive than with small molecule products and additional manufacturing suppliers may be needed to manufacture clinical supplies for these programs. If our contract manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to design such product candidates with the pharmacological properties that we desire or attractive pharmacokinetics; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to design and develop a suitable manufacturing process; or </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited financial and human resources and intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. In addition, we may seek to accelerate our development timelines, including by modifying the designs of ongoing or planned clinical trials or initiating certain clinical trials of our product candidates before earlier-stage studies have been completed. This approach may cause us to commit significant resources to prepare for and conduct later-stage trials for one or more product candidates that subsequently fail earlier-stage clinical testing. Therefore, our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or expend resources on product candidates that are not viable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of testing GB0139 and any of our other fibrosis or oncology product candidates in clinical trials and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense of these claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to bring a product candidate to the market; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, injunctions or criminal penalties; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate, if approved; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decline in our share price. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We will need to obtain additional insurance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for clinical trials as GB0139, and any of our other fibrosis or oncology product candidates continue clinical development and as additional product candidates enter the clinic. However, we may be unable to obtain, or may obtain on unfavorable terms, clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major biotechnology and biopharmaceutical companies, specialty biotechnology and biopharmaceutical companies, and other biotechnology and biopharmaceutical companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of large biotechnology and biopharmaceutical companies that are currently pursuing the development of products for the treatment of the biological processes that drive fibrosis and certain cancers. Companies that we are aware of that are targeting the treatment of various fibrosis indications include large companies with significant financial resources such as Pharmaxis Ltd, Biogen, Inc., AbbVie Inc., Gilead Sciences, Inc., Pliant Therapeutics, Inc., Galectin Therapeutics, Inc., FibroGen, Inc., Liminal BioSciences, Inc., Galapagos NV, Bristol Myers Squibb Co., Madrigal Pharmaceuticals, Inc., Inventiva, Akero Therapeutics, Inc., Boehringer Ingelheim, Roche/Genentech and Novartis AG. However, we know of no other companies currently in clinical development with an inhaled or orally available small molecule inhibitor of galectin-3 or an orally available small molecule inhibitor of LOXL2 for myelofibrosis. For additional information regarding our competition, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business&#x2014;Competition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, more convenient, or less expensive than any products that we may develop. Furthermore, products currently approved for other indications could be discovered to be effective treatments of the biological processes that drive fibrosis as well, which could give such products significant regulatory and market timing advantages over GB0139 or other fibrosis product candidates that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors. The availability of competitive products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if GB0139 or any other fibrosis or oncology product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, such as Medicare and Medicaid programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages of our current or future product candidates compared to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling approved for our current or future product candidates by the FDA or other applicable regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which our current or future product candidates are approved; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">availability of alternative treatments already approved or commercially launched in the future; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#x2019; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our products are safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and in other countries, patients who are prescribed treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory marketing approval will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. See the section entitled, &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2013; Government Regulation &#x2013; Coverage and Reimbursement.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities and other third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to commercialize any products successfully will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government health care programs and private health insurers. Moreover, a payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The MMA established the Medicare Part D program to provide a voluntary prescription drug and biologic benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs and biologics. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs and biologics, and each drug plan can develop its own formulary that identifies which drugs and biologics it will cover, and at what tier or level. However, Part D prescription drug formularies must include products within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs and biologics in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs and biologics may increase demand for products for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to these current laws and state and federal healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell any products for which we obtain regulatory approval, we may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop and for which we receive regulatory approval ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of biotechnology and biopharmaceutical products. Arrangements with third-party payors and customers can expose biotechnology and biopharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute, or AKS, and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute biotechnology and biopharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See the section entitled, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Business &#x2014; Government Regulation &#x2014; Other Healthcare Laws</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The distribution of biotechnology and biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biotechnology and biopharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#x2019;s attention from other aspects of its business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause a biotechnology and biopharmaceutical manufacturer to incur significant legal expenses and divert management&#x2019;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing post-marketing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing post-marketing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with current good manufacturing practice, or cGMP, for any drug products we distribute and with good clinical practice, or GCP, requirements for any clinical trials that we conduct post-approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. For example, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, sponsors of approved drugs and biologics must provide 6 months&#x2019; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#x2019;s ability to be marketed.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or withdrawal of approvals; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees or injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is not inconsistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA and of other regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. See the section entitled, &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Government Regulation &#x2014; Current and Future Healthcare Reform Legislation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC, and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to review and process our regulatory submissions timely, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, several companies announced receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the recent U.K. referendum on its membership in the EU resulted in a majority of U.K. voters voting to exit the European Union, often referred to as Brexit. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the U.K. determines which EU laws to replicate or replace. If the U.K. were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs. As a result, Brexit could impair our ability to transact business in the European Union and the U.K. Market acceptance and sales of our product candidates will also depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Much like the AKS prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to reward improper performance generally is governed by the national anti-bribery laws of the EU Member States, and in respect of the U.K. (which is no longer a member of the EU), the Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the U.K. despite its departure from the EU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#x2019;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in most foreign countries, including the EEA, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biotechnology and biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States, and generally, prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#x2019; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. California passed the California Data Privacy Protection Act of 2018, or the CCPA, which went into effect in January 2020, and was recently amended by the California Privacy Rights Act, which became effective on January 1, 2023, provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. The CCPA may lead to similar laws in other U.S. states or at a national level, which could increase our potential liability and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a California ballot initiative, the California Privacy Rights Act, or the CPRA, was passed in November 2020 and became effective January 1, 2023. The CPRA imposes additional obligations on companies covered by the legislation and significantly modifies the CCPA, including by expanding consumers&#x2019; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain other state laws impose similar privacy obligations and we also expect that more states may enact legislation similar to the CCPA, which provides consumers with new privacy rights and increases the privacy and security obligations of entities handling certain personal information of such consumers. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, on March 2, 2021, Virginia enacted the Consumer Data Protection Act, or the CDPA, which became effective on January 1, 2023. The CDPA regulates how businesses (which the CDPA refers to as &#x201c;controllers&#x201d;) collect and share personal information. While the CDPA incorporates many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of controllers. The law impacts how controllers collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, on July 8, 2021, Colorado&#x2019;s governor signed the Colorado Privacy Act, or the CPA, into law. The CPA will become effective on July 1, 2023. The CPA is rather similar to Virginia&#x2019;s CPDA but also contains additional requirements. The new measure applies to companies conducting business in Colorado or who produce or deliver commercial products or services intentionally targeted to its residents of the state that either: (1) control or process the personal data of at least 100,000 consumers during a calendar year; or (2) derive revenue or receive a discount on the price of goods or services from the sale of personal data and process or control the personal data of at least 25,000 consumers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With the CPA, Colorado became the third state to enact a comprehensive privacy law but it is quite possible that other states will follow suit. The existence of comprehensive privacy laws in different states in the country will make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to our operations in the United States, which may be subject to healthcare and other laws relating to the privacy and security of health information and other personal information, we have operations in Europe and are subject to European data privacy laws, regulations and guidelines. The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EEA, including personal health data, is subject to the EU GDPR and similar processing of personal data regarding individuals in the U.K. is subject to the U.K. GDPR and the U.K. Data Protection Act 2018.The GDPR is wide-ranging and imposes a broad range of strict requirements on companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the EEA, including to the United States, providing details to those individuals regarding the processing of their personal health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#x2019; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to &#x20ac;20 million (&#163;17.5 million) or up to 4% of our total worldwide annual turnover, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, national laws of member states of the EU are in the process of being adapted to the requirements under the GDPR, thereby implementing national laws which may partially deviate from the GDPR and impose different obligations from country to country, so that we do not expect to operate in a uniform legal landscape in the EEA. Also, as it relates to processing and transfer of genetic data, the GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty. In addition, further to the U.K.&#x2019;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the U.K. at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the U.K.&#x2019;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain U.K. specific amendments) into U.K. law, referred to as the U.K. GDPR. The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#x2019;s data protection regime, which is independent from but aligned to the EU&#x2019;s data protection regime. The U.K. Government has announced plans to reform its data protection legal framework in the Data Reform Bill, but those have been put on hold. Non-compliance with the U.K. GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the U.K. is regarded as a third country under the EU&#x2019;s GDPR, the EC has now issued a decision recognizing the U.K. as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the U.K. remain unrestricted. Like the EU GDPR, the U.K. GDPR restricts personal data transfers outside the U.K. to countries not regarded by the U.K. as providing adequate protection. To enable the transfer of personal data outside of the EEA or the U.K., adequate safeguards must be implemented in compliance with European and U.K. data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EEA (or otherwise subject to the EU GDPR) to controllers or processors established outside the EEA (and not subject to the EU GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The U.K. is not subject to the EC&#x2019;s new standard contractual clauses but has published its own version of standard clauses, referred to as &#x201c;International Data Transfer Agreement&#x201d; which entered into force on March 21, 2022 and enables transfers originating from the U.K. Transfers made pursuant to these new mechanisms need to be assessed on a case-by-case basis to ensure the law in the recipient country provides &#x201c;essentially equivalent&#x201d; protections to safeguard the transferred personal data as the EEA, and businesses are required to adopt supplementary measures if such standard is not met. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and U.K. GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the GDPR, the European Union is also in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European member state, without the need for further enactment. Originally planned to be adopted and implemented at the same time as the GDPR, the ePrivacy Regulation is still going through the European legislative process. Draft regulations were rejected by the Permanent Representatives Committee of the Council of EU on November 22, 2019; it is not clear when new regulations will be adopted. Preparing for and complying with the GDPR and the ePrivacy Regulation (if and when it becomes effective) has required and will continue to require us to incur substantial operational costs and may require us to change our business practices. Despite our efforts to bring practices into compliance with the GDPR and before the effective date of the ePrivacy Regulation, we may not be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful either due to internal or external factors such as resource allocation limitations. Non-compliance could result in proceedings against us by governmental entities, customers, data subjects, consumer associations or others.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are conducting clinical trials in the EEA, and the GDPR increases our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we are required to have in place additional mechanisms and safeguards to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is a rigorous and time-intensive process that increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. We expect that we will continue to face uncertainty as to whether our efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or biotechnology and biopharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national vendors or biotechnology and biopharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such vendors or biotechnology and biopharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the forgoing could materially harm our business, prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal, political and economic uncertainty surrounding the exit of the U.K. from the EU may be a source of instability in international markets, create significant currency fluctuations, adversely affect our operations in the U.K. and pose additional risks to our business, revenue, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.K. formally left the EU on January 31, 2020, and the EU and the U.K. have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA provides details on how some aspects of the U.K. and EU&#x2019;s relationship will operate going forward however there are still many uncertainties and how the TCA will take effect in practice is still largely unknown. This lack of clarity on future U.K. laws and regulations and their interaction with the EU laws and regulations may negatively impact foreign direct investment in the U.K., increase costs, depress economic activity and restrict access to capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The uncertainty concerning the U.K.&#x2019;s legal, political and economic relationship with the EU after Brexit may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These developments may have a significant adverse effect on global economic conditions and the stability of global financial markets and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be subject to increased market volatility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if other EU Member States pursue withdrawal, barrier-free access among the EEA overall could be diminished or eliminated. The long-term effects of Brexit will depend on how the terms of the TCA take effect in practice and any further agreements (or lack thereof) between the U.K. and the EU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the U.K.&#x2019;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our current and future operations (including business activities conducted by third parties and contract manufacturers on our behalf) and clinical activities in the U.K. In addition to the foregoing, our U.K. operations support our current and future operations and clinical activities in the EU and EEA, and these operations and clinical activities could be disrupted by Brexit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also face new regulatory costs and challenges that could have an adverse effect on our operations. The U.K. will lose the benefits of global trade agreements negotiated by the EU on behalf of its members, which may result in increased trade barriers that could make our doing business in the EU and the EEA more difficult. Since the regulatory framework in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime with respect to the approval of our product candidates in the U.K. now that the U.K. legislation can diverge from EU legislation. For instance, Great Britain will now no longer be covered by the centralized procedures for obtaining</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EEA-wide marketing and manufacturing authorizations from the EMA (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland) and a separate process for authorization of drug products will be required in Great Britain, resulting in an authorization covering the U.K. or Great Britain only. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or EU for our product candidates, which could significantly and materially harm our business. Even prior to any change to the U.K.&#x2019;s relationship with the EU, the announcement of Brexit has created economic uncertainty surrounding the terms of Brexit, and its consequences could adversely impact customer confidence resulting in customers reducing their spending budgets on our product candidates, if approved, which could adversely affect our business, financial condition, results of operations and could adversely affect the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional laws and regulations governing international operations, and the complexity associated with maintaining geographically diverse operations, could negatively impact or restrict our operations and ability to grow.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have offices and operations in six cities and in five countries. If we are unable to manage the risks of our global operations, including the potential for fluctuations in foreign exchange and inflation rates, international hostilities, the need for our executives to travel internationally, natural disasters, security breaches, failure to maintain compliance with internal control requirements and multiple legal and regulatory systems, our results of operations and ability to grow could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business entity from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biotechnology and biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and healthcare providers in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. As we expand our operations throughout the world, we will be required to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC may also suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals, and we could be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The patenting process is subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The strength of patents in the biotechnology and biopharmaceutical fields involves complex legal and scientific questions and can be uncertain. The patent applications that we own, or in-license, may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around the claims in our patents. If the breadth or strength of protection provided by the patent applications, we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for U.S. applications in which at least one claim is not entitled to a priority date before March 16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#x2019;s disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to disclaim part or all of the term of certain patents. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#x2019;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products that have the same effect as our products on an independent basis and that do not infringe our patents or other intellectual property rights or will design around the claims of patents that may issue that cover our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the America Invents Act, after March 2013, the United States moved from a &#x201c;first-to-invent&#x201d; to a &#x201c;first-inventor-to-file&#x201d; system. Under a &#x201c;first-inventor-to-file&#x201d; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear, as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#x201c;first-inventor-to-file&#x201d; provisions. In addition, the courts have yet to address many of these provisions and the applicability of the America Invents Act and new regulations on specific patents discussed herein, for which issues have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not covered by the claims of our patents or those of our licensors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications invented or developed using U.S. government funding, leading to the loss of patent rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#x2019; patents, as the case may be, or parts of our or their patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the laws of foreign countries may not protect our or our licensors&#x2019;, as the case may be, proprietary rights to the same extent as the laws of the United States; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#x2019; patents or other exclusive rights; or </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future pertaining to the in-license of rights to additional product candidates. Such agreements may impose various diligence, milestone payment, royalty, insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licenses or agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the agreements under which we may license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#x2019; infringement proceeding, or defense activities may be less vigorous than had we conducted them ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted, and our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, courts may be unwilling to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We also plan to adopt policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may be costly and time consuming to defend, and could prevent or delay our product discovery, development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#x2019;s attention from our core business; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#x2019;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates and any license that is available may be non-exclusive, which could result in our competitors gaining access to the same intellectual property; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the need to redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of manufacture or use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Others may claim an ownership interest in our intellectual property, which could expose us to litigation and have a significant adverse effect on our prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A third party may claim an ownership interest in one or more of our or our licensors&#x2019; patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek monetary damages and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product, in which case we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure you that any such license will be available on commercially acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product candidate or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing biotechnology and biopharmaceutical compounds. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established, or that have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or challenging the patent rights of others, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors or other third parties such as chemical and reagent suppliers may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose to challenge the patentability of claims in a third party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ex-parte</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> re-examination,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#x2019;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent offices. The costs of these opposition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent offices then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent or first to file a patent application covering the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#x2019;s time and expend other resources, even if we are successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on our owned and in-licensed issued patents and patent applications are or will be due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could have a similar material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent law in the United States and in other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March 16, 2013, under the America Invents Act, enacted in September 2011, the United States transitioned to a &#x201c;first-inventor-to-file&#x201d; system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#x2019;s patents or patent applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biotechnology and biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have limited intellectual property rights outside of the United States and Europe and may not be able to protect and enforce our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited intellectual property rights outside the United States and Europe. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States and Europe can be less extensive than those in the United States and Europe. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States or laws in Europe. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or Europe, or from selling or importing products made using our inventions in and into the United States, Europe or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest claimed U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension and data exclusivity or similar non-U.S. legislation extending the term of protection covering any product candidates we may develop, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents, or otherwise failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely and expect to continue to rely on third parties to conduct certain aspects of our ongoing and future preclinical studies and clinical trials, including investigator-sponsored clinical trials of our product candidates. If these third parties do not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely and expect to continue to rely on third parties to conduct certain aspects of our ongoing and future preclinical studies and clinical trials, under agreements with universities, medical institutions, clinical investigators, CROs, strategic collaborators and others. We expect to have to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will rely especially heavily on third parties over the course of our clinical trials, and, as a result, will have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also rely on academic and private non-academic institutions and clinical investigators to conduct and sponsor clinical trials relating to our product candidates, such as the planned Phase 2 clinical trial of GB1211 in metastatic melanoma and HNSCC patients that will be sponsored by Providence Cancer Institute. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or foreign regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including due to elements of the design or execution of the trials or safety concerns or other trial results. Such arrangements will likely provide us certain information rights, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials conducted by third parties comply with the GCP requirements.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any third parties conducting aspects of our preclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons or if, due to federal or state orders, they are unable to meet their contractual and regulatory obligations, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with these third-party CROs or other third parties terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties for materials, including tissue samples, required for our research and development activities, and if we are unable to reach agreements with these third parties, our research and development activities would be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties, primarily hospitals, health clinics and academic institutions, for the provision of tissue samples and other materials required in our research and development activities. Obtaining these materials requires various approvals as well as reaching a commercial agreement on acceptable terms with the hospital or other provider of the materials. While we currently have agreements in place with the institutions from which we receive our tissue samples, we do not have any exclusive arrangements with such sources, and there is no guarantee that we will be able to maintain or renew such agreements on commercially reasonable terms, if at all. If we were unable to maintain or renew such agreements, we would be forced to seek new arrangements with new hospitals, clinics or health institutions. If so, we may not be able to reach agreements with alternative partners or do so on terms acceptable to us. If we are unable to enter into such agreements, our research and development activities will be delayed and our ability to implement a key part of our development strategy will be compromised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates for preclinical development, clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party contract manufacturers to manufacture our product candidates for preclinical studies and clinical trials. We do not own manufacturing facilities for producing any clinical trial product supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited or interrupted, or that they will be of satisfactory quality or continue to be available at acceptable prices. For example, the extent to which instability in geographies where we have operations or the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on whether broad-based sanctions continue for long term or escalate or if the economic challenges caused by the COVID-19 continue to impact supply chain, among many other factors. Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to a back-up or alternative supplier, or we may not be able to transfer such skills or technology at all. Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturer or manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for GB0139 or any other fibrosis or oncology product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of the cooperation of an existing or future collaborator; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on a sole supplier or, in some cases, a limited number of suppliers for the manufacture of components of GB0139 and our other current fibrosis and oncology product candidates. If these suppliers are unable to supply necessary materials to us in the quantities we require, or at all, or otherwise default on their supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms, in a timely manner, or at all. We also do not have long-term supply agreements with any of our suppliers. Our current contracts with certain suppliers may be canceled or not extended by such suppliers and, therefore, do not afford us with protection against a reduction or interruption in supplies. Moreover, in the event any of these suppliers breach their contracts with us, our legal remedies associated with such a breach may be insufficient to compensate us for any damages we may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we contract with fill and finishing providers with the appropriate expertise, facilities and scale to meet our needs. Failure to maintain cGMP can result in a contractor receiving FDA sanctions, which can impact our ability to operate or lead to delays in any clinical development programs. We believe that our current fill and finish contractor is operating in accordance with cGMP, but we can give no assurance that FDA or other regulatory agencies will not conclude that a lack of compliance exists. In addition, any delay in contracting for fill and finish services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and launches, which could negatively affect our business. In the future, if we were to advance a biological product candidate into IND-enabling studies, we would need to identify and contract with suppliers who are able to produce biological product candidates and adhere to additional cGMP compliance obligations required for biologicals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may in the future seek to enter into collaborations with third parties for the development and commercialization of our product candidates, and our future collaborations will be important to our business. If we are unable to enter into collaborations, or if these collaborations are not successful, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A part of our strategy is to consider partnerships in indications and geographies where we believe partners can add significant commercial and/or development capabilities. Further, we have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we have entered and may in the future enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any future collaborations we enter into may pose a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not provide us with timely and accurate information regarding development progress and activity under any future license agreement, which could adversely impact our ability to report progress to our investors and otherwise plan development of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any future collaborations we enter into do not result in the successful discovery, development and commercialization of product candidates, if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in seeking appropriate collaborators for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully establish a collaboration for one or more of our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large biotechnology and biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Managing Our Business and Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth, which could adversely affect our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 45 full-time employees. As our clinical development and commercialization plans and strategies develop, and as we transition into operating as a public company, we will need to expand our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing and legal capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our development and commercialization efforts effectively, including the clinical and FDA review process for GB0139 and any other fibrosis or oncology product candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery activities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize GB0139 or any other fibrosis or oncology product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, we acquired PharmAkea Inc., or PharmAkea, and may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially harm our business, including the diversion of management&#x2019;s attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have previously identified a material weakness in our internal control over financial reporting, which has since been remediated. If we experience future material weaknesses or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our preparation and the audits of our financial statements as of and for the years ended December 31, 2020 and 2019, we and our independent registered public accounting firm identified a material weakness as defined under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and by the Public Company Accounting Oversight Board (United States) in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our previous material weakness related to our financial statement closing process, primarily related to the lack of sufficient skilled personnel with U.S. generally accepted accounting principles, or U.S. GAAP, and Securities and Exchange Commission, or SEC, reporting knowledge and expertise for purposes of timely and reliable financial reporting and our dependence on third-party service providers for the preparation and closing of our financial records. Specifically, the material weakness identified related to the lack of appropriate internal controls over the work performed by the third-party service providers and that, as a result thereof, management failed to timely identify material misstatements in accounting for our debt and equity instruments, research and development, and taxation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have remediated the material weakness and have taken steps to strengthen our internal control over financial reporting, such as the hiring of Jonathan Freve as Chief Financial Officer in the second quarter of 2020 and a Corporate Controller in the fourth quarter of 2020. Additionally, we have designed and implemented a cross functional risk assessment process to identify and assess changes in the business that could significantly impact internal control over financial reporting. If, in the future, we identify further material weaknesses in our internal controls over financial reporting, we may not detect errors on a timely basis, and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company, we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Select Market or other adverse consequences that would materially harm our business. In addition, we could become subject to investigations by Nasdaq, the SEC, and other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and our financial condition, or divert financial and management resources from our core business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An independent registered public accounting firm has not performed an evaluation of our internal control over financial reporting in accordance with the provision of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, because no such evaluation has been required. Had an independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, material weaknesses may have been identified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Hans T. Schambye, M.D., Ph.D., our Chief Executive Officer and President, Anders Pedersen, our Chief Operating Officer, Bertil Lindmark, M.D., Ph.D., our Chief Medical Officer, Jonathan Freve, our Chief Financial Officer, and Stephanie Oestreich, our Chief Business Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conduct our operations globally from several locations including Denmark, the United States, Sweden, the U.K. and Canada. Competition for skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To induce valuable employees to remain with us, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">teams may terminate their employment with us on short notice. Our key employees are at-will employees, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies, but we may enter into such policies, on the lives of these individuals or the lives of certain of our employees. There is no guarantee that any &#x201c;key person&#x201d; insurance policy we may enter into would adequately compensate us for the loss of any key employee. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior scientific and medical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems and those of any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, phishing or other unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, financial loss, a loss of our trade secrets or other proprietary information and damage to our reputation and otherwise negatively impact us. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial of service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#x2019; personal data could result in significant liability under state (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, state breach notification laws), federal (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, HIPAA, as amended by HITECH), and international (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the GDPR) law and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyberattacks, and any such attacks could result in the losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the CCPA, which went into effect on January 1, 2020, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. By way of example regarding foreign laws and regulations with respect to data privacy and security, the GDPR imposes strict requirements for processing the personal data of individuals in the EEA and U.K. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million (&#163;17.5 million) or 4% of the annual global revenues of the noncompliant company, whichever is greater.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from any such serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event were to occur that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, the most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including due to the economic challenges caused by the COVID-19 pandemic, could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers, some of which are located outside of the United States, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Social media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our product candidates, if any. Social media practices in the biotechnology and biopharmaceutical industry continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#x2019;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding our company, management, product candidates or products. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K or that we may otherwise provide may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market opportunity estimates and growth forecasts included in this Annual Report on Form 10-K or that we may otherwise provide are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accurate. The estimates and forecasts included in this Annual Report on Form 10-K relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts included in this Annual Report on Form 10-K, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners, collaborators and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws will also increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. We have a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We use and generate materials that may expose us to material liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research programs involve the use of hazardous materials and chemicals, which are currently only handled by third parties. We are subject to foreign, federal, state and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste products such as human tissue samples that may have the potential to transmit diseases. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot completely eliminate the risk of contamination or injury from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured party may seek to hold us liable for any damages that result. Any liability could exceed the limits or fall outside the coverage of our workers&#x2019; compensation, property and business interruption insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering environmental claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We or our CROs generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers&#x2019; compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA and comparable rules, regulations, and or obligations that may exist in many foreign jurisdictions. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and/or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. tax law could adversely affect our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 coronavirus outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could expose us to greater than anticipated tax liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax laws applicable to our business, including the laws of Denmark, Sweden, the United States, and other jurisdictions, are subject to interpretation and certain jurisdictions may aggressively interpret their laws in an effort to raise additional tax revenue. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for valuing intercompany arrangements or our revenue recognition policies, which could increase our worldwide effective tax rate and harm our financial position and results of operations. It is possible that tax authorities may disagree with certain positions we have taken and any adverse outcome of such a review or audit could have a negative effect on our financial position and results of operations. Further, the determination of our worldwide provision for income taxes and other tax liabilities requires significant judgment by management, and there are transactions where the ultimate tax determination is uncertain. Although we believe that our estimates are reasonable, the ultimate tax outcome may differ from the amounts recorded in our consolidated financial statements and may materially affect our financial results in the period or periods for which such determination is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our corporate structure and intercompany arrangements are subject to the tax laws of various jurisdictions, and we could be obligated to pay additional taxes, which would harm our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current corporate structure, we are subject to taxation in several jurisdictions around the world with increasingly complex tax laws, the application of which can be uncertain. The amount of taxes we pay in these jurisdictions could increase substantially as a result of changes in the applicable tax principles, including increased tax rates, new tax laws or revised interpretations of existing tax laws and precedents. The authorities in these jurisdictions could review our tax returns or require us to file tax returns in jurisdictions in which we are not currently filing, and could impose additional tax, interest, and penalties. These authorities could also claim that various withholding requirements apply to us or our subsidiaries and assert that benefits of tax treaties are not available to us or our subsidiaries. The relevant taxing authorities may determine that the manner in which we operate our business does not achieve the intended tax consequences. If such a disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties. Such authorities could claim that various withholding requirements apply to us or our subsidiaries or assert that benefits of tax treaties are not available to us or our subsidiaries. Any increase in the amount of taxes we pay or that are imposed on us could increase our worldwide effective tax rate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several countries in which we are located allow for tax incentives to attract and retain business. We have obtained incentives where available and practicable. Our taxes could increase if certain tax incentives are retracted, which could occur if we are unable to satisfy the conditions on which such incentives are based, if they are not renewed upon expiration, or if tax rates applicable to us in such jurisdictions otherwise increase. It is not anticipated that any material tax incentives will expire within the next year. However, due to the possibility of changes in existing tax law and our operations, we are unable to predict how any expirations will impact us in the future. In addition, acquisitions may cause our effective tax rate to increase, depending on the jurisdictions in which the acquired operations are located.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our subsidiaries may provide financing, products and services to, and may undertake certain significant transactions with, us or other of our subsidiaries in different jurisdictions. Several jurisdictions in which we operate have tax laws with detailed transfer pricing rules that require all transactions with non-resident related parties be priced using arm&#x2019;s length pricing principles, and that contemporaneous documentation must exist to support such pricing. There is a risk that the taxing authorities may not deem our transfer pricing documentation acceptable. In addition, the Organization for Economic Cooperation and Development continues to issue guidelines and proposals related to Base Erosion and Profit Shifting which may result in legislative changes that could reshape international tax rules in numerous countries and negatively impact our effective tax rate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have net operating loss carryforwards and tax credit carryforwards for U.S. federal and state income tax purposes which begin to expire in future years. Additionally, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50 percentage points within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Public offerings, private placements and other transactions that have occurred since our inception, may trigger such an ownership change pursuant to Section 382. Any such limitation, whether as the result of a prior public offering, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. The reduction of the corporate tax rate under the Tax Cuts and Jobs Act of 2017, or the Tax Cuts and Jobs Act, may cause a reduction in the economic benefit of our net operating loss carryforwards and other deferred tax assets available to us. Our ability to utilize those net operating loss carryforwards could be limited by an &#x201c;ownership change&#x201d; as described above, which could result in increased tax liability to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K, these factors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment or results of our current fibrosis- and oncology- focused Phase 2 clinical trials of GB0139, GB1211 and GB2064; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in identifying and advancing a clinical candidate for our other development programs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in our regulatory filings for GB0139 or our other fibrosis or oncology product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including, without limitation, the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse results or delays in future clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of GB0139 or any other fibrosis or oncology product candidate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in laws or regulations applicable to GB0139 or any other fibrosis or oncology product candidate, including, but not limited to, clinical trial requirements for approvals; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse developments concerning our manufacturers; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to establish collaborations, if needed; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to commercialize our product candidates, if approved; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns related to the use of GB0139 or any other fibrosis or oncology product candidate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in quarterly operating results; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our cash position; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of the healthcare payment systems; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">overall performance of the equity markets; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us or our stockholders in the future; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting practices; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general political and economic conditions; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general, and the market for biotechnology and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our common stock is delisted from The Nasdaq Global Select Market, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is currently listed on The Nasdaq Global Select Market and closed at $2.20 on March 1, 2023. The Nasdaq Stock Market LLC, or Nasdaq, has minimum requirements that a company must meet in order to remain listed on Nasdaq markets, including that we maintain a minimum closing bid price of $1.00 per share. If we fail to maintain such minimum requirements and a final determination is made by Nasdaq that our common stock must be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease. Our failure to be listed on Nasdaq or another national securities exchange would have a material adverse effect on the value of your investment in us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, our executive officers, directors and their affiliates beneficially held, in the aggregate, approximately 21.9% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an EGC as defined in the JOBS Act, enacted in April 2012. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations regarding executive compensation and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may remain an EGC until December 31, 2025, although circumstances could cause us to lose that status earlier. We will remain an EGC until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, or IPO, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting obligations by providing only two years of audited financial statements. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company,&#x201d; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) if the market value of our shares held by non-affiliates is more than $250 million but less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will continue to incur significant costs as a result of operating as a public company, and our management may be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we incur, and we will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201c;say on pay&#x201d; and proxy access. Recent legislation permits EGCs to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. The costs associated with operating as a public company may decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products, if approved, or services. Additionally, stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis, and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an EGC for up to five years. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#x2019;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management has broad discretion in the application of our existing cash, cash equivalents and marketable securities. Because of the number and variability of factors that will determine our use of our existing cash, cash equivalents and marketable securities, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash, cash equivalents and marketable securities in ways that ultimately increase the value of our common stock. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest our cash, cash equivalents and marketable securities in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our cash, cash equivalents and marketable securities in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or DGCL, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws will designate certain courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to litigate disputes with us in a different judicial forum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v) any action asserting a claim governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware forum provision. The Delaware forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Unless we consent in writing to the selection of an alternate forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the federal forum provision, as we are incorporated in the State of Delaware. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware forum provision and the federal forum provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Delaware forum provision and the federal forum provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. In addition, these forum selection clauses in our bylaws may limit our stockholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. The federal forum provision may also impose additional litigation costs on stockholders who assert the provision is not enforceable or invalid, and if the federal forum provision is found to be unenforceable, we may also incur additional costs associated with resolving such matters. The Court of Chancery of the State of Delaware and the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors, and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the facilities that we lease are the following:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.998%;"></td>
    <td style="width:1.342%;"></td>
    <td style="width:15.429%;"></td>
    <td style="width:1.322%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.884%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.322%;"></td>
    <td style="width:12.202%;"></td>
    <td style="width:1.311%;"></td>
    <td style="width:12.191%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Use</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximate Square Footage</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease <br />Expiration Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Renewal Option</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 31, <br />2025</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evergreen House North, Grafton Place, London, NW1 2DX</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 29, <br />2024</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sahlgrenska Science Park AB, Medicinaregatan 8A, <br />413 90 Gothenburg, Sweden</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 30, <br />2023</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stevenage Open Innovation Bioscience Park, <br />Stevenage, Hertfordshire, SG1 2FX</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory space</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,046</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 8, <br />2025</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our current facilities are sufficient to meet our current and near-term needs and that, should it be needed, suitable additional space will be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are not party to any material legal matters or claims. In the future, we may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Information Regarding the Trading of Our Common Stock</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#x201c;GLTO&#x201d; and has been publicly traded since October 29, 2020. Prior to that time, there was no established public trading market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, we had 25,673,474 outstanding shares of common stock and no outstanding shares of preferred stock. At March 1, 2023, there were 27 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial holders represented by these record holders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by Item 5 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from Registered Securities</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 2, 2020, we completed our IPO in which we issued and sold 6,342,207 shares of common stock, $0.00001 par value per share, including 675,540 shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock. The offer and sale of the shares in the IPO was registered under the Securities Act pursuant to registration statements on </span><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338ds1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (File No. 333-249369), which was filed with the SEC on October 7, 2020 and subsequently amended and declared effective on October 28, 2020, or the </span><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520282633/d39338d424b4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prospectus</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The underwriters of the offering were BofA Securities, Inc., SVB Leerink LLC and Credit Suisse Securities (USA) LLC and Kempen &amp; Co U.S.A, Inc.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We raised $86.3 million in net proceeds after deducting underwriting discounts and commissions of $6.7 million and other offering expenses of $2.1 million payable by us. No underwriting discounts and commissions or offering expenses were paid directly or indirectly to any of our directors of officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, $20.7 million of the net proceeds from our IPO have been used for general working capital purposes, including the funding of our clinical development programs. We have invested the unused net proceeds from the offering in money market accounts and marketable debt securities. We expect to use the net proceeds from the offering described in our </span><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520282633/d39338d424b4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">final prospectus filed pursuant to Rule 424(b)(4)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> under the Securities Act with the SEC on October 30, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. Res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">erved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. Our strategy is to focus on diseases without disease-modifying treatment options and where there is a high unmet medical need. We are concentrating on the development of a new class of medicines: small molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, that target underlying biology for the treatment of multi-factorial diseases like cancer and fibrotic diseases.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced product candidate, GB0139, is in Phase 2b clinical development and our other current fibrosis and oncology product candidates are in early stages of clinical development. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our operations to date have been financed primarily from our initial public offering, or IPO, the issuance of convertible preferred shares and convertible notes. Since inception, we have had significant operating losses. Our net loss was $61.6 million and $51.8 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $217.7 million and $66.1 million in cash, cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc. was incorporated in Delaware in October 2019. Shares in Galecto Biotech AB, a Swedish operating company, were exchanged at a one-to-one ratio for shares in Galecto, Inc. in a common control/tax-free reorganization. As of December 31, 2022, the Company&#x2019;s wholly owned subsidiaries were PharmAkea, Inc., Galecto Securities Corporation and Galecto Biotech AB. Galecto ApS, a Danish operating company, was Galecto Biotech AB&#x2019;s wholly owned subsidiary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. See &#34;Item 1A. Risk Factors - Risks Related Our Financial Position and Need for Additional Capital - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34; In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities of $66.1 million as of December 31, 2022, will be sufficient to continue funding our development activities into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not had any products approved for sale and, therefore, have not generated any product revenue. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of COVID-19 and identification of new variants and subvariants of the virus has impacted the global economy and, both directly and indirectly, businesses and commerce. As worker shortages have occurred, supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The ongoing economic challenges of the COVID-19 pandemic and its effects on our business and operations are uncertain.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, economic uncertainty in various global markets, including the U.S. and Europe, caused by political instability and conflict, such as the ongoing conflict in Ukraine, and economic challenges caused by the COVID-19 pandemic, have led to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions, which have caused record inflation globally. Our business, financial condition and results of operations could be materially and adversely affected by further negative impact on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although, to date, our business has not been materially impacted by these global economic and geopolitical conditions, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such instability could impact our business and results of operations. The extent and duration of these market disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian sanctions, geopolitical tensions, record inflation or otherwise, are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional information on the various risks posed by the COVID-19 pandemic and global economic uncertainty, please read the section entitled &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Operating Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel costs, which include salaries, benefits and equity-based compensation expense; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with consultants, and third-party contract organizations that conduct research and development activities on our behalf; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to sponsored research service agreements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory supplies and equipment used for internal research and development activities; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquired in-process research and development programs. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred, including for acquired in-process research and development. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to $0.9 million per year for losses resulting from research and development costs of up to approximately $4.1 million per year. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. We recorded a reduction to research and development expense of $0.8 million and $0.9 million for the year ended December 31, 2022 and 2021, respectively. The credits are available the following year, in 2023 and 2024, respectively.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our direct research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. The majority of our clinical spending in the years ended December 31, 2022 and 2021 was on GB0139.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur research and development expenses for the foreseeable future as we continue to invest in research and development activities related to developing GB0139, GB2064, GB1211 and any other product candidates we may develop, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful completion of preclinical studies and initiation of clinical trials for GB0139, our other current fibrosis and oncology product candidates and any future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful completion of our ongoing Phase 2 clinical trials for GB0139, GB2064 and GB1211, and any clinical trials for future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by the FDA, regulatory authorities in Europe, Health Canada or other regulatory agencies of regulatory filings for GB0139, GB2064, GB1211 and any future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful application for and receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">arrangements with third-party manufacturers for, or establishment of, commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effective competition with other therapies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">avoidance of infringement, misappropriation or other violations with respect to others&#x2019; intellectual property or proprietary rights; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to continue for the foreseeable future as we continue to implement our business strategy, which includes advancing GB0139, GB2064 and GB1211 through clinical development and other product candidates further into clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, depreciation expense and other expenses for outside professional services, including legal, human resources, audit and accounting services and facility-related fees not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and stock-based compensation expense, for our personnel in executive, finance and accounting, business operations and other administrative functions. We expect our general and administrative expenses to continue over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These expenses will likely include increases related to the hiring of additional personnel, legal, regulatory and other fees, director and officer insurance premiums and investor relations costs associated with our growth and continued expansion of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our other income (expense), net is comprised of:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income: The interest income earned on our cash, cash equivalents and marketable securities is recorded in our statements of operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain (loss) on sales of marketable securities: The loss on the sales of our marketable securities are recorded in our statements of operations.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign exchange: The functional currency of our subsidiaries in Denmark and Sweden is the Euro. Transactions denominated in currencies other than the Euro result in exchange gains and losses that are recorded in our consolidated statements of operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following sets forth our results of operations for the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.217%;"></td>
    <td style="width:1.426%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.416%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.426%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.498999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.426%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.416%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.426%;"></td>
    <td style="width:11.747%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percent</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,206</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,488</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,718</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,001</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,739</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(738</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-5%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,207</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,227</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,980</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(61,207</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52,227</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8,980</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(417</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">475</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(892</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-188%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(61,624</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(51,752</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,872</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were comprised of:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.275%;"></td>
    <td style="width:1.459%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.236%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.448%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.538%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.448%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.592%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies and clinical trial-related activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,488</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,358</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,130</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,989</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,970</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,331</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,383</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,948</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consultants and other costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,368</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,758</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,610</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,206</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,488</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,718</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $48.2 million for the year ended December 31, 2022, compared to $38.5 million for the year ended December 31, 2021. The increase of $9.7 million was primarily related to an increase in clinical trial-related expenses of $9.1 million resulting from our four Phase 2 clinical trials, increased personnel costs due to additional headcount of $1.2 million and personnel costs for non-cash stock-based compensation of $0.7 million and increased other research and development costs of $1.6 million, offset by decreased chemistry, manufacturing and control, or CMC, activities of $2.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $13.0 million for the year ended December 31, 2022, compared to $13.7 million for the year ended December 31, 2021. The decrease of $0.7 million was primarily related to a decrease in consulting costs of $1.0 million and legal related costs of $0.7 million, offset by increased personnel costs of $0.6 million due to additional headcount as well as non-cash stock-based compensation of $0.4 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense was $(0.4) million for the year ended December 31, 2022, compared to other income of $0.5 million for the year ended December 31, 2021. The decrease of $0.9 million was due to an increase in net foreign exchange loss of $1.4 million and an increase in the loss on the sale of marketable securities of $0.1 million, offset by an increase in net interest income of $0.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations to date have been financed primarily through our IPO, the issuance of common stock through our at-the-market program and the issuance of convertible preferred shares and convertible notes. Since inception, we have had significant operating losses. On November 2, 2020, we completed our IPO in which we raised $86.3 million in net proceeds. On November 4, 2021, we filed with the SEC, and the SEC declared effective on November 12, 2021, a registration statement on</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-3, or the Registration Statement, which registers the offering, issuance and sale of up to $200.0 million of our common stock, preferred stock, debt securities, warrants, subscription rights and/or units of any combination thereof. Simultaneous with the filing of the Registration Statement, we entered into an Open Market Sale Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with Jefferies LLC, as sales agent, to provide for the issuance and sale of up to $50.0 million of our common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Registration Statement and related prospectus filed with the Registration Statement, or the ATM Program. During the quarter ended December 31, 2022, we sold an aggregate of 71,363 shares of our common stock under the ATM Program at a weighted average selling price of $1.62 per share. During the year ended December 31, 2022, we sold an aggregate of 390,560 shares of our common stock under the ATM Program at a weighted average selling price of $1.92 per share. We had no sales under the ATM Program during the year ended December 31, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our net losses were $61.6 million and $51.8 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $217.7 million and $66.1 million in cash, cash equivalents and marketable securities. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.351%;"></td>
    <td style="width:1.325%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.491999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.338%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.491999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(42,932</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52,308</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,384</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(48,048</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">507</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(30,041</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100,356</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in operating activities of $42.9 million during the year ended December 31, 2022 was attributable to our net loss of $61.6 million, offset by a net increase of $11.9 million in our working capital and in non-cash items of $6.8 million principally with respect to non-cash stock-based compensation, non-cash amortization of premiums and discounts on marketable securities and non-cash amortization of the right of use lease asset.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in operating activities of $52.3 million during the year ended December 31, 2021 was attributable to our net loss of $51.8 million together with a net decrease of $6.6 million in our working capital, offset by an increase in non-cash items of $6.1 million principally with respect to non-cash stock-based compensation and non-cash amortization of premiums and discounts on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by investing activities of $12.4 million for the year ended December 31, 2022 was attributable to $57.5 million in proceeds from the sale of marketable securities, offset by $44.9 million for the purchase of marketable securities and $0.2 million for the purchase of property and equipment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities of $48.0 million for the year ended December 31, 2021 was attributable to $84.2 million for the purchase of marketable securities and $0.2 million for the purchase of property and equipment, offset by $36.4 million in proceeds from the sale of marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities of $0.5 million for the year ended December 31, 2022 was the result of net proceeds from the issuance of our common stock.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had no cash used in or provided by financing activities for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses; costs related to third-party clinical research, manufacturing and development services; costs relating to the build-out of our headquarters and other offices, our laboratories and our manufacturing facility; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; clinical costs; manufacturing costs; legal and other regulatory expenses and general overhead costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities of $66.1 million as of December 31, 2022 will be sufficient to continue funding our development activities into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Volatility in equity capital markets may adversely affect the market price of our equity securities, which may materially and adversely affect our ability to fund our business through public or private sales of equity securities. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders, will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates, including GB0139, GB2064, GB1211 and any other product candidates we may develop in the future; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical development plans we establish for these product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of, and development requirements for, other product candidates that we develop; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timelines of our clinical trials and the overall costs to finish the clinical trials due to geopolitical instability and conflict and economic challenges caused by the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates, and the terms of such arrangements;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are able to enter into and maintain collaboration agreements, including the terms of and timing of payments under any such agreements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, or technologies;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing clinical, technological and market developments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of completion of commercial-scale outsourced manufacturing activities;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in economic conditions, including rising inflation and interest rates, lower consumer confidence and volatile equity capital markets; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of continuing to operate as a public company. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosures of assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, and the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#x2019;s judgments and estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incur substantial expenses associated with clinical trials. Accounting for clinical trials relating to activities performed by CROs, CMOs and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include, the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CRO and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs, CMOs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimated amount of services provided by the CRO, CMOs and other vendors but not yet invoiced and include these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the consolidated statements of operations. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap-up periods, compensation arrangements and services received attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have issued stock-based compensation awards through the granting of stock options, which generally vest over a four-year period. We account for stock-based compensation in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 718. In accordance with ASC 718, compensation cost is measured at estimated fair value and is recognized as compensation expense over the vesting period during which service is provided in exchange for the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use a Black-Scholes option pricing model to determine fair value of our stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of stock options, the expected volatility based on the historical volatility of a publicly traded set of peer companies and the expected risk-free interest rate. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, stock-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, share-based compensation cost could be materially impacted in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of our awards in the year ended December 31, 2022 has been estimated using Black-Scholes based on the following assumptions: term of 6.0 years; volatility of 90.0%; risk-free rate of 1.7%; and no expectation of dividends. The fair value of our awards in the year ended December 31, 2021 has been estimated using Black-Scholes based on the following assumptions: term of 6.0 years; volatility of 90.5%; risk-free rate of 0.7%; and no expectation of dividends</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to use judgment in evaluating the assumptions utilized for our equity-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black-Scholes model, the amount of equity-based compensation expense we recognize in our consolidated financial statements includes stock option forfeitures as they occurred. We recognize forfeitures as they occur, and the compensation expense is reversed in the period that the forfeiture occurs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the level of historical operating results and projections for the taxable income for the future, we have determined that it is more likely than not that our net deferred tax assets will not be realized. Accordingly, we have recorded a full valuation allowance to reduce our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize tax benefits from uncertain tax positions only if (based on the technical merits of the position) it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We have not recorded any uncertain tax positions as of December 31, 2022 or 2021. We do not believe there will be any material changes in our unrecognized tax positions over the next 12 months. In the event we are assessed interest or penalties at some point in the future, they will be classified in the consolidated financial statements as a component of income tax expense. We have not incurred any interest or penalties.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate in multiple jurisdictions, both within and outside the United States, and may be subject to audits from various tax authorities. Management&#x2019;s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the extent to which our deferred tax assets may be realized and adjust the valuation allowance accordingly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; in the accompanying notes to our consolidated financial statements for the years ended December 31, 2022 and 2021 for a discussion of recent accounting pronouncements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. We have not included our payment obligations under these contracts in the table, as these contracts generally provide for termination upon notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate the timing of if and when they will occur. We could also enter into additional research, manufacturing, supplier and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an EGC under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited consolidated financial statements in a registration statement for an IPO, an exemption from the requirement to provide an auditor&#x2019;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may remain classified as an EGC until the end of the fiscal year following the fifth anniversary of the completion of our IPO, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of any year before that time, or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company,&#x201d; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) if the market value of our shares held by non-affiliates is more than $250 million but less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our independent public accounting firm is EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark, PCAOB Auditor ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52b372c0-a70d-48a6-8f7a-0f8edf80a062" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1757</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inherent Limitations of Internal Controls</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control &#x2013;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on our evaluation under that framework, management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disc_foreign_juris_ins"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">al Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference. All financial statements; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto. Those financial statement schedules required to be filed by Item 8 of this form, and by paragraph (b) below. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.864%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:39.003%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:17.998%;"></td>
    <td style="width:1.379%;"></td>
    <td style="width:12.757%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:15.002%;"></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference Herein from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or Schedule</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File/Reg. Number</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520285653/d53274dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Registrant.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 8-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 4, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520285653/d53274dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 8-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 4, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen Common Stock Certificate.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 4.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:26.65pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement among the Registrant and certain of its stockholders, dated September 25, 2020.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 4.2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Capital Stock.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Stock Option and Grant Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000156459021015916/glto-ex102_778.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Equity Incentive Plan, and forms of award agreements thereunder</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1800315/000156459021035806/glto-ex101_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Separation Benefits Plan</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 6,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Officer Indemnification Agreement between the Registrant and each of its executive officers.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Director Indemnification Agreement between the Registrant and each of its directors.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.5)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/glto-ex101_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Employee Director Compensation Policy, as amended</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 9, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Service Agreement between Galecto Biotech ApS and Hans Schambye, dated April 23, 2013.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.7)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Contract between Galecto Biotech ApS and Anders H. Pedersen, dated January 23, 2013, as amended on August 24, 2017.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.8)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addendum to Employment Contract between Galecto Biotech ApS and Anders H. Pedersen, dated August 24, 2017.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.9)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Contract between Galecto Biotech ApS and Bertil E. Lindmark, dated November 28, 2019.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.10)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.864%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:39.003%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:17.998%;"></td>
    <td style="width:1.379%;"></td>
    <td style="width:12.757%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:15.002%;"></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference Herein from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or Schedule</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File/Reg. Number</span></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addendum to Employment Contract between Galecto Biotech ApS and Bertil E. Lindmark, dated January 15, 2020.</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.11)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520273986/d39338dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 11, 2020.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.12)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000119312520265628/d39338dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 14, 2020.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.13)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 22, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-249369</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:30.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001800315/000156459021041147/glto-ex101_208.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">English language summary of Lease Agreement between Galecto Biotech ApS and COBIS A/S, dated April 5, 2021</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 5,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39655</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:57.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:45.35pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:39.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="glto-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Indicates management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.453%;"></td>
    <td style="width:5.061%;"></td>
    <td style="width:3.044%;"></td>
    <td style="width:46.442%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hans T. Schambye</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hans T. Schambye, M.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and President</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F ATTORNEY</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Hans T. Schambye and Jonathan Freve, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.004%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:40.002%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:27.997%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hans T. Schambye</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hans T. Schambye, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Freve</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer (Principal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Freve</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Carl Goldfischer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carl Goldfischer, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jayson Dallas</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jayson Dallas, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Chau Q. Khuong</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chau Q. Khuong</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ S&#xf8;ren M&#xf8;ller</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S&#xf8;ren M&#xf8;ller, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Amit D. Munshi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amit D. Munshi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Anne Prener</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anne Prener, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Shapiro</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Shapiro, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GALECTO, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:92.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGIST</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Shareholders and the Board of Directors of Galecto, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Galecto, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> changes in stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58e91b86-b4d9-44fb-95ad-08e16ef34b83" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EY Godkendt Revisionspartnerselskab</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2de2f96-2fcd-4428-b48f-26a104a6e0d1" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Copenhagen, Denmark</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GALECTO, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Ba</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.879%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.860000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.031%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37c0c6d3-456e-4f96-9eac-def4f177a7bc" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8515d22-1a38-4613-8e69-e2a6e0c89bd9" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,563</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_812a0b1d-8f2b-4a7f-b99a-c309780fc99c" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a61aa7cf-134d-4bd7-8515-ec0bfa961c68" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,628</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33f8444c-8fa0-4a36-8d1e-900cab848697" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9424e143-e1f3-4c97-9911-18131cff51df" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43bb997c-88eb-4b49-b5df-6f9905062222" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bdfd2e4-9105-43d5-9091-3d90f2eba4c2" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c8328c8-798b-4cdc-804d-7e1899908884" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89f4a766-77cd-48f0-aba7-dcf98c9c3942" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72ba8e02-26f8-4647-95a3-bad2851305f3" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3">810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b474408e-cc07-4744-9786-3c1818f4ee0d" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3">834</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01f44070-d70a-4841-aa6d-2cdb3f699049" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e40acee-2a36-45a6-827d-f3cf22b131e7" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3">203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets, non-current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f92bbcdc-993c-4a16-a0bf-b4e079a84232" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_244728a3-00a3-41fc-8bf2-15a0e9be24e7" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d19b6776-4d00-4e62-bdf6-4ede315ab58d" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_727f07d3-f753-4465-b92b-626a5d777739" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7087ee19-f441-4e76-b434-4d463c41c21c" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9abbe309-5ce3-4337-980f-c361bb22f74e" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f29803bb-1aa5-4c8a-8dea-ba96d3cc3fec" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ab9ccad-3da8-4c20-bd0f-74bde9e8a48a" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_668d1490-4970-47c6-954b-9bca46096c52" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e8a49e0-df1d-49d7-84de-c28047b97a38" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5872a9c-26ba-40e9-bc2f-31465fe08d85" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f2d99d3-868a-47cf-98f6-ded890a3a763" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3">448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39ab7405-e313-4a98-a52f-a42960d17d01" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_093d904c-2767-43f6-8216-a48182fac190" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,992</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c97e5a12-2637-4649-b0b9-ad9ec1e147a3;"><span style="-sec-ix-hidden:F_7ab5c9a0-ad7e-4429-bd8a-27616dd14ffc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3866de26-a723-4d46-a5f4-b689c3d8503c" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_39fe7ced-22cf-400e-a6b2-05bd87f13ae0" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;per share; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a12b366-b2a9-4190-8728-762f27759f7d" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_83bff830-a5ed-4fd0-bfc8-3fd5769fbacc" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized <br />&#160;&#160;&#160;&#160;&#160;at December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c63a0b18-1db8-40a4-b2b3-90df9d7f30d8" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cfea8a87-00ae-417d-8004-957079da74dc" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42fc3692-4b38-4800-8d67-cfa6a8787933" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dca6084e-9ab6-477b-9078-7f5f0734aa90" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued or outstanding as of <br />&#160;&#160;&#160;&#160;&#160;December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_63d7ab59-43c4-4301-ae5c-263a48395952;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9b9e6261-7f93-4be0-8e18-13b33f088337;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdb7e438-1b31-47d1-8c65-85d3f91e90c6" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_30303476-c940-4118-a0c8-aa6feb88c4ae" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;per share; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_455ba9af-7a5c-464e-9be0-145d7ffbb138" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dba68003-53de-4f36-88fa-dcf46e8cedb5" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized   <br />&#160;&#160;&#160;&#160;&#160;at December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71bb9d49-a1ee-4279-ae00-700888700815" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ae303b12-2a97-47dc-b788-fd84edd68d55" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,652,392</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e31665c1-6f4f-46a4-9497-a6dce7391fd5" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6accead8-adef-4b94-9c29-39c6f45ae048" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,261,832</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and  <br />&#160;&#160;&#160;&#160;&#160;outstanding at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0c600085-f026-40c1-bda9-1000262a6429;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_10c9ded1-f15d-437e-8e57-1eaa49edc1c9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bf7239a-d9da-43bb-8f9e-c0e1dea1f874" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1e29ebf-6847-427a-beff-fcd095479b99" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_601d3144-8c0a-45c0-8524-dbb68b41aae7" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">217,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_245440b3-c4f6-44f6-bb70-2bf78dc2643c" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">156,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46a53764-023b-4134-97cc-2d45cc7a5a6f" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_367774e5-aa57-4121-af6c-2b466ef547fb" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4495932-815b-468b-858f-262660b924e5" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92498537-643f-4e2c-8e12-5ca47e04ef0e" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d95e5bd-f381-4023-9871-a34fc9a55d1c" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a0652bd-248e-4202-b10c-7c42b36b139f" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc.</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Oper</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.879%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.860000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.031%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c4c3d99-acbc-4c94-8c40-fca1e2a25770" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c47c75e-d98f-4d99-b3ee-34688f9f2c4c" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,488</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffa1dab9-c266-44a0-8ae5-b6d9b88ff090" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24164a8f-3b51-4f99-8ab6-0928f27fdf5d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f483c633-1b34-48e3-a0e8-1e18e406d484" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67051373-6cc3-4785-adb2-ec58b0da00f6" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,227</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d39377ee-31b5-4203-a3ba-c6dcc49a06ec" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de88d807-9f68-4c9f-8b02-4a36dfa58a08" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,227</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_360f7cc3-9c20-4825-a004-2a444e37c670" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54ca8c53-f484-4988-b220-272a3005354a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on sale of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaf8a9bf-487d-4182-a21b-262c267ce689" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign exchange transaction gain (loss), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98740513-2ae3-4e79-9f7e-07b2bacc4814" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2eb7c2d-9fc6-4ea3-adea-c75a6eac9522" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61bca76c-5e4a-4d34-871e-b707b6b32d65" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddc68825-0440-47c0-8959-608a5b909abd" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3">475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb2540af-7cda-46d8-aacb-ec2fbac772a7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52abe849-b42d-41b7-8c27-73c362a49c4a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_363ef103-ba2d-47f7-85bb-234922859642" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_8cadee6b-3a55-4907-b6ad-42279e671aa4" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.43</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0565efb-d80c-4271-bc8e-674e1699edea" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_53029576-1aa1-4247-bf5e-15a88717963f" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.05</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of shares used in computing net loss <br />&#160;&#160;&#160;per common share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1619c7a-0135-4907-b8ff-ec54beccab55" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_48a02889-0e74-4923-a9f1-3a4b05b568ef" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,409,123</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cfd35b1-cd31-497c-9feb-4b8c59f30b32" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_cf35628e-cf02-48ce-a61b-42a9470b64e3" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,261,832</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain (loss), net of tax</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currency translation gain (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8b802d9-ad38-4374-820d-b143bb3ede65" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e086dd2-8eba-4537-bb08-9d468d565392" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a1321b1-fb9d-41cb-8849-ebc036975fe8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e00e888-c70e-4361-bafc-ec719499642d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-">77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification adjustment for loss included in net income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da913f6e-241b-40a7-b87b-ed2cc664aaf1" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain (loss), net of tax</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56eaf59e-737d-4537-b758-1106e10091eb" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7d3f08d-9367-433b-84b9-a77e0793f98d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-">994</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bfe07c2-9681-4035-a973-8a7d3abf23b7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,548</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ac4803c-9660-4cfa-8bb4-edcd16628db7" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,746</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc.</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Changes in Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.855%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.790999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.506%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.976%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.2620000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.2620000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.145%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.145%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7107b68-ac17-4c5d-97cb-e32674cce093" contextRef="C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,261,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_363ff404-47e7-43f1-b172-6714140f43e1" contextRef="C_06554741-f66b-460a-9c53-5b5182d21b98" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f23a4728-af25-48c0-af7e-9efad5a0e0fc" contextRef="C_b0f9c207-2ba8-436a-9aa4-8eea6b502e78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">104,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96daca1a-a330-4b88-9217-549f98de3837" contextRef="C_1f463f6f-54e1-43b8-b676-b1ff83a8e7b8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">674</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b44f3de-e5bf-446a-b56d-96404559677c" contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60b33d0e-80ac-4607-8705-811c131caeb4" contextRef="C_ad845729-af55-4659-b3e7-c758123fc0b7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94661279-d693-407a-bea3-47f7685c4628" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9ddf952-9456-43d3-a5b5-037e2d62ccf7" contextRef="C_298727fd-7dd4-400e-978d-2395c0ad7b94" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">994</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3821f64-396b-4604-b079-610199d800d3" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">994</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e9d2762-a5e4-4929-9d42-7b67c7248f21" contextRef="C_b896ceee-0f19-4736-be33-4c8a2a1b182f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fc5d79a-2b61-497a-b7e4-f4615de36605" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03310f04-23a6-490b-8644-dadf504565b0" contextRef="C_2d93c29f-7701-4844-9f33-6bb356fa3531" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,261,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_575b8c09-1ed5-4942-94b3-4ef576a886c9" contextRef="C_3e287338-bbea-4c9b-90ce-f4b9c66624f8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9224787b-bf0e-4363-a181-28d1e14d8b9e" contextRef="C_e70f639f-dec9-4e39-81e2-2e7b8c9db28e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">156,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ac7d29-ceee-42ac-b657-6f7ff495ba03" contextRef="C_f86986df-0846-4157-a5eb-a6c794351048" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_180540c3-988f-450c-8ee4-370749ac2ebc" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb55ccc4-fee3-404c-999e-b3759ca69db8" contextRef="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10c79776-e3ff-4bbe-bfe9-922bfbff8575" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock; net of issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d4e663-83ad-4a47-b49b-1a09dcbeaa24" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:StockIssuedDuringPeriodNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;million</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c46c0024-670b-490e-ae51-021a590099f1" contextRef="C_a066ec17-6b16-4df9-a0d7-0630872d95c8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">390,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34d5d252-a86b-4465-a9a2-f4f4b52a7052" contextRef="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28a0468c-0e47-49a9-a1e2-03b72277f2ab" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79b217e9-0d47-4b87-8473-5101db91f964" contextRef="C_1d11ae7c-daf5-4cf4-9476-65d6996dfc53" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48e47576-6a48-4377-bce3-4e717dad416c" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a31ad10-5a75-460c-8307-c50ad4654e43" contextRef="C_ad36967d-c20c-4021-8d2a-690baad2b403" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1751df0-f809-4938-bd32-063beabb5e6d" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5a02c6b-a049-4635-8899-381bc9be0a50" contextRef="C_cfe5cd33-6411-4f7a-8986-194fe9cbf159" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,652,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e24b34cd-5ea9-488b-bdd1-203cf093b5ff" contextRef="C_0c901782-4d88-468a-8b30-6a41c7e1f8ad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_129840e7-0739-4d10-90c6-a59303929653" contextRef="C_35bc5886-d1e6-4ce7-bdf0-d68aa785f64f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">217,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2789150-f54d-4bce-9e2a-84c2ea3ad1ec" contextRef="C_4fd6f295-aa8c-4dd2-a215-0f6504345d71" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_176637cc-f67c-411f-863a-c0130a9d173f" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc.</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea76159f-36ce-43fb-8bae-7a2bbb576076" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89b49ed3-0939-46c7-ae54-a02dc6b524be" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustment to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation of equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66206e4e-c883-497f-af7a-d2df9cc4e63a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_037c87ef-a4ed-4547-b03a-e50e1c720e86" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9db43ca2-4b5a-408d-b997-aa3ff1d908de" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5066d639-c8f2-4522-8ec3-1eb63bd31f90" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of premiums and discounts on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72622411-84b2-4b1e-a98d-f9dfe4c4904b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a9c9018-3100-4f2c-8c61-efcc296ac582" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss on sale of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f30cf0e-9e67-44f1-a4d1-71f5a7067dad" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:MarketableSecuritiesGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of right of use lease asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71b4ba22-bac3-4b4a-b0b0-fb21b53313c0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3">448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3c327cd-ccbc-43cf-8f86-68385e9b38a3" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3">421</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accretion of lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9cc1d36-9daa-4c6a-b2da-b28f55355dab" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:AccretionOfLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">58</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75a9577c-ba18-4286-b950-bc9475e63867" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:AccretionOfLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6fb53ef-f1be-408a-88ca-9a25a3ace5a3" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c8b44c3-d272-4a3d-a3f9-acce47a3cc7a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets, non-current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbd0afb2-6738-4877-9e20-395cd5073eee" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">257</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffdd5669-125f-4c61-901d-971dbbb0a5f9" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3">866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_080faa5e-1a4c-40d6-ae99-4117013501ac" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cebfad8-42e4-4279-95dd-7631bb8bb676" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d161df0c-bbe6-4ca3-8457-33a9dcabf565" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1fad2ae-d2c5-481d-8210-878e7dc8161c" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3">274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd1dc6b2-b196-4ecf-9d58-611d4c4d22e9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-">523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29572ea1-d0e8-4d1c-876c-fde07b47d84b" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-">513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdb63387-30fc-4c10-bfe7-24c633053d4e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc0b21d0-5717-4dd1-8967-49485444a5b4" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8296f4-5521-424f-8b25-87499b063ca5" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0982298b-e4eb-47d9-a050-1780756229c0" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ced55b84-46ab-4da5-b268-69979a43c000" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d1212a-6369-4413-a370-dc818b2b5c29" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd9a7a96-1bc7-4442-9d7e-5c663f2513cc" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">196</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_366589ee-ad29-4f4b-9bc8-d32639733663" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d164a2-be89-4a6a-b9d1-1eed2e1971ec" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51baeb37-5f05-4fa4-af94-33a3a18df592" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">48,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70dd1d81-1a02-40f5-af8b-dd061f1f06b0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9ef2e1e-94c9-4b6d-80a4-6f16f01b3a8f" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1a5eb2b-d103-4da5-842a-a66bb478f13a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5637315a-3f0e-4bcb-915c-7d3b35819035" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_708e8abd-7d0f-4c5f-9dbe-71a07b94c33f" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb38c7f4-1dab-4516-9cc1-5c4f1e232a0d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-">917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents, beginning of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0a97482-f408-4543-9893-5d98bc8252ca" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,563</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1502b85f-bab2-4138-937f-b5d8e36636c2" contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents, end of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b685dd0-1330-46f2-ba61-3c3ce488492e" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feb92335-eb65-4603-8a10-cbb219400907" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,563</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of cash flow information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of noncash activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability arising from obtaining right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6de8f25-790f-4003-9bca-0dbca00c8ba1" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">488</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fab9077-bb73-40ce-9806-c999cb7f363e" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc.</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to the Consolidate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39273670-ae1c-47d9-be49-482587bd37be" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. DESCRIPTION OF BUSINESS, ORGANIZATION AND LIQUIDITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc., together with its consolidated subsidiaries (the &#x201c;Company&#x201d; or &#x201c;Galecto&#x201d;), is a clinical-stage biotechnology company developing novel therapeutics that are designed to target the biological processes that lie at the heart of fibrotic diseases and cancer. The Company&#x2019;s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (&#34;LOXL2&#x201d;), which play key roles in regulating fibrosis and cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company&#x2019;s wholly owned subsidiaries were PharmAkea, Inc. or PharmAkea, Galecto Securities Corporation and Galecto Biotech AB, a Swedish company. Galecto Biotech ApS, a Danish operating company, is a wholly-owned subsidiary of Galecto Biotech AB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s product candidates are in development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and management plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has devoted substantially all its efforts to business planning, research and development,</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting management and technical staff and raising capital, and has financed its operations primarily through the issuance of redeemable convertible preferred shares, debt financings and, most recently, the Company&#x2019;s initial public offering, or IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2ab7597-d12c-4cb1-9992-b3e3868e5119" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">217.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, from recurring losses since inception in 2011. The Company has incurred recurring losses and has not generated revenue as no products have obtained the necessary regulatory approval in order to market products. The Company expects to continue to incur losses as a result of costs and expenses related to the Company&#x2019;s clinical development and corporate general and administrative activities. The Company had negative cash flows from operating activities during the years ended December 31, 2022 and 2021 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f2aa5a6-9f4b-4721-ba25-010f90093c02" contextRef="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">42.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15d32e2e-91f0-4e28-95a2-187662acbac6" contextRef="C_b98f82b2-780e-4b62-9d74-6429370aa2d4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">52.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and current projections indicate that the Company will have continued negative cash flows for the foreseeable future as it continues to develop its product candidates. Net losses incurred for the years ended December 31, 2022 and 2021 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb4b7122-a879-4957-b322-963f10bc4c5b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">61.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_364f8bca-1c34-431f-9cc9-95460256e56a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">51.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company&#x2019;s cash, cash equivalents and marketable securities amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c381c4e5-6b6c-41bb-8642-f3f8ae0055d3" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:InvestmentsAndCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">66.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, current assets amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b208e01-397e-493c-b6ef-d72f311c0f43" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">63.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and current liabilities amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0d0b783-5595-4f2a-94b1-f7ea60061033" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. At December 31, 2021, the Company&#x2019;s cash, cash equivalents and marketable securities amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab6bf0d8-7e00-4360-b644-9ca029b383b9" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:InvestmentsAndCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">109.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, current assets amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33639591-93a0-4c8e-811e-66a308afc5fe" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">110.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and current liabilities amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5f4e0ae-4619-4c66-adaa-3260d2f081d5" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, the Company will consider the following ways to fund its operations including: (1) raising additional capital through equity and/or debt financings; (2) new commercial relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. Volatility in equity capital markets may adversely affect the market price of the Company&#x2019;s shares of common stock, which may materially and adversely affect the Company&#x2019;s ability to fund its business through</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">public or private sales of equity securities. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, key developments and regulatory events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coronavirus pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The novel coronavirus (&#x201c;COVID-19&#x201d;) and its variants, and ensuing pandemic, has continued to spread worldwide, causing many governments to implement measures to slow the spread of the outbreak. COVID-19 and its variants have had a significant impact, both directly and indirectly, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services has fallen. The Company continues to monitor the impact of COVID-19 and its subvariants and assess its strategy accordingly. However, there can be no assurance that the Company will not experience additional negative impacts associated with the COVID-19 pandemic, which could decrease or delay enrollment of patients in the Company&#x2019;s clinical trials or otherwise cause interruptions or delays in the Company&#x2019;s clinical trials, programs and services, and negatively impact the Company&#x2019;s business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef5962a2-1d40-4cde-a929-c069735ab3c7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b87bad2e-4468-492b-9a63-a2d3a5398af3" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with United States, or U.S., generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0736cbb-17d0-41e3-924f-e1a6767a5c0e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:BasisOfAccounting" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s consolidated financial statements for 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> include Galecto, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c545b85-3dc1-4718-8ad1-9388703c277b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Significant items subject to such estimates and assumptions include contract research accruals, accounting for stock-based compensation and valuation of the Company&#x2019;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. The Company&#x2019;s actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_83686026-bbac-4acc-88aa-58fd8da38400" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Currency and currency translation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are presented in U.S. dollars, the Company&#x2019;s reporting currency. Galecto, Inc., Galecto Securities Corporation and PharmAkea&#x2019;s functional currency is the U.S. dollar. The functional currency of the Company&#x2019;s subsidiary Galecto Biotech AB, and its subsidiary Galecto Biotech ApS, is the Euro. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the year. Resulting translation adjustments are recorded to accumulated other comprehensive income (loss), or OCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_59883e41-68d1-4ff9-a3dc-86917c50680d" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities at the date of purchase of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_683b8dd8-a455-432b-8364-ecbf5cc4d3a9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:OriginalMaturitiesAtDateOfPurchase"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e96fb59-11ff-4f65-9398-e83538ad4537" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80664d7c-f05d-4c3f-838c-efb145b8a376" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">49.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 4).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cfe76d16-da43-4404-8902-c647509957e9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held at financial institutions that management believes to be of high-credit quality. The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_37bb26c1-f775-4a64-8342-7467da73350e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in marketable securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests excess cash balances in short-term and long-term marketable debt securities. The Company classifies investments in marketable debt securities as either held-to-maturity or available-for-sale based on the facts and circumstances present at the time of purchase and re-evaluates classification at each balance sheet date. All investments in marketable debt securities at each balance sheet date presented, are generally considered as available-for-sale. Marketable debt securities with maturities of twelve months or less are classified as short-term investments and marketable debt securities with maturities greater than twelve months are classified based on their availability for use in current operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reports available-for-sale debt securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value), net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity. The cost of debt securities is adjusted for the amortization of premium and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#x201c;other than temporary,&#x201d; including the intention to sell and, if so, marks the investment to market through a charge to the Company&#x2019;s consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5eab319-079e-4dec-9519-5455436abea5" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43c9bf0e-9553-435a-b68a-9924049e33fc" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the time it enters into a contract. For all leases, the Company determines the classification as either operating leases or finance leases. Operating leases are included in operating lease right-of-use, or ROU, assets and accrued expenses and other current liabilities and operating lease liabilities, noncurrent in the Company&#x2019;s consolidated balance sheets. The Company has not entered into any financing leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses the Company&#x2019;s incremental borrowing rate in determining the present value of lease payments. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. Refer to Note 6 for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09f46053-4eb8-45ea-8795-e133e4f0a184" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f43dbe76-eeb2-42b7-a3c1-bc8110b42261" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.981%;"></td>
          <td style="width:3.001%;"></td>
          <td style="width:60.018%;"></td>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
         </tr>
         <tr style="height:10.8pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c184b6c-1ff1-442e-90c4-2014e876ff2b" contextRef="C_333a7d4a-b385-4327-8cb4-b33035085d6f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4c068134-a202-4d6a-83ae-33ab11d745f4" contextRef="C_da11831e-2def-422d-b9ba-135e9cc96547" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.1pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_152108ab-292f-44d2-887c-33565c29b3a9" contextRef="C_b8b87670-6319-4b49-9747-781911421762" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14caa1a7-fb26-49d8-bebb-555b8b0214f5" contextRef="C_446278fa-fce1-4cd4-b15e-1085d37b326c" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of 10 years or the remaining term of the respective lease</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dbedc1a4-07ed-4e40-a1ee-329d49650059" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. Through December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, no such impairment has occurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51d915fd-6e91-4b24-b5e0-65092b77da6b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including stock-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f547dee-8b46-4f26-acc4-cc4c88b3db12" contextRef="C_0e4e962b-0c7f-427f-b8d8-253f1dfe01e0" name="us-gaap:IncomeTaxCreditsAndAdjustments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b6dc9e9-0dc3-4d27-8422-68c8d98b029e" contextRef="C_84f94529-71c5-4ff9-b7c7-bebbc7bcaa33" name="us-gaap:IncomeTaxCreditsAndAdjustments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00d8a224-39e8-415b-bbed-a94afb94aced" contextRef="C_b63f1cd8-2964-4478-ba13-1aca8bfd1025" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ab02bd8-3ffe-47b1-90a0-dcb7a38d85d9" contextRef="C_8c0c025b-fcd6-4855-aa25-24dcd9c881c6" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_640e3373-eff1-46e9-9f63-f1888358f8b6" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors, or collectively, CROs. These CROs generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the CROs, and correspondence with the CROs and clinical site visits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3aba541a-09bb-4a3a-bd7d-eab58a3bfa65" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock options granted in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 718. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#x2019;s consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The expected term of the Company&#x2019;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#x2019;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Expected dividend yield is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5982009-8dc9-487f-9746-c77663c293b7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:DividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a3e2dabb-4d65-41b5-a73e-296f0a5804aa" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows the provisions of ASC 740-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or ASC 740-10. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has identified the United States, Denmark and United Kingdom as its major tax jurisdictions. Refer to Note 11 for further details.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c73d69e-5da9-4329-8255-26685d769db2" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, both methods are equivalent. Basic and diluted net loss per share is described further in Note 12.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_131502ee-5409-4054-ac40-a3bf009174d8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer. The Company has determined it operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f250ce06-dfd3-4723-bb43-477f2bd52a38" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb199c29-37a7-4193-b403-d0a8f45e02f2" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other comprehensive gain (loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain (loss), or OCI, is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s OCI includes currency translation and unrealized gain or (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b855acc9-bd82-4755-8337-67fc7369ad29" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:EmergingGrowthCompanyStatusPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emerging growth company status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company may elect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, and as a smaller reporting company, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_29349d87-afbe-4053-b42d-f8584ff08909" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Codification Improvements to Topic 326, Financial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Instruments-Credit Losses, Topic 815, Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">and Topic 825, Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The ASU 2016-13 guidance became effective as of January 1, 2020, and must be adopted using a modified retrospective approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a SEC, excluding eligible smaller reporting companies for fiscal years beginning after December 15, 2019. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December 15, 2022. The adoption of ASU No. 2016-13 during the year ended December 31, 2022 did not have a material impact on the financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically reviews new accounting standards that are issued and has not identified any new standards that it believes merit further discussion or would have a significant impact on its financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_081b0bd6-31af-4e42-b7e3-c84b18d049c5" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. INVESTMENTS IN MARKETABLE SECURITIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash in excess of the Company&#x2019;s immediate requirements is invested in accordance with the Company&#x2019;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe316224-edc1-43a5-93c6-6c3cc301ce16" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#x2019;s available-for-sale investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.879%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.623000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.623000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.828000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.023%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0f88c296-6264-4042-8714-841aed812bb6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f0af89-b355-4b97-a4a1-318ded44efa8" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39e4b1a3-58f4-4aca-ae94-febc743b7771" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc7eb2da-46d5-4c0e-91b2-dd387e35223b" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_364fdb5a-4e08-4efa-8a2d-8f7249b259ce" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_135d8959-bc2c-4d38-840c-024652b7f151" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19e7b40f-444e-43a6-b916-83ec369a0885" contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4cdb346-e925-4c20-bbac-f4c84437e669" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f5ab487-4dc2-42ac-a187-696059f27b5b" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a682d07-fcf0-4c88-8b52-bcbc0497753c" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e998a0cd-a124-4469-90dd-18295d60ff42" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0af976a2-8e81-4cc5-a2c9-e8aba85b87f7" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_021c307e-4692-4c62-bcaf-6a6295f314fa" contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_44cda3a6-b017-451a-b0b6-7cab4805cade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44211e05-aafc-4c0a-98ca-73673faf675a" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb0feb11-594c-4058-9383-107ff055ccd0" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83717ba3-8bca-45a2-b76c-643c5d196842" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90a16ca4-335d-4fcb-b5af-ceb8a24901ef" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d50072b-381e-4bc1-8d73-853f63f3a2d5" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3707704b-f155-4a06-97f8-e61190b8f35e" contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e48a782-cb40-46b3-a747-b5a785eb2372" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49724d9c-fcae-4533-8f9e-825e8720dde0" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c145f367-7835-44a3-8624-5cf0e9c113ce" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,048</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_991867d4-7f51-498d-824b-9699b697b7fc" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_459523ac-6598-460e-9606-b1c6e8029a62" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62c9ef8e-9ae3-4512-b167-247d2268c682" contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,048</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d6434133-357e-47f1-813e-35608ff76877" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. FAIR VALUE MEASUREMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classified its money market funds within Level 1 because their fair values are based on their quoted market prices. The Company classified its debt securities within Level 2 because their fair values are determined using alternative pricing sources or models that utilized market observable inputs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_2d9c76a5-2f26-449a-bec2-40a18d63aae7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the assets that are measured at fair value as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.045%;"></td>
        <td style="width:1.798%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.911000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.788%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.788%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.473%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.788%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.032%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ef8177-77d4-42db-8858-2e00b6e505a0" contextRef="C_cd6ff40d-6e4b-4542-b39b-9a47a5dc2935" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad5aa444-009d-4bdb-94c2-4a078a241d56" contextRef="C_1a891281-b4a3-4bf6-89c4-3d7d6ec73b43" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31426537-09fb-4c76-81b7-f4daf270e4be" contextRef="C_4f2ccad7-282a-4f1b-bf36-002446285a34" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,270</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff996d0b-1205-4a98-bbcf-72ab84c2f344" contextRef="C_4b62815c-330f-4ecf-a0ae-127533136899" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,270</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88b7dd29-a2e9-4999-b70d-b84c39b084f7" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e857e30-9a93-49bd-bb58-3a820f644ee7" contextRef="C_578a6731-4436-4656-baa1-0e8306439eeb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c262add6-3338-48f2-b47c-91a2f3576f8e" contextRef="C_1a7732d2-f6dc-4da5-b07c-d4c3c940cae5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,270</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06dee806-a64a-4d84-8dcd-905db2003c0c" contextRef="C_38c70869-4934-4789-a4e2-402a3062df02" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b8848ed-0da8-4574-8bb9-2db7a244814f" contextRef="C_c5778128-4ddb-4ebe-97f8-350950f780c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99e0bf3d-2b02-4e40-be0c-b77057a836f1" contextRef="C_4935191f-2911-40cc-83d3-1839e14b12c2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,676</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64019a30-eb2d-4204-abc0-2b9aad42e5b3" contextRef="C_f74559e7-8f45-4159-a81f-b42a765ec89e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,676</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_905c4e9d-4ebd-4c64-bed3-2156b632c910" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43f29b27-e8bb-41bd-8122-036566d7c7c9" contextRef="C_5653da56-b435-4ded-887e-78f37a343b93" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_723d4d01-acdc-4cf2-8345-1983123a74b8" contextRef="C_5660b0e7-05a2-4c92-a655-1dd591e67b0a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,676</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></ix:footnote></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16df118b-c9de-4265-8298-f7b75069ef1a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dd567e6d-089e-49b9-a7d2-4efcf6f55bb0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.662%;"></td>
        <td style="width:1.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.146%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.291%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdae33ed-960f-44a3-80e8-ec69c0275564" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:ContractResearchAndDevelopmentCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5f713b8-87ef-4117-82a4-2fd1fcf0c1a1" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="glto:ContractResearchAndDevelopmentCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e28fa93-9390-4f0e-8af1-1380a4ed05f5" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad0654d0-c082-4daf-b1f2-4e3e2898649a" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cba9f84d-73a7-47a9-a508-84abc0f6ae85" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fe26057-4788-4be8-abb4-057fc6df59e5" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="glto:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,682</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82470597-1e95-4c15-96e5-6c3b73544fda" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3">587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08236ed4-5da0-4493-a24a-aa81fee70e8f" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3">598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63995381-7a25-46b7-b1c4-96983210fdfd" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3">52</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_237d2588-9072-4a6e-97c1-f43ade37a3cf" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3">334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbec6be4-ff11-4ee9-a31d-d5648191d2c1" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed9ddaed-b963-4385-a273-5609cf794ae0" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_018aceab-5735-4efb-acc2-3143ddffb2a2" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. LEASES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b1520e2-e458-4b48-968b-16b8de3fc4bb" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the following operating leases:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.194%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:20.741%;"></td>
        <td style="width:1.722%;"></td>
        <td style="width:14.944%;"></td>
        <td style="width:1.722%;"></td>
        <td style="width:15.963%;"></td>
       </tr>
       <tr style="height:19.45pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Use</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease <br />Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Renewal Option</span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate headquarters</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8865681-fb3c-46b3-8f81-199888594bde;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2025</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_23da31b5-f97d-4232-aa0d-8cfd9dd081da" contextRef="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8" name="us-gaap:LessorOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">London, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_63bad519-8d42-4588-8c64-dc3b578e5db5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2024</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ccf220c5-74db-4e13-a9a7-328497f4f65d" contextRef="C_f9b208c9-11e0-43f5-9a13-0c029853484f" name="us-gaap:LessorOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gothenburg, Sweden</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3cbffc48-b954-4828-9d21-d46a15257703;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2023</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c9453cb8-0f25-4063-9bef-602b6fdccf25" contextRef="C_6bb29e1b-fe16-4cff-8393-88bae5954f84" name="us-gaap:LessorOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stevenage, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d29c6159-b3c6-43bd-8e35-677bf4164550;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2025</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b79311d4-5a64-4435-8290-39cb1a651ee0" contextRef="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e" name="us-gaap:LessorOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></ix:nonNumeric></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no finance leases and has elected to apply the short-term lease exception to all leases of one year or less. Rent expense for years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a74145f4-c778-4258-9931-3f9ea669c92e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:OperatingLeaseRentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_5b3544a3-6f32-4771-ae54-43e708c06913" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:OperatingLeaseRentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for both periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e1119f47-6a8f-4737-9f2e-48ba52055317" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative information regarding the Company&#x2019;s leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.143%;"></td>
        <td style="width:1.933%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.367%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.933%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.623%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a2a0857-3dad-42b2-9f05-74294232fde8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_305f12a7-39af-4120-91ea-f0218047c2a6" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows paid for amounts included in the<br />&#160;&#160;&#160;measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4aa92e81-cf7f-42c0-9cc0-6ebd03ac1b56" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">523</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5515bade-77d8-4491-a36b-4d1017154496" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use<br />&#160;&#160;&#160;assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43391016-a1d2-4e7e-bc9e-66e9ed167834" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b55a9836-9d98-484a-839e-bdee6b1eb5a0" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted average remaining lease term for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_acf27a76-38eb-4bf3-a50c-803c50c34f1b" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a7485f7-fdc3-487c-addc-08e9c9dc1e99" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted average discount rate for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ae7fb05-ef80-4657-80bf-9c42f26daed2" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_bfcc546d-3ecf-4893-be63-f495a744b569" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for both periods.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4f33c115-8127-4599-aeb5-e93a0381a277" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities are as follows at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.535%;"></td>
        <td style="width:3.057%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:27.408%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br />Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_375f2e25-630f-4cf1-a941-d3b16c4df37e" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">523</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79d6cd7c-58d0-4064-ac97-0217c2886d44" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e84a83c-05ce-49e9-ae4a-b14ea2e3da6a" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_993cdef5-d867-4682-bb66-e167a51145f8" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24e5905c-dcbe-4cd0-accc-376e8f3e370c" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e417af1b-2d33-4d0d-95fb-f7ce0386f7a8" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_49889df7-8fc5-457b-9120-b5fc24747335" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. PROPERTY AND EQUIPMENT, NET</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0caa53fb-9636-420f-86ed-9f8864eaa4be" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.751%;"></td>
        <td style="width:2.156%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.156%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.468%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac9c3f1a-58b3-41e8-99e3-c69a7c6f34b4" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63b36adb-9cf4-435b-bc8f-7e99d0e7c030" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">223</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21574ff5-2b91-4216-8a4b-69f396a5f4e8" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52abb268-85c2-421a-97b6-047588670e37" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_341cf35a-eaae-4962-98bd-8f0689b90e26" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e957d6d-bc74-4140-948a-e0508481b5d9" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3">203</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff08d67f-86b2-4baa-b4ae-c8d44257df6f" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">42,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e72c9bbe-ad35-4f20-8fa1-dc3f4837c89c" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_331c11ab-6505-4b60-a209-a6da3efca742" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_12ea1a93-dbbb-4bb9-aa35-35aae6159d28" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.086%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.848%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.075%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c123012-618b-402e-8f27-fc8846ca4a31" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:ContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,145</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5e1f472-12c0-4652-97f8-8cdfb2591c73" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="glto:ContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6802d25-a182-4782-9d32-cb5ff5117561" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f5fec48-ce3f-4c1c-a3eb-1be9542f0d58" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9426828b-8ce6-4136-9592-73b208402ab8;"><span style="-sec-ix-hidden:F_9ab22cc5-86e7-43b0-9814-29ed771a3b70;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">current</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72dc6ac6-5a44-441f-8960-5519815bcd89" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">476</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed447ce9-4933-4da3-bd8d-4eb12c008bdc" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">399</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5d98303-d63f-47f0-a5c6-bbdca7718036" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e65f69a-3c8c-4165-b1cf-c29098949edd" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7063b3f6-8295-4b3f-a2c4-731d5ebfa175" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,757</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93f129df-7d79-4ad6-8793-e56b9caeab81" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,013</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0224114d-b7ec-46c2-b0a2-7e1d463f7c68" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s commitments related to lease agreements are disclosed in Note 6.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and, to its knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, as permitted under Delaware law and in accordance with its certification of incorporation and bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#x2019;s request in such capacity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#x2019;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#x2019;s acts or omissions with respect to the Company&#x2019;s products, technology, intellectual property or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_3e222e6e-0920-4935-9d33-5e1579de389b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK-BASED COMPENSATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee equity plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company's Board of Directors and stockholders approved the 2020 Stock Option and Grant Plan (&#x201c;2020 Plan&#x201d;). Holders of stock options under the 2020 Plan shall be entitled to exercise the vested portion of the stock option during the term of the grant. If a qualified exit, as defined in the 2020 Plan, occurs, then all of the holders' unvested options shall vest immediately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company's Board of Directors and stockholders approved the 2020 Equity Incentive Plan (&#x201c;2020 Equity Plan&#x201d;). Following the adoption of the 2020 Equity Plan, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a483221-0023-4b8b-8f02-6d87ef24ba3a" contextRef="C_83df5a70-5b7d-414e-98bc-028cfe3931af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> further options are available to be issued under the 2020 Plan. Stock options granted under the 2020 Equity Plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46e401c5-52c4-468c-b115-16fd079658f7" contextRef="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_94864ebe-a38e-4c5c-ab5b-9c8724349965" contextRef="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the grant date. The 2020 Equity Plan will cumulatively increase by 5 percent of the number of shares of common stock issued and outstanding on January 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each year until 2030. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b30c7fb9-e1b8-44e9-bf07-6892514a2ee7" contextRef="C_5e2554ff-8b5a-4c27-b47d-d3a252e0b453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">884,566</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options available for future grant under the 2020 Equity Plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70938594-ae92-4163-8009-86489acfe40e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the activity for the Company&#x2019;s stock options during the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.734%;"></td>
        <td style="width:1.131%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.119%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.459%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.119%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.065999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.119%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.389999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />average<br />exercise<br />price per<br />share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />average<br />remaining<br />contractual<br />term<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />intrinsic<br />value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf2f188c-446f-4579-9244-945bc207d8c0" contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,538,411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02c3855b-89db-4081-9050-16ac87903d95" contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3510e28e-b3bb-4c13-b98f-cf99fb0ece24" contextRef="C_c6c185ed-a9aa-4137-a7f1-09443c4dd1f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77abbfeb-bf26-4131-8dc4-781b72aec0a3" contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,009,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_916f5b5e-68c2-4172-921c-78a7e83e8662" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,631,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6885b5c3-314f-4ba3-804f-4017f705d336" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db0a3907-7957-41e4-85e7-55af26bdea4f" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aecc46f-9774-4ef5-914b-82c6488f278c" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">170,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98a63c1a-9c66-49ec-92a4-106d328f50e7" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cc00912-ae9b-43ea-8596-a0af1c3d94d6" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,998,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04163826-8235-48e4-9526-4e71e3b8db23" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9e5348b-c674-4450-b7f6-f2dd1527d7dc" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98794251-a7b6-48e3-a016-ea64f6f027eb" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,357,655</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dda9624-5afe-484e-84e7-9d002b00364d" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,827,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d72d6886-f984-40b7-9f51-576c40cedfe8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d904374-29ed-475b-af4a-93e1370107d7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">111,013</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecf614ee-b518-4b27-bbac-24a7f353face" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,593</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f5d76a8-e7a0-42d0-b507-d3886c57700a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80f8fb80-2257-4828-b997-f269e4eca731" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,778,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_671fb283-3104-4304-a216-547e9883f4c6" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e0ecf4b0-927a-4646-bb85-6c16454833a0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea0772fb-b664-40b6-8d7d-8d94d54551b5" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,474,743</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62076e4e-945e-44ff-90e1-874b7c535cae" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7048be55-f2dd-4450-bad9-d93644cc1a05" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6174da79-8a45-4ce5-99d6-477923748a08" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,667,144</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1caadc0c-e66d-4874-a15a-52b756749f3a" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb21d3a2-2437-4628-ba13-c6095f6d2f80" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair value of all stock options granted during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35ce86e3-7520-4aff-bafc-13589c35666f" contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The intrinsic value at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is based on the closing price of the Company&#x2019;s common stock on that date of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbb4a771-6423-4db6-9de7-82336c2c6f2f" contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c58fb633-8079-4ca2-b35b-c656b9fe56be" contextRef="C_dca04f3b-68dd-41e8-a315-ab386139707c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The grant date fair value of stock options vested during the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c716fd02-1103-4845-9bad-8bfed5be8f2d" contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59c9d3fe-a987-44bd-89a6-d3aa4c97fcfc" contextRef="C_dca04f3b-68dd-41e8-a315-ab386139707c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Total unrecognized compensation expense related to unvested options granted under the Company&#x2019;s stock-based compensation plan was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df6d988c-981d-4d69-bb34-a6d36d557482" contextRef="C_803e51c6-3b20-4c08-ab3e-92d3c19e9bab" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_250668ab-96f5-4768-a790-715080640802" contextRef="C_7c6a862c-3e11-4d68-aa36-13ca8e140e89" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The Company recorded stock-based compensation expense related to the issuance of stock as follows (in thousands):</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_e20a6832-69d2-4850-8a0b-0c7bed375c26" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.763%;"></td>
        <td style="width:2.403%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.687%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.759%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d7e74f4-38f4-4717-b880-d9e093cbe1ca" contextRef="C_95336a64-c52f-4870-b189-b6f50eb63e3e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7470c99-f921-47ec-a917-d4f9e851e3e9" contextRef="C_349093ed-5db6-4bb4-9588-93a0cf9b007d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,903</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84c2a63a-ea2b-4646-999f-ff1be1f27eeb" contextRef="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_065c84c3-62fb-4a59-bb12-f45d1af98121" contextRef="C_b98f82b2-780e-4b62-9d74-6429370aa2d4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d088eacf-b7b2-4080-8d33-0cff80829de3" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43285d73-c55a-4a37-8e56-375770561dcf" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of stock options, the expected volatility based on the historical volatility of a publicly traded set of peer companies and the expected risk-free interest rate based on the implied yield on a U.S. Treasury security. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d3b32cb-1d47-49a7-9a11-4358b8225ba0" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_1d3b32cb-1d47-49a7-9a11-4358b8225ba0_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_1d3b32cb-1d47-49a7-9a11-4358b8225ba0_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.1%;"></td>
        <td style="width:0.988%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.453999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.988%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.469%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ffaaaea-a58d-4e71-a74c-0165064f5bf3" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2192ca7a-8bab-4f03-89d6-9d5bd08d2789" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5e5c8e32-84da-42c4-8a74-933988dcd873" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81e12094-bed2-4e33-ad74-8a00599642b4" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65a1a9b9-c800-4bac-8777-a47eea3566cd" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">90.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d52a720-8a63-4c0c-a51b-49b6b5b8b274" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">90.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c69404f7-28ae-4545-9112-e570f5e5c122" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47422d99-2b4d-4bd9-aff6-f76109c4f523" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ef385365-82fb-4be5-898e-3b38719c8ea6" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f9d1e80-70da-48cd-86e1-997d13bc7710" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ed61d67e-107d-4128-b3ed-7337976367b7" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax expense or benefit for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has incurred net operating losses for all the periods presented. The Company has not reflected the benefit of any such net operating loss carryforwards in the accompanying financial statements. In 2019 the domicile of the reporting entity has changed from Denmark to the United States resulting in a tax rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ff931ca-c080-4cdd-8994-1874104fce0a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_79ea36ef-7e71-4d73-acfb-a79df77ce95a" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in 2022 and 2021. This is discussed further below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c5e20b5-4bb4-4f05-8517-3013ee8f87c9" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of net loss are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"></td>
        <td style="width:1.368%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.435%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.368%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.422%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be90ae3d-d9ea-4e02-a86a-2854a8e0d0b4" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b52ab788-4f67-45a0-a92d-71c3bc65088a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc796c01-1213-43b7-9aaf-13a6e175d807" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94230f39-d981-4bf2-bef0-11d266e68af3" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_effb797a-d314-4ea6-ab74-c770e4063fdd" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cf9e898-e005-4d3e-85b9-0baa7b4f8a58" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reconciliation of effective tax rate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is different from the statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span><ix:nonNumeric id="F_49e44a56-3259-481c-8370-125938b8cdcc" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_49e44a56-3259-481c-8370-125938b8cdcc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation of the statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_49e44a56-3259-481c-8370-125938b8cdcc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.728%;"></td>
        <td style="width:1.142%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.142%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.986999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acd2a6a1-4bf7-4b6c-bbf2-030be2cf6c38" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53f2fb91-90ba-4f54-bef7-b6bcbfa97ecd" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan Drug Credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a826fb0-9374-4b76-8b90-a43ad4fbdf0b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdd0fbdf-dc03-46de-838d-5ecf38f5886d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" unitRef="U_pure" scale="-2" decimals="3">5.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8746c48-6154-48e4-ba67-0b5c9b95beda" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3">2.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a29a1aeb-7828-4a15-a4ea-47e030db0801" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3">3.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90a4089e-5045-4378-8e55-ee0bc0fcb24e" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f83987de-7260-4471-99c7-602be787869e" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9b9b348-7b98-45e4-a8bd-d951f57609d6" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ecd6f22-67ff-43e6-a8eb-a6aa53971729" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_273ad9d6-27b5-4816-9d98-df32b52dcf32" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">32.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad18a81-a9a2-4fdc-984b-2d480b3ed2d6" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">32.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dddb7618-c2d0-42f9-a1e0-f9f472af6bd2" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_dddb7618-c2d0-42f9-a1e0-f9f472af6bd2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_dddb7618-c2d0-42f9-a1e0-f9f472af6bd2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.929%;"></td>
        <td style="width:1.597%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.446%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.597%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.433%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7aa6227c-e80e-4d45-bfa1-49be41034e8c" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa55da0f-ae0c-4ed3-b0c1-7cfa7e5939c5" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Orphan drug credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_327d355f-7205-47ad-93bc-a3c539245809" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:DeferredTaxAssetsOrphanDrugCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25e8b88f-0c88-44c6-ab6a-adc74ba390d1" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="glto:DeferredTaxAssetsOrphanDrugCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;U.S. research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b59df11f-bc43-4ece-b712-4bddeb695cae" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa8fd6df-2cf5-4eee-8691-138122d8cb05" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Bonus compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2573ce70-0d5e-418b-a012-03359f288a18" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:DeferredTaxAssetsBonusCompensation" unitRef="U_USD" scale="3" decimals="-3">544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cc1617e-1bda-426a-9a7a-7a0de9088527" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="glto:DeferredTaxAssetsBonusCompensation" unitRef="U_USD" scale="3" decimals="-3">274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38bdfa35-37e0-4067-9f4e-7f8541e8f975" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_071aa1e1-406d-498f-ac32-4264588e3d6a" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b9f3881-547c-40ad-b171-859b142ced98" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,472</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c812946-4e15-4a0d-8315-b06435d92f24" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aef3071-4f50-49ea-ae0e-23c65a8d466d" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14bc8b5f-0e95-4750-acf5-ca50134946a8" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="glto:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16d26cc6-aac5-46e1-a4e1-09a5783c5585" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net noncurrent deferred tax asset(liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable income. The Company considers projected future taxable income and ongoing tax planning strategies, then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more-likely-than-not able to be realized. Based upon the Company&#x2019;s assessment of all available evidence, including the previous three years of taxable income and loss after permanent items, estimates of future profitability, and the Company&#x2019;s overall prospects of future business, the Company determined that it is more-likely-than-not that the Company will not be able to realize a portion of the deferred tax assets in the future. The Company will continue to assess the potential realization of deferred tax assets on an annual basis, or an interim basis if circumstances warrant. If the Company&#x2019;s actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to change the valuation allowance against the gross deferred tax assets. On the basis of this evaluation, a full valuation allowance at December 31, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was recorded of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8baac61-5dc0-48e3-bbff-8ca750178f96" contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">53.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74182250-77d7-4749-9204-43cd03ae9cff" contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, to reduce the net deferred tax assets to their estimated realizable value. The change in valuation allowance was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_006ce632-b837-4b04-8e9b-cf972526a450" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to taxation in the United States, United Kingdom and Denmark. As of December 31, 2022, tax years 2019 and forward were generally open to examination by the Danish tax authorities and tax year 2021 and forward was open to examination by the United States tax authorities. The Company is not under examination by any taxing authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had gross U.S. federal net operating losses, or NOLs, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_045375e4-ecd1-477a-b64b-aaa5dd29c8de" contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and federal research and development credits, or R&amp;D credits, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66b6c9d7-f0b2-4331-a50a-a089e4f1cb1c" contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and Orphan Drug Credit, or ODC, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d175c1de-4db8-49ff-a42e-d7bdcf0fcf60" contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93" name="glto:DeferredTaxAssetsOrphanDrugCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to offset tax liabilities. The federal R&amp;D credit and ODC carryforwards begin to expire in 2033 and 2042, respectively. All of the federal NOLs have an infinite life. The Company also had gross state NOLs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7382e206-db10-46c4-a647-11b4542aadc3" contextRef="C_c3ec0dd0-9fe6-42b3-b80d-334a822298e2" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which are available to offset state tax liabilities. The state NOLs begin to expire in 2040. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5bd2fa7-aeba-4a9d-8168-371517923959" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also had NOLs in Denmark of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0a1f766-e440-48ad-88df-532bc05fa9cc" contextRef="C_4c5077bc-7856-49b1-b161-185d27434c17" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">161.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which have an indefinite life. Federal and state NOLs and R&amp;D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not completed an analysis to determine if the NOLs and R&amp;D credits are limited due to a change in ownership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;D expenditures. The deduction for R&amp;D expenditures is set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3585d1ad-9cab-4762-a0b2-398e65490699" contextRef="C_0fed39e7-58c4-4ac9-ab3d-13d15fe315f9" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">101.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2019, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc7e4732-3537-4104-8a48-ade869ba0ae8" contextRef="C_4336373f-aca3-4ad2-b03c-279e75f3a53f" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">130</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2020 through 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50456058-a1ef-47fc-a737-faf2835e3ea3" contextRef="C_68b96280-106d-4c4f-9050-7768f44a1658" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2023 through 2025 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7e208d5-6866-4699-a26a-a33f4e0d1f4c" contextRef="C_00b3ce82-ee23-4fad-a96c-75e32b50f767" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8198eff8-bc9a-4cbe-b160-27568327da81" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. NET LOSS PER SHARE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e093a051-eb27-4071-a2d2-a86f3d212e38" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"></td>
        <td style="width:1.368%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.435%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.368%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.422%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b7306b1-72d0-40f4-8c3f-595c5d5f9a83" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62af4297-e0ab-4cb7-82d7-970e004402fa" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,752</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of shares used in computing net<br />&#160;&#160;&#160;loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4d51319-7f81-4887-ac73-7d958c7f54a8" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_40d890cb-e153-4284-a82a-88a0244cfa74" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,409,123</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea4a4cf6-9565-48cc-a263-ea0f90468d8d" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_6e96bfb7-922c-4b6d-9945-6b31eb4c1022" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,261,832</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fac80c54-9707-4068-969d-980b3abf872f" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_01578d6d-0812-43fe-ae03-1a6ea56fe749" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.43</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b6201f3-e2e9-464d-9727-f1e6c21b3495" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_2b4505e4-d83a-428e-b829-6292950f3f0a" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.05</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c024ad86-223a-4184-a817-d16bb280f9c7" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.278%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.668%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.621%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.814%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75214625-75cf-49e8-8a2a-cab69d10afbf" contextRef="C_26d85074-1442-4534-bfb5-878f1c5c9abc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,778,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d499fb99-3a05-43f5-9401-cc041ed6a728" contextRef="C_97be5459-8e1d-4a9f-a3fe-24a288c0d7ed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,998,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8bfb4aed-af60-4bb3-9f34-1067483fdf2d" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. DEFINED CONTRIBUTION PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a 401(k)-defined contribution plan (the &#x201c;401(k) Plan&#x201d;) for its U.S. based employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the discretion of its Board, the Company may elect to match employee contributions. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company paid a match of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffcd315d-1294-4150-8dc3-7140b3e03a1d" contextRef="C_cfb03bcf-2388-41ae-925e-205c6106a3e1" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_491e9cfa-f5d3-41d7-b15f-19cfba1304c0" contextRef="C_30e1cab4-655e-4ed1-bfb8-3bd1c2074e24" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, up to the maximum permitted by the Internal Revenue Code, which amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f717969c-b433-4c3e-a434-0fe545454b70" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_97e55189-22c0-46a7-bfa9-61dad13c9f89" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during both periods and is expensed as personnel costs when incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0ec8a7d-9b7e-4180-8e33-a0f23be2b347" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7c251cc-07de-4815-ac59-5b814885c11b" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_239eab89-ddb6-4488-a2eb-490684f246f2" contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> material related party transactions.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8ba4a98-47e3-4612-8de7-17f129c77f11" contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. SUBSEQUENT EVENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>glto-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote of stockholders. Except as described under &#x201c;Anti-takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Bylaws&#x201d; below, a majority vote of the holders of common stock is generally required to take action under our amended and restated certificate of incorporation and bylaws. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, 25,652,392 shares of our common stock were outstanding and held by 27 common shareholders of record.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors has the authority, without action by the stockholders, to designate and issue up to an aggregate of 10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of us, which might harm the market price of our common stock. See also &#x201c;&#x2014;Anti-Takeover Effects of Delaware Law and Provisions of Our Amended and Restated Certificate of Incorporation and Bylaws&#x2014;Provisions of our amended and restated certificate of incorporation and bylaws&#x2014;Undesignated preferred stock&#x201d; below.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors will make any determination to issue such shares based on its judgment as to our best interests and the best interests of our stockholders.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had no shares of preferred stock outstanding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of 7,628,196 shares of our common stock, or their permitted transferees, which we refer to as our registrable securities, are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the Investors&#x2019; Rights Agreement. The Investors&#x2019; Rights Agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses incurred in connection with registrations under the Investors&#x2019; Rights Agreement, will be borne by us, and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Demand registration rights</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of our registrable securities are entitled to demand registration rights. Under the terms of the Investors&#x2019; Rights Agreement, we will be required, upon the request of holders of at least a majority of our outstanding registrable securities, to file a registration statement and effect the registration with respect to at least forty percent (40%) of the registrable securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of expenses related to the offering, would exceed $10 million) having an anticipated aggregate offering price, net of expenses related to the offering, of at least $5 million for public resale, unless our board of directors decides in good faith that such registration would be materially detrimental to us and our stockholders under the circumstances. We are required to effect up to two registrations pursuant to this provision of the Investors&#x2019; Rights Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short form registration rights</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of our registrable securities are also entitled to short form registration rights. Pursuant to the Investors&#x2019; Rights Agreement, if we are eligible to file a registration statement on Form S-3, upon the request of holders of at least 25% of our outstanding registrable securities to sell registrable securities with an anticipated aggregate offering amount of at least $3.0 million net of certain expenses related to the offering, we will be required to effect a registration of such shares, unless our board of directors decides in good faith that such registration would be materially detrimental to us and our stockholders under the circumstances. We are required to effect up to two registrations in any twelve-month period pursuant to this provision of the Investors&#x2019; Rights Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Piggyback registration rights</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of our registrable securities are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the Investors&#x2019; Rights Agreement, we and the underwriters may limit the number of shares included in the underwritten offering if the underwriters determine that marketing factors require a limitation of the number of shares to be underwritten.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investors&#x2019; Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses of registration</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will pay the registration expenses, subject to certain limited exceptions contained in the Investors&#x2019; Rights Agreement, of the holders of the shares registered pursuant to the demand, short form and piggyback registration rights described above, including the expenses of one counsel for the selling holders.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expiration of registration rights</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registration rights granted under the Investors&#x2019; Rights Agreement will terminate upon the earlier of (i) a deemed liquidation event, as defined in our amended and restated certificate of incorporation or certain other events constituting our sale, (ii) on a holder-by-holder basis, at such time after our initial public offering when a holder&#x2019;s registrable securities could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iii) the third anniversary of our initial public offering.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Effects of Delaware Law and Provisions of Our Amended and Restated Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain provisions of the Delaware General Corporation Law, or DGCL, and of our amended and restated certificate of incorporation and could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our board of directors or management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware takeover statute</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon completion of this offering, we will be subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div></div>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 203 defines a business combination to include:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and bylaws</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws to be in effect immediately prior to completion of this offering will include a number of provisions that may have the effect of delaying, deferring or discouraging another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board composition and filling vacancies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In accordance with our amended and restated certificate of incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of not less than two thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No written consent of stockholders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholder without holding a meeting of stockholders.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Meetings of stockholders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our amended and restated bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance notice requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our amended and restated bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in our amended and restated bylaws.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment to certificate of incorporation and bylaws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As required by the DGCL, any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, directors, limitation of liability and the amendment of our amended and restated certificate of incorporation must be approved by not less than two thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority vote of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least two thirds of the outstanding shares entitled to vote on the amendment, voting together as a single class.</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Undesignated preferred stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our amended and restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive forum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws, (iv) any action to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws, or (v) any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternate forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, as we are a Delaware corporation. Although our amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could rule that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#x2019;s address is 250 Royall Street, Canton, MA 02021, and its telephone number is (800) 962-4284.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Listing</font></p>
  <p style="text-indent:11.853%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;GLTO.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>glto-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSIDIARIES OF THE REGISTRANT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.313%;"></td>
    <td style="width:33.344%;"></td>
    <td style="width:33.344%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jurisdiction of Organization</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percentage Ownership</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PharmAkea, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto Securities Corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto Biotech AB</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sweden</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto Biotech ApS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denmark</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100% owned by Galecto Biotech AB</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>glto-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No 333-262823) pertaining to the 2020 Equity Incentive Plan of Galecto, Inc.,</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No 333-249852) pertaining to the 2020 Stock Option and Incentive Plan and 2020 Equity Incentive Plan of Galecto, Inc.,</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No 333-254805) pertaining to the 2020 Equity Incentive Plan of Galecto Inc.,</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-260778) of Galecto, Inc.,</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 9, 2023, with respect to the consolidated financial statements of Galecto, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ EY Godkendt Revisionspartnerselskab</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Copenhagen, Denmark</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>glto-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF CHIEF EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO RULES 13a-14(a) AND 15d-14(a)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Hans T. Schambye, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Galecto, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant&#x2019;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.001%;"></td>
    <td style="width:0.997%;"></td>
    <td style="width:5.183%;"></td>
    <td style="width:45.819%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hans T. Schambye</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hans T. Schambye, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>glto-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO RULES 13a-14(a) AND 15d-14(a)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Jonathan Freve, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Galecto, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant&#x2019;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.004%;"></td>
    <td style="width:0.997%;"></td>
    <td style="width:6.158%;"></td>
    <td style="width:45.841%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Freve</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Freve</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>glto-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Galecto, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.004%;"></td>
    <td style="width:0.997%;"></td>
    <td style="width:6.158%;"></td>
    <td style="width:45.841%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Hans T. Schambye</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hans T. Schambye, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 9, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Freve</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Freve</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img108642122_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )? ]0# 2(  A$! Q$!_\0
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MS;_&NDHHNPLCF_\ A /"O_0%M_S;_&C_ (0#PK_T!;?\V_QKI**+L+(YO_A
M/"O_ $!;?\V_QH_X0#PK_P! 6W_-O\:Z2BB["R.;_P"$ \*_] 6W_-O\:/\
MA /"O_0%M_S;_&NDHHNPLCF_^$ \*_\ 0%M_S;_&C_A /"O_ $!;?\V_QKI*
M*+L+(YO_ (0#PK_T!;?\V_QH_P"$ \*_] 6W_-O\:Z2BB["R.;_X0#PK_P!
M6W_-O\:A3P%X6-S*IT6WP N.6]_>NJJ"/_C\F_W5_K1<+(PO^$ \*_\ 0%M_
MS;_&C_A /"O_ $!;?\V_QKI**+L+(YO_ (0#PK_T!;?\V_QH_P"$ \*_] 6W
M_-O\:Z2BB["R.;_X0#PK_P! 6W_-O\:/^$ \*_\ 0%M_S;_&NDHHNPLCF_\
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M_-O\:Z2BB["R.;_X0#PK_P! 6W_-O\:/^$ \*_\ 0%M_S;_&NDHHNPLCF_\
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M_FW^-=)11=A9'-_\(!X5_P"@+;_FW^-'_" >%?\ H"V_YM_C72447861S?\
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M0GDXR<"M#3+.T\9>*?$S^(=3NH7L+@Q6L"W7E"&,$C>!^ Y_.E8+G<'Q8O\
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M\FM&BB@ HHHH **** "BBB@ IDW^HD_W3_*GTR;_ %$G^Z?Y4 )!_P >\?\
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M6K]% &>VB:<VMC66M5.H"+R1-N.=GIC./TK&D^''A"625VT*WW2G+8+#OG@
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MCV.>_P"$.LO^?S4/^_\ _P#6H_X0ZR_Y_-0_[_\ _P!:NAHHYY=PY(]CGO\
MA#K+_G\U#_O_ /\ UJ/^$.LO^?S4/^__ /\ 6KH:*.>7<.2/8Y[_ (0ZR_Y_
M-0_[_P#_ -:C_A#K+_G\U#_O_P#_ %JZ&BCGEW#DCV.>_P"$.LO^?S4/^_\
M_P#6H_X0ZR_Y_-0_[_\ _P!:NAHHYY=PY(]CGO\ A#K+_G\U#_O_ /\ UJ/^
M$.LO^?S4/^__ /\ 6KH:*.>7<.2/8Y[_ (0ZR_Y_-0_[_P#_ -:C_A#K+_G\
MU#_O_P#_ %JZ&BCGEW#DCV.>_P"$.LO^?S4/^_\ _P#6H_X0ZR_Y_-0_[_\
M_P!:NAHHYY=PY(]CGO\ A#K+_G\U#_O_ /\ UJ9+X/LEB<_;-0X4_P#+?_ZU
M=)3)O]1)_NG^5'/+N')'L<]%X/LFA0_;-0Y4'_7_ /UJ?_PAUE_S^:A_W_\
M_K5NP?\ 'O'_ +H_E4E'/+N')'L<]_PAUE_S^:A_W_\ _K4?\(=9?\_FH?\
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M^:A_W_\ _K5T-%'/+N')'L<]_P (=9?\_FH?]_\ _P"M1_PAUE_S^:A_W_\
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MX0ZR_P"?S4/^_P#_ /6KH:*.>7<.2/8Y[_A#K+_G\U#_ +__ /UJ/^$.LO\
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M\J $@_X]X_\ ='\JDJ.#_CWC_P!T?RJ2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ((O^/JX_X#_*IZ@B_P"/JX_X#_*IZ&""BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *@C_X_)O\ =7^M3U!'_P ?DW^ZO]: )Z*** "BBB@
MHHHH **** "BBB@ HHHH **** (8O^/F?ZK_ "J:H8O^/F?ZK_*IJ& 4444
M%%%% !1110 4444 %%%% !1110 C?=/TJ*U_X](O]T5*WW3]*BM?^/2+_=%
M$U%%% !1110 4444 %%%% !1110 4444 %%%% ''^$/O^(?^PS<?R6BCPA]_
MQ#_V&;C^2T4V)%CX<_\ )/=&_P"N!_\ 0C745R_PY_Y)[HW_ %P/_H1KJ*'N
M"V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDW^HD_W3
M_*GTR;_42?[I_E0 D'_'O'_NC^58/A3Q!<:]_;!N(HHQ8ZC+:)LS\RH>"<]Z
MWH/^/>/_ '1_*O)$DNHOA_\ $![0L)?[6N02O4(74-_X[FFD(ZOQ?XTM+3PO
MJ<^AZQ92:C:A3MCD20K\P!^7OUK;:^O/[;TV!;K3UMYK=GEAD8B=V X*#I@=
MZX+QW9>&8OA3#);162OY41LG0 .S<9P1R>,Y_6MN]_Y*=X5_[!\_\A3L*YU>
MI:[I.CE!J6I6EHS_ '5FF52?H":F_M*Q_L\ZA]L@-F%WFX$@*;?7=TQ7$^$8
M;*\\4>+'U6."74TOR@$X#,MO@;, _P .*P&6-/#'Q$CL-O\ 8ZRXM1&?W8?;
M^\"]L9QTI6'<]-_X2'1AJ*Z?_:ME]L;&V#SUWG/3C/6I-2UK2]&17U+4+:T5
M_N^=(%W?0'K7G6MVOAM/@Z)K1+/?]GC:&6/!D,_'1OO%LYSWZUKW6IS3:]IN
MCPZ5I\^N?V8D\]UJ!P(UZ%0 "S'=D\8HL%SK?[;TLZ4^J+J%JUB@R;@2J4'_
M  +I6-X;\;Z;XGTKSK::&&]*2,;,S*TB!21D@=NA_&L+P)&)-6\86LBV,D?V
MB-FCM%S!O*?-M!]QS[BI?AC#:K\/HG$4(NE-PCL%&_\ UC<$]>F/THL*Y;\'
M^-+6Y\*Z;<:_J]E%J%R7XDD2,MAR!\OX5OZS>W=M+IHM+O3H5FN523[6Q!D4
MC[L>.K^E<%X,T'2I_A%<7$MA \]Q!<-)*R L2"P'/;&!C%13R/+X4^&[R,68
MWUOR3D_=-.VH7T/2]2U?3='A$VI7UO:1L<*TT@7)]L]:FM+RUU"V2YL[B*X@
M?E9(G#*?Q%<3$EK<_%[4H]46*1H["+[ D^"-I^^5![Y]/>NOTN+2X8ITTI;5
M8Q,WFK;8VB3C=G'?IFD,Q_%VO:EH\VD6NEQ6K7&HW7V<-<[MJ<9S\IS56U\2
MZSI_B:RT3Q%:68-^KFUNK)V*,RC)5E;D'%4_B+'<RZGX4CLYT@N6U+$<KIO"
M';U*Y&:U=/\ "EP-<AUK6]6;4[VW1DMP(!#'"&ZD*"<D^I-'06MSH+>\M;MI
MEMKB*4PN8Y0C [&'53Z&N;\9^(WL/!&H:KHMY"\T#J@D3$@5MX# ]L\UG^";
MJWLM0\8)<SQPF+59)G\Q@NU"HPQSVX/-<AYB3?!/7Y8V#1OJ4C*P[@RI@TTM
M0N>O'4K6WCMA=W4,4LT9=1(X7=A<L1GT')JO;^)-$N[2>ZM]6LI+>W_UTJSJ
M5C^ISQ7'>+K.WU#Q5X(M;N)98)&EWQMT;$8.#[9'2DU#0=*D^+^G0M80>2VF
MM,T00!&=7PI*]#@>OH*5AW.[T_5+#5K;[1I]Y!=0YQOA<, ?0XZ&JL_B;0K6
M^^Q7&L6$5UG'E/<*&!]",\&N0@A;3_&OC*+2HA"YTR.6..(8'F[6P0!WS1X5
ML_#4OPNBFNH[)XWMF:\EE"EO,YW%B>=V?QZ46"YWL][:VS0K/<11&9MD0=@-
M[8S@>O JM8:[I.J320Z?J5I=2Q??2&97*_D:\J:VEO\ P5\/[;54:19=0",K
MD@M$=VT'_@./PKJ-=L+33OB%X/DL;:*V9VN(7\E @9!'D XZ@46"YU%]XFT/
M3+H6M]J]E;SG_EG).JL/J,\?C5V:^M+>V6YFN88X&*A9&<!26.!@^^:X-M0&
MLW.OC3M*T*WL[6XD@O+G4<[I7 PS$*.![DUSLQ:?X :>LK,?W\:9SR!YV*+"
MN>I#Q)HC-.!JUF3;R+'-^^7Y&)P >>"2"/PJ[=WEM80&>[N(X(@0I>1@HR3@
M#)]ZP]4\(:9>>$[O1;2S@MUF@"(40 AEY0D]3@\_G7&Z;JDOC>Y\-:-/DMIV
MZYU5".DD1V(I^K<XHL.YZK1112&%%%% !1110 4444 4IIC;+?SA=QCCW@'O
MA<UYV?BS< D?V5%_W]/^%=_?_P#'GJO_ %P/_H!KYY;[Q^M=%&$97N>9CZ]2
MDXJ#M>YZ-_PMJX_Z!,7_ ']/^%'_  MJX_Z!,7_?T_X5YQ16WLH=CS_KN(_F
M_(]'_P"%M7'_ $"8O^_I_P */^%M7'_0)B_[^G_"O.**/90[!]=Q'\WY'H__
M  MJX_Z!,7_?T_X4?\+:N/\ H$Q?]_3_ (5YQ11[*'8/KN(_F_(]'_X6U<?]
M F+_ +^G_"C_ (6U<?\ 0)B_[^G_  KSBBCV4.P?7<1_-^1Z/_PMJX_Z!,7_
M ']/^%'_  MJX_Z!,7_?T_X5YQ11[*'8/KN(_F_(]'_X6U<?] F+_OZ?\*/^
M%M7'_0)B_P"_I_PKSBBCV4.P?7<1_-^1Z/\ \+:N/^@3%_W]/^%'_"VKC_H$
MQ?\ ?T_X5YQ11[*'8/KN(_F_(]'_ .%M7'_0)B_[^G_"C_A;5Q_T"8O^_I_P
MKSBBCV4.P?7<1_-^1Z/_ ,+:N/\ H$Q?]_3_ (4Q?BM<+,[_ -E1?, /]:>W
MX5YW11[*'8/KN(_F_(]'_P"%M7'_ $"8O^_I_P */^%M7'_0)B_[^G_"O.**
M/90[!]=Q'\WY'H__  MJX_Z!,7_?T_X4?\+:N/\ H$Q?]_3_ (5YQ11[*'8/
MKN(_F_(]'_X6U<?] F+_ +^G_"C_ (6U<?\ 0)B_[^G_  KSBBCV4.P?7<1_
M-^1Z/_PMJX_Z!,7_ ']/^%'_  MJX_Z!,7_?T_X5YQ11[*'8/KN(_F_(]'_X
M6U<?] F+_OZ?\*/^%M7'_0)B_P"_I_PKSBBCV4.P?7<1_-^1Z/\ \+:N/^@3
M%_W]/^%'_"VKC_H$Q?\ ?T_X5YQ11[*'8/KN(_F_(]'_ .%M7'_0)B_[^G_"
MC_A;5Q_T"8O^_I_PKSBBCV4.P?7<1_-^1Z(OQ6N%D=_[*B^;'_+4_P"%/_X6
MU<?] F+_ +^G_"O.**/90[!]=Q'\WY'H_P#PMJX_Z!,7_?T_X4?\+:N/^@3%
M_P!_3_A7G%%'LH=@^NXC^;\CT?\ X6U<?] F+_OZ?\*/^%M7'_0)B_[^G_"O
M.**/90[!]=Q'\WY'H_\ PMJX_P"@3%_W]/\ A1_PMJX_Z!,7_?T_X5YQ11[*
M'8/KN(_F_(]'_P"%M7'_ $"8O^_I_P */^%M7'_0)B_[^G_"O.**/90[!]=Q
M'\WY'LGAWX@1:Y(]O+;+;W(Y1-^0X]N.OM72?VFW_/(?G7SU%*\,JRQ.4=#E
M64X(->I>%O$Z:U +>X(6^C'(Z>8/4>_J*PJTN75;'HX/&^T]RIO^9V?]IM_S
MR'YT?VFW_/(?G5"BL#TB\=3;!_=#\ZC@U%EMXU\H<*.]53T-,B_U2?2@#2_M
M-O\ GD/SH_M-O^>0_.J%% %_^TV_YY#\Z/[3;_GD/SJA10!?_M-O^>0_.C^T
MV_YY#\ZH44 7_P"TV_YY#\Z/[3;_ )Y#\ZH44 7_ .TV_P">0_.C^TV_YY#\
MZH44 7_[3;_GD/SH_M-O^>0_.J%% %_^TV_YY#\Z/[3;_GD/SJA1WH I^%8O
M+&LN#GS=4FD(],A>**?X:_U6I?\ 7_)_):* %^'/_)/=&_ZX'_T(US)OM4\<
M>)=4M8M5ETO1-,)5W@;:TA!(SN_X"3Z =JZ;X<_\D]T;_K@?_0C7+BQU;P/X
MEU2XBTB;5-$U(EG6W7<R9)."O_ B/0CO6M/=]SDQ%[1O\/7^NQJ^'=/L+37;
M=M,\:2WR$-YEE+<K+Y@VGI@\8//3M7)_:H;[QMX@BUCQ/?:;#!,WD>7<E1]X
MC 'L.U6_#]F=0^)=CJFE^';K3=+AB97\R#RP&V.,^G.0*9!#)I/C;Q!<ZEX4
MOM3M[F9O)*6?FJ/F)R"1CD>E:K1OT.1N\5965WWML;/@WQ#JL?@K6-3OYGNX
M+3>UI-+]Z0 'KWZXZ^IK%CT_5[_P-/XOEU_4%U%=TZ(DN(PJMC&W\#5[POX5
MU*XM?$IDLGTNQU*)DM;20\J3D@X[8Z50M[[6K7P1-X/;P[J3:@VZ%)!%^ZV,
MV2=WXGV]Z-+OE[A[W)'VE[6=M]^G_ .RLKK6_%'@S2[FPOX;*>X7%U.8]S #
M(.P= 2169\)+R[O-&U)KNZFN'6[P&E<L0-H]:UK62;P3X/TRT;3;W4)D79(E
ME'O*L<L2?;)Q7,?#*XO]&:;3+W0M4C-W<&03M;E8T&W^(GITJ+7C*QO>U6GS
M-WMK]R)/&EM8VG]I7-YXPO4U$9>WM(IMH3/*IL'/ISQZT^37_$.E?"-=0NFD
M&HNXC2:09=8V;AC[XZ$^HIWB76;&\-]97W@B^FOV#1Q3+:AP_96$@YQT/&:G
M\*Z=J&@_#RZ37=.N+Y7DW#3PHD<1G:,;3^+8_K5?95S/>I+D?1ZZZ>ISFJS2
M^&=(T?7M-\3W-Y=S.AN(9;G>K@C<?E]!TY]:]CBD$T*2KT=0P_&O'KK0K3Q1
M=6MCH'A:YTVW\X/=7MU&4(4?PKDG].X%>Q(BQHJ*,*HP![5%6UEW-L(G>7;3
MO\]QU%%%8G:%%%% !1110 4444 %,F_U$G^Z?Y4^F3?ZB3_=/\J $@_X]X_]
MT?RJO::586*7*6UI%&MU(TLX"\2.WWB?7-6(/^/>/_='\JP;CQWX7M+J6VGU
MFW2:%RDB\G:P.".!0(?'X(\,0B<1Z)9J)U*R8CZCT'I^%:CZ99/?6]\UM&;J
MW0QPRXY13U JN/$.DF;3H1>QF345+6@ /[T 9)''IZTMKKEE>:U?:3"SFZL5
M1I@5P '&1@]Z>H:$.J^%="UNX6?4M+MKF91@2.GS8]"1U%5_$&@+<^"K_1-(
MMX(/,@,<,2@(@/X5T%%*X['-Z9X*T*U^QW<NCV?]HQ1('E" _.% )],Y[XK0
MU;PYH^NM$VIZ=!=/%]QG7E1Z9'./:M2BBX6*.G:+IFDM*VGV,%J9MOF>4@7=
MM&!T]!5>U\,Z)8ZE-J-KIEO#=S!A)*BX+!NOYU:U/5++1K"2^U"X6"VCQND8
M$@9.!T]S5I'61%=#E6&0?44 5+32;"QTS^S;6UCBLMK+Y*CY<-G(_')J,Z%I
M9MK*W-C"8;%P]LF.(F'0BM&B@#,U?P[H^O*BZII\%UL^X9%Y7Z'K5G3]-LM)
MLUM-/M8K:W7D1Q+M&?7ZU:HH JW6G6=]-;2W5NDLEM)YL+,.4;U%6J** ,>^
M\*Z#J>H+?WNDVL]TN/WCQ@DXZ9]?QJ5O#NCMID^FG3X/L4\AEE@V_*S$Y)Q]
M0*TZ* *DVEV-Q=6ES-:QO/9Y-NY',>1@X_"E;3;-]334FMT-Y'&8EFQ\P0G)
M'TS5JB@"M'IUI%J$U_';HMW,BI)*!\S*.@-94W@KPS/?&]ET2R>X+;BQC&"?
M4CH3^%;U% %2ZTRRO6MFN;:.0VL@E@W#_5L.A%+<:=9W5Y:W<]NDEQ:EC!(P
MYC)&#C\*M44 8UUX2\/WNI'4+G2+26[)!:1H\[B.Y'0GZU,?#VD'25THZ?!]
M@5MRP;?E!SNSCZ\UIT4!8.@XKEO"'AVXTJ[UG4]0CA2^U*[:0K$<A(Q]T9]>
M2374T4 %%%% !1110 4444 %%%% &;?_ /'GJO\ UP/_ * :\5\+Z"FOZP\,
M\IBM8(S-.Z]=H["O:K__ (\]5_ZX'_T UXIX9UX>']6>>2'S[>:,PSQ@X)4^
ME=%*_*['E8[E]K#GVU-R.TT+4;9S:>$]6^QX8)J$4C.>.Y7I6=X4TO3)K>_U
M36XR^GVH6,+N*[G8X[>@_G6SI6O>&]!%V]GJ>J30RQ,D=C)&=L9/IVS[UGP^
M*[32/#%CIFGVUM>2LS2W8NX"R!STP#C/U]JT][9'-^[34I-:7[?+8<WAFTMO
MB/#I,L?F:?.WF1KN/,94D#/7@C'X5S>LVT=KKM]:VZ$1QW#1QIG/ . *[+_A
M,-)OKO0=4O,PW]D[).D,)V>60<;?TX]S53SO"/\ PD@U=M5O),W)G:%K0[>I
M.,_7%"<EN34ITY*T&M_P:_0NWGA/25T*YL;:,_V]96D=U,V\_-G)9<9QT]O2
MLG1M&TNU\+R>(]9BENHFE\JWMHWV;CTR3^!_*M*S^(Q_X2!I[K3[&.TE<K)+
M' ?.,?;)SSVJK!KF@3:5>^'KUKE=.^TM-9W,299 3D KUXR:7O[,M^P;YHVZ
MK_*Y4AU+PI+=1 >&9OWI"%#>MM0YQD'J>O>M3Q)8^'=-UZ+1+?1"LLCQ?Z3]
MI<X#,,C:?;(Z]ZYF^71+2[LSI=U=7(1PT\DT>P<$8VC\ZTO$FNV.I^-8-4MG
M<VJ&(EF0@_*>>*JVNES/G2@U*U[KHMNIKOX/TQ_%FKJX>#2--A661$8EFRN<
M GGL:YO5-0\/75DRZ?HLUE<!ALD-P7#+WW ]/PKH3XSTU?%>JS.DL^DZE"L4
MFU=KC"XS@_4UBS/H&D[;S1-1O;B_CD#0B: !$'?=D<\4HWZCJ^SL^2V[OM??
M2WR[&-IWV WBG4FG%L 21  68]EYZ9]:W?'&E6&DZG9QZ= 88I;592I<MR2>
MYJI+JY\1:A"?$%Z88(T8"2WMQD>V!UK5\9ZGH.M+!=6-]<O=01+"L30%58 \
MDDU3;YD9I0]E*UNEMK^9REI;27MY#:PC,DSA%SZFII-.F6UFND9)(([C[/N4
M\LV"1@=<<58\.3QVWB&RDE8(A<H6/1=P*Y_6I[:[AL---A<,PN(M3CF8!<C8
MH()S]:IMW,HQBXW?F9UMI]Q<7EM;&-XC<2"-'D0A<DXJ.>TGMYC%)%(#N*J2
MA&_!QQZUT4>OVS7EQ+//*ZMJT=W'N4G$8+9/L<$<5%!J]G,@2_N+EA_:37&Y
M2=RQE2,@]N<9 YI7?8KDAT9DVVEW%PUTK PM;V[7#+*I4E1C@#\:JM#*D:R/
M%(L;_==E(#?0]ZZB36].%HL2R;F73Y[<[4?:79P5&6).,9Y-.N?$=D;L3QK&
M]O)/#(]N8W+J$QQR=@QT^7K[4<S[#=.%OB.>?3+B/3&OI5,:+,L6QU*L25)R
M,]N*>-)F$4,D\]M;>>-T2SR;69?7&#@>YQ5_4M0MI=%N+1-0ENY9+[[0N]&
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MK46K>,KR?3O#UY#<?V3INI1E[F_,'G>0V.$]!DYY/I5A/#_C)=%&@?VII?V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!FW_\
MQYZK_P!<#_Z :^>6^\?K7T5/%YZ:A#G;YD>W/IE<5YF?AHQ.?[3Z_P#3#_[*
MNBC)1O<\O,*,ZCCR*^YP%%=__P *T;_H)_\ D#_[*C_A6C?]!/\ \@?_ &5;
M>UCW//\ J=;^7\C@**[_ /X5HW_03_\ ('_V5'_"M&_Z"?\ Y _^RH]K'N'U
M.M_+^1P%%=__ ,*T;_H)_P#D#_[*C_A6C?\ 03_\@?\ V5'M8]P^IUOY?R.
MHKO_ /A6C?\ 03_\@?\ V5'_  K1O^@G_P"0/_LJ/:Q[A]3K?R_D<!17?_\
M"M&_Z"?_ ) _^RH_X5HW_03_ /('_P!E1[6/</J=;^7\C@**[_\ X5HW_03_
M /('_P!E1_PK1O\ H)_^0/\ [*CVL>X?4ZW\OY' 45W_ /PK1O\ H)_^0/\
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M"K[#/6NH_LS_ *:_^.UA5JWT1Z6"P?L_WD]_R,^BM#^S/^FO_CM']F?]-?\
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MY\G_ #[2?FO^-'GR?\^TGYK_ (T 3T5!Y\G_ #[2?FO^-'GR?\^TGYK_ (T
M3T5!Y\G_ #[2?FO^-'GR?\^TGYK_ (T 3T5!Y\G_ #[2?FO^-'GR?\^TGYK_
M (T 3T5!Y\G_ #[2?FO^-'GR?\^TGYK_ (T 3T5!Y\G_ #[2?FO^-'GR?\^T
MGYK_ (T 3T5!Y\G_ #[2?FO^-'GR?\^TGYK_ (T 3T5!Y\G_ #[2?FO^-'GR
M?\^TGYK_ (T $7_'U<?\!_E4]4HYG%S.?L\A)V\9'''UJ;SY/^?:3\U_QIB1
M/14'GR?\^TGYK_C1Y\G_ #[2?FO^-(9/14'GR?\ /M)^:_XT>?)_S[2?FO\
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M% !1110 4R;_ %$G^Z?Y4^F3?ZB3_=/\J $@_P"/>/\ W1_*I*C@_P"/>/\
MW1_*I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH @B_P"/JX_X#_*IZ@B_X^KC
M_@/\JGH8(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"/_ (_)
MO]U?ZU/4$?\ Q^3?[J_UH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
MAB_X^9_JO\JFJ&+_ (^9_JO\JFH8!1110 4444 %%%% !1110 4444 %%%%
M"-]T_2HK7_CTB_W14K?=/TJ*U_X](O\ =% $U%%% !1110 4444 %%%% !11
M10 4444 %%%% ''^$/O^(?\ L,W'\EHH\(??\0_]AFX_DM%-B18^'/\ R3W1
MO^N!_P#0C745R_PY_P"2>Z-_UP/_ *$:ZBA[@M@HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9-_J)/\ =/\ *GTR;_42?[I_E0 D'_'O
M'_NC^525'!_Q[Q_[H_E4E !1110 4444 %%%% !1110 4444 %%%% !1110
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MX1U.:^\2:G,H ;[6JH981D#"@ #FL[QCJZ:7J'@^[EO9DM//9I7).9%\L8W
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MF1?ZI/I0 ^BBB@ HHHH **** "BBB@ HHHH **** "CO11WH SO!_P!W7/\
ML*S?^@I11X/^[KG_ &%9O_04HIL19^'/_)/=&_ZX'_T(UU%<O\.?^2>Z-_UP
M/_H1KJ*'N"V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:ZN(DB8LV0J+G 4=N3DU?H;!(\PTS2[IM \$PSV$Q\G4Y'F22$_NQ^]P6!'
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M[^M_\31_PJ_7O^>EE_W];_XFO=OL0H^Q"CZQ(/[.IGA/_"K]>_YZ67_?UO\
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M5.G+F2*_]F/_ ,]%_*C^S'_YZ+^5:5%8G:9O]F/_ ,]%_*C^S'_YZ+^5:5%
M&;_9C_\ /1?RH_LQ_P#GHOY5I44 9O\ 9C_\]%_*C^S'_P">B_E6E10!F_V8
M_P#ST7\J/[,?_GHOY5I44 9ATQ\']XOY4R#3G:WC;S%Y4=JU6^Z?I45K_P >
MD7^Z* *?]F/_ ,]%_*C^S'_YZ+^5:5% &;_9C_\ /1?RH_LQ_P#GHOY5I44
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M%_Q]7'_ ?Y5/5**VC-S./GP-N/G/I]:F^R1?[?\ W\;_ !IB)Z*@^R1?[?\
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MH 6+_CYG^J_RJ:J<=M&;B8?/@$?QGT^M2_9(O]O_ +^-_C3$3T5!]DB_V_\
MOXW^-'V2+_;_ ._C?XTAD]%0?9(O]O\ [^-_C1]DB_V_^_C?XT 3T5!]DB_V
M_P#OXW^-'V2+_;_[^-_C0!/14'V2+_;_ ._C?XT?9(O]O_OXW^- $]%0?9(O
M]O\ [^-_C1]DB_V_^_C?XT 3T5!]DB_V_P#OXW^-'V2+_;_[^-_C0!,WW3]*
MBM?^/6+_ '12&UBVG[__ 'VW^-1VUM&UM&3OR5'\9_QIB+=%0?9(O]O_ +^-
M_C1]DB_V_P#OXW^-(9/14'V2+_;_ ._C?XT?9(O]O_OXW^- $]%0?9(O]O\
M[^-_C1]DB_V_^_C?XT 3T5!]DB_V_P#OXW^-'V2+_;_[^-_C0!/14'V2+_;_
M ._C?XT?9(O]O_OXW^- $]%0?9(O]O\ [^-_C1]DB_V_^_C?XT 3T5!]DB_V
M_P#OXW^-'V2+_;_[^-_C0!RWA'[_ (A_[#-Q_P"RT4G@]0K>(%&<#6;@<GV6
MBFQ(L_#G_DGNC?\ 7 _^A&NHKE_AS_R3W1O^N!_]"-=10]P6P4444AA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %,F_P!1)_NG^5/IDW^HD_W3
M_*@!(/\ CWC_ -T?RJ2HX/\ CWC_ -T?RJ2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ((O\ CZN/^ _RJ>H(O^/JX_X#_*IZ&""BBB@ HHHH **** "BBB@
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MQP=W3V/O0;4JRJ;'245A>;)_ST?_ +Z-'FR?\]'_ .^C0:F[16%YLG_/1_\
MOHT>;)_ST?\ [Z- &[16%YLG_/1_^^C1YLG_ #T?_OHT ;C?=/TJ*U_X]8O]
MT5CF63!_>/\ ]]&FPRR"%,2-T_O&@#H**PO-D_YZ/_WT:/-D_P">C_\ ?1H
MW:*PO-D_YZ/_ -]&CS9/^>C_ /?1H W:*PO-D_YZ/_WT:/-D_P">C_\ ?1H
MW:*PO-D_YZ/_ -]&CS9/^>C_ /?1H W:*PO-D_YZ/_WT:/-D_P">C_\ ?1H
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MN53@<D=Z'"R3ON.-;FE*-MB_17E_A$:A:?%35-/O=4N+XQ6V6>1B Q(0\+G
MZUZA2G'E=AT:OM(MVMK8****DU"BBB@ HHHH **** "F3?ZB3_=/\J?3)O\
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MT4#K0!E^"O\ 5:Y_V%Y_Y+11X*_U6N?]A>?^2T4V)%SX<_\ )/=&_P"N!_\
M0C7-?V;K/@GQ/J5W::5)JNC:D2TD<(RZ').,>V2/0BNE^'/_ "3W1O\ K@?_
M $(UU%4I<K9E4I*:3O9H\HT.QN-1^)=CJ]EX=N-+TV&)E<20B,;MCC./<L!4
M=K#<Z-XV\07-[X7O=2@NI6\G9;!U^\3G)&,$'M7K=%5[7R,EA$EOK>_3T//?
MA_H>I:=J.L:K<:>VG6ET<P6.<D<D].V!Q^-8NL:CJ>H^.=)UV/PSK"P62;7C
M: [FY8\=OXJ]<HH]IK=H;PON*"EMK^IPOC+7?$#>';0:)I5ZDU\I,K"(F2W'
M'&!T8YZU4\#W2Z/Y&F0>%]6A>X8?:+VXCQN;'5CV'M7HM%+G7+RV*=!NI[3F
M_K_@GE_Q,N-0UNU&D6>A:D[6]T)//$),;@*1P1_O5V&G:_--X?GO6T7487M@
M%%M)'B27 '*COU_2N@HI.::2L.-%J;GS;GD>GZAJ=I\0M1\0MX9U@V]U$(TC
M$!W X0<]OX37K:G*@X(R.A[4M%$Y<W0=&DZ=U>]]0HHHJ#8**** "BBB@ HH
MHH *9-_J)/\ =/\ *GTR;_42?[I_E0 D'_'O'_NC^5>;^&]7N/"]WK]O>Z!K
M<IN-5GN(WMK,NC(QX.<^U>D0?\>\?^Z/Y5)3$<7Y-U>_$O2M56RN8[1M)<,T
ML97RV+9"MZ-[5A^*=%UJ#Q#J5AI%K,]CXD6)9YD!*VS!L2,?3*?GGVKU"BBX
M6."\;>&6EB\/SVEC/=V6DN4EM+60I*T14+E""#D8' /-'AVQ\/3Z_;7%EH.N
M1W-N'*7-_P"?LB)&"/WCGD@XX%=[11<+''_#ZQN[&TUM;NVE@,FK7$B"1<;E
M)&&'J*Z754>32+V.-2SM!(JJ!R25/%6Z*0SD/ WAZTM_!VE"^TBW2]2/+^=;
MJ) VXXSD9STI;.RND^*FI7K6\HM7TV)%F*G:6#<@'UKKJ*=Q6/-/"^JZAX6L
M]2M[_P .ZK(L^H3RVSVT!D\S+=".J].">"#[54N/#>KP?#=89;*0WUUJRWLE
MM&-YB#2 X./0 9KU:BBX6.7\>Z1>ZMX=3^SXA-=6EU%=I"3CS=AR5SZX-8?B
M._N_&^C#0++0]4MI+F2/[1->6_E);J&#-R?O'C@"O1**+A8\]\6QZ?)J,A_L
M?7HM7AB"6NH:;$V9>,@;E." >H:C4+'7;NU\#R:C;R37T%ZDEXT:Y"?*>6QP
M.V>V:]"HHN%CSWQ>MC/J<[C1]>AUF*/;:W^G1-^]XR!N4X(SP0U=AX?_ +2_
MX1^Q_MC']H^2//QC[WX<9]<=ZTJ*+A8****0PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,^\_X]M3_ .N)_P#0#7BMO=W%C>+<VLK13(25=>HK
MVJ\_X]M3_P"N)_\ 0#7B##YS]:9PXK=&^_C35V20 6B22+M>5( '(^M4M,\0
M:AI,,D%N\;P2'+0S('0GUQ6710<_M)7O<T]2U[4-5:'[3(@CA.8XHT"HI^E7
M+OQ?J5]'(D\%BQ==A?[.-P'L<U@44!SR[F_<>,-2NH6CG@L7RGE[FMP6 QC@
MYK.U+5KK5C;FZ*?N(Q$FQ<?*/7WJC10)SD]V:VI^)-2U>RAM+MXS%$01M7!)
M QD\\U+9^*=0LM/BL4BM)((B2HFAWD9.?7WK$HH'SRO>YJGQ#>^7?HJVZ)?
M"94BP!@8^7GBH9=7NIM&BTJ3RVMH7WQDK\R]>,^G-4**!<S[E_2-8NM#NGN;
M(1>8R;#YB;AC-6-0\17>IVK6\UO9(K,&+10!6SG/6LBB@.:25KZ%RUO$AL;V
MTE1F2X52I'\+J<@_3J*D76+@/%,8X'N8E"I.R9<8Z=\$CL2*SZ* YF6FU"X:
M"WB+#%O(TJ-CG<2"23WY%7/^$AO1,LJI;JRSFX.$/S.002<GT/2LFB@.9EFV
MO9;:.6)0CPS8\R*1<JV.A]01ZBK']M7."GEP>281!Y.P[0@;=CKGKSUK.HH$
MI-%^[UBZO(YHY?+"RNCML7'*KM&/08J&WO/LX'^C6\K!MZM*A)!_,9'L:K44
M!S/<MKJ-R);R5G#R7:,DS,,D@D$_0\4Z35;J66[D;R]UT%63"]E((QZ=!5*B
M@.9FA_;-W]HN)_W>^>9)G^7C<IR,>V:>NNW0V$QV[-'*\T;-'DH[')(Y]>U9
ME% ^9]S036+I1$"(G6.%X=KKD,K$DYYZY/6A-8N45-J0^9'&8HYMGSHA[ Y]
MR,XS6?10',R]'J'F7UE-=KOBM51 L8P2J\@<U6N)WNKJ6XD^_*Y=OJ3FHJ*!
M7;"BBB@04444 %%%% !1110 4444 %6;&QGU&Z2WMTW.W?L!ZGVIMI:3WURE
MO;H7D<X ]/<^U>D:-H\&CVGEIAIFYDD_O'T'M0;4:3J/R'Z3I4&DV@AB^9SS
M)(1RQ_PJ_112/2225D%%%% PHHHH #T-,B_U2?2GGH:9%_JD^E #Z*** "BB
MB@ HHHH **** "BBB@ HHHH *!UHH'6@#+\%?ZK7/^PO/_):*/!7^JUS_L+S
M_P EHIL2+GPY_P"2>Z-_UP/_ *$:ZBN7^'/_ "3W1O\ K@?_ $(UU%#W!;!1
M112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R;_42?[I_E3Z
M9-_J)/\ =/\ *@!(/^/>/_='\JDJ.#_CWC_W1_*I* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH JA0\MVC $, "#WXK(_X1_3?^@?;?]^A6U%_Q]7'_ ?Y5-M'
MI0R7%/<Y_P#X1_3?^@?;?]^EH_X1_3?^@?;?]^EKH-H]*-H]*!>SCV.?_P"$
M?TW_ *!]M_WZ6C_A']-_Z!]M_P!^EKH-H]*-H]* ]G'L<_\ \(_IO_0/MO\
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M #O(A_YY)_WR*/(A_P">2?\ ?(J2B@"/R(?^>2?]\BCR(?\ GDG_ 'R*DHH
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M\J $@_X]X_\ ='\JDJ.#_CWC_P!T?RJ2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ((O^/JX_X#_*IZ@B_P"/JX_X#_*IZ&""BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *@C_X_)O\ =7^M3U!'_P ?DW^ZO]: )Z*** "BBB@
MHHHH **** "BBB@ HHHH **** (8O^/F?ZK_ "J:H8O^/F?ZK_*IJ& 4444
M%%%% !1110 4444 %%%% !1110 C?=/TJ*U_X](O]T5*WW3]*BM?^/2+_=%
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M% !1110 4444 %,F_P!1)_NG^5/IDW^HD_W3_*@!(/\ CWC_ -T?RJ2HX/\
MCWC_ -T?RJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ((O\ CZN/^ _RJ>H(
MO^/JX_X#_*IZ&""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@C
M_P"/R;_=7^M3U!'_ ,?DW^ZO]: )Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** (8O^/F?ZK_*IJAB_P"/F?ZK_*IJ& 4444 %%%% !1110 4444 %%%%
M!1110 C?=/TJ*U_X](O]T5*WW3]*BM?^/2+_ '10!-1110 4444 %%%% !11
M10 4444 %%%% !1110!Q_A#[_B'_ +#-Q_):*/"'W_$/_89N/Y+138D6/AS_
M ,D]T;_K@?\ T(UU%<O\.?\ DGNC?]<#_P"A&NHH>X+8****0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "F3?ZB3_ '3_ "I],F_U$G^Z?Y4
M)!_Q[Q_[H_E4E1P?\>\?^Z/Y5)0 4444 %%%% !1110 4444 %%%% !1110
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M- 52.)O[I=B!GV%;^G9_LJTQU\A/_017'_"AD_X1.>-BOVQ+Z<70_B$F[O\
MAB@9TVB:PVL6\K2Z=>6$\+[)(;I,$'&<J1PP]Q6I1FBD,**** "BBB@ HHHH
M **** "BBB@ HHHH R=6_P"07K/_ %[/_P"@&OD4]37UUJW_ ""]9_Z]G_\
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M4*ZJ*SW-2BBBL#H"BBB@ HHHH ****  ]#3(O]4GTIYZ&F1?ZI/I0 ^BBB@
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M*?##1TN6N5OM5$[##2"YPQ'N<9[5VJC:H'/ QS2T42DY;CA2A3^%6"BBBI-
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M3595^8]1"#_"/?U-=K7GUZ_-[L=CT</0Y/>EN%%%%<IUA1110 4444 %%%%
M >AID7^J3Z4\]#3(O]4GTH ?1110 4444 %%%% !1110 4444 %%%% !0.M%
M ZT 9?@K_5:Y_P!A>?\ DM%'@K_5:Y_V%Y_Y+138D7/AS_R3W1O^N!_]"-=1
M7+_#G_DGNC?]<#_Z$:ZBA[@M@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *9-_J)/]T_RI],F_P!1)_NG^5 "0?\ 'O'_ +H_E4E1P?\
M'O'_ +H_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8![4?6IA]4@?/7_"I/$/_/:P_P"_K?\ Q-'_  J3Q#_SVL/^_K?_ !-?0OV
M>U'V >U'UJ8?5('SU_PJ3Q#_ ,]K#_OZW_Q--'PF\0&1D\ZPRH!/[UN__ :^
MA_L ]JB2Q4WDW3[J?UH^LS#ZK ^?_P#A4GB'_GM8?]_6_P#B:/\ A4GB'_GM
M8?\ ?UO_ (FOH7[ /:C[ /:CZU,/JD#YZ_X5)XA_Y[6'_?UO_B:/^%2>(?\
MGM8?]_6_^)KZ%^P#VH^P#VH^M3#ZI ^>O^%2>(?^>UA_W];_ .)H_P"%2>(?
M^>UA_P!_6_\ B:^A?L ]J/L ]J/K4P^J0/GK_A4GB'_GM8?]_6_^)H_X5)XA
M_P">UA_W];_XFOH7[ /:C[ /:CZU,/JD#YZ_X5)XA_Y[6'_?UO\ XFC_ (5)
MXA_Y[6'_ '];_P")KZ%^P#VH^P#VH^M3#ZI ^>O^%2>(?^>UA_W];_XFC_A4
MGB'_ )[6'_?UO_B:^A?L ]J/L ]J/K4P^J0/GK_A4GB'_GM8?]_6_P#B:/\
MA4GB'_GM8?\ ?UO_ (FOH7[ /:C[ /:CZU,/JD#YX'PF\0,[*)K#*XS^];_X
MFG?\*D\0_P#/:P_[^M_\37T!'8K]HG''5?Y5+]@'M1]9F'U6!\]?\*D\0_\
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MX/Y+13O"'W_$/_89N/Y+138D6/AS_P D]T;_ *X'_P!"-=17+_#G_DGNC?\
M7 _^A&NHH>X+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "F3?ZB3_=/\J?3)O]1)_NG^5 "0?\>\?^Z/Y5)4<'_'O'_NC^524 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!!%_Q]7'_ ?Y5/4$7_'U<?\  ?Y5/0P04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4$?\ Q^3?[J_UJ>H(_P#C
M\F_W5_K0!/1110 4444 %%%% !1110 4444 %%%% !1110!#%_Q\S_5?Y5-4
M,7_'S/\ 5?Y5-0P"BBB@ HHHH **** "BBB@ HHHH **** $;[I^E16O_'I%
M_NBI6^Z?I45K_P >L7^Z* )J*** "BBB@ HHHH **** "BBB@ HHHH ****
M./\ "'W_ !#_ -AFX_DM%'A'[_B'_L,W'_LM%-B0_P"'=O&_P_T8D'/DG^(_
MWC73_98?[I_[Z/\ C7._#G_DGNC?]<#_ .A&NHH>X+8A^RP_W3_WT?\ &C[+
M#_=/_?1_QJ:BD,A^RP_W3_WT?\:/LL/]T_\ ?1_QJ:B@"'[+#_=/_?1_QH^R
MP_W3_P!]'_&IJ* (?LL/]T_]]'_&C[+#_=/_ 'T?\:FHH A^RP_W3_WT?\:/
MLL/]T_\ ?1_QJ:B@"'[+#_=/_?1_QH^RP_W3_P!]'_&IJ* (?LL/]T_]]'_&
MC[+#_=/_ 'T?\:FHH A^RP_W3_WT?\:/LL/]T_\ ?1_QJ:B@"'[+#_=/_?1_
MQH^RP_W3_P!]'_&IJ* (?LL/]T_]]'_&F2VT0A<A3D*?XC5FF3?ZB3_=/\J8
M$,-M$8(R0<E1_$?2G_98?[I_[Z/^-.@_X]X_]T?RJ2D(A^RP_P!T_P#?1_QH
M^RP_W3_WT?\ &IJ*!D/V6'^Z?^^C_C1]EA_NG_OH_P"-344 0_98?[I_[Z/^
M-'V6'^Z?^^C_ (U-10!#]EA_NG_OH_XT?98?[I_[Z/\ C4U% $/V6'^Z?^^C
M_C1]EA_NG_OH_P"-344 0_98?[I_[Z/^-'V6'^Z?^^C_ (U-10!#]EA_NG_O
MH_XT?98?[I_[Z/\ C4U% $/V6'^Z?^^C_C1]EA_NG_OH_P"-344 0_98?[I_
M[Z/^-'V6'^Z?^^C_ (U-10!#]EA_NG_OH_XT?98?[I_[Z/\ C4U% $/V6'^Z
M?^^C_C1]EA_NG_OH_P"-344 0_98?[I_[Z/^-'V6'^Z?^^C_ (U-10!#]EA_
MNG_OH_XT?98?[I_[Z/\ C4U% $/V6'^Z?^^C_C1]EA_NG_OH_P"-344 0_98
M?[I_[Z/^-'V6'^Z?^^C_ (U-10!#]EA_NG_OH_XT?98?[I_[Z/\ C4U% $/V
M6'^Z?^^C_C1]EA_NG_OH_P"-344 4XK>,W,X(.!MQ\Q]*F^RP_W3_P!]'_&D
MB_X^KC_@/\JGIL1#]EA_NG_OH_XT?98?[I_[Z/\ C4U%(9#]EA_NG_OH_P"-
M'V6'^Z?^^C_C4U% $/V6'^Z?^^C_ (T?98?[I_[Z/^-344 0_98?[I_[Z/\
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M5IONGZ5%:_\ 'I%_NBF(/LL/]T_]]'_&C[+#_=/_ 'T?\:FHI#(?LL/]T_\
M?1_QH^RP_P!T_P#?1_QJ:B@"'[+#_=/_ 'T?\:/LL/\ =/\ WT?\:FHH A^R
MP_W3_P!]'_&C[+#_ '3_ -]'_&IJ* (?LL/]T_\ ?1_QH^RP_P!T_P#?1_QJ
M:B@"'[+#_=/_ 'T?\:/LL/\ =/\ WT?\:FHH A^RP_W3_P!]'_&C[+%_=/\
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M_P" S_X4?\+?\&?]!";_ ,!G_P */93[,/;4_P"9'=45PO\ PM_P9_T$)O\
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M>AV5YJ]_#;B6)#OE8#>Q4$X'?\*X75='72_ /C"5=5M+[[6XE=+2,)'"^1D
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MK.U+VMG9:!8$06=M#=+(PSP&8 ]2!^%<_P##9TC^(>CO(ZHHE.68X ^4UR@
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MZK7/^PO/_):*/!7^JUS_ +"\_P#):*;$BY\.?^2>Z-_UP/\ Z$:ZBN7^'/\
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M_GD_Y4?9I_\ GD_Y5MT4 8GV:?\ YY/^5'V:?_GD_P"5;=% &)]FG_YY/^5
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MZN/^ _RJ>H(O^/JX_P" _P JGH8(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J"/\ X_)O]U?ZU/4$?_'Y-_NK_6@">BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"&+_CYG^J_RJ:H8O^/F?ZK_ "J:A@%%%% !1110 444
M4 %%%% !1110 4444 (WW3]*BM?^/2+_ '14K?=/TJ*U_P"/2+_=% $U%%%
M!1110 4444 %%%% !1110 4444 %%%% ''^$/O\ B'_L,W'\EHH\(??\0_\
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D<?R6BI?"=AJ=M!JDM_8_9I+K49;A8O.5\*P7'(X[&BA@C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img108642122_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,I!@L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYVM%<[X(TF^T3PM;V&HD&Y1W+8?<,%B1S]*Z*DU9V'"3E%-JP4444B@HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGP_;Z9')YC)EI),8W.>2?IZ>PK9HI2J.2MLBJ6&C3DYMMM]6%%%%9G0%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-P_OCK^(K:BFCG0/$X9?45QM20SRV[[XG*GV[U+B4I'8T5E66LQS82XQ&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH(KD-\K\'U]:GI%IW"BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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M.J92YO0NE2Y%KJWNPHHHJ34**** "BBB@ HHHH **** "BBB@ HHHH ****
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M*O'![BM3A3N24444%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDC8JRG(-#5Q)V.RHJG87Z7L799%^\O\ 45<K(U"BBB@ HHHH **** "BBB@
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M;R8W;)9E0X]<$U;5E=0RL&5AD$'((KY[^-7_ "/2?]>4?_H35[QI'_(%L/\
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M;2_#<C2R2@I)>;2%4'@A,\D^_;MGJ #U6UU73KV9H;2_M;B51N9(IE=@.F<
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX KS2O3_ !?\4DUCPY!8Z3%):SW*8OCC&WU13GD$DG/I]3CS%%9W5$4LS'
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M#Y^C^#?B^($1W-BF>NVX89_\=I6^#GC"4!)+NQ*D_P 5RY _\=KZ HH \]\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+&&[@.8Y4#+[>U6*S.E--704444#"BBB@ HHHH **** "BBB@ HHHH ****
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M(^/XHY1@@^O0&NTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+NX%M 6_B/"CWJ>L
M&^N/M%P<'Y%X7_&@F3LBN268L3DGDFDHHH, HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "HYI5AB+MVZ#U-25DWT_FR[%/RIQ]33BKL&5G=I'+L<DG)IM%%;$!1
M110 4444 %%%% !1110!Q^N'^R_&^E:B>(;A?(<GH#TS_P"/#\JB\9^(=3TC
M4;>&RD$4;1;R2@;<<D8Y_#\ZW_$6CKK6D2VV )E^>%CV8?X]*YRWV>+-%?2;
MW]SK%D,*9!R2.,_CT/YUO!IV;Z'3!Q=I/IN9MO\ $34XT"SV]O,1_%@J3^7%
M<WJFHS:MJ,U[.%#R'HO0 # 'Y5%=V=Q874EM<Q-',APRG_/2FVUK/>3K!;1/
M+*W1$&2:ZHQC'5'7&$(^\B*NF\(>'%UJZ:>Y!^R0$;A_?;T^GK447@G7I64&
MT5 3RSR+Q^N:](T+24T728K-6#,,L[#^)CU_S[5G5JI1]UZF5:LE&T7J:$<:
M11K'&JHBC"JHP *Y_P ;7HM/#<T8/[RX81*/KR?T!_.N@DD2&)I)'"(@+,S'
M  ]:XNT+>+O$JWS(PTJQ.(@W21^O^!^@'K7-36O,]D<M-:\SV1HW^D,G@46.
M/WL$"N?]Y>3_ %K1\.WHOM!M)<Y8($;ZKQ_3/XUID @@@$'J#7'6TA\):]);
M3 C2[QMT3]HV_P \'VP:%[R:.2H^6I[1[/1G57UXEA9R74B2/'&,L(QD@>N*
MX#Q%XM;583:6D;16Q/SEOO/[>PKT;AE[%2/P(KB]9\#>9*T^ENB!N3 YP!_N
MG^AHIN*>IGBHU7'W-CA:*VCX2UP/M^PG/KYBX_/-;VC>!F619]4=2 <B!#G/
M^\?\*Z'.*ZGG0P]23M8L^!=+:WLY;^52&GPL8/\ ='?\3_*NM)"J22 !R2:%
M544*H 4#  ["N9\3ZI)*1H>G@R7ES\K[3]Q3US]1^E<VLY'JI1H4[#/">;[4
M=5U8_=FEV1_0<_RVUU54]+T^/2].AM(N0@Y;^\W<_G5RE)W95*#C!)[A1114
MF@4444 %%%% !1110 4444 %%%% %NVER-AZCI5BLU6*L&'45H(P= P[T&D6
M.HHHI%!1110 4444 %%%% !1110!R?C^X==$ALHOO7<ZQGZ#G^>*Z6SMDLK*
M"UC^Y#&J#\!BN5\<?+?:#(W^J6[^8?BO^!KL:M_"CGAK6F_0JWVG6FIPB&\@
M6:,'<%8G&?6O.O&'@^+28?[0T_=]FW 21$Y\O/0@^F>.?45Z?6)XOFBA\+7Y
ME(PT>Q0>[$\4X2:>@L31A.#;6O<\8HHHKK/!/4_A[JCWFBR6<K;GM&"KG^X>
MGZ@_ABNJN;=+JUFMY!F.5"C?0C%<!\,D;S]1?^ +&#]<M7HE<E16D['O81N5
M%7.2\ 32#2[O3Y3EK.X9!]#_ /7#5UM<=X,^;6O$DB_ZMKOY?^^G_P 178TI
M_$5AOX2"BBBH-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *UM%O?+D^
MS2'Y7/RGT/I630"000<$4-7!.QVM%5-/NQ=VJN?OKPX]ZMUB;!1110 4444
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M1[:UU>]U0-))=781&:0@[$4<(HQP,Y/J2?IC0H **** "BBB@ HHHH ****
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M</@=UV?^9KJP894@CU!JI=:MI]DNZXO(8_8L"3^ YK";P'I9/$]VH/4!U_\
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MJQ/X.T5]&T15F7;<SGS)!_=]!^ _4FM;4[Y--TRYO)" (8RPSW/8?B<"K9(
MR3@"N%U2ZD\9:RFD6)/]FVSA[F=>C8[ _GCU//05SKWG=GJR:HTU".^R-+P'
M9O!H!NI<^;>2M*2>N.@_D3^-=13(HDAB2*-0D:*%51T '04^ID[NYK3AR04>
MP4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +FFW?V2Z!8_
MNVX?_&NIKBJZ31[O[1:^6Q^>/CZCM4274N+Z&C1114%A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50U.X\N$1*?F?K]
M*ODX&37/74WGW#/VZ#Z4$3=D0T444&(4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !56_G\J':#\S\?A5JL6[F\ZX8C[HX%5%78F04445J2%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !14CP31HKO$ZH_W692 ?I4=
MPHHHH$%%%% !1110 4444 %%4M4U:STBU,]Y*$7HJCEF/H!7&S_$B3>?(TY0
MG8R2<G\A6-2O3INTF>CA,KQ>+7-1A==]E^)W]%<':_$<&4"[T_;&3RT4F2/P
M(Y_.NTLKZVU&U2YM)1)$W0C^1'8TZ=>G4^%DXS+<5@[.O"R?7=?@6****U.
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M=PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 4]2G\JV*@_,_'X=ZQ*MZC-YMT0#\J?*/ZU4H,)N["BBB@D**** "BBB@
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MTJO2J2K CJ*!IV-*BD4AE!'0TM(U"BBB@ HHHH **** "BBB@ HHHH ****
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M%,AFCN((YX7#Q2*'1UZ,I&013ZQ("BBB@ HHHH **** "BBB@ HHHH ****
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M?S;$*3\T9V_AVK0KGM#FV7;1$\2+^H_R:Z&NV2U/E(O0****0PHHHH ****
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MPNH(_(U!!I6G6S[X+"UB?^]'"JG]!5NBE9/4I5)I63T"BBBF22VTOD7,<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHW(?4KBVME/WY)9C*^/8#.3]2*^@Z*?,Q<J,#PEX1TWP?I9L[%2\DA#3SO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5BZHV;S']U0*VJP+YMU[*??%!%38KT444
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !63J+9NL>B@5K5BWC;KN0^^*N&XF
M04445H2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*!1110 4444 %%%% !1110 5H0G,*?2L^KUN<P+07'<EHHHI%A1110 4444
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M:.WA7;'&H51Z 5W8"D^;VCV/FN*,=3]FL+%WE>[\B6BBBO4/APHHHH ****
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M]XBT^#0+*XF>)#$K;,/*2<X ]!ZGU->T:!X<-CX%MO#]ZY)^RF&<QM@@OG<
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MN/\ B)XQ3PEX?9H64ZC= QVR_P!WU<^PS^>*Z:_OK72=-GO;N016UO&7=CV
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M^L16:V^HZ:C^;;2$LH=5R#V.#^!X(]ZS/"_CSQ9XIEL9+/0;8V"RK'J%T25
M)//E@OG@8_O?A6?H]EX;M_AOXNF\-SW\\#0O'))>;1N*H2-H ''S=QFNB^$'
M_)/+3_KM+_Z$:%<'8[6[N8[.SGNI<^7#&TCX&3@#)KR^R^('CC6XI-5T;PQ:
M3Z0CE=OF;ICCJ/O@D_13^->FZC<0VFF7=Q<QF2"*%WD0+N+* 21COQVKY_UF
M\\+Z4%U;P-K^H6FH.ZYL!&^W![9(Q@>A+9HDPBC;^,]WK4LNGK-9QPZ6")+>
M7/[PRE?F5AN[?05W5KXHUK1?"%[J_C#3H+26!PL,-JP/F*0 O\;<DD]^G:N0
M^+C7MUX)\.7M[ 8YRRFX7&-DC1@D8[<@_E6GXYU*U\;?#2YN/#\CW26DZ/,H
MC92 !\PP0,X# _@:.K#HB!_'_CNVT\:]<>%;4:&0)!B3$@C/0D[B?QV5M>+?
MB!+I7@O3/$.CPPRK>RH-EPI.U2K$CY2.01CK7E^G:=\,I=&@GO\ 6M9AOO+!
MFMU0'Y\<A3Y1&,],GZUTGQ MK"U^$.@1Z9]H^Q&=)(OM!'F89';YL<9Y[4KL
M=D7]2^)OBO3X;;69?#$4&@3N!&TK'S7!Y!R#\N1R,KCW-+J?Q.\46]I%KMOX
M:BC\.R.%22X8^:X]>&^4'L=I'N:N?$W_ ))-9_6V_P#0:3QK_P D.MO^O:T_
MFE/46AJ>,?'=QHO@[3-?TJ"&07LD>$N5)PC(6[$<\5@:G\2O%UC;0ZW_ ,(Q
M%%H$K (TS'S6!Z$D-\N>V5Q[FLGQI_R1/PO_ +\7_HMZZKXB_P#)'Q_URMOY
MK1=AH;6O^.K+1/"5IKJPO<?;50VT ."Y9=P!/; ZURT_C_QMH"0ZAXD\,6\6
ME2N%+0/B1<],_.W..Q YXXK$\<:=<W/PH\*7D4;R06L*>?L_A#( &/MD8S[B
ML=M-^%2V(G&MZ\\I4$VZHN\'TR8PN?\ @6*3;&DCT[QAX[N=(N=+TW0K**^U
M'4T$D!E?;&%/W>XSGGN*M>'?$'B0Q:C_ ,)9HJ6!M(?/66W^9'7G('S,,C'K
MWKG_ !M'X%$.F:+X@DN[1X;-6M;R-"S!/N[25!R?EZ%<?3-9?PZUZZCO=>LW
MO[K6/#=C:O*DTL1S@8^4!N1E=WRGT[4[ZBMH7;+X@>.-;BDU71O#%I/I".5V
M^9NF..H^^"3]%/XUZ+JE^]GX>NK]4*2);F158<AL< _C7@^LWGA?2@NK>!M?
MU"TU!W7-@(WVX/;)&,#T);->RZBUW??#R66\B,=Y)IXDFCQC:^T,PQ]<U,FU
M%FU",95H*6S:_,\8=VD=G=BSL26)ZDUZO\.O ^GBW35/$,<,IO(':TLY!G,8
M'S2D?0C'IG/4C'DU=_\ "N>:;Q3,LLKNL>FS*@9B0HXX'H*\6@USJZN?H^:Q
MJ?59>SERVW[^B[&#XO\ ##^&M2013+<:==+YMG<J<B2/_$9'Z'O4W@/4WT_Q
M/!%N(ANOW+CU)^[^N/S-<V\TLD<<;R.R1@A%+$A03DX';GFM;PG;O=>*M-1
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M=G[A3N,87=U(XR=W0>G6@#RKXK?\E+U?_MC_ .B4KU&/X+^%FC5C)J.2 ?\
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M,6&N:S?PZSIQGBCMPR"3<H#;@.Q':OH*.-8HUC081 %4>@% #J*** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ KEM:U2ZU+4?[#TABLG_ "\3CH@[C/\
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M((BXWE0<%L=<9(&:;:7MIJ%N+BRN8;F$D@20R!U)'49'% $RJJ*%50JCH ,
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MT.>_X_H<>M=I;SQ75O'<0L'BD4,K#N#422W6QM2FVW">Z_JY)1114FP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &YH"_).WJ5'\ZV:RM!7%I(W
MJ^/T%:M92W-8[!1112&%(S!5+,0 !DDTM07L;36%Q$G+/$RCZD&@#E/ LAUF
M'4O$\P!DU"X9("?X+>,[44?B&)QU)J'X2_\ (A0?]?$W_H9JQ\,9%D^'>FJ%
MVM$)(W7T8.V:Q?ACXAT33O!4-O>ZQI]M.)Y28Y[E$8 N<<$YH Z+Q]K%YI/A
MQ5TY_+OKZXCLX),?<9S][ZX!Q[T[3? 'AO3[(02:5:WLIYEN;R)99)&/5BS
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M%2W=W-8Q44HH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"M(#  ]*ST&9%'J16C07$****184444 %%%% !1110 4444 %<MX]NW@\/BU
MBYDNY5B 'IU/\@/QKJ:X[QQ_Q_Z '_U7VOY_S7^F:N'Q(PQ+M29T^FV2:=IE
MM9H!B&,+QW/<_B<FB^TZTU.$0WD"S1@[@K$XSZU:HJ;ZW->56Y>AYAXP\'Q:
M3#_:&G[OLVX"2(G/EYZ$'TSQSZBN,KV?Q?-%#X6OS*1AH]B@]V)XKQBNJE)N
M.IXN-I1IU/=ZA7J?P]U1[S19+.5MSVC!5S_</3]0?PQ7EE=]\,D;S]1?^ +&
M#]<M157NA@I-5DEU.\O[./4-/N+24 I,A0Y'3/?\.M<YX!NG?1);*7_66<S1
MD>QY_GFNKKCO!G_(;\2!/]5]K^7_ +Z?_P"M7.OA9ZD]*L'WNOU.QHHHJ#H"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z;1TVZ;&?[Q)_6K]5[
M%-EA O\ L _G5BLGN:K8****0PHHHH YW1-)NM$\0:K#%%NTF^?[9&^X?N9C
MPZ8ZX/W@1P.1];)\(^&B<GP]I)/_ %Y1_P#Q-;-% %6QTRPTN)HM/L;:TC9M
MS);Q+&"?4@ <U#>:%H^H7 N+W2K&YF'22:W1V'XD9K0HH 9Y,7D>1Y2>3MV>
M7M&W;TQCTJ.TLK73[9;:RMH;:!<E8H8PBC/)P!Q4]% %:ZT^ROFA:[L[>X:%
M]\1EB5S&WJN1P?<55N_#FAW]RUS>:-IUS.^-TLUJCL<# R2,]*TZ* ,N#PUH
M-J9#;Z)IL/F(8W\NU1=Z'JIP.0?2HO\ A$/#/_0NZ3_X!1__ !-;-% %>RT^
MRTV#R+"TM[6');RX(PBY]< 8S2W-G:WGE?:K:&?RI!+'YL8;8XZ,,]"/6IZ*
M (/L=K]M^V_9H?M?E^5Y_EC?LSG;NZXSSB@V5HU\MZ;6$W:IY8G,8\P+G.W=
MUQ[5/10!!;6=K9^;]EMH8/-D,LGE1A=[GJQQU)]:8FF6$<=S&EC;*ET2UPJQ
M*!,3U+C'S9[YJU10!5.F:>T5M$;&V,=JP:W0Q+B$CH4&/E(]J9::1IEA<27%
MGIUI;SR_ZR2&!49^_) R:NT4 0&SM3>B]-M";L)Y8G\L;PF<[=W7&><5&=+T
M\ZB-1-A:F^ VBY\E?, QC&[&>E6Z* *-SHFE7MTMU=:993W"_=EEMU9Q]"1F
MI[JSM;ZW-O=VT-Q"2"8YD#J2#D<'CK4]% &;KW]H'1+J/28EDOI$\N+<P54+
M<;R3V4'/'/'%.T/2(-!T2TTRV_U=O&%W8Y8]2Q]R<G\:T** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K,U=.(G^HK3JGJ:;K,G^Z0?Z?UH)EL8E%%%!@%%%% !111
M0 4444 %%%% !1110 5Q7Q1W_P#"(KMZ?:4W?3#?UQ7:USWC?3VU+PA?Q(,O
M&GG+_P !.3^@-:4G::9=-VDC;M=@LX!']SRUV_3'%9D'A30[;4FU"+3HA<,=
MVXY(!]0#P*Q[3Q!<'X9+JMGM:Z@MPA!&<,I"DD?3FN*L_BCKL#YN$MKE<=&3
M:?S%7&C4=^4I4YN]C<^*FAQ_9X-9B4+(&$4W^T#]T_IBO+:ZSQ/X[NO$MA'9
MM:QV\2N';:VXL1T[<5R==U",HPM(ZZ,91C:05HZ+HEYKVH)9V<9+'EW/W4'J
M346E:;/J^IP6-N/WDS;<]@.YKWS0= LO#VGK:VB#/624CYI&]3_A4UZWLU9;
MDU:O)HMR31=)@T328+"WY6,<L>K-W-<IH_'Q<UT1_P"K^RKN^N(__KUW3,$4
MLQ 4#))["N%\ [M3U?7M?(.RXG\J+_='/\BM<4'I*3.6&TFSNZ***Q,PHHHH
M **** "BBB@ HHHH **** "BBB@ K/U-?EC?W(K0JKJ"[K0G^Z0:<=P9D444
M5L0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <YJ7A."><W>G3-8W><[D^Z3]!T_#\JK+=^+--^6>SAOXQ_'&?F_3'
M\JZRBKYWUU,G15[Q=O0Y7_A*-5^Y_P (U=^9]6Q]?NTAO/%FH_+;V45@A_CE
M/(_/_"NKHHYET0O92>\W^!SFG>$X8K@7FISM?7><Y<Y4'Z'K^/Y5T=%%2VWN
M:0A&"M%!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M );<9F7VYJ]52T'SL?05;I&D=@HHHH*"BBB@ HHHH **** "BBB@ KE?'UJ\
MN@)=Q?ZRTF63\.G\R#^%=545Q;Q75M);S('BD4JRGN#51=G<SJPYX./<CT^\
M34-.M[N/&V:,/@=LCI5;6]5;1M/:\^RO<1H<.$(!4>OTS7->'KR3PUJTGAW4
M6(A=RUG,W0@GI^/\\^M=LRJZE64,I&"",@BFU9^1-.;J0TT?Y,\:\0^*+OQ!
M(JR*(;9#E(5.>?4GN:PZ])UCX=07$K3:7.+<L<F&0$I^!'(^G-8J_#G63)M:
M:S"_WM['_P!EKHC.%M#R:N'KN5Y*YR(!8@ $D\ "O8/!VBOHVB*LR[;F<^9(
M/[OH/P'ZDU!H'@FRT>1;F=_M5TO*LRX5#Z@>OO745E4J<VB.W"85TWSSW(+V
MZ2RLI[J0_)#&7/X#-<UX!MY!HT]]+]^\G:3\!Q_/=57Q)?2>(=2C\-Z:Q*AP
MUW,O10#T_#^>!78VMM%9VL5M NV*)0BCV%0](V[FZ?M*O,MH_F2T445!T!11
M10 4444 %%%% !1110 4444 %%%% !1110 4J*7=5'4G I*M:;'YFHP+Z-N_
M+F@#JE4*H4= ,"EHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% &5J2;9P_9A_*J=:VHQ[K;=W4YK)K6+T)844450@HHHH ****
M"BBB@ J6VD$-U%*>B.&_(U%10,Z7Q!92WA@N[9#*I3!V#)QU!_6L_3;2>TU&
MUFN86BC:3:"XQSCCBJMMJ=[:)L@N&5?[IP0/SIMU?W5[C[1,S@<@8  _ 5*3
MV+<DW<Z:^F:&].-$%P>")@,D_P#CIQ5:">6X\3Q--;^0ZQ$;-V[L3U_&LE-;
MU&- BW38']Y03^9%5UO[I+O[4)F\_P#OGG^=+E&YHZ/3?^1DU#Z'^8KF)_\
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MC\V%T_O BN;(P<'K73UA:A%Y5VV.C?,*#.HNI5HHHH,@HHHH **** "BBB@
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M:!0<?*<C/(]#P>E%PL>H2RK#"\KG"(I9C["L'PIXRTSQA;W,VFI<(+=PCB=
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M< <'D#G)QEAT[T7"QUM<];>,M.N_&-SX8CBN1>VZ;W=D7RR, \'.?XAVKFM
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MV*N54G=G%%604444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5GZK%NA64#E3@_0UH4R6,2Q-&>C#% FKJQS=%*RE'*MP0<&DH.<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ JGJ,>Z ..JG]*N4UU#HRGH1BFG9@8%%.=#&
M[(>H.*;6Q 4444 %%%% !1110 4444 %%%% !1110 A(4$D@ <DFN+O=2O\
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MKX*T^YU3X1>*;2S1GG:965%&2VT*Q ]20",5[7::+I6GS2366F6=M+*,2/#
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-J
MD.RX$@'#C]:HUOWL'GVS*!\PY6L"@QFK,****" HHHH **** "BBB@ HHHH
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M* %4%F '4UHJH10H[56M8\DN>W JU0:104444B@HHHH **** "BBB@ HHHH
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MZ1X5,=W_ &EK,_VV_.",\HGT]?Z5TU%%3*3EN1*3D[L****DDS-5T&PU=?\
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MEHJD?.WS-]:R-'L_/N/.<?NXSQ[FNBJ)/H7%=0HHHJ"PHHHH **** "BBB@
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M6Q/M,@^9AA!Z#UI-V&E=FC:VZVMND2_PCD^I]:FHHK(U"BBB@ HHHH ****
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M3D4B-%,<61U)ZD?0<?C5X=2G63\S+-73P^75(O:UE\]$>AT445[I^7!1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5#4++S1YL8^<=1ZBK]% FKZ',45I:C98S/$./X@/Y
MUFT&#5F%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7=J+A,CAQT]_:K-%"=@.
M?(*D@C!'44E:M[:>:/,0?..H]:RJV3N2PHHHIB"BBB@ KD=6U^]U*_?1_#Z[
MI1Q-=9^5/7![?7\JM>+]5FM;2+3[(G[=>MY:;>JKT)_I^?I3XH+/P;X:DD #
M2*H+MWED/0?3^E:Q5E?KT-H1LKO=[%6S\-Z)H["75;J&XNW^8O=. "?92>?J
M<U:O/%^AZ=%MCG$Q7@1VZY_7I7EE[>3ZA=R7-S(9)7.23_+Z5!71[&^LF=/L
M.;6;N>@K\28C( VEN$SU$P)_+']:V3IF@^*M/%U'"GS_ /+6,!)%;T/O]<UY
M+6[X9\1/H%XQ93):RX$J#J/0CWI2HI*\-PG025X:,Z83:KX+G5+EGOM'8X#_
M ,47^'TZ'VKL[>XAN[>.X@D$D4@W*P[BL.T\3Z'KI-@7.9AL\J9,;_;/2LS1
MG?PUXEDT.9V-E<_/:LQZ$]OYCZ@>M8R3ENM3GE%R6JL_S.TK*UW6XM%L]Y >
MXDXAB_O'_"M4G R:Y#14_P"$@\07&LSC-O;MY=LIZ9'?^OU/M6<4MV<=635H
MQW9+IGAR6]F&IZ\WGW#C*P-]U!Z$?TKJ $BCP J(H^@ IL\R6\$DTF=B*6.!
MD_E7ENO:_>ZM<LDN^&!3A8.1C_>]35).;,ISAAX]VST=M;TI7V'4;4'_ *ZK
M_C5V.2.9 \3JZ'HRG(->)5>TS5KS2;D36LI S\T9/RO]15NCV9A''Z^\M#U/
M4M'LM6A*74(8XPL@X9?H:YRTN[SPI?1V&HR&;39#B&<C[GM_];\JZ/2=3AU?
M3X[N'C/#H3RC=Q3M4TZ+5-.EM)0,./E;'W6[&LT[:,ZY04ESPW_,M@A@"""#
MR"*6N<\(WTSVD^F77%Q8MY9R>J\X_+!'Y5T=2U9V-(34XJ2"BBBD4%%%% !1
M110 445)#$96_P!D=30,?!#O.YONC]:N4@    P!2TC1*P4444#"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *O:=8->2[FR(5/S'U]JBLK-[V;8O"#EF]!74Q1
M)!$L<:X51P*F4K%15QRJ$4*H  & !VI:**S- HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L>_L?*)EB'R'J/2MB@@$8(R*!25SF**O7UB829(QF,]1
M_=JC08-6"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4+VSW9EB'S?Q*.]7Z*:=
M@.>HK1O++.98AS_$H[UG5JG<D****8CC[8?VG\1KF5^4L(=B#WZ?S9J@^)#R
M"RL4&?*:1BWID 8_F:L^&OE\7>(5?ES("#[;C_B*ZJ:"&XC\N>))4SG:ZAA^
M1K9RY9I]CH<N2:?8\1CTZ]FM'NX[65K=/O2!#M'XU6KWCR8A!Y(C01;=NS:-
MN/3'I7BFL6J6.LWEM']R.5E7Z9XKHIU>=M'32K>T;5BE110 20 ,DUL;CX1(
M9XQ%GS-PVXZYSQ7IOCN!ETVUU&(XFLYU93['_P"N%JAX/\)/#)'J>H)AQ\T,
M)[?[1_I6SXV91X3NP>I* ?7>*Y9S3J)(XZE12J12+>KWN/#%S=QG;OM\K[;A
MQ_.F>%;=;?PW: #!=3(WN2<_RQ52]A=_A\L;<LMG&3^ 4_TK0\.2"7P[8,.T
M07\N/Z5@](_,\Y_Q_E^IJ5DZ]HD&LV+JR*+E5)BD[@^GT-:U5[Z\BL+&:ZF;
M"1KD^_H/SJ4VGH7-1<6I;'C%%*S%W+'J3DTE=IX!U_@"[=-0N;0D^7)'Y@'^
MT"!_(_I7H%><^ X&?6Y9L?+'"<GW)&/ZUZ-7+5^(]?!M^R5SE5'V/XB%4X6[
MM]S#U./_ +&NJKE;C]_\1K4#_EA;'/Y-_P#%"NJI3Z&E'[7JPHHHJ#8****
M"BBGQQF1L#IW- Q8HC*V!T[FKRJ$4*!P*1$"*%4<4ZD6E8****"@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "I[2TDO)A&@X_B;L!1:VDMW,(XQ]6/0"NHM;6.
MTA$<8^I[DU,I6*C&XMM;1VL(CC& .I[D^M2T45F:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:NH@1=JCBE50B@*,"EI&B5@HHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M9L[*2\EVH,*/O,>@J2PTZ2]?/*Q#JW]!720P1V\0CB4*H_6I<K%*-QMM;1VL
M0CB&!W/<FIJ**S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH51P .U+114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %,EB29"DB@BGT4 8EUI[P9=,O'Z]Q]:IUT]4+
MK34DR\.$?T[&@RE#L8]%/DB>)RCJ5/O3*#,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D(!!!&0>QI:* ,ZYT_J\/\ WS_A6>00<$8(KH:@N+6.<9(PW]X5:GW$T8M%
M33VTD!^897LPZ5#6@@HHHH$%%%% !1110 4444 %%%% !3XXFD.%''<U+%;$
M\OP/2K0 48 P*"U'N,CA6,<<GUJ2BBD6%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44JJ68*H))Z 5L66BEL277 _N#K^-)NPTKF?:6,UX^(UPHZN>@KHK.PAL
MU^0;G/5SU-6$18T"(H51T IU0Y7+4;!1114E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 1RPQSIMD4$?RK*N=-DBRT?SIZ=Q6S102XIG,45O7%E%<<D;7_ +PK*GL9
MH,DKN7^\M!DXM%:BBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(# @@$'L:HW&G
MY:$X/]TU?HIIM 8#HT;;74@^AIM;TD23+M=016=/ISIDQ'</3O6BDF38I44I
M!4X((([&DJA!1110 44Y(V<X49JU';*O+_,?3M0-)LKQPO)T&!ZFK<<*Q].3
MZFI**1:5@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJQ;64]T?W2$CNQX H
MKU=M-,GN\,!LC_OM_3UK6M-'A@P\O[V3WZ#\*TJAR[%J/<JVEA!9K\BY?NYZ
MU:HHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I/I\,
MV2!L;U7_  K,GL9X,DKN7^\O-;U%!+@F<Q16]/8P3Y)7:W]Y>*SYM,FCYCQ(
M/;@T&;@T4:*5E9&VLI!]"*2@@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y8(YAAU!]
M^]9\VG.O,1WCT/6MV&PGFYV[5]6XK1@TR&/!D_>-[]/RIJ312@V<.(9"VW80
M?<8JQ':@<N<GTKN);:&=-DD2LHZ<=/I65<:%U:WD_P" O_C5J8_9V,,  8 P
M*6II[2>V/[V)E'KV_.H:H HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **4 L0 "2>PJ_
M;Z/=38+*(E]7Z_E1>P6N9]6;:PN+K_5QG;_>;@5NVVD6UO@L/-?U;I^57^E0
MY]BU#N9EKHL,6&F/FOZ?PC_&M( *    .@%+14MW*2L%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R2*.5<2
M(&'N*HRZ3&W,3E?8\BM&B@32>Y@RV%Q%_!N'JO-5B,'!KIZCD@BE_P!9&K>Y
M'-!#I]CG**V)-*A;[C,A_,54DTN=/N[7'L<4$.#12HJ1X)8_OQLON14=!(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444Y(WD.$1F/L,
MT -HJW'IUR_5 H]6-6H])4<R2$^RC%!2BV95316LTWW(R1ZG@5M1VD$7W8ES
MZGDU/06J?<RXM)/663'LO^-7H;6&#[B#/J>34U%!:BD%%%% PHHHH " 1@C(
MJA<:1:SY(4QMZIQ^E7Z*+V"QST^AW"9,3+(/3H:SI8986VRQLA]QBNRI&577
M:RA@>Q&:I39+@CBZ*ZB;2;.7_EGL/JAQ_P#6JA-H+#F&8'V<8_6J4D3RLQJ*
MMRZ9>1=8&(]5Y_E55E93A@0?0BJ)$HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **ECMIYO\ 5Q.WN%XJY%HMW)]\+&/<Y/Z47069
MG45T$.A0)S+(TA]!P*OPVEO!_JH44^N.?SJ7)%*+.;@TV[GP5B*K_>?@5I0:
M"@P9Y2WLG _.MBBI<F4HHA@M8+<8BC5??O\ G4U%%24%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'WF=OQQ5^B@?(B!+*WCZ1+^//\ZG  & ,"BB@JP4444 %%%% !1110 4444
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img108642122_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Q:^>5@X0DE-! 0      #\< 5H  QLE1QP"   "!"T< E  #TAA;G,@
M5"!38VAA;6)Y91P"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E
M       0?:GP?" \!BM4[6T^80HKWCA"24T$.@     !,P   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4    * !< %P 3 !+ $, 30!7 %0 4 !2 $X ,  T "X
M80!S "X 80!D "X <@!R &0 +@!C &\ ;0!< $P 2P!# $T 5P!4 %  4@!.
M #, .       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!N;[Z         "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              WH   2*          $
M     0             $B@   WH                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   WH     4F=H=&QO;F<   2*    !G-L:6-E
M<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO
M;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53
M;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53
M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   -Z     %)G:'1L;VYG   $B@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     SA"24T$#      490    $   "@
M>P   >   .:@   420 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ >P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MJI@VLK8 UK0/S6L;[6HZ#=;9.V@[O/\ V_-D9/V@^N;O3^QP=O\ Q&W;]/\
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M.%[2ZFSZ/LLAN[:7.;;[-_JU,9]FWWLM]*W^;_1>JB#1M$@2*NG:    $ :
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MQSG;6,M>/4^A]-/A(QUW&S#GQC+4+X9#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(!(4CS)_TGZ@=,=9UM^Y\\#-J4G)U.8OTNTQ2IX?W,5R2Z(WVM=CM=2K?:;
MW*B:^:632,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)3;U#Y&-A6K:
M+[D#QTT]CNWHD/DSO6S5!1=ZBT0@8XH/'\],'*>%EIV*$3"N@X<GAXV03+%*
M-['8"KU8LQU?3N/5BKM^HKFP==_-1C#E<S/(X*K4GAUK?GP0 S*0_-=9%LI[
MJ?U$V.5M;.C_ $ZPJ][U(/LV&R8AM+T\I;L>S,O\U79%1YYI[BB6#VF7(R%;
M#.9<L>*S7.L[,&^.H;&[ZRZJF5DY:;V/L<%9BKU>4,(+_AT*IR8K1[9"*6$$
M8R9DVBCUJ1!-2 855JH:+)T[3JG)R:OH-76NIU2 HF-C<)9:OQW9%R@.S./Y
MT5@K<_Q#:P[YE]+>EFMUF7^_^I\E^K>K;B+;]KLP;<?%M_F]O6X=G---=)^V
MFUD-B ?P%Q4/LBU\  H 4H 4I0 "E      ]   ']  !_0 '] &126M/SB(Q
M$T)=^8-$;#DE9BSZ[BEI9P<5',C%.I6NN72IC?(ZSP:^_C$WJZ@^_FN\376-
M[]B?V "%.]6>@'I!UKG6;/J#HG76[&YC9?G:_(V.DR,FUCW-;E-I<S 7+N<D
M]]N4MUC<\EN0I$TU'J'UEH\=<77;W)3%K';71DUXV=76H' 2H9U&0U*+_E2I
MD0<< <>)EVOM,ZOU6FJ6@TN(KRJY/K7?)%</I9=+V _2M,2B[V551]@ _2=X
M9+Y  _#W_>23HOTN]/\ T\KL3HWI;6:6RY>R[+K6[+V5U?//M6[3/MRMC95S
MY]I\IJ^[[NWN\S5[SJOJ+J-E.ZVV5G*A[DI<I3C(WQW)BXZ4XROQX[UJ#<>.
M>)LW)](_&(C$2N;L#QFZ%ZJ7)?8PK_1W1$.H60J6_M6 ,!;V,PV+\F*UE0C'
M$8E;6B*Q4A%1VY:6%LDE],18HM-1<JTAU'4N?J@:&*YVOL!6[7Y?\2AD/\PK
M[@QI;CX[0:R?+UOP)775_IIH.JV7/K%FCZBH/N8?4.I_V;/JN4?PSD>TU0S*
MP0.18RW*H*TY%/<Q,1]0]V;_ .+]BP/,GD^;-1B)QR2)T]V;!-A'7]Z0(;Z&
M;#8RS9J@E"3)2@1-],.FL<^8?X/+3&FC%3W1YM\O18&YQGV?3!;OK4OFZ6P_
M[1CD#EFQN23;7_PJ"X;GBMN_^ D4U'7._P"C-CC],>J"I[60XHTO6V.G&LV(
MY[4JV?:H7#RN..^UUK[?Y\BL4_[;9>0S>-)%HUD(]TW?,'S=!XR>LUTW+1XT
M<IE6;NFKA$QT7#=PB<BJ*R1SIJIG*<AC%, C"""I*L"&!((((((/!!!\@@^"
M#Y!EW(Z6(ME;*Z.H9'1@R.K#E65E)#*P((()!!Y!XGTY\G*,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1*-NNNEMT=C;GE_'WP?8!AB1 ?C=8=,QQW!H?4T"H
MY.T?TBMRS11 '%J>@B\CI D4[+).7Q5Z]'.6!6%JEX*;ZG6X6GPDZ@WM??WG
MG4ZQN._,L !6^U6!XH7D,O>.WCBQ@P:I+:1ZMZEW75^[O]/N@\GZ<T#MZNZH
MK[C5I<=F*O@8EJ%0VPM"O6XJ<6*X>A&K:O*OQ;+N3^2=-<:ZIC=4:<@ 8LDQ
M3>V:S2 (N+7>;"*0)N;%:91-)(SQZKZ$C5JD1&.B6GP81;1JU3!,8WM=MF[G
M+;+S;.YC]M=:\BJBOGD5U(2>U1\D^6=N6<EB3+)Z4Z3TO1NIJU&EQA54I[\C
M(LX?+SL@@!\G+N !LM;C@#@5U(%KJ1*U"B3>:R26,1&(C$1B(Q$8B,1&(C$3
M5FZ-*:PZ$US8M4;?J,7=:/9VIF\C$R:7LZ"X$.#65BGJ8D>1$W&J'%Q%S$<L
MWD(]P *MER#[]Y6'FY6OR:\O#N>B^H\JZ'CD<^4<?#HW'#HP*L/!!FKW.EUG
M4&NR=3N,.G.P,I"EM%R\@'_+;6PX>JZH_?5=6RV5. R,".92+JK9&SO$'M^
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M*O&MUS,&29W!VD=%SU>,H!:<BL_E'4.'C['$KZGUB=M&2P3:8PXYP\[P&?@
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M)9N7+$DGD^3/7&WRAI-#L\W$QJF&IU.9E8V&@6FDC!Q++:L=0@"U5<5+6 @
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M6"XYKIQZR3VI1[:6(5!\#W>\VL1\LY_H!^A7HKK]9@^G6AMURUEMA5=F["]
M/<NSVR+:;Q:P\EL;VAB(#_)70H'Y)M<R*RUIJ[=^OY?;&E]N:MK]SE=<SVR=
M9WNAPNP8(%33=&EK=5Y2 C[?$%0=QZYI.MNY!&88E0?L5A<LTP2>-5!*NFB5
M)5+Q8;!K,]=]C5J?YMU#?$FW&TYIRJZ=U'*P.JJO>N3+;MV<D7%\CTI2)G+O
M'[DB=K3\+8IT',=:Z\QFOQ$'<\M4HN5FT294GHGHZ];8YSW_ ':>TC!W_4$A
MN"HV&E51K?)FI/-,;JA]?-IYG#W"8/#R[_9,!8-=1<[%3CRFPE;D8Q\YK+J
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MXWC#2-;MA&Z&P*NT0=.W#4A$&UBAU%2M@F$FI/16KMLX.BWE$$@!M]KEJY;
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M\$'R)>*.EBJZ,KHZAD=&#*RL.596!(92""""00>09].?)RC$1B)^!$"A[,(
M'_V(@ ?_ /1SX2!Y) 'ZD\1P3\#F?G_O_K/L1B(Q$8B!$  1$?0!_8B/_0!_
M]CB)3AU=Y&[18+\ZX_\ 'E!-=X]12P+Q]ENS 6[[5NAF(* SD[#9Y\X*PDA-
M0AU2E,T455A8F0%-M*&DYDB=2D)AJNG:J\<;CJ&PX.K3AJJ6!&7GMY*U55^'
M5' /W>'=?*=J<W)3_57J+E7[!^C_ $]QTWO5=G=7E9B]KZCIZOD);DYV1YIL
MOH+ "GEJZ[>$M%EP7#MD-P;P36N0("PVVUV%?;73.UG!YO=.[IW[WDQ.RKY8
MK]W P+E^*CYE5FC\3+?\ADWTZ\(23E2D!&,C8G7;W>V[>RNJJL8FMQ![>%@U
M^$K11VBRP#A6M9?!/'"#[5^69]_T'T%C='X^3EY62VWZFVSF_>;W(Y:_*N<]
M[44,_+U8E;^53D-:P%EOQ775,&KZ@UE2;UL+9=1I4%7+SM=.LDV-88AH#)U<
M%*>6;)7GDTBB8K-S),4[#+)'E ;DD7R*Z*4@Z=IL6)6VHMR\FZC'QKK[+*,3
MW?IJW;N6D7=GN"OGRJL:T/:#V@CE0"6YF&+J-9A9VPV6)@X^-G;48HV.336M
M=F8<,7C&?([>!994,BU1:1[C*P5V940+LC,>;&,1&(C$2!^VN45[A-;(V=8+
MLNH]793$K"049%$(F@C$Q1R0;%W(NG2IE0^EFV3=E;L$?9Q5%);V<#A+-=U
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M"&^E:+BY:3,A S3@7(&1:L$WK.PK>BBXK[-4WTEU.RZ4VVO7WTJ7/PR.Y,S
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MU/RK%6!FLWNDPMYK,_1[:@786?CM1D5GCGM<!J[:GX(6RMPE^/:O/;8J6*?
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M68L@@ML'R@T08M)<JCAC5>,-5N'CQ#[?D9N22DY"-28_\?\ QE6_6O3@'KY
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MA:RR('^GQ5?W\NX"FE22S+F=4=5ZGI/6W9^QOK]Q488N$KK]3F7]O*4U5^6
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M;R1\D->5Y^>% /P *4](.=;G>H_3)Y T_6N;EXZGGE</:+QB\<@ *:\(6<*
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M&T[--%3"*R<6,X[GHM<?D &_&_:/K)%,?Z^ M(=/ZS"0  LLZUI0[2G94_\
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M%V5BBOW&*%.WN 7MX[2/'''!XXGS(IW)LM8U[$H+'*GC(8!>X]I''/ X^"/
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M1B(Q$8B,1&(FI]GZBK&Q]([ T6JQ:1M0O.L[1K'\!J@"3.*A;%6GU;338H)
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MIRC9J@_3JL+(N52(IR,PW.[D4Q6)78>PO$C,1DFBZ3V/47>RUICZQ PR]AF
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M/'[:]MAT[!/ -]!&)DC]6955L>P_HJ5XX_YI(,7J?)KX7*J3(7\NG%5G]3P
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img108642122_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +<!3L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD) ZD#M0
MM%("#T(I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP]F]N_Z5Z+7'*+B[,]FE5A5CS084445)H%%%% !1110 4444 %%%% !1110
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M";H>[+.W_M(5')X^\< 9_P"$52(?[<<G_LQ6F?\ "IGE_P"/KQ)=S'OF//\
MZ&S4]/@YHX.9-0NV/M%"/YH:- U*K_$7QHIP=(TZ,^D@ _G.*C/Q)\7@_-;:
M&O'\3QC_ -N:V$^$?AU!_KKUO?,0_D@J9?A7H"])M0_"XQ_(47069SK?%+Q0
MGWDT 'WEC_\ DFD'Q4\38SLT'\'C/_MS74+\,M!4?Z[4S_V^O1_PK+0ATN-4
M'TO7HN@LSEU^+^NJ0'LM*<^TF/\ T&1JL1_&+55;$GA^&3U,4DN/_19K>;X8
MZ(P(^U:I@^MV6_F#4$GPHT1\D7=[G_:2!_\ T*,T706D5(_C$Y \WPZZ$_\
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M<V+CJMY9RQ8_$KC]:+,=T=31699>(M$U''V+5[&X)XQ%<*Q_('-:=(84444
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M ,>=O<1=<'2]9,8'_ 9$Y_[ZKV"BCF8<J/"[OPWK,1S<VVIL1U^TZ/#>=_\
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MAXB/^N4RC/YT6079[!9ZC8Z@F^RO+>Y3&=T,JN,?@:LU\^7.DW-K,);N,QL
M?GU#0W@P>>LML23]<YJUINLZU"L:Z=J<\P!_YA^KI,!](+@%S^8%'*',>\T5
MY%'\1M;TN4Q:A<0KSPNKZ=+:2-]&CWI^8%=%IWQ(^U-MET667C.[2[J*]'U*
MJ0X_[YS2LQW1W=%<U:^/_#-S((GU1+2;O%>JUNP_[[ 'Y5T,%Q#<Q"6WFCEC
M/1XV# _B*0R2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP#XI:ZVJ^+)+1'S;V/
M[I0.F[^(_GQ^%>_D9&*P++P5X=L9'E72X)IG8NTMP/-8L3G/S9Q^%:TIJ#NS
MEQ5&=:*A%V74^:,'T-)7U=_9UB5VFSM]OIY2X_E61J?@CPYJRM]HTN!7;GS(
M1Y;9]<CK^-;K$KJC@EE<K:2/FBBO1O%GPIO-)CDO='D:\M5!9HB/WB#_ -F'
MZ^U><D$'!X-;QFI*Z//JT9TGRS044451F%%%% !1110 4444 =E\--?.B>*X
MHY'(M;P>3("> ?X3^?\ .OH6ODI':.174X93D'WKZDT'41JV@6&H9&9X$=L=
MFQR/SS7)B8ZJ1[.65;Q=-]#1HHHKE/4"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HKF-=^(/AGP^&6[U*.2=?\ EWM_WDF?0@<#\2*YAO&GC/Q,
MI7PSX>^P6S=+W4#C@]PIX_+=3L*YZ5-/%;0O-/*D42#+.[!54>I)Z5Q6K?%C
MPSITIM[66;4[G.T1V2;@3_O' /X9K N/ :3+_:7CSQ3-=JISY9E\F!3SP,_T
M"U'#XT\+Z*QL/!F@2:C>8(_T2 @'_><@LWY$>].PKEX^(?B+XCR-+T:WT.V;
M&)[T[I!^!'_LGXUGW_@NPC*W?COQA/=MG<L3S")/<!223_P'%6_[.^(GB?F]
MOX/#UFQ_U5M\TV/J#_[,/I5_3/A9X=LY?M%\L^J71.6EO)"P)_W1P?QS1>P6
MN<_9>+O"VE2FV\%^%Y]1NU'$D,!!_%R"^/J*OFU^)7B3/GW-IX?M6_@B^:7'
MU&3G\5KT*UM+:R@6"UMXH(5&%CB0*H^@%34KCL<!9_"71?.^TZS>7VKW)^^T
M\I56/KQ\W_CQKK].T+2=(7&GZ;:VW&-T40#'ZGJ?QK0HHNPL@HHHI#"BBB@
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M3+%/J4UNI&"T4.IQ$>K2PE& _ UK:?\ %*Y=BDUKIE\5.UFLKSR7_"*<*Q_
MFNANO!'AVZD\U=,CM9^TUF3 X]\H1G\:Q]1\ 7%PN(M8%X@Z1:O:I=?^1.''
MUS1=!9FU#\0]!\Q8M0:[TF9C@1ZC;-#_ ./<K^M=):7UI?P^=9W4%S$?XX9
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M?XRLO.B#A9\P>1/!ZG:  ?7! SZU]%VMU!?6<-W;2++;SQK)'(O1E(R"/P-
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MK>X8#)C5\.OU0_,/Q%*P[FK1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R3XEW>
M.?CS-873L8)=5%C\A^[#&^PX_!2?J:^JB=.T'2AN>VL-/M4"Y=A''$HX')X
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M7M5A98T.ZUA<8W'^^1Z>GKUJWX)^%@MWCU+Q BNXPT=IDX4^K^_M7JH 4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%;=%8SJRENSLI86E2UBM0HHHK,Z HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#[&M"D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ<6_1-G3T55L-3L=4@\^PNX+F/NT3AL?7'2K54G?8RE%Q=I*S"BBB@04444
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MEM-[V6H$ FSNQLD/NO9AZ$$UTE24%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4456U#4+32K&6]OKA+>VB7<\CG '^
M)]N] %AF"J68@*!DDG@"O-]:\=ZAK]])H7@:,7$P.VXU-A^Y@'^R>YZ\\].
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M/3S;B;:5D:-55CG)/)YYH ]0HK@/&'Q>\.>#[YM/E\^^OT'[R&U (B/8.Q(
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MX6MLH+*O9F)( 'Z^U8GAWXX>'=;U:+3+NUN],N)6"1M< %"QZ D'()]QCWH
MZ7QQX[T[P'86UWJ%M<SBYD,:+;A2<@9).2.*;JWC_2])\#6_BR6"[>RN$C:.
M)%7S/GZ @G ]^?SK@/VC?^1?T3_KZ?\ ] J#QG_R;;HG_7*T_E0!ZOX4\36?
MB_P];ZS8Q3103%E"3 !@5)4]"1U%;5>8?"/4[/1O@S;:CJ$ZP6ENT[R2-T \
MQOS/8#N:SI/VA-#$[&'1=4EM$;!G 0?CC/\ ,B@#V"J&M:O;:%H]SJ5T?W4"
M9QGECV4>Y.!3])U.WUG2+34[0L;>ZB6:/<,':PR,CUKSSXT7CQZ3IEFIPDTS
MR,/78 !_Z'6=6?)!R.S 898G$PHO9O\ #=GF/B+Q+J/B;4&NKZ4[<_NX5/R1
MCT _KU-9R6=U)9R7B6\K6T;!'F"$HK'H">@-05W>E?\ )&M?_P"O^'^:5Y"3
MFVVS]$J2CA:<8TXZ72MZNQR6D:Q?Z'?I>Z?</#,O7!X8>C#N/:OHOPEXDA\4
MZ#%?QJ$E!\N>,'[CCK^'((]C7S-7IWP7O736M2L<GRY+<38]U8#_ -GK?"U'
M&?+T9Y>?X*%7#.LE[T>OEV/9Z***]0^#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)''-&T<J
M*\;##*PR"/<5Q^I^ +;;+)H,PTYY/];:LGFVD_L\1X'U7&.:[*BBX6/#=6T6
MXTK%M?6JZ=&7RD<[-+8,W7,<H^> D]B>>YQ6QI'CC7?#TT=I>[[F(KN2UU"5
M1(R^L-R/DE&/7!).!FO5YH8KB%X9XTEB<;61U#*P]"#UKB=6^'D1@E&A31V\
M;G<VG7:^;:2-_N]8S[K57ON3:VQU6A>+M(\0%HK6=HKQ/];9W"^7-&?0J?YC
M(K<KYZU#2+C3;E+2YMFLIEP(+:[F)C)];:Z'W#W"/P,\Y/%=-H/Q$U;2[@V.
MIQ7&HK&!O@EC$=]",<G'W9EQW'S8&2 *''L"EW/7Z*S]'US3-?LA=Z7>1W,7
M0[3\R'T93RI]C6A4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(%ZC</7V_/G@>BT;#W(K>WAM+>.WMHDBAC4*D:+A5'H!4M%%(84444 %%%%
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MLG4J26Z=CV(%=-X-UOXF>)O%]A=:UI1TG1+82&XB\AH/-)1@O#DN?F(/''%
M'E]OKMXGQKU361H%SK]U#>3F*SCW%EVDJAX5ON #MV%:7Q&O/$_Q ET^9?AW
MK.G7-KN4S""60R*<8!_=KC!!]>IK?\5^!_%GA+XB2>,?"-H;Z*>9IFA4;V5G
MSO5DX)4DD@CI[8!J^/B!\5=7*VFG^!S93,0#-<VTBJ/<%RJC\<T 4?CF;H^
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M-,\1,;9=]IJ2+F2RN.' ]5[,O?([$=,TFK%)W.CHHHI#"BBB@ HHHH ****
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MO!=Q!>MXD\22?:M<N/F"MRML#V';....!T'J>[HVV#?<****0PHHHH ****
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M?\)-\5_^??5O_!2O_P ;HY0YCWFBO!O^$F^*_P#S[ZM_X*5_^-T?\)-\5_\
MGWU;_P %*_\ QNCE#F/>:*\&_P"$F^*__/OJW_@I7_XW1_PDWQ7_ .??5O\
MP4K_ /&Z.4.8]YHKP;_A)OBO_P ^^K?^"E?_ (W1_P )-\5_^??5O_!2O_QN
MCE#F/>:*\&_X2;XK_P#/OJW_ (*5_P#C='_"3?%?_GWU;_P4K_\ &Z.4.8]Y
MHKP;_A)OBO\ \^^K?^"E?_C='_"3?%?_ )]]6_\ !2O_ ,;HY0YCWFBO!O\
MA)OBO_S[ZM_X*5_^-T?\)-\5_P#GWU;_ ,%*_P#QNCE#F/>:*\&_X2;XK_\
M/OJW_@I7_P"-T?\ "3?%?_GWU;_P4K_\;HY0YCWFBO!O^$F^*_\ S[ZM_P""
ME?\ XW1_PDWQ7_Y]]6_\%*__ !NCE#F/>:*\&_X2;XK_ //OJW_@I7_XW1_P
MDWQ7_P"??5O_  4K_P#&Z.4.8]YHKP;_ (2;XK_\^^K?^"E?_C='_"3?%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP=/MF^[$G56Q_+_OKJ0:]*HVT#?4****0PHHHH **** "BBB@ HHHH ****
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MO"(\0S>.B-=>V-TL37(."5W;"V[=N(X)]>QKMO@]XUU#Q/X0U2UU.=YKW30
M+AC\SHRMMR>Y!5N>_'>@#UBBOE/X?#QGXN:\\.Z5K,UM:R[9KRZDE8LBC( !
MSGDGH,9[G%,G/B[X6^.Y='T[4FGNI@$C R8Y_,X4[&.-P8]^X[CJ ?5]%?,'
MC7P+XO\ ".EV_BN_\0R7%[),JSF.5]\+-R,/GD9&.,8XQD5Z]HGCV5?@O%XN
MU!?.N8;9@XZ>9*KF,9QTW, 3CUH ]!HKYL\*^%/$_P 7Q>ZUJ_B6>VM4E\M
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M/HXX)_ 5DP>+/'7@2Y2WU:.>6WZ".\^=6_W9!_0D>U>_5#=6MO>V[V]U!'/
MXPT<JAE;Z@U7-W)Y>QQWASXI>']>V0SR_P!G7;<>5<, I/\ LOT/XX/M7;@@
MC(.17E_B3X-Z=>A[C0IS8SGGR)"6B)]CU7]?I7&Z;XH\6?#>^73=2MY)+0=+
M:<Y4CUC?G'X9'MFBR>P7:W/H*BN>\,^--&\509L;C;< 9>VE^61?P[CW%=#4
ME!7!_&?_ ))-K?\ VP_]'QUWE<A\4-'O]>^'6JZ9IEN;B\F\KRX@P!;;*C'D
MD#H#0!Y-H'A__A(/V<=0C1-UQ9W<MY#QSE "V/JI8?C6#!\0S'\#YO#7FG[?
M]J^S*,\_9F^<G\\K]#7L_P (O#VI>'_ ?]G:S9FWN&N97,3LK94X'."1V->1
MI\%=?'CX6C:<_P#8(O?^/KS4P;?=GIG.=O'3K0!J>(?#W_"._LY:?$Z;;B[N
MXKN;URX) _!=H_"O2_@Q_P DFT3_ +;_ /H^2F_%[P]J7B'P&=/T:S-Q<+<Q
MN(D95^49'&2!W%9NDZ!XGTKX!C1;.VDM]?6&55B610P#3LQPV< [&/?]: .7
M^+GQ!EUR[_X0?PR&N9)I!%=20\F1L_ZI?Q^\?;'K7H'PP\!)X&\/&.?8^J79
M#W<B\@8^Z@/HN3]23[5XIX;\&?$[PG?O?:3H'EW3+L\V00R%1WV[B<9]J](\
M&7_Q:F\5V4?B2S":0V_[0QCA&/D;;RIS][;0!ZW7SGKW_)T<7_7[:_\ HB.O
MHRO$]7\$>([GX_Q>(8=,=M)^TV\AN?,3 58D5N,YZJ>U '.>*C_PKKX]V^L*
M#'8WDBW+XZ;),K+^NYL?2K'AYO\ A8OQ^GU4_O-.TUS+&>VR+Y8\?5L-^==O
M\:O ]_XMT2PN=(M?M&HV<Q'EAE4M$X^;DD="%_6G?!;P1>^$M!O9]6M?L^HW
MLPS&6#%8T'R\@GJ2Q_*@#@=!_P"3HY?^OVZ_]$25Z!XW^)&@^$O$Z6UOH7]J
M^(VC2/\ =(%=5;E4W[2V3NR% /6N?TCP1XCMOC_+XAETQUTDW-Q(+GS$QM:)
MU7C.>K =*K?$+P3XLL/B4OC3PU9B_P O'+Y8PQC=4"%2N02I"]1Z]N* .0^+
M6O\ B#Q!%I4^N>%FT58S((7D)+R9VY!R!TP.W>NT^*=[<1_ KPTBL^+I;-9F
M!X(\@M@_BH/X5C^-/#OQ/\?V%OJ&I:-! MM)L@T^%E5\,,M(=S'^ZHP3WX'4
MUZ=K'@=_$WPHL/#ET1;7T%G;[&8Y$<Z(!@XSD=0<9ZT 1?![3+*U^%^F-##&
M6O%>2X;:/WC%V'S>N  /PJC\8-/L]+^$-]:6%K#:VR31%8H4"J"903@#W)-<
M%H5M\8?!E@^A:;I1>VWL8F*QRK&2>2K9P 3SAO7I79:[X7\7:A\$I-(O]^H^
M()9EED7S@QP9MV-Q('"]AP,8% %?X&^%]&D\#'5+BP@N+N[F=)'GC#X53@*,
MC@=SZ_E7(_'R5[GQ_HVFRLT=HEFA49X&^1@S#\% _"O5OA+H>I>'O %MI^JV
MK6UVLTK&-F!(!8XZ$BLCXO?#:Z\:VUKJ&DF/^T[1&3RY&VB:,\A0>@(.<9P.
M3DT =EKFAZ9)X)OM'-K"FGK9NBQ!1M0!3@CT((!!]1FO%OV?IYO)\4V^6,'V
M>-^O ;YQ^H_E3[BY^,^J:$WAN71V$;Q>3)<E$5W0C!!D+;>1P2.:]"^'O@#_
M (03PC?17$D<VI7B%[F2/.T *=J#/4#+<^I- 'EW[/ND6&H>)=2O+NVCFFLX
M4:W+C(C9B06 ]>.O:D_: L;6P\9:=>6:+#<W%KOE,?RDLK$!CCOVS["N6^'%
MCXMDOK[4_!\H%]8QJ9(,C]\C$@C!X;IG!_#D"NST_P  >-OB!XU@U?QE:M:V
M<17S?-"INC4Y\I$!R,\\GU)R3U '?M".\C^%WE&)&MI2P]#\F:]#UWPQHMA\
M%]0L[;3H$BCTMIU^0%O,5-P<GJ3GG-<_\</!WB#Q3=Z+)HNFO>+!'*LI1U&T
MDKCJ1Z&O0?$&F7EY\.M1TN"'?>RZ8\"1!@,N8R ,YQUH \T_9]NXK7PAX@FN
MI EK!.)9&;HJB/+$_@/TJ;3_ (MF>633/ ?@2:[M(#]Z(")%ST)1%(7/N14O
MPO\  >LV7@7Q-HFM6KZ?)J0:*-F96P&C*[OE)Z$US/A+3?BC\/)K[2M,\-PW
MD=RX8228:,,!@,'#+P1V;T[<T 9GPXGNI/CYYEU9BPN)IKHS6J](V*.2OX&M
M#XD:C_PB_P =[77"B7ZQQQ3M;*V60!"I!]#@;Q]0:U/!?@'QCI7Q@AUO6[99
MHF\V:XO8W787DB;( R#PS;>G;TK$\4?VE>_'RX?P/<R/JX.)'<+LB=8]D@RV
M05"C!R.N0.U ":UJMQ\8/B%HTN@:3=6\-IL26ZD'**'W%F9<A0.<#.23[UT/
M[1]W,EGX?LU+""22>5QG@LH0#\@S?G5/7?&GQ5\ M:W.O1Z?/92OL4+&FQB!
MDKE,$''\N_-=KXS\-+\6?A[IE_IQ6WO2BW5L)B<?,OS1L1_/'51VH Y.S\0>
M.Y/!,.AV_P /4DTV2Q%NC G#H4QNQZG.?J:M_"3P3KUIX6\5Z1KEI/I\.I1+
M#"7QG+(ZNP /;*?6J&CZU\8_#6F6^BKX9BO$MU\N*6>(R%5' &Y) , =,UZ!
MX>'C^[\%:PVMO!;:],)#IZH(\0_(-N<9'WL]<GUH \@TC4/&WP4N;J&\T5+C
M2YY 7DP3&Y' *RK]TD=F'X5[OX*\6:9XRT :IID9A!D*3PL &CDX)!QUZ@Y[
MYKRC5]7^+VL:'=>'+[PK"YN8S#)=+$,E3U^;?L!]_P#]==_\*?!5SX(\*/:W
M[HU]=3&>81G*Q\ !<]\ 9SZGVS0!Y3\08VB\>:NK=3*&_ J"/YU@0WES;Q31
M07$L<<Z[941R!(/1@.OXU[#\4_!D^I!==TV(R3Q)LN8D'S,@Z,/4CH?;'I7C
M%>/7@X5&?I&5XBGB<)"W1)->:_JZ/0?BG=W-MXI2."XEB2;384E5'*AUYX;'
M4>U>?5>U;6+_ %N[6ZU"?SIEC6(-M ^51P.*V/!GA&Z\4ZLB>6RV$3 W$W0
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M.V_Z ,O_ ($C_P")H_X7G;?] &7_ ,"1_P#$T<K#F1ZW17DG_"\[;_H R_\
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M_A=GB3_GQTG_ +]2?_'*/^%V>)/^?'2?^_4G_P <HY6',CWFBO!O^%V>)/\
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M'_A6Q11<+&/_ ,(EX;_Z%[2?_ */_"C_ (1+PW_T+VD_^ 4?^%;%%%PL8_\
MPB7AO_H7M)_\ H_\*/\ A$O#?_0O:3_X!1_X5L447"QC_P#")>&_^A>TG_P"
MC_PH_P"$2\-_]"]I/_@%'_A6Q11<+&/_ ,(EX;_Z%_2O_ */_"IO^$=T3_H#
MZ?\ ^ R?X5I44 9O_".Z)_T!]/\ _ 9/\*/^$=T3_H#Z?_X#)_A6E10!F_\
M".Z)_P! ?3__  &3_"C_ (1W1/\ H#Z?_P" R?X5I44 9O\ PCNB?] ?3_\
MP&3_  H_X1W1/^@/I_\ X#)_A6E10!F_\([HG_0'T_\ \!D_PH_X1W1/^@/I
M_P#X#)_A6E10!F_\(]HG_0'T_P#\!D_PJ;^R=-_Z!]I_WY7_  JY10!3_LG3
M?^@?:?\ ?E?\*/[)TW_H'VG_ 'Y7_"KE% %/^R=-_P"@?:?]^5_PH_LG3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHK)\-:];^)=!MM3M\ 2KB1,\QN/O*?Q_3!K6J2@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *PO&6B#Q#X4O]/"YE:/?#Q_RT7E?SQC\:W:* /E"-3=:+/"W^NLG
M\U0>Z,0K_DVS _VFKZ*^%^O?V[X'LV=RUQ:?Z-*3URH&#^*E:\=\1Z='H7Q1
MN;650EG>R$$XX6.8$$@?[)8D>ZUO?!;49-,\5ZEH5Q\OGH3M)Z21G!'Y$_\
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M)O"UK?%A]H4>5< =I%Z_GP?QJGKJ2M-#H:***DH**** "BBB@ HHHH ****
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M8DSC=!Y7_?9"_P#LU9WPEMA!\/K.0#!GEED/O\Y7^2BGT#J=O1114C"BBB@
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M&/&^5SV&?8$D^@H Z"BO !\<O&&H!KG2O"43V:L<MY4TV![LN!GIVKJ?A_\
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MZZIJ20)<>>\1\A2JD+C!P2>>:X34O^35D_Z]X?\ TJ6M_P" G_)-A_U^R_\
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M?"/2?&UP=0CG?3]5( :X1=ZR@# #+D<XP,@C\:X:T_9WOG=(]0\3(+53G9#
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M/C74O[(\%ZM> X=;<HA'9G^13^;"J,3R#PH/^$L^,+Z@PWPI<27?/.$7B/\
M([*]]KR#X'Z9B+5=58=2MLA^GS-_-*]?JI;DQV"BBBI*"BBB@#Y5^.?_ "5"
M[_Z]X?\ T 5[=\0?^2,:C_UX1?S6O$?CG_R5"[_Z]X?_ $ 5[=\0?^2,:C_U
MX1?S6@#RS]GG2K:[\3ZGJ$\*22V=NHA+#.QG)R1[X4C/N:WOVC;.#^SM#O?*
M7[2)I(O, Y*8!P?;/\SZUG_LX?\ (0\0_P#7*#^;UK_M&_\ (OZ)_P!?3_\
MH% &Y\);MK+X*Q78R3;I=2*.OW7<UY'\%]/AUOXG12Z@!<-#%+=?O?FWR< $
MYZG+9^HKV+X+0I<?"6SAD&4D>X1A[%V!KQ&T?4_@_P#$L27-LTRVS,F#\JW,
M##&Y3CZ'V(P>] 'TOXM\':3XTTM+#54DV)()$DB(5U(]"0< ]ZS&\*:5X/\
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MS#M\N8J, DDY7.!G@^U>2W%WJ&H^/X=0U.%H;J\O8KED88PKL&7 ]-I&/;%
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M*_\ S\:M_P"#9?\ XY1R^8<WD>\T5X-_PC/Q7_Y^-6_\&R__ !RC_A&?BO\
M\_&K?^#9?_CE'+YAS>1[S17@W_",_%?_ )^-6_\ !LO_ ,<H_P"$9^*__/QJ
MW_@V7_XY1R^8<WD>\T5X-_PC/Q7_ .?C5O\ P;+_ /'*/^$9^*__ #\:M_X-
ME_\ CE'+YAS>1[S17@W_  C/Q7_Y^-6_\&R__'*/^$9^*_\ S\:M_P"#9?\
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M4O#URV/.#( #D&2,GI^&[\A6CU1FM&>[4445F:!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5)X0A@KX^NY?RKC=2>?XD?&8VEU.PAGOC;(5_P"6=NA/"^^T$_4DUZS\)9/
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MS>N6^.1*_%&[()!$$)!'^Z*ZG]G#_D(>(?\ KE!_-ZY;XY_\E0N_^O>'_P!
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M1J":KJ<<K>2PD=PQ; 1"S ' .2?;- 'HU%?.WA_2_B9\2[2;7T\43:=;F0K
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M\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8_-M;F-HI4W%=RD8(R""./2L[PYX2T/PE;S0:'8"TCG</(/,=RQ P.6)/X4
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MY\.%N;,J/"]W*R%I8Y)!(68HVY6&[&5(Z=!40^"/@,7'F?V7,5_YY&[DV_\
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M7NH<%HH_D!.,L>!^IKYNN)Y;JXDGG<O+(Q9V8\DFO9?BY/(OARTMX\XGN0&
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MU4ZU&7NH^UEC,NS&DO:R2MKJ[->5_P"OO.7U/4[O6-1FO[Z9IKB9MS,?Y#T
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M:_\ Q->^42"(4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]3'_ .2/_P!LH_X45_U,?_DC_P#;*++N%WV/2?\ A+?#?_0PZ3_X&Q_XT?\
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M);X;_P"AATG_ ,#8_P#&C_A+?#?_ $,.D_\ @;'_ (UYM_PHK_J8_P#R1_\
MME'_  HK_J8__)'_ .V467<+OL>D_P#"6^&_^AATG_P-C_QH_P"$M\-_]##I
M/_@;'_C7FW_"BO\ J8__ "1_^V4?\**_ZF/_ ,D?_ME%EW"[['I/_"6^&_\
MH8=)_P# V/\ QH_X2WPW_P!##I/_ (&Q_P"->;?\**_ZF/\ \D?_ +91_P *
M*_ZF/_R1_P#ME%EW"[['I/\ PEOAO_H8=)_\#8_\:/\ A+?#?_0PZ3_X&Q_X
MUYM_PHK_ *F/_P D?_ME'_"BO^IC_P#)'_[919=PN^QZ3_PEOAO_ *&'2?\
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M/YU\BU]4^$Y[2X\):2UE,);=+6.-6_W5"D'W!&#2F.!LT445!84444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5X=\3T.@_$C3]:B'WQ%.<=V1L$?DH_.O<:\M^-UCYFA:;? <P
M7#1'CLZY_P#9*J.Y,MCF]%D'AOXX".-@MO<W!4 ="DR[D'YLOY5]!U\O^)))
M4MO"_B"$D/)9HN\]3+ VTG]%KZ8L+N._TZVO(CF.>)9%/L1D42")8HHHJ2@H
MHHH **** /G?5LP'70!_Q[^+$D_ ^;_@*][KP?Q7'L?QXH&#'J=K,,GU,G/_
M (\*]VC<21JXZ, 152)B>/\ B^+/C+Q?'_STT(2_4JT?^%>C^#I/-\%Z(W_3
MC"/R0#^E<+XNC_XN%JL?4W'AJ<#ZX;_XFNN^'<OF_#_1VXXA*_DQ']*'L"W.
MGHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBN3\0_$30?#L[6TLLES=+PT-N Q0_[1)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44V22.)=TCJB^K' I5974,C!E/((.0: %HJ*YN8+*UDN;F5(H
M(E+.[G 4"O)=>^,<_P!I>'0[.(0J2//N027]PH(Q^.?PK.I5C3^)G;@\!7QC
M:HK;KT/7Z*\%7XN>)U?)-FP_NF#C]#7:>$_BK:ZQ<QV.KPI9W4AVI*A/E.W8
M<\J?J2/>LX8JG)V.O$9%C*,'-I-+L>C4445T'CA1110 4444 %%%% !1110
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M4ZI^_N[)'CD/ \V0-M3..F=RY^IKS7POX9\7?%T7NM:AXEFM;>.7RTR&92X
M.%0$!0,CGW[T ?2M%><:&=?^''P^UJY\3WW]I&Q=GM'\TN70JH523R!N.,'I
M^5>=>%= USXIP7FNZ]XOGLHQ,8X(HVP-P .0FX!5&1TY//U(!]&45X5\+O%&
MM:-\0KOP-K&HOJ, :5+>5WW[70%LACSM903C/!Q[US?C/Q!XFL_C1JUKH5Y=
M-=S.MK;Q+(2!OC4<#. 1G(/8\]J /IFBO-/A?X"\1>#[[4+G6M5BNUO(D^1)
M7<B3)))W >O7O73?$'6[SP[X#U;5; 9NH(@(SC.TLP7=CVW9_"@#I:S/$6L)
MX>\.W^KR0M,MG"TIC4X+8[9[5\^^!O"#_$2PFU&Y\=746MB5L0%R[H/[Q!8$
M@^V ,5V7Q+\':[-\-=/>XU]I)=%M96O26<_;,[<$\\D;3U]30!VWP_\ '4/C
MW2+F_BL'L_(G\DH\@?/R@YS@>M=;7R[\*_ FL>)H3JFGZZVGV]I>JLD2E\O@
M*Q(P<=#CFNU^+/C/6KCQ=9>"- O&L7F,:W,ZML):0C:-PY50,$XZY_, ]MHK
MYR\7>$M8^'.FV_B'1?&EU=3),JSH7QR>C8W$,.,$$'K78>,O%5SKOP 37K>5
M[:XN1")#"Y7#B4(X!';*G\* /7:*^;/"_A_QY\2?"T*C7C9Z19*T$(>5\W#Y
MR=V.6QD#)Z=AUK)\':U\0-0GN? ^DZE*DDKD22S2$M:JA(?:_55Z9QSP,=3D
M ^J:*^6=73Q5\'O&5DSZQ)=QR@3D+(WESKNPZLK=^.ON"#FO2OC_ ']U:>#]
M,>SNIH/,O@&,4A3</+8\XH ]<HKYTM?"GQ"^(?AB/7+G6_L]O' !96AE<><$
M& Q Z$D'YFR2?08KHO@'XNU/6(M2T;4[N6Z%JJ36\DS[G522&7)Y(SC&>E '
MM-%?.\NLZU\6OB#>:7!KLND:#:!V7RWVY12%R0"-S,>>3@#/XU[V]UCX/>-]
M/BA\03:IHER%:2-WR#'NPR[<D*PZ@C'\Q0!](45X;\=?%6K66LZ7H%I?RZ?8
M7$(FGGB)!;+E<$CDA0N<#KFM?PC\-)])UC3==T/QO-J%COW7,>XE+A<<\JQ!
MYQP1^- 'K=%?/GQ4\1ZCJ/Q/A\+3ZW+HVC1F)7F5BJG>H8NV",XSCDX&/J:[
MGP/\.[SPKKL>HV'BN;4=&FA8-;N3M8G&U@0Q4]^<"@#4^)?BF;P[H4<-F^R]
MO241QU10/F8>_( ^M> DEF))))Y)/>O4/C46_M/21_#Y+X^NX?\ UJ\]T744
MTG6;6_DM(KM8'W^1+]UCVS^//X5Y6)DY5;/9'W^1T8TL"JD%>4KOUWLCH+[X
M=ZO8>#8?$,H)W'=+:[#OBC/1S_4=LCWQREO<36MQ'<6\KQ31L&1T."I'0@UZ
M_<^.]5MO ^E>()!'-)<ZA,D\#CY'B.X;/8  8^G?G/D-S*L]U-,D2PI([,L2
M=$!.<#V'2HJQA&W(=.7U<154UB$MVM/6UOEWZGT=X(\1GQ/X9AO9,"Y0F&X
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MQ[?I6[:?'&Q?'VW1;B+U,,RR?S"TN5CYD>L45P4'Q@\*3*"\MW <=)("<?\
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M7_-7"BBBMCS@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVA^$K+4[+5Y98GN9HW@*1E]YP01QT[=?6OHZ""&U@C@MXDAAC4*D<:A54#H
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MHJ);/&"BA1A< ],=C6+8_#/P9IMTMS;>'K,3*<J9 9 #Z@,2* .,\5P:K?\
M[.,;WXEDOTM;>:7>#O*AU.6[Y"\G/H:R?@IX^T/3O#]KX:NY94U*:^9(46,L
M'WXP<]!SG\J]RDCCFB>*5%>-U*LC#(8'J".XKFK'X=^$=-U6/4[/0;6&[C;>
MCJ#A#ZA<X'X"@#P;Q#-8:C\<[V'QS/.FE17#Q %F 6( F(<<A3P3CUS[UA_$
MN3P:VLVT/@R +:0Q;9Y4W['?/&"YR<#O_.OI_7?!GASQ+*DNL:1;W4J#:LC
MJ^/3<"#CVJ%_ /A.33X+!] L3:P.9(X_+P QP"?4DX'7T% &#\7[26[^$FI"
M)2S1+#*0!GY5=<G\!D_A7&?!3Q]H>G>'[7PU=RRIJ4U\R0HL98/OQ@YZ#G/Y
M5[C)%'+"T,D:/$RE61AE2#P01Z5S=C\._".FZK'J=GH-K#=QMO1U!PA]0N<#
M\!0!XMXC_P"3GX?^O^R_]%14OQ>@NO#'Q<T[Q1]G+V\CP7"'/#M%M#(3V.%'
MYU[K-X2T"YUY=<FTFV?5%96%R5^?*@!3]0 /RJ]J>E:?K5DUEJ=G!=VS$$Q3
M(&&1T//?WH \^E^.?A1TLTT\7=Y=W,B1B#RC'Y98@'<QXX]L_P!:]-KF=*^'
MOA+1;Y;W3]!M(KE3N20@N4/JNXG:?I734 ?)/PG\:6?@GQ1+=ZC#(UG<P>1)
M)&,F+Y@0V.XXZ?\ ZJU/B?XKA^)?B[2=/\/1RSQ1CR(2Z%3))(PR0.H'"\GT
M-6?@/I=GJWB'6K'4K..YMGL-LD4R9&?,7UZ&O>M#\$^&O#=P;C2-'MK6<@KY
MH!9P#U 9B2!0!XQ\>O#=S8IX?U.%"UK;VJV#R+_ R\KGZY;'TKKYOCOX7/A5
MKJ.:;^US!Q9>0^1+C^]C;MSWSG';/%>I7-K;WMM);74$<\$J[7BD4,K#T(/6
MN67X7>"$N?/'ANRW^A!*_P#?)./TH \X_9W\/W4*:IK\\12"95MK<D8WX.7(
M]L[1GUSZ5R>AZU:^!OCEJMUK/F16RW5TCN$)(#$E6P.2#Q^=?3T44<$211(L
M<: *J(,!0.@ ["L+6_ WACQ'="ZU;1K:YN, >:05<@= 2I!/XT >8?&A8_&'
MP]T?Q3I >:RMY7+,5*L(W.W<0>VY /Q%9'A.\^#EUX;LO[;LX;74XXE2Y643
MG>X&"X*\8.,X[9KWRRTVRT[3H].L[6*&SB38D*K\H7TQ7-7'PM\$7,YFD\.6
M@<G)\O<@_)2!0!4^&TW@FYAU*7P98^1$LBQSRE&7S#@D8W'..3Z5Y3^SK_R-
M^J_]>'_M1:^@M*T;3-#M/LNE6%O9P9W%((PH)]3CJ?<U3T;PEH'AZYEN=(TF
MVLYI5VN\2X)&<X^F: /"?V@O^1_TG_KP3_T;)7:_M"VDLW@6RN(U+)!?J9,#
M[H*.,G\<#\:]!U?PEH&OWD5WJVDVUW<0KM225<D#.<?3)-:=Y96NHV<MI>V\
M5Q;2KMDBE4,K#W!H \P^$7C[0[WP_HGAA)91JT<+HT7EG;A=QSNZ=!FN%\$?
M\G):G_U_ZA_.2O;M&\!^%_#^HF_TK1K>VNB"HE4L2 >N,DX_"K%KX2T"RUR3
M6K;2;:+4I&=GN57YB6^\?J<G\Z /GGQ#-8:C\<[V'QS/.FE17#Q %F 6( F(
M<<A3P3CUS[UA_$N3P:VLVT/@R +:0Q;9Y4W['?/&"YR<#O\ SKZ?UWP9X<\2
MRI+K&D6]U*@VK(P*OCTW @X]JA?P#X3DT^"P?0+$VL#F2./R\ ,< GU).!U]
M!0!PG[0'_).-,_["47_HF6NI^$G_ "2S0O\ KD__ *,:NDUC0=*U^R6RU6QA
MN[9'$BQR#(# $ C\"?SJQI^GV>DV$-C86Z6]K"-L<48P%&<_S- '!_%7PG-K
M%A%JUC&9+JS4K*B]7BZ\>I!R<>YKP^OK6N-\0?#30=>F:Y5)+*Z8DM);X <^
MK*>/RP:XL1AG-\T=SZ;*,\CAZ?L*_P *V?8\3U#Q%=:CH&EZ/+'$L&G>9Y;J
M#N;><\\XX]JSK2TN+^[BM;6)Y9Y6"HB#))KUN/X*6HFS+K<S19^ZMN%;\]Q_
ME7;>'?!^C>&$/V"WS.PPUQ*=TA'IGL/88K&.%J2?OZ'I5L_P="FUA_>>O1I7
M>NMP\'>'E\,^'(+ [3.?WD[*>&D/7'L, ?A6]117I1BHJR/BZM656;J3>KU"
MBBBF9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!X-X(/F_&:X<=//N6_]"_QKK/@VGE:WXPC_NW$0_\ 'IJY
M+X:$7'Q3N90<C;.^1[G_ .O76_!I_,UKQ?)_>N(C_P"/35;(1ZU1114%A111
M0 4444 ><^,AY7Q2\&SD<2"XB^ORX_\ 9JB^$)*^#)8">8+V6,^WW3_6IOB)
M^[\8>![CIB_>//\ O&,5#\+OW4'B*S.<PZO-_0?^RU70GJ'Q:/E^'--GSCR=
M4A?_ ,=>CPG_ */\3O&5OTWF"7'_  $G_P!FIWQ>0MX"E<8_=W$3?KC^M1:+
M)M^,VM@=+G38INOH(Q1T#J>@T445)04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 45Y=X\L/B!-XB:709KDZ:8U$:VTZIM./FW D$G.>?3
M%<O_ &9\5_\ GIJW_@6O_P 556)N>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ
M7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X
M%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^
M8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5
MX-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_
M .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\
M@6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51
M_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ
M:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\
M51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD
M>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9
MGQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>F
MK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_
M ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ
M7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X
M%K_\51R^8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^
M8<WD>\T5X-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5
MX-_9GQ7_ .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\T5X-_9GQ7_
M .>FK?\ @6O_ ,51_9GQ7_YZ:M_X%K_\51R^8<WD>\UX-XF_Y+U!_P!A"R_]
M!BH_LSXK_P#/35O_  +7_P"*J/1O!OC*?QQIFHZM8W+,EU#--<S2*WRHPZG)
MYPN *:5A-W/?:***@L**** "BBB@ HHHH **** "BBB@#P3XU2(_C6V565BE
M@BL ?NG?(<'\"#^->E_\+3\&?]!G_P E9O\ XBF^(_AGH?B;5WU.[EO8;AU5
M7\B10&P, D,IYP /PK(_X4GX;_Y_M6_[^Q__ !NJNFB;.YL_\+3\&?\ 09_\
ME9O_ (BC_A:?@S_H,_\ DK-_\16-_P *3\-_\_VK?]_8_P#XW1_PI/PW_P _
MVK?]_8__ (W1[H>\;/\ PM/P9_T&?_)6;_XBC_A:?@S_ *#/_DK-_P#$5C?\
M*3\-_P#/]JW_ ']C_P#C='_"D_#?_/\ :M_W]C_^-T>Z'O&S_P +3\&?]!G_
M ,E9O_B*/^%I^#/^@S_Y*S?_ !%8W_"D_#?_ #_:M_W]C_\ C='_  I/PW_S
M_:M_W]C_ /C='NA[QL_\+3\&?]!G_P E9O\ XBC_ (6GX,_Z#/\ Y*S?_$5C
M?\*3\-_\_P!JW_?V/_XW1_PI/PW_ ,_VK?\ ?V/_ .-T>Z'O&S_PM/P9_P!!
MG_R5F_\ B*/^%I^#/^@S_P"2LW_Q%8W_  I/PW_S_:M_W]C_ /C='_"D_#?_
M #_:M_W]C_\ C='NA[QL_P#"T_!G_09_\E9O_B*/^%I^#/\ H,_^2LW_ ,16
M-_PI/PW_ ,_VK?\ ?V/_ .-T?\*3\-_\_P!JW_?V/_XW1[H>\;/_  M/P9_T
M&?\ R5F_^(H_X6GX,_Z#/_DK-_\ $5C?\*3\-_\ /]JW_?V/_P"-T?\ "D_#
M?_/]JW_?V/\ ^-T>Z'O&S_PM/P9_T&?_ "5F_P#B*/\ A:?@S_H,_P#DK-_\
M16-_PI/PW_S_ &K?]_8__C='_"D_#?\ S_:M_P!_8_\ XW1[H>\;/_"T_!G_
M $&?_)6;_P"(H_X6GX,_Z#/_ )*S?_$5C?\ "D_#?_/]JW_?V/\ ^-T?\*3\
M-_\ /]JW_?V/_P"-T>Z'O&S_ ,+3\&?]!G_R5F_^(H_X6GX,_P"@S_Y*S?\
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MA[QL_P#"T_!G_09_\E9O_B*/^%I^#/\ H,_^2LW_ ,16-_PI/PW_ ,_VK?\
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MW1[H>\;/_"T_!G_09_\ )6;_ .(H_P"%I^#/^@S_ .2LW_Q%8W_"D_#?_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF1$Y1A[?T*^M=Q28T%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCWTNW/\ 6ICX"U'O;>$'_P![1?\ [.F'P%J7_0.\&'ZZ4X_D] $?_"+2R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9[.UN?]?;0
MR_\ 71 W\ZFHH QY_"?ARY_UV@Z8Y]3:)G\\50?X=^$W8LNC11$]3!(\7_H+
M"NGHHN%CEO\ A =*C/\ HMYK%H/2#4I@/U8TA\'W<.#9^*];B8?\]GBF'Y,G
M]:ZJBG<5CB+CP=KDH)DUK3+\]UOM'1MWU*L/Y5DS^ ]1+;Y/#OA&?'(^SB6U
M;VQ@'!_&O3:*+A8\J_X1K5+5L0>%]3MA_>TWQ$3^.'*_E2%M6L^4N/&]H>_G
M6<5ZH_[Y#''UKU:BBX6/*!XON[1@K>+-/+'^#4])FMC^8(%:=MXNUB3_ %0\
M-:EGH+/5MC>W#*>?:O0V574JP!4\$$=:R[KPQH%]G[5HNGS$]WMD)_/&:+H+
M,P/^$GU2%3]N\(ZHJD=;9X;@'\G%9MUJ_@VZS_:^@R6[=,WNCN#_ -]!#CZY
MK?;X?>&1DP6#VK=C:W,L.#]%8"F'P2T?-GXEU^ CHK70F4?@ZD_K1H&IS=O:
M?#:Y;-E?6=I(3QY%\]NV?IN'/X5K0>&HYD+Z9XLUD*.FV]6=1_WV&_G3KKPA
MK\H^;Q!97X_N:AI,;Y_%2/Y5CW'@._+;Y/#?A:YP>/LCRV;?A@$#\Z8C0NO"
MFMS9,NLZ=J /5-0TB-MWU*D?RK*G\$WF_P QO#?AN8]S9S36;?AM!Q^=)_8F
MJV6=NA>)+./O_9VMK.!]%D;GUY%,.I:I9]=9\3V*?]1+1!.!]6C7G\#0 G]E
MZM8CY=)\2VL8_P"?#6DN%'T60^WI2-K.KV9PVL>(K-!_T$="69?^^HAS^9J:
M#QI>JQB7Q+X9N&':[CEM&_')('Y5K6WBG7)>(]$L-0'][3]6C?/X,!_.@#(M
M_'%^'"#7O#$YQG%R)K-OQW9 _*M>W\6:S,!Y>A6=YQUL=6BDS^#!:GD\3&1-
MFH^$]9 '4?94G7\-K$_I61=W_P .Y_\ D(Z7!;.>IN-+DA(^K;!_.@#:7Q=/
M'Q=>&-=A/<I;K,/_ !QB?TH/C[P]'Q=7%S:-W%S9S1X_$KC]:QK:Q\ W!']F
M:Z+1^PMM7DC/_?)?^E:L7AV9TW:9XQU8@=VEBN%_5?;UI:!J:%KXN\.7F!!K
MFGL3T4W"J?R)S6M#/#<)OAE21?5&!'Z5R5SX5UJ53OU?3+W/\-]I$;9^I4C^
M59,W@:]+;W\/^%IR#G_1C-:-^&W.#19#NST>BO-5\/ZM;#$.@:G;@=K#Q&V#
M^#XI!_;5J.1XVA;J>;:Z4?UHL%STNBO-?[=UJVYFUO5X1GK>^&R0?;,>*!XY
MOHL ^(O#YYQ_I5C<P']3_2BP7/2J*\_B\<7YY%_X1G'HNJ-$3^#+5Z+QAJLA
M"KHVGSD_\^^LQ-G\P*+!<[*BN87Q+K.W<_A*^(]8;J"3^3T[_A+9E_UOA?7T
M^ENCC_QUS18+G2T5S7_"9P#[^A^(%^NF2'^0-!\<:6O^LM-6C_W]-F'_ ++1
M8+HZ6BN:_P"$\\/K]^>\0^CZ?<#_ -DH_P"$^\-=[^0?6UF'_LE%F%T=+17-
M_P#"?>&.^J ?6&0?^RTA^('A4#)UB$?5'_PHLPNCI:*YH?$'PH?^8U!_WRW^
M%+_PG_A7_H-6_P"3?X46871TE%<U_P + \*YQ_;4!^BL?Z4?\)_X6S@:O&?I
M&Y_]EHLPNCI:*YK_ (3_ ,,$\:H#]()#_P"RTO\ PGWAKMJ+'Z6TO_Q-%F%T
M=)17-?\ "?>&\9%]*1[6<W_Q%'_"?>',9^UW'_@#/_\ $46871TM%<T/'OAT
MC(N;H_\ </N/_B*/^$]\/DX$UX?II]Q_\119A='2T5S7_"=Z#_STOO\ P77'
M_P 11_PG6B?]1#_P73__ !%%F%T=+17-?\)UHQ. FI'Z:=/_ /$4O_"<Z/\
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MB/\ F,Z:![:'"/ZT 4O)\/9Y^(5X?^XS'3?+\,XY^(-V?^XXG^-:(\":D/\
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MH ;)\/;U68I9>&ICT!6WFM6/XQN<?E40TKQ'IF#%9Z[;HO\ SX:JEU&/I',
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M=V>HT5YFOC;5[ ;+G4++(YQJNG7%F_7NRADK4M/']S-@?V5:W8[G3M4AF/\
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MVERD?\\[$S']%-/05V22_$VW7[NFJ/\ KMJ5JA_+S#51_BJJG L+#Z'5D/\
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MM3C&8850_F!5^BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^.*M%@N9%OK/A2 C^S/#EQ,1]TVFBN/U*"K,OC.2%"(O#>HQ@?\ /R\%N/\
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MT^/&RQMEQ_=A4?TJPD4<?W(T7_=4"GT4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img108642122_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &; >T# 2(  A$! Q$!_\0
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MT$;3_O\ K_C5RN9\*:5ITWA'2))+"U=VM(RS-"I).T=3B@#:_M?3/^@C:?\
M?]?\:/[7TS_H(VG_ '_7_&F_V-I?_0-L_P#OPO\ A1_8VE_] VS_ ._"_P"%
M #O[7TS_ *"-I_W_ %_QH_M?3/\ H(VG_?\ 7_&F_P!C:7_T#;/_ +\+_A1_
M8VE_] VS_P"_"_X4 ._M?3/^@C:?]_U_QH_M?3/^@C:?]_U_QIO]C:7_ - V
MS_[\+_A1_8VE_P#0-L_^_"_X4 ._M?3/^@C:?]_U_P :/[7TS_H(VG_?]?\
M&F_V-I?_ $#;/_OPO^%']C:7_P! VS_[\+_A0 [^U],_Z"-I_P!_U_QH_M?3
M/^@C:?\ ?]?\:;_8VE_] VS_ ._"_P"%']C:7_T#;/\ [\+_ (4 ._M?3/\
MH(VG_?\ 7_&C^U],_P"@C:?]_P!?\:;_ &-I?_0-L_\ OPO^%']C:7_T#;/_
M +\+_A0 [^U],_Z"-I_W_7_&C^U],_Z"-I_W_7_&F_V-I?\ T#;/_OPO^%']
MC:7_ - VS_[\+_A0 [^U],_Z"-I_W_7_ !H_M?3/^@C:?]_U_P :;_8VE_\
M0-L_^_"_X4?V-I?_ $#;/_OPO^% #O[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_
MU_QIO]C:7_T#;/\ [\+_ (4?V-I?_0-L_P#OPO\ A0 [^U],_P"@C:?]_P!?
M\:/[7TS_ *"-I_W_ %_QIO\ 8VE_] VS_P"_"_X4?V-I?_0-L_\ OPO^% #O
M[7TS_H(VG_?]?\:/[7TS_H(VG_?]?\:;_8VE_P#0-L_^_"_X4?V-I?\ T#;/
M_OPO^% #O[7TS_H(VG_?]?\ &C^U],_Z"-I_W_7_ !IO]C:7_P! VS_[\+_A
M1_8VE_\ 0-L_^_"_X4 ._M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&F_V-I?
M_0-L_P#OPO\ A1_8VE_] VS_ ._"_P"% #O[7TS_ *"-I_W_ %_QH_M?3/\
MH(VG_?\ 7_&F_P!C:7_T#;/_ +\+_A1_8VE_] VS_P"_"_X4 ._M?3/^@C:?
M]_U_QH_M?3/^@C:?]_U_QIO]C:7_ - VS_[\+_A1_8VE_P#0-L_^_"_X4 ._
MM?3/^@C:?]_U_P :/[7TS_H(VG_?]?\ &F_V-I?_ $#;/_OPO^%']C:7_P!
MVS_[\+_A0 [^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:;_8VE_] VS_ ._"
M_P"%']C:7_T#;/\ [\+_ (4 ._M?3/\ H(VG_?\ 7_&C^U],_P"@C:?]_P!?
M\:;_ &-I?_0-L_\ OPO^%']C:7_T#;/_ +\+_A0 [^U],_Z"-I_W_7_&C^U]
M,_Z"-I_W_7_&F_V-I?\ T#;/_OPO^%']C:7_ - VS_[\+_A0 [^U],_Z"-I_
MW_7_ !H_M?3/^@C:?]_U_P :;_8VE_\ 0-L_^_"_X4?V-I?_ $#;/_OPO^%
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M_P! %;5 !6+X0_Y$W1O^O.+_ -!%;58OA#_D3=&_Z\XO_010!M4444 %%%%
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M1110!BZE_P C/H?TN/\ T 5M5BZE_P C/H?TN/\ T 5M4 %8OA#_ )$W1O\
MKSB_]!%;58OA#_D3=&_Z\XO_ $$4 ;5%%% !1110 5X/J%C+>?$SQ2UAX&3Q
M*BRQ"62[F2(POL'";CRIKVK5[N]L=/>>PTYM0G4C%NLJQEAWP6XKR'5[/3;G
MQ!=ZSJ\/C/0;BYV^<\",T( & -T6<B@#N_A]:7%I97JW'@^'PT6D4B**=)1-
MQ]XE>F.E=C7&?#S^P_L-Y_8OB.ZUI#(IE:YF9WB.#@8;E<\_E79T %%%% !1
M110!S_A3[FL?]A6X_P#0JZ"N?\*?<UC_ +"MQ_Z%704 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%<Y?>)+^RU**R_L"XD,\CI ZSQ@
M2;03GKQP,\UO6TDDUM')+"89&4%HV()4^F1Q0!+1110 4444 %%%% &!XS_Y
M%Y?^O^R_]*HJWZP/&?\ R+R_]?\ 9?\ I5%6_0 4444 %%%% !1110!GZ[_R
M+VI_]>DO_H!I=$_Y 5A_U[I_Z"*37?\ D7M3_P"O27_T TNB?\@*P_Z]T_\
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MA3[FL?\ 85N/_0JZ"N9\%0O;V>J1/<2W#)JEP#++C<WS=3M 'Y"NFH ****
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MZ5Q7_"H+/_H;/%/_ ('+_P#$4 7_ (?:X-0N_$>CPZ=:6-GHFH-9VT=LFT%
M3R1Z\=J[>N8\'>!]/\%1WZV-W>W37THFFDO)%=BV.N0H]:Z>@ HHHH ****
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M05S/@J*6&RU2.:<SR+JEP&D*A2QW=<"NFH *@O+N*QM)+F99FCC&6$,+RO\
M@J L?P%3T4 8%GXRT>_NS;6ZZFTJR")PVDW2A&(!PQ,8"\,#R1P16_6%H'_(
M7\3_ /837_TDMZW: "BBB@ HHHH \?\ B!_R4";_ +!MM_Z,GKGZZ#X@?\E
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MNCZ5['XW_P"1!\1_]@NY_P#135XXOW1]* %HHHH 9-_J)/\ =/\ *O:/!_\
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MXH?\B@O_ %^V_P#Z&*\RH **** (+K_5+_UUC_\ 0Q7T*GW%^@KYZNO]4O\
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M ,B=I'_7K'_*O%YO]1)_NG^5>T>#_P#D3M(_Z]8_Y4 ;=%%% !1110 4444
M8NI?\C/H?TN/_0!6U6+J7_(SZ']+C_T 5M4 %8OA#_D3=&_Z\XO_ $$5M5B^
M$/\ D3=&_P"O.+_T$4 ;5%%% !1110 4TQ1M&T;(I1NJD<&G44 (JJBA5 50
M,  8 I:** "FLBN '4, 0<$9Y'2G44 1-;6[7"W#01&=1A9"@W >@/6I:**
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M_P"O6/\ E7B\W^HD_P!T_P J]H\'_P#(G:1_UZQ_RH VZ*** "BBB@ HHHH
MQ=2_Y&?0_I<?^@"MJL74O^1GT/Z7'_H K:H *Q?"'_(FZ-_UYQ?^@BMJL7PA
M_P B;HW_ %YQ?^@B@#:HHHH **** "BBB@ HHHH *PM7\6Z;HMVUO<BX8QH)
M9WBB+K AZ,Y'05NUP_B[4K*]OY?"R7%O;/>0C^TKF1E4I;GC:,]689 ] 2:
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MQ7T*GW%^@KYZNO\ 5+_UUC_]#%?0J?<7Z"@!U%%% &#XW_Y$'Q'_ -@NY_\
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M/_0JZ"N?\*?<UC_L*W'_ *%704 >%:S_ ,C5KG_7\W_H*U4JWK/_ "-6N?\
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M45RDNJ>*HM:M=,-IHQDN+>:X#^?+@"-HU(^YU/FC\C5W?XM_YX:+_P!_Y?\
MXB@#E/BG_P A#0?]VY_]IUQ%>@>)O"_BGQ)/8RN^CP&U$@ 664[M^W_9_P!G
M]:Q?^%;^)_\ GZTC_ON3_P")H YFBNF_X5OXG_Y^M(_[[D_^)H_X5OXG_P"?
MK2/^^Y/_ (F@#(\.?\CKX?\ ^OM__1$M>XUY9I_@#Q/8:S8:B+C2':TE,H0O
M)\V49,?=_P!K/X5VN_Q;_P \-%_[_P O_P 10!O45RE_JGBJPDLD>TT9C=7
MMUQ/+\I*LV3\G^S5W?XM_P">&B_]_P"7_P"(H ROBA_R*"_]?MO_ .ABO,J]
M*\2Z)XJ\1Z2+!_[&A FCEWK+*?NMG'W*YO\ X5OXG_Y^M(_[[D_^)H YFBNF
M_P"%;^)_^?K2/^^Y/_B:/^%;^)_^?K2/^^Y/_B: .2NO]4O_ %UC_P#0Q7T*
MGW%^@KR23X9^)I5"F[TD896^_)V(/]WVKO@WBT*!Y&B\?]-Y?_B* -^BN5U3
M4O%6EZ7<WTEKHSI A<JL\N3_ ..5:27Q:Z*XM]%^8 _Z^7_XB@!WC?\ Y$'Q
M'_V"[G_T4U>.+]T?2O5=9L/%>L:%J&ENFC1K>6TEN7$TI*AU*YQL[9KD1\-O
M$X 'VK2/^^Y/_B: .9HKIO\ A6_B?_GZTC_ON3_XFC_A6_B?_GZTC_ON3_XF
M@#EIO]1)_NG^5>T>#_\ D3M(_P"O6/\ E7G[_#7Q,Z,OVK2.1C[\G_Q-=AI-
MEXLTK2;2P6/19%MXEC#F:4$X'7[E '5T5@[_ !;_ ,\-%_[_ ,O_ ,15W0-3
M.M>'=.U1HA$UY;1SF,'(4LH.,]^M &C1110 4444 8NI?\C/H?TN/_0!6U6+
MJ7_(SZ']+C_T 5M4 %8OA#_D3=&_Z\XO_016U6+X0_Y$W1O^O.+_ -!% &U1
M110 4444 %%%% !1110 4444 4I-'TV;4DU&2Q@:]C&%G*#>!]:NT44 1PV\
M-OO\F)8_,<R/M&-S'J3[U)110 51U?4XM'TN>^EC>01@!8XQEG8D*JCW)('X
MU>K"\812R>')7AADF:":&X,<8RS+'*KL .YPIX[T 2Z)K4VIR7=K>6#V%]:%
M?-@,@D&UAE65AU!P1[$&MBN9\.7D>K^(-8U:T60V,L5O;Q2O&4\QD\PL0#@X
M'F 9]0?2NFH **** (T@B2:29(U623 =P.6QTS]*DHHH *R/$OB*S\+Z-+J-
MX'=5^6.*,9>5\$A5'KP?I@FM>L?Q5$9O"FJ(L9>3[+)L &3G:1Q^= $ZZW8I
MI]G=W=S#:BZC5T660#J <<]>M: (8 @@@\@BO+?$!"KIUM<1^03HL:QL-.-S
M+<.0084R"JL,#KS\WH*[[PNLB>$M&64,)!8P!@PY!\M<Y]Z -6BBB@",P1-<
M)<&-3,B,BN1RJL02 ?0E5_(5)110 4R66."%YI7"1QJ6=F. H'))I](RJZE6
M 92,$$9!% ')Q>/;&?1K_58[6;[+:WR6@,GR&0,(R),'HO[P$>H&>]=/:WEM
M?0":TGCGB)(WQL&&1]*\_P#$]N?[&\4^;;220MK%LY18BV^,0VVX@ 9(X/3T
M-:O@I5FUGQ'J%@OEZ)<SPBT3RFC#.L0$KJI X)VKGN4- '8T444 1RP13F,R
MQJYC?>A89VM@C(]\$_G4E%% !1110!AKXHLY/%R^'84>2<6\DTDH'R(5*#;G
MN?G!]OQK3AU"SN;B6W@NH9)HO]9&C@LOU%8^HV[GQEI4D41Q]AO0SJO 8M!C
M)]3@_E6%X*?35ET^RCTN9-7M;:1+Z<PE/+?<-P9B,.6.2.3QSWH [ZBBB@".
M:&*YA>&:-9(G&&1AD$4\    8 I:* "N9LO%TEUJT%O+I,]O97<LD-K=/(I\
MUDSG*=5!P<'OCM735P.B:]:>(O%WVJ\DGB:!Y(=/LVM95P.C2LQ7;E@.!G@>
MYH [6YU"SLWC2YNH87E.$61PI8^V:5;ZT:\-HMS$;D#)B#C<!QV_$?G7">+O
ML4&N:J=4LI+@W>EI#IQ6W:3,H+[E4@':Q)C/;I[5?\"Z4UM?:]=7MJ!?&\B3
MSG3YF46L&<'TW;OQS0!HOXHFAUN*TGTB>*QFNOL<5ZTB_-+@G[G7:<$;O7MC
MFNCKS[6KV'5/%.F+;VM['KUCJ*QK$4<Q_9\G?*3C;M*$X/7) KT&@ J.WMX;
M2VCM[>)8H8E")&@P%4<  5)10 4444 %%%% &+J7_(SZ']+C_P! %;58NI?\
MC/H?TN/_ $ 5M4 %8OA#_D3=&_Z\XO\ T$5M5B^$/^1-T;_KSB_]!% &U111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8NI?\C/H?TN/_ $ 5M5BZE_R,^A_2
MX_\ 0!6U0 5B^$/^1-T;_KSB_P#016U6+X0_Y$W1O^O.+_T$4 ;5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!BZE_R,^A_2X_\ 0!6U6+J7_(SZ']+C_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7^U]6_Z%J\_\"8/_ (NC^U]6_P"A:O/_  )@_P#BZVJ* ,7^U]6_Z%J\_P#
MF#_XNC^U]6_Z%J\_\"8/_BZVJ* ,7^U]6_Z%J\_\"8/_ (NC^U]6_P"A:O/_
M  )@_P#BZVJ* ,7^U]6_Z%J\_P# F#_XNC^U]6_Z%J\_\"8/_BZVJ* ,7^U]
M6_Z%J\_\"8/_ (NC^U]6_P"A:O/_  )@_P#BZVJ* ,7^U]6_Z%J\_P# F#_X
MNC^U]6_Z%J\_\"8/_BZVJ* ,7^U]6_Z%J\_\"8/_ (NC^U]6_P"A:O/_  )@
M_P#BZVJ* ,7^U]6_Z%J\_P# F#_XNC^U]6_Z%J\_\"8/_BZVJ* .>4ZEJ&OZ
:=<3:1/:0VPEWO)-$V=RX'"L3VKH:** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img108642122_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X 9 # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8?B^\OK#PQ=3Z=<1VMP7BC^U21>8MLCR*DDQ4D
M#$:,S\G VY/&:W*S]<65]#O?)U;^R9%B9Q?E$86^.=S!QM*C'.<<9Y!Y !Y7
MHVL0Z;JT5GHWCB[UJ>/78[6&VN+L7S7MK-#;F5CMY41$2NL@PJ['4YW&O9*\
MG\)ZWIUIXO;3=%T3PYJC&58)]3\-V;6_V>%X]X,F5:/;N0YQ.2<#"E@17K%
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M.TU73K6_)4*3.EY &;:,85^)%X&4=3@9KN*\_P#&O_$JUBTD/%KK6H:9" .
MMU%=QL"0.K21;LL<8%LH).5 ] H **** "BBB@ HHHH **** "BBB@ HHHH
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M3[XYXJQ_PDOQ;_Z&JQ_\!HO_ (S6A10!DW?B[XL6=E/=2>*;,I#&TC!;6+)
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MQYTR1;L_:3TWYQWQCCK6A]C\8?\ 0=T/_P $TW_R50!T%%%% !1110 4444
M%%%% !1110!XA\?/^1A\"?\ 7W-_Z'!6?6A\?/\ D8? G_7W-_Z'!6?0 444
M4 9^O?\ (O:G_P!>DO\ Z :]O\"?\D\\-?\ 8*M?_12UXAKW_(O:G_UZ2_\
MH!KV_P "?\D\\-?]@JU_]%+0!T%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6'XPBAG\)W]O/HDFMI,BQ#3TP#,S,%7YC]P!B&+_
M , !;M6Y7-^/;::\\&7L,5K=W:%X3<6UHQ66>W$J&9%P5)+1!Q@$$YQWH XO
M1/#/BG2-6TJ?QJ)_%4<7DK;2VLQ9-.G61HUD>)BOFY60,9BK.NPY& &KUBO(
M]!FTR]UVZA\)VUW9/#XC4QO;Z7)!;Q0"V@%U%*6C 0-Y;C9PWF")L# 8>N4
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MNKK3[>:9]H&YVC4L<#@9)/2@#8HHHH **** "BBB@ HHHH \0^/G_(P^!/\
MK[F_]#@K/K0^/G_(P^!/^ON;_P!#@K/H **** ,_7O\ D7M3_P"O27_T U[?
MX$_Y)YX:_P"P5:_^BEKQ#7O^1>U/_KTE_P#0#7M_@3_DGGAK_L%6O_HI: .@
MHHHH **** "BBB@ HHHH *IZEJVFZ-;K<:IJ%I8P,X19+J98E+8)P"Q S@$X
M]C5RLO7]-FU+2V%FT<>H6[BXLI)"0JS)RH8@9"-RCXY*.X[T 4_^$[\'_P#0
MUZ'_ .#&'_XJC_A._!__ $->A_\ @QA_^*JGXFU*'5_A1KM_ LB)-H]T3'*
M'B;RG#(X!.UU8%6'8@CM764 1P3PW5O%<6\L<T$J!XY(V#*ZD9!!'!!'.:DH
MHH **** "BBB@ HHHH *IZIJEIHU@U[>O(L"NB?NXGE8L[A% 5 6)+,!@ ]:
MN5S_ (VCMW\(7TEU?SZ?';^7<B\@MS.UN\4BR)(8PIW*K*I88^Z#D@<@ S])
M^(VEZE/;0W-AJNDR7%V]D@U.V\G$X2.18VY.UG63* XW;6QSC/85Y/X1LO$G
MBV=]2O-=\.3:)<ZA!J<_]B^8\CSQ)#Y<+>8/W:_NHG8$;\C' ;CUB@ HHHH
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MX$_Z^YO_ $."L^M#X^?\C#X$_P"ON;_T."L^@ HHHH S]>_Y%[4_^O27_P!
M->W^!/\ DGGAK_L%6O\ Z*6O$->_Y%[4_P#KTE_] ->W^!/^2>>&O^P5:_\
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M* /G_P#::_YE;_M[_P#:-> 5[_\ M-?\RM_V]_\ M&O * "BBB@ K[?\"?\
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M^&__ &$G_P#1EO7LM>-?&G_D=_AO_P!A)_\ T9;T =U1110 5B^,?^1(U_\
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M1FY,YA0!21D!=^T>@&:]$H **** "BBB@#S_ ."7_)(="_[>/_2B2O0*\_\
M@E_R2'0O^WC_ -*)*] H ^?_ -IK_F5O^WO_ -HUX!7O_P"TU_S*W_;W_P"T
M:\ H **** "OM_P)_P D\\-?]@JU_P#12U\05]O^!/\ DGGAK_L%6O\ Z*6@
M#H*\4^.O_(U?#_\ Z_9?_0X*]KKQ3XZ_\C5\/_\ K]E_]#@H N44450!7+_$
M3_D1-2_[9?\ HU*ZBN7^(G_(B:E_VR_]&I0![/X$_P"2>>&O^P5:_P#HI:Z"
MN?\  G_)//#7_8*M?_12UT%2!XA\?/\ D8? G_7W-_Z'!6?6A\?/^1A\"?\
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M/_CE 'F&O?\ (O:G_P!>DO\ Z :]O\"?\D\\-?\ 8*M?_12US_\ PI+X>?\
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M@X8#(R"1^-%% $FF^&M!T:X:XTO1--L9V0HTEK:I$Q7(."5 .,@''L*U***
M,.#P7X5M;B*XM_#6C0SQ.'CDCL(E9&!R""%R"#SFK&I>&M!UFX6XU31--OIU
M0(LEU:I*P7). 6!.,DG'N:** +DUA9W%Y;7DUI!)=6N[[/,\8+Q;AAMK'E<C
M@XZU'/I.FW5Q+<7&GVDT\MN;6222%69X2<F,DC)0GG;THHH IV/A/PWIEY'>
M6'A_2K2ZCSLF@LHXW7((.& R,@D?C6A]@L_[1_M'[)!]N\KR/M/ECS/+SNV;
8NNW/..F:** +%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img108642122_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1!(T# 2(  A$! Q$!_\0
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M49IIHL!*;VX_YZ?H*;]MN/\ GI_XZ*B---.PR8WUS_ST_P#'13?M]S_SU_\
M'1_A4!I#19 3_P!H77_/7_QT?X4AU&Z_YZ_^.C_"J]--.R L?VE=_P#/7_QT
M?X4AU*[_ .>W_CH_PJM3319 6?[3O/\ GM_XZ/\ "D_M2\_Y[?\ CH_PJK3:
M+("T=5O?^>W_ (Z/\*3^UKW_ )[_ /CB_P"%5#2&G9 6CJ]]_P ]_P#QQ?\
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M[(W#XSU__G__ /(,?_Q-)_PF?B#_ *"'_D&/_P")K"-(:.2/8+(W#XT\0?\
M00_\@Q__ !-(?&OB'_H(?^08_P#XFL$TTT^2/8+(WO\ A-O$/_00_P#(,?\
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MOJD:YDM\\-_M)ZCVZC]:["O/E%Q=F8-6W"BBBI$%%%% !1110 4444 %%%%
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M,---.---4,2F&GTPT (:8:>:8:8#:2EI*8#33:<:;0,::;3C3:8#:::=330
MVFFG4TTP&TTTZFF@8TTTTXTTTP&FFFG&FF@!II#2FD-,!IIIIQIIH&,-(:4T
MAI@-IIIU--,8TTTTXTTT"&TVG4VF,::::<::: 'V]S/97,=S;2O#/$P9)$."
MI]0:]Y\ ?$J#Q$L>FZHR0:J!A6Z+<>X]&]OR]!X":MZ5IM]JVIPV>FPR2W3M
M\@3@CWSV ]:SJTXS6I,HIK4^MJ*S= M-1L=#M;;5;P7E[&F))@N-Q_KCIGOU
MK2KRFK,Y@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4AI:0T -I*6DH ::::<:::8#33:<:;3&----.--- "&F&GFF&@!M--.III@
M(:::<:::8QIIIIQIIH 8:0TII#3 ;333J:: &TTTZFFF VFTZFT#&FD-*:0T
M ,--IQIM,!IIIIQIII@)333J::!C*0TM(:8#33:<:;0 TURNO>%)KS5HM;T>
M^_L_5XTV%RNZ.9?[KC^O^ QU1IAHM<#A-5\/^+_$MB=-UB]T:VLV96=K..1W
M;!R!\Q %:/BO0=2U2/27TJ2U6?3[E9Q]J+!6P./N@G^5=2:;1RH+'$7V@^*_
M$=O]@UR]TJVT]F#2KIZ2%Y #G;E^@XZBM#Q#X:EOWTZ\TNY6TU#3C_H[.NY&
M4C!1N^,#^==*:::.5!8XY/#VN:OJMG>>)+NQ\BRD\V&UL5?8S]F8MSQZ5JZX
M/$+&-=$_LO85(E^V^9G/;;M_'K6T:::=@.,\(Z)XF\/Q0:?<OI#Z<K.SF,R&
M;G)XR .N/PJ_?P>+8[V5],O-*FMG.5CO(G4QCT!3K^-=%3334=+!8YO0/#MU
M8:E>:OJEXEUJ5V K&)=L<:C^%?7H.?;ZU'=0^,C<31VUWHPMF8[)7CD\U%/3
MC[I(KIS3#1RCL9.A:)'H=BT(F:>XE<RW%PXPTLAZGV^E:1IQIIJDK (:::<:
M:: &&D-*:0TQF=JL.IRPQMI=U#!,C999X]R2#T..1^%8%SH.NZ[+;IKMU81V
M<,@D,-DK_O2.F2W3\*ZZFFDXIA8Q-8TF>_U72+J)XECLIFDD#$@D$8XX_P *
M;KNDSZG=:5+"\:K:72S2;R02H],#K6V:::?*@L8FOZ3/JDFF- \:BUO$G?>2
M,J.H& >:Q9(+F^\<Z@NF:DUA)%;QK.2BR>8>HVJ>@ QD^OUKLZRM1\/:5JLP
MFO+-))1TD5BC?FI!-*4;[":,NQO]3L_$R:/>WD5^LD!E\U8A&\>/[P!Q@_UK
MI#5+3]&T_259;&U2'=]YADLWU)Y-735136XT,---.---4,2F&GTPT (:8:>:
M8:8#:2EI*8#33:<:;0,::;3C3:8#:::=330 VFFG4TTP&TTTZFF@8TTTTXTT
MTP&FFFG&FF@!II#2FD-,!IIIIQIIH&,-(:4TAI@-IIIU--,8TTTTXTTT"&TV
MG4VF,::::<:W_"G@_4?%NH>3:KY=LA'GW+#Y8Q_4^@I.2BKL3=BCH'A[4?$N
MII8Z=#O<\NYX2-?[S'L/\BOHGPCX-T[PCI_DVR^;=2 >?<L/FD/H/1?0?S-7
M?#WAW3O#.F+8Z=#M7J\C<O(WJQ[_ -*UJ\ZM7<]%L83G?0****YR HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3;[TFSWIU%
M ##'[TAB]_TJ2B@"(P_[7Z4GD?[7Z5-11<"#[-_M_I2?9O\ ;_2K%%%P*WV3
M_;_2D-G_ --/TJU13N!4^Q?]-/\ QVD^P_\ 33_QVKE%%V!2-AG_ ):_^.__
M %Z3^SO^FO\ X[_]>KU%%V%R@=-S_P M?_'?_KTG]F?]-O\ QW_Z]:%%%V%S
M._LO_IM_X[_]>D_LK_IM_P".?_7K2HHNPN9G]D_]-_\ QS_Z](='_P"F_P#X
MY_\ 7K4HHYF%S*_L;_IX_P#'/_KTAT7_ *>/_'/_ *]:U%',QW,C^Q/^GC_Q
MS_Z]']A_]//_ (Y_]>M>BGS,+F.=!_Z>?_'/_KTG]@?]//\ Y#_^O6S11S,+
MF*?#_P#T]?\ D/\ ^O2?\(]_T]?^0_\ Z];=%',PNS#/AW_IZ_\ (?\ ]>D_
MX1S_ *>__(?_ ->MVBCG879@_P#"-_\ 3W_Y#_\ KTA\,Y_Y>_\ R'_]>M^B
MCG879S__  C'_3Y_Y"_^O2'POG_E\_\ (7_UZZ&BCGD%V<[_ ,(M_P!/G_D+
M_P"O2?\ "*_]/O\ Y"_^O71T4<\@NSFSX3_Z??\ R%_]>D_X1+_I^_\ (7_U
MZZ6BGSR"[.9/A'_I^_\ (7_V5)_PB'_3]_Y!_P#LJZ>BCGD%V<O_ ,(?_P!/
M_P#Y!_\ LJ0^#O\ I_\ _(/_ -E74T4<\@NSE?\ A#/^G_\ \@__ &5(?!?_
M %$/_(/_ -E75T4>TD%V<G_PA7_40_\ (/\ ]E2?\(3_ -1#_P @_P#V5=;1
M1[27<.9G(GP1G_F(_P#D'_[*D_X0;_J(_P#D#_[*NOHH]I+N',SC_P#A!?\
MJ(_^0/\ [*D/@3_J)?\ D#_[*NQHH]I+N',SC?\ A _^HE_Y _\ LJ0^ O\
MJ)?^0/\ [*NSHH]I+N',SB_^$ _ZB?\ Y _^RI/^%?\ _43_ /('_P!E7:T4
M_:R[AS,XG_A7W_43_P#)?_[*D/P]_P"HI_Y+_P#V5=O11[6?<?,SB#\//^HI
M_P"2_P#]E33\._\ J*_^2_\ ]E7<T4>UGW#F9PO_  KG_J*_^2__ -E1_P *
MX_ZBO_DO_P#95W5%'M9]PYF<(?AO_P!1;_R7_P#LJ3_A6W_46_\ );_[*N\H
MH]K/N',S@C\-?^HM_P"2W_V5)_PK3_J+_P#DM_\ 95WU%'M9]PYF<!_PK/\
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M=)_PIS_J/?\ DG_]G7J5%/V]3N'/(\L_X4W_ -1[_P D_P#[.D_X4U_U'O\
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M1->BL<Z]_P!.W_C_ /\ 6I/[?_Z=O_(G_P!:CE8>TCW-FBL4^(/^G7_R)_\
M6I/^$A_Z=?\ R)_]:GRL/:1[FW16'_PD7_3K_P"1/_K4G_"1_P#3I_Y$_P#K
M4<K%[6'<W:*P?^$D_P"G3_R)_P#6I/\ A)?^G3_R)_\ 6HY6'M8=S?HKG_\
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M]SK:*Y$^.,?\P[_R/_\ 8TG_  G/_4._\C__ &-')(/K%/N=?17'_P#"=?\
M4-_\C_\ V-(?'?\ U#?_ "/_ /8T>SD'UBGW.QHKC?\ A/?^H;_Y'_\ L:0^
M/O\ J&?^1_\ [&CV<@^L4^YV=%<7_P )_P#]0S_R/_\ 8TA^('_4,_\ (_\
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MU!/_ ":_^PH]E/L'UNC_ #?F>DT5YK_PMG_J"?\ DU_]A2?\+:_Z@G_DW_\
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M_P#4 _\ )S_["CV,^POKU#^;\&>K45Y1_P +I_ZE_P#\G/\ ["D/QJ_ZE_\
M\G/_ +71[&IV#Z]0_F_!GK%%>3_\+K_ZE_\ \G?_ +76_P"%?B9I_B*]-E<V
M_P#9]RQ_<JTN]9/8-@8/M2=*:5VBH8RC-\JEJ=S11169TA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M](?S/^%.Z%R2[&4:::UCH-U_STA_,_X4AT&Z_P">D/YG_"CF0N278R:;6O\
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M%G_WVW_Q-'/'N+V%3L<H:::ZP^ =5_Y^+/\ [[;_ .)II\ :K_S\67_?;?\
MQ-/GCW%["IV.3-(:ZP_#_5?^?BR_[[;_ .)I/^%?:M_S\67_ 'V__P 31SQ[
MA["IV.2IIKKO^%>ZM_S\67_?;_\ Q-(?AYJW_/Q9?]]O_P#$T<\>XO85.QR%
M--=A_P *[U?_ )^;'_OM_P#XFD/PZU?_ )^;'_OM_P#XFG[2/<7U>KV..---
M=C_PKG5_^?FQ_P"^W_\ B:0_#C6/^?FQ_P"^W_\ B:/:1[B^KU?Y3CJ;79?\
M*WUC_GYL?^_C_P#Q-)_PK;6/^?FP_P"_C_\ Q-'M(]P^KU?Y3C#3:[0_#76?
M^?FP_P"_C_\ Q-)_PK36?^?FP_[^/_\ $T>TCW%]7J_RG%FFFNU_X5GK/_/S
M8?\ ?Q__ (BD/PRUK_GZL/\ OX__ ,13]I'N+ZO5_E.)--KMC\,=:_Y^M/\
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M&WD>A?:#;W-_]KC(C;S-F53 9USC)X .1VKU"@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $)UG_W\_P#ME%@N>G45YC_PE'Q0_P"A.L_^_G_VRC_A*/BA_P!"=9_]_/\
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MOVO_ (1JV_M?^P?*^R[_ )?(\_._._KNXZ_A18+GO5%>8_\ "4?%#_H3K/\
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MN**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S_XV_P#)(==_[=__ $HCKT"N'^+]A>:G\+=9L["TGN[J
M3R-D,$9D=L3QDX4<G !/X5W% !1110 4444 %%%% !1110 4444 %>?_ /-P
MO_<J?^W=>@5P_P!@O/\ A>O]H_9)_L/_  C7D?:?+/E^9]IW;-W3=CG'7% '
M<4444 %%%% !1110 4444 %%%% !1110 4444 %>?_&W_DD.N_\ ;O\ ^E$=
M>@5P_P 7["\U/X6ZS9V%I/=W4GD;(8(S([8GC)PHY. "?PH [BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_ -H[
M_DGFG_\ 85C_ /14M=!\$O\ DD.A?]O'_I1)7/\ [1W_ "3S3_\ L*Q_^BI:
MZ#X)?\DAT+_MX_\ 2B2@#T"BBB@#S_XV_P#)(==_[=__ $HCKG_V<?\ DGFH
M?]A63_T5%70?&W_DD.N_]N__ *41US_[./\ R3S4/^PK)_Z*BH ]@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8/&7_ "=#;?\
M85TW_P!!AKZ?KQ'Q%\,?$FI?&^'Q5;Q6QTM+^SG+-, ^R)8PWR_\ ->W4 %%
M%% !1110 4444 %%%% !1110!X_^T=_R3S3_ /L*Q_\ HJ6N@^"7_)(="_[>
M/_2B2F_&+PAJWC7PC::;HZ1-<17Z3L)9-@V".13S]6%:WPTT"^\+_#[2]&U)
M8UO+?S?,$;;E^:5V&#]&% '64444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG9WBRSZ8XCO%"L/*8@G&2,'H>F>E9NH>+PV@6>H^']-N]9DU '[&D431H?\
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ME &_17#_  V\0:[KT6OGQ (X[JTU)X%MXPNV!0BG9N ^;!)Y.<UW% !1110
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M^NO!<7^CW*P->6Z[4N%9=RDKV;'4#I0!V%%%% !1110 4444 %%%% !1110
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M &Y!-#<6\<UO(DD,BAHWC8%64C(((X(Q4E,AABMH(X((DBAC4(D:*%55'
MZ"GT %%%% !1110 A (((R#U%>%1:-_;UX_PYG&Z+1'U"?[O&QU'V8_4>>2/
M=*]VJM'I]E%?RW\=G;I>3*$EN%B42.HZ!FQD@>] 'DOA/[3X_P!.US5V$F]=
M#71(0XV_OC'NG_\ 'RHS[5/'\0-"C^#/V1K^ :PFF_V>=-W?Z1]H">5M\O[W
MWN^.E>IV6G66FPM#86=O:Q.YD9((E0%CU8@#J?6JYT#1CJG]J'2; Z@/^7O[
M,GF_]]XS^M $/A6PFTKPCHVGW'$UK90PR#_:5 #^HK7HHH **** "N%^(LRZ
M)-H/BQB!'I5[LN3C_EA,/+8_@2AKNJ@O+*UU"TDM+VVAN;:08>&:,.C#KRIX
M- '@<BWGAS3K26!)$U'QKICQ$JG_ "]2SAE)/8B.=A_P 5V^K^#_ !A!K^CW
M'AV30)--TBR6WL[;5&FQ')MVM)MC&"VW !).!G '6O09M+T^X:U::PM9#9L&
MMB\*GR". 4R/E/TJW0!Y3\)_^$E_X2#Q9_:?]D_9O[2E^T_9O,W_ &K"?<W<
M>7MSU^;->K57MK&TLWG>UM8(&N)#+,8HPID<]6;'4^YJQ0 4444 5=3L(M4T
MJ[T^<9BNH7A?C/# @_SKP8+=^)]#N))5+7W@S2A&"%SMNXY\DCWV6X_!Z^@Z
MJ1:7I\!NO)L+6/[8Q:YV0J//)&"7P/F./6@#RN+4]2NO OC/QUI"S&ZU.0"S
M(CRR6L6(PP4]P/,:L"_T_P"'^B:9I>L>!=327Q2)X?LB1W9GEN7<@,LL1)V@
M@MGA<'\J]WL[*UT^TCM+*VAMK:,82&&,(BCKPHX%5+7P[HEC?-?6FCZ?;WCY
MW7$-JB2'/7+ 9H T1G SU[TM%% !1110 5XSJ=J/^$UO/ 4J![35M8AU;9MX
M:WV-),#QT\R$#_@5>S56;3[)]0CU![.W:]C0QI<F)3(JGJH;&0/:@#R?X>K-
MJGB?3]+F,AC\&P7%L^Y< S/(T<?U_<K_ ./5U/Q,_P"//PU_V,-E_P"AFNOM
MM.LK.>XGM;.W@FN6#SR11*K2MZL0,L?<TZZLK6]$0N[:&<12++&)8PVQU^ZP
MST(['J* .=\<>-+;P=IUN3Y#W][)Y-I%/.L,9;NSNQ 5%XR?<#O6/X(_L0ZQ
M-J-YXLTG7/%5^FQS:W<;"*,?-Y4*!B0@QDGJ<9-=AJ>@:-K31MJND6%^T0(C
M-U;)*4SUQN!QT%0V/A3PYI=VEWI^@:5:7*9"S6]G'&ZY&#A@ 1Q0!KT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U
M.PBU32KO3YQF*ZA>%^,\,"#_ #KP8+=^)]#N))5+7W@S2A&"%SMNXY\DCWV6
MX_!Z^@ZJ1:7I\!NO)L+6/[8Q:YV0J//)&"7P/F./6@#@/"NOV,.C^)OB+J$C
MI8WT^825PWV>$>7& #W9MV!ZM6?I6M:1XIUBTU_Q9XGT*"*V<2Z;HD>I1,('
M[22G=\\OH.B_6O2GT+2)-)72GTJQ;35QBS:W0PC!R/DQMZ\].M4!X%\(JP9?
M"NA@@Y!&GQ<?^.T >>2V'A73_B_X@?QFMF$O8HKG36U(J;9AL"R$;_DWY51S
MS@<5M?#!=/&M^*V\.C_BF3=1?9-F?*\[9^^\O/\ #G;TX].,5WFHZ1IFL0+!
MJ>G6E["IW+'<P+(H/J P-3V]M!9V\=O:PQP01C:D<2!54>@ X% $M%%% !11
M10 4444 5=3L(M4TJ[T^<9BNH7A?C/# @_SKP8+=^)]#N))5+7W@S2A&"%SM
MNXY\DCWV6X_!Z^@ZJ1:7I\!NO)L+6/[8Q:YV0J//)&"7P/F./6@#@/"VN1KH
M_B;XARVMY=6]]/NABMXP9?LL(V*0I([[V//3-8/C+4?!MQY7B7PCJD+^,[N:
M$69LKAI)922H*219("[1R& Z>O!]AL[*UT^TCM+*VAMK:,82&&,(BCKPHX%5
M+/P[HFGWKWMEH^GVUV^=\\-LB2-GKE@,G- ''>,O'AM=9'A?2]5TO3-0,0DN
M]1U"=$CM$;H$5B/,D(Y Z#@GK6WX&M_#=CH[V7A[5K;4RC^;=W,=TL\DLK]7
MD92?F;'Z>U7[SPCX:U&[DN[[P]I-U<R'+S3V4;NW&.6*Y/ JUIFAZ1HHD&E:
M58V EP9!:VZ1;\=,[0,]30!?HHHH **** "BBB@ HHHH **** *NIV$6J:5=
MZ?.,Q74+POQGA@0?YUX,%N_$^AW$DJEK[P9I0C!"YVW<<^21[[+<?@]?0=5(
MM+T^ W7DV%K']L8M<[(5'GDC!+X'S''K0!Y?I]EK?C3POXFU[P]=Q6MWK]TL
M5K+<EHPMI%\F!M!*D_/T'?M6+J]CX^TSQ+X(L6A\)0R6\DT>FQVOVGREQ%AA
M)NYQMZ8YSUKVZSL[73[2.TLK:&VMHQA(88PB*.O"C@4DUC:7-S;W,]K!+/;$
MM!*\89HB1@E2>5R..* . @UBP\*_%?Q NN7EO80ZO:VUQ;3W$@CC<QJ4==S8
M (X.,U/X#NH]<\9>,/$5DPDTRXEM[2VF .)3"A#LI[C+8R/2NTU'2=-UB 0:
MGI]I>PJ=PCN85D4'UPP-3V]O!:6\=O;0QPPQC:D<:A54>@ X% $M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5=3L(M4TJ[T^<9BNH7A?C
M/# @_P Z\&"W?B?0[B252U]X,TH1@A<[;N.?)(]]EN/P>OH.JD6EZ? ;KR;"
MUC^V,6N=D*CSR1@E\#YCCUH \TTNXT[5_"7B_P 8ZK87M_I>K2;1;6X(E:SA
M^08&Y2.=['D<9K'\5CX>3>&; >"X]+/B%IX3I0TP*+D2;@<R;?F  SG?_.O9
M[.RM=/M([2RMH;:VC&$AAC"(HZ\*.!52R\.Z)IMX]Y8Z-I]K=/G?-!:HCMGK
ME@,F@#C?&7CPVNLCPMIFJZ7IFH&(27>HZA.B1VBMTVJQ'F2$<@=!P3UK<\#6
M_ANQT=[+P]JUMJ91_-N[F.Z6>265^KR,I/S-C]/:K]YX1\-:C=R7=]X>TFZN
M9#EYI[*-W;C'+%<G@5:TS0](T42#2M*L; 2X,@M;=(M^.F=H&>IH OT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
M!'>6\UW/:QR!IX ID3!^7<,BIZ "BBB@ HHHH **** "BBB@ HHHH **KW=]
M;6(A-S)Y8FE6&/@G+GH./I5B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#%8?\ 4#_\C4?\5A_U _\ R-0!T%%<_P#\5A_U _\ R-1_Q6'_ % __(U
M'045S_\ Q6'_ % __(U'_%8?]0/_ ,C4 =!17/\ _%8?]0/_ ,C4?\5A_P!0
M/_R-0!T%%<__ ,5A_P!0/_R-1_Q6'_4#_P#(U '045S_ /Q6'_4#_P#(U'_%
M8?\ 4#_\C4 =!17/_P#%8?\ 4#_\C4?\5A_U _\ R-0!T%%<_P#\5A_U _\
MR-1_Q6'_ % __(U '045S_\ Q6'_ % __(U'_%8?]0/_ ,C4 =!17/\ _%8?
M]0/_ ,C4?\5A_P!0/_R-0!T%%<__ ,5A_P!0/_R-1_Q6'_4#_P#(U '045S_
M /Q6'_4#_P#(U'_%8?\ 4#_\C4 =!17/_P#%8?\ 4#_\C4?\5A_U _\ R-0!
MT%%<_P#\5A_U _\ R-1_Q6'_ % __(U '045S_\ Q6'_ % __(U'_%8?]0/_
M ,C4 =!17/\ _%8?]0/_ ,C4?\5A_P!0/_R-0!T%%<__ ,5A_P!0/_R-1_Q6
M'_4#_P#(U '045S_ /Q6'_4#_P#(U'_%8?\ 4#_\C4 =!17/_P#%8?\ 4#_\
MC4?\5A_U _\ R-0!T%%<C?\ B/5] (_MB"QD6:-S"UJ7QO7'#;O7-74;Q@Z*
MVW1%R,[6\W(]C0!T-%<__P 5A_U _P#R-1_Q6'_4#_\ (U '045S_P#Q6'_4
M#_\ (U'_ !6'_4#_ /(U '045S__ !6'_4#_ /(U'_%8?]0/_P C4 =!17/_
M /%8?]0/_P C4?\ %8?]0/\ \C4 =!17/_\ %8?]0/\ \C4?\5A_U __ "-0
M!T%%<_\ \5A_U __ "-1_P 5A_U _P#R-0!T%%<__P 5A_U _P#R-1_Q6'_4
M#_\ (U '045S_P#Q6'_4#_\ (U'_ !6'_4#_ /(U '045S__ !6'_4#_ /(U
M'_%8?]0/_P C4 =!17/_ /%8?]0/_P C4?\ %8?]0/\ \C4 =!17/_\ %8?]
M0/\ \C4?\5A_U __ "-0!T%%<_\ \5A_U __ "-1_P 5A_U _P#R-0!T%%<_
M_P 5A_U _P#R-1_Q6'_4#_\ (U '045S_P#Q6'_4#_\ (U'_ !6'_4#_ /(U
M '045S__ !6'_4#_ /(U'_%8?]0/_P C4 =!17/_ /%8?]0/_P C4?\ %8?]
M0/\ \C4 =!17/_\ %8?]0/\ \C4?\5A_U __ "-0!T%%<_\ \5A_U __ "-1
M_P 5A_U _P#R-0!T%%<__P 5A_U _P#R-1_Q6'_4#_\ (U '045S_P#Q6'_4
M#_\ (U'_ !6'_4#_ /(U '045S__ !6'_4#_ /(U'_%8?]0/_P C4 =!17/_
M /%8?]0/_P C4?\ %8?]0/\ \C4 =!17/_\ %8?]0/\ \C4?\5A_U __ "-0
M!T%%<_\ \5A_U __ "-1_P 5A_U _P#R-0!T%%<__P 5A_U _P#R-1_Q6'_4
M#_\ (U '045S_P#Q6'_4#_\ (U'_ !6'_4#_ /(U &=\1B6T:UB'4SE_P5&_
MQKJ[2036<$HZ/&K?F*YZ31-7U>\B?6Y+$0112JJ6F_)+KMR=WH*6TM?%MC9P
MVL;Z,\<*!%:3S=Q X&<4 =-17,7>J^(-&2.[U6/3'LO,5)3;>9O4$XW?-QQ2
M66H>)]5M$O;2+28K>7)C2?S-X7.!G'% &KXC?R_#>I,>]NZ_F,?UJ?2(S%HM
MA&>J6\:_DHK#OM.\3ZM:M97DNDQVTI42M!YF_:""<9X[5TZJ%4*HP , 4 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!RNHVX?XC:3*1TMG_ $#?_%5U54Y=-@EU6#46+^=!&T:@'Y<'UJY0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '*^-[<3Q:2",YODC_ .^L_P"%
M=55/4--@U(6PG+@6\ZW";#C++G&?;FKE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'X
MPC\WPG?J>R*WY,#_ $J]HL8AT+3XP/NVT8_\=%2W]E%J-A-9S%A',NUBAP1]
M*FAB6"".%,[8U"C/H!B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5R&N?$33=&UB72;?3-9UB_@56N(=)LC.8 PRN\Y
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M;'4M"^).J:+<^(M2U:R33(IX!?3%WCW2,"">A/!^; ."!VH ]&HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ.H:A<J(Y;[4KDSS,@Z+G@ #V%4C\--!_X1C5= 5[M+34KHW4CK(OF1OE2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img108642122_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K W # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!!_A)XQFK^KZOJTOBV_MX/$L>GF VG]D27NISQB6$JIW+&J,L^_D,6.<GVH
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MVW]H_P#"&_8?-3[1]G^U>9Y>1NV9XW8SC/&: .XHHHH **** "BBB@ HHHH
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M^R@)>Z5&CK%<[^3/E6.W&..GZUZC7+>(_!$/B6>7[5K6L0V4Z*EQ8V]P%AE
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M&<'TK-L?"-A8:QI^IQ37)FL--&F1*S+M,0*G)XSN^4<Y ]J -^BBB@ HHHH
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MUEXPAO+R.SA^SO.L*QW+['"YP,#81CY< G[WI0!U?_"F/A__ - #_P G)_\
MXNC_ (4Q\/\ _H ?^3D__P 74_@75KW6M!U*VN+^^.K6LI@F-W'#NMY"@^Z8
MQL=<G(./8UP=K\5M<MWTZ[OY UGIT#6NM+Y:@F[/G!.@X_U*GC ^?I0!UT7P
MD^&L]Q/;PZ3#)/;D":--0F+1DC(W 29&1R,TD/PF^&ES=7-K#I,4EQ:E1/$E
M_.6B+#*[AYG&1S7 7EYKU[X#\;'4KX+?0QZ=/.\5K%&\F^-6*.RJ"<;ASU&W
M'0FK,MUK^BW?CK6],\3>:^GFQDD<VT3"\)C488@84 $CY<?6@#OO^%,?#_\
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MF6-"R,Q&<9+>^3UX% '3_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z '_DY/\
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MC_A3'P__ .@!_P"3D_\ \77>44 <'_PICX?_ /0 _P#)R?\ ^+H_X4Q\/_\
MH ?^3D__ ,77>44 <'_PICX?_P#0 _\ )R?_ .+H_P"%,?#_ /Z '_DY/_\
M%UWE% '!_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z '_DY/\ _%UWE% '!_\
M"F/A_P#] #_R<G_^+H_X4Q\/_P#H ?\ DY/_ /%UWE% '!_\*8^'_P#T /\
MR<G_ /BZ/^%,?#__ * '_DY/_P#%UWE% '!_\*8^'_\ T /_ "<G_P#BZ/\
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M/_A3'P__ .@!_P"3D_\ \71_PICX?_\ 0 _\G)__ (NN\HH X/\ X4Q\/_\
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MF')16QG Y_,T >=:!K'B'4=&\!:7INJQ:7_:MO>M<R064.!Y; C:@4*IZC@
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M4+&<==I/- '>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 174KP6D
MTT<#SR1HS+"A :0@9"C) R>G)Q7&^'O'KWGA_P 1:MKUE'IPT6]FMI8HY?,^
MXJG&> S$MCCJ<5V5R9Q:S&U6-KG8WE"4D(7QQN(!(&<9P*\RTKX=:]=PZQ9>
M(KJTMK2_U0ZNLNDW+&5)\KA")(MI0;<^N0* .D\ >+-0\5V.I2:GIJ:?=65Z
M;9H%<L1A%;DGN-V#]*ZZN,\">#;[PI=Z]+>:K->KJ%Z9XO,D#';@?,_R+^\/
M?'& *[.@ HHHH **** "N(\>>)O$GA2RNM6L['29M)MXE9FN+B196<G&T*%(
M.20!SWKMZY7Q5X:O?$NM: CRP+HEC<F\NXF8^9-(H_=*!C&T').3^% &A<:A
MJT?A.*^2TLX]4:"-Y(;JX,<,+L!OW/@G"Y/;G%9G@3Q7>>*;34C>VMM'+87C
M6OGV<IDMY\ ?-&Q R*LZK;>)KH:Q EMH-U9/Y(LK>[$F)%Q^]$W!'7[N ?>L
M[X?>$=0\,'6)[YK* :C<":/3]/+?9[4 $83<!R<\X ' H [6BBB@ HHHH **
M** .0\8>+=1\-ZGHEO;Z0L]G?WT%I+>23!50R,1M51R6 !.3@#CKGC-\9^+?
M%OABYC>WTK2+FSNKN.TLD-S()YG?H-NW []^@JSX_P##_B7Q%-I$>CC21;6%
M[#?EKR:1':2-F.W"HPVD$<YS5F;PUJNK>.-&UK5GLQ9:79DQ6T+LV;QQAWY4
M#:!PO?O@4 =?1110 4444 %%%% !1110 5P>A?$&;7?B!/H<%@@TK[/++;7N
M\[I_+=8V('3;N+ 'OMS7:WEL+VQN+5I)(UFC:,O&<,N1C(/8\\5Y_H?PQN/#
M_C;3-3M=<O9M+L=/:U6*XE0R9W<)A8P/+QSUSN H ]'HHHH **** "BBB@ K
M@]"^(,VN_$"?0X+!!I7V>66VO=YW3^6ZQL0.FW<6 /?;FNUO+87MC<6K221K
M-&T9>,X9<C&0>QYXKS>R^&.J>'_$MKJ6B:[/-!8Z5):VL5_*#B7^!&"1C]ST
M)P=V10!L>//$WB3PI976K6=CI,VDV\2LS7%Q(LK.3C:%"D')( Y[UUNF37-S
MI5G/>P"WNY($>:$'(C<J"RY]CD5RVM^&=9\2W/A=-3EL196,BWFIQ0L_[^X5
M?D5 1_JPV3\QZ8XKLZ "BBB@ HHHH **** ,_7M1;1_#NIZFD8D>SM);A48X
M#%$+8/Y5A>!_$>K>)+1[N_&B^0T:/&-.O#,READK("!M(XX^M='J<=S-I=U'
M:1VTEP\3+&ET"8F)'1\<[3WKCO"/@_4M-\7:AXCU*#2K!KFU2U2QTK=Y> VX
MR.2JY;MP.E '=T444 %%%% %*XN4MUDEFF6*),EG=MJ@>Y-1VU[#>0B6UNHY
MXB<;XI P_,5YW\1?LL_CKPO9ZX8O["D^T,4N&VP27(4>6)#TQZ9]3UK 3Q5)
MH?ACQ3+H^C:1IE]:7EM;/+IC!X"7P/, 8*N0#CD 9Z]* /:=[?WC^=&]O[Q_
M.O'9M?\ &UL+.R;4&MA=ZS;6EO=7 M9YO*DCDWAUB)7AE!!X)_.H[CQEXFL=
M,ETMK^2YND\1/I?V](X8Y#$$#@#?B,.>F3Q^- 'LV]O[Q_.D,C 9+G\Z\ABU
MCQQ>:KH.A3ZO_9TMY-?(UP([>>5HHUC>,L$R@?EE.,#OCI2IXTU-_&E@EIJM
M[=Z9=ZE/8R)<06\<6%#<1A3YORG'S-P?TH ]6LM1M]2LX[RQNX[FVE&4EB?<
MK#..".O(J";7=-MI+F.?5+6)[789Q).J^5O^YNR>,]L]:\LT?6[WP_\ L]:5
M>Z?*D%PVV$7#J&6 /<%2Y!X. >_?%8>HW=S83>/I1JUOK$T7]E)]JDMXG5\R
M8PR8*$@'&<=L\&@#W[>W]X_G1O;^\?SKR.3QGKNC7WB'^T;J6>[CM+JZT^"-
M87M)(D8;6#(/,!4=0QYY]JQM<\;>)]"M(A9>)X]5DN].AO#(;>+_ $5VGC4_
M='W&#E<'GT- 'N4UPMO#)--,(XHU+N[-@*!R23V%-MKR.\MHKFVN%F@E0/')
M&^Y74C(((ZBO(?$VH:];76J>'[[Q<D*66B273S36T2F_=V<;<'HH&%&WG//-
M9]KXC\2C3]#T31)9K?[/X<MKJ(1&V7S9"N 7,Y&8QC!"\\GVH ]SWM_>/YT;
MV_O'\Z\HM-8\9ZMJOB-H]9MK-M+M;=H[-HXC$T\ML#@R_P!T/D@Y.2>N*TO#
MWBJ4>"->N=3U._2^TS>MS)<P0N]L^P'Y/+ 21<\CZX/% 'HN]O[Q_.C>W]X_
MG7AEQX\\36.G^($BU*Y9X(+*YM9;Z*V,J>;,JL"(LKAE/0\CVK2U;Q5XG\-Q
M^*M-FUI;N:S:Q\C4);9$^SB<X=BH&"!VS^.: /68M1MYKR>SBNXWNK<*9H5D
M!>,-]TL.HS@XJQO;^\?SKR[P-*UOX^\:/<ZTFJ^3;V>Z]5%&0$<\A.,CIQZ5
MS\7Q#UZTFFN;>^O-1M9]'N;R#[=!;I\\?W758B65.OROSQ0![2=1MQJ"V!NX
MQ>-$9A!Y@WE <%MO7&>,U8WM_>/YUX0NJZE:^(KO5!XECU6_B\'3W4=PD48,
M#[E8+A1@X/(R,X/-:4>J>-)[]+/_ (2LK]J\/#6MXL(LQ.#CRUX^Z<C).3QV
MS0!Z]%?P3W$]O#=QR3VY FC20%HR1D;@.1D<C-%Q?P6AA%S=QPF:011"20+Y
MCGHJYZGCH*\/L?&^N/X6\5:W!+;0:BHTEEE2UC&6D6,/N^7+9R>I. <#%7[[
M6M>L?&]KH&I:E%JBV^MZ>8YYK*(,JRQRE@!M^7E1AA\P]: /:-[?WC^=&]O[
MQ_.O O'&N:Z^E^(].U36+J.5D>XM8K9('M9[=9E VNH\Q& /.3SBNPBU#7I/
M&]KI$?BLOIMKI$>HW$XM8F:YQ,X8948 *X!Q_=XY)H ]-WM_>/YU!)?P174-
MK)=QI<3AC%$T@#R!>6VCJ<=\=*\2_P"$KUS51=6<6M:A+9:CHMU<QS7-O;(V
M8QG=&L9)56 9</SSD<C(8OB#4?#_ (?\&WL%Y#JDJZ->3J9;>)FA*6\96,,!
MN 7OR"1US0![OO;^\?SHWM_>/YUXX_BS7],CN(X_$B:N9_#<^I^8((@;295R
MI&T8VDG&&STK:\(ZSXA_X2W3['5M7&H0:GH:ZD$^SI%Y$FY1M7;R5PW>@#T6
M>Z2U@DGN)UBAC4N\DC[551U))X I8KA9X4FAF$D4BAD=&R&!Y!!'45Y%>^)=
M8@/BNRUB^>2=M.O;BQA6*WFLY(D'RD8!;<!P5?(.3FLG1-5U71]0\3ZNNJF2
M:WT2SNH[(PQJDN;=F4!0!A8_]G&1UH ]VWM_>/YT;V_O'\Z\[^'^J^)K_43_
M &I.]SIL]@EPDL\EJ7$Q(SL6$Y\L@Y&X9&,9K)A\8:RVF^(?$#Z[")K&:\A@
MT(Q1XQ$IVY/WRPQO//0'@=@#UK>W]X_G1O;^\?SKQQ_%FOZ9'<1Q^)$U<S^&
MY]3\P01 VDRKE2-HQM).,-GI6?JWC3Q=H$4 FUV.X.J:1!>+-):1HMB[S1H6
M  Y4*Y^]GG!]J /9)M=TVVDN8Y]4M8GM=AG$DZKY6_[F[)XSVSUJQ=W\%A;M
M<7EW';P*0#)-($4$G Y/')(%>$:C=W-A-X^E&K6^L31?V4GVJ2WB=7S)C#)@
MH2 <9QVSP:?)/J&F^&_'<LFLK>2PZX(_LMU;0R!B9H092I4]0<8QM'4<\T >
M][V_O'\Z-[?WC^=>.-XSUXR-K":W&'&O_P!F#0O)CYBW[,9QOWX^;.<>U-D\
M4^*XI)=6_MU#:P^*'T@64EK&$,)D(RS@;L@$8(].<T >R[V_O'\Z-[?WC^=>
M?_#S7-4O;S4--UZ]NI=6@CCEEB=83 %8MAH7B'*GCAN1CZUWU #M[?WC^=&]
MO[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_
M.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4
M .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=13WD=K%YMQ<)#'
MG&Z1PHS]33Z\4^-%U<7PO[2[T_4AIVGVBR6TL=J[02W+D N\@&T!$R!G^)SZ
M4 >V;V/\1_.EWM_>/YU2TJX%WI-I<+'+&)(58),A1UR.A4\@^U6Z ';V_O'\
MZ-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.J\^H6]K)''<7D4+R'"+)*%
M+GV!/-35Y3\6+;0=5N8=#2VLG\2:@B*MW<$+]CMU?)D+$_*/O  <G/?I0!ZQ
MO;^\?SJ.&Z2YB$L$ZRQG.'1]P..#R*PY/["U+19]%N=2AN8+>&%;O%UM;:0"
MI<J00' ]?F!/4&N>^#,L+?#33X8I$+123AD5@2N9I,9';B@#T'>W]X_G1O;^
M\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G44=Y%-+)
M%%<H\D1Q(BN"4^H[5F^)=1N])\-W]]864M[>0PDPV\2%V=^@X')&3DX[ UYG
M\*6BM/'7B"T$&I>=-:6TL\UY:O$SR_,9&<,/EW,Q*@]0..E 'L>]O[Q_.C>W
M]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G
M3:* ';V_O'\ZC2Z22:2%)U:6/&] ^67/3([9IU>9> X-*TWXF>,K+3IH_)9+
M(Q_O_,:1O+<N=Q)+'))- 'I^]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH
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M*L&N;5+5+'2MWEX#;C(Y*KENW Z5UYD8 DN0!U)-0VU_;WJ,]K=Q3JIVL8I
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MVG^%](TF02:=I.GV;@,H:WMU0@,02,@="0/R'I34\*:+'?M?IH^G+>-)YK7
MMD\POS\V[&<\GGW- 'C$?CGQCIGAK0?$-QK"W_\ :EI>[K1K2-%C:&-BCY4
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MV*=G,AD2V0,6(()SC.2"1^)]: /-=,\1^+X_#VMW]Q=O);KH3WMM<SM:,Z7
M4G*+$3^[.<C<.,8J/4]8\6Z3X>TC5KSQ#/-97$'VV^>R@MEGMPZIL"HXP\:G
M=G')S7IMKX0T*QCN8[31=,@2Z0QW"Q6R*)5/56 '(]CQ3[OPKHU^+47FD:?<
M"U 6W$MNK>4!T"Y' X' ]* +4$JSV\4R-N21 RMC&01G.*DJ7R&]5H\AO44
M145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44
M145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44
M145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44 145+Y#>HH\AO44
M145+Y#>HH\AO44 145+Y#>HH\AO44 15Y3\6+;0=5N8=#2VLG\2:@B*MW<$+
M]CMU?)D+$_*/O  <G/?I7K?D-ZBLO4/">B:M<_:=2T73+R?:%\VYM4D; Z#+
M G% $]C&D6GVT<<QG1(E592<[P ,-GOGK5BE@L4MK>.WMXXHH8E"1QQKM5%
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MD6  @D<!B,@G&.* .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;65F";F4DJ%R,%&SGICGJ* -V_\ #FF:K-#-J.FV-W+ <Q/<0*Y3Z$CBF_\
M",:1_:IU7^RK#^T#UNO(7S>F/O8STXK(\2_$70=#T[<NH1O=W%@UY9JL3R*R
M;?D=BH^52<#)(JUH_BVWD\+>&M1U>5(+K6D@2-8XV*M/(F[:,9P.#U./>@#0
MA\/Z;;"T$&G640LMWV4)"J^1NX;9@?+G)SCK6+J7P\TC4M6TNZDM;1;6P%P#
M8_9U,4QF W%AC&<C/3K5R\\?>&=/AGFNM3$4<%\=/D8PR'%P%WE.%YX'4<'I
MG-1I\0_#,NCQZG%?220R7)M$CCMI6F,P&2GE!=^0.>G2@#0;PUI+P0POI=@T
M4$3PPH;=2L<;C#*HQPI'! X--NO"^CWWV;[7I.GS_90%M_-MU;R@.@7(X' X
M'I63=?%'P?93F&XU5HY%\OS%:UF'E"1592_R_*"&7DXP3CJ#5_4/'/AW2]5.
MFW=^4G4QB1EA=HX2_P!P22!2J;NVXB@"6S\)Z)I\QFLM&TVVE.[YX;9$;YL;
MN0.^!GZ4ZS\+Z1IS0M9:3I]LT!=HC#;JAC+@!BN!QD  XZX%9>J?$'18%U:T
ML=0B.HV,,Q+36\S6Z21H796=%() &2JDMP>]<K!\4+Z_UK4K>VNM-BM]-TD7
M4DDME<E)I?*9V8, "L:D#@C+#.,GH =W'X1T.*:YFCT73$END9+AUMD!E5OO
M!N.0>X/6II?#NF3 "73;%P+?[*-T"G$/'[OI]S@?+TXK)B^(6@0+907^I1_:
MY88'F>""4P1M*H*;G*XC#9X#D'&,UF^/_B9IWA;3M4MK*ZBDUVUB1U@D@D>-
M2Q& [+@ E<D L#0!UFG:)9:1:_9=-LK6SM\EO*MXPBY/4X ZU;\AO45SVO>(
M;RT\0^%M&LO+$VJSR/.SKD+!%'O<#T))4 U83QQX>?7/['6_)N_/-L#Y+^49
M@,F,2;=F\#^'.: -GR&]11Y#>HK-U[Q7H_AKR1JES(CS*[I'%!),Y5!EFVHI
M(4 C)/%7M*U2TUK2[?4K"1I+2X3?$[1LA9?7# $?E0!)Y#>HH\AO45G:]XIT
M?PT+?^U+IHY+EBL,44+RR28&6PJ G '4XP*J+X]\-/I=YJ2ZEFULYDAF;R9-
MRN^W8 NW<<[A@@']#0!N>0WJ*/(;U%<;XA^*V@:)IFH74 N;Z6S8Q[8[>58I
M'#!643;"G!//-:L7CWP_/=6=M%<7+SW:*Z(ME,2BLQ13)\G[L%@1EL>O3F@#
M=\AO44>0WJ*R-=\::%X;N1!JES-$WEB5V2UED2-"2 SLJD*,@]35/4OB3X2T
MG49;"\U81W$+HLH$,C+'O564LP4@*0R\YQS]: .C\AO44>0WJ*XCQ_\ $S3O
M"VG:I;6-U%)KMK$CK#)#(\:EB,!V7 !*Y(!8&NAUKQCHGAS[&FKW9@FNT9X(
MTA>1I-NW<%"@\_,./\#0!K>0WJ*/(;U%8$OQ!\,1:/8:H-1,MOJ!86HA@DDD
ME*_>Q&JEOE[\<5C)\3=/?Q)<.MY _AN+15U'[5'"[.&,YC.0.<#'(VY!SF@#
MN/(;U%'D-ZBL'5_B%X6T*]AM-1U58IIHDEC BD<%6W;>54C)VM@=3^(ID?Q$
M\,3:2FHQ7\DD3W)M%B2VE:8S 9*>4%WYQSTZ4 =#Y#>HH\AO45S>A^*)M0\:
M:GI$I5K5K*WU#3V\HQN87!5@P/.0P[@'G!Z5UE %?R&]11Y#>HJQ10!7\AO4
M4>0WJ*L44 5_(;U%'D-ZBK%% %?R&]16;J/A;1M8G6?4]'TV]F1=BR7-LDC!
M<YP"P/&2?SK:KD/&'BW4?#>IZ);V^D+/9W]]!:2WDDP54,C$;54<E@ 3DX X
MZYX .DALDMH(X((XXH8U")&@VJJ@8  '0 =J?Y#>HJQ10!7\AO44>0WJ*L44
M 5_(;U%'D-ZBK%% %?R&]16?J/AK2M7EAEU+3+&\DAYB>X@60I]"1Q6Q7!^*
M?&VKZ=K6H:=H6F6EV=*T_P#M&^>ZF9,ISB- H/S$*3D\4 =)<>&M*NQ=_:=+
ML9OMFS[3YD"MYVS[N_(^;';/3M4VGZ+9Z3:BUTZSMK2W!R(K>,(N?7 '6L37
M/&9L/AJOBVQMXY/-@MYXHIWVJ!*R#YB.F-_Z5?\ "FJ:EJVFR7.I'2&/F;8V
MTNZ,\97 ZL0.<]J -;R&]11Y#>HJQ10!7\AO44>0WJ*L44 5_(;U%'D-ZBK%
M% %2:R6X@D@G2.6&12CQN-RLI&""#U!%9^G>%M&T>=I],T?3;*9EV-);6R1L
M5SG!*@<9 X]JT[Z2YAL+B2SMUN+I(V,4+/L$CXX4MVR>]<EX2\7:QJGBG6?#
MFN:=:6]YIL<4IELIFDC(<9"G(!!Q^?/IR =;Y#>HH\AO458HH K^0WJ*/(;U
M%6** *_D-ZBCR&]15BB@"OY#>HH\AO458HH K^0WJ*S[+PUI6FWDUY8Z98VM
MS/\ ZV:&!4=^<G) R>>:U+B>.UMI;B4XCB0NY] !DUY]X=^(>K:GJ^@KJ6DV
MMMIWB%)WTYXIV>6/RQNQ*" /F7D8H [WR&]11Y#>HJQ10!7\AO44>0WJ*L44
M 5_(;U%'D-ZBK%% %?R&]145SIT5Y;26UU##/!(NUXI5#*P]"",$5=K \8^)
M#X5\.R:C';?:KAI(X+>#=M#R.P503V'.3]* +FG:'8Z/:_9=-LK6S@R6\NWC
M"+D]\ =:M^0WJ*YSPGXFU'5-7UK0]:L[:WU/2FA,C6DC/%*DJEE*[@#V(.:Z
MN@"OY#>HH\AO458HH K^0WJ*/(;U%6** *_D-ZBCR&]15BB@"LUKO1D<(RL,
M%3R"*HZ9X=TS15D72].LK)93ND%M"L>X^^!S4GB'6H?#OAW4-8G1I([.!I2B
MG!? X7/N<"N;\+^,-8OO$BZ'KVFVEK<W&FKJ=LUI,SKY98*4;<!\X)'3B@#K
M_(;U%'D-ZBK%% %?R&]12K"P8'(X-3T4 <OX@\+R:YXKT#4'^SOI]E#>0W4,
MI.Z19HU0 #&".#G)%<):?!W5K;0/$FEMJMO(+J>U?3I&=\B. G8DN "/E(7*
MDXQGM7JLUU'#,L<DZH\C$1JSX+'T [T+<*\CQK,&DCQO4-DKGID=J /.!\.M
M85H-6L[/2[/6+6_BN@CZA<W27*HC)B220%E.&^7 .._ME^(/"^OZ8NEW[FRD
MUO4_%<%X8X@[6T&(W"@G 8CCEL#K7KV]O[Q_.C>W]X_G0!YOHOP[\0P>,K?Q
M/?7>GQW<D][/<1VY=EB,L2)&$ROS8VDDG'XU4L/AOXH_M"*]U>33=1E2PN+6
M875_<S"Z:3&"0RXC4C(P@XP#SV]3WM_>/YT;V_O'\Z /.?#/P]\0:9XFT74[
MZ\MOL.GR79BLOM4DYMHY8T5$1W4%@"I)SC&>,U)I7PZU;3]'\(VKS:>\NC7=
MW//\S%'67S-H7Y>?OKG.._6O0M[?WC^=&]O[Q_.@#D/ OA/5_#MSJ9N6MK33
MIT06VF6MU+<10N,[G4R*"@.?NCBN>\/_  V\2P0^&]+UFZTH:7HGG2+)9M(9
MI7D5AM^90  6//?CBO4-[?WC^=&]O[Q_.@#RC3_A3JMMHTVF3V^F2RPV%U:V
MFH-J-TQS+&R ^2P*1Y!&[&?85L:A\/=5NDC$4]DNWPI)HAR[#]\P&&^[]S@\
M]?:N_P![?WC^=&]O[Q_.@#P*RM=0T3Q88;BQ>_EM=1M%CTT&XC,SQQ1QBX0*
MOELJD%@S$9QDXX%=U<> M3M]$N5::U9E\4G7?D+L3 'W;0 N3)@=!QGO7H>]
MO[Q_.J%MKNFWAMQ;:I:S&YWB ).I,NPX?;SSM[XZ4 9<=OK_ (J^%MS;:M!;
M66LZG831F+#(D1<,$# [B#M*YZX.:SH/ VHQ:M:W336GEP^%O[&(#-GSL@[A
M\OW.#SU]J[3>W]X_G1O;^\?SH \?C^%?B]M/M-.NM2LIX+8V;0DW]PJ0B+;O
M180NPY()#$9^F<C7O_ &L0:3(ZR6LKP^)I]=V)N=GA*MA I7F3D?+T]Z]!N]
M1M[!8FN[N.!995AC,L@7>[<*HSU)["K&]O[Q_.@#P;P1IM_J&G3Z&EL+F[O?
M#\UE]LDDN NG97B)PZ;5RQ'"9^[QP*[^?P+KRW-G<Z?J%K:7%MX9.DI,I;<L
M^5(8?+]WY3SU'I7=;V_O'\Z-[?WC^= 'DMI\*_$C>*M+UF[N+$"WN;2:=7O[
MBY=O*\S<=TBY).X$#@#D=LG8U#X?:V]IJCVD]@;M_$J:W:I([A&50OR.0N03
M@] ?K7H6]O[Q_.C>W]X_G0!SWB[1_$>LZ3IB:==0P3Q3))?6Z7<MNDZ[2&02
MH-ZC)STY%<?X6^%NM:)>:S-=7.GNM[I5Q91B.61R'DE=P267.,,,G).?7K7J
M.]O[Q_.C>W]X_G0!YDGP[\3Z=#"FFW.DN;G0(]'OC<M(?***1OCPOS#!/!QS
M6QJ'@O66\$>$K"QFL3JV@36L^)F80RM$A5EW 9 .>#CM7:[V_O'\Z-[?WC^=
M 'G-I\//$&^"XOKG3&N/^$H37)O)9PGE^7M*KE<[MW3/;G(Z4[4?A[JLUIK:
M);:9=27VLR:C;,]W+ ]N&155U=%)#@@Y'(([UZ)O;^\?SHWM_>/YT >)V?A+
MQCJ%_P",O#RW=C/]JCL+>_O[P2!V(@7+QX'S]&'..<'/6NAO?A==_P!O:B\=
MO9:EI>H-"S)=ZC<V[1%%53E(OED^Z",XYKTO>W]X_G1O;^\?SH \_A\%>*;+
M1?$7ARVFTA](U+[8\,\CR"<&96VJP"X&&(RV3P.GHMK\/=6@T_Q/;M<61?5=
M#MM.@(=L+)' T;%OEX7)&",G':N_WM_>/YT;V_O'\Z /*HOA1J-M=2QRV^G:
MG97<=L)EFU&Z@$3QQJK?)'\L@RN1G!JWXG^'WB;4)?%=GI5QI/\ 9WB!HIFD
MNFD$L3H!\H"J002HY[#/%>E;V_O'\Z-[?WC^= '(^)[2:T\>>"-7$;O;Q23V
M,Y12=AEC 0^PW+C/N*Q])^&M[IOB/S)K:QOK!=4;48+B74+E)(B6W#]P/W9<
M$GYL\]_2O1M[?WC^=&]O[Q_.@#QOQZGB!M4T(ZY+:V]VNG7:W,]F+E+:7?(H
M$2N@+DE ,J1CKCJ*ZBRU?QC:>"4N+'0;*V>6*SM]'TW9*[P9PLGVCIA0!D'C
M Z\UWF]O[Q_.C>W]X_G0!S/BCP]K=QXGT?Q'H+6#W=C#-;R6]\SHCI)CD,H)
M!!'IR*Y35/#-W??&32$D=3#/;0:GK$<*,(FGM]R1L">Q9@,'G"\UZCO;^\?S
MHWM_>/YT >6ZK\,M?U1O$$-M-I^E6>HP.#;6]U+)%<3F1761D9<1'"X.W/6M
M74O"7BC5=<TG50FE:;J$'E"YO[*\F#^6K$M$8]H652.F[&,G\>]WM_>/YT;V
M_O'\Z ."\?\ @KQ-XHO[Q+._@.FW%CY$<$U[/ L$N22Y2,8ER,#YNGH<8->\
M^&^KW&C>,;-;BQ\W6H+*.W)=L*88U5M_R\<J<8S^%>B[V_O'\Z-[?WC^= 'F
M7B'X=^)[Q?$]AI=SI/\ 9^O>3*\ETT@EBD15!484@@E1SV&>*O\ C:#65^(7
M@F318;:6[A@OL?:MPA_U: @LH)7(S@^M=]O;^\?SHWM_>/YT >:Z9\._$7AX
M:'J>G7&F76K6GVHW<$[.D#>>VX^6P4D;3@<CGVJ7PI\+KK1]4NYM5N;2YM;_
M $F6TNTBW#][).\CA01]P*V <YR.@KT7>W]X_G1O;^\?SH ^>]*T#6D\/:!J
MR$7&I3^([6"TDN8F"?9[>.2.(L!RJD@Y_ UW,WP\UVYTC4IKRVTFYU;4=2:^
M(2[F@6S.S:C12*NXL.IR #FO2][?WC^=&]O[Q_.@#@O!NE:FGQ!O+C4KB2[F
MTO1;;2Y;ME(%Q*6,K$$_>QD GW]:](JIO;^\?SHWM_>/YT 6Z*J;V_O'\Z-[
M?WC^= %NBJF]O[Q_.C>W]X_G0!;HJIO;^\?SHWM_>/YT 6ZX?Q_X?\2^(IM(
MCT<:2+:PO8;\M>32([21LQVX5&&T@CG.:ZW>W]X_G4<MTD&SSIUCWL$7>^-S
M'H!GJ?:@"U;&X-I";M8EN=B^:(B2@?'.TD D9SC(%2U4WM_>/YT;V_O'\Z +
M=%5-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MUYYXI\'^(KGQ#JNH:!/IW
ME:SIHT^[6\9U:(C($B;0=WRL>#CFNXWM_>/YU!<:A;VAC%S=Q0F0[4\R0+N/
MH,GF@#GX-$\1:;H,^BVT.AWMA:6]K!IT5V)!YJHH$OG<$ DC*X!]Z3P'X2O?
M#MQK=_?BQ@GU6X27['IX/D0!5P-N0,DYR3@5TDUREO$TLTXCC7[SN^ /J33;
M>^@O$+VUU'.H."T4@8 ^G% &C153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\
MZ +=%5-[?WC^=&]O[Q_.@!-574'TF[727@34#$PMVN,^6KXX+8!.,^U<A\//
M#7B+PT+F+68])E^TEI[B^M[B62XN)R1R^Y%&W&< =...2:[#>W]X_G4<5TD^
M_P F=9/+8H^Q\[6'4''0^U %^BJF]O[Q_.C>W]X_G0!;HJIO;^\?SHWM_>/Y
MT 6Z*J;V_O'\Z-[?WC^= %NBJF]O[Q_.C>W]X_G0!+=VR7EE/:R9V31M&V.N
M",'^=>=>%_ GB&RU/PX-:N=.:P\-Q3I9M:ES)<&0;07# !<+V!/->@;V_O'\
MZ@BU"WGN)((;N*2:+_61I("R?4 Y% &E153>W]X_G1O;^\?SH MT54WM_>/Y
MT;V_O'\Z +=%5-[?WC^=&]O[Q_.@"W7->.O#ESXH\--964\4%[%/%<VSS E/
M,C8, V.<'D<>M;6]O[Q_.FO-L1G>3:JC)8M@ 4 <_P"$O#VJV.M:YK^N-9C4
M=5:%3!9LS1PQQ(54!F ))R2>*ZVLZVO8;R$36MTD\1. \4@9<_45-O;^\?SH
M MT54WM_>/YT;V_O'\Z +=%5-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH I
M^*M#'B7PMJ>C&7RC>0-&LA&0K=B1Z9Q7.>%?"^OP^)DU[Q')IXN+;2TTRWBL
M6=E90VYI&+ 8)(' [5U^]O[Q_.H+;4+>\#FUNXIPAVOY4@;:?0X/% &E153>
MW]X_G1O;^\?SH MT54WM_>/YTJ.Q=?F/7UH \L^*^B3>(/%GA:PM)F@O/+OY
MK653C9,BQNAS_O*/SKEM/\<ZB+'QKXBM(?L^HR/IMO,'0?Z/+M,4APW'#!L9
MXZ9KWB;3;>>\ANY+>![B#=Y,K("\8;AMIQD9 &<=<57'A[30+P#3K$"].;H"
M!?WY_P!OCYNIZYH \GN-?\;VZ6EB=1:V^UZS;6EM=W M9YO*DBDWAUB)7AE!
M4\$_G3M5\5^)]#U*]\)-J<EWK$US:'3[O[/&':W9296VA=IQY;CD'[U>GVOA
M'0[&-([31M-@2.83H([9%"R $!Q@<, 2 >O-6Y-%LI=1BU&2RM7OH5*17+1
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M% !1110 4444 %<AXP\6ZCX;U/1+>WTA9[._OH+26\DF"JAD8C:JCDL "<G
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MV%I;VL&G178D'FJB@2^=P0"2,K@'WI/ ?A*]\.W&MW]^+&"?5;A)?L>G@^1
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MW<<"RRK#&99 N]VX51GJ3V%6-[?WC^=>$:MKFHZY<V%U?:[%M7Q;%:QZ/Y2
MQ+'+@-G[^?7/'S=J]UH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V
M_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\
MZ-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?
MWC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=
M-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH
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MHTD=G TI13@O@<+GW.!7-^%_&&L7WB1=#U[3;2UN;C35U.V:TF9U\LL%*-N
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M+F5FR)3&ZA8SCKM)YKO** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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9*&W-(Q8#!) X':NZHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img108642122_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_8.jpg
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M%Q@C,B0S-R4T0E%WMB=24V$U-EAB8\'5_\0 '@$!  $% 0$! 0
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MEKQ7(^8$4B?E3Z'1[<A$PLK@ZK$KDZ('!*V[&>>),86(X X\1\#^\*J,9#^
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M%6<H51".HWVI:^>6<O\ "4-4P!S;E31 V)M6.J%K:]" E=G DP!^RI>0YQ(
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M8,B%F>R+Q/*ZVH<^25Y,KE7=#ML:2%_E&MK&8T4'?9F8<2A&M;%S_&(4ZH&
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M^NYD9KF $<^W-#@D9 Z*?Y5.US3/LZU[)JFN@9^EN6E9Y*F&.,=9GQ4[KW$
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MJEV_\.,>"A)_\0G%SS[_ ,.C<ZBGO]?;^ 3YW4_%Z_N]GYI#)?7T_A\GR?\
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MVH;UQ+4X+$I*5>8C4@3&&;),T$GX_'VA1[">J.9+*LN2TQ7?0](SNW89]?\
MFVKX?:<(DE@1O\)4@1.^GJ(,[XL?F[;.M,+1.^E2 O;4L-*2N&DZ@P!8BG!
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M=S8J65YW[8W ]/*5*F0IDZ)$G(1HT9!*5(D2DEITR5,G+"40G3D%! 40004
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M/Q.I06RRXVBEZ>(M[BV&GMR]P:37=251+=XX=G+>01C.!S@CS]_V+>'Q432
M6OT/U78[C%38?'9#POXO%550ZREB5X>(=S*_\]3-\5QH3NZIDA;M%29\HF!$
MJ=TZ1(T/[H@(<W1*2,Q*46_'X_\ -4.& !UP7 GS((Z?+!^?VZ$7!S[5]F_H
MTT.M&PHJMD$II6CY2[T0\.,AEZ$J.1!SZ",(KUQ*8D;VA8GHL5;D10+&?(6E
MU^A;?@VV;3 -%L8?C*K!(E&/%P!\^O/7GKG*Z%[J2U<^]*11) '2 )_(1$>:
M[+?>?@VTUVD]P!DJ646!7+%:+\<S1AUCL9<%*I\:(@RN1K2^I;%0(5"4!(BH
MJXNA2XK?./[N1GIG/[^A^"H=YE;+0:)S7LD(BM0VAU=S!Y/_ "%H[:Y_;K7B
MU>Q?HZQKAJMBF,WL?C<R?HV=L:W.DX?+V X4 F!VWMF93+''()LG>'(+BI*X
M['F0"QO.,]. '<^[CY>"LD\7*ZV9'U3Y8IK8E>QNJ&Z2=&T> NO(;*$<U88M
M8K9S=!PV B<I8SM[;'7RQ5+$KK=QM(^/E*VU#-EKFSEO#[MM_&%K\?C[E0[H
MWG/!'W_N\OGTZ+?KJPGF)>GY\9>GS$_T+SU#4A-'H5_YR_"W7I%HV_R>ID#E
MJ*%C0&!"M87->VIYT(N$JGU"TIENS7HUA3G% SSCR.?AXJO?DC=U1?RP]41[
MJ8%3OUV6-QQ0\XA$NYZ3R*.5BBI& 6I9L/)CDVA4S.>9:DM=7-Y0ZN94G7S.
M4-+W$$J1J8B(Z".+D:PJCC:,?VG=<9Y Z>[ &1Y^)XQ%U^,EN7'U5Y8&O_-1
MTY5L-YAY6YSL6HH535LO->L;-9,FJF_)&HE:S;27]>K3E+X,VF+HH!:1$I48
MJ-.F+*_GMK 8U/''P^_/\$!'L\ ^T0<^(]GC]_/7Y+7MQNWI/E..\)]'HN@[
MTOJ>=3^/[L#H"Z(#:DP,D56R6S*OX]C_ $O! 5W5K<A;(S5B9LFHSHTB15\B
M9C'"*JMM[P8[.(S7$^,Y&?=E3@'(P.'  @8."<<^? \<\Y4M@16=3Z_P_6BW
M]T]&V5).QKYK,5X0N9VL3(*_MUJF/-EG6>^2&$PHAO3((! XQ)BV- DAM?Z:
M(*8VR*,;D;:[OS1'78$I@'>,8#0<<<C! Y/B?CS\N%T785M,(F$3")A$PB\1
MY(%!!R<>S @/*,)&(HP9)H0&@$ 6RSBQ!,*,UH6]@,+$$8!>@@"T+6MX1<P?
M&]%M?,/E)\QM:T"?/'!P9N0.?Y%#E<YGLQM*;KYT^0!\>D1RV8SIW?Y2\*3)
M <G A+7N2G24D*=$E"6G)**"5QSB6LSCASA@ #CV3CCXJNSBF-5!'*^_1LIY
M1[3#D?04ZZ%Z)1VW*HNC:"K.F$>-W-$MT%6,\( !DK^B9FX>T>PR50K+:641
M)*32="8$ WX_'X^"J<23*#T &.>!R-N!QU'EYGKE?3\WO:5VMG=3_P 23OFJ
MC(1$I:DB5IUCT3'D1Q'04ZK-MB4A1I%#G,F&7*CF]H-GD2E\5-8'1M9G';9%
MT1VVT+<I;EZ_GO:-14,>FKM<VT-";BSZ/:VN?1TTE4 ;A1PD=_)$Z3'<N='C
M=PPEHXX7>O1%[+>S?7_I*Z"H];:%TIJJFND6JXKE%?+#;;@ZL90Z&U%54;*F
M:HIWS3,IIZ2EEA:Z0MC=#%M # %5H@;W-_7F)F] XN[FJT<H E:T1JU4:9H7
MS'F?2I2QF;+"#Y!F;*+]"_L+>M #O6?,K623/(8QTCW;G;8F9)/4X8P<-'/#
M0 T=  ,+^CBG@LNEK/;K?2-MMBL-FHZ*U4%-NAH+=;K=1P,HJ"AI0YT<$$-/
M#'!3TT((:V-C8V >SCI1\07)W;D43%3K;DP493T@?(1820,NK2 6#(;2:-'J
M4+\SLZM1)"9Y6(S6-%I,!:K1(=F?C('!(F.$FV [M79UI_4].T5>^&U6V:6E
MK&^L4-'635\>7-ECC<9Q5T.8F[0YS69$N]@)'/Y:>FYVS]@%ZF?IX4EQ[0]<
M6RWZ@TS,ZR:LU+IFV:/K3'%46ZNK8([5)IS5S67"<S.IX*BH#?4'4LTS&RAT
M=_LDY1Y;F+ZZ2B7\UT#*I,^+#'!ZD4DIRNWQ]>%YWI\RYT=W..*G!P6&^FOD
M4JU!QP_37N'OTSKDU@L53+)/466TSSRN+Y9IK;1RRR//5TDCX7/>X^+G$D^:
M_-NU=LO:_8K=1VBR=JO:39[3;X&TU!:[5KG4]OMU#3,SLIZ.BI+I#34T#,G;
M%#$R-N3AH4:7AP=SM>-.(J%41I15-7(Y>1-S(M1@62KVES?"$JI-H3PSLK&-
MB=$YAB@I>86K:C#=N3>V+@'@.1%"SPW32EGNEM;:3"ZWT+:D51@M7=4,<DH:
MYOYV..(Q2-)(>0Z,G>R-X(+ MK[/_2+[3^S[74_:/%=HM9:OFLDFGVWCM#-P
MU=6TEODFAE(H:ZON#;C1RM;$^F8Z"L:P4E55T[HW1U#PM4:^\(W#4!EK7*QL
MM@3D#9I>$<7L"3M#]$G0*]N5MVPNS2FB[8<J^DTK^N0"+6D#2N29&M +Y$X-
M;U^C[,-+4E1'4&.LJ@S?F"LGBEIY-[',_.1MIXR[;NW,P\;7M:X<M"[)J;T_
MO2$U)9:RS-K]-:>=5FG(N^FK376V]4AIJJ&J!HZV6[U;(>^,/J]2'4\C9J26
M>!PV2N7*WTOS])D/0ET(:;HVUVVK$5E2]% 4&Z]L,6DD92/*M.V$ V]MREWV
M4605K1/XB>8K^+V?,+W>NM<'O=GJ&7>YLMUJN#*!M=4LI&>IUAVP-E<(P.]8
MZ0@-'&\EV.J_8;LH[2[34=F>@ZC77:%HVJUA4:4LD^I*G\IM, S7::AADJY'
M"WU45$'ND>=_JL;(=^[8,<FT"5^(RR+8Y&Y^L>@95<4[L&4((PJF=7W1(&V$
MQZ"%)XRYH)&".LDJ0L+@D T2M$6RQ[Y#C@K8P>6XH_JD*DA7O>:CL]K;AIVT
M5MIGN5763M@=4T%SF92PT@;!(R<0Q5#(GM$=0P10Y)WP$/;N8X.7R+9O36TK
MHSMK[2]+]I-GT+IW35HJ;O#8M7Z"ME5?KIJ)\MWI*FUNNEPL]3<::=U;9IWU
M]SV1QF"[Q.II^ZJ(I(1^<PTQW[XFY!)[YE7-:*R:K?F=+';2;XE+6:1R1CC:
M-;IU#(VW49<'18V!:S"C3EJ]P8W)BTDT:0Z*&;1Q#LEBQ6W5W9_-/=JBR-K:
M":-L->RGJ(IIXH6N[P3,[A\CHQ&02Y[XGQ;<B1T>1(VKM<UWZ-OIFVVT=G-G
M[5:C2FL;;73732%3>K+76NU7"Z3TYHW6NK-VIJ."K-6QS&4]-37&DN)GV24D
M=<6244UG"?SR<-&D$&FI[J2FFDEF&IC8 V#-3&# $0R#!IY:<0,PD6]EC&0:
M:2(0=[+,&#81;W@=J^EB 2VZ-) )::2,D$CD$BI(R.AP2/(D+Y+D_P G1Z0C
M))&,ET%,QCWM9*S4M6UDK6N(;(QLEE9(UKP YHD8QX! >UKL@70EF!-++-#Z
M^TP 3 ^NO3?M&'0M>NOX;]-Z]=9TL'(!'0@'[5\'N:6.<P]6N+3CIEI(/WA?
MWDJE,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%\]V(<534
MYIFA>4U.RAO6D-;H>BTY$-KB<F-+1+SFX1Z4+@4C4B*4&(A*DVE0"]D;/)T9
M\@:)6O='(V)XBD<Q[8Y"SO!&\M(8\QES=X8[#BS<W<!MW#.19J63R4\\=-,V
MGJ7PRLIZA\0G9!.YCFQ3.@+XQ,V*0M>Z(R,$@:6;VYW"I4SQW7T=9(;6,Z&I
M8<M#%CHCO>^2(#MC&W'O@)$8N-C>WK\$,D.W(&MZDHT0GL*78D.END@A%;YH
M=#7DU_TD;[:C4^K&ES^3%#W7=NF$Y<:?ONY,V\?S@L,P:2S?M.%\Y.[%-8.O
MHU$[6NEC<A;W6W)[-[-ZH8'U8K72NH?6_5'5O?C(KC$:L1DPB7NR6FV5B3.R
M)C9D;\Z$O;ZD:FY,]/29O"TIW=V(2$E.+H0U 4*P-A+@L <K*;P*E(40#@I@
MJ#M%Z,%TJ%LC(8F32":9L;&RRM8(FRR-:!)(V,.<(P]P+@P.<& [=QQD_1=)
M'4Q4E+%65#*NKCIX(ZJJ9 *9E34LB:V>H93!\HIV32ATC8!)((@X1A[PW<?J
MY<7H3")A$PB81,(F$3")A%#5\\\TET_7B^J+_K6,6G '!:B=!Q^3HQG 0O+;
MLP3:_,;DE-2O$<D3;\Q^FZ0L#@V/2 "A2!(O) H."84@D'(.%K_3_C6X@HA_
M9)=6M!,+?-HW*6Z9L4^DTDGEC6$UOS1')7$FLQ)/[(E<MF0&M!'IQ+&Y+'-O
M>XX2%\6J0-6EFRE!9"2>I_!^"CDOP\>,X"\3@=R%6KA\CN>^*&QY4RY\CBUR
M5.1CNJ-<8H\R5=&'(A4YFFK5*%>T*4"@\P8CDP]"WK9-Q\S]JFF^^!.0^FW6
M+OET4NT21XAT4/@+*Y,DAFM>JQUXI4%JCZX?3JWDL1%*ZX,4@V=NOY5MZAVC
M#E0@LFMK%?S$#B.A4SSNAJ=LRG7'GR:UW&GBE'2,M<,5UF6BVTQ3438_H-,T
M=1MS*8W!;6AK UMQ3>A;A)2$A",A.0 !!>B\("0<^/7/O\U@O1'('.G5A,/U
M>M= ECC7JUT7P64,\JFU>3J'G/B4E"_$QNP:UDD0G#,WOZ1,D3OS4@D!#8]E
MHD.G1&K^B2[)("1T\>JP-?X[^,%]+0_GT-#QMHJZOY6?/80VQ9XE\.E,5GJS
MZ_3C/&.S(G(F6SF^<.X'1R*?)@GF )&^)URM.[N:T@\PL1-QSG/)ZYYR/(@\
M$>[HIYI2C:FYUK]MJZEH2UP*#M:QT<RFAM-7K5"YY?5YSH^O[\]O*QR?Y-)'
MQR4'+GJ1R)T='QV5F"/<'!09Z"T4+^;OHFHND:Y>:EO"!LMBU\^G-RM?'GL*
MHL);BSKB7-F>&IS;5*%Y87UG<4Q"YH?F)Q;GEK5E!4(%R<W7NPI!(.1P5@'.
M_'7-_*@I>JHNMB8H]6 <UG3F7O,HFMB3^7:8B5"=B2R.Q++DDPG+PVL9*M6!
ME:ETA/;&C2Q9MN2)A*E&S"$D]3^/DL^-H>HCI%<,M-@K0.1W]%8Y"+C=MC7?
M4SV*1%GDC!&V1XUI7HH"1H9Y=)$";: M&?LEV4[--,,T4,LH6+//,U2G-M4[
MC<+C#')^>(#*X#SH^KFU8^HZD;)3 DU=*4Z!C4.B9.^-0XRW-+2O:W=0=MP;
M4.DOUB8TXQ5A3D\^_K[^<JG[G/Q2SZ/7_P XV595%<6T8T\X35QM%SE'-<VN
M2:26Y; ! )O"&%KBD&L:"1&+<N4YIRL)XL.25A 7Z8MCK*&:,-0/^!9DSUHJ
MB[@\N)=P<^ R#UR23P!ST'"Z!<*A,(F$3")A$PB811>QTI4\9M2<W>P0"---
MN68S1N/3^PD3> F32UDAZ?:6,-;TXZW[U:1C3;V2WE"UK1!?[.O7"9XQX<G[
M<9_<%"E7<"<64G<3[T!4O,5-U[<TDV\"=+"BT+:FM^T.1#&.0&M8R"M)6$Y]
MV:<%Y.84S::Z%J%)2X9Y2D\!A5%SB-I)('@N+;]*-CZ%Q\GU'N ;9::Z>@<<
MUNA;R2RIL"4&_4W3T*G^9"N9&;3(G1N %BANWHV2IW(0@* &-HD9I9IN U+.
M8+3.\V87R,D=]1.%*Z-L;&NF]9F95YB?'!)$QVT,>\/+'M: TN;V;L&M3;MV
MA6J!O:<_LEK6"0VO54!OT==+7UDE/:_H2VU.G"RX4E9=J.X5<!GDGIJ1U*VI
MIYIG.G9!-=#X3/Q:.06'+$_$YLN'*+)F@2NO4X:R(7Q&/J&M QN#*%>[Z)GP
MF=M5M"Y,M;VM<%.HVZ*](T*L\TXE3S#LQ[R&EIG#3!J._K:K&HAZB'TT)C;$
M^(/DQ5]VQT;VN9&\!W>.#6.<2'??'I]^I7/4-\IY>WUME;:-*V$N[$I3JV2G
MO=SBJZBX4U>ZGHC)IL5U5!6T\T%564YDB%)"9ZB&-C)(NF/.W+\GTPB81,(F
M$3")^_\ ?A%R+RWP$=>/LJDSV@LKFPA"\2!Y=41!\KLXH\E(X.*E6G*.+)J
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M*#:(K3<ZMNH+,Q@X,<5IOT=RH*9KV^RYU+!!)C!;(U[6N;H"X>&YQJM<J?\
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M15,;'R%SHY(6$1-PLF@J=]8Z1E:^.B<\O]7;$#,QI.>Z9,YY;M&<->Z-S@T
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M[7?OMN/?G;CQPGTWJ6+]/IMTF.O<3YS\-@J/\?N3]<W:<7^]N>,?KVO0E_\
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M)A$PBC^Q:GJRWVE(P6S6E?VBQ-[@!V0,MBPV.39I1.I:<](!S2-LE;7-&F<
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M&P5DC'R]WN,;7N:TNP'$#)'K&J+'(QW<W&G$FUVP3LJ(6;\':'E\32&[L;B
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ME17NUH'N%HI#(W' ><GI[)_Q _>ND;E&Y5W1G+W./03FQI(PY7G1-2V^X1M
ML.<$,?6V3 F"8JF1&O4$IU"Y*UGO(T*=6>G(-4E$ .,)+&/8 E:<,$CR)'V%
M3]A0F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6F
MG6GC[Y#[D!#A=.5 EL%PK_\ &BX?(6^63ROI6QH9(G*1R-F(EE:RB(20^/OZ
M0H"=VCZQT4LRT.OD,0[/T$[12'%O0_N(^PY"^W&>&>3(7+.>YO$J2BT<DO*D
M*DM=\_+690_-Z:MH=,FA8Q2IG;6A.[ELSI^/MK@O Z.,B;WAU5*UJIS,7;<U
M!JP9-Q.<D\G)]Y45T+XL.!N8[H5=!4?SM'X/:I@),4TOA4FGKXTPLF9F*#)6
M36\,DLK>836A3]]8N3KRX%'H\';>N7-).B6E6H1&%)<XC!/'CTYQTR>IQX9R
MMG&CGFFF&]I?TPT0=$BO.>P9CK676 !Q?#%[S!XVM"XLC <V'.9C G3H%H G
MEJ432F7FBU[5"LT&]AV49.,9XSG'O4>=F<H\]=G4>YTAT^VGNE3N,@CDA<$J
M>7.4(,V\L"[:AC'M_:5S<K)"%8;H/TVE02U0AA*& ?KH.$!+3D'!'_3Q6R<>
M8VV,,#'&F8H9+/'F=L8VHDPXQ0,IM:41"!"4-0:(9IXRTJ<H(CC!",-WK8QB
M$(6][*%]C")A$PB81,(L*LF&Q6QJ\G5=SDO9T+L"(2.#2PC2\UK&ICDO:%D=
M>4I3D0:0>@.5-[DH3D*TYQ2@@TP!A PFA!O1.BB3DSFJC^/Z+B'.G.S>>SU3
M7Y\C.C[0LDSA+ER$V7RE[F;SM2]NRQ<Y*?JGY^=%)(52@>B"3 IB-!((+ $I
M)+B23DG_ *>"V0PH3")A$PB81>NK6)$! U2Y4G1I2]@T8I5GE)R"]FF *+T,
MXX0"P;,-, 4#0A:]Y@P #ZB%K6R+4.@N-N:./9]T?;=6-*J'RKK>T-V=<[K(
MIH[.:"1S]P?)>_ /:4C^X&H6$*AVG,C,):64"9.,*HD@LC8$B<("DDG )Z#
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M=E?+[<I.K.TO,^FYDZJ:/SCS]6GB2L.]('#GEX=FZ.,MMR:_1UW(+.1$MR]
M R2-,+* G2*QC,&VB94CB7HLY*4: @);&7-."7X)\<;<CY9S\?DMU_ O8D[M
M+Q)<9RVR')T>91J&SB*_BKRH4*W);'*_MVPH#"C%"E4,Q2?HJ&1I@3$GG#&,
M].04=H8@&!%LHDP'NQTS_A\OQYJWG"H3")A$PBT/\D]2/UN<>W0CCUZW?0BR
M%UY8]@&OU$R2.Q60RQ/'*TF6_P BR1V?HG*E!<->%"HA6[EQO\O202EL;Q-\
MC;RP*"U)2#@YP#\<_;P0J 2:#L3J/P0>)*BZVC=3SM=);;HN0S&N;BMM%4$3
MGU=PYQLUR?8RI>2E0)B[)7)\.BR1Y:*W;GB>;8U#BKCJ 3DF3#"5S(;(\G(Y
M?R.HR2/A]OBK$/!VMJN'M/9G,\8Y3KSE*X.:^@$40OA@IVP9]952SU\=8X+\
MJ3J%O]DN"Z4HBEC*R*$2MA7Z*4(B4C>O5A3K752TM14OR2#DN!'!/7@G(/P.
M?=Y*]["H3")A$PBUH[*@#/:7*U]U_)+G=^>(K)ZTDB&8W6Q+V]J<Z[A1:/:N
M9/Q3JZFD(&H@,73.R->Z*#R--S>J5+"SBC2"S E(."#C.#T*XXG"'AJFC_(C
MV-XO*[M'G?@=F\>:'G9FGSTKE\66=:78.U(XROG2]?1&0KQR1K112MW65-J>
MT#4[&L&Z"6C9TR9P<),2T%>ZEC7D%V[..NT?V<CSXXSQCW\V$\/TM6/&GE-X
M=K/EMH%$:\Z5\3Z.>7RP,[V\.+'.Y9''-&Y1RY9 A7N*Y(9+G1P )K!(""T^
MA$.CHE1Z* ZN(514N)<TYQEK\ ]."#D >0P#CXKJKPK281,(F$3"+CBJ[D*J
MU_?_ #G$?'P[6G=O17+_ &%(K;\E/DJD3B[H(J]Q9X>7=PL#F!Z?"W;<5GTY
ME+4X)X2IBT.:U*>-E-XU+FJ$<LG"EA?C\?C[^EW)VG=P" &-\>,$'[.23];/
MCP%&%.463R/U#SWUWU=Q?S):S=UKY/93$(#T[6O3LQGEV1&WKPMR;RRJI>;%
M(,[*J/<83'3$2A O9$:Y]DA2EG=S9 ) X*&YC4%.=P(#SPP>SC@X SR3GGJ.
M!U!\UVV85E,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBTG["\?G-G<6J^77:R3!++JJ/D8Z]L:LK EE86'%D4R0)VJ9
M,:&51!R;EAS!*VU*F1/;0O"K2*"2=;) 08,TPPI#BW./'J" 1]AXX_'4J>J$
MH:I^8J?@E#4=$$4$JNMF?;)$8NA4+EA:!*:L5.:Y0J<'-2M='1T=G9>O>'EV
M<UBMQ=79>M<%RDY4I-,$0DDDGDGDJ7L*$PB81,(F$6NO4G*='=E5.LICH"(F
MRR%G/;-*FP3>]O47D<6F,;.,41R8Q&4QQ<V/L=DK(<<?]$XMRTK9B92L;EI:
MML7KD2DI!(.1[QX'@]00>"L/Y%X>Y[XCCDT8Z-C\A+=;,DH)A9U@3V922QK,
ML>2)THD*%RF,XEK@Y/+F%K1#-3M3> Y,UM^U3@J2H2U[JZJUI"XNZ^'0 8 '
MN X6W6%"81,(F$3"* .F.8:8Z\JQ53%]1A5+J\6R**RI0S(Y!((P>-\A;XDD
M4=5Z=8RY-3J ")W0IE(TP%FDRL)>R%91Q QEB*02TY!QP1\BH,[&\;?+/<SM
M#9-=\>F:6:09DD4299U6-BR^KY>H@LO" ,JK]]>8>YMQD@A3][-[6,;P6L)(
MVH</PX:'3L[:7%+7%O3&#X$9&1XX/BMKZEJBO**K."TY4\700NMJVC+5$(7%
MFT2DU(S,+,F E1)=*5QZIP7*-@!LY:Y.2M8YN:TU0X.2Q6N4J%!A022<GDE2
M'A0F$3")A%C4SB+#8$/E<#E*0;A&)M&GV(R- 6I4HC%K#)&M4S.Z0"Q$:0L2
M#4MZU02%2D/)4D"'HT@TLT !A(M)YQXR..Y_RY57'[U7CTDIZBG%D?:5&Q3Z
M;LU@U9)HV:Y&L<IAMEI'T,T0/[=MW<@ 6J'=8!22J$2M)5%%E +*H.()/B<Y
MR 0<G)R.BE;DOC.@>)X$^5_0D7<VA)+Y:YS^>RB52>03J?6'.7D!!3E*YO-9
M4O<WU]=E!*8@H/RJ2T24 3-HT:<:E4,\H<XN.3Y8'&  .@ '@MI\*$PB81,(
MH<Z"H6L^H*;GE!W(T.#_ %A9;20QS)D:Y"_158ZM)+DA==H0OT8<6E\1$*%+
M>G+6!0N"?ZQ%M0@4_*C5*"3"D$@@CJ.1^"M%*5\,7CWH)1*A0&I9:>V3:KI7
M3$HB\UNNY[!ASM6LU0)FJ11DR)S.=O;"G(5MR0E&F6(T*=P;"0[TV*T8M[%A
M27N/4]#G( !SYY !4B\?^+[D3AZ9/]B4?%9H;.GN%-U8(Y99-F3>T'J(U0T.
M!+JU59!U,S>'345@B%Q3)%9;,V +$>:A0?6JE0$*0))'.+N#C'7  &3TR<=3
MCC]RL)PJ4PB81,(OY$'WA$'>Q:T(.P[V$6PBU[M;UZA%KTV$6O7UT+6];UOT
MWK[ZPBJ"JOP4^-ZE9[#K*KBK[-8)5!)\PV:P'?YC^@E[7^=(X_(9(W.SLP.%
MDJ61^T8[MR10Y(WI N1NY8!IG,A4F--*&59>XC!(Z8^JWITZXRLYKGPW\$55
M?+'T##:QDR-^B$[>K4@->KK/L!VI*NK1D(C#'>PH+43D_J8;'I*<<<8H1#3M
MXFUC4Z2*6!M:CFMH&@*"]Q&,\? 9(\B>I'X\E:-A4IA$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+DM:.L+AYI\Z7EK-K/D>_.P 2
M*)<=HUL>I54R;,K\E!04&5DN3P1(EJ9,2F?CUR@E)M%K9@U"%4([7W#O972W
M,<?+1]?KGGVO<#T_Q6JG!OD8N/FCG7K-VK"I$[SU+V5YLIMS]2U778\.*6-5
MG/[7:XJM$FM(]B5DKC6Z#KSB8V[M+ Z-HS798%2G7%($2K8RJ<P$MY&UL8)(
M\<9Z#CD^]6-SCRP]X<CK>U>>.OZ]YAD'3E#\;&=HT/8-,I[*#25EP4B8MT%<
MX],XM)I @FJ)Y:Y&N6$E'MSRQ$KTK(Z!^ K13>Y/94[&D-+=V"[8<XR">G0>
M7N^:VG7^3&ZDML^$:!%PRKA-/DPIZ3V'=2H;9+-N,,=V2BJTM%*DJXP,P"F;
M&TQ\FCDA/+EB67JA-*9"46J*6 /6J"IVC#SGZI&/?DD+0ZH/,QY+YQPWT+Y!
M'GE7G1XI*EHS8$2CS'!EUGFV-/KE:KAAL/:IC^6OQ^1E,-&U[!I&]O%E@5.1
MDJ=G6'NCBTN<:C:C9[<518W<&[CDD9ST (S@^\G&/#S6Y/B?\FUX]N6I-8-8
M$WX9N.$-E3-=CLMB\F2.PH5*HU(E+ZV-+C7]@<_7X_'7*!.G+<35!=BM\?0P
MQ*>E;FA2J4N[^60W%2]NWP</##A]X(X^7WJLKS;$\VNGF3Y$8NO8=<ECT"IX
MLDZJ0P>D"+)<)HX/Q$]MH4;7I&RK'5IE1R9 Z 3'N)R94%.4C*WM=H:8(@85
M;,['8(!W#EV,??PH]X]ZXO3QY4+V!+*1I*^EE']#=NT+S?XI:>[&.FL?,)FU
MFMUB"F3H[$R-PU+$M8IB&6.*"=H75.6\NR0EG4R%)(3)0\(WX\/?^/L]Z.:"
M0#C(:7/+0/CX<9QQUQE67)/)[WCRC=UR\K]U4Q1MPW0@XTL#L#G-UX[#8R)A
ML_\ P\22(Q[J-^89WM[DB9\$JC+Z<E?FAN ,EG9@[+8'UP>4>B7X"IV-(W-.
M!NVG=C(SC!XXQUS\/%0_P%YA>T.V)2D@\9D?C5G\EL2BIW,6*,0^3W54L^H&
MVV6.&O+)"KAKRU']?.K9BR5>6&.RR4<_Q]]1M*H:B1$.AD<2IU*XCF!O.'8R
M!DX((\2"!QX8!^U;0_HX=B=(6IXT*ZFM_P S06&WNDLLLJM9F[2V>32VWEG;
MK/G#=(@VP\S4Q62-8VR%*H;(84P.2]*5"TC44N$F7%C2E$E #R ,=., #H.F
M/QE5N<4>,?E;R#=/>8^4=$M=CKIG ?(Q?,*K^6PRVK!A#A"VQ;))"Z%J&IK8
M7]-&5BYO<S?KD1CXQNQ !EED&D&I-?!LI+BT,QCZH)R <\GQ(SX+%>!O+%VR
MKY*XGX]I\,"NSLB[>B>EJ!K^[>D726N, ;*:YP9HU-%L^FQD:7)Y;,71)&Y>
M<Q1TQ,Z*%)J"#*!NP7UT,3D.+\?CI^/!2YC<N<<AH#20W&?:\!T&%MS.O-3V
M#SE37D KN^J J66=N\)R2E$3FY5*78JWG235K?1*)?&+J>FDP]PL5HCD.9%B
M%QF324XI%2Y5(&!"D-CHQNWX25(8"6D$[7;NN,C:,XZ@'/@>/>L?AGGLM>&\
MO]@=!V>KXFZ;9:1B=9.-/RGD:<3>% EDSL^4-4,0Q&T:1N5W=;S@"%E='K;L
MHESC'VAE=FN-/S4U;.>CD.M%/=Y<UH#AG.=PZ >1 P?\#@%2EXX?-):W179L
M6X]O9\XPM97;%0/-G5_9G$C[9:V.PF3QA$I>I+4=H-EGKW-6I?T3&WNRY/)(
MZJ(9C=(VTM,2Z?C"HUA*',P"X;AAVW#ACP^MGR/E]ZZ3<*VF$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%2MR/7K*Q^93RN3](J=#'F;
M0OD=.ZIE)R0;8G Q5!'D"3;>24B)5%#,))")3M2M5Z&;L0B@D@WH&BK)]A@\
MMWWE5!G<>UI(>&/*581<@L&.V)SYY.[D[*IV>QE\:&R3P:Z8;MFTSK6M49'E
M24QAT!:=I0UK$2E0(TM&M(<$[BWH5B:#P"?(%5;CEG /L-:0>A'VKV/$13)'
ME%YF[G[([9L*PK>Z"O.G9AQ\\3'Y85%44(IIL;$\G(0UK%HG"6>+QEX-DB%H
M?E2Q0TNR ]T:0*A-6A.\FT^RCSM+0T  8?CGDGGGGPZ#W*!/'/%YE9/47BTF
M=I7=;5DZYLLZ_P#GFDHM)U$ 3Q6"5?7]'0Y*R-:-)&*_CKJZ.BA&_%HG>0O[
MPZO+BACT71#6 2LY9)I2XX#P !G:3C/7<?,D#Y!62\;T.E1^"V\(-"[6O&J5
ML?E_0=D1^R*CLA=7-HLD@B\U43%.0WRV,HT6P,SHH;=LKZUG(3R7*/KUZ,8B
MU8TR]*5#C[9. <8&",CZH'X]_1:_?H^[>[=-];7]VO=DD'*;UA%2MM'MKHQ0
MBI*QC[K&9)*MO[H_RMAJ:N8*3+)X:JCY"7\VOYR]>8VJ3$"D*@EO8-,Q52<-
M:T< Y=X]1QX_;\2K/;FKMD<//+Q_9ARIT"^L/&%G1]&D*/2!:#$2QWM(PTU2
M0-"-8-4':TW18REY)6M!+]Q(MZ%L94@^PX>&6E; ^7KG6!]$\+VJ5,ELH8WN
MD $='51,84[$,DL@]M5(A='6)R1E<53>Z)BC-$K'5F7!-0&FB:GA?] >WN>D
M+FB*&$APQX\'W@]0J /#!$9GY.XIUYW%UQ?5X2?J%EJ-TY2KNUX%)8Y43Y3]
M=JDSQ)1/=5 K2(1E+%)\!W2&*!2,)*PA6%T?BG%K6EOSN%85R0ANUH  P'GQ
MR>>N2<CW+"/"\VR3KGR/QRS>B; D-DSGBVL;$9ZGE:J.57'9;)"I$RE54L7W
M/.(?74>G5RO:>+/:X:)\GTG>'0IZ-5/)RH]8[/HW4C^&X P'8R.<#!/09XY"
MME_1\F=UK&DND.;44QD<FJSG?H&1P^I6V4)HEMTCC&^N+]*7XD]XC<7C:Q[.
M=Y&Y+G=0>]B<!I3E DC7^'MH"4)94O.=KCU(Y]_ _'"Y_KG<;FK'MON^J:>Z
M:OJFX!TCV)=*ZUF*MGR%,AKLJDL_?V9Q/;7U7 W.2,AP6I28@2G-SP2<41K6
MQ&&&>\P15@ AN6@X  SGX^! \?)6U>4GAFGN /&_S?=')+K.JAN#QRO"M^Y_
MLEI<HVY2)R=KB,3$VDKM$A\BCDP3D$X5DEN+TA-9&UMUZ&L:!&BB*E7'#RH:
MXEQS@A_U@?=R.A'3'"@?DFG7RTO$1U3Y&7WH#HED[6Z1=VBYK)O^!V"@K^6F
MN5#*C&6#01G21&--,>150-I<'!M?J^5,R]G=6\]&A]$Z2/Q<AC*HG#]N 6MR
M ",CD9)^)/.5"?C5XYK+R<U/Y%[WZR<GM_LRP:CCE1.KS7<=J2GV]"V1M^;K
M>:I<VQNM*PC4<,L$,UJF'J5LG>FIY$Z-B9:S.:-6W+SR-D<2P@-\'$C.3T&,
M=>F/ *Q'P.VKT?U)/KBM'HKJF_+9,HEE:J=@< >7^)1RKS&A6I<?;+I?#8!"
MH@FG5D)4S5M$1-I:I=W,TAP5G+OK%Z=H6-<#G[3]Q(5#\# #0/'C.?'Q)/"Z
M<<E4)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
-B81,(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img108642122_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '% E,# 2(  A$! Q$!_\0
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M[I'VEMHZ9P 30!:HI RD9!&.]58M3LY]1N;".8&YME1IDVD;0^=O.,'.#TH
MMT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5P'Q'\.W^JV\U[8VZ!H;0H9;?S&NI<M_J@BD*5[\[O8#K7?
MT4)V!JYRWA_P]=:5H.IV5S;6-Q-<,Y\S?)_I>5QF;?N()Z'!(]*X_2O ^KP^
M)G,T5O-;VIM7^S3&X%J/O'$+%CN,?;<"/FZ+P*]9HIW%8****0PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_P#:._Y)YI__ &%8
M_P#T5+70?!+_ ))#H7_;Q_Z425S_ .T=_P D\T__ +"L?_HJ6N@^"7_)(="_
M[>/_ $HDH ] HHHH **** "L_7-9M/#^BW.JWI?[/;J&8(,L<D  #CDD@5H5
MQGQ-._PW:6IY%UJ5M"1[%\_TIH3$_P"%B9_YD[Q=_P""S_[*C_A8G_4G>+O_
M  6?_95VE%&@:G%_\+$_ZD[Q=_X+/_LJ/^%B?]2=XN_\%G_V5=I11H&IQ?\
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M<:@8"JTS1L!_P$ 5*?N7ZM7_ !L4U[_+V=CU&S^//@J\UQ=-66]C1W$:7DL
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M#:O09.*][L;.'3M/MK*W!$-O$L48/95&!^@JQ157T)LKW/'_ -H[_DGFG_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'C7CSXWW7@[QA>Z%'H<-TEN(R)6N"I;<BMTVGUKS'PK\8[OPCJ
MFIOI^CP'2K^X-R;%YC^Y<CG8^.AXX(/0?C]9T4HW0V[GR9XK^,%WXSU+3%U'
M2HTT>SN5N&L89L-,XZ;I"IXY(P%[GVQ]8H=R*V,9&<4ZBJNN6Q+WN%%%%(84
M444 %%%% 'C_ .T=_P D\T__ +"L?_HJ6N@^"7_)(="_[>/_ $HDKG_VCO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BN/\=_$+3O ?]D?;D\S^T+L1-RP\J$8\R7A6W;=R_+P3NXZ&NPH
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MC/3G_6>;][G\,5ZA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*Y))R6!ST.17644 1P00VMO%;V\4<,$2!(XXU"JB@8  '  '&*DHHH ****
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M<-T*EE[XW9P2!6WH7B+P)X=T*RTBP\4:&MM:1+$F;^ %L=6;! +$Y)..22:
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M,K;X?>,-?\/ZI=^)_#Y.G7!-PIO[?]_#@L$;.=P\P+P2!M:3N10!)\"_"/\
MPCG@==2N%Q?:SMN6Y^[" ?*7AB#P2^< _/@_=KU"N?\ ^$[\'_\ 0UZ'_P"#
M&'_XJC_A._!__0UZ'_X,8?\ XJ@#H**KV-_9ZG9QWEA=P7=K)G9-!()$;!(.
M&'!P01^%6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \?_:._
MY)YI_P#V%8__ $5+70?!+_DD.A?]O'_I1)7/_M'?\D\T_P#["L?_ **EKH/@
ME_R2'0O^WC_THDH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB(*A2HE**44'".N>N1]#T >?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
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M7/\ P1+_ /&: /I^BOF#_A,OCG_SZZY_X(E_^,T?\)E\<_\ GUUS_P $2_\
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M7/\ P1+_ /&: /I^BOF#_A,OCG_SZZY_X(E_^,T?\)E\<_\ GUUS_P $2_\
MQF@#Z?HKY@_X3+XY_P#/KKG_ ((E_P#C-'_"9?'/_GUUS_P1+_\ &: /I^L?
MQ5X>M_%7A?4-#NFVQW<10/@GRW!RCX!&=K!3C/.,'BOGC_A,OCG_ ,^NN?\
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M^BO!_AWXF^*VH>.]-M?$MOJJZ0_F_:#/I*PH,1.5RXC&/F"]_:O>* "BBB@
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MR]-\-:#HUPUQI>B:;8SLA1I+6U2)BI(."5 .,@''L* -2BBB@ HHHH ****
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M%5//,9#<[EZ$XQ]#Q7?TTN5W?]7$WS)I;!1112&%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img108642122_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E!24# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&BHB\!5& *=11<$DM@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444=J (+N\M;"W:XO+F&VA7K)-($4?B>*S[+Q5
MX=U.<06&OZ7=S'I'!>1R-^0-<-?_  I\.,9-;\=:[>:M(B_O)[VY^SP1C/15
M4C8/;=5"P^'_ ,'/$$:)I:6[/,[Q1-%?S!F=0"P4._S$!E/0]:%N#/7Z*YGP
MAX0;P@ES:PZWJ-_I[[/L]O?.)#;8SD*W'RG(XQQCWKIJ&)!1110,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%8OB.YU>VCTYM)-H U]$MV;E@H
M%OSO*Y(^;IB@#QB/Q=HGA7QKXJ@N_!=WJ<=QJ4DHNC:J[ANC*,CE-P)!S_%T
MKTGX>^+-)\3G4!I?AR?1_L_E^9YMND7F[MV,;>N,'\ZY[5]:^*BZQ>C2E\.-
MIXG<6S2S+O,>3M)^?KC%=-X#OO&5X;__ (2Q=+&W9]G^P.&_O;MV&/\ LX_&
MB'PZ]@GNWYG9T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZV_KYCE;EO\ UU_KY'OZG<H/J,\U6?3;&348M0DLK=[Z)"D=RT2F1%/4!L9
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M?A_HTEE92R7$]PZR7-S*BAG8*!@8&0@.2%).-QY.: .LHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /$7CC5E'C"RA
MUI_[6O\ 6$T>PL%D(:VB7(,JJ#D;LXW =<<]*[3X71W&D:YXI\,#5+G4[#2Y
MH/(GN'WLK.A,B9Z<$=.QSZUSOB?QG\.=(^),MY+X8OM0UZSDV/=6\>4\Q5[*
M7 9E_O;<C'7@5UGPP\3:+XE_MJXT+0;S3[9[GSY[FY'-Q.Y)?D$CC XSQN'
M[E/X;^7^5OU?S">_S_K]$=U>65KJ%I):7MM#<VT@P\,T8=&'7E3P:/L=K]B^
MQ?9H?L@C\KR/+&S9C&W;TQCC%3T4 4=,T32=%21-*TRRL%D(+K:VZ1!B/7:!
MFFRZ%H\^IIJ<VE6,FH)C9=/;H95QTPY&1^=:%% !7C_[./\ R3S4/^PK)_Z*
MBKV"O'_V<?\ DGFH?]A63_T5%0![!1110 4444 %%%% !1110 4444 %%%%
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M444 %>/_ +./_)/-0_["LG_HJ*O8*\?_ &<?^2>:A_V%9/\ T5%0![!1110
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MJTYTFY=VM[F &.567:3W^8$!AP>E-\=?$K3?%VC0Z5#X/U2,/-&\EU+;#S(
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MP^T/P*;PZ,+D?:]GF^=+O^[G&../O&NJI%974,K!@>X.:=[!86BBBD 4444
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M5[?4DNM4OI+-2EE'?W7FQVBGJ(UP,<>N:[:BG?6X=+'G_P ;?^20Z[_V[_\
MI1'70>!/^2>>&O\ L%6O_HI:Y_XV_P#)(==_[=__ $HCKH/ G_)//#7_ &"K
M7_T4M(#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAA>%)98T>9]D2LP!=MI;"^IVJQP.P)[4 24444 %%%% !1110 4444 %%%%
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M#/Y>% /SL<G)!//3..U '845Y_\ \(E\0_\ HI__ )0+?_&C_A$OB'_T4_\
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MZW#I8\_^-O\ R2'7?^W?_P!*(ZZ#P)_R3SPU_P!@JU_]%+7/_&W_ ))#KO\
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M!P/I7!?%_P#Y*'\,?^PJ?_1MO7L%>/\ Q?\ ^2A_#'_L*G_T;;T7 ]@HHHH
M*P_&,VM6W@[59_#HC.K1V[/;AXR^2.3M4 [GVYVC!!;;GC-;E% 'SA^SSJWB
M"Y\6ZK;F:>YTR:)KF]::1B%G+#;)D@YD;Y@02NX DD[ *^CZ\_\ A9_S.O\
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MBTO[+_8'A?\ MSS-_G?Z?';>3C&W[X.[.6Z=-OO7/_\ "6_$/_HF'_E?M_\
M"@#T"OG#_A2^G?\ "Y/[ ^W_ /$L^R?VOY'DM_J?M&S[/NW[ON\>9G/M7I__
M  EOQ#_Z)A_Y7[?_  KC_P#A(O&7_"Y/MO\ P@G_ !,_^$?\K^S_ .UX?]3]
MHSYOF8V_>^7;U[T >X45Y_\ \);\0_\ HF'_ )7[?_"C_A+?B'_T3#_ROV_^
M% 'H%%<_X8U?Q%JGVK^W_"_]A^7L\G_3X[GSLYW?< VXPO7KN]JZ"@ HHHH
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MPW4C+#<%"8RX:4'&03P&'RG/8$^&7@?X=^-_"L5V?#%WY]JD=O=7,UU(JS7
M0&0H%E)QD@\A1\PQW  /=**\_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y
M.W'_ ,<H ] HHHH **** "N-^('C[2_!EE!!=64NI7M^3';V$2@F7L=V<X&2
M!T))/ /..RKPWXCZUIWA_P"//AG4]7=EL;:P+N0A?:29@" /?;2W:7<I;-]A
MEIX^_P"$6G75+WX.OHEF?]9>VMNJO&I..?W2]3@8++UKVK2]2M-9TNUU*PE$
MMK<QB6)P,94^W8^U>5^*?C/X&U;PGK&GP7TTD]S9311HUJX!9D('48ZXK?\
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M L5Y_P#\W"_]RI_[=T?\+3_ZD+QS_P""?_[.O/\ _A;FC_\ "Y/[7_L?7/\
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M,+BQU?2KO6O$USK%MHRE=,M7MUB6#C +$$ER !@G'3\*]#HHOK?^M Z6//\
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M$M\HY;?UXKU"PL;?3-.MK"SC\NUM8EAA3<3M10 HR>3@ =: +%%%% !1110
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MT'!/(. <<X% %R&>&Y0O!+'*@=D+(P8!E8JPX[A@01V((K@_%O\ R5[X=?\
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M47R>%&< =A0![O17R9XX\4QZ?<6;>#?B1XGU."1&%PEU=SJT3 C!#$("&!/
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M"LG_ **BH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\_^+'A'Q)XVT.UTC0[RQMK4RF6\^TRR(9-N-BC8I!7))((ZJA'2O0*
M* .3^'.AZ]X:\'6^C>(+JTN9[1V2"2VD=_W/!4,7 .02R@ 8"A1VKK*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ^H#2=%OM1,32BTMY)S&O5
M]JEL#ZXJY5'6Y;J#0=0ELH!/=I;2-#"1GS'"G:N.^3@5,W:+:*@KR29XN/\
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M47!$;*@9>.W)HCJ_FE]X2T7WO[CI?C;_ ,DAUW_MW_\ 2B.N@\"?\D\\-?\
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\
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M-*UF.<H#(D<<3JK8Y 8N"1GO@9]!4G_#1W@__H&ZY_WXA_\ CM 'L%%>/_\
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M,/\ HDVN?G-_\8H_X6_XP_Z)-KGYS?\ QB@#V"BO'_\ A;_C#_HDVN?G-_\
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M_P"B3:Y^<W_QB@#V"BO'_P#A;_C#_HDVN?G-_P#&*/\ A;_C#_HDVN?G-_\
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MB3:Y^<W_ ,8H ]@HKQ__ (6_XP_Z)-KGYS?_ !BC_A;_ (P_Z)-KGYS?_&*
M/8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YPNF^&A\=>*QXWN
M;BZO?[1<PS)YVP1X V83G<IRISQP,5Z5\+?^%?9U3_A!?,S^Z^U[_._VMG^L
M_P"!=*S-;\6^%+:+Q;?R^$;&<:/.MN+B6WC/VRZ8G<F=IZ'&3DGDG'KM?#36
MH]2&JV5SX9M- UBR>-;NWMD50ZLNZ-L@>F>,GZ\T4_AMY+] GO\ ,[ZBBB@
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MUS\YO_C%'_"W_&'_ $2;7/SF_P#C% 'L%%>/_P#"W_&'_1)M<_.;_P",4?\
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MFD"*OU)XJ#2M<TK7;=KC2=1M;Z)3M9[>57"GT..A^M %^BBB@ HHHH ****
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M,XN+G3(;HK:32==S1XZYYX(KOJ*.MPZ6$1%C1410JJ,!0, #TI:** "BBB@
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M7^)(?"/A:^UN:%IA;(-L2G&]B0JC/89(YK@O^%G>)/"NJV,/C_1;*TT[4?\
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M^)6E>(+/P?<>%[+2[>6*X^T0B$W+,NU45 !D#).[IV["A)WY7O\ \/\ ALK
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M  .N<D<>C525EY:_K_P_W=D2]7YJW]?I]Y1TC1M.T'38].TJTCM;2/)6*,<
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M1JPR^<<D@?=!!/!V@C%>ZCIS5;6DO^'V_KY$O6\7_P -_6Z]0HHHI#"BBB@
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M-9E9;R:^B_>VL@(WR%R/D0=L?CT(KZ&\/Z;)HWAW3=,FN#<26EM'"TQ_C*J
M3S]*=::%I5AJEYJ=I800WU[C[1.B8:3'3)_SFM"JNDK+^K$VU"BBBD,****
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M=112&E8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH%[94 #(]#BNVK1V3T_KJ_QZF>_]?=_PP4445)04444 %%%% !1110 4444
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MR!)#;_ZII1O9.,9#')S[]:L444#L%%%% !1110 4444 %%%% !1110 4444
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M*+DW%][?Y7[IO1AS)6DNU_Z\[:FEI.CVFM6]GXP^%P@TO6+7;;ZAI$AV1N.
M4D';IG/?&>&%>O6&AZ=8ZA=:I#IUM;ZC>A?M<L0R7('K@9'X#/4TMCH.E:=J
M5[J5G80P7E^0US*BX:0CIG_/)Y/-:-._]?UT$E_7]=0HHHI#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XF>)[[PIX1-
M[IWE)<37$=L+B9=T=N'.#(P[@?S(X/2N7C\9^)_ 6M6EMXUNX-6T'4& MM<M
MH5C$;'H'5>,8Y^G()P0/2]8TBQU[2+G2]2@$]G<ILD0]QZ@]B#@@]B*\CNO
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MC\Z71-!TKPWIJ:=H]E%:6JG(2//)]23RQX'))-:-%"T **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIX((!!R#T(J9PE#<UHUX5DW!["T45YMXJ^*D.GS266AQ)<SQDK)/(#Y:D'!
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M&+19WDLM:C7=$B?9Y2/X>25/T.2/R]:V6DH*6]CBFG*E6E#X;K_@G:27.E^
M/"ML)HW6WBVQ'RD!9W(Y)Z=<&LNW^)_AK4;N"T\NZS+(JJ981M#$\$\GO3M
M\7^'?$VA00:M+8BX15$UO>[=K.!]Y=W!]?:O/?%']ECXD6BZ0+06HE@&+0*$
MW;AG[O&:RA33;4EJ=E;$2A&,J37+HK'1_&G_ %.B_P"]-_[)5_0_B9X=L- T
MVSGDN1-;VL43@0DC<J ']15#XT_ZG1?]Z;_V2NG\.^%/#]SX8TF>;1[*262S
MA=W:$$LQ0$DT>[[*/,3:J\74]FULM_1'26NH6MW86]['*!#<1K)&7.TD$9'7
MZU.DT4A(CD1R.NU@:Y;Q/X#L?$HL5-Q):1V<9CC2%1M"\8&.V,4SPKX!M/">
MI37T-]-.TD)B*R*  "0<\?[M8VA:]]3MYZW/RN.G>_Z',?%O4)+R_P!+\/VW
MS2.PE91W9CM0?^A?F*R?B%H?_"+ZEHE_8#:(X4C#@?\ +2+&&/N1C\C5#&L>
M,?'U]J&B%?/A<RPR.0 B*0J'GC.,'\ZTO$OA[QY=:-++K-Q%<VEJ#.5#)D8!
MR1@ ]":ZXKEY5<\BI)U?:346[O1]-#U_3;Z+4],M;Z'_ %=Q$LB^V1G%>5>.
MY&\3_$73O#\3$Q0%8WQV+?,Y_!0/RK7^%_B*)?!U[#=/@:7ND/\ UR(+?S#?
MI7$>'++Q/X@UR^UO172.[60M)*S 8+YX&0>V:SIPY)2?8Z<17]K2IQ2OS;I>
M6YI^*H_^$-^)UMJ<";+:1DN JCC:?ED4?^/?G7M:.LB*Z,&5AD$="*\+\8:#
MXR_LU=1\031W$%J<!E924W$#L!QG%>D_#G5_[6\&VF]LS6N;:3_@/W?_ !TK
M2JQO!2O>VA6#GRUYPLTGJDSK****YCU HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N%\3^$/$WBG5Y(W\5R:3H2[1';:<A6:7Y?F+R9&/FSP,C&.,UW5<K\29M
M2M_AUKDND%Q>+;$JT>=P7(WD8[A=U3)V5RHZNW<X:W^!'A#[9)]C\2ZR+^(X
M=H[R+>C'GD!,CH>_:NS\)>&?$OAN_D@OO%,FM:0T1\M+N+$\3Y&/GR=PQG.?
M; KP);KP+96?BFWL=7O((@EG<Z1)"7$TETD3Y)../G<YZ 9X[5]-^'WOI/#>
MF/J8Q?M:1&Y&,?O-HW?KFM+65_ZU7]?@0]6OZ[?Y_F:5%%%2,**** "BBB@
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M]R1\Q3=W Y'3I7IO@_Q''XL\*V&MQPF#[2AWQ$YV.K%6&>XR#S6BORO^N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *S]>U!M(\/:EJ2*'>TM99U4]"54MC
M]*T*9+%'/"\,J!XW4JRL,A@>"#4R3::0XM)IL^?-(OOBMXAO)+>W\6V<=Q)I
MT.I11R01A)(I,\ ^6<$'@]O>O6?AG?W&I_#[2[ZZU&74+F=7>6>50K;M[97
M)&%/RC'8=!TKSC7M#^$-PUEHO_"4MI\]B9(4>VN,@([LQC9RI7 +-U.1GDFO
M7_#>C:;H'AVQTS2.;"&,>4V_=O!YW9'7)).1QS6BM9V_K?\ 2Q+3NC5HHHJ1
MA1110!Y_\;?^20Z[_P!N_P#Z41UT'@3_ ))YX:_[!5K_ .BEKG_C;_R2'7?^
MW?\ ]*(ZZ#P)_P D\\-?]@JU_P#12T =!1110 5GZYK-GX>T.]U>_?9:VD32
MO@@%L=%7) +$X &>20*\,^/7BOQ?HOB6TL+&_N].TF2W66%[21D,T@+!\N%!
M!&X H&(QL8\G ]+T.QN/B!\([*V\7Q_OM3M%:9H&"$C=NBE&,@,0$?'3)P5
M^6@ \$?%7P_X]U&YL-,BOH+J"+SBEW$J[TR 2"K,."5ZX^\,9YQW%>7_  [^
M#-GX$UR75YM4_M.Z\HQ6^;41"'/WF&68[B. 01@%ASGCU"@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *SM?TNPUO0+[3=4Q]BN(669MVW:O7=GMC&<^U:-<?\
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M>:G]K_VAY^WR_+;;YW^ULSY>_C=M[4 ?4]%%% !1110 4444 %%%% !1110
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M -*(ZZ#P)_R3SPU_V"K7_P!%+0!T%%%% !1110 4444 %%%% !1110 4444
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M;9UC^Q3?;.<=?,QTW;>/UZUT&E/J?@GXI:9X9E\0:EK&G:O9O(/[2E\V2*9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>'I##=P6[YCE8\(4)Y 8\<YQ5;2O'GBNRUG08O%FEZ7#8>(/ELY+%W,D#D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^20Z[_V[_\ I1'70>!/^2>>&O\ L%6O_HI: .@HHHH **** "BBB@ HHHH
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M0QR$C#L1U4?E7T/2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZWJ(U&_AWA[KG]X-QVYSSG;@?AU-5%KDT[_\#\"9?%KV-FBBBD,**** //\
MXV_\DAUW_MW_ /2B.N@\"?\ )//#7_8*M?\ T4M<_P#&W_DD.N_]N_\ Z41U
MT'@3_DGGAK_L%6O_ **6@#H***KW]];Z9IUS?WDGEVMK$\TS[2=J*"6.!R<
M'I0!8HKS_P#X7;\//^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !N@#T"BO/\
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M!M+AD;@X7;SN9B5SPS8H ^BZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#V%8__ $5+7L%>/_M'?\D\T_\ ["L?_HJ6O8* "BBL_6_[8_L>?^P/L/\
M:?R^3]OW^3]X;MVSYON[L8[XH T*\'\5^%-4\8^)?B7IND7/EW22Z5/Y);:M
MT%MW_=$YP,DAAGC<JYQ]X<YXM^+WQ(\/>,9=.O9M-M);%U66UM8 \$X^^&+-
ME\,K#HRD#'"G-=WX?T;XIQZGJ/BB%/"D-UK\5M+<6UV+I3#Y<>U5V@95L'Y@
M2>10 ? [P!XB\'?VQ<Z[']C^U>7'':++')NV[CO8KG&-V!AN[9'W37L%>?\
M_%W_ /J1O_)NO0* "BBB@ HHKE_$G@O_ (2/48[S_A)O$>E[(A%Y.F7_ )$;
M8).XKM.6YQGT ]* .@O[7[=IUS9_:)[?SXGB\ZW?9)'N!&Y&[,,Y![&N'_X5
M9_U/OCG_ ,''_P!A7/\ B?0O#O@[[+_;_P 3?'-G]JW^3_Q,9)-VW&[[D1QC
M<O7UH\,:%X=\8_:O[ ^)OCF\^R[/._XF,D>W=G;]^(9SM;IZ4 <Q_P *4\-_
M\+3_ .$7^VZK]A_L3^T/,\V/S/,\_P O&?+QMQVQG/>O1_\ A5G_ %/OCG_P
M<?\ V%<?_P (!_Q>3^R/^$M\5_\ (O\ VK[;_:7^D_\ 'QM\O?M_U??;CKS6
MYJ7A#0=&N%M]4^*_B>QG9 ZQW7B)(F*Y(R R@XR",^QH ]0@A6VMXH$,A2-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHKRO4OCQH.C7"V^J>'?$]C.R!UCNK)(F*Y(R T@.,@C/L:
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M6RU3P/J6A0)>I*MS=%]KL$<;!NC49(8GK_">*^FZ\?\ VCO^2>:?_P!A6/\
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MR_C@CNKKS=Z0*0@VRN@P"2>BCO6IK7AO1?$20IK&EVE\('#Q>?$&*'<K<'J
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M#_\ !C#_ /%4?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P /\R7>Z_K^NQU=%%%2,**** //_C;_ ,DAUW_MW_\ 2B.N@\"?\D\\-?\
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MUC5/%&K:K-Y,KZ?#:W5X\J;T;]Z^#E3AE"!E)Z2"O8* "BBB@ HHHH ****
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MJR9FM;&A1114E!1110!X_P#M'?\ )/-/_P"PK'_Z*EKV"O'_ -H[_DGFG_\
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M)J%Y=.8?/EU.W@,:(Q!50P+8+#).<, A P 3]!T4 >/ZO/\ $/5/%_AS7_\
MA7?E?V-]I_<?VU;MYWG1A/O<;<8ST.?:H_'.H_$W7O#4D%GX,U+19X'%P+G3
M]>B9R%!RI1 &<$$_*#G(7KC!S_'NM_$W2?B;:Z#H>LR?8]7=6L"]E$ZQ@G#J
MS>5G"'+'[Q"%2237N$$;0V\43S23NB!6ED"AG('WCM &3UX 'H!0!Y?\"%UJ
M[\'7.M:WJFI7KWUP5MOM=V9E$4?R[E!)*DN7!SUV+QW/JE1P00VMO%;V\4<,
M$2!(XXU"JB@8  '  '&*DH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J6LM>IH=^VF@&_%M(;8$9!D
MVG;^N*NUE^)21X6U<BZ%H193?Z00?W7R'Y^.>.O'I45/A94/B1XKX?\ #+Z_
MH\&HWWQ>U"&^F4/<6PO=AMW/6-E,F00>.@Z=*]C\(Z>NE^&;2S769=9$>_\
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MCG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H ]@KG_P#A!O"W_"0_V_\
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MX3[1]QNI[?2MC_A(?CG_ -"9H?\ W^7_ .2* /8**\?_ .$A^.?_ $)FA_\
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M^A,T/_O\O_R10![!17C_ /PD/QS_ .A,T/\ [_+_ /)%'_"0_'/_ *$S0_\
MO\O_ ,D4 >P45X__ ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)%
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M >P45X__ ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)% 'L%%>/\
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MLY Y=>N.M;'_  D/QS_Z$S0_^_R__)% 'L%%>/\ _"0_'/\ Z$S0_P#O\O\
M\D4?\)#\<_\ H3-#_P"_R_\ R10![!17C_\ PD/QS_Z$S0_^_P O_P D5ZII
M,E]-HUC+JD,<&H/;QM=11G*I*5&]1R> V1U/U- %RBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFJ3VEKI%[<
M7ZJ]G% [SJRA@4"DL"#UXSQ5NJFJ:?%JVD7NG3,RQ7<#P.5Z@,I4X_.IE>SL
M.-KJYX_J'BK2GT/0)-&^'>F3ZSK9ED@T^6WCR($)^<G:/O* 0/KR<<^E^"-6
ML-<\':=J6F6,=C;3QEOLL2@+$^XAU& !PP/.!FO//#'PY\2:+JEUJ6I^(=/N
MK^QTM].T8(<"(8(1G!48QZ?-U/)QSZ#X$T2#P[X,T[28+N*[^SJPDGB;<K2%
MB7Q_P(D?A6FFMOZW_2Q.NG]?UV7DCHJ***D8R6*.>%X9HUDBD4JZ.,JP/!!!
MZBN<T+X>>$_#.IR:CI&C0VUVX(\W>[E0>NW<2%_#%=-11L[ATL%%%% !1110
M 5Q^G>!?L'Q0U;QI_:/F?VA:+;?8_(QY>!$-V_=S_JNFT?>]N=+Q3XMT[PG9
MP37B7%Q/<R>5;6EI'YDT[^B+W_SZBL[PE\1-+\67]UIBVM]INK6HW2V.H0^7
M*%X^8#/3D>AYZ4+78'IN=?1110 4444 %%%% !117G/C+7O$=UXWLO!WAO4[
M32+F6R:]:\N8A(9,$@1HI!'8D\=![<G6P_,UM1\"_;_BAI/C3^T?+_L^T:V^
MQ^1GS,B4;M^[C_6]-I^[[\=A7F'@+XD7M]XBNO!_BM((=>M79(YX>([K;UQZ
M-CGC@C/ QBO3Z.B?<75KL%%%% !1110 4444 %<?XP\"_P#"5^(?#&K?VC]E
M_L.[^T^5Y&_S_GC;;G<-O^KQG!Z^U5/B%XCU?3]1T#P_HEW;:?>ZU,Z"_N4#
MK"$ . IX+,2 ,_3OD8/AWXB:SH?C5O!?CF6VENG*K::G H1)2PRH<# !.<#
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M5&W1114C"BBB@ HHHH 0G )/:N&D^+'AR30GU+3?M6HS"Z^QQV%O"?M#R\X
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M *^5V2]7_6O]?C;L%%%%(84444 %%%>3:]XIU#QIXSN?!VA:JVAV.FJ9=5U
MOY4[!3RD0." .[_CTQN7D.W4TOBWK-[ID&@VRZI<Z1I-]?>3J&HVIQ)"N,J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[HD%EX\M;#4[G3+K=8W1.]I%7[KL".#_ #QR,\GMZ**IML25@HHHI#"BBB@
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M)) 0-_>X_P GBCK8'HKF1KWQ:\.>']9GTZXAU*<6KJEY=VUMO@M6;H';/7Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME(P01D$4M% %+3M'TO2$D73--L[)96W2"V@6,.?4[0,FKM%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img108642122_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  \$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+--- N>7<UO^$ANO^>4/Y'_&D_X2*[_YY0_D?\:R:BGFBMXFEGE2*-1EG=@
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MX6WY-_C2'QC?_P#/"V_)O\:Y\TTTQ>TGW.A_X3/4/^>%M^3?XTG_  FFH?\
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M_P ^UG_WRW_Q5<L>M-- O:S[G5?\+ U3_GVL_P#OEO\ XJD_X6#JG_/K9_\
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M[_GZM_R;_"D_X0:^_P"?JW_)O\*[NB@7L('!GP-?_P#/U;?DW^%)_P (+?\
M_/W;?DW^%=[10'L(' GP)?\ _/W;?DW^%)_P@>H?\_=M^3?X5W]% >P@>?\
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M** "BBB@ HHHH **** "BBB@ KA/&^MZB()+2TM;F*T'RS7)C8!O8''3^?\
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M **** "BBB@ HHHH **** "BBB@#Q'Q%_P C'J/_ %\R?^A&N[^&W_(#NO\
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MO^0Q=?\ 7 _^A+3.#_F(/3****1WA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &?KO_( U#_KWD_\ 037A_P#'^->X:[_R -0_Z]Y/_037
MA_\ '^-!PXOXD>ZZ5_R![+_KWC_]!%6ZJ:5_R![+_KWC_P#015N@[8[!1110
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3X!_YYFO=*I6&KZ;JAD&GZA:W9C.'$$JOM/O@\5=H,Z5+V=]0HHHH-@HHHH
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MCDSP2RF5"I!7=(Y7.1W'-=Q1128T%%%% !1110 4444 %%%% !1110 4444
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M)H=S.77+)G(XSWZ\CUK3/B/79?$(M7E2RAO8,:<#;"1))/*W89PV58-_"1C
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M!MC=)4+<KGAE..AHL%STFBO-)?%?B1=-O DD4HTW49;>\O;>W#OY**&WB(L
M<$X;!X J2_\ &FJ0W<NFVT\$MWJ(M)-(E$)VO')PY(_V<$\^M%@N>CT4@R ,
MG)]:6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:"=2D$WG37]V]U*^P)C=T4#T'^-;5%%24%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0W=I;W]I):W4*302KM>-QD,/0UGVOA?0K*TN+2V
MTJUB@N5VS(L8'F#T/J*UJYGQ_>W>G^#KNXL;E[:X\R)%E3JNZ10<?@330F:5
MSX;T2\NX+JYTNTEG@4+'(\0)4#H/PJA;^#-,77[_ %>[AAO)[F=)XO-A&8"J
MA>#WZ9KB-6\6:PWA1-,@O7CUNS-U]OG3 8);J3N_X'F/\S4>O^([Z#4;L/K&
MJ6[Q:7;2VJVR@QM.X_Y:$J0 3CJ1WIV8KH].M]"TJSU&;4;;3[>*]FSYDZQ@
M,V>O/O5;PSX?B\-Z2;))?.=YGGEEV!-S,<]!TP,#\*R=%U'5)?&]Q8W\^0FD
MV\LD*D;%F)(<BNOI#04444AA1110 4444 %%%% !1110 4444 %%%% !1110
M 5D3^%M!N=3.I3Z3:2WA8,9GC!)(& 3^5:]% %";0]+N!>":PMY!>[?M(= ?
M-VC"[O7 Z5E:EX+TN\L-/L+>&"TL[6\2[:!(05EP""K#WSUYKE+'Q9?:5XOU
M>;5;YY-':YNK:)'QB%XE$B@?52P^HK*/B'Q%%X9\03W>I7*7(DL94V8W0+,=
MQ1>/[I _"JLR;H],?PIH$EA#8/I%F;6%B\<7E#:K'J?QIESX;@NO$VF:PSJJ
MZ= \4$"Q@ %L#.?0 8 Q7 SZ_JL7ASQ)/8:K?265K<VT5I/=@+<*Y=?-5A@'
M'(^\!U->L#H*3T&K,6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M]S'_ &EY/VA8G 4M$058<<'C!]JZ*BBD,**** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img108642122_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y \\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'R*/*E_Y[M_WR*EHH B\J7_ )[M_P!\BCRI?^>[?]\BI:* (O*E_P">[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK]X?6J,SZ1L?^/"V_P"N2_R%3U!8_P#'A;?]<E_D*GKS6?6QV"BBB@84444
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MA;?]<E_D*GKS6?6QV"BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'S]XK_Y&O5/^OF3_P!"-8];'BO_ )&O5/\
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M+>E?\A:S_P"NR?SKW:O"=*_Y"UG_ -=D_G7NU([<)LPHHHH.P**** "BBB@
MHHHH **** "BBB@#Y_\ %G_(V:I_U\O_ .A&L:MGQ9_R-FJ?]?+_ /H1K&KT
M([(^5J_'+U84J_>'UI*5?O#ZU1F?2-C_ ,>%M_UR7^0KQ'5O^0Q>_P#7=_YF
MO;K'_CPMO^N2_P A7B.K?\AB]_Z[O_,UYQ]#B?AB4Z***#C+VC?\AS3_ /KY
MC_\ 0A7N=>&:-_R'-/\ ^OF/_P!"%>YTCNPFS"BBB@ZPHHHH **** "BBB@
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M_P#H0KW.O#-&_P"0YI__ %\Q_P#H0KW.D=V$V84444'6%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYD_WC7O@Z"O [G_CYD_WC7FGT.+Z$5%%%,XBWI7_ "%K/_KLG\Z]VKPG2O\
MD+6?_79/YU[M2.W";,****#L"BBB@ HHHH **** "BBB@ HHHH ^?_%G_(V:
MI_U\O_Z$:QJV?%G_ "-FJ?\ 7R__ *$:QJ]".R/E:OQR]6%*OWA]:2E7[P^M
M49GTC8_\>%M_UR7^0KQ'5O\ D,7O_7=_YFO;K'_CPMO^N2_R%>(ZM_R&+W_K
MN_\ ,UYQ]#B?AB4Z***#C+VC?\AS3_\ KYC_ /0A7N=>&:-_R'-/_P"OF/\
M]"%>YTCNPFS"BBB@ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y^\5_\C7JG_7S)_P"A
M&L>MCQ7_ ,C7JG_7S)_Z$:QZ]".R/E:OQR]6%3V7_']!_P!=!_.H*GLO^/Z#
M_KH/YTR%N?25%%%><?6A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <YXTC\S2K42AC9_;8?M0&?]5GG\,XK U.P\.:/K6HPZG8PPVES:HULZQ<
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MO<Z\,T;_ )#FG_\ 7S'_ .A"O<Z1W839A1110=84444 %%%% !1110 4444
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MS)_O&O?!T%>!W/\ Q\R?[QKS3Z'%]"*BBBF<1;TK_D+6?_79/YU[M7A.E?\
M(6L_^NR?SKW:D=N$V84444'8%%%% !1110 4444 %%%% !1110!\_P#BS_D;
M-4_Z^7_]"-8U;/BS_D;-4_Z^7_\ 0C6-7H1V1\K5^.7JPI5^\/K24J_>'UJC
M,^D;'_CPMO\ KDO\A7B.K?\ (8O?^N[_ ,S7MUC_ ,>%M_UR7^0KQ'5O^0Q>
M_P#7=_YFO./H<3\,2G1110<9>T;_ )#FG_\ 7S'_ .A"O<Z\,T;_ )#FG_\
M7S'_ .A"O<Z1W839A1110=84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_>*_^1KU3_KY
MD_\ 0C6/6QXK_P"1KU3_ *^9/_0C6/7H1V1\K5^.7JPJ>R_X_H/^N@_G4%3V
M7_']!_UT'\Z9"W/I*BBBO./K0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .>U+2= L=+^RW=L3;7-V&$89B7F;@8P<UAZQI/@O1KF.WGTJ669D\
MPQP%W*)_>/S<"NIU[2Y=4LXA;3+#=6\R3P.XRN]>Q'IUK-TBQF@EU&\NKVSN
M]9NDV[(WPB #Y5'<#/6M8O2]SCJ4TY<JBO6R-K25LDTJV&G8^Q[ 8L$GY3SW
MYJY6;X?TU](T&SL)7#20IAB.F223C\ZTJS>YU0ORJZL%9&JZT^EW=G";)Y([
MF=(?-W@ %O;J>E:]<SXJ%U/<:;';Z?=3BVNH[EWC4%=HSD#GK3BKO4).RT.F
MHID4AEA20H\990=CC#+['WIYY%24%%1&%B<^=(/RH\EO^>TGZ?X4 2T5%Y+?
M\]I/T_PH\EO^>TGZ?X4 >$^,_P#D;]3_ .NQK!K<\8C'B[4QDG]\>M8=>A'X
M4?+5?XDO5A3XO]:GUIE.C_UJ_6J,SZ7'05X'<_\ 'S)_O&O=Q"W'[Z3]*\'N
M.+F3G/S&O./H<7T(Z***#B+>E?\ (6L_^NR?SKW:O"=,&=5M!DC]\G(^HKW'
MR6_Y[2?I0=N$V9+147DM_P ]I/T_PH\EO^>TGZ?X4CL):*B\EO\ GM)^G^%'
MDM_SVD_3_"@"6BHO);_GM)^G^%'DM_SVD_3_  H EHJ+R6_Y[2?I_A1Y+?\
M/:3]/\* ):*B\EO^>TGZ?X4>2W_/:3]/\* ):*B\EO\ GM)^G^%'DM_SVD_3
M_"@#P3Q9_P C9JG_ %\O_P"A&L:MCQ4,>*]4&2?])?K]36/7H1V1\K5^.7JP
MI5^\/K24HY([51F?2-C_ ,>%M_UR7^0KQ'5O^0Q>_P#7=_YFO:;*(_8;8^;)
M_JE]/05XKJ@QJ]X,D_OWY/\ O&O./H<3\,2I1110<9>T;_D.:?\ ]?,?_H0K
MW.O"]'&=;L!DC_28^1_O"O;_ "6_Y[2?I0=V$V9+147DM_SVD_3_  H\EO\
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M5^.7JPI5^\/K24J_>'UJC,^D;'_CPMO^N2_R%>(ZM_R&+W_KN_\ ,U[=8_\
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MK"KT(_"CY:K_ !)>K"GQ?ZU/K3*?%_K4^M49GTMVHH[45YI]:%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\_>*_P#D:]4_Z^9/_0C6/6QXK_Y&
MO5/^OF3_ -"-8]>A'9'RM7XY>K"I[+_C^@_ZZ#^=05/9?\?T'_70?SID+<^D
MJ***\X^M"BBB@ K \;_\B/K7_7G)_*M^L#QO_P B/K7_ %YR?RJH?$AK<^6Z
M***]DZPKM?A/_P E$T__ '9?_1;5Q5=K\)_^2B:?_NR_^BVK.K\#]"9;,^CJ
M***\@Y0HHHH **** "BBFNZQHSL<*HR3Z"@#.U^ST^\TF1-4E,5HIW.PD*>W
M)_'I7"P_\($TBPK>WL:YVJS/(J?GCBKWBKQ5H.I:9$L%\D_DW$<SVY1AYRJ>
M5R1CI5S4?&WA:319D#I.&B(6V\DC)(X'(P*VBI)=3SZLZ4YMWCHNNM_Q.JL+
M6&SL(;>V8M"BX0LVXD=>O>K-8WA2/RO"NG)YZS8A'SKT^@^G3\*V:R>YVTW>
M"84444BPHHHH **** "BBB@#P3QG_P C?J?_ %V-8-;WC/\ Y&_4_P#KL:P:
M]"/PH^6J_P 27JPI\7^M3ZTRGQ?ZU/K5&9]+#H*\#N?^/F3_ 'C7O@Z"O [G
M_CYD_P!XUYI]#B^A%1113.(MZ5_R%K/_ *[)_.O=J\)TK_D+6?\ UV3^=>[4
MCMPFS"BBB@[ HHHH **** "BBB@ HHHH **** /G_P 6?\C9JG_7R_\ Z$:Q
MJV?%G_(V:I_U\O\ ^A&L:O0CLCY6K\<O5A2K]X?6DI5^\/K5&9](V/\ QX6W
M_7)?Y"O$=6_Y#%[_ -=W_F:]NL?^/"V_ZY+_ "%>(ZM_R&+W_KN_\S7G'T.)
M^&)3HHHH.,O:-_R'-/\ ^OF/_P!"%>YUX9HW_(<T_P#Z^8__ $(5[G2.[";,
M****#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP>__P"0A<?]=&_G
M7O%>#W__ "$+C_KHW\Z#CQ>R*U%%%,XC3\/?\C'IW_7S'_Z$*]NKQ'P]_P C
M'IW_ %\Q_P#H0KVZD=V$^%A1110=84444 %%%% !1110 4444 %%%% '@?C/
M_D;]3_Z[&L*MWQG_ ,C?J?\ UV-85>A'X4?+5?XDO5A3XO\ 6I]:93XO]:GU
MJC,^ENU%':BO-/K0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G
M[Q7_ ,C7JG_7S)_Z$:QZV/%?_(UZI_U\R?\ H1K'KT([(^5J_'+U85/9?\?T
M'_70?SJ"I[+_ (_H/^N@_G3(6Y])4445YQ]:%%%% !6!XW_Y$?6O^O.3^5;]
M8'C?_D1]:_Z\Y/Y54/B0UN?+=%%%>R=85VOPG_Y*)I_^[+_Z+:N*KM?A/_R4
M33_]V7_T6U9U?@?H3+9GT=1117D'*%%%% !1110 4=:** ,!K^==/EN!X=D:
M5)S$L V[F7^_TZ52_MN__P"A.N?S3_"K/A;4GN+;43>789TU":-/,<9501@#
MVI_A75&O-#6:\NU>8S2C+, <!R!^E:;7T.1/FM:5KKR-BPE>>QAEDM6M79<F
M%L93VXJQ2*P90RD$'H0:6LSJ6P4444#"BBB@ HHHH **** /!/&?_(WZG_UV
M-8-;WC/_ )&_4_\ KL:P:]"/PH^6J_Q)>K"GQ?ZU/K3*?%_K4^M49GTL.@KP
M.Y_X^9/]XU[X.@KP.Y_X^9/]XUYI]#B^A%1113.(MZ5_R%K/_KLG\Z]VKPG2
MO^0M9_\ 79/YU[M2.W";,****#L"BBB@ HHHH **** "BBB@ HHHH ^?_%G_
M "-FJ?\ 7R__ *$:QJV?%G_(V:I_U\O_ .A&L:O0CLCY6K\<O5A2K]X?6DI5
M^\/K5&9](V/_ !X6W_7)?Y"O$=6_Y#%[_P!=W_F:]NL?^/"V_P"N2_R%>(ZM
M_P AB]_Z[O\ S-><?0XGX8E.BBB@XR]HW_(<T_\ Z^8__0A7N=>&:-_R'-/_
M .OF/_T(5[G2.[";,****#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KP>_P#^0A<?]=&_G7O%>#W_ /R$+C_KHW\Z#CQ>R*U%%%,XC3\/?\C'IW_7
MS'_Z$*]NKQ'P]_R,>G?]?,?_ *$*]NI'=A/A84444'6%%%% !1110 4444 %
M%%% !1110!X'XS_Y&_4_^NQK"K=\9_\ (WZG_P!=C6%7H1^%'RU7^)+U84^+
M_6I]:93XO]:GUJC,^ENU%':BO-/K0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /G[Q7_P C7JG_ %\R?^A&L>MCQ7_R->J?]?,G_H1K'KT([(^5
MJ_'+U85/9?\ ']!_UT'\Z@J>R_X_H/\ KH/YTR%N?25%%%><?6A1110 5@>-
M_P#D1]:_Z\Y/Y5OU@>-_^1'UK_KSD_E50^)#6Y\MT445[)UA7:_"?_DHFG_[
MLO\ Z+:N*KM?A/\ \E$T_P#W9?\ T6U9U?@?H3+9GT=1117D'*%%%% !1110
M 4444 <[<>!O#UU<R7$MCF21B[$2,,D\GO47_"O_  U_SX'_ +^O_C73T57/
M+N8_5Z3^RON(+*S@T^SBM+9-D,2[47).!^-3T45)JDDK(****!A1110 4444
M %%%% '@GC/_ )&_4_\ KL:P:WO&?_(WZG_UV-8->A'X4?+5?XDO5A3XO]:G
MUIE/B_UJ?6J,SZ6'05X'<_\ 'S)_O&O?!T%>!W/_ !\R?[QKS3Z'%]"*BBBF
M<1;TK_D+6?\ UV3^=>[5X3I7_(6L_P#KLG\Z]VI';A-F%%%%!V!1110 4444
M %%%% !1110 4444 ?/_ (L_Y&S5/^OE_P#T(UC5L^+/^1LU3_KY?_T(UC5Z
M$=D?*U?CEZL*5?O#ZTE*OWA]:HS/I&Q_X\+;_KDO\A7B.K?\AB]_Z[O_ #->
MW6/_ !X6W_7)?Y"O$=6_Y#%[_P!=W_F:\X^AQ/PQ*=%%%!QE[1O^0YI__7S'
M_P"A"O<Z\,T;_D.:?_U\Q_\ H0KW.D=V$V84444'6%%%% !1110 4444 %%%
M% !1110 4444 %%%% !7@]__ ,A"X_ZZ-_.O>*\'O_\ D(7'_71OYT''B]D5
MJ***9Q&GX>_Y&/3O^OF/_P!"%>W5XCX>_P"1CT[_ *^8_P#T(5[=2.["?"PH
MHHH.L**** "BBB@ HHHH **** "BBB@#P/QG_P C?J?_ %V-85;OC/\ Y&_4
M_P#KL:PJ]"/PH^6J_P 27JPI\7^M3ZTRGQ?ZU/K5&9]+=J*.U%>:?6A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?/WBO\ Y&O5/^OF3_T(UCUL
M>*_^1KU3_KYD_P#0C6/7H1V1\K5^.7JPJ>R_X_H/^N@_G4%3V7_']!_UT'\Z
M9"W/I*BBBO./K0HHHH *P/&__(CZU_UYR?RK?K \;_\ (CZU_P!><G\JJ'Q(
M:W/ENBBBO9.L*[7X3_\ )1-/_P!V7_T6U<57:_"?_DHFG_[LO_HMJSJ_ _0F
M6S/HZBBBO(.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\$\9_P#(WZG_ -=C6#6]XS_Y&_4_^NQK!KT(_"CY:K_$EZL*?%_K4^M,I\7^
MM3ZU1F?2PZ"O [G_ (^9/]XU[X.@KP.Y_P"/F3_>->:?0XOH14444SB+>E?\
MA:S_ .NR?SKW:O"=*_Y"UG_UV3^=>[4CMPFS"BBB@[ HHHH **** "BBB@ H
MHHH **** /G_ ,6?\C9JG_7R_P#Z$:QJV?%G_(V:I_U\O_Z$:QJ]".R/E:OQ
MR]6%*OWA]:2E7[P^M49GTC8_\>%M_P!<E_D*\1U;_D,7O_7=_P"9KVZQ_P"/
M"V_ZY+_(5XCJW_(8O?\ KN_\S7G'T.)^&)3HHHH.,O:-_P AS3_^OF/_ -"%
M>YUX9HW_ "'-/_Z^8_\ T(5[G2.[";,****#K"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KP>__ .0A<?\ 71OYU[Q7@]__ ,A"X_ZZ-_.@X\7LBM11
M13.(T_#W_(QZ=_U\Q_\ H0KVZO$?#W_(QZ=_U\Q_^A"O;J1W83X6%%%%!UA1
M110 4444 %%%% !1110 4444 >!^,_\ D;]3_P"NQK"K=\9_\C?J?_78UA5Z
M$?A1\M5_B2]6%/B_UJ?6F4^+_6I]:HS/I;M11VHKS3ZT**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Y^\5_\C7JG_7S)_Z$:QZV/%?_ "->J?\
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M444 %%%% !1110 4444 %%%% 'S]XK_Y&O5/^OF3_P!"-8];'BO_ )&O5/\
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M7E3[KV3L/H5K"=-1FFNIZF!Q#JIJ6Z/EVBBBO3/8"NU^$_\ R433_P#=E_\
M1;5Q5=K\)_\ DHFG_P"[+_Z+:LZOP/T)ELSZ.HHHKR#E"BBB@ HHHH ****
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M $(5[=7B/A[_ )&/3O\ KYC_ /0A7MU([L)\+"BBB@ZPHHHH **** "BBB@
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MMK))'.I^1XF(8'IP16[IZOS.%8FRBK;-7\[;%N^@DN?$=U!$NZ22[=%'J2Y
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MQO\ GDWZ5F^(;&?6/#NH:="H26Y@:)6?H"1WQ6M123L[FAX-_P *4\0?\_\
M8?\ C_\ A1_PI3Q!_P _]A_X_P#X5[S16_UJH7[21X-_PI3Q!_S_ -A_X_\
MX5T'@KX9:QX:\4VNJW5S:2PPAP4BW;CN0KW'O7K-%)XF;5F#G)D?F-_SR;]*
M/,;_ )Y-^E245@01^8W_ #R;]*!(Q/\ JV%244 %%%% !1110 4444 %%%%
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M.&22@(!W9]*] TN;S]*M9?(, :)2(C_ ,=*)126@XR;>H:I?II>FS7KH76(
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M+WN_,C("#@+C@GIG-=4!@8%3*UE8<;W=PHHHJ2PHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #6C1R"Z*Q'3(SBG444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E/CSX8RWEU+JN@HID
MD.Z:USC)[LGU]*\FN[&[L)C#=VTL$@."LB%3^M?5]1RP13@"6)) .SJ#71#$
M.*L]3SZ^7PJ2YHNQ\I6]I<WDHBMH)9I#T2-"Q_(5ZGX'^%TZW46I^((PBQG=
M':'DL>Q?T'M^=>M16\,&?*ACCS_<4"I*)XAM66@J.70@^:;N%%%%<YZ(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img108642122_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (O!+$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<Y_2M*@ HK(E\5^'+>Z-K-K^E1W .#$]Y&'_ ")S6J9$$?F%U"8W;L\8]<T
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MCQ5X=M+PV=SKVEPW2G:89+R-7!]-I.<T"->BD!# $$$'D$4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+3=6O(V;R4.5B99-T>>3U"KGZGZ5Y]X5\2>/OA_HZ^';KP'?:G%;.X@EMP^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "O'_#W_)T/BS_ +!4?_H-K7L%>/\ A[_DZ'Q9_P!@J/\ ]!M: /8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6J "O'_#W_)T/BS_ +!4?_H-K7L%>/\ A[_DZ'Q9_P!@J/\ ]!M: /8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHJGJ6JV6DV_GWMPL2=@>K'T ZFDVDKL<8N3LEJ7*I-J^GKJ"V
M!O(OM;=(MW/T]C[5P]WXHUKQ-<-8Z#;R0P]&D'#8]2W11].?>MKP[X)M](F2
M]NY?M-Z.01]Q#[>I]S^58*LYRM36G<[)86-*-ZTK/HEO\SJZ***Z#B"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %'09-%9^O07%UX=U.WM"1<RVDJ18_OE"!^N* /--;_:#\,:7J
M4EG:6E[J*Q/L>>+:L9P<':2<M]< &NWU;QOI>B^)='T.]CN4GU8?Z-,$!BW9
MQM)SD')'8]17S<=8\,Q_!&?0_(BM_$\=X#.)("))!YA.0V.RX&,\8/'-=KXQ
M\5:7X[^(?@33/#DS7CV-XLLTZ(P"Y:,G&0,X$9)/3I[T ?0%%%% !1110 44
M44 %%%% !1110 5X_P"'O^3H?%G_ &"H_P#T&UKV"O'_  ]_R=#XL_[!4?\
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M3S)%$Z_>4N2!QCG'%=%X<\1Z9XKT6'5M(N/.M9<CD;61AU5@>A'_ -<9!!H
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MY_U\SDAGP%\02#E=+O?3H$8_^RG]/K7JW6O)O&OB6P\26*6]K93>;$^Z.9R
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M<CO+*?\ V7%:0IS7PP2]=3"I7I2_B592]%8I7/Q(TN/(M[:YF/J0%'\\_I5
M^/M7O3C3=%W>G#R_^@@5V=MH>E6F#!IUJA'\0B&?SZU?  & , 5I[.L]YV]$
M8>VPT?AIW]6>>^=X^U'[L9MD/^RB8_/YJ3_A"_$5_P#\A'6OE/\ "97DQ^'
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MG@*]U+5]5_MR^60+;R2P);@LV JD)Q@'))ZXS7):EXE\3:'H[Z^WQ$\/:E/
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M@W6I@?[,46?U)_I7-:YH%KX2\56ANDDN-)GP3DD$CHPXQR,Y_*O9V957<Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7B.H?LYV=]J5U=_\)).GGS/+M^R@[=Q)QG=SUKVZJ.LWS:9H6H7Z)O>UMI)
ME7&=Q52<?I0!X?<?L[:1:,JW/C$PEN%$ENBY^F7K7T']GVTT/Q!IVK#Q%/,;
M*YCN!']F"[RC!@,[N.E>6ZIX2N=5^&<OQ&U369;J_NKK:(2,X'F%#DYXY!(
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M63OY+1??NSA(/#/B/7D0:A,+&S_AAVA0![1K@#\<&NHTKP7H^E[7\C[3,/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$,)%"@51Z\"K5 !7C_A[_DZ'Q9_V"H__ $&UKV"O'_#W_)T/BS_L%1_^@VM
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MXCZL?E%;FF> ]'L,/.C7DH[S?=_[Y''YYK3N]>T724\N:]MXMG'E1_,5_P"
MKR*ZE3FE[S45Y?YGGNM3<O<BZDN[_P CE;7P!>7TPN==U)W<]41BS?3<>GX
MUUVEZ'IVCH5LK98V(PSGEF^I/-<O??$JSCRMC92S'^]*0@_3)/Z5S.H>,-<U
MK_14;RTD^7RK9""WMGDU'M</2^'5FCP^,Q'\1\L?N_#_ #.P\1^.;;3-]KI^
MVYNQP6ZI&??U/M7FMU?W%]=M=7DC3S-U+GC_ /5[5T&F> =7OMKW"K9Q'O+R
MV/\ =']<5T'_  C_ (5\-*)-4N!<3@9"2G.?H@[?7-93C6K>]+1>9TTIX;#>
MY3]Z7EJSAH+75=<E5((9KDI\JA5^1!Z>BC\JZ2S^'TD<7VC6;^&SA'+*K D?
M5CP/UJU<^.KB?_1/#VF^6JCAF3)4>H4<#\<UB3Q+=S>?XAUX,P_Y8P'SG^@Q
M\B_G4*-)?WG]R-'4KRT^!=EJS6;6?"WA_P"72;#[?=+TFEZ9]<G^@%.\KQAX
MJ_UC&QLV[',:D?3[S?CQ5*T\0Z9IKB/0=",UQ_#/<G?(?P'3\"*T-GCK7.I:
MQA/N(<?^SUHI<VF_E%:?>8RBX/FLD^\W=_)&A:>#O#^AHLVJW4<SCG,[A$_!
M<\_CFK%SX[T'3HQ#9AYPHPJ01[4'YX_2L^U^&XD?S=3U*25SRPB'_LS9S^5=
M%8^$M$L,&*PC=Q_'-\Y_7@?A6\(5$K0BH_BSCJU*#=ZLW-_<CEF\:Z_JS%-'
MTG:IXWA3(1^/ 'XTG_",^+-:YU34?)C;JC29_P#'5^6O0U4*H50 !P !TI:O
MZNY?')O\#+ZZH?P8*/XO[SCK'X<Z5!@W<T]TW<9V*?P'/ZUTEEI&G:<!]DLH
M(3_>5!N_/K5VBM84H0^%'/4Q-6I\<FPHHHK0Q"BBB@ HHHH **** /-?B'IL
MVDZM9^)[ ;75U6;']X?=)]B.#]!ZUWNDZE#K&E6U_;_ZN9 V/[I[@_0Y%.U/
M3X-5TVXL;A<Q3(5/MZ$>X.#^%>?> -0GT/7KSPO?G!+DQ<\;P.<>S#!'T]ZU
M^*'FCB_@U_[L_P _^">F4445D=H4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH>HDG"#_ +Y!_I4J,).]G)FDIU8*UXP7X_Y&W%X+\-Z4 VIWWF,!R)IA$I_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKR?P<!IOQ]\;:9!\EO<6\5V4'0OA"3]<RM^=>L4 %>/^'O\ DZ'Q9_V"H_\
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MIW_@4G^-'*P]I#NC3HK,_P"$DT+_ *#6G?\ @4G^-'_"2:%_T&M._P# I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3;)((H884+R32'HB*.I- 'G'_#./@_\ Z"6N?]_X?_C5'_#./@__ *"6N?\
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M[_P__&J]@HH \?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\ P_\
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M +_P_P#QJNQA^(^AW/CO_A$;=+N6]!=&G1%\@.B[F3=NSD=#@<'BNOH \?\
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M$M<_[_P__&J]@HH \?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\
MP_\ QJO8*XWQ1\2=+\*W4T-QINLWBVP4W4]E9EX;;=@C>Y( R"#QF@#D?^&<
M?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __ !JN]U+QUH.F>&;37Y+E
MY;.]V"T6&,O).S#*HJ]=WL<8[XJ;PSXG7Q+#<.-&UC2V@8*8]4M/(9LC.5&3
MD4 >>?\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#.
M/@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z
M"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_
M .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./
M@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG
M_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5>A>$/"5AX*T%='TV:YEMU
MD:0-<LK/ENO*@#]*PM:^*^BZ%?30W6FZVUG!-Y$VI16)-K&^<$%R1G!] ?;-
M:/B3Q[IWAQ8C]@U74V>#[25TVT,WEP\_O&.0H7@]Z .JHK)\-^(]-\5Z'!J^
ME2M):S9 WKM96!P58=B#_G%:U !1110 4444 %<'X6^)(\0^.M9\*W&E&QN=
M.+[9#/O\X(^TG&T;>H/4]:[RO#/$"'PG^TEH^I(-EMK2+&^. 68&,C\PA_&@
M#J?'7Q?M/!/BRRT.33#="9$DGG%QL\E68C[NT[B ">H[5TOCKQA#X(\*3:V]
MM]K*.B1P>;Y?F,QQ][!Q@9/0]*^?O%^E/XTUCXA^)%RZZ1)%%!@\$*P1C_WR
MA/XUN>,]9D\:^"OASHD4A:?5)%\XC^]'B(G\RQ_"@#WCP_J<NM>'M/U2:T-I
M)=VZ3F ON,>X9 S@9X/H*TJ^=?C%XHB7QM:^%+^[U"U\-6EO']IATX+YDI(R
M!\Q (QM'.0.3@UA^ _$NG:+\3-&M/!]WKK:/>R""[M-2\OYF8XW (2IQP<X!
M&",X)H ^IJ*^8?B-XML=;^)6I:7XGO=83P]I[&&&UTP)N:1< LV\A>N[D@GH
M!CK6A\'?$L5M\2CH6@W>K3^'+N!S'!J.W?"ZKNW84E1T(R,9R,C@4 =[\./%
M^N:_X^\8:9J=]Y]GI\Y2UC\I%\L>8Z]5 )X ZDUZC7RHOC2Z\&>(?B%/81O]
MMO+UK>&8*2L),LA+$^N <#UYY ->H:#X,O?"7PBU2Z\/7/V_Q'J=J+AKR!BQ
MD)Y C)Y.%9B#U).?0  ];HKY<\ 67A"]U:QFN_$NMZ1XOCN5,IO"/*F</DH#
M@'G&/F8')Z&OJ.@ HHHH **** "BBB@ JKJ32+I=VT5NMQ((7*0L,B0[3A3]
M>E6JCGGCMK>6>9@D42%W8]@!DF@#Y@\.S_%3PDU\F@^&;ZUL[N8S?9&LVDCB
M;_9W<CC Z]AZ5U_ASQ?\7[KQ+IEOJF@RII\MU&ER[:>4"Q%@&.[M@9-4)/BG
M\1_&.H7+>"M&*:;$Y1'%N'/MN=_E#$8.!T]^M;?@KXJ^(XO%MOX6\=:6;2ZN
MR%MY_*,1W'[H*]""> P[\?0 ]HHHHH **** "BBB@ HHHH *\^^-<$UQ\*=6
M$*,VPQ2.%_NB12?TYKT&D95=2K ,I&"",@B@#R'4]9TOQ7\1?AZOA^\M[LVB
M37-P(&#^1&8UP'Q]T\$8/(I/#W_)T/BS_L%1_P#H-K7J&G:%I&CO(^F:58V3
M2_ZQK:W2,O\ 7:!FO+_#W_)T/BS_ +!4?_H-K0![!2,H92K %2,$$<$4M% '
M!^)?AS:WP>YTH+#/U,)X1OH>W\OI7EU_I=WIUP\%Q"Z2)U5A@BOHVL[5]#L-
M;M_*O(0Q ^21>'3Z'^G2I3G3UIOY=/\ @"JT:&)TKK7^9;_/O\]?,^=JNVNH
MW<"B-9$EB'2&=1(GX!L@?AS73^)/ ]WI!:95,]KU\Z,<K_O#M]>E<JUM(BEF
MC\V,<DKP5'^?J*Z:>*IU7R2TEV?Z'DXG+,1A5[6#YH=U^JZ?/0U([K0+IO+U
M'3;BQE[RV3Y&?>-\_H:V]-T*]^_X5\413'KY'F-!(?JAR#^/%<U:QS2J$M/+
MO%'_ "ZRK\_OM'7_ +X.?7%/BATNZ?:+B73+H'I,"\6[_>'S)^(;ZUJXOH_U
M.6%2+^*/S6C_ ,CJ[K6?%6GC;X@\/P:A"O5YK96'_?2Y7]*@BU?P)J?_ !_Z
M)-82G^.!B47_ +Y(_P#0:+?7/&/AN%9I&^WZ?VE)\^,C_?4Y'XG\*T8?%OA'
M7_DUS2([:9NLH3<#_P "7#"HO;=?<=22D[*>O::_4CB\#^%M8 _L?Q PD;HC
MLKG_ +Y^4U6N?A5JT+;K._M9@.1NW1M_(C]:UI/AQH&K0FXT75'13TVL)D'\
MB/Q-5?\ A'/'6@\Z9J7VN)>B"7/'^Z_'Y4*=]I?>$L.E\=+YQ?Z&6=*^(&C@
M&)M0,:<*L4_FK_WSD_RH'C[Q=I4FV_B5B?X;JUV?RVUK)\0]?TAA'KFB''3>
M%:(G\\@_ABMVQ^)'AZ^ 2>26U8\%9X\J?Q&1^>*&Y=8W%%4[VA5<7V?](Y^U
M^+<@4"[TE&;/+0S;>/H0?YUY+K'B2VU6\\675CJ_]@VMS*6ET>4LZZ@RG+%F
M4@H7Z84<YP2!S7T9_8_A?7(B\=IIURIZO %S^:\URFO_  >T:^D-UID<,%SV
M2=/,4_\  CEA^M9OD?D=<5B(*[?,C>\'>*]#U'POI302VE@3:Q@61F ,/R@!
M1G!(%=4K*ZAD8,IZ$'(-?.VK:'J.AW/D:A;/$3]UNJO]".#5:WO+JT;=;7,T
M+>L;E3^E:>P3U3.;^TI1=IP/I.BO!;7QOXDM,!-5F<>DP$GZL":W+3XJ:S&0
MMQ:6DX]E9&/ZD?I4.A(VCF5%[W1Z]17GEK\6;%L"\TRXB]?*</\ SVUMVOQ#
M\-W6 ;YH&/\ #-$P_4 C]:ATY+H=$<51EM)'4452M=8TR^Q]EU"UF)[1S*3^
M6:NU%K&Z:>J(I[6WNDV7$$4R^DB!A^M8MUX*\.7F?,TJ!#ZPYCQ_WR16_133
M:V)E3A+XE<X6Z^%>C2Y-M<W<#=AN#J/P(S^M99^&NLV!+:3KVT]N7A/_ (Z3
M7IU%6JL^YA+!47K:WH>8^1\2=*^Y*;N,=?FCDS_WU\U'_"?^)]-_Y"N@_*.K
M&)XL_B<BO3J*?M$]T3]5E'X*C7XGS_\ %#XCZ?KWANTT\VYM[I+Z&<H95;Y1
MG)[']*[CQ#\9?#FG:#]JTNY2]OYSY=I"WR(7Z99SA0H/4Y_QKL-1\)^'-7F,
M^HZ#IEW,1M,LUHCOCTW$9JA'\.?!T4BN/#FGN$!"QRQ>9&N>N$;*C\!4-Q9M
M&-563=^YB_"72M+TC0+F.VUS3]6U6YF^U:C)97*2JDC]%^4G X/)ZG->@UGZ
M9H.CZ+YO]E:38V'FX\S[+;I%OQG&=H&<9/YUH5)L%%%% !1110 4444 <G\0
M- _MKP^TT*9NK/,J8'++_$OY<_4"E\ :_P#VUX?6&5LW5GB*3)Y9<?*WY<?4
M&NKKRF[4^ OB MR@VZ9>Y) Z!&/S#_@)P?ICUK6/O1Y3BK?N:JK+9Z/]&>K4
M4BL&4,I!!&01WI:R.T**** /)_CIJNG1^&K+3WO[5;T:A;S&W,RB01Y;Y]N<
M[??I57XJWEEJ6K>!M1BUW[/HKWDT;ZG8SJ5B8A0"'Y4'AAGM@^E>FZCX9T#5
M[D7.IZ'IM[.%""6YM(Y&VCH,L"<<FI1H.CC2AI0TFQ_LX9Q:?9T\GDY^YC'4
MD]* //OAA?W;^+/$^EV^OWFOZ#:&$VM]=3^>WF,N642=&'TXX'J:]1JM8Z?9
M:7:K:Z?9V]I;J<K%;Q+&@_  "K- !1110 4444 %%%% !1110 4444 %%%%
M'B_Q!\2:7XV\0KX(_M>QT[2K*<2:M>W=PD.XJ?\ 4Q!B-QSG)Z CVYMW.IZ/
MH?QPTZ_N[RU@TFZ\/"*RNY)@(>'R,.3M^Z/7N/45Z%<>#/"UW<27%SX:T>:>
M5B\DLEC$S.QY))*Y)/K5NZT'1[ZPAL+O2;"XLX !%;RVR/'& , *I&!@<<4
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M:(W!=B<8"L3_ !,W-?0%% 'E'C[P'XD/C:S\;^#7MWU.",1RVLY $F 5R"<
MY4X()'0$'-7?#5U\6=2\0V;^(=/TG2=)B9C<1P,K/,-IP!\\F.<'JO2O2J*
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M,G:W.?R&>V1S6=:VM_X/_9NEAG+PWL>G2L0>&C,SL0/8@2 ?45T_PJL8-/\
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M7VBWURTL*[EA(^=O7#+CG'MS7%Z5K^J:+J8O(9I2ZMB5)&)5_4,*[73?BG-
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M -" %81\2^ =5CWWEO!'(>HFM#O_ .^E!_G7-ZXO@IE(TNSN7D(X>*5D0?\
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M:;$;>YAN)EC9-A(!PV.",<_4=J[O1= TKPY9-9Z/8PV=N\AE:.(8!8@ GZX
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MO^$'\.?] [_R/)_\51_P@_AS_H'?^1Y/_BJY)?#?CYE!7700>A%V_P#A2_\
M",^/_P#H.?\ DV_^%+ZK2\ON'_:>*[2^_P#X)UG_  @_AS_H'?\ D>3_ .*H
M_P"$'\.?] [_ ,CR?_%5R?\ PC/C_P#Z#G_DV_\ A1_PC/C_ /Z#G_DV_P#A
M1]6I>7W!_:>*[3^__@G6?\(/X<_Z!W_D>3_XJC_A!_#G_0._\CR?_%5R?_",
M^/\ _H.?^3;_ .%'_",^/_\ H.?^3;_X4?5J7E]P?VGBNT_O_P""=9_P@_AS
M_H'?^1Y/_BJ/^$'\.?\ 0._\CR?_ !5<G_PC/C__ *#G_DV_^%'_  C/C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKVM]:7R;[2YAG7UC<-C\JL5LFGL<K33LPHHHIB"BBB@ HHHH **** "BBB@
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M='_/V:K_ /PMC2?^?"]_\<_QH_X6QI/_ #X7O_CG^-'O_P J"]#_ )_2^_\
MX!0^S?$V3YFGVD]M\(_EQ1]C^)?_ #\_^1(JO_\ "V-)_P"?"]_\<_QH_P"%
ML:3_ ,^%[_XY_C1[_P#*@OA_^?K^_P#X!0^Q?$L\&ZQGOYD5']C?$7_H)?\
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MC2?^?"]_\<_QJ/WO8WM@_P";\64/^%;Z[_T,'_CS_P"-'_"M]=_Z&#_QY_\
M&K__  MC2?\ GPO?_'/\:/\ A;&D_P#/A>_^.?XT7J]@Y<%_-^+*'_"L=4E^
M:;7\MT'RLW'XFC_A5E]_T'O_ "$W_P 55_\ X6QI/_/A>_\ CG^-'_"V-)_Y
M\+W_ ,<_QHO5#EP/?\64/^%67W_0>_\ (3?_ !5'_"K+[_H/?^0F_P#BJO\
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M_P".?XT6J]OR#FPG\WXLQ/[&^(__ #\7?_@:O_Q5']C?$?\ Y^+O_P #5_\
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MV?XG?WY/^_D'^-:J?%?12/GL[\'_ &40_P#LU._X6MH7_/IJ/_?M/_BZ/?\
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M(1MF4?PN.H_K]"*TF[I21QX>*IS=&2VU7H6?[$TG_H&67_@.G^%']B:3_P!
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M>98ZQ)&P^Z)(LG\P1_*HQX/\;VG[NVU_='V_TJ08_ CBGITD2V_MT?R9T_\
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M^7]R.T'A/P^ !_8]GQZQ"E_X13P__P! >R_[\BN*_P"$9\?_ /0<_P#)M_\
M"C_A&?'_ /T'/_)M_P#"CE_O#]HO^?+^Y':_\(IX?_Z ]E_WY%'_  BGA_\
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M_P#T'/\ R;?_  HY%_,/ZQ+_ )]L]-HJCHT-_;Z1;1:G.L]XJXED7H3DX_3
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M],XJXS@DU8PJX?$RDI*2NOD4?^%K:%_SZ:C_ -^T_P#BZ/\ A:VA?\^FH_\
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MZ NG?^ J?X4KT^P^3$_S+[CF/^%K:%_SZ:C_ -^T_P#BZ/\ A:VA?\^FH_\
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M,,:A4CC4*J@=  .@KG-8^'?A'7KY[W4M!M)[ISEY0"C.?5BI&?QH X[X>/\
M\)-\4_%OC&VR=,*)86DI4@2A0NXJ?3]V#_P(5ZQ5>QL+32[&*RL+:*VM85VQ
MQ1*%51[ 58H *\?\/?\ )T/BS_L%1_\ H-K7L%>/^'O^3H?%G_8*C_\ 0;6@
M#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5+W3+#44V7MG!<#MYD8;'T/:K=% FDU9G&:A\,M!N\M;>?9N?^>;[E
M_)L_H16&? WBG1"6T36/,0?\LPYC)_X"<J?Q->GT5HJLD<TL'2;NE9^6AY;+
MXL\5Z3"\&OZ*MU;,NV1I(MH8=QN7*_I7)V^NKH^MC4="$MNA^];RG<N.Z9_B
M7ZX/\Z]^K&U#PIH6J9-UIL!<]7C&QOS7&:N-6*W1A5P=5V<9WMM??[QOAWQ/
M8>([)9;=U2X _>6[-\R'^H]ZVZ\@\7> 9=$3^T=):66T3F12<O%[Y'5?Y54\
M/:OXODA9M*O7O!%]^WD<2,!_NMSC_=H=)-7BPCC)PE[.K'7RZGM5%>:0?$V_
ML91!KFBM&_<IF-O^^6_QKI=/\?\ AW4,#[;]F<_PW*[,?C]W]:S=.2Z'3#%T
M9Z*6OGH=-13(9HKB,20RI)&>C(P(/XBGU!T!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !574=-L=7L9++4;2&ZM9!AXID#*?P/?WJU10!YW)\#O $
MEP)1HTB#.3&MW*%/_CV?R(KK]!\,Z+X7LC::+IT%G"3EO+&6<^K,<EC]2:U:
M* "BBB@ HHHH BN;F&SM9;FYE2*"%#))(YP%4#))/IBO.1\7TNK:74-*\(>(
M-0TB,MF^BMP%8#JR@G) P?3&.<5VOBC1F\0^%M4TA)O)>\MGA63LI(X)]L]?
M:O'= ^+"^ _#A\):UI3C7=+'V:!8I4,,W/REGSA.HS^?L #V#PQXFTSQ=H<.
MKZ3*SVTA*D.,.C#JK#L?\17)WWQ:LSJ5U9>'] UCQ ;1ML\]A#NA4]P&YR?P
MY[9K.\/:+>?#WX)ZW<2W,9U&>"XORT#!DBD>,!0I'!QA>1QG..,5L_!O3X=/
M^%FC>4@5KA'GD;'+,SGD_A@?0"@#<\(^,M)\::4U]ICR*T;^7/;S+MEA?T8?
MUZ?K705Y+X47^S?VAO&&GP?);75E'>,@Z%_W>3]<R/\ G7K5 !7C_A[_ ).A
M\6?]@J/_ -!M:]@KQ_P]_P G0^+/^P5'_P"@VM 'L%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%Q_(].HJ*VG%S:PSA'02HKA7&&&1G!'K4M9G8M0HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<#XQ\$O-,=:T(&*_0[WBC.-Y_O+CHW\_KU[ZBJC
M)Q=T95:4:L>61QG@WQLFM*-/U$B'4TXY&T38]/1O4?E[=G7$>,O! U,G5-)'
MDZDGS,JG;YI'?/9O?_\ 73/!OC<W[C2-9/DZBAV*[C;YI'&#Z-_.KE%27-$P
MIU94Y>RK?)]_^"=U11161V!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7C_A[_DZ'Q9_V"H__ $&UKV"O
M'_#W_)T/BS_L%1_^@VM 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>,O!,6NH;ZQ"PZF@SD
M<"7'8^A]#^?MV-%.,G%W1G4IQJ1Y9'GWA#QK+]H&AZ^6BO8V\M)9."QZ;6_V
MO?O]>OH-<KXO\&V_B. SP[8=1C7Y).SC^ZW^/:L+PIXRN-.N_P"P/$>Z*:(^
M7'/+U![*Q]/1O_UUHXJ2YHG-"I*C+V=7;H_\ST>BBBLCM"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SGBOPE:^);3/
MRPWT8_=3X_\ '6]1_+^?1T4TVG=$3A&<>62T/,O#/BR[\.WW_"/^) T:1G9%
M,_/ECL">Z^A[?3IZ8"&4,I!!&01WK#\3^%[/Q+8^7,!'<H/W,X'*GT/J/:O)
M]+\;:]H4:6<5PLD$+8$,R X'IGJ!^-:\OM-8[G#[9X5\E36/1_YGNM%>9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%--K8F48R5I*Y!9V5MI]JEK:0I#!&,*B# %3T44AI)*R"BBB@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7C_ (>_Y.A\6?\ 8*C_ /0;6O8*\?\ #W_)T/BS
M_L%1_P#H-K0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5+_[50!] 45\_P#_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 'T!17S_\
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M7_4H_P#E2_\ M5 'T!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4
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M17S_ /\ #37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 ?0%%?/_P#PTU_U*/\
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M_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\ _P --?\ 4H_^5+_[51_PTU_U*/\
MY4O_ +50!] 45\__ /#37_4H_P#E2_\ M5'_  TU_P!2C_Y4O_M5 'T!17S_
M /\ #37_ %*/_E2_^U4?\--?]2C_ .5+_P"U4 ?0%%?/_P#PTU_U*/\ Y4O_
M +51_P --?\ 4H_^5+_[50!] 45\_P#_  TU_P!2C_Y4O_M5'_#37_4H_P#E
M2_\ M5 'T!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\
M_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50!] 45\__ /#37_4H_P#E2_\
MM5'_  TU_P!2C_Y4O_M5 'T!17S_ /\ #37_ %*/_E2_^U4?\--?]2C_ .5+
M_P"U4 ?0%%?/_P#PTU_U*/\ Y4O_ +57<?#7XK_\+#U&^M/[%_L_[+$LF[[5
MYN[)QC&Q<4 >D4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img108642122_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ))!$,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+DD 8'Z 4 3ZCJFGZKX5U>73KVWNXUM9E9X)0X!V'@D5SOP6_P"24Z/])/\
MT8U=3I?AC1-$T^XL--TRWM;2X),T4:X5\C!S^'%6M+TJQT73X[#3;6.VM(L[
M(HQA5R<G]30!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I
M:OJMIH>D76J7\GEVMM&9)& R0!Z#N:NUY1\=-<M[30=+T.>X$,>IWB"X<Y^6
M!""Q('.,D4 =YX6\6:1XQTMM1T>=I8%D,3;T*LK#!Y!^HK#UKXM>$-!U673K
MJ_DDN(3B;[/"TBQ'T8C@&N)^&GB/0H/BIKVDZ%>)+I&IQ+=6P52H211\RX('
M;)_"H[/0O$^A:CK&I^!+K2/$>A7]R\EQ:2LI;>?O)GUY]>G:@#TW4/'>@:?X
M8A\1&[:XTR9@B2VT9D))SV'(Z5S<7QQ\%S2B*.:_9]P7 LWX)]:T/A;J^CZQ
MX5<:5I":3]GN7BN;)>1'+QG'L:QOAF ?'OQ"R!_R$E[?[U 'J"L&4,.A&:6B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***;)(D4;22.J(@+,S'  '4F@!U%<//\6O"D5P8XY[RYC!P9
M[>SDDB'_  (#!_"NJTG6-/UW3TOM,NH[FV<D!T]1U!!Y!]C0!>HHHH ****
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M[L6JQ3RD11L9"OS,.< *2<5TOAC4[C5]&6\N+C3KAG=@LFG2,\14>[<YZY%
M":7_ ,C%KO\ OP_^BQ6S7+Q7=_;>)M:6TTPW:EH26$ZI@^7TP:T[74-4EN4C
MGT5H(B?FD^THVW\!UH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***9+((8GD;.%!)Q0 ^BL4^)K,$@I)D?3_&C_A)[+^Y)^G^-!'M(
M=S:HK%_X2>R_N2?I_C1_PD]E_<D_3_&@/:0[FU16*OB:S8@!)/T_QK9!R ?6
M@:DI;"T444%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!PWB#_D+2_7^@K+K4\0?\A:7Z_T%9=,\^?Q,****"0KM?#7_ ""?^!G^
M0KBJ[7PU_P @G_@9_D*#:A\9L4444CL"BBB@ I&8*I9B H&22>!2U7O[<W6G
MW-NHC)EB9 )1E#D8^8=QZT >,ZU8VK>--=N-5\'WNO0SS(UK<K?H@5-@!55W
MC"YY%>SV046-N$B,2B)<1DYV#'3/M7S[J^F6UGKLVG:E/X--[!"'G;^S)V6)
M%"@!F#8X!7CL.M?0-BH2PMD4QD+$H!B^Z>/X?;TH L4444 %%9EMXATF\L[V
M\@OX7M;&1XKB8-\B,@RPSTXS4>B^)M)\0&9=.N2[PA2\;QM&P5ONMA@#M/8]
M* (]6_Y&'0?^NLW_ **-;=8FK?\ (PZ#_P!=9O\ T4:VZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?%G_'Q#_N?U-=57*^+
M/^/B'_<_J:#*M\!SE%%%,X@HHHH OZ-_R%(/]X?SKOJX'1O^0I!_O#^==]2.
MK#[,****#H"BBB@ HHHH **** .4\6?\?,'^Y_4USM=%XL_X^8/]S^IKG:9P
MU?C84444&85H:+_R%K?_ 'Q_.L^M#1?^0M;_ .^/YT%1W1WM%%%(] **** "
MBBB@ HHHH *Y3Q7_ ,?,/^[_ (UU=<IXK_X^8?\ =_QH,JWP'.T444SB"BBB
M@#0T7_D+6_\ OC^==[7!:+_R%K?_ 'Q_.N]I'7A]F%%%%!N%%%% '->/HYKG
MP/JUI:M)]KFMV$212!'<Y&0"2/Q]JY/X>6VEPZTIMO!5SH]T+8A[J2\653TR
MN Y//KCM6W\1=(FOM.CO4DT6*WM(Y/M,NJ0/(%C8#(7:1UQSZ\5R7PJAL'U_
M[5;/X?5I+5V1+.QE@F90^TG+DC;D<CKTH ]CHHHH XNRT'6=*\(V-I#;6%W=
MVMV\TEO/RLB%V.%8CY6PP(..U:/A/1KO3!J=Y>QQ6\^I79N3:PMN2$;0H&<#
M).W)([FNCHH QM+_ .1BUW_?A_\ 18K9K&TO_D8M=_WX?_18K9H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@OO^/&?_KF?Y5/4%]_Q
MXS_]<S_*@3V/.W^^WU--IS_?;ZFFTSS@HHHH ?#_ *U:](3[B_05YO#_ *U:
M](3[B_04CIP_4=1110=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <-X@_Y"TOU_H*RZU/$'_(6E^O\ 05ETSSY_$PHHHH)"NU\-
M?\@G_@9_D*XJNU\-?\@G_@9_D*#:A\9L4444CL"BBB@ HHHH \$\>1Z#'XMU
M*YM[[6P3(T&HVUG C(P:,&8JS<C"*N[]*]RT_P C^S;7[+_Q[>2GE?[F!C],
M5X7XUU+3HO&6OM#X66<E6@N;B74S '*HKN0@'&5P/5@"*]TTYUDTRT=%15:%
M"JI]T# Z>U %FH;NUAOK.:UN%+0S(4=02,J>HR.:FHH \AELXK;X>^.+6RA6
M.UM]9<&&->%B4Q%A@=MH-=5:W5KJ'Q2CGTZ:*:&/1,320L&4;I08P2.^ Q ]
M*Z^.UMXA*(X(U$S%Y J@;V/4GU)J#3]*T_28WCTZQM[1';<ZP1A Q]3B@#(\
M1V-MJ.L:%;W<?F1&:4E<D<B,XZ58_P"$0T+_ )\!_P!_7_QHU;_D8=!_ZZS?
M^BC6W0!';P16MO'!"NV*-0JKG.!^-2444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<KXL_X^(?]S^IKJJY7Q9_Q\0_[G]3095O@.<H
MHHIG$%%%% %_1O\ D*0?[P_G7?5P.C?\A2#_ 'A_.N^I'5A]F%%%%!T!1110
M 4444 %%%% '*>+/^/F#_<_J:YVNB\6?\?,'^Y_4USM,X:OQL****#,*T-%_
MY"UO_OC^=9]:&B_\A:W_ -\?SH*CNCO:***1Z 4444 %%%% !1110 5RGBO_
M (^8?]W_ !KJZY3Q7_Q\P_[O^-!E6^ YVBBBF<04444 :&B_\A:W_P!\?SKO
M:X+1?^0M;_[X_G7>TCKP^S"BBB@W"BBB@#!\:_V9_P (9JO]LM*NG^0?-,0R
MXY&-H]<XQ[UYQ\,8]-M_&4UJUWJ]W<0P3"REO($CCP75IPNWJP8C.?PKT3QU
M<6=KX'U>;4+,WEJMN=\ ;:7R0!\W;G!SVQ7G?PQO86\516G]@PZ<\5E-%&YU
M$W#G;(-_&."68$L>HQ0![+11574M/AU6PELKDR"&48<1R%"1GID<X- $;ZSI
MD>F/J3W]N+%,[K@R#8,'!Y^O%36-_::G:1W=C<1W%O)RLD;;@:\LTM((/!_@
MU9%C338M:=9%;[BX:41Y]MVWKWQ76>"BC:GXI:U*FQ.J'R3']S=Y:>9C'^UG
M/OF@#4TUE7Q'KFY@/GAZG_IF*V0Z$X#J3]:YJ'1].U+Q-K4EY9Q3NK0J&<9(
M'E]*U;;P_I%I<)<6^GP1RIRKJO(H TJ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *@OO\ CQG_ .N9_E4]07W_ !XS_P#7,_RH$]CSM_OM
M]33:<_WV^IIM,\X**** 'P_ZU:](3[B_05YO#_K5KTA/N+]!2.G#]1U%%%!T
MA1110 4444 %%%% ',S>*)8IGC\A#M..IIG_  EDO_/NGYFL*\_X_)O]\U!3
M.'VL^YTG_"62_P#/NGYFC_A+)?\ GW3\S7-T4![6?<Z3_A+)<_\ 'NGYFNBL
MYS<V<4Q4*77.!7G0ZCZUZ!I/_(*MO]RD;49RD]2Y1110= 4444 %%%% !111
M0!PWB#_D+2_7^@K+K4\0?\A:7Z_T%9=,\^?Q,****"0KM?#7_()_X&?Y"N*K
MM?#7_()_X&?Y"@VH?&;%%%%([ HHHH *:[K&C.[!44$LS'  ]33J9+%'/"\,
MJ*\;J5=6&0P/!!H \+\9:Q;:OJ6O7XG\+&TTN6-EM;E!)+J!"@@[P?<J,?C7
MM]C)YVGVTOEB+?$K>6.BY X_"O--6NOA=H^K7&F2^&X)[FV($PM=*,RQDC."
M57&<=J]-M6B:TA:!-D1C4HNW;A<<#';B@":BBB@ HJO?7MMIMC/>WDRPVT"&
M221NBJ.IK-T/Q1IVORS06RW,-Q$BR-!=0M$Y1ONN >JGUH 35O\ D8=!_P"N
MLW_HHUMUB:NP7Q!H)8@#S9N2<?\ +(UL>=%_SU3_ +Z% #Z*8)8ST=3]#2[T
M_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT>8@_C7\Z ,[5=7&F.BF/=N&>
MM9W_  E:_P#/O_X]_P#6J+Q21)+ 4(;"]CGO7.[&_NFF<M2I)2:3.G_X2M?^
M??\ \>_^M1_PE:_\^_\ X]_]:N8V-_=-&QO[IH(]M/N=/_PE:_\ /O\ ^/?_
M %JFM/$:W5RD(AQN(&<UR6QO[IJ[I*E=3@+< ..3]10-59WW.^HIGG1?\]4_
M[Z%'G1?\]4_[Z%([!]%,\Z+_ )ZI_P!]"E$L9Z.I^AH =13=Z?WE_.C>G]Y?
MSH =13=Z?WE_.C>G]Y?SH =7*^+/^/B'_<_J:ZCS$'5U_.N6\4D23PE"&PG8
MY[F@RK? <[13MC?W31L;^Z:9Q#:*=L;^Z:-C?W30!=T;_D*0?[P_G7?5P6D*
M5U.$MP PY/UKNO.B_P">J?\ ?0I'5A]F/HIGG1?\]4_[Z%'G1?\ /5/^^A0=
M ^BFB6,]'4_0T;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT&1 ,EU_.@
M#EO%G_'S!_N?U-<[71>*2)+B$H0V$['/<US^QO[IIG#5^-C:*=L;^Z:-C?W3
M09C:T-%_Y"UO_OC^=4=C?W35_1@5U2!FX 89)^M!4=T=Y13/.B_YZI_WT*/.
MB_YZI_WT*1Z ^BF>=%_SU3_OH4HEC/1U/T- #J*;O3^\OYT;T_O+^= #J*;O
M3^\OYT;T_O+^= #JY3Q7_P ?,/\ N_XUU)D0#EU_.N6\4$27$10AAM['/K09
M5O@.=HIVQO[IHV-_=-,XAM%.V-_=-&QO[IH O:+_ ,A:W_WQ_.N]K@M'!75(
M&;@!QR?K7=>=%_SU3_OH4CKP^S'T4U9$<X5U8^QS3J#<**** .:\=ZY;Z%X1
MU&>46<TQ@816UTX"S=B,'J #D@5Q/@!TL_'LEL9O#^I3WNG?:&O-,B$;0@%0
M(R,G((QCOQS7?>*;/PX^E2:CXDLK2>TL4:0O<Q!_+'?&?7BN=\&ZEX(N]9*>
M'=!>QO#"6\XZ8T *<9&X@>W% '?T444 59--L9;%[&2S@:T<$- 8QL.3D\=.
MO-26EG;6%K':V<$<$$8PD<2A57Z 5-10!C:7_P C%KO^_#_Z+%;-8VE_\C%K
MO^_#_P"BQ6S0 4444 %%%% !115/4[MK*Q:= "00,'ZT";LKERBN3_X2N?\
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M^VUSQ7K^M::YFTV5+>"*X"D),Z!BQ4GJ!N S78A%"[0H"^F.*%144*BA5'0
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M]E_SYV__ 'Z'^%']GV7_ #YV_P#WZ'^%6:* *W]GV7_/G;_]^E_PI/[,T_\
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MB10IO>1V.%51W)- &E17*6OCS3WL-2N-0M+[3)M.19+BVNHL2;6^Z5 )#9/
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M)[DQS36</VHQJ$+'@'&>G7UK;T2\2^TB"=;O[63E6E\ORR6!((*_PD'@CVH
MK:8/^*BUS_?A_P#18K9KF5AU27Q#JYL+RW@0/%N66$N2?+'?(K1M;;7$N4:Z
MU"UD@!^=$MRI/T.Z@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<?B
M-_R/FJ?]=%_]!%<M74_$;_D?-4_ZZ+_Z"*Y:O3A\*/EZ_P#%EZL****HR"O?
M/A'_ ,B0/^OF3^0KP.O?/A'_ ,B0/^OF3^0K#$? =^6_QOD=W1117">\%%%%
M !1110 4444 >)_&?_D8;'_KV_\ 9C7FE>E_&?\ Y&&Q_P"O;_V8UYI7HTO@
M1\UB_P"/(****T.<*];^"GWM6^D?_LU>25ZW\%/O:M](_P#V:LJ_P,Z\#_O$
M?ZZ'KE%%%>>?1!1110 4444 %%%% 'F'QI_Y NF?]?#?^@UXO7M'QI_Y NF?
M]?#?^@UXO7?0^!'SV8?QW\@HHHK8XPKO/A'_ ,CLO_7O)_2N#KO/A'_R.R_]
M>\G]*BK\#-\+_&CZGO=%%%>:?3!1110 4444 %%%% !1110 5%<1&>VEA61X
MC(A42(<,N1C(]Q4M% 'B%SHYT\>*]0M/$WBMVT=HUNY5NHD-PP4%L?+U52.3
MUZ5[-I\B2Z=:R1R/(CPHRO)]Y@0.3[USFL^!/"FLZZM]J-L#>28+QBX9%GV]
M"Z @/CW%=6JJBA5 "@8 '0"@#.UO2YM7T_[-!JEYIK[PWGV94/@=OF!&/PKF
MKV1_AWH-[JM_K&K:YN*)#%=E6VN20,;$&!SR>>!7;T4 >0_:[;7_  _K%_:W
MS:OKF^VNKJ.WMY$5(8I PBB# 9 &X^I))KJ- U6W\3^.9M9TQ)VTZWTX6IGD
MB:,/*TF_: P!.T#GZUVU% &'K"+)KVA*ZJR^=+PPR/\ 5-6M]DMO^?>+_O@5
MEZM_R,.@_P#76;_T4U;5 "*H50J@ #H .E+110 4444 %%%% !1110 4444
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M_P"_R_XUZ$*D5%:GSE;#U74DU%[OH<517:_\*J\5?\^D7_?Y?\:/^%5>*O\
MGTB_[_+_ (U7M(=S/ZM6_E?W'%5[Y\(_^1('_7S)_(5YQ_PJKQ5_SZ1?]_E_
MQKU?X>Z)?>'_  Q]BU"-8Y_/=\*P;@X]/I6-><7"R9VX"C4A6O*+6AU=%%%<
M9[04444 %%%% !1110!XG\9_^1AL?^O;_P!F->:5Z7\9_P#D8;'_ *]O_9C7
MFE>C2^!'S6+_ (\@HHHK0YPKUOX*?>U;Z1_^S5Y)7K?P4^]JWTC_ /9JRK_
MSKP/^\1_KH>N4445YY]$%%%% !1110 4444 >8?&G_D"Z9_U\-_Z#7B]>T?&
MG_D"Z9_U\-_Z#7B]=]#X$?/9A_'?R"BBBMCC"N\^$?\ R.R_]>\G]*X.N\^$
M?_([+_U[R?TJ*OP,WPO\:/J>]T445YI],%%%% !1110 4444 %%%% !1110!
M\^^.;"4?$+5)1J6E2FZC> 2W&IB%[3<$VY7J-A7<,=<U[KI%Q#=:1:RP7L=[
M&8E'VB-@RR$#!.1[BO&_&L<%EXEU^RFN?";G5"C_ &J_E"W%B H&-NT[L8R.
M><\UZ-\/="NM \,>1=RV[RW%Q)<XMEVQ*'.0%'88Y^IH ZNBBL_6]7BT32Y;
MZ2">X*D*D,";GD=CA5 ]R: -"BN2MO'EN--U6XU33;S3;K2PAN+23;(YW_ZO
M:5)#%NF/6KGA[Q0VLWEQ87NE7>E:A BS&VN2I+Q,<!U920>001V- $VK?\C#
MH/\ UUF_]%&MNN=\17MMI^L:%<7<HBB$TH+$'J8F]*G_ .$NT'_H)1_]\M_A
M0!MT5'!/%=6\<\+AXI%#*P[BI* "BBB@ HHHH **** "BBB@ HHHH **** "
MO&?C5_R%]+_ZX-_Z%7LU>,_&K_D+Z7_UP;_T*MJ'QHXLP_@/Y?F>74445WGS
MX4444 ;W@K_D=-(_Z^D_G7TS7S-X*_Y'32/^OI/YU],UQXGXD>UE?\.7J%%%
M%<QZ84444 %%%% !1110!XO\:?\ D-:;_P!>Y_\ 0C7F%>G_ !I_Y#6F_P#7
MN?\ T(UYA7HT?@1\WC/X\@HHHK0Y@K>\%?\ (Z:1_P!?*?SK!K>\%?\ (Z:1
M_P!?*?SI2^%ETOXD?5'TS1117EGU04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!@>-87N?!>JPI?1V+/ 0+B238J<C
MJW8'IGWKR[X4>78Z_"L^H:39I'!+;I;P:DLS73/)O7Y?]D9 /4YKU+QI9?VC
MX,U:T^UP6GFV[#S[C'EIW^;/:O'M/TM_&6O6"V#>$K)[80^9!IK^;(R1R!C*
M"%&TC  '<,: /?Z*9,LC0.L+JDI4A&9=P![$C(S6;:V.JL9(]4O[6ZMI(RAC
MBM3$3GWWGMF@![:_I2Z?/?\ V^%K6"0PO*IW .#@J,=3GC [U/IVI6FJV@NK
M*=9HMQ4D @AAU!!Y!'H:\\M[-=.T2%X[8PV&G^)7ED1(R!'"&8!L?W02#G\:
MZ;P?^_N]?U&+<;.\O]]NQ4@.!&JEA[$@\]\4 .CUC3],\1ZPMW<>6[M"0-C'
MCRQZ UI6OB+2KRY2WM[K?*YPJ^6PS^8INF_\AW6O^ND7_HL5K4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2276;F=%/,;QQ@-^2YIFFD?V_K0[AX?_18K7H **** "BBB@ HHHH ****
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MAQODC*C/'<U[714RQ#DK6+IY=&$U-2V"BBBN<]$**** "BBB@ HHHH ****
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M4SR0M&'E:3?M 8 G:!S]:[:B@#%U7_D8-!_ZZS?^BFK:K%U;_D8=!_ZZS?\
MHHUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (55NJ@_44GEI_<7\J=10 WRT_N+^5'EI_<
M7\J=10 WRT_N+^5 C0'(1<_2G44 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-5UMKEY=/N;MET^/^$0QC;N7_>8,?RH Z"YU*RM+RUM+BYCCN+MF6")C\TA
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MSL?3Z5[50 4444 %%%% !1110 5S^I^-_#>CZA)8:AJT,-W& SQ%6)4$9&<
M]:Z"O-XH=?F^)'BS^Q)M,C4+9^;]MA=R3Y9QC:1@4 >@V5[;ZC90WEI*);>9
M=\;@$!AZ\U5O=>TK399HKR^BA>& 7$BL?NQEMH8^V>*Y/46O-6\87&C76LW&
MEV]EID=RALY!%YLC%@SDGJJ[1QTYYKA]0U.YUG2;G4+YE:YG\+QEW"[0^+O
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MTVXNU$<LK0;@4P020",M@G!/XUJZ+I-OH6BV6E6@(@M(5B3/4@#J?<]:O44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9VMZQ'H>G&]EM;RY0,%,=G 97Y[[1V]ZT:CN 6MI0H)8H0 /
MI0!R>B?$;2]?N+6.ST_6%BNB1%<S63)"<9S\YX[&NJ%Y;%687,.U0"3O&!GI
M^=>2V7A[6D\,> H&TVY66R>[-RA3F+='*%W>F21^=8-G\-Y$TFT23P]/YC^&
M9C.I!^:]!_=[AGEQGCTH ]Z::))$C:5%=_NJ6 +?0=Z<[I&A=W"J.K,< 5X)
M>>#?$EWXBT^>[MM6:5K6Q%K/!'&WV8H@\P/(YS$002<?>KTSXJ#'PNUX$Y_T
M<>V?F6@#K4GBD#%)48(<,58''UJG>ZQ;6<%O,!)<)/.D"FV7S,,QQDXZ =S7
MC+>%=9N['7)/#N@7FD6,UC;1RV4D@1KR19-TNP@GJF1N[U:@\-ZD]\+K2?#U
M[I6B-K&GR1:=(FUD,9/FS; 3M7&![XS0![,MU;L^Q9XBQ!. XSQUJGHVNZ?K
M]M+<:;<":**9X&8?WE.#^&:\FTGP/<VS:'J!T.9-1/B*=KN4J=PM6:3[W/W"
M"/S]ZZWX6:*=!T_5[&319-.G&H2MYC1A5FC+,8]ISR O'M0!WU%%% !1110
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M.\@EE3<'C!W1@].V[=[8KU&@ J#[%:_;?MOV:+[7L\OS]@W[<YV[NN/:IZ*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+#%<1F.:-)(SC*NH
M(/?H:?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=UC0N[
M!5'4L< 5!_:%E_S^6_\ W]7_ !H%=(LT5%%=6\[%89XI& R0C@FI:!A1110
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M]Y1D# )%='7(MX*8-)9PW^S1Y;J.[DMO+S)O3:=H?/"DHI/&>O-==0 4444
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M^Y6.WLVM&83+M0_-(#\N2Q&>W6NGNM;U.'Q=H^FBSB2PNXY#).T@9F=4W;5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_H3]1_\  B+_ !H_X7#/_P!"?J/_ ($1?XT![2'<]1HKR[_A<,__ $)^H_\
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M?_0DZE_X$Q?XT?\ "S=3_P"A)U+_ ,"8O\: YEW/1J*\Y_X6;J?_ $).I?\
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MLW4_^A)U+_P)B_QH#F7<]&HKSG_A9NI_]"3J7_@3%_C1_P +-U/_ *$G4O\
MP)B_QH#F7<]&HKSG_A9NI_\ 0DZE_P"!,7^-'_"S=3_Z$G4O_ F+_&@.9=ST
M:BO.?^%FZG_T).I?^!,7^-'_  LW4_\ H2=2_P# F+_&@.9=ST:BO.?^%FZG
M_P!"3J7_ ($Q?XT?\+-U/_H2=2_\"8O\: YEW/1J*\Y_X6;J?_0DZE_X$Q?X
MT?\ "S=3_P"A)U+_ ,"8O\: YEW/1J*\Y_X6;J?_ $).I?\ @3%_C1_PLW4_
M^A)U+_P)B_QH#F7<]&HKSG_A9NI_]"3J7_@3%_C1_P +-U/_ *$G4O\ P)B_
MQH#F7<]&HKSG_A9NI_\ 0DZE_P"!,7^-5Y_BW>6UU:V\O@S45ENF98E-S%\Q
M R>_I0/F7<].HKSG_A9NI_\ 0DZE_P"!,7^-'_"S=3_Z$G4O_ F+_&@7,NYZ
M-17G/_"S=3_Z$G4O_ F+_&C_ (6;J?\ T).I?^!,7^- <R[GHU%><_\ "S=3
M_P"A)U+_ ,"8O\:/^%FZG_T).I?^!,7^- <R[GHU%><_\+-U/_H2=2_\"8O\
M:/\ A9NI_P#0DZE_X$Q?XT!S+N>C45YS_P +-U/_ *$G4O\ P)B_QH_X6;J?
M_0DZE_X$Q?XT!S+N>C45YS_PLW4_^A)U+_P)B_QH_P"%FZG_ -"3J7_@3%_C
M0',NYZ-17G/_  LW4_\ H2=2_P# F+_&C_A9NI_]"3J7_@3%_C0',NYZ-17G
M/_"S=3_Z$G4O_ F+_&C_ (6;J?\ T).I?^!,7^- <R[GHU%><_\ "S=3_P"A
M)U+_ ,"8O\:/^%FZG_T).I?^!,7^- <R[GHU%><_\+-U/_H2=2_\"8O\:/\
MA9NI_P#0DZE_X$Q?XT!S+N>C45YBGQ;O'U&6P7P9J)N(HEE=/M,60K$@'K[&
MK'_"S=3_ .A)U+_P)B_QH'S+N>C45YS_ ,+-U/\ Z$G4O_ F+_&C_A9NI_\
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M*** "BC!]** "BC!]*,'TH **** "BBB@ HHHH **** .>M/^2AZI_V#;?\
M]#>NAKGK3_DH>J?]@VW_ /0WKH:8V%%%%(04444 %%%% !111B@ HHHH **,
M44 %%%% !1110 4444  ZUL?"_\ Y FK?]A>Y_F*QQUK8^%__($U;_L+W/\
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M)O\ 42_[C?RH$;/@[_D3-'_Z]EK;K$\'?\B9H_\ U[+6W4':]PHHHI %%%%
M!1110!5U*]33M,N;R3[L,9?ZGL/SKB?#-QJ&G:Y8KJ-Q+)'JUN9%$C$A7R2
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M\+M9ZA/"]WJ]]%K22[I(I)2%?!^Z >#]*T-,TS5/#^OZBEM%+>V]Q!YB2RD
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MN[N/-"D_:)-^WCMZ5ITU 1&H/4 4ZH)"BBBD 4444 %%%% '/6G_ "4/5/\
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M4B2RPA$9PQW#IZUCW%_?7BA;F\N)U!R!+*S ?F:?%JFI01+%#?W<<:_=1)F
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M_"/VO?J?FQ7J^5-?8$@^4YVD<@<5R",\;JZ,R.IR&4X(/L:FGO;RY!%Q=3S
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M/I0 E%+@^E&#Z4 )12X/I1@^E "44N#Z48/I0 E%+@^E&#Z4 )12X/I1@^E
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MY_\ P-F_^*KK**07.3_X5IX3_P"@?/\ ^!LW_P 51_PK3PG_ - ^?_P-F_\
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M0Q6-MX>^(5A;:7"MM9ZE92^=;Q#$>^,@JP'0'!(KLJ07.3_X5IX3_P"@?/\
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M_P *T\)_] ^?_P #9O\ XJC_ (5IX3_Z!\__ (&S?_%5UE%(+G)_\*T\)_\
M0/G_ / V;_XJC_A6GA/_ *!\_P#X&S?_ !5=910%SD_^%:>$_P#H'S_^!LW_
M ,51_P *T\)_] ^?_P #9O\ XJNLHH"YYA:> O#C_$;5;!K*8VT6F6\J+]JE
MR&9W!.=V3P!Q71_\*T\)_P#0/G_\#9O_ (JEL?\ DJ^M?]@>U_\ 1CUU= V<
MG_PK3PG_ - ^?_P-F_\ BJ/^%:>$_P#H'S_^!LW_ ,57644"N<G_ ,*T\)_]
M ^?_ ,#9O_BJ/^%:>$_^@?/_ .!LW_Q5=910%SD_^%:>$_\ H'S_ /@;-_\
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M\J&ZGOY;J L=Z?ZS>F['8XP1[U?^R?$#_H,>'?\ P E_^+H^R?$#_H,>'?\
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M_P#%T?9/B!_T&/#O_@!+_P#%T =717*?9/B!_P!!CP[_ . $O_Q='V3X@?\
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MY_T%_#__ ( R_P#Q='V7QY_T%_#_ /X R_\ Q=(+'445R_V7QY_T%_#_ /X
MR_\ Q='V7QY_T%_#_P#X R__ != 6.HHKE_LOCS_ *"WA_\ \ 9?_BZ/LOCS
M_H+^'_\ P!E_^+H"Q'\3/^2?:G_O0?\ H^.NM;[QKS'Q];^,4\$W[7^I:+);
M!H=Z0VDBN?WR8P2Q'7'X5TS6OCS<?^)OX?\ _ &7_P"+H'T.GHKE_LOCS_H+
M^'__  !E_P#BZ/LOCS_H+>'_ /P!E_\ BZ!6.HHKE_LOCS_H+^'_ /P!E_\
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M(GD;D[ESC!/K4]WX7O+72]#ETMVFU#2I?.$=W.6\P,NUTWGH/3L*G^R^//\
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M-1UO4$556-;6P0,&VQ=68^A8U7^R^//^@OX?_P# &7_XNC[+X\_Z"_A__P
M9?\ XND%BUXMTV_UG2H]+LP%ANIT6\D+X*0 Y;'J3C%;D<:0QI%$H6-%"JH[
M < 5S/V7QY_T%_#_ /X R_\ Q='V7QY_T%_#_P#X R__ != 6.HHKE_LOCS_
M *"_A_\ \ 9?_BZ/LOCS_H+^'_\ P!E_^+H"QU%%<O\ 9?'G_07\/_\ @#+_
M /%T?9?'G_06\/\ _@#+_P#%T!8ZBBN7^R^//^@OX?\ _ &7_P"+H^R^//\
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MA'&,K[D]*@,:-\6H'9%+1Z(2C$9VGS0,CT.*RO)EFM?B5;P(S/)(VU%'WF,
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M8.*XCQ9+=WGA3P^EW$$U"ZO[,O&.-KYW-CZ8-=PW+L?>DP.2^)G_ "3[4_\
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M'0"SX=U36KGQ1K&GZN]L/L\,,L<5NORQ[]V1N/+=!S73RR)#"\LAQ'&I=CZ
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MS3.ZWMW(T"%LK'$AV* .V<$_C4WB35[G3DLK/3UB.HZA/Y,#3?<C !9G8=P
M.E9/@N">\^'6GV]M>26,\1>-Y8T5F!5R",'CFJ?BS35M)/#UUKEQ+J.GVUY(
MMW-+&%VJZX4L$_A! JNH'1V?]H:;9WE]?ZTFJ01P-(%C@5-K*"3@J3P0,8KG
M7UGQ+;>%H/%LM];26S!)Y=.6W 5868# ?.=P!!S3M#32F\:WDN@+'_8BZ>5O
M3"#Y#R[N !T)VYSBL;5['P_>:2-&\-ZK>WTUVZI;V,-TSPP*6RSL.R@9X)H
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MC)]30!R*>.;*) D?ASQ&B#HJZ2X _ 4I\>6C AO#OB4@]CI3FNMR?4T9/J:
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MZI__ $$T >8^"_&-O9^"M&MFT77I3%;*I>'3G=&Z\@CJ*W?^$ZMO^@#XD_\
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M,CN.M,;QA8?\)%;:+"MQ/+-(T1G1?W2.HR5+'J?8=*+ 5/\ A.K;_H >(_\
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MG!X@OM8DT;Q+)-<Q1PHITIP(HUYP/7)YKO<GU-&3ZF@#E?\ A.K;_H ^)/\
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M2_O))#QLP>AX.<],4[3/$?V[56TNZTZ\TZ_$7G+#<%6\Q,X)5E)!P>U,#/\
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MB2@,C Y#!LYW9YS3N!GZ^,^._"@3_6AKEF]0GE\_AG%+XA 7Q=X0   ^TW'
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M310!RW_"M_!G_0MZ?_WZH_X5MX,_Z%O3_P#OU74T4 <JOPU\%JH4>&]/P/\
MIG2_\*V\&?\ 0MZ?_P!^JZFB@#EO^%;>#/\ H6]/_P"_5'_"MO!G_0MZ?_WZ
MKJ:* .6_X5MX,_Z%O3_^_5'_  K;P9_T+>G_ /?JNIHH Y;_ (5MX,_Z%O3_
M /OU1_PK;P9_T+>G_P#?JNIHH Y;_A6W@S_H6]/_ ._5'_"MO!G_ $+>G_\
M?JNIHH Y;_A6W@S_ *%O3_\ OU1_PK;P9_T+>G_]^JZFB@#EO^%;>#/^A;T_
M_OU1_P *V\&?]"WI_P#WZKJ:* .6_P"%;>#/^A;T_P#[]4?\*V\&?]"WI_\
MWZKJ:* .6_X5MX,_Z%O3_P#OU1_PK;P9_P!"WI__ 'ZKJ:* .6_X5MX,_P"A
M;T__ +]4?\*V\&?]"WI__?JNIHH Y5OAIX+=2K>&]/P?^F=+_P *V\&?]"WI
M_P#WZKJ:* .6_P"%;>#/^A;T_P#[]4?\*V\&?]"WI_\ WZKJ:* .6_X5MX,_
MZ%O3_P#OU1_PK;P9_P!"WI__ 'ZKJ:* .6_X5MX,_P"A;T__ +]4?\*V\&?]
M"WI__?JNIHH Y;_A6W@S_H6]/_[]4?\ "MO!G_0MZ?\ ]^JZFB@#EO\ A6W@
MS_H6]/\ ^_5'_"MO!G_0MZ?_ -^JZFB@#EO^%;>#/^A;T_\ []4?\*V\&?\
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MFB@#EO\ A6W@S_H6]/\ ^_5'_"MO!G_0MZ?_ -^JZFB@#EO^%;>#/^A;T_\
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M25$+G:H9@-Q]!ZT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ<>C:)>ZC+C;;0M)@]R!P/Q.!6;<^'KLZ8]E#J]]*9YHS+/<3?.D:G)";0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img108642122_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img108642122_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- [\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)/XGN[>[NK>**>* 0L\9/[S'<Y[\UBUI&]E<YZO+SODV"BBBF0%%%% 'T?\
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MM17U3_PB'AK_ * &F?\ @*G^%'_"(>&O^@!IG_@*G^%'UR/8/:H^5J*^J?\
MA$/#7_0 TS_P%3_"C_A$/#7_ $ -,_\  5/\*/KD>P>U1\K45]4_\(AX:_Z
M&F?^ J?X4?\ "(>&O^@!IG_@*G^%'UR/8/:H^5J*^J?^$0\-?] #3/\ P%3_
M  H_X1#PU_T -,_\!4_PH^N1[![5'RM17U3_ ,(AX:_Z &F?^ J?X4?\(AX:
M_P"@!IG_ ("I_A1]<CV#VJ/E:BOJG_A$/#7_ $ -,_\  5/\*/\ A$/#7_0
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MB<0FJLKN^KU[Z[_,****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,]CDYYS5VJC>RN95N5U)<BLKNR\@HHHIF84444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F2RQP0O-*ZI'&I9W8X"@<DD^E/JGJ\5M/HM_#>RF*UDMY%FD!
MQL0J0Q_ 9H MJRNH92"I&01W%+45LL:6L*Q-NC"*%;U&.*EH **** "BBB@
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M\K2,RCGT4@?A5^L_1K&73M.^SS3^>_G32;^>CR,P'/H& _"@#0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH S]%M+JQTQ(+V?SYQ)(Q?<3D-(S*,GT4@?
MA6A6?HEC+INEI:SS^?(LDKF3GD-(S <^@('X5H4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U>2UBT6^DOHS)9I
M;R-.@&2T84[A^6:N53U>:WMM%OY[N+SK:*WD>6/ .] I)'/J,B@">V,;6L+1
M#;&44H/08XJ6HK9D>UA>-=L;(I5?08X%2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#"D_X3+0O^?QO^_+_X5Y@:8:/91%]=J>1ZC_PFF@_\_C?]^7_PI/\ A-=
M_P"?UO\ OR_^%>5FFFG[*)/UZKY'JO\ PF^@?\_K?]^7_P *3_A./#__ #^M
M_P!^'_PKR<TPT>QB+Z_5\CUK_A.O#W_/ZW_?A_\ "D_X3SP[_P _K?\ ?A_\
M*\C-1FG[&(O[0J]D>O\ _">^'!_R_/\ ]^)/\*/^$^\.?\_S_P#?B3_"O'C4
M9H]C$7]H5>R_KYGLG_"P/#?_ #_/_P!^)/\ XFMC2]8L-:MC<:?<+-&#M;@@
MJ?<'D5X :N:3K%[H=^MY92[7'#*?NN/1AZ4G05M"H9C/F]]:'T#16)X<\367
MB.S\R ^7<(/WL#'YD/K[CWK;KG::=F>M"<9QYHO0*IZO<Q66BWUW/")HH+>2
M1XCC#JJDE>>.0,5<JGJUV+#1KZ\,(F$%O)+Y1_CVJ3C\<8I%$]M(LMK#(B[%
M=%8+Z CI4M16TGG6L,NW;O0-M],CI4M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R
M'Q*FU6#PF7T=KI;K[0@S:[M^WG/3G'2NOK$\5>)(?"NC?VE/;O.GF+'L0@')
MSSS]*BI;D=W8Z<$Y+$0<(\SNM._D7='TVUTC2;>PLBQMH5VQEFW'&2>OXU>K
M#\&Z==:3X1TZQO8_+N88RKKN!P=Q/45N4X_"M+&==6JR][FU>O?7?YA1115&
M04444 %%%% !1110 4444 %%%% !1110 4444 %9VB6]I:Z9Y5E/Y\'GS-OR
M#\S2L6''HQ(_"M&L[1(K&'3=FG2F6W\Z8[B<_.96+C\&+#\* -&BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#.T6WM+72DALI_/MQ)(0^0<DR,6''H21^
M%735+18K*'2D33I3);"20JQ.?F+L6_)LBKIH$,-,-/-,-,ED;4PT]J8:9+&&
MF&GFF&F2,-1FI#49H$,-,-/-,-,D8:8:>:8:9)5O96@L;B9 "\<3NN?4*2*Y
M/0_$U[=GYI8-70V4=RS6,8C\F1B!Y3$MMZ$G)(( .:ZZYA%Q;2P,2%E1D)'4
M C']:RKK0(+C0;?21*T<<'E;7"*=QCQC<I&&!QR#0":MJ4!XGDN;G2TL].EE
M2ZN)K><,Z!HFC'(!W8/KD9!'3FH&\6VMG8V[W#-//,9F"_NX3LC<J3\S >@
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M-][/W_-;?U_V]U:-9VB/8R:;NTZ,QVWG3#:0?OB5@YY]7W&@#1HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK+=W2?.S7.Z-P/NQ ;?E0 GUYR3UJ;1=.GLIKR:2"&TCG9/+M()-Z1[1@MG
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M&X>M "T4FY?44F]?[PH =13?,3^\/SI/-C_OK^= #Z*9YT7_ #T7\Z3SX?\
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M\UV[LUU W,*+/#_J+;RV!92X17WYPZG(SC&,XJ?3[B_G6=;ZV:%D8!',>SS
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M^R3^7O4]0W!_/J/6MR6J4M4C*1S</ANQT^\2>Q>ZM4545K>&8B*38NU2R]R
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M5WN%%%%9G49^BQ7T&EI'J4GF70DE);=GY3(Q7G_=*UH50TBWN[334AO9_.N
M\A+[BV078J,GT4@?A5LD^IH$245"6/J?SIA9O[Q_.@+EFBJ9=O[S?G3"[_WV
M_.G87,7Z*S3(_P#?;\Z89)/[[?G187.:M%8YDD_OM^9IAED_YZ/_ -]&G87M
M#;HK!,LG_/1_^^C49ED_YZ/_ -]&CE%[7R.BHKFC+)_ST?\ [Z-,,LG_ #T?
M_OHT<HO:^1U%%<HTLO\ ST?_ +Z-,,LO_/5_^^C3Y1>V\CKJ*XXS2_\ /5_^
M^C49FE_YZO\ ]]&CD%[?R.UHKB#-+_SUD_[Z-1F:7_GK)_WT:.07UCR.[HK@
MC-+_ ,]9/^^C3#/-_P ]9/\ OHT^07UGR/0**\\,TW_/:3_OLTPSS?\ /:3_
M +[-'LQ?6O(]&HKS4SS?\]I/^^S3#/-_SVD_[[-'L_,7UOR/3:*\O,\W_/:7
M_OLTPSS?\]I?^^S3]GYA];\CU.BO*3<3_P#/:7_OLTPW$_\ SWE_[[-'LO,7
MUS^Z>LT5Y&;B?_GO+_WV:8;B?_GO+_WV:/9>8OKO]T]?HKQTW$__ #WE_P"^
MS49N9_\ GO+_ -]FG[+S%]>_N_B>S45XN;B?_GO+_P!_#49N9_\ GXF_[^&C
MV/F+Z_\ W?Q/;**\0-S<?\_$W_?PTPW-Q_S\3?\ ?P_XT_8^8O[0_N_B>Y45
MX4;FX_Y^)O\ OX?\:8;FX_Y^)O\ OX?\:/8^8O[1_N_B>\45X(;FX_Y^)O\
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MHWPW\2'I!;?]_P ?X5$WPS\3'_EWMO\ O^/\*I3CW'='$OUJ%Z[=OAAXH/\
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MJL3B%)5IJ;N[N[[ZA1115&(4444 %%%% !1110 4444 %%%% !1110 4444
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MDMT+JYGL[:>7-NK-G:Q4=R#SD\9- *W4U;K6M-M+%[V6^@^SHXC:1) P#$@
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M&.!4M16SK+:PR(NQ&165?0$=*EI%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>,?#
M7_"5Z%_9OVK[-^]63S-F[IGC&1ZUOUR'Q)N=4M/"ADT=[E+K[0@S; [MO.>G
M..E14MR.^QU8)3>)@J;M*ZL^QOZ%JT>NZ):ZG#$\4=PNY4?&1R1V^E:%4='T
MRVT;2;?3[,L;>!=J%VW'&2>OXU>JHWLK[F-7D]I+V?PW=O3H%%%%,S"BBB@
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M\2_9YHV>Q?[(]H;SSA(-Z1@ _-'C())VCGK5;4-<O%MI8)+233[P>1*G[U9
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M #S:M.BBXN0R3;S?\\VIAMIO^>3?E6S11<7LT89MI_\ GDWY4PVL_P#SQ?\
M*M^BGS![-'/&TN/^>+_E3#9W/_/!_P JZ2BCF%[)',&SN?\ GA)^5--E=?\
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M,V\>9Y<6_(#(&48.<$ Y !XJS!X_UR\O+6"VT:Q*WL]Y;VS27;##6Y.2X"'
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MY+K)'+Y;,K;>QZ=B"<\@5)X&UB]U/7[!I[NYDCF\-6]P4EEW9D,K@L< #<0
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ML<")81WUM=PP^7($,VP@ 2,0".<MM/7*\U["^FV$E\M\]E;->(,+<&)3(H]
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M;9\RSVL[?O?XK<*(_P ,*,^M :'-3?$1Y-=TV\6&YM/#_P!GOYI)75&%TL
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MO97,JW+[27(K*[MZ!1113,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ=S?P1V4NWRYMV5?=]W;CKGVJ!_%.AQWD-HVJ6PGF0/&F[[P*[ACW(Y ZD4
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MNY)Z?C6I5QO97,*W+[27([J[L_(****9F%%%% !1110 4444 %%%% !1110
M4444 %%%% !5#1[>\M=.\J_F\Z?SI6W[BWRM(Q09/HI4?A5^J&C65Q8:=Y%U
M/YTOG3/OR3\K2,RCGT! _"@"_1110 4444 %%%% !1110 4444 %%%% !111
M0!GZ+;7EII:0W\WG7 DD)?<6RID8J,GT4@?A6A6?HME<:?I:6UU/Y\PDE8OD
MG(:1F Y] 0/PK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JGJ[6B:+?-?J7LUMY#.HSDQ[3N''MFKE1W$$5U;2V
M\Z"2&5"CHW1E(P0?PH 2V,9M83",1%%V ]ACBI::B+&BH@ 50  .PIU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>glto-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-08T13:45:16.5940+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:href="glto-20221231.xsd#Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="glto-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" xlink:href="glto-20221231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="glto-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="glto_AccretionOfLeaseLiability" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="glto_IncreaseDecreaseInOperatingLeaseLiabilities" order="11" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccretionOfLeaseLiability" xlink:label="glto_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="glto_ContractResearchAndDevelopmentCostCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="glto_ContractResearchAndDevelopmentCostsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostsCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="glto_DeferredTaxLiabilitiesFixedAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="glto_DeferredTaxAssetsOrphanDrugCredit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="glto_DeferredTaxAssetsBonusCompensation" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxLiabilitiesFixedAssets" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsOrphanDrugCredit" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsBonusCompensation" xlink:label="glto_DeferredTaxAssetsBonusCompensation"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>glto-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-08T13:45:16.3232+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="glto-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="glto-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:href="glto-20221231.xsd#Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:href="glto-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="glto-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="glto_StockIssuedDuringPeriodNetOfIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccretionOfLeaseLiability" xlink:label="glto_AccretionOfLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="glto_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="glto_AccretionOfLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_InvestmentsAndCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesTable" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_OriginalMaturitiesAtDateOfPurchase" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendIncomeOperating" xlink:label="us-gaap_DividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="glto_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="glto_OriginalMaturitiesAtDateOfPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DividendIncomeOperating" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LongTermInvestmentsMember" xlink:label="glto_LongTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="glto_LongTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="us-gaap_DebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_DebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="country_DK"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_CopenhagenMember" xlink:label="glto_CopenhagenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SE" xlink:label="country_SE"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_GothenburgMember" xlink:label="glto_GothenburgMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="country_GB"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LondonMember" xlink:label="glto_LondonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StevenageMember" xlink:label="glto_StevenageMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="country_DK" xlink:to="glto_CopenhagenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="country_SE" xlink:to="glto_GothenburgMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="country_GB" xlink:to="glto_LondonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="country_GB" xlink:to="glto_StevenageMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SE" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="glto_TwoThousandTwentyStockOptionAndGrantPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="glto_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentySixMember" xlink:label="glto_TwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsOrphanDrugCredit" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentySixMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="glto_DeferredTaxAssetsOrphanDrugCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockOptionsToPurchaseCommonStockMember" xlink:label="glto_StockOptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glto_StockOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>glto-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-08T13:45:18.3886+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentySixMember" xlink:label="glto_TwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_CopenhagenMember" xlink:label="glto_CopenhagenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LondonMember" xlink:label="glto_LondonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockOptionsToPurchaseCommonStockMember" xlink:label="glto_StockOptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccretionOfLeaseLiability" xlink:label="glto_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="country_DK"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendIncomeOperating" xlink:label="us-gaap_DividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StevenageMember" xlink:label="glto_StevenageMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesTable" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxLiabilitiesFixedAssets" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsOrphanDrugCredit" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_OperatingLeaseRentExpense" xlink:label="glto_OperatingLeaseRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_GothenburgMember" xlink:label="glto_GothenburgMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="us-gaap_DebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SE" xlink:label="country_SE"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:label="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_OriginalMaturitiesAtDateOfPurchase" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsBonusCompensation" xlink:label="glto_DeferredTaxAssetsBonusCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LongTermInvestmentsMember" xlink:label="glto_LongTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" xlink:label="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_NumberOfOfficeAndLaboratorySpace" xlink:label="glto_NumberOfOfficeAndLaboratorySpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostsCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="country_GB"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock; net of issuance costs of $0.2 million</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options allowed to award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Six [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty six.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance costs, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_CopenhagenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Copenhagen, Denmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_CopenhagenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Copenhagen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_CopenhagenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Copenhagen.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business organization and liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LondonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">London,United Kingdom</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LondonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">London Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LondonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">London.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, grants in period, intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease,renewal option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issuance costs, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance or sale of equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value per share of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value-added tax refund receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used in computing net loss per common share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Organization and Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Series D preferred stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends per share paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increase of number of shares of common stock issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DENMARK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Useful Life of Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Life Of Asset Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful life of asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued or outstanding as of December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quantitative Information Regarding Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used in computing net loss per common share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Clinical Development and Corporate General and Administrative Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Orphan Drug Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation orphan drug credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense or benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock; net of issuance costs of $0.2 million (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Income (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividend Income, Operating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Income, Operating</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business organization and liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StevenageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stevenage, United Kingdom</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StevenageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stevenage Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_StevenageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stevenage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive gain (loss), net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments - Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2022 and 2021; 25,652,392 and 25,261,832 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification adjustment for loss included in net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification adjustment for loss included in net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss on sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss on sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 through 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Through Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty through two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit receivable current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities fixed assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan drug credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Orphan Drug Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets orphan drug credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss) , net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation gain (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OperatingLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OperatingLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OperatingLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease rent expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Vested and expected</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_GothenburgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gothenburg, Sweden</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_GothenburgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gothenburg Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_GothenburgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gothenburg.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period, net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Deduction, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_SE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sweden</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_SE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SWEDEN</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense that is expected to be recognized over a weighted-average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss), net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently adopted accounting standards and Recently issued accounting standards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investments in marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange transaction gain (loss), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Option And Grant Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock option and grant plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency and currency translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit refund receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging growth company status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research And Development Cost Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract research and development cost current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available for Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refundable tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Credits and Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price per share, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price per share, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of credit risk and off-balance sheet risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original maturities at the date of purchase of liquid investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Original Maturities At Date Of Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Original maturities at the date of purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsBonusCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsBonusCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Bonus Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DeferredTaxAssetsBonusCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets bonus compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets Measured at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments - Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends per share declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net noncurrent deferred tax asset(liability)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period, price per shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_NumberOfOfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of office and laboratory space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_NumberOfOfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Office And Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_NumberOfOfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of office and laboratory space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Company's Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sales Type Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sales Type [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indicates type of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution paid by employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments and Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments and Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 through 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Through Two Thousand Twenty Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three through two thousand twenty five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted to underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research And Development Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract research and development costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right of use lease asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TwoThousandTwentySixMember" xlink:to="glto_TwoThousandTwentySixMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="glto_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_StockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="glto_StockIssuedDuringPeriodNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_CopenhagenMember" xlink:to="glto_CopenhagenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_LondonMember" xlink:to="glto_LondonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="glto_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="glto_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_StockOptionsToPurchaseCommonStockMember" xlink:to="glto_StockOptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_AccretionOfLeaseLiability" xlink:to="glto_AccretionOfLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" xlink:to="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" xlink:to="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendIncomeOperating" xlink:to="us-gaap_DividendIncomeOperating_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="glto_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_StevenageMember" xlink:to="glto_StevenageMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="glto_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" xlink:to="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DeferredTaxLiabilitiesFixedAssets" xlink:to="glto_DeferredTaxLiabilitiesFixedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DeferredTaxAssetsOrphanDrugCredit" xlink:to="glto_DeferredTaxAssetsOrphanDrugCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_OperatingLeaseRentExpense" xlink:to="glto_OperatingLeaseRentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_GothenburgMember" xlink:to="glto_GothenburgMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesMember" xlink:to="us-gaap_DebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SE" xlink:to="country_SE_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:to="glto_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:to="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_ContractResearchAndDevelopmentCostCurrent" xlink:to="glto_ContractResearchAndDevelopmentCostCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_OriginalMaturitiesAtDateOfPurchase" xlink:to="glto_OriginalMaturitiesAtDateOfPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DeferredTaxAssetsBonusCompensation" xlink:to="glto_DeferredTaxAssetsBonusCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_LongTermInvestmentsMember" xlink:to="glto_LongTermInvestmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" xlink:to="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_NumberOfOfficeAndLaboratorySpace" xlink:to="glto_NumberOfOfficeAndLaboratorySpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" xlink:to="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" xlink:to="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glto_ContractResearchAndDevelopmentCostsCurrent" xlink:to="glto_ContractResearchAndDevelopmentCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>glto-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-08T13:45:16.3579+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="glto-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="glto-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="glto-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="glto-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:href="glto-20221231.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities" xlink:href="glto-20221231.xsd#Role_DisclosureInvestmentsInMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="glto-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="glto-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="glto-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="glto-20221231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="glto-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="glto-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="glto-20221231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="glto-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="glto-20221231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="glto-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="glto-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables" xlink:href="glto-20221231.xsd#Role_DisclosureInvestmentsInMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="glto-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="glto-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="glto-20221231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="glto-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="glto-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" xlink:href="glto-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:href="glto-20221231.xsd#Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:href="glto-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="glto-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" xlink:href="glto-20221231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="glto-20221231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="glto-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails" xlink:href="glto-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="glto-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="glto-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="glto-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="glto-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="glto-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_8"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="glto_StockIssuedDuringPeriodNetOfIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="glto_StockIssuedDuringPeriodNetOfIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glto_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccretionOfLeaseLiability" xlink:label="glto_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="glto_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="glto_AccretionOfLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" xlink:label="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:label="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="glto_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProfitLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="glto_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_OriginalMaturitiesAtDateOfPurchase" xlink:label="glto_OriginalMaturitiesAtDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_SummaryOfSignificantAccountingPoliciesTable" xlink:label="glto_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendIncomeOperating" xlink:label="us-gaap_DividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="glto_OriginalMaturitiesAtDateOfPurchase" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="glto_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesTable" xlink:to="glto_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DividendIncomeOperating" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glto_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LongTermInvestmentsMember" xlink:label="glto_LongTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" xlink:label="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="glto_LongTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="us-gaap_DebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_DebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="glto_ContractResearchAndDevelopmentCostCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DK" xlink:label="country_DK"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_CopenhagenMember" xlink:label="glto_CopenhagenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SE" xlink:label="country_SE"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_GothenburgMember" xlink:label="glto_GothenburgMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="country_GB"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_LondonMember" xlink:label="glto_LondonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StevenageMember" xlink:label="glto_StevenageMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_DK" xlink:to="glto_CopenhagenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_SE" xlink:to="glto_GothenburgMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_GB" xlink:to="glto_LondonMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_GB" xlink:to="glto_StevenageMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SE" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_NumberOfOfficeAndLaboratorySpace" xlink:label="glto_NumberOfOfficeAndLaboratorySpace"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_OperatingLeaseRentExpense" xlink:label="glto_OperatingLeaseRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="glto_NumberOfOfficeAndLaboratorySpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="glto_OperatingLeaseRentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ContractResearchAndDevelopmentCostsCurrent" xlink:label="glto_ContractResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="glto_ContractResearchAndDevelopmentCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="glto_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="glto_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="glto_TwoThousandTwentyStockOptionAndGrantPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="glto_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" xlink:label="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" xlink:label="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_TwoThousandTwentySixMember" xlink:label="glto_TwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsOrphanDrugCredit" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="glto_TwoThousandTwentySixMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="glto_DeferredTaxAssetsOrphanDrugCredit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" xlink:label="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxLiabilitiesFixedAssets" xlink:label="glto_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsOrphanDrugCredit" xlink:label="glto_DeferredTaxAssetsOrphanDrugCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_DeferredTaxAssetsBonusCompensation" xlink:label="glto_DeferredTaxAssetsBonusCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="glto_DeferredTaxLiabilitiesFixedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="glto_DeferredTaxAssetsOrphanDrugCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="glto_DeferredTaxAssetsBonusCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="glto-20221231.xsd#glto_StockOptionsToPurchaseCommonStockMember" xlink:label="glto_StockOptionsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glto_StockOptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>glto-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-08T13:45:16.4819+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://galecto.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:glto="http://galecto.com/20221231" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glto-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glto-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glto-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glto-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity">
        <link:definition>100070 - Disclosure - Description of Business, Organization and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities" id="Role_DisclosureInvestmentsInMarketableSecurities">
        <link:definition>100090 - Disclosure - Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100120 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100190 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100200 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100210 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100220 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables" id="Role_DisclosureInvestmentsInMarketableSecuritiesTables">
        <link:definition>100250 - Disclosure - Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100280 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100290 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100300 - Disclosure - Accrued Expenses And Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100310 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100330 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails" id="Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails">
        <link:definition>100370 - Disclosure - Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100390 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfOperatingLeasesDetails">
        <link:definition>100400 - Disclosure - Leases - Summary of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails" id="Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails">
        <link:definition>100420 - Disclosure - Leases - Quantitative Information Regarding Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails">
        <link:definition>100440 - Disclosure - Property and Equipment, Net - Summary of Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100470 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails">
        <link:definition>100500 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100510 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails" id="Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails">
        <link:definition>100520 - Disclosure - Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Summary of Components of Net Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100570 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100580 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="glto_AccretionOfLeaseLiability" name="AccretionOfLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_ContractResearchAndDevelopmentCostCurrent" name="ContractResearchAndDevelopmentCostCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_ContractResearchAndDevelopmentCostsCurrent" name="ContractResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="glto_DeferredTaxAssetsBonusCompensation" name="DeferredTaxAssetsBonusCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_DeferredTaxAssetsOrphanDrugCredit" name="DeferredTaxAssetsOrphanDrugCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" name="EffectiveIncomeTaxRateReconciliationOrphanDrugCredit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_NumberOfOfficeAndLaboratorySpace" name="NumberOfOfficeAndLaboratorySpace" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_OperatingLeaseRentExpense" name="OperatingLeaseRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_OriginalMaturitiesAtDateOfPurchase" name="OriginalMaturitiesAtDateOfPurchase" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_ResearchAndDevelopmentTaxCreditReceivableCurrent" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_StockIssuedDuringPeriodNetOfIssuanceCosts" name="StockIssuedDuringPeriodNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" name="TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="glto_DebtSecuritiesAvailableForSalesTypeExtensibleList" name="DebtSecuritiesAvailableForSalesTypeExtensibleList" type="xbrli:tokenItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems" name="DescriptionOfBusinessOrganizationAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_CopenhagenMember" name="CopenhagenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_GothenburgMember" name="GothenburgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_LondonMember" name="LondonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_StevenageMember" name="StevenageMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_StockOptionsToPurchaseCommonStockMember" name="StockOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_TwoThousandTwentySixMember" name="TwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_TwoThousandTwentyStockOptionAndGrantPlanMember" name="TwoThousandTwentyStockOptionAndGrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" name="TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember" name="TwoThousandTwentyThroughTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_DescriptionOfBusinessOrganizationAndLiquidityTable" name="DescriptionOfBusinessOrganizationAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" name="AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" name="ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554729034096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GALECTO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001800315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">37-1957007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">75 State Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">70 70 52 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLTO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,673,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EY Godkendt Revisionspartnerselskab<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Copenhagen, Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728640352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,786<span></span>
</td>
<td class="nump">$ 62,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">27,438<span></span>
</td>
<td class="nump">37,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">9,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">63,910<span></span>
</td>
<td class="nump">110,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">5,832<span></span>
</td>
<td class="nump">9,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, non-current</a></td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,188<span></span>
</td>
<td class="nump">122,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,757<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,107<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,435<span></span>
</td>
<td class="nump">4,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued or outstanding as of December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2022 and 2021; 25,652,392 and 25,261,832 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">279,733<span></span>
</td>
<td class="nump">273,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(217,736)<span></span>
</td>
<td class="num">(156,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">61,753<span></span>
</td>
<td class="nump">117,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 73,188<span></span>
</td>
<td class="nump">$ 122,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728952096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">25,652,392<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">25,652,392<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731324928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 48,206<span></span>
</td>
<td class="nump">$ 38,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,001<span></span>
</td>
<td class="nump">13,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">61,207<span></span>
</td>
<td class="nump">52,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(61,207)<span></span>
</td>
<td class="num">(52,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Loss on sale of marketable securities</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange transaction gain (loss), net</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(417)<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,624)<span></span>
</td>
<td class="num">$ (51,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">25,409,123<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">25,409,123<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation gain (loss)</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="num">$ (917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for loss included in net income</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(994)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (61,548)<span></span>
</td>
<td class="num">$ (52,746)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728816368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 165,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,175<span></span>
</td>
<td class="num">$ (104,360)<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss) , net</a></td>
<td class="num">(994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,752)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,752)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">117,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,655<span></span>
</td>
<td class="num">(156,112)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock; net of issuance costs of $0.2 million (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock; net of issuance costs of $0.2 million</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss) , net</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,652,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 61,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,733<span></span>
</td>
<td class="num">$ (217,736)<span></span>
</td>
<td class="num">$ (244)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734644944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_StockIssuedDuringPeriodNetOfIssuanceCosts', window );">Common stock issuance costs, net</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_StockIssuedDuringPeriodNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_StockIssuedDuringPeriodNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554733819008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (61,624,000)<span></span>
</td>
<td class="num">$ (51,752,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of equipment</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,571,000<span></span>
</td>
<td class="nump">4,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">566,000<span></span>
</td>
<td class="nump">1,072,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Net loss on sale of marketable securities</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use lease asset</a></td>
<td class="nump">448,000<span></span>
</td>
<td class="nump">421,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_AccretionOfLeaseLiability', window );">Accretion of lease liability</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,232,000<span></span>
</td>
<td class="num">(4,199,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets, non-current</a></td>
<td class="num">(257,000)<span></span>
</td>
<td class="num">(866,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,819,000<span></span>
</td>
<td class="num">(1,320,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,666,000<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(523,000)<span></span>
</td>
<td class="num">(513,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,932,000)<span></span>
</td>
<td class="num">(52,308,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(44,865,000)<span></span>
</td>
<td class="num">(84,209,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">57,445,000<span></span>
</td>
<td class="nump">36,384,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(196,000)<span></span>
</td>
<td class="num">(223,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">12,384,000<span></span>
</td>
<td class="num">(48,048,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(30,041,000)<span></span>
</td>
<td class="num">(100,356,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="num">(917,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">62,563,000<span></span>
</td>
<td class="nump">163,836,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">32,786,000<span></span>
</td>
<td class="nump">62,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 488,000<span></span>
</td>
<td class="nump">$ 411,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_AccretionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_AccretionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728813824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Organization and Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. DESCRIPTION OF BUSINESS, ORGANIZATION AND LIQUIDITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Galecto, Inc., together with its consolidated subsidiaries (the &#8220;Company&#8221; or &#8220;Galecto&#8221;), is a clinical-stage biotechnology company developing novel therapeutics that are designed to target the biological processes that lie at the heart of fibrotic diseases and cancer. The Company&#8217;s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 ("LOXL2&#8221;), which play key roles in regulating fibrosis and cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company&#8217;s wholly owned subsidiaries were PharmAkea, Inc. or PharmAkea, Galecto Securities Corporation and Galecto Biotech AB, a Swedish company. Galecto Biotech ApS, a Danish operating company, is a wholly-owned subsidiary of Galecto Biotech AB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s product candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and management plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has devoted substantially all its efforts to business planning, research and development,</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting management and technical staff and raising capital, and has financed its operations primarily through the issuance of redeemable convertible preferred shares, debt financings and, most recently, the Company&#8217;s initial public offering, or IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, from recurring losses since inception in 2011. The Company has incurred recurring losses and has not generated revenue as no products have obtained the necessary regulatory approval in order to market products. The Company expects to continue to incur losses as a result of costs and expenses related to the Company&#8217;s clinical development and corporate general and administrative activities. The Company had negative cash flows from operating activities during the years ended December 31, 2022 and 2021 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and current projections indicate that the Company will have continued negative cash flows for the foreseeable future as it continues to develop its product candidates. Net losses incurred for the years ended December 31, 2022 and 2021 amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company&#8217;s cash, cash equivalents and marketable securities amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, current assets amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and current liabilities amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. At December 31, 2021, the Company&#8217;s cash, cash equivalents and marketable securities amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, current assets amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and current liabilities amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, the Company will consider the following ways to fund its operations including: (1) raising additional capital through equity and/or debt financings; (2) new commercial relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. Volatility in equity capital markets may adversely affect the market price of the Company&#8217;s shares of common stock, which may materially and adversely affect the Company&#8217;s ability to fund its business through</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">public or private sales of equity securities. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, key developments and regulatory events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coronavirus pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The novel coronavirus (&#8220;COVID-19&#8221;) and its variants, and ensuing pandemic, has continued to spread worldwide, causing many governments to implement measures to slow the spread of the outbreak. COVID-19 and its variants have had a significant impact, both directly and indirectly, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services has fallen. The Company continues to monitor the impact of COVID-19 and its subvariants and assess its strategy accordingly. However, there can be no assurance that the Company will not experience additional negative impacts associated with the COVID-19 pandemic, which could decrease or delay enrollment of patients in the Company&#8217;s clinical trials or otherwise cause interruptions or delays in the Company&#8217;s clinical trials, programs and services, and negatively impact the Company&#8217;s business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554814409232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with United States, or U.S., generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s consolidated financial statements for 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> include Galecto, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Significant items subject to such estimates and assumptions include contract research accruals, accounting for stock-based compensation and valuation of the Company&#8217;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. The Company&#8217;s actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Currency and currency translation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are presented in U.S. dollars, the Company&#8217;s reporting currency. Galecto, Inc., Galecto Securities Corporation and PharmAkea&#8217;s functional currency is the U.S. dollar. The functional currency of the Company&#8217;s subsidiary Galecto Biotech AB, and its subsidiary Galecto Biotech ApS, is the Euro. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the year. Resulting translation adjustments are recorded to accumulated other comprehensive income (loss), or OCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities at the date of purchase of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 4).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held at financial institutions that management believes to be of high-credit quality. The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in marketable securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests excess cash balances in short-term and long-term marketable debt securities. The Company classifies investments in marketable debt securities as either held-to-maturity or available-for-sale based on the facts and circumstances present at the time of purchase and re-evaluates classification at each balance sheet date. All investments in marketable debt securities at each balance sheet date presented, are generally considered as available-for-sale. Marketable debt securities with maturities of twelve months or less are classified as short-term investments and marketable debt securities with maturities greater than twelve months are classified based on their availability for use in current operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reports available-for-sale debt securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value), net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. The cost of debt securities is adjusted for the amortization of premium and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other than temporary,&#8221; including the intention to sell and, if so, marks the investment to market through a charge to the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the time it enters into a contract. For all leases, the Company determines the classification as either operating leases or finance leases. Operating leases are included in operating lease right-of-use, or ROU, assets and accrued expenses and other current liabilities and operating lease liabilities, noncurrent in the Company&#8217;s consolidated balance sheets. The Company has not entered into any financing leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses the Company&#8217;s incremental borrowing rate in determining the present value of lease payments. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. Refer to Note 6 for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.981%;"/>
          <td style="width:3.001%;"/>
          <td style="width:60.018%;"/>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
         </tr>
         <tr style="height:10.8pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.1pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of 10 years or the remaining term of the respective lease</span></span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. Through December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, no such impairment has occurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including stock-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors, or collectively, CROs. These CROs generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the CROs, and correspondence with the CROs and clinical site visits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock options granted in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 718. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#8217;s consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The expected term of the Company&#8217;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Expected dividend yield is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows the provisions of ASC 740-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or ASC 740-10. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has identified the United States, Denmark and United Kingdom as its major tax jurisdictions. Refer to Note 11 for further details.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, both methods are equivalent. Basic and diluted net loss per share is described further in Note 12.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. The Company has determined it operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other comprehensive gain (loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain (loss), or OCI, is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s OCI includes currency translation and unrealized gain or (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emerging growth company status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company may elect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, and as a smaller reporting company, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Codification Improvements to Topic 326, Financial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Instruments-Credit Losses, Topic 815, Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">and Topic 825, Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The ASU 2016-13 guidance became effective as of January 1, 2020, and must be adopted using a modified retrospective approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a SEC, excluding eligible smaller reporting companies for fiscal years beginning after December 15, 2019. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December 15, 2022. The adoption of ASU No. 2016-13 during the year ended December 31, 2022 did not have a material impact on the financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically reviews new accounting standards that are issued and has not identified any new standards that it believes merit further discussion or would have a significant impact on its financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554814474752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. INVESTMENTS IN MARKETABLE SECURITIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash in excess of the Company&#8217;s immediate requirements is invested in accordance with the Company&#8217;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s available-for-sale investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.879%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.623000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.623000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.828000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.023%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0f88c296-6264-4042-8714-841aed812bb6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_44cda3a6-b017-451a-b0b6-7cab4805cade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,671</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,628</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,048</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,082</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,048</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554814482352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. FAIR VALUE MEASUREMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classified its money market funds within Level 1 because their fair values are based on their quoted market prices. The Company classified its debt securities within Level 2 because their fair values are determined using alternative pricing sources or models that utilized market observable inputs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the assets that are measured at fair value as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.045%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.911000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.032%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735790624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.662%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.146%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.291%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">587</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,686</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554814482352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. LEASES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the following operating leases:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.194%;"/>
        <td style="width:1.713%;"/>
        <td style="width:20.741%;"/>
        <td style="width:1.722%;"/>
        <td style="width:14.944%;"/>
        <td style="width:1.722%;"/>
        <td style="width:15.963%;"/>
       </tr>
       <tr style="height:19.45pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Use</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease <br/>Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Renewal Option</span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate headquarters</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8865681-fb3c-46b3-8f81-199888594bde;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2025</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">London, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_63bad519-8d42-4588-8c64-dc3b578e5db5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2024</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gothenburg, Sweden</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3cbffc48-b954-4828-9d21-d46a15257703;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2023</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stevenage, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d29c6159-b3c6-43bd-8e35-677bf4164550;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2025</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no finance leases and has elected to apply the short-term lease exception to all leases of one year or less. Rent expense for years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for both periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.143%;"/>
        <td style="width:1.933%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.367%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.933%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.623%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows paid for amounts included in the<br/>&#160;&#160;&#160;measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">513</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use<br/>&#160;&#160;&#160;assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted average remaining lease term for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted average discount rate for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for both periods.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities are as follows at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.535%;"/>
        <td style="width:3.057%;"/>
        <td style="width:1.0%;"/>
        <td style="width:27.408%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">293</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554821324096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. PROPERTY AND EQUIPMENT, NET</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.751%;"/>
        <td style="width:2.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.468%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554814325216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.086%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.848%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.075%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,145</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9426828b-8ce6-4136-9592-73b208402ab8;"><span style="-sec-ix-hidden:F_9ab22cc5-86e7-43b0-9814-29ed771a3b70;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">current</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">476</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">399</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">539</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735708768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s commitments related to lease agreements are disclosed in Note 6.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and, to its knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company, as permitted under Delaware law and in accordance with its certification of incorporation and bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#8217;s request in such capacity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the Company&#8217;s products, technology, intellectual property or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734521168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK-BASED COMPENSATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee equity plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company's Board of Directors and stockholders approved the 2020 Stock Option and Grant Plan (&#8220;2020 Plan&#8221;). Holders of stock options under the 2020 Plan shall be entitled to exercise the vested portion of the stock option during the term of the grant. If a qualified exit, as defined in the 2020 Plan, occurs, then all of the holders' unvested options shall vest immediately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company's Board of Directors and stockholders approved the 2020 Equity Incentive Plan (&#8220;2020 Equity Plan&#8221;). Following the adoption of the 2020 Equity Plan, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> further options are available to be issued under the 2020 Plan. Stock options granted under the 2020 Equity Plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the grant date. The 2020 Equity Plan will cumulatively increase by 5 percent of the number of shares of common stock issued and outstanding on January 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each year until 2030. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">884,566</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options available for future grant under the 2020 Equity Plan.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the activity for the Company&#8217;s stock options during the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.734%;"/>
        <td style="width:1.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.065999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.389999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,538,411</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,009,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,160</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,998,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,357,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,593</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,778,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,474,743</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,667,144</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair value of all stock options granted during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The intrinsic value at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is based on the closing price of the Company&#8217;s common stock on that date of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The grant date fair value of stock options vested during the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Total unrecognized compensation expense related to unvested options granted under the Company&#8217;s stock-based compensation plan was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The Company recorded stock-based compensation expense related to the issuance of stock as follows (in thousands):</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.763%;"/>
        <td style="width:2.403%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.687%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.759%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,953</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,577</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of stock options, the expected volatility based on the historical volatility of a publicly traded set of peer companies and the expected risk-free interest rate based on the implied yield on a U.S. Treasury security. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.1%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.453999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.469%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734605888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax expense or benefit for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has incurred net operating losses for all the periods presented. The Company has not reflected the benefit of any such net operating loss carryforwards in the accompanying financial statements. In 2019 the domicile of the reporting entity has changed from Denmark to the United States resulting in a tax rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in 2022 and 2021. This is discussed further below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of net loss are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.435%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.422%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,461</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reconciliation of effective tax rate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective tax rate for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is different from the statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.728%;"/>
        <td style="width:1.142%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.142%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.986999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan Drug Credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following (in thousands): </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.929%;"/>
        <td style="width:1.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.446%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.433%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Orphan drug credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;U.S. research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Bonus compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">544</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">274</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,435</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,472</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net noncurrent deferred tax asset(liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable income. The Company considers projected future taxable income and ongoing tax planning strategies, then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more-likely-than-not able to be realized. Based upon the Company&#8217;s assessment of all available evidence, including the previous three years of taxable income and loss after permanent items, estimates of future profitability, and the Company&#8217;s overall prospects of future business, the Company determined that it is more-likely-than-not that the Company will not be able to realize a portion of the deferred tax assets in the future. The Company will continue to assess the potential realization of deferred tax assets on an annual basis, or an interim basis if circumstances warrant. If the Company&#8217;s actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to change the valuation allowance against the gross deferred tax assets. On the basis of this evaluation, a full valuation allowance at December 31, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was recorded of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, to reduce the net deferred tax assets to their estimated realizable value. The change in valuation allowance was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to taxation in the United States, United Kingdom and Denmark. As of December 31, 2022, tax years 2019 and forward were generally open to examination by the Danish tax authorities and tax year 2021 and forward was open to examination by the United States tax authorities. The Company is not under examination by any taxing authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had gross U.S. federal net operating losses, or NOLs, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and federal research and development credits, or R&amp;D credits, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and Orphan Drug Credit, or ODC, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to offset tax liabilities. The federal R&amp;D credit and ODC carryforwards begin to expire in 2033 and 2042, respectively. All of the federal NOLs have an infinite life. The Company also had gross state NOLs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which are available to offset state tax liabilities. The state NOLs begin to expire in 2040. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also had NOLs in Denmark of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which have an indefinite life. Federal and state NOLs and R&amp;D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not completed an analysis to determine if the NOLs and R&amp;D credits are limited due to a change in ownership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;D expenditures. The deduction for R&amp;D expenditures is set at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2019, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2020 through 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2023 through 2025 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734495536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. NET LOSS PER SHARE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.435%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.422%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of shares used in computing net<br/>&#160;&#160;&#160;loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,409,123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,261,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.278%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.668%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.814%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,778,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,998,728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728958480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. DEFINED CONTRIBUTION PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a 401(k)-defined contribution plan (the &#8220;401(k) Plan&#8221;) for its U.S. based employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the discretion of its Board, the Company may elect to match employee contributions. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company paid a match of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, up to the maximum permitted by the Internal Revenue Code, which amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during both periods and is expensed as personnel costs when incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734554288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> material related party transactions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734601168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. SUBSEQUENT EVENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728701680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with United States, or U.S., generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Principles of consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s consolidated financial statements for 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> include Galecto, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Significant items subject to such estimates and assumptions include contract research accruals, accounting for stock-based compensation and valuation of the Company&#8217;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. The Company&#8217;s actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Currency and currency translation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Currency and currency translation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements are presented in U.S. dollars, the Company&#8217;s reporting currency. Galecto, Inc., Galecto Securities Corporation and PharmAkea&#8217;s functional currency is the U.S. dollar. The functional currency of the Company&#8217;s subsidiary Galecto Biotech AB, and its subsidiary Galecto Biotech ApS, is the Euro. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the year. Resulting translation adjustments are recorded to accumulated other comprehensive income (loss), or OCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities at the date of purchase of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, which are included in cash and cash equivalents and reported at fair value (Note 4).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Concentrations of credit risk and off-balance sheet risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held at financial institutions that management believes to be of high-credit quality. The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in marketable securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in marketable securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests excess cash balances in short-term and long-term marketable debt securities. The Company classifies investments in marketable debt securities as either held-to-maturity or available-for-sale based on the facts and circumstances present at the time of purchase and re-evaluates classification at each balance sheet date. All investments in marketable debt securities at each balance sheet date presented, are generally considered as available-for-sale. Marketable debt securities with maturities of twelve months or less are classified as short-term investments and marketable debt securities with maturities greater than twelve months are classified based on their availability for use in current operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reports available-for-sale debt securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value), net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. The cost of debt securities is adjusted for the amortization of premium and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other than temporary,&#8221; including the intention to sell and, if so, marks the investment to market through a charge to the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the fair value hierarchy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the time it enters into a contract. For all leases, the Company determines the classification as either operating leases or finance leases. Operating leases are included in operating lease right-of-use, or ROU, assets and accrued expenses and other current liabilities and operating lease liabilities, noncurrent in the Company&#8217;s consolidated balance sheets. The Company has not entered into any financing leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses the Company&#8217;s incremental borrowing rate in determining the present value of lease payments. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. Refer to Note 6 for further details.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.981%;"/>
          <td style="width:3.001%;"/>
          <td style="width:60.018%;"/>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
         </tr>
         <tr style="height:10.8pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.1pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of 10 years or the remaining term of the respective lease</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. Through December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, no such impairment has occurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including stock-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, research and development expenses include refundable tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock', window );">Accrued research and development costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors, or collectively, CROs. These CROs generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the CROs, and correspondence with the CROs and clinical site visits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock options granted in accordance with ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 718. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense is classified in the Company&#8217;s consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The expected term of the Company&#8217;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Expected dividend yield is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows the provisions of ASC 740-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertainty in Income Taxes, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or ASC 740-10. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has identified the United States, Denmark and United Kingdom as its major tax jurisdictions. Refer to Note 11 for further details.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, both methods are equivalent. Basic and diluted net loss per share is described further in Note 12.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. The Company has determined it operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other comprehensive gain (loss)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other comprehensive gain (loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive gain (loss), or OCI, is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s OCI includes currency translation and unrealized gain or (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock', window );">Emerging growth company status</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emerging growth company status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company may elect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, and as a smaller reporting company, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards and Recently issued accounting standards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Codification Improvements to Topic 326, Financial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Instruments-Credit Losses, Topic 815, Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">and Topic 825, Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The ASU 2016-13 guidance became effective as of January 1, 2020, and must be adopted using a modified retrospective approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a SEC, excluding eligible smaller reporting companies for fiscal years beginning after December 15, 2019. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December 15, 2022. The adoption of ASU No. 2016-13 during the year ended December 31, 2022 did not have a material impact on the financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically reviews new accounting standards that are issued and has not identified any new standards that it believes merit further discussion or would have a significant impact on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728636896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock', window );">Summary of Estimated Useful Life of Asset</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.981%;"/>
          <td style="width:3.001%;"/>
          <td style="width:60.018%;"/>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
         </tr>
         <tr style="height:10.8pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.1pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:21.6pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of 10 years or the remaining term of the respective lease</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful life of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734586672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s available-for-sale investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.879%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.623000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.623000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.828000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.023%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0f88c296-6264-4042-8714-841aed812bb6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_44cda3a6-b017-451a-b0b6-7cab4805cade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,671</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,628</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,048</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,082</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,048</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728901008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the assets that are measured at fair value as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.045%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.911000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.473%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.788%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.032%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,270</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurement at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying <br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,676</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734530576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.662%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.146%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.291%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">587</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,686</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735379840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Summary of Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the following operating leases:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.194%;"/>
        <td style="width:1.713%;"/>
        <td style="width:20.741%;"/>
        <td style="width:1.722%;"/>
        <td style="width:14.944%;"/>
        <td style="width:1.722%;"/>
        <td style="width:15.963%;"/>
       </tr>
       <tr style="height:19.45pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Use</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease <br/>Expiration Date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Renewal Option</span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate headquarters</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8865681-fb3c-46b3-8f81-199888594bde;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2025</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">London, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_63bad519-8d42-4588-8c64-dc3b578e5db5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2024</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gothenburg, Sweden</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office space</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3cbffc48-b954-4828-9d21-d46a15257703;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2023</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
       <tr style="height:11.5pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stevenage, United Kingdom</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory space</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d29c6159-b3c6-43bd-8e35-677bf4164550;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2025</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Quantitative Information Regarding Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.143%;"/>
        <td style="width:1.933%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.367%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.933%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.623%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows paid for amounts included in the<br/>&#160;&#160;&#160;measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">513</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use<br/>&#160;&#160;&#160;assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities are as follows at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.535%;"/>
        <td style="width:3.057%;"/>
        <td style="width:1.0%;"/>
        <td style="width:27.408%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">523</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">293</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">804</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734576080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.751%;"/>
        <td style="width:2.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.156%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.468%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554734605888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses And Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.086%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.848%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.075%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,145</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9426828b-8ce6-4136-9592-73b208402ab8;"><span style="-sec-ix-hidden:F_9ab22cc5-86e7-43b0-9814-29ed771a3b70;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">current</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">476</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">399</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">539</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735752768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the activity for the Company&#8217;s stock options during the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.734%;"/>
        <td style="width:1.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.065999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.119%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.389999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,538,411</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,009,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,631,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,160</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,998,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,357,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,593</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,778,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,474,743</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,667,144</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.763%;"/>
        <td style="width:2.403%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.687%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.759%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,953</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,577</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.1%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.453999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.469%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735816960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Components of Net Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of net loss are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.435%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.422%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,461</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.728%;"/>
        <td style="width:1.142%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.142%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.986999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan Drug Credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Company's Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following (in thousands): </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.929%;"/>
        <td style="width:1.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.446%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.433%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Orphan drug credit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;U.S. research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Bonus compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">544</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">274</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,435</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,472</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Fixed assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net noncurrent deferred tax asset(liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728665728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.408%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.435%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.368%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.422%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of shares used in computing net<br/>&#160;&#160;&#160;loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,409,123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,261,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.278%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.668%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.621%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.814%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,778,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,998,728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730388624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 217,736<span></span>
</td>
<td class="nump">$ 156,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(61,624)<span></span>
</td>
<td class="num">(51,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">66,100<span></span>
</td>
<td class="nump">109,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">32,786<span></span>
</td>
<td class="nump">62,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">63,910<span></span>
</td>
<td class="nump">110,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">11,107<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Clinical Development and Corporate General and Administrative Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (42,900)<span></span>
</td>
<td class="num">$ (52,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business organization and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731349280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_OriginalMaturitiesAtDateOfPurchase', window );">Original maturities at the date of purchase of liquid investments</a></td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="nump">$ 49,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendIncomeOperating', window );">Expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Refundable tax credit</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority', window );">Tax credit refund receivable</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_OriginalMaturitiesAtDateOfPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original maturities at the date of purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_OriginalMaturitiesAtDateOfPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating dividend income on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554729821648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life of asset</a></td>
<td class="text">Lesser of 10 years or the remaining term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731355424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available for Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DebtSecuritiesAvailableForSalesTypeExtensibleList', window );">Debt Securities Available For Sales Type Extensible List</a></td>
<td class="text">us-gaap:CorporateDebtSecuritiesMember<span></span>
</td>
<td class="text">us-gaap:CorporateDebtSecuritiesMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Investments - Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available for Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 27,573<span></span>
</td>
<td class="nump">$ 37,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,438<span></span>
</td>
<td class="nump">37,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=glto_LongTermInvestmentsMember', window );">Investments - Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available for Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,963<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 5,832<span></span>
</td>
<td class="nump">$ 9,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DebtSecuritiesAvailableForSalesTypeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DebtSecuritiesAvailableForSalesTypeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:tokenItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=glto_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=glto_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731376096">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49,715<span></span>
</td>
<td class="nump">$ 96,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,445<span></span>
</td>
<td class="nump">49,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,270<span></span>
</td>
<td class="nump">46,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,445<span></span>
</td>
<td class="nump">49,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,445<span></span>
</td>
<td class="nump">49,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,270<span></span>
</td>
<td class="nump">46,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Debt Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33,270<span></span>
</td>
<td class="nump">$ 46,676<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731364896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_ContractResearchAndDevelopmentCostCurrent', window );">Contract research and development costs</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 5,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance costs</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value-added tax refund receivable</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,686<span></span>
</td>
<td class="nump">$ 9,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_ContractResearchAndDevelopmentCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract research and development cost current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_ContractResearchAndDevelopmentCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728678352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glto_CopenhagenMember', window );">Copenhagen, Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease, expiration date</a></td>
<td class="text">Jan. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Operating lease,renewal option</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glto_LondonMember', window );">London,United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease, expiration date</a></td>
<td class="text">Feb. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Operating lease,renewal option</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glto_StevenageMember', window );">Stevenage, United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease, expiration date</a></td>
<td class="text">Aug. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Operating lease,renewal option</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glto_GothenburgMember', window );">Gothenburg, Sweden</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease, expiration date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Operating lease,renewal option</a></td>
<td class="text">None<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glto_CopenhagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glto_CopenhagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glto_LondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glto_LondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glto_StevenageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glto_StevenageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glto_GothenburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glto_GothenburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728920832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_OperatingLeaseRentExpense', window );">Rent expense</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_OperatingLeaseRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_OperatingLeaseRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554733855328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Quantitative Information Regarding Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728693136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554729018880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728940400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730127344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_ContractResearchAndDevelopmentCostsCurrent', window );">Contract research and development costs</a></td>
<td class="nump">$ 6,145<span></span>
</td>
<td class="nump">$ 1,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,757<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_ContractResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_ContractResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728704112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">25,261,832<span></span>
</td>
<td class="nump">25,652,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends per share declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends per share paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730467392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,750<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic value per share of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glto_TwoThousandTwentyStockOptionAndGrantPlanMember', window );">2020 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options available for future grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glto_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense that is expected to be recognized over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glto_TwoThousandTwentyStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glto_TwoThousandTwentyStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glto_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glto_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730069280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">3,998,728<span></span>
</td>
<td class="nump">2,538,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,827,750<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="num">(47,593)<span></span>
</td>
<td class="num">(170,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">5,778,885<span></span>
</td>
<td class="nump">3,998,728<span></span>
</td>
<td class="nump">2,538,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">5,474,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options, Vested and exercisable</a></td>
<td class="nump">2,667,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Outstanding</a></td>
<td class="nump">$ 6.51<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Granted</a></td>
<td class="nump">2.98<span></span>
</td>
<td class="nump">9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Cancelled</a></td>
<td class="nump">2.73<span></span>
</td>
<td class="nump">7.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Outstanding</a></td>
<td class="nump">5.43<span></span>
</td>
<td class="nump">$ 6.51<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Vested and expected</a></td>
<td class="nump">5.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Vested and exercisable</a></td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Vested and expected to vest</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Vested and exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 1,357,655<span></span>
</td>
<td class="nump">$ 20,009,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, Granted</a></td>
<td class="nump">$ 111,013<span></span>
</td>
<td class="nump">8,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,357,655<span></span>
</td>
<td class="nump">$ 20,009,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, grants in period, intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730470592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation</a></td>
<td class="nump">$ 5,571<span></span>
</td>
<td class="nump">$ 4,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation</a></td>
<td class="nump">$ 2,953<span></span>
</td>
<td class="nump">$ 2,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730175248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731728192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense or benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 53,472,000<span></span>
</td>
<td class="nump">$ 36,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DeferredTaxAssetsOrphanDrugCredit', window );">Orphan drug credit</a></td>
<td class="nump">$ 8,036,000<span></span>
</td>
<td class="nump">$ 3,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, Limitations on Use</a></td>
<td class="text">The Company also had NOLs in Denmark of $161.7 million which have an indefinite life. Federal and state NOLs and R&D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember', window );">2020 through 2022 | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember', window );">2023 through 2025 | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentySixMember', window );">2026 | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 30,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and Development tax credits</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DeferredTaxAssetsOrphanDrugCredit', window );">Orphan drug credit</a></td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">26,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 161,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DeferredTaxAssetsOrphanDrugCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DeferredTaxAssetsOrphanDrugCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=glto_TwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=glto_TwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728809136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Net Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (10,163)<span></span>
</td>
<td class="num">$ (11,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(51,461)<span></span>
</td>
<td class="num">(40,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (61,624)<span></span>
</td>
<td class="num">$ (51,752)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730169552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit', window );">Orphan Drug Credit</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.00%)<span></span>
</td>
<td class="num">(32.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730151360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,716<span></span>
</td>
<td class="nump">$ 31,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DeferredTaxAssetsOrphanDrugCredit', window );">Orphan drug credit</a></td>
<td class="nump">8,036<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">U.S. research and development credits</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DeferredTaxAssetsBonusCompensation', window );">Bonus compensation</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">53,487<span></span>
</td>
<td class="nump">36,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(53,472)<span></span>
</td>
<td class="num">$ (36,435)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glto_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DeferredTaxAssetsBonusCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets bonus compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DeferredTaxAssetsBonusCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DeferredTaxAssetsOrphanDrugCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DeferredTaxAssetsOrphanDrugCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glto_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glto_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glto_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554731334848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,624)<span></span>
</td>
<td class="num">$ (51,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">25,409,123<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">25,409,123<span></span>
</td>
<td class="nump">25,261,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554728715712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glto_StockOptionsToPurchaseCommonStockMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,778,885<span></span>
</td>
<td class="nump">3,998,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glto_StockOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glto_StockOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554730064016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution paid by employer</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140554735366800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>glto-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:glto="http://galecto.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="glto-20221231.xsd" xlink:type="simple"/>
    <context id="C_c3ec0dd0-9fe6-42b3-b80d-334a822298e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b98f82b2-780e-4b62-9d74-6429370aa2d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_30e1cab4-655e-4ed1-bfb8-3bd1c2074e24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b62815c-330f-4ecf-a0ae-127533136899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd6ff40d-6e4b-4542-b39b-9a47a5dc2935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4935191f-2911-40cc-83d3-1839e14b12c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4336373f-aca3-4ad2-b03c-279e75f3a53f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentyThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4f2ccad7-282a-4f1b-bf36-002446285a34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cfb03bcf-2388-41ae-925e-205c6106a3e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f74559e7-8f45-4159-a81f-b42a765ec89e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_06554741-f66b-460a-9c53-5b5182d21b98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e70f639f-dec9-4e39-81e2-2e7b8c9db28e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1d11ae7c-daf5-4cf4-9476-65d6996dfc53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f86986df-0846-4157-a5eb-a6c794351048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_95336a64-c52f-4870-b189-b6f50eb63e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b896ceee-0f19-4736-be33-4c8a2a1b182f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0e4e962b-0c7f-427f-b8d8-253f1dfe01e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1a891281-b4a3-4bf6-89c4-3d7d6ec73b43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad36967d-c20c-4021-8d2a-690baad2b403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5660b0e7-05a2-4c92-a655-1dd591e67b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c0c025b-fcd6-4855-aa25-24dcd9c881c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_803e51c6-3b20-4c08-ab3e-92d3c19e9bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_beca966d-84f3-4639-bf46-46255ba1cc93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_446278fa-fce1-4cd4-b15e-1085d37b326c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c901782-4d88-468a-8b30-6a41c7e1f8ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a066ec17-6b16-4df9-a0d7-0630872d95c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b63f1cd8-2964-4478-ba13-1aca8bfd1025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_741ac39e-ead2-496d-9277-da672f7a8e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <instant>2023-03-06</instant>
        </period>
    </context>
    <context id="C_da11831e-2def-422d-b9ba-135e9cc96547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_68b96280-106d-4c4f-9050-7768f44a1658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_76a1124d-1bc4-461a-9175-009a2d8648c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2d93c29f-7701-4844-9f33-6bb356fa3531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d6c004f9-30fd-424c-9fb9-45d6fde33858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1f463f6f-54e1-43b8-b676-b1ff83a8e7b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_349093ed-5db6-4bb4-9588-93a0cf9b007d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_333a7d4a-b385-4327-8cb4-b33035085d6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5653da56-b435-4ded-887e-78f37a343b93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_298727fd-7dd4-400e-978d-2395c0ad7b94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cfe5cd33-6411-4f7a-8986-194fe9cbf159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0fed39e7-58c4-4ac9-ab3d-13d15fe315f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_7c6a862c-3e11-4d68-aa36-13ca8e140e89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c6c185ed-a9aa-4137-a7f1-09443c4dd1f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b321da6e-9abd-4c83-b727-c755898fb0a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:StevenageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fe9a0289-03cd-4c28-8cea-41cc4570e327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">glto:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_35bc5886-d1e6-4ce7-bdf0-d68aa785f64f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5778128-4ddb-4ebe-97f8-350950f780c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1a7732d2-f6dc-4da5-b07c-d4c3c940cae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_578a6731-4436-4656-baa1-0e8306439eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3e2888de-d4a3-488c-aaae-ba1b2eadce87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2bd75575-ee9b-4149-8e99-700c763cf2a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4fd6f295-aa8c-4dd2-a215-0f6504345d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5e2554ff-8b5a-4c27-b47d-d3a252e0b453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4c5077bc-7856-49b1-b161-185d27434c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6af6e762-621d-4e84-b2aa-92985a786e0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">glto:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_97be5459-8e1d-4a9f-a3fe-24a288c0d7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glto:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b0f9c207-2ba8-436a-9aa4-8eea6b502e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6bb29e1b-fe16-4cff-8393-88bae5954f84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:GothenburgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a5e23dbf-7189-4f00-9cce-e1174083d383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_26d85074-1442-4534-bfb5-878f1c5c9abc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glto:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f9b208c9-11e0-43f5-9a13-0c029853484f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:LondonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_83df5a70-5b7d-414e-98bc-028cfe3931af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glto:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_dca04f3b-68dd-41e8-a315-ab386139707c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_00b3ce82-ee23-4fad-a96c-75e32b50f767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">glto:TwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glto:CopenhagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ad845729-af55-4659-b3e7-c758123fc0b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3e287338-bbea-4c9b-90ce-f4b9c66624f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e754f68-08d0-4938-98da-48e6218005eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_84f94529-71c5-4ff9-b7c7-bebbc7bcaa33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8b87670-6319-4b49-9747-781911421762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa9917ab-7682-4151-a140-fba905b103eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_38c70869-4934-4789-a4e2-402a3062df02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001800315</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>glto:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_c97e5a12-2637-4649-b0b9-ad9ec1e147a3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_f9b208c9-11e0-43f5-9a13-0c029853484f"
      id="F_63bad519-8d42-4588-8c64-dc3b578e5db5">2024-02-29</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e"
      id="F_d29c6159-b3c6-43bd-8e35-677bf4164550">2025-08-31</us-gaap:LeaseExpirationDate1>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_707da240-abd0-4f6e-a72b-cfce036aa3ae">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_63d7ab59-43c4-4301-ae5c-263a48395952"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b321da6e-9abd-4c83-b727-c755898fb0a5"
      id="F_a8a21157-12a4-455d-8c10-d3493597fa16">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <glto:DebtSecuritiesAvailableForSalesTypeExtensibleList
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_0f88c296-6264-4042-8714-841aed812bb6">us-gaap:CorporateDebtSecuritiesMember</glto:DebtSecuritiesAvailableForSalesTypeExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_9ab22cc5-86e7-43b0-9814-29ed771a3b70">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_163c3014-e0f2-4cb5-a85c-2be49b326607"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_a45c38bf-025d-4c16-a12b-c4a73e7af421">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_7ab5c9a0-ad7e-4429-bd8a-27616dd14ffc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <glto:DebtSecuritiesAvailableForSalesTypeExtensibleList
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_44cda3a6-b017-451a-b0b6-7cab4805cade">us-gaap:CorporateDebtSecuritiesMember</glto:DebtSecuritiesAvailableForSalesTypeExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3e2888de-d4a3-488c-aaae-ba1b2eadce87"
      id="F_39cd0535-b15b-47f4-8148-6db41c88544a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_6bb29e1b-fe16-4cff-8393-88bae5954f84"
      id="F_3cbffc48-b954-4828-9d21-d46a15257703">2023-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8"
      id="F_b8865681-fb3c-46b3-8f81-199888594bde">2025-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:CommonStockValue
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_10c9ded1-f15d-437e-8e57-1eaa49edc1c9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_9426828b-8ce6-4136-9592-73b208402ab8">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockValue
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_0c600085-f026-40c1-bda9-1000262a6429"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_e1741f4a-98e5-4588-8510-d2daf22196c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <dei:EntityCentralIndexKey
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_a4ca3aef-639a-4ed8-ada7-89dde4d411d6">0001800315</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_5407b56e-40d4-49ec-bb45-36fa98160e23">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_9b9e6261-7f93-4be0-8e18-13b33f088337"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_cf63fc32-9e22-408c-bb2f-5f03a27e67d9">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_1a3a687e-f767-4623-b8cf-8fd0b92bc4a9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_08a6e39f-e8b2-4c33-9717-cccbf2fc2005">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3ff069c8-b070-4747-89cb-dc0356af07fb">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_ca3ad775-ab92-4b12-8196-4bc8d63c6a17">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_953afe47-29cd-49e9-8f71-6614d68d099c">001-39655</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3de62753-c629-44a5-8210-6c290288fee8">GALECTO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_c6fcd16c-b6bc-41ad-88d4-1addebe3525c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_f983c271-417e-49eb-831c-accec163f7c4">37-1957007</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_fe782ae6-973f-4b39-a4ae-8f2a0d3cfb98">75 State Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_df635d12-688c-4306-a0c6-58833ec9574b">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_1fadb46f-0bf8-4226-a17e-7a9a4ce566f7">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_99d7d578-9efd-40c3-b86c-c966e1806938">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_7678fac3-f4a0-4d42-8883-03b56582e8f0">02109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_1695959c-7d76-48a8-a0bc-360f39ccd906">+45</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3fb2eb62-b8ea-4ae5-b4e1-6d91a64b4b04">70 70 52 10</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_9102cfc6-72d6-44aa-a1c4-b516d4f50452">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_b926260c-8d12-48ff-801e-7395f9d85d77">GLTO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_25568a94-1b31-4c46-937d-9f9afae16710">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_27235aea-5a86-4b9b-9ff0-39fe1ba737a8">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_03a55891-04fa-43e9-a99e-34f4ca675ccb">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3708a931-899d-440c-891a-fb9c14cbe755">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_752687b3-5253-474f-8e89-1e96a0fb66b9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_0ba0145c-a763-44e1-81af-8293a1eb1d2a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_a81cd068-24f3-4780-ad1f-1835a5fd4d53">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_902f2c67-bf4b-49c2-989b-509dd5f61980">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e51b3787-0d57-4504-a051-d3aa07e65752">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_78af297e-269f-454e-bdaf-c69496b62740">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_412597bc-1e47-4f2b-9f63-83b8f7dd9ac6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_6164ffdf-1cc7-4bc0-8767-1eecf5cbb29b"
      unitRef="U_USD">37500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_741ac39e-ead2-496d-9277-da672f7a8e05"
      decimals="INF"
      id="F_5550d6a9-9553-4f57-93c7-db5abc5cdfb5"
      unitRef="U_shares">25673474</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_426c4f9a-62b1-4d37-8173-1d64157ea6c9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120 days of the end of the registrant&#x2019;s fiscal year ended December 31, 2022. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_52b372c0-a70d-48a6-8f7a-0f8edf80a062">1757</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_58e91b86-b4d9-44fb-95ad-08e16ef34b83">EY Godkendt Revisionspartnerselskab</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_a2de2f96-2fcd-4428-b48f-26a104a6e0d1">Copenhagen, Denmark</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_37c0c6d3-456e-4f96-9eac-def4f177a7bc"
      unitRef="U_USD">32786000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_a8515d22-1a38-4613-8e69-e2a6e0c89bd9"
      unitRef="U_USD">62563000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_812a0b1d-8f2b-4a7f-b99a-c309780fc99c"
      unitRef="U_USD">27438000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_a61aa7cf-134d-4bd7-8515-ec0bfa961c68"
      unitRef="U_USD">37628000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_33f8444c-8fa0-4a36-8d1e-900cab848697"
      unitRef="U_USD">3686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_9424e143-e1f3-4c97-9911-18131cff51df"
      unitRef="U_USD">9911000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_43bb997c-88eb-4b49-b5df-6f9905062222"
      unitRef="U_USD">63910000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_3bdfd2e4-9105-43d5-9091-3d90f2eba4c2"
      unitRef="U_USD">110102000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_1c8328c8-798b-4cdc-804d-7e1899908884"
      unitRef="U_USD">5832000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_89f4a766-77cd-48f0-aba7-dcf98c9c3942"
      unitRef="U_USD">9048000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_72ba8e02-26f8-4647-95a3-bad2851305f3"
      unitRef="U_USD">810000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_b474408e-cc07-4744-9786-3c1818f4ee0d"
      unitRef="U_USD">834000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_01f44070-d70a-4841-aa6d-2cdb3f699049"
      unitRef="U_USD">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_5e40acee-2a36-45a6-827d-f3cf22b131e7"
      unitRef="U_USD">203000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_f92bbcdc-993c-4a16-a0bf-b4e079a84232"
      unitRef="U_USD">2279000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_244728a3-00a3-41fc-8bf2-15a0e9be24e7"
      unitRef="U_USD">2028000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_d19b6776-4d00-4e62-bdf6-4ede315ab58d"
      unitRef="U_USD">73188000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_727f07d3-f753-4465-b92b-626a5d777739"
      unitRef="U_USD">122215000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_7087ee19-f441-4e76-b434-4d463c41c21c"
      unitRef="U_USD">3350000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_9abbe309-5ce3-4337-980f-c361bb22f74e"
      unitRef="U_USD">1531000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_f29803bb-1aa5-4c8a-8dea-ba96d3cc3fec"
      unitRef="U_USD">7757000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_8ab9ccad-3da8-4c20-bd0f-74bde9e8a48a"
      unitRef="U_USD">3013000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_668d1490-4970-47c6-954b-9bca46096c52"
      unitRef="U_USD">11107000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_5e8a49e0-df1d-49d7-84de-c28047b97a38"
      unitRef="U_USD">4544000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_d5872a9c-26ba-40e9-bc2f-31465fe08d85"
      unitRef="U_USD">328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_6f2d99d3-868a-47cf-98f6-ded890a3a763"
      unitRef="U_USD">448000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_39ab7405-e313-4a98-a52f-a42960d17d01"
      unitRef="U_USD">11435000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_093d904c-2767-43f6-8216-a48182fac190"
      unitRef="U_USD">4992000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_3866de26-a723-4d46-a5f4-b689c3d8503c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_39fe7ced-22cf-400e-a6b2-05bd87f13ae0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_8a12b366-b2a9-4190-8728-762f27759f7d"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_83bff830-a5ed-4fd0-bfc8-3fd5769fbacc"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_c63a0b18-1db8-40a4-b2b3-90df9d7f30d8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_cfea8a87-00ae-417d-8004-957079da74dc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_42fc3692-4b38-4800-8d67-cfa6a8787933"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_dca6084e-9ab6-477b-9078-7f5f0734aa90"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_fdb7e438-1b31-47d1-8c65-85d3f91e90c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_30303476-c940-4118-a0c8-aa6feb88c4ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_455ba9af-7a5c-464e-9be0-145d7ffbb138"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_dba68003-53de-4f36-88fa-dcf46e8cedb5"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_71bb9d49-a1ee-4279-ae00-700888700815"
      unitRef="U_shares">25652392</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_ae303b12-2a97-47dc-b788-fd84edd68d55"
      unitRef="U_shares">25652392</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_e31665c1-6f4f-46a4-9497-a6dce7391fd5"
      unitRef="U_shares">25261832</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_6accead8-adef-4b94-9c29-39c6f45ae048"
      unitRef="U_shares">25261832</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_6bf7239a-d9da-43bb-8f9e-c0e1dea1f874"
      unitRef="U_USD">279733000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_a1e29ebf-6847-427a-beff-fcd095479b99"
      unitRef="U_USD">273655000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_601d3144-8c0a-45c0-8524-dbb68b41aae7"
      unitRef="U_USD">-217736000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_245440b3-c4f6-44f6-bb70-2bf78dc2643c"
      unitRef="U_USD">-156112000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_46a53764-023b-4134-97cc-2d45cc7a5a6f"
      unitRef="U_USD">-244000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_367774e5-aa57-4121-af6c-2b466ef547fb"
      unitRef="U_USD">-320000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_b4495932-815b-468b-858f-262660b924e5"
      unitRef="U_USD">61753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_92498537-643f-4e2c-8e12-5ca47e04ef0e"
      unitRef="U_USD">117223000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_0d95e5bd-f381-4023-9871-a34fc9a55d1c"
      unitRef="U_USD">73188000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_7a0652bd-248e-4202-b10c-7c42b36b139f"
      unitRef="U_USD">122215000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_2c4c3d99-acbc-4c94-8c40-fca1e2a25770"
      unitRef="U_USD">48206000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_0c47c75e-d98f-4d99-b3ee-34688f9f2c4c"
      unitRef="U_USD">38488000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_ffa1dab9-c266-44a0-8ae5-b6d9b88ff090"
      unitRef="U_USD">13001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_24164a8f-3b51-4f99-8ab6-0928f27fdf5d"
      unitRef="U_USD">13739000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_f483c633-1b34-48e3-a0e8-1e18e406d484"
      unitRef="U_USD">61207000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_67051373-6cc3-4785-adb2-ec58b0da00f6"
      unitRef="U_USD">52227000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_d39377ee-31b5-4203-a3ba-c6dcc49a06ec"
      unitRef="U_USD">-61207000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_de88d807-9f68-4c9f-8b02-4a36dfa58a08"
      unitRef="U_USD">-52227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_360f7cc3-9c20-4825-a004-2a444e37c670"
      unitRef="U_USD">722000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_54ca8c53-f484-4988-b220-272a3005354a"
      unitRef="U_USD">156000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_aaf8a9bf-487d-4182-a21b-262c267ce689"
      unitRef="U_USD">-70000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_98740513-2ae3-4e79-9f7e-07b2bacc4814"
      unitRef="U_USD">-1069000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_c2eb7c2d-9fc6-4ea3-adea-c75a6eac9522"
      unitRef="U_USD">319000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_61bca76c-5e4a-4d34-871e-b707b6b32d65"
      unitRef="U_USD">-417000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_ddc68825-0440-47c0-8959-608a5b909abd"
      unitRef="U_USD">475000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_eb2540af-7cda-46d8-aacb-ec2fbac772a7"
      unitRef="U_USD">-61624000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_52abe849-b42d-41b7-8c27-73c362a49c4a"
      unitRef="U_USD">-51752000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_363ef103-ba2d-47f7-85bb-234922859642"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_8cadee6b-3a55-4907-b6ad-42279e671aa4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_e0565efb-d80c-4271-bc8e-674e1699edea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_53029576-1aa1-4247-bf5e-15a88717963f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_a1619c7a-0135-4907-b8ff-ec54beccab55"
      unitRef="U_shares">25409123</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_48a02889-0e74-4923-a9f1-3a4b05b568ef"
      unitRef="U_shares">25409123</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_7cfd35b1-cd31-497c-9feb-4b8c59f30b32"
      unitRef="U_shares">25261832</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_cf35628e-cf02-48ce-a61b-42a9470b64e3"
      unitRef="U_shares">25261832</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_c8b802d9-ad38-4374-820d-b143bb3ede65"
      unitRef="U_USD">265000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_3e086dd2-8eba-4537-bb08-9d468d565392"
      unitRef="U_USD">-917000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_2a1321b1-fb9d-41cb-8849-ebc036975fe8"
      unitRef="U_USD">-259000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_0e00e888-c70e-4361-bafc-ec719499642d"
      unitRef="U_USD">-77000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_da913f6e-241b-40a7-b87b-ed2cc664aaf1"
      unitRef="U_USD">-70000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_56eaf59e-737d-4537-b758-1106e10091eb"
      unitRef="U_USD">76000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_a7d3f08d-9367-433b-84b9-a77e0793f98d"
      unitRef="U_USD">-994000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_4bfe07c2-9681-4035-a973-8a7d3abf23b7"
      unitRef="U_USD">-61548000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_4ac4803c-9660-4cfa-8bb4-edcd16628db7"
      unitRef="U_USD">-52746000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297"
      decimals="0"
      id="F_e7107b68-ac17-4c5d-97cb-e32674cce093"
      unitRef="U_shares">25261832</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_06554741-f66b-460a-9c53-5b5182d21b98"
      decimals="-3"
      id="F_363ff404-47e7-43f1-b172-6714140f43e1"
      unitRef="U_USD">269175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b0f9c207-2ba8-436a-9aa4-8eea6b502e78"
      decimals="-3"
      id="F_f23a4728-af25-48c0-af7e-9efad5a0e0fc"
      unitRef="U_USD">-104360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1f463f6f-54e1-43b8-b676-b1ff83a8e7b8"
      decimals="-3"
      id="F_96daca1a-a330-4b88-9217-549f98de3837"
      unitRef="U_USD">674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"
      decimals="-3"
      id="F_3b44f3de-e5bf-446a-b56d-96404559677c"
      unitRef="U_USD">165489000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ad845729-af55-4659-b3e7-c758123fc0b7"
      decimals="-3"
      id="F_60b33d0e-80ac-4607-8705-811c131caeb4"
      unitRef="U_USD">4480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_94661279-d693-407a-bea3-47f7685c4628"
      unitRef="U_USD">4480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_298727fd-7dd4-400e-978d-2395c0ad7b94"
      decimals="-3"
      id="F_f9ddf952-9456-43d3-a5b5-037e2d62ccf7"
      unitRef="U_USD">-994000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_a3821f64-396b-4604-b079-610199d800d3"
      unitRef="U_USD">-994000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_b896ceee-0f19-4736-be33-4c8a2a1b182f"
      decimals="-3"
      id="F_8e9d2762-a5e4-4929-9d42-7b67c7248f21"
      unitRef="U_USD">-51752000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_9fc5d79a-2b61-497a-b7e4-f4615de36605"
      unitRef="U_USD">-51752000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_2d93c29f-7701-4844-9f33-6bb356fa3531"
      decimals="0"
      id="F_03310f04-23a6-490b-8644-dadf504565b0"
      unitRef="U_shares">25261832</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3e287338-bbea-4c9b-90ce-f4b9c66624f8"
      decimals="-3"
      id="F_575b8c09-1ed5-4942-94b3-4ef576a886c9"
      unitRef="U_USD">273655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e70f639f-dec9-4e39-81e2-2e7b8c9db28e"
      decimals="-3"
      id="F_9224787b-bf0e-4363-a181-28d1e14d8b9e"
      unitRef="U_USD">-156112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f86986df-0846-4157-a5eb-a6c794351048"
      decimals="-3"
      id="F_71ac7d29-ceee-42ac-b657-6f7ff495ba03"
      unitRef="U_USD">-320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_180540c3-988f-450c-8ee4-370749ac2ebc"
      unitRef="U_USD">117223000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7"
      decimals="-3"
      id="F_cb55ccc4-fee3-404c-999e-b3759ca69db8"
      unitRef="U_USD">5571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_10c79776-e3ff-4bbe-bfe9-922bfbff8575"
      unitRef="U_USD">5571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <glto:StockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-5"
      id="F_19d4e663-83ad-4a47-b49b-1a09dcbeaa24"
      unitRef="U_USD">200000</glto:StockIssuedDuringPeriodNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a066ec17-6b16-4df9-a0d7-0630872d95c8"
      decimals="0"
      id="F_c46c0024-670b-490e-ae51-021a590099f1"
      unitRef="U_shares">390560</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a77244bb-6ccb-4641-8816-9f4a998f4ad7"
      decimals="-3"
      id="F_34d5d252-a86b-4465-a9a2-f4f4b52a7052"
      unitRef="U_USD">507000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_28a0468c-0e47-49a9-a1e2-03b72277f2ab"
      unitRef="U_USD">507000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1d11ae7c-daf5-4cf4-9476-65d6996dfc53"
      decimals="-3"
      id="F_79b217e9-0d47-4b87-8473-5101db91f964"
      unitRef="U_USD">76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_48e47576-6a48-4377-bce3-4e717dad416c"
      unitRef="U_USD">76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_ad36967d-c20c-4021-8d2a-690baad2b403"
      decimals="-3"
      id="F_9a31ad10-5a75-460c-8307-c50ad4654e43"
      unitRef="U_USD">-61624000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_a1751df0-f809-4938-bd32-063beabb5e6d"
      unitRef="U_USD">-61624000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_cfe5cd33-6411-4f7a-8986-194fe9cbf159"
      decimals="0"
      id="F_d5a02c6b-a049-4635-8899-381bc9be0a50"
      unitRef="U_shares">25652392</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0c901782-4d88-468a-8b30-6a41c7e1f8ad"
      decimals="-3"
      id="F_e24b34cd-5ea9-488b-bdd1-203cf093b5ff"
      unitRef="U_USD">279733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_35bc5886-d1e6-4ce7-bdf0-d68aa785f64f"
      decimals="-3"
      id="F_129840e7-0739-4d10-90c6-a59303929653"
      unitRef="U_USD">-217736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4fd6f295-aa8c-4dd2-a215-0f6504345d71"
      decimals="-3"
      id="F_f2789150-f54d-4bce-9e2a-84c2ea3ad1ec"
      unitRef="U_USD">-244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_176637cc-f67c-411f-863a-c0130a9d173f"
      unitRef="U_USD">61753000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_ea76159f-36ce-43fb-8bae-7a2bbb576076"
      unitRef="U_USD">-61624000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_89b49ed3-0939-46c7-ae54-a02dc6b524be"
      unitRef="U_USD">-51752000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_66206e4e-c883-497f-af7a-d2df9cc4e63a"
      unitRef="U_USD">42000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_037c87ef-a4ed-4547-b03a-e50e1c720e86"
      unitRef="U_USD">20000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_9db43ca2-4b5a-408d-b997-aa3ff1d908de"
      unitRef="U_USD">5571000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_5066d639-c8f2-4522-8ec3-1eb63bd31f90"
      unitRef="U_USD">4480000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_72622411-84b2-4b1e-a98d-f9dfe4c4904b"
      unitRef="U_USD">-566000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_6a9c9018-3100-4f2c-8c61-efcc296ac582"
      unitRef="U_USD">-1072000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_4f30cf0e-9e67-44f1-a4d1-71f5a7067dad"
      unitRef="U_USD">-70000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_71b4ba22-bac3-4b4a-b0b0-fb21b53313c0"
      unitRef="U_USD">448000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_b3c327cd-ccbc-43cf-8f86-68385e9b38a3"
      unitRef="U_USD">421000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <glto:AccretionOfLeaseLiability
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_a9cc1d36-9daa-4c6a-b2da-b28f55355dab"
      unitRef="U_USD">58000</glto:AccretionOfLeaseLiability>
    <glto:AccretionOfLeaseLiability
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_75a9577c-ba18-4286-b950-bc9475e63867"
      unitRef="U_USD">75000</glto:AccretionOfLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_a6fb53ef-f1be-408a-88ca-9a25a3ace5a3"
      unitRef="U_USD">-6232000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_1c8b44c3-d272-4a3d-a3f9-acce47a3cc7a"
      unitRef="U_USD">4199000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_bbd0afb2-6738-4877-9e20-395cd5073eee"
      unitRef="U_USD">257000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_ffdd5669-125f-4c61-901d-971dbbb0a5f9"
      unitRef="U_USD">866000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_080faa5e-1a4c-40d6-ae99-4117013501ac"
      unitRef="U_USD">1819000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_0cebfad8-42e4-4279-95dd-7631bb8bb676"
      unitRef="U_USD">-1320000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_d161df0c-bbe6-4ca3-8457-33a9dcabf565"
      unitRef="U_USD">4666000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_f1fad2ae-d2c5-481d-8210-878e7dc8161c"
      unitRef="U_USD">274000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <glto:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_fd1dc6b2-b196-4ecf-9d58-611d4c4d22e9"
      unitRef="U_USD">-523000</glto:IncreaseDecreaseInOperatingLeaseLiabilities>
    <glto:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_29572ea1-d0e8-4d1c-876c-fde07b47d84b"
      unitRef="U_USD">-513000</glto:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_fdb63387-30fc-4c10-bfe7-24c633053d4e"
      unitRef="U_USD">-42932000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_fc0b21d0-5717-4dd1-8967-49485444a5b4"
      unitRef="U_USD">-52308000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_db8296f4-5521-424f-8b25-87499b063ca5"
      unitRef="U_USD">44865000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_0982298b-e4eb-47d9-a050-1780756229c0"
      unitRef="U_USD">84209000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_ced55b84-46ab-4da5-b268-69979a43c000"
      unitRef="U_USD">57445000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_d3d1212a-6369-4413-a370-dc818b2b5c29"
      unitRef="U_USD">36384000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_cd9a7a96-1bc7-4442-9d7e-5c663f2513cc"
      unitRef="U_USD">196000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_366589ee-ad29-4f4b-9bc8-d32639733663"
      unitRef="U_USD">223000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_d3d164a2-be89-4a6a-b9d1-1eed2e1971ec"
      unitRef="U_USD">12384000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_51baeb37-5f05-4fa4-af94-33a3a18df592"
      unitRef="U_USD">-48048000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_70dd1d81-1a02-40f5-af8b-dd061f1f06b0"
      unitRef="U_USD">507000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_e9ef2e1e-94c9-4b6d-80a4-6f16f01b3a8f"
      unitRef="U_USD">507000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_b1a5eb2b-d103-4da5-842a-a66bb478f13a"
      unitRef="U_USD">-30041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_5637315a-3f0e-4bcb-915c-7d3b35819035"
      unitRef="U_USD">-100356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_708e8abd-7d0f-4c5f-9dbe-71a07b94c33f"
      unitRef="U_USD">264000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_fb38c7f4-1dab-4516-9cc1-5c4f1e232a0d"
      unitRef="U_USD">-917000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_b0a97482-f408-4543-9893-5d98bc8252ca"
      unitRef="U_USD">62563000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"
      decimals="-3"
      id="F_1502b85f-bab2-4138-937f-b5d8e36636c2"
      unitRef="U_USD">163836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_8b685dd0-1330-46f2-ba61-3c3ce488492e"
      unitRef="U_USD">32786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_feb92335-eb65-4603-8a10-cbb219400907"
      unitRef="U_USD">62563000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_f6de8f25-790f-4003-9bca-0dbca00c8ba1"
      unitRef="U_USD">488000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_4fab9077-bb73-40ce-9806-c999cb7f363e"
      unitRef="U_USD">411000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_39273670-ae1c-47d9-be49-482587bd37be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. DESCRIPTION OF BUSINESS, ORGANIZATION AND LIQUIDITY&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Galecto, Inc., together with its consolidated subsidiaries (the &#x201c;Company&#x201d; or &#x201c;Galecto&#x201d;), is a clinical-stage biotechnology company developing novel therapeutics that are designed to target the biological processes that lie at the heart of fibrotic diseases and cancer. The Company&#x2019;s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 ("LOXL2&#x201d;), which play key roles in regulating fibrosis and cancer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company&#x2019;s wholly owned subsidiaries were PharmAkea, Inc. or PharmAkea, Galecto Securities Corporation and Galecto Biotech AB, a Swedish company. Galecto Biotech ApS, a Danish operating company, is a wholly-owned subsidiary of Galecto Biotech AB.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and uncertainties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s product candidates are in development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and management plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since inception, the Company has devoted substantially all its efforts to business planning, research and development,&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recruiting management and technical staff and raising capital, and has financed its operations primarily through the issuance of redeemable convertible preferred shares, debt financings and, most recently, the Company&#x2019;s initial public offering, or IPO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;217.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, from recurring losses since inception in 2011. The Company has incurred recurring losses and has not generated revenue as no products have obtained the necessary regulatory approval in order to market products. The Company expects to continue to incur losses as a result of costs and expenses related to the Company&#x2019;s clinical development and corporate general and administrative activities. The Company had negative cash flows from operating activities during the years ended December 31, 2022 and 2021 of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, and current projections indicate that the Company will have continued negative cash flows for the foreseeable future as it continues to develop its product candidates. Net losses incurred for the years ended December 31, 2022 and 2021 amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company&#x2019;s cash, cash equivalents and marketable securities amounted to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, current assets amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and current liabilities amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. At December 31, 2021, the Company&#x2019;s cash, cash equivalents and marketable securities amounted to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, current assets amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and current liabilities amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the future, the Company will consider the following ways to fund its operations including: (1) raising additional capital through equity and/or debt financings; (2) new commercial relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. Volatility in equity capital markets may adversely affect the market price of the Company&#x2019;s shares of common stock, which may materially and adversely affect the Company&#x2019;s ability to fund its business through&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;public or private sales of equity securities. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, key developments and regulatory events.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Coronavirus pandemic&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The novel coronavirus (&#x201c;COVID-19&#x201d;) and its variants, and ensuing pandemic, has continued to spread worldwide, causing many governments to implement measures to slow the spread of the outbreak. COVID-19 and its variants have had a significant impact, both directly and indirectly, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services has fallen. The Company continues to monitor the impact of COVID-19 and its subvariants and assess its strategy accordingly. However, there can be no assurance that the Company will not experience additional negative impacts associated with the COVID-19 pandemic, which could decrease or delay enrollment of patients in the Company&#x2019;s clinical trials or otherwise cause interruptions or delays in the Company&#x2019;s clinical trials, programs and services, and negatively impact the Company&#x2019;s business, financial condition and results of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_d2ab7597-d12c-4cb1-9992-b3e3868e5119"
      unitRef="U_USD">-217700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a"
      decimals="-5"
      id="F_1f2aa5a6-9f4b-4721-ba25-010f90093c02"
      unitRef="U_USD">-42900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_b98f82b2-780e-4b62-9d74-6429370aa2d4"
      decimals="-5"
      id="F_15d32e2e-91f0-4e28-95a2-187662acbac6"
      unitRef="U_USD">-52300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-5"
      id="F_cb4b7122-a879-4957-b322-963f10bc4c5b"
      unitRef="U_USD">-61600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-5"
      id="F_364f8bca-1c34-431f-9cc9-95460256e56a"
      unitRef="U_USD">-51800000</us-gaap:ProfitLoss>
    <us-gaap:InvestmentsAndCash
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_c381c4e5-6b6c-41bb-8642-f3f8ae0055d3"
      unitRef="U_USD">66100000</us-gaap:InvestmentsAndCash>
    <us-gaap:AssetsCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_1b208e01-397e-493c-b6ef-d72f311c0f43"
      unitRef="U_USD">63900000</us-gaap:AssetsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_b0d0b783-5595-4f2a-94b1-f7ea60061033"
      unitRef="U_USD">11100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:InvestmentsAndCash
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-5"
      id="F_ab6bf0d8-7e00-4360-b644-9ca029b383b9"
      unitRef="U_USD">109200000</us-gaap:InvestmentsAndCash>
    <us-gaap:AssetsCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-5"
      id="F_33639591-93a0-4c8e-811e-66a308afc5fe"
      unitRef="U_USD">110100000</us-gaap:AssetsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-5"
      id="F_e5f4e0ae-4619-4c66-adaa-3260d2f081d5"
      unitRef="U_USD">4500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_ef5962a2-1d40-4cde-a929-c069735ab3c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States, or U.S., generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements for 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; include Galecto, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Significant items subject to such estimates and assumptions include contract research accruals, accounting for stock-based compensation and valuation of the Company&#x2019;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. The Company&#x2019;s actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Currency and currency translation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements are presented in U.S. dollars, the Company&#x2019;s reporting currency. Galecto, Inc., Galecto Securities Corporation and PharmAkea&#x2019;s functional currency is the U.S. dollar. The functional currency of the Company&#x2019;s subsidiary Galecto Biotech AB, and its subsidiary Galecto Biotech ApS, is the Euro. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the year. Resulting translation adjustments are recorded to accumulated other comprehensive income (loss), or OCI.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities at the date of purchase of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had money market funds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, which are included in cash and cash equivalents and reported at fair value (Note 4).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held at financial institutions that management believes to be of high-credit quality. The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments in marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company invests excess cash balances in short-term and long-term marketable debt securities. The Company classifies investments in marketable debt securities as either held-to-maturity or available-for-sale based on the facts and circumstances present at the time of purchase and re-evaluates classification at each balance sheet date. All investments in marketable debt securities at each balance sheet date presented, are generally considered as available-for-sale. Marketable debt securities with maturities of twelve months or less are classified as short-term investments and marketable debt securities with maturities greater than twelve months are classified based on their availability for use in current operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reports available-for-sale debt securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value), net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity. The cost of debt securities is adjusted for the amortization of premium and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#x201c;other than temporary,&#x201d; including the intention to sell and, if so, marks the investment to market through a charge to the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the time it enters into a contract. For all leases, the Company determines the classification as either operating leases or finance leases. Operating leases are included in operating lease right-of-use, or ROU, assets and accrued expenses and other current liabilities and operating lease liabilities, noncurrent in the Company&#x2019;s consolidated balance sheets. The Company has not entered into any financing leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses the Company&#x2019;s incremental borrowing rate in determining the present value of lease payments. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. Refer to Note 6 for further details.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.981%;"/&gt;
          &lt;td style="width:3.001%;"/&gt;
          &lt;td style="width:60.018%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.8pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.1pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of 10 years or the remaining term of the respective lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. Through December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, no such impairment has occurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including stock-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, research and development expenses include refundable tax credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Substantial &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors, or collectively, CROs. These CROs generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the CROs, and correspondence with the CROs and clinical site visits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock options granted in accordance with ASC 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, or ASC 718. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity-based compensation expense is classified in the Company&#x2019;s consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The expected term of the Company&#x2019;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company follows the provisions of ASC 740-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Uncertainty in Income Taxes, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or ASC 740-10. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has identified the United States, Denmark and United Kingdom as its major tax jurisdictions. Refer to Note 11 for further details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, both methods are equivalent. Basic and diluted net loss per share is described further in Note 12.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer. The Company has determined it operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other comprehensive gain (loss)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other comprehensive gain (loss), or OCI, is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s OCI includes currency translation and unrealized gain or (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Emerging growth company status&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company may elect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, and as a smaller reporting company, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Codification Improvements to Topic 326, Financial&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Instruments-Credit Losses, Topic 815, Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;and Topic 825, Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The ASU 2016-13 guidance became effective as of January 1, 2020, and must be adopted using a modified retrospective approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a SEC, excluding eligible smaller reporting companies for fiscal years beginning after December 15, 2019. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December 15, 2022. The adoption of ASU No. 2016-13 during the year ended December 31, 2022 did not have a material impact on the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically reviews new accounting standards that are issued and has not identified any new standards that it believes merit further discussion or would have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_b87bad2e-4468-492b-9a63-a2d3a5398af3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States, or U.S., generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_b0736cbb-17d0-41e3-924f-e1a6767a5c0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements for 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; include Galecto, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3c545b85-3dc1-4718-8ad1-9388703c277b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Significant items subject to such estimates and assumptions include contract research accruals, accounting for stock-based compensation and valuation of the Company&#x2019;s deferred tax assets. Changes in estimates are recorded in the period in which they become known. The Company&#x2019;s actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_83686026-bbac-4acc-88aa-58fd8da38400">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Currency and currency translation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements are presented in U.S. dollars, the Company&#x2019;s reporting currency. Galecto, Inc., Galecto Securities Corporation and PharmAkea&#x2019;s functional currency is the U.S. dollar. The functional currency of the Company&#x2019;s subsidiary Galecto Biotech AB, and its subsidiary Galecto Biotech ApS, is the Euro. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of Galecto Biotech AB and Galecto Biotech ApS recorded in their Euro functional currency are translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the year. Resulting translation adjustments are recorded to accumulated other comprehensive income (loss), or OCI.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_59883e41-68d1-4ff9-a3dc-86917c50680d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities at the date of purchase of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had money market funds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, which are included in cash and cash equivalents and reported at fair value (Note 4).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <glto:OriginalMaturitiesAtDateOfPurchase
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_683b8dd8-a455-432b-8364-ecbf5cc4d3a9">three months or less</glto:OriginalMaturitiesAtDateOfPurchase>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_0e96fb59-11ff-4f65-9398-e83538ad4537"
      unitRef="U_USD">16400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-5"
      id="F_80664d7c-f05d-4c3f-838c-efb145b8a376"
      unitRef="U_USD">49600000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_cfe76d16-da43-4404-8902-c647509957e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held at financial institutions that management believes to be of high-credit quality. The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_37bb26c1-f775-4a64-8342-7467da73350e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments in marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company invests excess cash balances in short-term and long-term marketable debt securities. The Company classifies investments in marketable debt securities as either held-to-maturity or available-for-sale based on the facts and circumstances present at the time of purchase and re-evaluates classification at each balance sheet date. All investments in marketable debt securities at each balance sheet date presented, are generally considered as available-for-sale. Marketable debt securities with maturities of twelve months or less are classified as short-term investments and marketable debt securities with maturities greater than twelve months are classified based on their availability for use in current operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reports available-for-sale debt securities at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value), net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity. The cost of debt securities is adjusted for the amortization of premium and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses are determined using the specific identification method and are included in other income (expense). If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#x201c;other than temporary,&#x201d; including the intention to sell and, if so, marks the investment to market through a charge to the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_d5eab319-079e-4dec-9519-5455436abea5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, our policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_43c9bf0e-9553-435a-b68a-9924049e33fc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the time it enters into a contract. For all leases, the Company determines the classification as either operating leases or finance leases. Operating leases are included in operating lease right-of-use, or ROU, assets and accrued expenses and other current liabilities and operating lease liabilities, noncurrent in the Company&#x2019;s consolidated balance sheets. The Company has not entered into any financing leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses the Company&#x2019;s incremental borrowing rate in determining the present value of lease payments. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. Refer to Note 6 for further details.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_09f46053-4eb8-45ea-8795-e133e4f0a184">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.981%;"/&gt;
          &lt;td style="width:3.001%;"/&gt;
          &lt;td style="width:60.018%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.8pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.1pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of 10 years or the remaining term of the respective lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_f43dbe76-eeb2-42b7-a3c1-bc8110b42261">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Costs associated with maintenance and repairs are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.981%;"/&gt;
          &lt;td style="width:3.001%;"/&gt;
          &lt;td style="width:60.018%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.8pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.1pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:21.6pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of 10 years or the remaining term of the respective lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_333a7d4a-b385-4327-8cb4-b33035085d6f"
      id="F_3c184b6c-1ff1-442e-90c4-2014e876ff2b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_da11831e-2def-422d-b9ba-135e9cc96547"
      id="F_4c068134-a202-4d6a-83ae-33ab11d745f4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b8b87670-6319-4b49-9747-781911421762"
      id="F_152108ab-292f-44d2-887c-33565c29b3a9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_446278fa-fce1-4cd4-b15e-1085d37b326c"
      id="F_14caa1a7-fb26-49d8-bebb-555b8b0214f5">Lesser of 10 years or the remaining term of the respective lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_dbedc1a4-07ed-4e40-a1ee-329d49650059">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. Through December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, no such impairment has occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_51d915fd-6e91-4b24-b5e0-65092b77da6b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred for the development of its product candidates and include expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct clinical trials and preclinical and non-clinical studies, costs to acquire, develop and manufacture supplies for clinical trials and other studies, salaries and related costs, including stock-based compensation, depreciation and other allocated facility-related and overhead expenses and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has met the requirements to receive a tax credit in Denmark for losses resulting from research and development costs of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The tax credit is reported as a reduction to research and development expense in the consolidated statements of operations. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, research and development expenses include refundable tax credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_0e4e962b-0c7f-427f-b8d8-253f1dfe01e0"
      decimals="-5"
      id="F_4f547dee-8b46-4f26-acc4-cc4c88b3db12"
      unitRef="U_USD">3600000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_84f94529-71c5-4ff9-b7c7-bebbc7bcaa33"
      decimals="-5"
      id="F_1b6dc9e9-0dc3-4d27-8422-68c8d98b029e"
      unitRef="U_USD">3800000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
      contextRef="C_b63f1cd8-2964-4478-ba13-1aca8bfd1025"
      decimals="-5"
      id="F_00d8a224-39e8-415b-bbed-a94afb94aced"
      unitRef="U_USD">800000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
      contextRef="C_8c0c025b-fcd6-4855-aa25-24dcd9c881c6"
      decimals="-5"
      id="F_4ab02bd8-3ffe-47b1-90a0-dcb7a38d85d9"
      unitRef="U_USD">900000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <glto:AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_640e3373-eff1-46e9-9f63-f1888358f8b6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Substantial &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors, or collectively, CROs. These CROs generally bill monthly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the CROs, and correspondence with the CROs and clinical site visits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</glto:AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3aba541a-09bb-4a3a-bd7d-eab58a3bfa65">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock options granted in accordance with ASC 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, or ASC 718. In accordance with ASC 718, compensation expense is measured at the estimated fair value of the stock options at grant date and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity-based compensation expense is classified in the Company&#x2019;s consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes model. The following summarizes the inputs used:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies because we lack company-specific historical and implied volatility information due in part to the limited time in which we have operated as a publicly traded company. We expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The expected term of the Company&#x2019;s stock options has been determined based on the expected time to liquidity. The Company uses the simplified method prescribed by the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to calculate the expected term of options granted because we lack company-specific historical and implied expected term information due in part to the limited time in which we have operated as a publicly traded company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the implied yield on a U.S. Treasury security at a constant maturity with a remaining term equal to the expected term of the option granted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; because the Company does not pay cash dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:DividendIncomeOperating
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_f5982009-8dc9-487f-9746-c77663c293b7"
      unitRef="U_USD">0</us-gaap:DividendIncomeOperating>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_a3e2dabb-4d65-41b5-a73e-296f0a5804aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company follows the provisions of ASC 740-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Uncertainty in Income Taxes, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or ASC 740-10. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has identified the United States, Denmark and United Kingdom as its major tax jurisdictions. Refer to Note 11 for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_5c73d69e-5da9-4329-8255-26685d769db2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as if-converted method, for convertible securities, if inclusion of these instruments is dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, both methods are equivalent. Basic and diluted net loss per share is described further in Note 12.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_131502ee-5409-4054-ac40-a3bf009174d8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer. The Company has determined it operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_f250ce06-dfd3-4723-bb43-477f2bd52a38"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_bb199c29-37a7-4193-b403-d0a8f45e02f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other comprehensive gain (loss)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other comprehensive gain (loss), or OCI, is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s OCI includes currency translation and unrealized gain or (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <glto:EmergingGrowthCompanyStatusPolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_b855acc9-bd82-4755-8337-67fc7369ad29">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Emerging growth company status&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company may elect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, and as a smaller reporting company, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</glto:EmergingGrowthCompanyStatusPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_29349d87-afbe-4053-b42d-f8584ff08909">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Codification Improvements to Topic 326, Financial&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Instruments-Credit Losses, Topic 815, Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;and Topic 825, Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The ASU 2016-13 guidance became effective as of January 1, 2020, and must be adopted using a modified retrospective approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a SEC, excluding eligible smaller reporting companies for fiscal years beginning after December 15, 2019. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December 15, 2022. The adoption of ASU No. 2016-13 during the year ended December 31, 2022 did not have a material impact on the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically reviews new accounting standards that are issued and has not identified any new standards that it believes merit further discussion or would have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_081b0bd6-31af-4e42-b7e3-c84b18d049c5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. INVESTMENTS IN MARKETABLE SECURITIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash in excess of the Company&#x2019;s immediate requirements is invested in accordance with the Company&#x2019;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s available-for-sale investments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.879%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.623000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.623000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.828000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.023%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_0f88c296-6264-4042-8714-841aed812bb6;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_44cda3a6-b017-451a-b0b6-7cab4805cade;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_fe316224-edc1-43a5-93c6-6c3cc301ce16">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s available-for-sale investments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.879%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.623000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.623000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.828000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.023%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_0f88c296-6264-4042-8714-841aed812bb6;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_44cda3a6-b017-451a-b0b6-7cab4805cade;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_c2f0af89-b355-4b97-a4a1-318ded44efa8"
      unitRef="U_USD">27573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_39e4b1a3-58f4-4aca-ae94-febc743b7771"
      unitRef="U_USD">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_cc7eb2da-46d5-4c0e-91b2-dd387e35223b"
      unitRef="U_USD">27438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_364fdb5a-4e08-4efa-8a2d-8f7249b259ce"
      unitRef="U_USD">27573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_135d8959-bc2c-4d38-840c-024652b7f151"
      unitRef="U_USD">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d6c004f9-30fd-424c-9fb9-45d6fde33858"
      decimals="-3"
      id="F_19e7b40f-444e-43a6-b916-83ec369a0885"
      unitRef="U_USD">27438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_c4cdb346-e925-4c20-bbac-f4c84437e669"
      unitRef="U_USD">5963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_5f5ab487-4dc2-42ac-a187-696059f27b5b"
      unitRef="U_USD">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_7a682d07-fcf0-4c88-8b52-bcbc0497753c"
      unitRef="U_USD">5832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_e998a0cd-a124-4469-90dd-18295d60ff42"
      unitRef="U_USD">5963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_0af976a2-8e81-4cc5-a2c9-e8aba85b87f7"
      unitRef="U_USD">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fe9a0289-03cd-4c28-8cea-41cc4570e327"
      decimals="-3"
      id="F_021c307e-4692-4c62-bcaf-6a6295f314fa"
      unitRef="U_USD">5832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_44211e05-aafc-4c0a-98ca-73673faf675a"
      unitRef="U_USD">37671000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_fb0feb11-594c-4058-9383-107ff055ccd0"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_83717ba3-8bca-45a2-b76c-643c5d196842"
      unitRef="U_USD">37628000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_90a16ca4-335d-4fcb-b5af-ceb8a24901ef"
      unitRef="U_USD">37671000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_4d50072b-381e-4bc1-8d73-853f63f3a2d5"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a5e23dbf-7189-4f00-9cce-e1174083d383"
      decimals="-3"
      id="F_3707704b-f155-4a06-97f8-e61190b8f35e"
      unitRef="U_USD">37628000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_6e48a782-cb40-46b3-a747-b5a785eb2372"
      unitRef="U_USD">9082000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_49724d9c-fcae-4533-8f9e-825e8720dde0"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_c145f367-7835-44a3-8624-5cf0e9c113ce"
      unitRef="U_USD">9048000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_991867d4-7f51-498d-824b-9699b697b7fc"
      unitRef="U_USD">9082000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_459523ac-6598-460e-9606-b1c6e8029a62"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6af6e762-621d-4e84-b2aa-92985a786e0b"
      decimals="-3"
      id="F_62c9ef8e-9ae3-4512-b167-247d2268c682"
      unitRef="U_USD">9048000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_d6434133-357e-47f1-813e-35608ff76877">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classified its money market funds within Level 1 because their fair values are based on their quoted market prices. The Company classified its debt securities within Level 2 because their fair values are determined using alternative pricing sources or models that utilized market observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the assets that are measured at fair value as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.045%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.911000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurement at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurement at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_2d9c76a5-2f26-449a-bec2-40a18d63aae7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the assets that are measured at fair value as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.045%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.911000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.473%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.788%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurement at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurement at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying &lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cd6ff40d-6e4b-4542-b39b-9a47a5dc2935"
      decimals="-3"
      id="F_70ef8177-77d4-42db-8858-2e00b6e505a0"
      unitRef="U_USD">16445000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1a891281-b4a3-4bf6-89c4-3d7d6ec73b43"
      decimals="-3"
      id="F_ad5aa444-009d-4bdb-94c2-4a078a241d56"
      unitRef="U_USD">16445000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4f2ccad7-282a-4f1b-bf36-002446285a34"
      decimals="-3"
      id="F_31426537-09fb-4c76-81b7-f4daf270e4be"
      unitRef="U_USD">33270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4b62815c-330f-4ecf-a0ae-127533136899"
      decimals="-3"
      id="F_ff996d0b-1205-4a98-bbcf-72ab84c2f344"
      unitRef="U_USD">33270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_88b7dd29-a2e9-4999-b70d-b84c39b084f7"
      unitRef="U_USD">49715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_578a6731-4436-4656-baa1-0e8306439eeb"
      decimals="-3"
      id="F_6e857e30-9a93-49bd-bb58-3a820f644ee7"
      unitRef="U_USD">16445000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1a7732d2-f6dc-4da5-b07c-d4c3c940cae5"
      decimals="-3"
      id="F_c262add6-3338-48f2-b47c-91a2f3576f8e"
      unitRef="U_USD">33270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_38c70869-4934-4789-a4e2-402a3062df02"
      decimals="-3"
      id="F_06dee806-a64a-4d84-8dcd-905db2003c0c"
      unitRef="U_USD">49626000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c5778128-4ddb-4ebe-97f8-350950f780c6"
      decimals="-3"
      id="F_5b8848ed-0da8-4574-8bb9-2db7a244814f"
      unitRef="U_USD">49626000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4935191f-2911-40cc-83d3-1839e14b12c2"
      decimals="-3"
      id="F_99e0bf3d-2b02-4e40-be0c-b77057a836f1"
      unitRef="U_USD">46676000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f74559e7-8f45-4159-a81f-b42a765ec89e"
      decimals="-3"
      id="F_64019a30-eb2d-4204-abc0-2b9aad42e5b3"
      unitRef="U_USD">46676000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_905c4e9d-4ebd-4c64-bed3-2156b632c910"
      unitRef="U_USD">96302000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5653da56-b435-4ded-887e-78f37a343b93"
      decimals="-3"
      id="F_43f29b27-e8bb-41bd-8122-036566d7c7c9"
      unitRef="U_USD">49626000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5660b0e7-05a2-4c92-a655-1dd591e67b0a"
      decimals="-3"
      id="F_723d4d01-acdc-4cf2-8345-1983123a74b8"
      unitRef="U_USD">46676000</us-gaap:AssetsFairValueDisclosure>
    <glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_16df118b-c9de-4265-8298-f7b75069ef1a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.662%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.146%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_dd567e6d-089e-49b9-a7d2-4efcf6f55bb0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.662%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.146%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <glto:ContractResearchAndDevelopmentCostCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_bdae33ed-960f-44a3-80e8-ec69c0275564"
      unitRef="U_USD">1450000</glto:ContractResearchAndDevelopmentCostCurrent>
    <glto:ContractResearchAndDevelopmentCostCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_d5f713b8-87ef-4117-82a4-2fd1fcf0c1a1"
      unitRef="U_USD">5569000</glto:ContractResearchAndDevelopmentCostCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_8e28fa93-9390-4f0e-8af1-1380a4ed05f5"
      unitRef="U_USD">805000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_ad0654d0-c082-4daf-b1f2-4e3e2898649a"
      unitRef="U_USD">1728000</us-gaap:PrepaidInsurance>
    <glto:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_cba9f84d-73a7-47a9-a508-84abc0f6ae85"
      unitRef="U_USD">792000</glto:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <glto:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_9fe26057-4788-4be8-abb4-057fc6df59e5"
      unitRef="U_USD">1682000</glto:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_82470597-1e95-4c15-96e5-6c3b73544fda"
      unitRef="U_USD">587000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_08236ed4-5da0-4493-a24a-aa81fee70e8f"
      unitRef="U_USD">598000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_63995381-7a25-46b7-b1c4-96983210fdfd"
      unitRef="U_USD">52000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_237d2588-9072-4a6e-97c1-f43ade37a3cf"
      unitRef="U_USD">334000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_cbec6be4-ff11-4ee9-a31d-d5648191d2c1"
      unitRef="U_USD">3686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_ed9ddaed-b963-4385-a273-5609cf794ae0"
      unitRef="U_USD">9911000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_018aceab-5735-4efb-acc2-3143ddffb2a2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. LEASES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has the following operating leases:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.194%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:20.741%;"/&gt;
        &lt;td style="width:1.722%;"/&gt;
        &lt;td style="width:14.944%;"/&gt;
        &lt;td style="width:1.722%;"/&gt;
        &lt;td style="width:15.963%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:19.45pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Primary Use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease &lt;br/&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Renewal Option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate headquarters&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_b8865681-fb3c-46b3-8f81-199888594bde;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;London, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_63bad519-8d42-4588-8c64-dc3b578e5db5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12.25pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gothenburg, Sweden&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3cbffc48-b954-4828-9d21-d46a15257703;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stevenage, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d29c6159-b3c6-43bd-8e35-677bf4164550;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has no finance leases and has elected to apply the short-term lease exception to all leases of one year or less. Rent expense for years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for both periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.143%;"/&gt;
        &lt;td style="width:1.933%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.367%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.933%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.623%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Information:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the&lt;br/&gt;&#160;&#160;&#160;measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right-of-use&lt;br/&gt;&#160;&#160;&#160;assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted average remaining lease term for operating leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted average discount rate for operating leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for both periods.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities are as follows at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.535%;"/&gt;
        &lt;td style="width:3.057%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:27.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_5b1520e2-e458-4b48-968b-16b8de3fc4bb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has the following operating leases:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.194%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:20.741%;"/&gt;
        &lt;td style="width:1.722%;"/&gt;
        &lt;td style="width:14.944%;"/&gt;
        &lt;td style="width:1.722%;"/&gt;
        &lt;td style="width:15.963%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:19.45pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Primary Use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease &lt;br/&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Renewal Option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate headquarters&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_b8865681-fb3c-46b3-8f81-199888594bde;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;London, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_63bad519-8d42-4588-8c64-dc3b578e5db5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12.25pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gothenburg, Sweden&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3cbffc48-b954-4828-9d21-d46a15257703;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.5pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stevenage, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory space&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d29c6159-b3c6-43bd-8e35-677bf4164550;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="C_32e6c654-8b0a-4d94-9d79-61927bfc66d8"
      id="F_23da31b5-f97d-4232-aa0d-8cfd9dd081da">None</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="C_f9b208c9-11e0-43f5-9a13-0c029853484f"
      id="F_ccf220c5-74db-4e13-a9a7-328497f4f65d">None</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="C_6bb29e1b-fe16-4cff-8393-88bae5954f84"
      id="F_c9453cb8-0f25-4063-9bef-602b6fdccf25">None</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="C_d8e5d26c-d55e-42eb-a73a-fdf21acb720e"
      id="F_b79311d4-5a64-4435-8290-39cb1a651ee0">None</us-gaap:LessorOperatingLeaseOptionToExtend>
    <glto:OperatingLeaseRentExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-5"
      id="F_a74145f4-c778-4258-9931-3f9ea669c92e"
      unitRef="U_USD">500000</glto:OperatingLeaseRentExpense>
    <glto:OperatingLeaseRentExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-5"
      id="F_5b3544a3-6f32-4771-ae54-43e708c06913"
      unitRef="U_USD">500000</glto:OperatingLeaseRentExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e1119f47-6a8f-4737-9f2e-48ba52055317">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.143%;"/&gt;
        &lt;td style="width:1.933%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.367%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.933%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.623%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Information:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the&lt;br/&gt;&#160;&#160;&#160;measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right-of-use&lt;br/&gt;&#160;&#160;&#160;assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_3a2a0857-3dad-42b2-9f05-74294232fde8"
      unitRef="U_USD">506000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_305f12a7-39af-4120-91ea-f0218047c2a6"
      unitRef="U_USD">496000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_4aa92e81-cf7f-42c0-9cc0-6ebd03ac1b56"
      unitRef="U_USD">523000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_5515bade-77d8-4491-a36b-4d1017154496"
      unitRef="U_USD">513000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_43391016-a1d2-4e7e-bc9e-66e9ed167834"
      unitRef="U_USD">488000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_b55a9836-9d98-484a-839e-bdee6b1eb5a0"
      unitRef="U_USD">411000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      id="F_acf27a76-38eb-4bf3-a50c-803c50c34f1b">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      id="F_3a7485f7-fdc3-487c-addc-08e9c9dc1e99">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="2"
      id="F_0ae7fb05-ef80-4657-80bf-9c42f26daed2"
      unitRef="U_pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="2"
      id="F_bfcc546d-3ecf-4893-be63-f495a744b569"
      unitRef="U_pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_4f33c115-8127-4599-aeb5-e93a0381a277">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities are as follows at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.535%;"/&gt;
        &lt;td style="width:3.057%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:27.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_375f2e25-630f-4cf1-a941-d3b16c4df37e"
      unitRef="U_USD">523000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_79d6cd7c-58d0-4064-ac97-0217c2886d44"
      unitRef="U_USD">293000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_5e84a83c-05ce-49e9-ae4a-b14ea2e3da6a"
      unitRef="U_USD">51000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_993cdef5-d867-4682-bb66-e167a51145f8"
      unitRef="U_USD">867000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_24e5905c-dcbe-4cd0-accc-376e8f3e370c"
      unitRef="U_USD">63000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_e417af1b-2d33-4d0d-95fb-f7ce0386f7a8"
      unitRef="U_USD">804000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_49889df7-8fc5-457b-9120-b5fc24747335">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.751%;"/&gt;
        &lt;td style="width:2.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_0caa53fb-9636-420f-86ed-9f8864eaa4be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.751%;"/&gt;
        &lt;td style="width:2.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.156%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_ac9c3f1a-58b3-41e8-99e3-c69a7c6f34b4"
      unitRef="U_USD">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_63b36adb-9cf4-435b-bc8f-7e99d0e7c030"
      unitRef="U_USD">223000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_21574ff5-2b91-4216-8a4b-69f396a5f4e8"
      unitRef="U_USD">62000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_52abb268-85c2-421a-97b6-047588670e37"
      unitRef="U_USD">20000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_341cf35a-eaae-4962-98bd-8f0689b90e26"
      unitRef="U_USD">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_0e957d6d-bc74-4140-948a-e0508481b5d9"
      unitRef="U_USD">203000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_ff08d67f-86b2-4baa-b4ae-c8d44257df6f"
      unitRef="U_USD">42000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_e72c9bbe-ad35-4f20-8fa1-dc3f4837c89c"
      unitRef="U_USD">20000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_331c11ab-6505-4b60-a209-a6da3efca742">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.086%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.848%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.075%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9426828b-8ce6-4136-9592-73b208402ab8;"&gt;&lt;span style="-sec-ix-hidden:F_9ab22cc5-86e7-43b0-9814-29ed771a3b70;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;current&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_12ea1a93-dbbb-4bb9-aa35-35aae6159d28">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.086%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.848%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.075%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9426828b-8ce6-4136-9592-73b208402ab8;"&gt;&lt;span style="-sec-ix-hidden:F_9ab22cc5-86e7-43b0-9814-29ed771a3b70;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;current&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <glto:ContractResearchAndDevelopmentCostsCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_0c123012-618b-402e-8f27-fc8846ca4a31"
      unitRef="U_USD">6145000</glto:ContractResearchAndDevelopmentCostsCurrent>
    <glto:ContractResearchAndDevelopmentCostsCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_f5e1f472-12c0-4652-97f8-8cdfb2591c73"
      unitRef="U_USD">1575000</glto:ContractResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_e6802d25-a182-4782-9d32-cb5ff5117561"
      unitRef="U_USD">597000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_1f5fec48-ce3f-4c1c-a3eb-1be9542f0d58"
      unitRef="U_USD">601000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_72dc6ac6-5a44-441f-8960-5519815bcd89"
      unitRef="U_USD">476000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_ed447ce9-4933-4da3-bd8d-4eb12c008bdc"
      unitRef="U_USD">399000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_e5d98303-d63f-47f0-a5c6-bbdca7718036"
      unitRef="U_USD">539000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_1e65f69a-3c8c-4165-b1cf-c29098949edd"
      unitRef="U_USD">438000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_7063b3f6-8295-4b3f-a2c4-731d5ebfa175"
      unitRef="U_USD">7757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_93f129df-7d79-4ad6-8793-e56b9caeab81"
      unitRef="U_USD">3013000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_0224114d-b7ec-46c2-b0a2-7e1d463f7c68">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Lease commitments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s commitments related to lease agreements are disclosed in Note 6.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Legal proceedings&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and, to its knowledge, no material legal proceedings are currently pending or threatened.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Indemnification agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company, as permitted under Delaware law and in accordance with its certification of incorporation and bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#x2019;s request in such capacity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#x2019;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#x2019;s acts or omissions with respect to the Company&#x2019;s products, technology, intellectual property or services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_3e222e6e-0920-4935-9d33-5e1579de389b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee equity plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2020, the Company's Board of Directors and stockholders approved the 2020 Stock Option and Grant Plan (&#x201c;2020 Plan&#x201d;). Holders of stock options under the 2020 Plan shall be entitled to exercise the vested portion of the stock option during the term of the grant. If a qualified exit, as defined in the 2020 Plan, occurs, then all of the holders' unvested options shall vest immediately.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company's Board of Directors and stockholders approved the 2020 Equity Incentive Plan (&#x201c;2020 Equity Plan&#x201d;). Following the adoption of the 2020 Equity Plan, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; further options are available to be issued under the 2020 Plan. Stock options granted under the 2020 Equity Plan generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period and expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the grant date. The 2020 Equity Plan will cumulatively increase by 5 percent of the number of shares of common stock issued and outstanding on January 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;st &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;each year until 2030. At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;884,566&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options available for future grant under the 2020 Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the activity for the Company&#x2019;s stock options during the periods presented:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.734%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.862%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.065999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.389999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,538,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,009,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,998,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,357,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,778,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,474,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,667,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average grant date fair value of all stock options granted during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The intrinsic value at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; is based on the closing price of the Company&#x2019;s common stock on that date of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The grant date fair value of stock options vested during the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. Total unrecognized compensation expense related to unvested options granted under the Company&#x2019;s stock-based compensation plan was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The Company recorded stock-based compensation expense related to the issuance of stock as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.763%;"/&gt;
        &lt;td style="width:2.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.687%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.759%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of stock options, the expected volatility based on the historical volatility of a publicly traded set of peer companies and the expected risk-free interest rate based on the implied yield on a U.S. Treasury security. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.1%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.453999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.469%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_83df5a70-5b7d-414e-98bc-028cfe3931af"
      decimals="INF"
      id="F_3a483221-0023-4b8b-8f02-6d87ef24ba3a"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f"
      id="F_46e401c5-52c4-468c-b115-16fd079658f7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0a3e2d68-dea0-48fb-9570-575e3b6c4b7f"
      id="F_94864ebe-a38e-4c5c-ab5b-9c8724349965">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5e2554ff-8b5a-4c27-b47d-d3a252e0b453"
      decimals="INF"
      id="F_b30c7fb9-e1b8-44e9-bf07-6892514a2ee7"
      unitRef="U_shares">884566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_70938594-ae92-4163-8009-86489acfe40e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the activity for the Company&#x2019;s stock options during the periods presented:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.734%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.862%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.065999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.119%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.389999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,538,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,009,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,631,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,998,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,357,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,778,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,474,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,667,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"
      decimals="INF"
      id="F_cf2f188c-446f-4579-9244-945bc207d8c0"
      unitRef="U_shares">2538411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"
      decimals="2"
      id="F_02c3855b-89db-4081-9050-16ac87903d95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c6c185ed-a9aa-4137-a7f1-09443c4dd1f3"
      id="F_3510e28e-b3bb-4c13-b98f-cf99fb0ece24">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_17daa140-585d-49ab-9d6c-3a1ffdb3e717"
      decimals="0"
      id="F_77abbfeb-bf26-4131-8dc4-781b72aec0a3"
      unitRef="U_USD">20009769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_916f5b5e-68c2-4172-921c-78a7e83e8662"
      unitRef="U_shares">1631000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_6885b5c3-314f-4ba3-804f-4017f705d336"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_db0a3907-7957-41e4-85e7-55af26bdea4f"
      unitRef="U_USD">8160</glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_8aecc46f-9774-4ef5-914b-82c6488f278c"
      unitRef="U_shares">170683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_98a63c1a-9c66-49ec-92a4-106d328f50e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="INF"
      id="F_8cc00912-ae9b-43ea-8596-a0af1c3d94d6"
      unitRef="U_shares">3998728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="2"
      id="F_04163826-8235-48e4-9526-4e71e3b8db23"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      id="F_e9e5348b-c674-4450-b7f6-f2dd1527d7dc">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="0"
      id="F_98794251-a7b6-48e3-a016-ea64f6f027eb"
      unitRef="U_USD">1357655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_6dda9624-5afe-484e-84e7-9d002b00364d"
      unitRef="U_shares">1827750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_d72d6886-f984-40b7-9f51-576c40cedfe8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_0d904374-29ed-475b-af4a-93e1370107d7"
      unitRef="U_USD">111013</glto:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_ecf614ee-b518-4b27-bbac-24a7f353face"
      unitRef="U_shares">47593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_6f5d76a8-e7a0-42d0-b507-d3886c57700a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_80f8fb80-2257-4828-b997-f269e4eca731"
      unitRef="U_shares">5778885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="2"
      id="F_671fb283-3104-4304-a216-547e9883f4c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e0ecf4b0-927a-4646-bb85-6c16454833a0">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_ea0772fb-b664-40b6-8d7d-8d94d54551b5"
      unitRef="U_shares">5474743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="2"
      id="F_62076e4e-945e-44ff-90e1-874b7c535cae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_7048be55-f2dd-4450-bad9-d93644cc1a05">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="INF"
      id="F_6174da79-8a45-4ce5-99d6-477923748a08"
      unitRef="U_shares">2667144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="2"
      id="F_1caadc0c-e66d-4874-a15a-52b756749f3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_bb21d3a2-2437-4628-ba13-c6095f6d2f80">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8"
      decimals="2"
      id="F_35ce86e3-7520-4aff-bafc-13589c35666f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8"
      decimals="2"
      id="F_cbb4a771-6423-4db6-9de7-82336c2c6f2f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="C_dca04f3b-68dd-41e8-a315-ab386139707c"
      decimals="2"
      id="F_c58fb633-8079-4ca2-b35b-c656b9fe56be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_2bd75575-ee9b-4149-8e99-700c763cf2a8"
      decimals="-5"
      id="F_c716fd02-1103-4845-9bad-8bfed5be8f2d"
      unitRef="U_USD">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_dca04f3b-68dd-41e8-a315-ab386139707c"
      decimals="-5"
      id="F_59c9d3fe-a987-44bd-89a6-d3aa4c97fcfc"
      unitRef="U_USD">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_803e51c6-3b20-4c08-ab3e-92d3c19e9bab"
      decimals="-5"
      id="F_df6d988c-981d-4d69-bb34-a6d36d557482"
      unitRef="U_USD">10900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7c6a862c-3e11-4d68-aa36-13ca8e140e89"
      id="F_250668ab-96f5-4768-a790-715080640802">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e20a6832-69d2-4850-8a0b-0c7bed375c26">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.763%;"/&gt;
        &lt;td style="width:2.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.687%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.759%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_95336a64-c52f-4870-b189-b6f50eb63e3e"
      decimals="-3"
      id="F_5d7e74f4-38f4-4717-b880-d9e093cbe1ca"
      unitRef="U_USD">2618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_349093ed-5db6-4bb4-9588-93a0cf9b007d"
      decimals="-3"
      id="F_f7470c99-f921-47ec-a917-d4f9e851e3e9"
      unitRef="U_USD">1903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_aa78d7bd-1b5f-433d-b347-4f093d16e23a"
      decimals="-3"
      id="F_84c2a63a-ea2b-4646-999f-ff1be1f27eeb"
      unitRef="U_USD">2953000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b98f82b2-780e-4b62-9d74-6429370aa2d4"
      decimals="-3"
      id="F_065c84c3-62fb-4a59-bb12-f45d1af98121"
      unitRef="U_USD">2577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_d088eacf-b7b2-4080-8d33-0cff80829de3"
      unitRef="U_USD">5571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_43285d73-c55a-4a37-8e56-375770561dcf"
      unitRef="U_USD">4480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_1d3b32cb-1d47-49a7-9a11-4358b8225ba0">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values of the options granted were estimated based on the Black-Scholes model, using the following assumptions: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.1%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.453999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.469%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_1ffaaaea-a58d-4e71-a74c-0165064f5bf3"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_2192ca7a-8bab-4f03-89d6-9d5bd08d2789"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_5e5c8e32-84da-42c4-8a74-933988dcd873">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      id="F_81e12094-bed2-4e33-ad74-8a00599642b4">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_65a1a9b9-c800-4bac-8777-a47eea3566cd"
      unitRef="U_pure">0.900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_8d52a720-8a63-4c0c-a51b-49b6b5b8b274"
      unitRef="U_pure">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_c69404f7-28ae-4545-9112-e570f5e5c122"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_47422d99-2b4d-4bd9-aff6-f76109c4f523"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_ef385365-82fb-4be5-898e-3b38719c8ea6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. INCOME TAXES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; income tax expense or benefit for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has incurred net operating losses for all the periods presented. The Company has not reflected the benefit of any such net operating loss carryforwards in the accompanying financial statements. In 2019 the domicile of the reporting entity has changed from Denmark to the United States resulting in a tax rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% in 2022 and 2021. This is discussed further below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of net loss are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.408%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.435%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.422%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Reconciliation of effective tax rate&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective tax rate for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; is different from the statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The reconciliation of the statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.728%;"/&gt;
        &lt;td style="width:1.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.986999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.929%;"/&gt;
        &lt;td style="width:1.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.446%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Orphan drug credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;U.S. research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Bonus compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net noncurrent deferred tax asset(liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable income. The Company considers projected future taxable income and ongoing tax planning strategies, then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more-likely-than-not able to be realized. Based upon the Company&#x2019;s assessment of all available evidence, including the previous three years of taxable income and loss after permanent items, estimates of future profitability, and the Company&#x2019;s overall prospects of future business, the Company determined that it is more-likely-than-not that the Company will not be able to realize a portion of the deferred tax assets in the future. The Company will continue to assess the potential realization of deferred tax assets on an annual basis, or an interim basis if circumstances warrant. If the Company&#x2019;s actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to change the valuation allowance against the gross deferred tax assets. On the basis of this evaluation, a full valuation allowance at December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was recorded of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, to reduce the net deferred tax assets to their estimated realizable value. The change in valuation allowance was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to taxation in the United States, United Kingdom and Denmark. As of December 31, 2022, tax years 2019 and forward were generally open to examination by the Danish tax authorities and tax year 2021 and forward was open to examination by the United States tax authorities. The Company is not under examination by any taxing authorities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had gross U.S. federal net operating losses, or NOLs, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and federal research and development credits, or R&amp;amp;D credits, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and Orphan Drug Credit, or ODC, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to offset tax liabilities. The federal R&amp;amp;D credit and ODC carryforwards begin to expire in 2033 and 2042, respectively. All of the federal NOLs have an infinite life. The Company also had gross state NOLs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;which are available to offset state tax liabilities. The state NOLs begin to expire in 2040. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also had NOLs in Denmark of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which have an indefinite life. Federal and state NOLs and R&amp;amp;D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not completed an analysis to determine if the NOLs and R&amp;amp;D credits are limited due to a change in ownership.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes accrued interest related to unrecognized tax benefits and penalties as income tax expense. The Company does not have any material unrecognized tax benefits which would affect the effective tax rate if recognized. The Company does not have any unrecognized tax benefits which would reverse within the next twelve months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is eligible for the Danish enhanced research and development tax allowance, providing for an increase in the deductible value of the amount of certain R&amp;amp;D expenditures. The deduction for R&amp;amp;D expenditures is set at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for 2019, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for 2020 through 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for 2023 through 2025 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for 2026.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_2f9d1e80-70da-48cd-86e1-997d13bc7710"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_ed61d67e-107d-4128-b3ed-7337976367b7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_3ff931ca-c080-4cdd-8994-1874104fce0a"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_79ea36ef-7e71-4d73-acfb-a79df77ce95a"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_7c5e20b5-4bb4-4f05-8517-3013ee8f87c9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of net loss are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.408%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.435%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.422%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_be90ae3d-d9ea-4e02-a86a-2854a8e0d0b4"
      unitRef="U_USD">-10163000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_b52ab788-4f67-45a0-a92d-71c3bc65088a"
      unitRef="U_USD">-11252000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_dc796c01-1213-43b7-9aaf-13a6e175d807"
      unitRef="U_USD">-51461000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_94230f39-d981-4bf2-bef0-11d266e68af3"
      unitRef="U_USD">-40500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_effb797a-d314-4ea6-ab74-c770e4063fdd"
      unitRef="U_USD">-61624000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_9cf9e898-e005-4d3e-85b9-0baa7b4f8a58"
      unitRef="U_USD">-51752000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_49e44a56-3259-481c-8370-125938b8cdcc">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The reconciliation of the statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.728%;"/&gt;
        &lt;td style="width:1.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.986999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Orphan Drug Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_acd2a6a1-4bf7-4b6c-bbf2-030be2cf6c38"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_53f2fb91-90ba-4f54-bef7-b6bcbfa97ecd"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_7a826fb0-9374-4b76-8b90-a43ad4fbdf0b"
      unitRef="U_pure">0.066</glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit>
    <glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_fdd0fbdf-dc03-46de-838d-5ecf38f5886d"
      unitRef="U_pure">0.057</glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit>
    <glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_c8746c48-6154-48e4-ba67-0b5c9b95beda"
      unitRef="U_pure">0.025</glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_a29a1aeb-7828-4a15-a4ea-47e030db0801"
      unitRef="U_pure">0.035</glto:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_90a4089e-5045-4378-8e55-ee0bc0fcb24e"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_f83987de-7260-4471-99c7-602be787869e"
      unitRef="U_pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_e9b9b348-7b98-45e4-a8bd-d951f57609d6"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_8ecd6f22-67ff-43e6-a8eb-a6aa53971729"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="3"
      id="F_273ad9d6-27b5-4816-9d98-df32b52dcf32"
      unitRef="U_pure">-0.320</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="3"
      id="F_8ad18a81-a9a2-4fdc-984b-2d480b3ed2d6"
      unitRef="U_pure">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_dddb7618-c2d0-42f9-a1e0-f9f472af6bd2">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.929%;"/&gt;
        &lt;td style="width:1.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.446%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.433%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Orphan drug credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;U.S. research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Bonus compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net noncurrent deferred tax asset(liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_7aa6227c-e80e-4d45-bfa1-49be41034e8c"
      unitRef="U_USD">43716000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_fa55da0f-ae0c-4ed3-b0c1-7cfa7e5939c5"
      unitRef="U_USD">31022000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <glto:DeferredTaxAssetsOrphanDrugCredit
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_327d355f-7205-47ad-93bc-a3c539245809"
      unitRef="U_USD">8036000</glto:DeferredTaxAssetsOrphanDrugCredit>
    <glto:DeferredTaxAssetsOrphanDrugCredit
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_25e8b88f-0c88-44c6-ab6a-adc74ba390d1"
      unitRef="U_USD">3948000</glto:DeferredTaxAssetsOrphanDrugCredit>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_b59df11f-bc43-4ece-b712-4bddeb695cae"
      unitRef="U_USD">1191000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_fa8fd6df-2cf5-4eee-8691-138122d8cb05"
      unitRef="U_USD">1191000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <glto:DeferredTaxAssetsBonusCompensation
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_2573ce70-0d5e-418b-a012-03359f288a18"
      unitRef="U_USD">544000</glto:DeferredTaxAssetsBonusCompensation>
    <glto:DeferredTaxAssetsBonusCompensation
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_2cc1617e-1bda-426a-9a7a-7a0de9088527"
      unitRef="U_USD">274000</glto:DeferredTaxAssetsBonusCompensation>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_38bdfa35-37e0-4067-9f4e-7f8541e8f975"
      unitRef="U_USD">53487000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_071aa1e1-406d-498f-ac32-4264588e3d6a"
      unitRef="U_USD">36435000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_0b9f3881-547c-40ad-b171-859b142ced98"
      unitRef="U_USD">53472000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-3"
      id="F_5c812946-4e15-4a0d-8315-b06435d92f24"
      unitRef="U_USD">36435000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_5aef3071-4f50-49ea-ae0e-23c65a8d466d"
      unitRef="U_USD">15000</us-gaap:DeferredTaxAssetsNet>
    <glto:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_14bc8b5f-0e95-4750-acf5-ca50134946a8"
      unitRef="U_USD">15000</glto:DeferredTaxLiabilitiesFixedAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-3"
      id="F_16d26cc6-aac5-46e1-a4e1-09a5783c5585"
      unitRef="U_USD">15000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a"
      decimals="-5"
      id="F_a8baac61-5dc0-48e3-bbff-8ca750178f96"
      unitRef="U_USD">53500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_aa9917ab-7682-4151-a140-fba905b103eb"
      decimals="-5"
      id="F_74182250-77d7-4749-9204-43cd03ae9cff"
      unitRef="U_USD">36400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-5"
      id="F_006ce632-b837-4b04-8e9b-cf972526a450"
      unitRef="U_USD">17000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93"
      decimals="-5"
      id="F_045375e4-ecd1-477a-b64b-aaa5dd29c8de"
      unitRef="U_USD">30700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93"
      decimals="-5"
      id="F_66b6c9d7-f0b2-4331-a50a-a089e4f1cb1c"
      unitRef="U_USD">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <glto:DeferredTaxAssetsOrphanDrugCredit
      contextRef="C_beca966d-84f3-4639-bf46-46255ba1cc93"
      decimals="-5"
      id="F_d175c1de-4db8-49ff-a42e-d7bdcf0fcf60"
      unitRef="U_USD">8000000.0</glto:DeferredTaxAssetsOrphanDrugCredit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c3ec0dd0-9fe6-42b3-b80d-334a822298e2"
      decimals="-5"
      id="F_7382e206-db10-46c4-a647-11b4542aadc3"
      unitRef="U_USD">26800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_b5bd2fa7-aeba-4a9d-8168-371517923959">The Company also had NOLs in Denmark of $161.7 million which have an indefinite life. Federal and state NOLs and R&amp;D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. </us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_4c5077bc-7856-49b1-b161-185d27434c17"
      decimals="-5"
      id="F_e0a1f766-e440-48ad-88df-532bc05fa9cc"
      unitRef="U_USD">161700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_0fed39e7-58c4-4ac9-ab3d-13d15fe315f9"
      decimals="3"
      id="F_3585d1ad-9cab-4762-a0b2-398e65490699"
      unitRef="U_pure">1.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_4336373f-aca3-4ad2-b03c-279e75f3a53f"
      decimals="2"
      id="F_dc7e4732-3537-4104-8a48-ade869ba0ae8"
      unitRef="U_pure">1.30</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_68b96280-106d-4c4f-9050-7768f44a1658"
      decimals="2"
      id="F_50456058-a1ef-47fc-a737-faf2835e3ea3"
      unitRef="U_pure">1.08</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_00b3ce82-ee23-4fad-a96c-75e32b50f767"
      decimals="2"
      id="F_e7e208d5-6866-4699-a26a-a33f4e0d1f4c"
      unitRef="U_pure">1.10</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_8198eff8-bc9a-4cbe-b160-27568327da81">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. NET LOSS PER SHARE&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.408%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.435%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.422%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,409,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,261,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.278%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.668%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,778,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,998,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e093a051-eb27-4071-a2d2-a86f3d212e38">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.408%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.435%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.422%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,409,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,261,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-3"
      id="F_5b7306b1-72d0-40f4-8c3f-595c5d5f9a83"
      unitRef="U_USD">-61624000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-3"
      id="F_62af4297-e0ab-4cb7-82d7-970e004402fa"
      unitRef="U_USD">-51752000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_f4d51319-7f81-4887-ac73-7d958c7f54a8"
      unitRef="U_shares">25409123</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="0"
      id="F_40d890cb-e153-4284-a82a-88a0244cfa74"
      unitRef="U_shares">25409123</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_ea4a4cf6-9565-48cc-a263-ea0f90468d8d"
      unitRef="U_shares">25261832</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="0"
      id="F_6e96bfb7-922c-4b6d-9945-6b31eb4c1022"
      unitRef="U_shares">25261832</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_fac80c54-9707-4068-969d-980b3abf872f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="2"
      id="F_01578d6d-0812-43fe-ae03-1a6ea56fe749"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_9b6201f3-e2e9-464d-9727-f1e6c21b3495"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="2"
      id="F_2b4505e4-d83a-428e-b829-6292950f3f0a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_c024ad86-223a-4184-a817-d16bb280f9c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.278%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.668%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,778,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,998,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_26d85074-1442-4534-bfb5-878f1c5c9abc"
      decimals="0"
      id="F_75214625-75cf-49e8-8a2a-cab69d10afbf"
      unitRef="U_shares">5778885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_97be5459-8e1d-4a9f-a3fe-24a288c0d7ed"
      decimals="0"
      id="F_d499fb99-3a05-43f5-9401-cc041ed6a728"
      unitRef="U_shares">3998728</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_8bfb4aed-af60-4bb3-9f34-1067483fdf2d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. DEFINED CONTRIBUTION PLAN&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a 401(k)-defined contribution plan (the &#x201c;401(k) Plan&#x201d;) for its U.S. based employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. At the discretion of its Board, the Company may elect to match employee contributions. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company paid a match of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, up to the maximum permitted by the Internal Revenue Code, which amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during both periods and is expensed as personnel costs when incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_cfb03bcf-2388-41ae-925e-205c6106a3e1"
      decimals="2"
      id="F_ffcd315d-1294-4150-8dc3-7140b3e03a1d"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_30e1cab4-655e-4ed1-bfb8-3bd1c2074e24"
      decimals="2"
      id="F_491e9cfa-f5d3-41d7-b15f-19cfba1304c0"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="-5"
      id="F_f717969c-b433-4c3e-a434-0fe545454b70"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="-5"
      id="F_97e55189-22c0-46a7-bfa9-61dad13c9f89"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_f0ec8a7d-9b7e-4180-8e33-a0f23be2b347">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; material related party transactions.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      decimals="INF"
      id="F_d7c251cc-07de-4815-ac59-5b814885c11b"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_76a1124d-1bc4-461a-9175-009a2d8648c1"
      decimals="INF"
      id="F_239eab89-ddb6-4488-a2eb-490684f246f2"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_7e754f68-08d0-4938-98da-48e6218005eb"
      id="F_e8ba4a98-47e3-4612-8de7-17f129c77f11">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. SUBSEQUENT EVENTS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_70ef8177-77d4-42db-8858-2e00b6e505a0"
          xlink:label="F_70ef8177-77d4-42db-8858-2e00b6e505a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_06dee806-a64a-4d84-8dcd-905db2003c0c"
          xlink:label="F_06dee806-a64a-4d84-8dcd-905db2003c0c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5b8848ed-0da8-4574-8bb9-2db7a244814f"
          xlink:label="F_5b8848ed-0da8-4574-8bb9-2db7a244814f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ad5aa444-009d-4bdb-94c2-4a078a241d56"
          xlink:label="F_ad5aa444-009d-4bdb-94c2-4a078a241d56"
          xlink:type="locator"/>
        <link:footnote id="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a" xlink:label="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_70ef8177-77d4-42db-8858-2e00b6e505a0"
          xlink:to="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_06dee806-a64a-4d84-8dcd-905db2003c0c"
          xlink:to="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5b8848ed-0da8-4574-8bb9-2db7a244814f"
          xlink:to="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ad5aa444-009d-4bdb-94c2-4a078a241d56"
          xlink:to="FNT_ecb54fff-b3f8-417c-a139-e46edc51827a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB%CE_Y--<6_GHD&"3&F1;(.A!$F4%G_9Z_9%O NX="H"Z#: ?@IPVQ4!WC;
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M+R/#,I#.!Y98F^$!H6^][P-_]GA&1@_^N=5H'0SCEA#CXABR->I#C970&D<
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ME6SCX20R\H<3TLO"2 M)>EIS:&EY!UJU5'M K[I_J8-MO))M/)Q)=A:K&/Q
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M\#CM[2-\*K(V@V&\\(-CA+;8(HX'>!EW3(?'J6XCBH)K0Q_[[9N(TL29E0G
M16__$IJA^)T3]ZAA=W5 SC+SZX8.G>^8$\>C5?5&B^0^$WG*I'KS:DEP=%FW
MT/JGT^%1'GYV<7TA:X<'I(Z:R3@U0Z^[99 S*5(F"%,HLA+!T:%B2&S1:^_"
M@S^,(.^0RJADEPA[4WAE/OLWL%\JG0G)_P,C5",XQ+'B%N2?SH'U?C(GNDM(
MT2<=KI0IF4(B46FE0<1D-55FUF$+SB/<J(//V'\O8.AP$;JN@XQW'2;Y1'GV
M"OC>+RP!":9A0*9^W+P,IB3$4^BGCU:FYK#^THR9G2+0W+'ZJB9W)LUX!)ZS
M2K]NZ'"5>I<)HWW.^D.:<G,E!:7<' ]GO(3#]HY#:7<Z3!P'V#CR_:-Z[I3S
MPV"@521=VT1.MDU54>7UA4_*MCSA3EHD=D\T@P(($(Z!.@1Q$&(\P#VDZY_(
MR?ZI1=JT3:* U<O,+>(#L+Q0[LL;NQ^:D5Z3T>!V2/G$&P#==4WDG*Y)/8LY
MB-T5A3@*K"WAZK$B0@8Z/=*U3^2<*X)>'U(G\#-]"*UK(=<)R"'F/ '->U>:
MYC[Y,Y5WO%30WVU!T;N(( IR?T6['VBQJV\Y;X76HJ@?,T8!NQ& W[<"6I5F
M8"Y.VXOR]?]02P,$%     @ .C!I5BUD#9S: @  MPD  !@   !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6RMEEUOFS 4AO^*Q:9ID]KR%?+1)4AMJFJ[F!0U
MVG8Q[<*!DV#5V,QVDFZ_?L= 66C)E[1<!!O.>?V\YAA[O)7J46< ACSE7.B)
MDQE37+NN3C+(J;Z2!0A\LI0JIP:[:N7J0@%-RZ2<NX'G]=V<,N'$X_+>3,5C
MN3:<"9@IHM=Y3M7O6^!R.W%\Y_G& UMEQMYPXW%!5S '\[68*>RYC4K*<A":
M24$4+"?.C7\]]3V;4$9\8[#5.VUBK2RD?+2=S^G$\2P1<$B,E:!XV< 4.+=*
MR/&K%G6:,6WB;OM9_;XTCV865,-4\N\L-=G$&3HDA25=<_,@MY^@-A19O41R
M7?Z3;14;#1R2K+61>9V,!#D3U94^U1.QD^#W]B0$=4)P:D)8)X2ET8JLM'5'
M#8W'2FZ)LM&H9AOEW)39Z(8)^QKG1N%3AGDFGDJA)6<I-9"26\JI2(#,K9PF
M[V=4@3 9&)90_H%<DK?$)3K#NWKL&AS=:KA)/=)M-5*P9Z0[2*Y(Z%^0P N"
MCO3IZ>E^.]U%SXWQH#$>E'KA'KVY0<M8CX;();EG HTSRLE,:E;6UX^;A38*
MJ^QGE]5*N]>M;9?>M2YH A,'UY8&M0$G?O?&[WL?NXS_)['6-(3--(2'U.,9
MKAI0"E\^EEKR>$$*JLB&\C5TV:ZTAJ66_4!L8A\NO6CL;G;]'(MJ@?8:T-YY
MH'1M,JG8'TB[2"NQ:)?!JWXO8$\(;/%&#6]T'B_3>MW-&KU"> EY**)%UV_H
M^N?1X1=>&RI2)E9=B/VCB(<B6HB#!G%P$'$J\QS7X2EE.3BI+(]%M2B'#>7P
M#,K#-3E\-46AUUV4IT2V<$<-[N@,W/TE.7H%$$3]* A'P0O2KL"@[P_#H!O4
M]_YM3-X9J$?JL]8Z ;@SLI/8W=E5[9'F"U4K)C3AL,14[VJ &JHZ)50=(XMR
MHUU(@]MVV<SP9 7*!N#SI93FN6/W[N:L%O\%4$L#!!0    ( #HP:5:.L%!'
M!P4  $04   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5AK<Z,V%/TK
M&G>GDYW9!"1>=NIX9N/TL3/=-I-LNI\5D T-2*XDG&Q_?:^ @ V"IFF^V 9?
M'<ZYDNZY:/DHY(-*&=/HJ<BYNIBE6N_.'4?%*2NH.A,[QN&?C9 %U7 IMX[:
M24:3:E"1.\1U0Z>@&9^MEM6]:[E:BE+G&6?7$JFR**C\=LER\7@QP[/G&S?9
M-M7FAK-:[NB6W3)]M[N6<.6T*$E6,*XRP9%DFXO91WR^)IX94$7\D;%'=? ;
M&2GW0CR8BT_)Q<PUC%C.8FT@*'SMV9KEN4$"'G\UH+/VF6;@X>]G])\J\2#F
MGBJV%OG7+-'IQ6P^0PG;T#+7-^+Q%]8("@Q>+')5?:+')M:=H;A46A3-8&!0
M9+S^ID]-(@X&X'!D &D&D/X ?V2 UPRH,N?4S"I95U33U5**1R1--*"9'U5N
MJM&@)N-F&F^UA'\S&*=7:\&5R+.$:I:@6PU?,$=:(;%!O^^8I";7"E&>H+4H
M8*&D9@;W#/TJE$*GZ.[V"IV\>X_>H8RC+ZDH%82JI:.!FGF $S<T+FL:9(0&
M)NBSX#I5Z$>>L.08P %-K3#R+.R23")>L?@,>?@#(BXA%D+KEP_'$W2\-L]>
MA>>-X#7)Y%O$GF +*F9-4HWAVS',CCY7.QJSBQG,A&)RSV:K[[_#H?N#3> ;
M@1W)]5NY_A3ZZ@80J8S3:N4D; _E8F<6EDUTC1152*;J[%?^G+CATMD?JAE&
M>7-_/F^CCF@&+<U@DN;/C,.TY!5+FL#VRI0VT[1G-J(U5G!  7NNBWM$;5&1
MM[ 3#5NBX231+T(#3?&B110."(28N%&/YC J((1$=II12S.:I%E5A8T4Q3-5
M*!XVBM'@X:<VCI:P"9+SEN1\>BOJE$FH5[$H&#II,OG^ ^+,NCSG;[DGWPCL
M2/>BU;V8G)Q/7#- U8WT4<&+0=8C4T&/9F88@X/0/BW8[:S(_??5 ]:N:,Z,
M 4%?\< TO8<KQ>)29CJSK_@&]VBA1&Z/\O3#7YE[?."S>%(<-!W04G#8N7%*
M^98A*#1<T;J9V4*_A4YRT#^^#AO\(Y'8#1=]F<,P#X]4'TPZ]N0E]>>_[9P&
M\XBQC_N;W!+E1\$(X<YN\:2]K7Z##MCDT\K+&W@)E)^0^'UFEK@ 1P$9(=>9
M(YYVQV=R"(HD@F069M&G5,*>A)8TBZVD:\C%(1ERYGM]SM8P=RR?G5'B::><
MH)QD>:G[/5M#.G@9:6O8*.G.-/&T:WZMFGB6G-(]N!'L.5X6]\ ?:DO%7:%2
M0=L+>P\4[<K*6?EKYF9HIB3PW04F Z6V2!+BN3>VJ#KKQ=/>^\9BIV9UZ,MC
M<FV1DW([$\<O<?'XZ*6D7T:-=DV?K!K>U-;?"NTX%YVQXVEG7Y=2,AY_JSTE
MIWU/L29@,2AN) SZ\S<,.EW@D?Z+=$9/IHW^CDM&\^QO6(YYX_DO]GIB\7H2
M]%W0%A6-\>X\G$Q[^ V+<ZI4MLGB.L<T^1->T<V+#=H(68L!>\S+I-YI9@W6
M=FF5,K3J0=<RS>B5*XMTOD^F??]_[C(R]/:H_V)GB3E=+/R1N>H: #+= -0=
MRS'SL8: 6!N"P)_WJ=H: A+Y_<[7.3B/*9C<5L=4"LB47-<G&.W=]BCL8W4
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M3J+I0PY6>)<,1^+_!"L,]]D^+9.X)ILD3/@ 2# >Y"\>DP*(!HKA(I;]^(6
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M8[BA0BP*J! Z:6N$V@4*YV"1_N>]9[Q,C/&AO%3%1)3YR[&,_.@:#?IM:M;
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M-+*9F9J9NJ+L%^,$)B@*@F ^V1]:X)",81JC0\DC>'$'+_;&YSK_6Z617M5
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M7W\\3=UPI82LNP-PZOTHDID1V+B-4#%CTT:"Y4H.6Z80\U0!.XN _><A-+?
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M%ET\<[^:D^?#?M[[MQ]G>=V52X VR]AS)E "08U_1Z59O#W88U3K;7P3YZG
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MT185?&2_TW!,W:RC(TH1Z*."^F'"S+9?W&ZZT,I;Q:4'Y&4+('3K6!M4?4G
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M(0V]GJZ9TN<**AM \TLIS;YC"U0?0,/O4$L#!!0    ( #HP:5;)0<$=B 0
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M&$]#3UAF-&6B90&ZGQK*E^6&">JY=?0O4$L#!!0    ( #HP:5;8"" /] (
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MEN2F(H@CVW#0AW X:-77%0;0Z71;*Z%9#N6;*W<&'0K7HW'8'OH^O-13[I%
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M;L!H6(#V4ZW=9L(&MJ^\R;]02P,$%     @ .C!I5I,[76Z[ @  $08  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULE551;]I #'[G5UC9-+42(N&
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M[K _I#'N!F$,+Y6/?]#\!:JMDSA[H;O2U#K0[K8J.JW%XX]Y+<&?F=KR4H/
M#;D&)\.^!ZJ6M7IA9.6D9"T-"9.;YO0G0&4-Z'PCI7E>V #MOV7R&U!+ P04
M    "  Z,&E6MU_;%=H%  !7#@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6R=5]MN&S<0_15"!8(6$"19=BY-; &^I350NT'LM@]%'RCN2,N$2VY(
MKF3]?<^0J]4JD8TV+])>.&?.W&=/U\Y_#B51%(^5L>%L4,98OQV/@RJIDF'D
M:K)XLW"^DA&W?CD.M2=9)*'*C*>3R:MQ);4=S$[3LP]^=NJ::+2E#UZ$IJJD
MWUR0<>NSP=%@^^"C7I:1'XQGI[5<TCW%/^H/'G?C#J70%=F@G16>%F>#\Z.W
M%R=\/AWX4],Z]*X%6S)W[C/?W!1G@PD3(D,J,H+$WXHNR1@& HTO+>:@4\F"
M_>LM^OMD.VR9RT"7SOREBUB>#=X,1$$+V9CXT:U_I=:>EXRGG GI5ZSSV9?3
M@5!-B*YJA<&@TC;_R\?6#SV!-Y,G!*:MP#3QSHH2RRL9Y>S4N[7P?!IH?)%,
M3=(@IRT'Y3YZO-60B[-+5U4ZPLLQ"&D+<>ELU'9)5FD*I^,(%7QPK%JXBPPW
M?0+N:"IN@5 &<6T+*O8!QN#6$9QN"5Y,GT6\(C42QT=#,9U,I\_@'7<&'R>\
MX^\Q6%SIH(P+C2?Q]_D\1(^L^>>0&[*2D\-*N)+>AEHJ.AN@5 +Y%0UF+WXX
M>C5Y]XP))YT))\^A__^8/0MWF.S/(W'Y^^WMS</M]=W#O3B_N\+]W</-W2_7
M=Y<WU_?B-T(M"-6C\E 2J%2UM)L7/[R9'KU^%_;>>S(R4B&B$R8)RZ4G:LV
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MQFV(0\I1-UK.-?<#MK?M!=A3V)F0U3[;@0P,I:Z'L 7&[,S]+NJ[U.W1 F;
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M0B#W10&AK9+6"46A%@B4RN;*UL$2,D_H(A+]@QT<J2^MA52.,H."8F6A\Z5
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M:(H+J(-<Q;R$F!=[YLUZ@]%4C'IOQ[/.C_YMGY(2Q$>W(#<2=8<*NJ:B'P1
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M(E4+B*+33;K"^I^-_$UAUOQ3S=P4A<GX<J4DLIX6X/W"8-(.-[1!_=O=Q?\
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M=/#QA('MAD1G>%/'QEP:3VT>CR7-5;0A@.Y7QOB=$1+TDSK_ U!+ P04
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M^S[6014C .+P/V7K)ZM'M-*?LD?/5T^RRI0E,2Z]?ZUS76UA+Y].B*'% GV
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M^O@>WZ_RO[3V2'^* "+UUE;T(S:;Z@8'P/N=A4!;?L$-PA^G>/6_4$L#!!0
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MA':W[:BSII'\,V_:\3U3&TH6Y+@FJ'\SB%Q038MK%D:6=5M924--JIYF]%=
M90WH?"VE.2ZL0/N?B?\"4$L#!!0    ( #HP:5;15G 7Z ,  (T)   9
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ME+I4^<O?"T;6[L)-I*'KVRWM($1E%6@_E])L!>N@_0-;_ M02P,$%     @
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M0F.#9(<;[$A!&@/<7PFA=Q-S0-?CSO\%4$L#!!0    ( #HP:5;Z'V7T8 ,
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M%2#?KR@5^XXZS]K?E^@?4$L#!!0    ( #HP:58D$*6/*0,  -X-   9
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MJN- <1FI QAP/4#=7S,FMPT]07VD\WX#4$L#!!0    ( #HP:5:Q05ACN (
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MA<;V:H<Y7H @30!^SX30VXG9H+M2X[]02P,$%     @ .C!I5L.=,X=L @
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MI*;DABOZ"X"V ;2^4 I?)K8SM?^5[ ]02P,$%     @ .C!I5BW8$\%P @
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MTGQ9W9'7K]Z05X0)\KF4C4:LGOD&<[+*_+S5_^Z@/WI!_QWD5R0.1R0*HF@
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M58KG7QUN^,/ R-I=DFMI\,IUKR5^%(&R ;B^D=(<!_;>[3ZSLG\!4$L#!!0
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M9KXQ0-H <W\FA%Y-;('FJR7Y!5!+ P04    "  Z,&E65*C$1.0$  !M&@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6S%66UOVS80_BL'K1A:(+%$
M^25.YAA(K!8+L*Q!@ZP?AGV@)=HF(HDN2=OQL!\_DE)DR5:8&..0+S9%\1[R
M'MX=[\31AO%'L2!$PE.6YN+26TBYO/!]$2](AD6'+4FNWLP8S[!4CWSNBR4G
M.#%"6>J'03#P,TQS;SPR?7=\/&(KF=*<W'$0JRS#?'M-4K:Y])#WW/&-SA=2
M=_CCT1+/R3V1#\L[KI[\"B6A&<D%93EP,KOTKM!%A,ZU@!GQ!R4;46N#5F7*
MV*-^N$DNO4"OB*0DEAH"J[\UF9 TU4AJ'3]*4*^:4PO6V\_H7XSR2IDI%F3"
MTN\TD8M+;^A!0F9XE<IO;/,K*17J:[R8I<+\PJ8<&W@0KX1D62FL5I#1O/C'
M3R41-0&%TRX0E@+AGD#XDD"W%.CNS]![0:!7"O0,,X4JAH<(2SP><;8!KD<K
M--TP9!III3[-];[?2Z[>4B4GQ_>2Q8^GUXJY!"8L4^8DL-F04[A*$JJ;.(6;
MO+ P_>)C1"2FJ?BDACS<1_#QPR?X #Z(!>9$ ,WA(:=2G*A.U;ZE::JDQ,B7
M:K5Z3C\N5W9=K"Q\864(;EDN%P(^YPE)6N0GK\B'%@!?T51Q%3YS=1U:$;_&
ML@-== )A$ 9M"[*+1R2NQ,,6\>CMXLBB3;?:^:[!Z[ZT\WJ_3J>'.W_%.<[G
M1#FWA.D6ZN/N\-9T7VTP3^#/WQ0DW$B2B;_:]K>8O]<^OPYH%V*)8W+IJ8@E
M"%\3;_SS3V@0_-+&K4NPR!%8@_=>Q7O/AC[^?95-"0<V [;4?"M/F2O"9:N-
M7UNQCN6P .L;,'T@K,=H&)Z=]94QK^OTM(P;=%$0[,8U-.]7FO>MFIM8 U\+
MK=N4M8H?JZQ+L,@16(.V047;X)T==>"2=Y=@D2.P!N]G%>]G5G/];G(&DISB
M->$J!RK<%!(L"<PPY;#&Z8IH1Q;&L$MWMGFS=<)CB2[ SFM>&G;TP=)P94<S
M-@@<5@0.K03>Y))3E2'&)5-+%?9,EG# 61M75NQCN1H><(4ZJ+_'U>&@;B?H
MML>\\XJ#<RL'7RR&LB;B!3NQ8AZK>P$VJ*DUZ SW5#\<$W8&[9JC8)=:!E;=
M=9H$=RG.X1]X-?;;L8[5V2E:Y JMR6,M14?O? "4"W!%ODNTR!5:D_QP1W[X
MAJ3EV67Q6I4^>)JJ$X!QF*WDBI?G0BNMX4$BM9=J3>RS'\V5([0F5[N* ED3
MY_%#SDG,YCG]6UE@7+=4\J3;I)4DIV5"B5:/9"CHG.^%.U=S-GG:50#(7@*8
MP/CYQXK*K2JM8^6G=$W>'BF=U@1.T2)7:$UB=P4&ZK]WI'1:HSA%BURA-<G?
ME2G(FHTW(^6)R6YH/M=9'V6M6<XK>#W8$LS;7&!BESR:M_^CRD"[,@/9ZXP]
MWE2HI+RP6@MU=D@46+AS681$KM":W.TJ#&0O,?[3Z>RTPBC1ZF?]<-CK#P;[
M1X^C69N$[<H19*]'7CVB02ZP!"K,<ZSJ$Y ,I@1J8DS5PX!ALU\?6\S5:4'S
MBHIA8?L00E9\_T6A*MJW;<X0N5I8L1M^[3M\1OC<W&<(1?,JE\5GYJJWNC.Y
M,C<%>_T3?9=BON_O8(J+F%O,YZJFAI3,%&30.5,&QXN[C>)!LJ7YVC]E4K+,
M-!<$)X3K >K]C#'Y_* GJ&Z8QO\"4$L#!!0    ( #HP:58R-8U\$ 4  $D:
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+59VV[C-A#]%4(MBBRP
ML43=E=H&$JO;]F&[P0:[^U#T@99I6X@DNB1M)W]?4I(EZV+&=A4$<'29.9QS
M>)L1QWM"G]D:8PY>TB1C$VW-^>9.UUFTQBEB([+!F7BS)#1%7-S2E<XV%*-%
M[I0FNFD8KIZB.-.FX_S9(YV.R98G<88?*6#;-$7T]0$G9#_1H'9X\#5>K;E\
MH$_'&[3"3YA_VSQ2<:=7*(LXQ1F+208H7DZT>W@7FKE#;O$]QGMV= TDE3DA
MS_+FS\5$,V1$.,$1EQ!(_-OA&4X2B23B^+<$U:HVI>/Q]0']4TY>D)DCAF<D
M^1$O^'JB^1I8X"7:)OPKV?^!2T*.Q(M(PO)?L"]M#0U$6\9)6CJ+"-(X*_ZC
MEU*((P?3/>%@E@YFV\$YX6"5#M:Y#G;I8.?*%%1R'4+$T71,R1Y0:2W0Y$4N
M9NXMZ,>9[/<G3L7;6/CQZ1,GT?/M@U!N 68D%<.)H;Q#;L%3,10 68+<"GS9
MR#<,W,N^BODKN DQ1W'"/@CK;T\AN/GYPUCG(BJ)K4=E! ]%!.:)"* )/I.,
MKQGX+5O@11- %W0J3N:!TX.I1 QQ- (6_ A,PS1[ IJ=[PY[W,/SW0T%&ZOJ
M(2O'LT[UT!I17/;0(WH5<XZ#>TI1ML+Y]=_W<\:IF#__]&E?8-O]V')1N6,;
M%.&))E8-AND.:]-??H*N\6N?;D."A0.!-32U*TUM%?KTKVTZQU2.['),?P1?
MMIQQE"WB;-6G8X'GY'AR+=U-K2#P/=,?Z[MCB;IVIF/Y-H1-NU 9WY7LG8J]
M<RG[W\5XXNW)5S!W.HR@;WJ>8[28]]BY%C2,EEVHC.U*YF[%W+V4^0QED=AU
M^KF['4ZWMN<$5HMZCQGT#-=OV87*X*ZD[E74O8&'O-=AY7B>[_M.BWW7KG=J
MA%V[]M1H$/,K8OZEQ+YC)@8S$-0 ?MF(#$/<< )VXG$?4;]+U/;$7[N;E7%<
MNOP-!-:0+*@D"_Z79)A&,4/S!/>I%72[T74]:-LMM90A7*K60& -M:!1YTB&
M4J\?>?8HY=EA*K+A@T08;&@<B5\A)I/;])MSJFPH.%+/'3FMS6'68V6/7*\U
MG]1!7RO*4>((AQ)%L;N4C4!X/)Y&07M;[3,+1G;0ED09\K62F+4DYE"2*+>=
MLIF6*%Y[/>HS\T9N>]=1!WVM*'7Z"I69W)"3Q^KR=4:=9;HT4\^QL,>J,<>:
M;.O$$JHSRPO8]NQ2O:SM\U@/E%&6ZKQ'?@KK!!6J,]1K551N7&6;04-'MYW-
MJ".[6,?WR'9AG>Y"=;[;T9%B^2U(S"\0B9I;5HU;E ".:0INX@R\8D39A[<G
MHKI5K\ !T !I4=F;-EB@5]974[Z!Y9=8U@$*^J>@PC.A B544^DZNX;J]/I:
MI2],5=^(X@*U9FJHBP?Z0&A-^>L: *J+@$'D5Z\>Z@"J,5\H#]S3N@]:1@R%
MUM2]+B2@NI*X7ZTH7B&.02Q4CC,61V"'DNT9FWD![!U_+[ <SW4Z"W+7T#0,
M(_#<3O;W'E6"65<)IKI*4&BA2(!+T(8.$!JPO;^7=L=UER]";TF@#O%:">J:
MP%37!-</!S7PI1\J2[0W!U?88]@97(46^M$W]A3357Y6P<3JLLUX\6FZ>EJ=
MA]SGIP"MYP_P+BQ.-6J8XI#E,Z(KH1E(\%) &B-/=#8MSBV*&TXV^9?\.>&<
MI/GE&J,%IM) O%\2P@\WLH'J]&CZ'U!+ P04    "  Z,&E6][L/\QL#  "N
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6S%5FMOFS 4_2L6JZ9.
M6LLKY-$E2'ET6Z55BIIV^S#M@P,W 15L9CM)^^]G&T(A)=$J(?5+8IM[C\\Y
MOI@[W%'VR", @9[2A/"1$0F179DF#R)(,;^D&1#Y9$59BH6<LK7),P8XU$EI
M8CJ6U353'!/#'^JU.?.'=".2F,"<(;Y)4\R>)Y#0W<BPC?W"7;R.A%HP_6&&
MU[  \9#-F9R9)4H8IT!X3 EBL!H98_MJ:ELJ04?\C&''*V.DI"PI?523FW!D
M6(H1)! (!8'EWQ:FD"0*2?+X6X :Y9XJL3K>HW_5XJ68)>8PI<FO.!31R.@;
M*(05WB3BCNZ^0R'(4W@!3;C^1;LBUC)0L.&"ID6R9)#&)/_'3X41E02[>R3!
M*1*<PX3.D02W2'"UT)R9EC7# OM#1G>(J6B)I@;:&YTMU<1$'>-",/DTEGG"
M7P@:/%Y,I!$AFM)45@?'VM\+M,A/%M$5RJ.6KZ.NG]08T/D,!(X3_DGF/2QF
MZ/SL$SI#,4'W$=UP3$(^-(6DJS8U@X+:)*?F'*%F.^B6$A%Q=$U"".L IM19
MBG7V8B?.2<09!)?(M3\CQW*<!D+3_T^W3]!Q2^]=C><>\S["#)I<'3.&R1KD
MVR+0\AE5X^;X62^/=YB%Z/</"8EN!*3\3Y/!^?Z=YOW5#7'%,QS R)!7  >V
M!</_^,'N6E^:S&D)K&95I[2J<PK=OZ<")[4R#"J&-4G/\7H:3]UE6]_S>O+4
MME5)KX,ZG;Y5!M6H>B55[R35.RD>LR!"LNK1#+;RILS4D361/(GTUO-I":PF
MNEN*[KYS*7?;M*HEL)I5O=*J7LNEG.-YE2IUNG;_H)1?!]D#RVTNY7Y)M7^2
MZC<@P"195<GC4'Y]8BX85M_=)IHGL=YZ0BV!U60/2MF#=R[F09M6M016L\JV
M7OH'J^5R+@"KMZXS\-R#>FZ*\GJ]@X(V*YU/"FRM&T(N*6R(R/N"<K5L.L>Z
MU3I8GZAF5'=4+S!Y)WN+V3HF'"6PDI#694^^8RQO#O.)H)GNKY94R&Y-#R/9
M4 -3 ?+YBE*QGZ@-RA;=_P=02P,$%     @ .C!I5HE-X6WM @  $ @  !D
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M<VAE970U-"YX;6RMEEMOVC 4Q[^*E6E3)VWD!H%V$*E I_6A&H)='J8]F.0
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M*&N [[=2FL>)O>.U=_KE3U!+ P04    "  Z,&E6JG7ROPD#   6"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R]5EUOVC 4_2M65DV=U)(/(- .
MD ITVJ1U0F5='Z8]F.1"K"9V9CO0_?M=.R&C+" V37L!?]QS<HY]<V\&&R&?
M5 *@R7.6<C5T$JWS:]=540(952V1 \>=I9 9U3B5*U?E$FAL05GJ!IX7NAEE
MW!D-[-I,C@:BT"GC,)-$%5E&Y8\QI&(S='QGNW#/5HDV"^YHD-,5S$$_Y#.)
M,[=FB5D&7#'!B83ET+GQKR=]$V\#OC#8J)TQ,4X60CR9R8=XZ'A&$*00:<-
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MK1Y>NRR[<#G1(K>-;"$TMD4[3/##!:0)P/VE$'H[,0^H/X5&/P%02P,$%
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M@Y,1JE)U2Z\G1I:N*SY(@SW6#7-\!4'9 -S/I#3;B3V@?5?C/U!+ P04
M"  Z,&E6MQNEG;,"  !["   &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6RU5FMOTS 4_2M6F-"0H'FT2]%H(ZWM$).H5&T:?$!\<)/;QIH?P7;:[=]C
M.VEHIBPPJ7Q)_+CW^)QCQS>3O9 /*@?0Z)%1KJ9>KG5QZ?LJS8%A-1 %<#.S
M$9)A;;IRZZM" LY<$J-^% 2QSS#A7C)Q8RN93$2I*>&PDDB5C&'Y- ,J]E,O
M] X#MV2;:SO@)Y,";^$.]'VQDJ;G-R@98< 5$1Q)V$R]J_!R/K;Q+N ;@;TZ
M:B.K9"W$@^W<9%,OL(2 0JHM C:O'<R!4@MD:/RJ,;UF29MXW#Z@?W;:C98U
M5C 7]#O)=#[U/GHH@PTNJ;X5^R]0Z[FP>*F@RCW1OHX-/)262@M6)QL&C/#J
MC1]K'XX2POB%A*A.B)XGC%Y(&-8)0R>T8N9D+;#&R42*/9(VVJ#9AO/&91LU
MA-M=O-/2S!*3IY,%;,Q(AN:":TG6I?-V13%'']!5EA';QQ3=\.K V-GS!6A,
MJ'IG0N[O%NC\[!TZ0X2C):'4!*B)KPTSB^^G-8M9Q2)Z@448H:4AD"MTS3/(
MV@"^D=3HB@ZZ9E$OX@+2 1J&[U$41%$'H?F_IX<]=(:-S4.'-WRUS0NB4BI4
M*0']^&IBT(T&IGYV>5@M,>I>PG[NEZK *4P]\STKD#OPDK=OPCCXU*7_1& M
M-T:-&Z,^]*3E0H%)AM9/"%A!Q1/(+N457.S@[+VT2X*!V9;=L:#^F!;/BX;G
M12_/)7XDK&1=C'H37[L7)P)K:8P;C?'_/YGQ*=TX$5C+C7'CQKAWQZ_K0VBN
M6)WFA&]1>N1+E_0*+PQ:YRZ(GQW.OT559/VC>YR!W+KRI@R%DNOJZFM&FPIZ
MY0K'L_&9J:Q5(?P#4Y7E)99;PA6BL#&0P6!LSIZL2EW5T:)PU6(MM*D]KIF;
MOP.0-L#,;X30AXY=H/G?2'X#4$L#!!0    ( #HP:59S5=A93 (  +P%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;*U4RV[;,!#\%8(MB@1HK8>=
MI'!E 7ZT2 X!#*=I#T4/M+2VB%"D2J[MY._+AZPZ@6.T0"\2E]P9[HRTF^V4
M?C 5 )+'6D@SHA5B,XPB4U10,]-3#4A[LE*Z9FA#O8Y,HX&5'E2+*(WCRZAF
M7-(\\WMSG6=J@X)+F&MB-G7-]-,$A-J-:$+W&PN^KM!M1'G6L#7< =XW<VVC
MJ&,I>0W2<"6)AM6(CI/A=.#R?<(W#CMSL"9.R5*I!Q?<E",:NX) 0(&.@=G7
M%J8@A".R9?QJ.6EWI0,>KO?L7[QVJV7)#$R5^,Y+K$;T(R4EK-A&X$+MKJ'5
M<^'X"B6,?Y)=R+U**2DV!E7=@FT%-9?AS1Y;'PX R>4K@+0%I"\!@U< _1;0
M]T)#95[6C"'+,ZUV1+MLR^86WAN/MFJX=%_Q#K4]Y1:'^0($0RC)G&E\(E\U
MDX9Y@PWY0,9ER=V:"7(CPQ_CK#^; 3(NS+E-N;^;D;.WYUF$MAA'&17MQ9-P
M<?K*Q4E*;I7$RI#/LH3R.4%D5712TKV427J2<09%C_23]R2-T_1(0=._AR<G
MRNEWSO8]7__?G?TQ7AK4-OIYS+= .SA.Z[IZ:!I6P(C:MC6@MT#S=V^2R_C3
M,<W_B>R9 X/.@<$I]LZ!QCN !PX<DQVXKCR7FSW;/,ZB[:&64QFAP.B@$6K0
M:S\?#"G41F+XD;K=;@2-?>>]V)_8T10FR1^:,-=NF5YS^PT%K"QEW+NZH$2'
M61$"5(UOMZ5"V[Q^6=GQ"MHEV/.54K@/W 7=P,Y_ U!+ P04    "  Z,&E6
M%7:>'CL#  #P$P  #0   'AL+W-T>6QE<RYX;6S=6%UOVC 4_2N1NTZM-#5
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M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ .C!I5LOQV_T$"   ="D  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #HP:5;<>O\LA 4  #07   8
M              " @4<0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  Z,&E6+60-G-H"  "W"0  &               @($!%@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ .C!I5HZP4$<'!0
M1!0  !@              ("!$1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( #HP:58@4"57WP0  $P;   8              " @4X>
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  Z,&E6C+LS
MYQ<"   Q!   &               @(%C(P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ .C!I5B%C.\M:!@  AQP  !@
M ("!L"4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #HP
M:58_7@-T8PL  "@=   8              " @4 L  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  Z,&E6_?[ET( <  "Q5@  &
M        @('9-P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ .C!I5E_USJR0 P  # D  !D              ("!CU0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  Z,&E6R4'!'8@$  ##"@
M&0              @(%66   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( #HP:5;8"" /] (  (L&   9              " @15=  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ .C!I5HSIRII3
M!   \0D  !D              ("!0&   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  Z,&E6DSM=;KL"   1!@  &0
M@('*9   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #HP
M:5:RWTE>Z (  &<&   9              " @;QG  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ .C!I5K=?VQ7:!0  5PX  !D
M         ("!VVH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  Z,&E69^]E"G\'  !$$@  &0              @('L<   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #HP:5;,FV%)=@H  ,<;
M   9              " @:)X  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ .C!I5H3IP;U  P   P<  !D              ("!3X,
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  Z,&E6.)JB
M=SL#  #N!@  &0              @('&A@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( #HP:593\F?/30(  #(%   9
M  " @3B*  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M.C!I5H#!:8YU @  M04  !D              ("!O(P  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  Z,&E6Q2%7K=H=  "H8@  &0
M            @(%HCP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( #HP:58&++N;[@(  #X&   9              " @7FM  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ .C!I5B_Z'N<G P
M)@@  !D              ("!GK   'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  Z,&E68*E8"4P#  #4!P  &0              @('\
MLP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #HP:5:#
MM_A7V@(  ',&   9              " @7^W  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ .C!I5M%6<!?H P  C0D  !D
M     ("!D+H  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #HP:5;Z'V7T8 ,  .('   9              "
M@<+-  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ .C!I
M5A,%TL2I P  * P  !D              ("!6=$  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  Z,&E6#!3-^<,#  #3#   &0
M        @($YU0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( #HP:5;AR?L%9 ,  -$/   9              " @3/9  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ .C!I5O B2XEV P  J T
M !D              ("!SMP  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  Z,&E6#*;K,HP$  !P&   &0              @(%[X
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #HP:5;;EKVN
M_ (  ,H(   9              " @3[E  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ .C!I5B00I8\I P  W@T  !D
M ("!<>@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  Z
M,&E6L4%88[@"  !J!P  &0              @('1ZP  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #HP:5:.JV+3TP(  %X'   9
M          " @<#N  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ .C!I5L.=,X=L @  8P8  !D              ("!RO$  'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  Z,&E6+=@3P7 "  !=
M!@  &0              @(%M]   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( #HP:58-M#F18P(  ,(%   9              " @13W
M  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ .C!I5B[C
MMK0U P  <@D  !D              ("!KOD  'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    "  Z,&E64IQ#I=\"  #!"   &0
M    @($:_0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M #HP:594J,1$Y 0  &T:   9              " @3   0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ .C!I5C(UC7P0!0  21H  !D
M             ("!2P4! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    "  Z,&E6][L/\QL#  "N"P  &0              @(&2"@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #HP:5:)3>%M[0(
M ! (   9              " @>0- 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ .C!I5G.."[WJ!@  BS,  !D              ("!
M"!$! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  Z,&E6
MTJ/]@:,"  #I!@  &0              @($I& $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( #HP:58PIS_K$P,  #T)   9
M      " @0,; 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ .C!I5IA2!^!I P  WPL  !D              ("!31X! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  Z,&E6JG7ROPD#   6"0
M&0              @('M(0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( #HP:593W[EBQ0(  &,'   9              " @2TE 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ .C!I5K<;I9VS
M @  >P@  !D              ("!*2@! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    "  Z,&E6<U7864P"  "\!0  &0
M@($3*P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #HP
M:585=IX>.P,  / 3   -              "  98M 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ .C!I5I>*NQS     $P(   L              ( !_# !
M %]R96QS+RYR96QS4$L! A0#%     @ .C!I5I9$FK[/!   >2<   \
M         ( !Y3$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #HP:599
M=@'X]0$  #@C   :              "  >$V 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #HP:587R,P;VP$  -$B   3
M      "  0XY 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(
' !H[ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>78</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business, Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity</Role>
      <ShortName>Description of Business, Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities</Role>
      <ShortName>Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables</Role>
      <ShortName>Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses And Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses And Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Organization and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Summary of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Leases - Quantitative Information Regarding Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails</Role>
      <ShortName>Leases - Quantitative Information Regarding Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Property and Equipment, Net - Summary of Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Summary of Components of Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="glto-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CommonStockDividendsPerShareCashPaid, us-gaap:CommonStockDividendsPerShareDeclared, us-gaap:LeaseExpirationDate1, us-gaap:PropertyPlantAndEquipmentUsefulLife -  glto-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="glto-20221231.htm">glto-20221231.htm</File>
    <File>glto-20221231.xsd</File>
    <File>glto-20221231_cal.xml</File>
    <File>glto-20221231_def.xml</File>
    <File>glto-20221231_lab.xml</File>
    <File>glto-20221231_pre.xml</File>
    <File>glto-ex21_1.htm</File>
    <File>glto-ex23_1.htm</File>
    <File>glto-ex31_1.htm</File>
    <File>glto-ex31_2.htm</File>
    <File>glto-ex32_1.htm</File>
    <File>glto-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img108642122_0.jpg</File>
    <File>img108642122_1.jpg</File>
    <File>img108642122_10.jpg</File>
    <File>img108642122_11.jpg</File>
    <File>img108642122_12.jpg</File>
    <File>img108642122_13.jpg</File>
    <File>img108642122_14.jpg</File>
    <File>img108642122_15.jpg</File>
    <File>img108642122_2.jpg</File>
    <File>img108642122_3.jpg</File>
    <File>img108642122_4.jpg</File>
    <File>img108642122_5.jpg</File>
    <File>img108642122_6.jpg</File>
    <File>img108642122_7.jpg</File>
    <File>img108642122_8.jpg</File>
    <File>img108642122_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="436">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glto-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 436,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 78,
   "dts": {
    "calculationLink": {
     "local": [
      "glto-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "glto-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "glto-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glto-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glto-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "glto-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 429,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 16,
    "http://galecto.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 22
   },
   "keyCustom": 19,
   "keyStandard": 247,
   "memberCustom": 11,
   "memberStandard": 21,
   "nsprefix": "glto",
   "nsuri": "http://galecto.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Investments in Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities",
     "shortName": "Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Defined Contribution Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Investments in Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables",
     "shortName": "Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses And Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses And Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
     "shortName": "Description of Business, Organization and Liquidity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InvestmentsAndCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:OriginalMaturitiesAtDateOfPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "glto:OriginalMaturitiesAtDateOfPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_333a7d4a-b385-4327-8cb4-b33035085d6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "glto:ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_333a7d4a-b385-4327-8cb4-b33035085d6f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_d6c004f9-30fd-424c-9fb9-45d6fde33858",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails",
     "shortName": "Investments in Marketable Securities - Summary of Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_d6c004f9-30fd-424c-9fb9-45d6fde33858",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glto:ContractResearchAndDevelopmentCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "glto:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glto:ContractResearchAndDevelopmentCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_32e6c654-8b0a-4d94-9d79-61927bfc66d8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Summary of Operating Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails",
     "shortName": "Leases - Summary of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_32e6c654-8b0a-4d94-9d79-61927bfc66d8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glto:OperatingLeaseRentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glto:OperatingLeaseRentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Leases - Quantitative Information Regarding Leases (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails",
     "shortName": "Leases - Quantitative Information Regarding Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Property and Equipment, Net - Summary of Equipment (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glto:ContractResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "glto:ContractResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_aa9917ab-7682-4151-a140-fba905b103eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_2bd75575-ee9b-4149-8e99-700c763cf2a8",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_aa9917ab-7682-4151-a140-fba905b103eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_6ceff22d-e6e8-4fcf-aca2-4151bbc67297",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails",
     "shortName": "Stock-Based Compensation - Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Summary of Components of Net Loss (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails",
     "shortName": "Income Taxes - Summary of Components of Net Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "3",
      "lang": null,
      "name": "glto:EffectiveIncomeTaxRateReconciliationOrphanDrugCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Components of Company's Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_be645df8-d52d-4b5a-ae91-b1b37c2f9c9a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_26d85074-1442-4534-bfb5-878f1c5c9abc",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_26d85074-1442-4534-bfb5-878f1c5c9abc",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glto:StockIssuedDuringPeriodNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "glto:StockIssuedDuringPeriodNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of Business, Organization and Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity",
     "shortName": "Description of Business, Organization and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "glto-20221231.htm",
      "contextRef": "C_7e754f68-08d0-4938-98da-48e6218005eb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "country_DK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "Denmark"
       }
      }
     },
     "localname": "DK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWEDEN",
        "terseLabel": "Sweden"
       }
      }
     },
     "localname": "SE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "verboseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "glto_AccretionOfLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of lease liability.",
        "label": "Accretion Of Lease Liability",
        "terseLabel": "Accretion of lease liability"
       }
      }
     },
     "localname": "AccretionOfLeaseLiability",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs policy.",
        "label": "Accrued Research And Development Costs Policy Policy [Text Block]",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsPolicyPolicyTextBlock",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glto_ContractResearchAndDevelopmentCostCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract research and development cost current.",
        "label": "Contract Research And Development Cost Current",
        "terseLabel": "Contract research and development costs"
       }
      }
     },
     "localname": "ContractResearchAndDevelopmentCostCurrent",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_ContractResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract research and development costs current.",
        "label": "Contract Research And Development Costs Current",
        "terseLabel": "Contract research and development costs"
       }
      }
     },
     "localname": "ContractResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_CopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Copenhagen.",
        "label": "Copenhagen [Member]",
        "terseLabel": "Copenhagen, Denmark"
       }
      }
     },
     "localname": "CopenhagenMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_DebtSecuritiesAvailableForSalesTypeExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sales Type [Extensible List]",
        "terseLabel": "Debt Securities Available For Sales Type Extensible List"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalesTypeExtensibleList",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "tokenItemType"
    },
    "glto_DeferredTaxAssetsBonusCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets bonus compensation.",
        "label": "Deferred Tax Assets Bonus Compensation",
        "terseLabel": "Bonus compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsBonusCompensation",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_DeferredTaxAssetsOrphanDrugCredit": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets orphan drug credit.",
        "label": "Deferred Tax Assets Orphan Drug Credit",
        "terseLabel": "Orphan drug credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsOrphanDrugCredit",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities fixed assets.",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "negatedLabel": "Fixed assets",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_DescriptionOfBusinessOrganizationAndLiquidityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Line Items]",
        "terseLabel": "Description Of Business Organization And Liquidity [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityLineItems",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glto_DescriptionOfBusinessOrganizationAndLiquidityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Table]",
        "terseLabel": "Description Of Business Organization And Liquidity [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityTable",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glto_EffectiveIncomeTaxRateReconciliationOrphanDrugCredit": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation orphan drug credit.",
        "label": "Effective Income Tax Rate Reconciliation Orphan Drug Credit",
        "terseLabel": "Orphan Drug Credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOrphanDrugCredit",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glto_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "glto_EmergingGrowthCompanyStatusPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status .",
        "label": "Emerging Growth Company Status Policy Policy [Text Block]",
        "terseLabel": "Emerging growth company status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyPolicyTextBlock",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glto_GothenburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gothenburg.",
        "label": "Gothenburg Member",
        "terseLabel": "Gothenburg, Sweden"
       }
      }
     },
     "localname": "GothenburgMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_LondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London.",
        "label": "London Member",
        "terseLabel": "London,United Kingdom"
       }
      }
     },
     "localname": "LondonMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Investments - Noncurrent"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_NumberOfOfficeAndLaboratorySpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of office and laboratory space.",
        "label": "Number Of Office And Laboratory Space",
        "terseLabel": "Number of office and laboratory space"
       }
      }
     },
     "localname": "NumberOfOfficeAndLaboratorySpace",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "glto_OperatingLeaseRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rent expense.",
        "label": "Operating Lease Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseRentExpense",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_OriginalMaturitiesAtDateOfPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original maturities at the date of purchase.",
        "label": "Original Maturities At Date Of Purchase",
        "terseLabel": "Original maturities at the date of purchase of liquid investments"
       }
      }
     },
     "localname": "OriginalMaturitiesAtDateOfPurchase",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glto_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glto_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit receivable current.",
        "label": "Research And Development Tax Credit Receivable Current",
        "terseLabel": "Research and development tax credit receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful life of asset.",
        "label": "Schedule Of Estimated Useful Life Of Asset Table [Text Block]",
        "terseLabel": "Summary of Estimated Useful Life of Asset"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLifeOfAssetTableTextBlock",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "glto_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, grants in period, intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_StevenageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stevenage.",
        "label": "Stevenage Member",
        "terseLabel": "Stevenage, United Kingdom"
       }
      }
     },
     "localname": "StevenageMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_StockIssuedDuringPeriodNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period net of issuance costs.",
        "label": "Stock Issued During Period Net Of Issuance Costs",
        "terseLabel": "Common stock issuance costs, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNetOfIssuanceCosts",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_StockOptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options to purchase common stock.",
        "label": "Stock Options To Purchase Common Stock [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock"
       }
      }
     },
     "localname": "StockOptionsToPurchaseCommonStockMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glto_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "glto_TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period net of issuance costs.",
        "label": "Temporary Equity Stock Issued During Period Net Of Issuance Costs",
        "terseLabel": "Preferred stock issuance costs, net"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodNetOfIssuanceCosts",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "glto_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_TwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty six.",
        "label": "Two Thousand Twenty Six [Member]",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "TwoThousandTwentySixMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_TwoThousandTwentyStockOptionAndGrantPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock option and grant plan.",
        "label": "Two Thousand Twenty Stock Option And Grant Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyStockOptionAndGrantPlanMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three through two thousand twenty five.",
        "label": "Two Thousand Twenty Three Through Two Thousand Twenty Five [Member]",
        "terseLabel": "2023 through 2025"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeThroughTwoThousandTwentyFiveMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "glto_TwoThousandTwentyThroughTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty through two thousand twenty two.",
        "label": "Two Thousand Twenty Through Two Thousand Twenty Two [Member]",
        "terseLabel": "2020 through 2022"
       }
      }
     },
     "localname": "TwoThousandTwentyThroughTwoThousandTwentyTwoMember",
     "nsuri": "http://galecto.com/20221231",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r282",
      "r429",
      "r442",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r548",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r282",
      "r429",
      "r442",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r548",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r274",
      "r282",
      "r309",
      "r310",
      "r311",
      "r405",
      "r429",
      "r442",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r544",
      "r548",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r274",
      "r282",
      "r309",
      "r310",
      "r311",
      "r405",
      "r429",
      "r442",
      "r478",
      "r479",
      "r491",
      "r496",
      "r505",
      "r544",
      "r548",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r504",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r504",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65",
      "r143"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r149",
      "r437",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r99",
      "r390",
      "r443",
      "r444",
      "r524",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r532",
      "r533",
      "r534",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r86",
      "r87",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r121",
      "r145",
      "r169",
      "r207",
      "r215",
      "r217",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r348",
      "r352",
      "r363",
      "r503",
      "r546",
      "r547",
      "r586"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r139",
      "r150",
      "r169",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r348",
      "r352",
      "r363",
      "r503",
      "r546",
      "r547",
      "r586"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r222",
      "r234"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r221",
      "r234",
      "r431"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "verboseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business, Organization and Liquidity"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r141",
      "r482"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r43",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r105"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r169",
      "r188",
      "r189",
      "r191",
      "r193",
      "r200",
      "r201",
      "r226",
      "r246",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r258",
      "r259",
      "r261",
      "r265",
      "r272",
      "r363",
      "r480",
      "r518",
      "r529",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r113",
      "r126"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r240",
      "r241",
      "r465",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends per share paid"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends per share declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r532",
      "r533",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2022 and 2021; 25,652,392 and 25,261,832 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r154",
      "r156",
      "r162",
      "r433",
      "r439"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r111",
      "r120",
      "r329"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r95",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Foreign research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net noncurrent deferred tax asset(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r95",
      "r580"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r93",
      "r95",
      "r580"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "U.S. research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfCompanysDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution paid by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r40",
      "r63"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of equipment",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r286",
      "r314",
      "r315",
      "r317",
      "r321",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendIncomeOperating": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating dividend income on securities.",
        "label": "Dividend Income, Operating",
        "terseLabel": "Expected dividend yield",
        "totalLabel": "Dividend Income, Operating, Total"
       }
      }
     },
     "localname": "DividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r163",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r186",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r357",
      "r358",
      "r434",
      "r440",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per common share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r163",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r357",
      "r358",
      "r434",
      "r440",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per common share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r171",
      "r325",
      "r341"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "terseLabel": "Tax allowance",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r578",
      "r581"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation costs",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense that is expected to be recognized over a weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r137",
      "r158",
      "r159",
      "r160",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r199",
      "r227",
      "r273",
      "r318",
      "r319",
      "r320",
      "r336",
      "r337",
      "r356",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r390",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r359",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r360",
      "r402",
      "r403",
      "r404",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r255",
      "r275",
      "r280",
      "r360",
      "r402",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r255",
      "r275",
      "r280",
      "r360",
      "r403",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r360",
      "r404",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r402",
      "r403",
      "r404",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r257",
      "r270",
      "r354",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r487",
      "r539",
      "r540",
      "r541",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Denmark"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange transaction gain (loss), net",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Currency and currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "verboseLabel": "Clinical Development and Corporate General and Administrative Activities"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r170",
      "r340"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r107",
      "r114",
      "r129",
      "r207",
      "r214",
      "r216",
      "r218",
      "r435",
      "r486"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r170",
      "r340"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Refundable tax credit"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r326",
      "r327",
      "r334",
      "r338",
      "r342",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.",
        "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority",
        "terseLabel": "Tax credit refund receivable"
       }
      }
     },
     "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r184",
      "r185",
      "r206",
      "r324",
      "r339",
      "r343",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense or benefit",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r322",
      "r323",
      "r327",
      "r328",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net",
        "totalLabel": "Interest Income (Expense), Net, Total"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "totalLabel": "Investments and Cash, Total"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r108",
      "r119",
      "r130",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Quantitative Information Regarding Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Operating lease, expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessor's operating lease.",
        "label": "Lessor, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease,renewal option"
       }
      }
     },
     "localname": "LessorOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r169",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r349",
      "r352",
      "r353",
      "r363",
      "r485",
      "r546",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r112",
      "r124",
      "r503",
      "r530",
      "r542",
      "r583"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r140",
      "r169",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r349",
      "r352",
      "r353",
      "r363",
      "r503",
      "r546",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "negatedLabel": "Net loss on sale of marketable securities",
        "terseLabel": "Net loss on sale of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Loss on sale of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized loss on marketable securities, net",
        "verboseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r41",
      "r115",
      "r128",
      "r138",
      "r152",
      "r155",
      "r160",
      "r169",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r190",
      "r207",
      "r214",
      "r216",
      "r218",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r358",
      "r363",
      "r486",
      "r546"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting standards and Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and off-balance sheet risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r207",
      "r214",
      "r216",
      "r218",
      "r486"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Operating Income (Loss), Total"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r382",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r380",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right of use lease asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r386",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r385",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Summary of Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Operating loss carryforwards, Limitations on Use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, non-current"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation gain (loss)",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r71",
      "r153",
      "r156",
      "r161",
      "r369",
      "r374",
      "r375",
      "r432",
      "r438",
      "r524",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss) , net",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r21",
      "r24",
      "r59",
      "r151"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassification adjustment for loss included in net income",
        "terseLabel": "Reclassification adjustment for loss included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r522",
      "r543"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Series D preferred stock issuance costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r33",
      "r55",
      "r164"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "verboseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued or outstanding as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r483",
      "r488",
      "r543"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance costs"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance or sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r138",
      "r152",
      "r155",
      "r165",
      "r169",
      "r176",
      "r184",
      "r185",
      "r207",
      "r214",
      "r216",
      "r218",
      "r226",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r347",
      "r350",
      "r351",
      "r358",
      "r363",
      "r435",
      "r486",
      "r500",
      "r501",
      "r526",
      "r546"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful life of asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r64",
      "r142"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r66",
      "r125",
      "r436",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Equipment, net",
        "totalLabel": "Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfEquipmentDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r106",
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r89",
      "r131",
      "r594"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r42",
      "r45",
      "r109",
      "r122",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r73",
      "r123",
      "r446",
      "r448",
      "r503"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r137",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r227",
      "r318",
      "r319",
      "r320",
      "r336",
      "r337",
      "r356",
      "r443",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r384",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liability arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesQuantitativeInformationRegardingLeasesDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issued during period, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available for Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Company's Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Components of Net Loss"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule Of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r283",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value Assumptions of Options Granted Estimated Based on Black-Scholes Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r519",
      "r520",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock",
        "verboseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of stock options allowed to award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Stock options available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "terseLabel": "Intrinsic value per share of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, granted",
        "verboseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding",
        "periodStartLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding",
        "periodStartLabel": "Number of Options, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price per share, Outstanding",
        "periodStartLabel": "Weighted average exercise price per share, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of Options, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Vested and expected"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage increase of number of shares of common stock issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueAssumptionsOfOptionsGrantedEstimatedBasedOnBlackScholesModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Stock issued during period, price per shares"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Investments - Current"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r169",
      "r188",
      "r189",
      "r191",
      "r193",
      "r200",
      "r201",
      "r226",
      "r246",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r258",
      "r259",
      "r261",
      "r265",
      "r272",
      "r363",
      "r480",
      "r518",
      "r529",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r71",
      "r137",
      "r158",
      "r159",
      "r160",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r199",
      "r227",
      "r273",
      "r318",
      "r319",
      "r320",
      "r336",
      "r337",
      "r356",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r390",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r199",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r71",
      "r72",
      "r73",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares granted to underwriters"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock; net of issuance costs of $0.2 million (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock; net of issuance costs of $0.2 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r54",
      "r503",
      "r530",
      "r542",
      "r583"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r168",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r273",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r3",
      "r4",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and Development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r257",
      "r270",
      "r354",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r539",
      "r540",
      "r541",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureInvestmentsInMarketableSecuritiesSummaryOfAvailableForSaleInvestmentsDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r202",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "Value-added tax refund receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r187",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average number of shares used in computing net loss per common share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average number of shares used in computing net loss per common share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://galecto.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://galecto.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.2)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r512": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r513": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r514": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-23-006807-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-006807-xbrl.zip
M4$L#!!0    ( #LP:58,Q0F%\B$$ ,\',@ 1    9VQT;RTR,#(R,3(S,2YH
M=&WLO6E7W$BV*/K]_ I=]^U>]KH$UCS@JKJ+PN##*=OX&MS#^\(*181(M952
ME@8@^]>_O2,TY<!@.P$EUAE<9*84XY['7_[O]331+D5>Q%GZZPMC5W^AB91E
M/$XO?GVQ?WIP?/SB__[VR_\B1'M[=/Q1^RBNM'U6QI?B;5RP)"NJ7&@O3S^\
MTH[3)$Z%]L_?/[_7WF:LFHJTU(@V*<O9WNO75U=7NSR*TR)+JA*F*G99-GVM
M$:+&/L@%Q:^UM[04VIZIFQ;1X?_\,\/:LYT]P]_U+%W_/[J^I^O=6]ELGL<7
MDU)[R5YI^!+,G*8B2>;:49S2E,4TT4Z;*7=@C6Q7VT\2[3.^56B?12'R2\%W
M<<C_^F52PEG >:3%KR]ZZ[ZR=K/\XK41!,'K:WSFA7IH[SK,$QZWS^)'^:2I
MZ^YK]>/"H^7:1QWU:-E_-%Y80/]IZS4<8@E;$\WS<.Q?;WD<?PYIT3Y^O?+\
MPO[PU^;1^/JF<0U<!MXW7G?S>)JE'^':\YBM?XV7^>MR/A.OX4&2JB>[J<KU
M+W73O"YSFA91ED\EJ. J'**;Q'1[@Y!"+,X.GW<OLLL[Q_&)9;1'5,3K#@B.
MTWC]SP_O3]E$3"E9O@<NED"AF1I^@'=-LWFP*L@%I;/VX8@6H9R@_F'AX;C(
M;-/P;H,']43S@H"3-=<!FJF_%M>E2(LX3 01\@+D"13$1+2O=U'F!"^IN.,.
M<3RB&\1L3^TB*;/VI0N:"%9F$LMQ.X;9'2_+JK3,Y^L/J_YQX0R*O%P]+/AR
M\53+_,9#"E[#KR]^^R_MEXF@'/ZK_5+&92)^,W3RQR^OU=_X[5245)(L(OZL
MXLM?7QQD*1Q92<Y@SR\TIC[]^J*$DWRM2,%K'/9U/>XO8<;G6E'.$_'KBRG-
M+^)T3Z-5F?VO>#K+<H"7\LV,<J2N>YH_NW[S0D[+X\OF)1X7LX3.$9D$_/I+
M?+V'8XM<_1ES+E+Y)SQPE%,FJ6;,?WUQ=,X"3SC40(RP/&*[=D!"/0P(Y8%@
MAC!LCUHOM)1.89H:U/8.LNDT+I%6%_LIQ]W"TH !Q**HMWM=?A81',0YI4%@
M>#0DGNN;Q#8<@U##UDD4TD!W0D.W1/A"J])8O?#E_,OI6[B<(MY+XP2.+*\$
M[.?UXM*;K=2$H]Z):X64.T9 ?&[#5([O$Y^Y-N',"AW/%PX/G>6=O!= Y ZO
M9[$":F0DQO(6HB T=9\%Q#"$3FPK<DA #> S3#<#W[%LWXY>:(HT_/H"R,D>
MAV&F,,:$T_E<T%RD+WX[$F%>T7RNF<$.0*#=[*G>P_HM<3-@KN' E5C,A:E#
M3GQA.<3UO#"R#==V'/U[ML3Q-$R7$>XX@MBF" GU+$HB'ID&9:%GZN+N+>U7
M%U51:I:Q@VS4N=>./-WCU 0 H"&'PXQ< 3.;(6$1$[KE4FI1T>P(2.#>097#
M7.41R TT^1=,?)ARW-+RCCSA.3":#S09QPTLGP0^I\3VA6L:/C!,@+/?" %
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MEI=G(I]VCJWMB8^.;)"HW8@X-AIAK!#D:==S06./(M\"^<T+!WLQ6Q),L\&
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M(<JR&)KC>QISGHB?5;[T7,^/*$!\9%. 8VZ;Q =&3G0K=%S'-X4?Z1N%_4]
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M]Q[&A@GU_%/LB-/O"UA@&Z)NBY**PPFB (X]$/HGA)H6HT6Y?%BPO2*&>Z-
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MB**ZN$"7J 0=6$&];2:M<W6B:FUH;'A&LY.&$N+ H5@5"R3$J(C6"L-:_JQ
M%H%U]4&R@QY 9@R\:T,SEB#$"%\O @FVIL?]=K>'5F N9")N6D@W2H(4%YVH
M^>0."'KWY?W[X[\??B9F T3R-/!4T1V#83R%#!=&9VI'^[HKDN92-9_B?G#2
M:,?1#!/F$U_5_;?R@O1<WG-4D#JD1U;Q#AGP/)UV,<]T!D)7?WM4%:[M2X3X
M50UHO(ZU4I*6(N;P=2[JU=?7> -LQNJXHC@O2NGPG4N8 ^8PJ[.7<8T'$V#Y
MY%,%XMZ!E-1^7[J8]DJZZX/7TBPEES$N2I2UI(6K@SOHQV5320A5Y3NUY!G-
M*3!ZD?=VVW(K.-H&$;#Z@Z 8[A!5B=Q@S1OAAYK-R<+!=>QV0R47\4@QM7>_
MZX85[#3H@O>@0'+D:YM6L+%$:@;05C<1XZN\::>]CIJ^I<#Z$&UOT @6%0*,
MOQ<-3?LJY=VZJ731RJE%7(-6FYM6T\2>R(2.B5AY8L[>'9'',AC=__A/I3_F
M?J<>#F_YWP4](.@C;5-:4DV=>KH@7&L58DVI$IV-<;JLE?0#F_J_)A7RR_J1
MFK%V.@A@Y*3ECI*XQG6Z2ZL\+&A@6%0< !5=7ZPJ,6X'CBL/Z]!1I/D\SE#?
MP"8R50(B"3;T[.0B@.CC3T>M&@W4JB9\/7N#PI#UFBN\#*N #42"( D$E)(Q
M8>TJ+\6*BM@@#)[$+HX [$[EYLC(AFL98P5+,'2 !%W79B*;=>&#7V")<%:G
MI0K$0@=A$D_E=ZNV!$F:I9 #K"1CL>0@DMOW>681\S;S: =D*,KKV,]9IO;<
M6%: D$R4%U(V>L^*GN0F1189K[I$\Y7Z4JK[533G2@HV&"*5XV&3ANK4)ZVX
M;!W(! >!5PR4/9%=$;D"FK*A21CSUH/*M#W:FN/A*DG3@1%=L2!<Y^K",?PO
M"]&U+&.ZI @G%P <%\,[D0[.00'%]"DI61;*C)(C0Y6M/8!#3VE/RN@RF?[U
MQWMBZW*M,]2"X01('0S5Q.@I>X>$P4]OWQW5<E-W91U63$'WH"K+:AUNO,X6
M#!.X[SY0=YRZ[F*+MTLUQR0H7>%N>#8%^L%A]*P"(9^$,#5\DHJ[<F/M2$DA
M202(=S)&-\Q(3="33BL*:RDS3B]1,+Z@K2)?=Y>3]HBFO9R41>5YK\BB$JUN
MECCWW^\?G!T?-&J+DD=:,!,IKDK%NJUH=DN2M%K1=1U.O2A&*S!<B-^=QIS
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MAT\YQE2?NK)^/SU6U:,'Q2''I-'X/XJW-05N@!<G22-;KLD>C%7DZZR&KMI
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M801HI0:";NI2#FXS!3US6TT_'Q/X8[!\_R&^1YD_Z&[8C%!M?->@U;X0@H_
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MO(E2=^VRXMR._7H@RLPY+U9FY@=;8[RBS7QP%X!?\%**9/,D8<'F0"1=LDV
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MCZ^;L[/'X^MK'U^OTP\YN'HL&Y;VAB&OV#FZ[@%4PBTZ2;C+H3;*.D,6I\B
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M="VSC]A?TPF\FM5I:2:*E;:78Z( ]G8E"FK(8RK/6FY;VJ*>0CL$HO'-'[;
MRIU8"#FU&>%J-%1..I<<'@<H7Z7DR7ZPX.8M-U8!VCW&)6E-0? W,Z!X\TE\
M+D=&[$8![98C )(<'QZ;)H##<\W2L0H@)DTQ[JJH95^(C37(3<1O;6?S@6M[
MQD]DD9^E]"Q.B$6_;"_;DVUF+HG4I10=AC&FC1#&NDA'8-=<3I/3<F-EZ#1
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MOMM"VJ3)R2$-SKP/L'J "'4ST ;2:Z2?^$02PP$4$T(E@Z[#@AYS5O'MZZH
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M5AQY#T\^3-V+$?N&#$Y>>B3,E6$NZYI.@QIA4491H.TZ<?A?5$;3A=':1V.
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M=.F*4QBRT.XDAN)KIB<&<JRNUK4JL*]9HP(^BR-'VR(G]J,7R +.P[K-&\=
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M5=G#1F@@QT'"7Y>7,9T\OS<"1Q@P>B"A5D=[F'T!="[=K!-J2C)\;H&-0;_
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MV"N_P*VV>]4,Q/#JFA!6$+.6# +:"0Q0U4R]5&^L*0+P #C9#5M":2@Q3+*
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M/(8&H>5=KN$:^(,2@2S:M2MWB4X:_Y"TE0/TIO.X$^.#73:=KY6F/>^^=?G
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M']-5%#QT*U#P:.1F?[TC;6PS1;/I,[Q^*8]G5 @T2)H%!O#YI1'6OW7&>;)
M\XCL!0OS&-R*6G!>H<2@OPZL!+Q%),V;LP\F"62<T;J+:;8TZZO9%<.NR?*E
MS2E5@$S0C/&:X>,YNC5/YEA,D?OJ><)@YG<80AC__&*Q?/J_.+ O!E&2,$H$
MJ%M(4Z<SB]"HXO@#?I!:J $]7+ DYCPD5?86%HO>84$;0NZL3BZ]Z'@G2AE&
M5G3@6Q ;CM\NC_I-4R?K)*XFT6I=7!3U>6B_#0\#&H3:B?<DR:^.'AS:ZN9W
M8Q(6C%^4.CNF8S]6S'792^OL"/787WVN?0PUPW-.)G,]]0%^LUY0=/#Z/7[
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M:K/7TH/)KWUZRV0823Q=D(G45SW492F85FK#<DOAP0JP*'2IZ=]$0AH-;R!
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M7@>8ED;+"+-P.&R/^([\G#HV"1V;045A?*V$*=!\>Z,16O)OFF??FFTM\'8
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M[V'<_5$!VLVF4^0AH"L!O9=:\ ZHK1&+\L/@-1YH ;X[NW?ZW0>T -__!!W
M- ;N5?W:WOSGZ "^.WMP[_3DP7?W[WY_>N?!W0>G][ZU'N!?4<Y[/<M^[)?G
M;LOH,=#2<N&0#B6RUR?CIZS1<O@:T$K(2FNMP3&"!4<;8PGIYRT<$:CM*"T$
M8QK/N?3%98GP?;JKY[8(K: >>RI@T=._<!4G6Y4=>RT[.C)FV>M^WKE_]1RY
MQ""ZY)"FW_E;>8(0YCKL B0K,V6*T^,[Q[/LL7B?_.O7OJWL9;$[.NN._J?I
MCWYJHLDB=X5\OW(MO:\RI0PG7I3A=-RK;< <K>DU,:/]*SI_Z8XOJZ(.UST]
MD5.X&WW$_%T39K40DWC"%#B W+21B'VMTWM9,4>IT[X7W>-@J^-D*"=#^:T8
M2K])?RTHQ-K1#GE%Z]"M(@-PNK?)1O=FQX5;T>4P5MA0._8D-!("<YF0L?)D
M;X$(%S"6^N5IL.-YHU>1TC"@$F6S]-H?<1-^8RH,Z&0;-Q]JI%B7!(WQY':Q
MQ0T]4)-)F$S"-V@2?J$3>M.657:"=HB3!SE3;@D=/UHUBT@.49NH$3AK/X""
M-C*>WE+;*1D:Y81B9.[JQ07S2HAO94P@%MC$PB_L&M"34K!-,[B).0J[/&)3
M\4P'UC:S E#IK6%ER$53T(IFS(QTW_ . Q8V$:]B&FL6J5UZQPGP^G@0DZ6X
M*:MVLA2?R5*\H/UW!_JL)]])3A--6'RB_MIJ*R/G(SA]:LU457$EB"[T<HU%
M87I(=Y' \:HMUNZJ:=\D^3WNFK>37;+"_B/ALU/4OG*1QXW7FMPS>8E-Y41>
MXB4K$6<G@_8"!8FJ^AS,A?0C)+?!V)X^/O-Z=Z8A>X#HA7;L.3@!_'.P&P9\
M67",.(W.K8:2/=6X9MA$(5HH\L4 \N2A !8H_//!RO$'DD^G9YZH^CX1*O_!
MQZ;J&SM!IN/CC[^KR[)33^6'BW))\WJ##I1OX2!1TZUE%QP.4H*LFUAX$]J2
MU_%X>(D+X* 38Q\X;1FONF=WH2XH"2Q#X@X/LLG;NRD+YN9LSF_+VY.G73UD
MI^]4@L/OKP\.&V8*:JY"MNALR?R*=/HA%2P,@LW&JL<BUMIMW08HA&*SPYY_
M2:\B^U'JMA2\T8*'=S/@1ICVYTU9*]/^_$S1V&.W$"*+TV/;G8QJ [>,\IC0
M:=:O-\-X3(("3?$R(4U3E4M4>\XXDMFTUBW#*>%;SV:O9MG)=_?OW0YT]!M7
M5)[;9EE65;%@/$8>(Y5*3PIO65CYBC7@&3N]BC*ZMPNF4*6O&'4?>I>4O*^)
MN!&N+IRTNYG@+H @GIN0&4:*J'@N#>2'[,4$=?@(-87G]4H+E:]\83+4_4YS
M$Q!X_LIWK;I.EH70TRB7+1<;Y)#HMT?-ZFC3+-ZX;:C(+HI-JAN L^*QIO@6
M9=%J%]-_GN;'Q\>YM;]Q-B#Q'/G4JM'0Q:+;DK6,I._D[#&.HE060>^9ZUFW
MM=IS6I"HW7FS!5M^^KL?L?QUV,:]FPAUTCL[0L^6#(*_'E0=+.B'Y)K(I=*'
MMA$B#NI\O+N+E>P-.T;_Z<>&IC7QH*7+*T%"K8INBU1"P8F6E15L>6A+1U95
M.?( %@MI8E%P]PS/!3K4)+<:F'AW7BA6D&%M/+SDM49402&S@075M!L>F<X7
M4PF^9<E=5L^SRK1_T/"0_A4)Z9BBX9AUNZE9K4\%TI4UA1X,/R<3Q3-"RY>V
M<" S#L(:6+VU*.I!)QXY;FU(+4W%D*;'+B6$&$);(8R<GBP00H:<:U]SI7U3
M'1Z$L&X5T3=';@_96<\8#+SE:N<+:M$LZ@1Z[BK)M/NFQ>?,0I/RR'BC'C.(
M&PR35K5)!"H_*+/'L%YL/9N 9Q_7&I]Y I1J%^#(BFJ]P!!<#71N1(3;+5H6
MK-Z-P\WV:;/-;H6N4/IA94VY, 9E)VWGTGNZ#\A,[=HL\EA^Y/_!F,NNZQF<
M8TM:A;5Y/[:HZ8:4;L=F12O!.$3V[FBLP&<56U"R03$*6QF@ N6?8?$\,&@-
MPRFF3-N#%09K-BUFMXJ0.S!CH([Q&-'@ LFSQM2S] NY%0A-/8<$V.5#:V[G
M_,CR@%8?O1K?RJ!+,E=J$)QFN&'E]OC&D)7F8S/&,/K9$'X?8*RBN?VJT*Y3
MZOL#4M_?380TG]']CCM./"AGT#URY^[QC\'Y$>.M+D\L!LT%M9*K3F"QB)W!
M$8$)KE[1;9A9@IT(B>?$&Y%*>C.0GQ?4/UV '6ZX=$D4^R N+#XNE5/C$6L!
M>R_%_YFL]J.F(@M>%ER5*RR"+8)."7QQCHC[JC#C&5S':V8$-O/%ZPBIR/Y<
M)0R1B)W_IT/ C6_RF _<E.8PD,I8.$'^NR:B]2B\)3T%BX>O'_WR6!6-EP]O
MB^\%*61XU4OAOM$'X3(KNU+T#NSGQ9)S)Z%)8?E0WRU_ER,'/=Y?._+KF:P\
M]#(P@Q$3R\N!A:0Z>\+\0PZG78%4'TU>H2Z#CD*OF#Z]"<**J'5SQ2LREQ85
M8\?-P:[)O*-W$N)11%+RQND%GVTXS]!=__(?<9&5_%J>75J8M;ZBI7T7$Q@]
M*;V.+KCM?1V.0;]GKGA+73]AGO,4:_BUHW #B_CD;OPXPC!2KE;=$?GCKJJX
M=X5%65!Z-KD@?KQ7[D(DT[,G=?8CQ:;9K7+F9G2Z<Z>B-J/TE4ICW\[]ZR&#
M"<:B.OMEL6TPA/N:(>6DZ^';;^+;%]E56WI^V[*A.*/,=%9>]QMF/;'74F=/
MW;R55"SR3J<GWI_QU^21T5ZJMS(TO.E3^3(F[+][BJA.[N6:'MB_34_Q>;EN
M^J[RSI"FFP:+PPN VXO-,R8>%C00/<&S9Z_#6\-6U3W[_6#5MG!V>3)@&0)^
M$:M!..Y;KV)H($51@*J**WHYX J,G2@:>,DXA)BS54@]#:R$6UDA;(J%/GHG
M9Z#GCY!FBEP;#79$;0+43I+]H#=5>8[:V+%7VB]ALW(),;I&YL+,:X[R7@PE
M,;X>/@GM$M(3C$K38V)@7ND.M!:9NDBHYYA*"NRO@>@R3F;9G;3LF@H]2:;)
M\]?)3F;BJ@T=U35WE?HX@SY"0R-T9%B4!%J8X4'IZ[0WN=C#OD2[U2HNIV &
M-)@2_/75FVS3MV1T>9*GU?^15__?#S>?27@;!+7(()G0AK+NB^6W)N<1.0 V
M:5A^K71L%MNXSY<[9.G<]S)<E@<(V:%\$'*B-!%EZV%*A1B9)H\;K!4OZGMM
MLUA9;= O)Q=)^?3XM( L"8,YY7';I.F9K75G)&$*#C4?#*/DZUBWL.8Y0AHE
MC^H=/N6:7]/O&J<;I%T[F:"@NZ<VA+=R8XA\)?-.?Z&=TYKS%BNBUD<2&$.9
ME!^^U(A]TC;])JJ\W[JV*>(8M[8" R?<[3!?,#G"4B@01.1)N0@C,V^PU(<?
MV/8V;:-I&WU-VXCW3:3TU;FM<(DNK%#)J;.J=)< (4+-=[#=NFD+W9P7.FVA
MS[Z%/.\MYYK/+;Z(@U0[>PS%*_MHVD8WYZ5.V^BS;R-!18 Y H380OVRN,!1
MQ!453O)H"H<NI+^<-M'->:73)OH\41'R3TC" /MI;AQG07R7K\#=1,U]VC$W
MY?U-.^;S[!CMB"I-06-1H+QUD!)GRK__421>O8MHFI"922 "7!?QL%2O%12A
MB#TMH0#"T*S&NH(>]YY<W;.>B,RX*F5(9CFF3]B3RF:?1#76$C=C@G/=T'7[
M)Q,,!]&F[)=#XN43>?*7LGC^O)*[ "!"37RLW X51R-VBV4<(6#LY*0:7$3L
M9,*[K%839?11FK\1^H2"S#.TBENT@8B<,SH: !R:]]:E&*<!K1PHU4Q'?@8:
M(<%2G+![!D$?H4<6X5D3!Z.'V_%OTH=@.!U- SW)+JY+1I#E-0_:)+P8'"W
MK1[8A&).D[ G/#S"_PQ!5SU#*H_YQCM\ZP'<3WY39JZQ^1; CD_QF/[0I;3?
MS-WVBI&(:;D_?5;E!%-E7)?J=DJ%8\M$&ZJ7''T<PYLOG4%LA!Q,WP_+(R5A
M@*:K_(#WA3E'AK@&GGU9KEC""X<J4 L4>] "LVX8[5O:NU7*"O)JOR:#,=1.
M1\ :QLGMLV7C!-^G8DLC91TX W4C+3$,!RLX=UWUXDY(8P[?Q?.#'+C&=<-
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MU8B.MIPK@^^+6_'"NX3\7I\EN6]YQ@@@?W;.M(/B/#QC=0>_9H)GZ8M>N1X
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MT32[FO(0>6P1.9^^XOY(S[DIEHU^O/$C<DQ><A3JDC:9S(L6GC,:!\Z%QKG
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M,T$J$@!V<+8^U>+3/W)6R,IQ3"D8WF#8/QH@XRBUJRZGOC'-,]*OB;_#4N5
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MRW&H'Y[ H3QJ#-6H!7MBZ2@72"D++%HR9FVIG$:I<*B=:I#/3[3B@6D)G*1
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MYH=5>F/C1KYSQN47?>L9<O:9P_6],9!WK5SG6?9E]U#>Q!7!:<F!(:7,M#I
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M>4\)V,V2O,7ZS.)/2TL'=>HL:%-O4!QEX6<E#98!.TRZD'_)%DM0"O:'.O)
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M.M1DV]O7K!U#&F$K?$=&W]X>N/?$8$AK*W#TKX'GF>>8O?;'.H'RV=O5D/F
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MON9/II_+M1XEF:W2&PCHE_:#GY((7$?,V%2ECT(?DIF.(F:\2BM<M"@E-U7
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M\'1F7;\^9LCDC%,7]00^GCBI \K+,S7X,AG]FJDD&^#N_,"OT$Y$_1NIH)B
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M)D:<SP3!U_6&9ZNZE%4Q/VQ>^HI'R[055JVOCHN6(D(=B&MGUN!W]2)^IC>
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MS*<]N=792T@($R7Z#SL:,4"WVDF8"%_3%1I>1>BLDP\[QANC=YL4=-&X_ 6
M) T?U(#UQ.1OK5J;SAM&HM'[.%"&VYQSB'Q:^V?.5*)I2 8.KD]T>Y6(<> W
M.;(29Y?XRJ)]U5KNCEK LB]*7U('W1#^,;',<4 UB#/(][F,T:L6I- G.<"X
MXZ7\9T]+NBGP=6OZT;I'J.)]6(1_E2\M7;Y&GW2 P^H:#<88 XQ/RCW;[J %
M;>NJ<J75;@1L5QZ51HF1;(XA*8>=3D[R% /]D5M/7J]S^5Z[]1HI@R:RS/U;
MTM-&8(<;!>V>LK;1*TQVH*0S^?J.[X=NK:#MH#V->&?F$=5/A%''!N.# @RQ
MJUW-B0<V=5GFRUKQV^-CBJM&V)=K>H,K>P%T.JUT-6*,3TI&?VQY5B=;Z-P$
M'XG]5E:BES9T=+$),GOY>T#!JT59N-Y6\+%_ZI]Y<#A&AW1X?%/;W0F,L.**
M45Y)?,UC O+*7'-7K"*B+3Q5V]*7<^9:5(]XJ1O*RO3;JH6'(SH&*.85.*88
M-M@*L5+'$)*)S&QPK"<*&@$=*7"\ZIAYXD6 &Z2;D)!T^1<>IAO"?0(,(7]T
M[R0=E.?++'")'G$PB6$\3!9V&?[#QS83_&VA.\&00_)#\B85HP%WBBU)C]B5
M>%F49=.GN<$!CYP\DN*'Y BB1]MC,2SUHONJE:W*3TE' :- CY +R>B$?V"-
MWI+<*/(H<3 )F)8?29B*:%,-/C48!?GS;L=+:0 QRIN&N^918,DU7SYUZL8-
MG_R!X) 79:!-:T1=&EF+TR%GW2>8[;@F4]9MZSXP%,><"+YIG,XS6AB%8L^Q
M*PZZ1Z>IIQ,^:^N XQ=D?;N\Q7]/C4O1+QOA31XJ"P$%942&&GA%A:](>8@K
M8#>OBM4K7O5LL6GR7A!S^;)O3Z +//2A\8QI;<HY2U$;GZR"7J?G81(B/NK5
ME]*M4X!#H9BC'XN-PGW124Y!SV*=[RD,:3E2.O2=57HXBE,GBX[(#OBW&C@R
M^%,Q8:<Z\7..]]X8YSOV=?_U@-5I'C#!7'J"[-:5K;M'WL"SO<CR*'7C$[.6
M&NM84$P'%B/H)1W#RZ)&-L8HT:,A1D]D*Q1@CXZ\B7M&);YOZ75R6,;U>S7%
MQWP7K6C/+&/"=,]:!TV=K\MC["]^A8/P:9',Y=1]#-&4<1E#4#UGK_1_U2MA
MZ2FD0BSX_/_^'/A@[>/?4#CO%B_*O*!(^3G/WM GOWGQW)P2G_X<S"(SPE\N
MC0B2=>E]R)E$%7Z<U?MP"S[DHHBQ)!T%D2V%1%E<S8IBP:>]Z.]D.I=;0WGC
MQXC(KZUVYQ N.<.Y."QKK:VPKV5EIY(VNE#TPL GH#4XQ/;I]:Q_XE<M62A=
MTOARU9KV8$,1-Q+K</!@TAC)/[;(VG$TI<![;1AA@V4+.Y):1->;FS67Z&-$
M&_:?R##3EN5;QD1>.[W[#%9';V35Z?32KE@6]*K0W%K@>03+C3%4;L^UZ+C@
M'VDF$Z]MU_1L,6%$;K\O6AXQ_GW[A\ROG-FDS_@'L\SR2-/KZQF%;WEOT\&I
MQ,E^5;OHL3FO-<P!>F][9GIQC<U4%14#$C4]CK .DD"#CY@70<<UR(DU?1'8
MC@<MQG-<LN\9[O/QY[.1Y ZX9/]XGDN6?OT#WG%T&GU/;^P]6Z:'6&1OY^#E
M[0^1#0N:3SE.N#$>1_XQGCCJJYX^K".?S2$-!1ROG#O *9*5\&]0?.UJ/R9)
MOJ"'&M:@<TN76:>^'K.>E0*]_J7EQ2='1A]4SCW;QM-L@\[H@\K.5ZB#6I$9
MG0E? ,;A6+2GL2"LA;WFC)K# #L/%>KOJKNBJ2N[\@C>GRTP-%R@5HXJ+6:D
M!*%9<@1;;^(8FO$[;NU4WR@RN]O%UTQBPE8W'0K$$(GH@H/0.XG=>*"YEFD
MMKR:8A-1F8GH>EJ&7DX+-&1((EB>B^D ](:E+C@D!P"O 5VC"VV:0+P2RH<
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M''E Z*6A"!YZAWC@S9AH.Q[T 94&VEO**!;:H1$$?\B\P+R/58XF:"0:K&/
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M'LG>6+?8#*)_-&OTPX@U+J*EY,8T[5<U?U6[4ZTARUGP>#;R.:B-G7XMIJ*
M9UHL!]9K[9$P>D@0-'^?EY0\><!+.ZNY=-^NX!H8V%./5G6$7BJ-&<$BV\[A
M2.R9?+GJ90:.2E'Z&735M]KJ RBIZIEX^]:$L,PH?YV,8=+RYN?OXSIABSL?
ML4>(FY3?Z)$Q$]W>*-Z9N.FU=$[0)/^5-Z1C<1*HV3^B>_C(9F[F=/K0+0VF
ME2V:X&@K  P]8V*1]J*[D%-RA 'C5EYRBCC8YX0CAG6F$,FA@QEF.&6052PT
MMSJ9RK:VVD-WGE'R]?:,& Z,(BZ8Q\TA!O'6.A1^*D!?=K%<<SC305RQI/V
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MF-D1^&A1N)_/I-+W-?=?U7VWOY2H?)<BS5)HG1&)H%R+P(*T@:,<I107)+W
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MI/(&.0VCV/%' OQ/.0-53E88(P2!TD#U1\X7P04=XFE(?Z"X-F]0[K(;>?5
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M[P08.%Z]9 SFP83E6B3$ 2&*>HDL,)'=#RG049I>IE++.")X^\_LCX]O$WR
M[L3))=NL^F5YB7Y]\E)6Q!(MZSSAY^/L_QE5G1)H#QE[5U)M]MNJHX!3V!0*
M3[ @V8:)?4*P;7(F>I_Z(WU;1E''_ "?@)M-)>3%J']$=IB"D_AK2C_V5=CH
MM8(/N/5"R^^H+<B<Q#Z4 ?WVM=UL49ZU!  "!JD.:T*:(5+R$8KNNU'"@DRW
M*1S-2M/#MR-CM"J[53^@_#*V+N0QP1%]X#P%.8\196%!\QJ(\XJU=(6>(O)2
M$*E!>"<>G%$W&6^)@T%*75U:N^,SFJ*L0QBP_:E\UCH%C[&TM,PHK8[6OS&4
M)U%. 4]Z]HYB<M1HP4W>LO*,"D[ZW=Q\MO"$Z:9$Q*\RR.F:9KE0OZ:I/%9M
MUB>^K\?>:9[?52]%/+CP+ 5#8K3 RJ04>/^,[(JJ[[::*\K4A55Q3H6G'0TY
M)^(#0Z;(AK+J_.GB-17WVK"92C!(5>R+N;]^16;B35=?D9KVFV@N3)B8>L%D
MJ;U^_>:5]:4)/UVK?4GA.?]/V>PI8T?-'&)1L,67W/=:4@T[EH#=(/3^WY.-
M[.G>>IM@A<+/%A::T5O5VSRG5K47GQ4QVX?N.[9[?,&.+[AF#7-J^.AXR]$W
M[0 M1W2Y#;/O=Y.0A' [DUMYO. 2U%-.9T]SMS@')XA[\+!&ZA7N6?T"5/Q*
MAQS[LK@'&0A_SCS:5G$&K*!,)Z'W4;90HJV1+V*[F<57@/.*VL4W\.R=VC5L
MX 4W.T[<%T%"KUE>/*2]#4PCA#"L5H&_7=7MV%$@;XT:&6@*$!CP6@1A'KU6
MRJ.$L% "^+H72AD._^WEN*\N-B;K?KKXZ:*6&!UGX)))4VEA$KDN09[T9G)L
M&DW,J%*#.QG__LV;5]S/F!K^P;$7[WD=SJJP5 K;6+S N$%/7V!.7>%[&7_P
MO]-X4WLT8*/H K"':.3H(\4_I4AB18S9YSSV-5GF(RM:6&V.M:0^J2!L]D#O
MP&R8L#Z5WMB=4?+(TR,5MSD'].QY\SV=/93DXG,LK.Y_AM./NY:I>Q#IJ_RX
MR,X*V3;A6N)*]-Z7:,/I?*ZJ@8UKVP)$,9Y<.0=CFD1BWO*J=T>FZ[H^B*5G
MKD,YDLR]$N.?,[NJ/>@)""/5WZ$M=@\'=!?[?F18(17.SCE3<K"[*^C]<":1
MJ<---9$%#\^X);V7&@V69G;HCK\5A]W-JE6_8AM-[XGW0DK]_ _/7C[DZ7B$
M5N6U'HB2Q@=M*LXX#@CTW%._S^]DB6RQ)92"#B(ZK7("<I8%#,;)WM:K:O^B
M<W_-R8EN)?8/,_XDSB?#%OE$[37[BR\PBY:$K8GQ64=G_B)\:P-K<<RK"[]@
MK0(=CG,0N#(0C!GM\I+B=D%%<J6?*#^5NF+ WGS"1-HZ8C<[IXNW0@?(: 'W
M44&Y92&$+J2#=#4(V@C"'HX(*EN7"J[U;GA&()MYU^@Y8*R,_,C?H&[(J&E6
M.UPG."=+Y18TMSV2.8O?!7!-=:[LJ&.P=6(IHS([:%$K$O:"N\ED!VG8IR]]
M-1HJ$/C)J3N8C^<2 $JW].0Z7N>#X$%,QR,\"!)L4[ 9PAX![R[X>/^J:1*"
M)QG%W"KBL(=-U%R'SW%$__*K:-QOD700\QI^I#$>F>H0*NL^#O_\)+(1RA?7
M=$YP1Y6*F$BQ=F->X.KEIS$+.4R/)?Z>1;1\ ](-["[;3HXT8FR5$RS<A>);
M*Y.:_\9N-<?$X*8%P9'P%A![7/!E!7!D'40H_16>3Z 8I#'E/N&,=KXFFSM\
MX',OT>(QY%+G@^>8+L'FF2?8?2&9)V7;L9F*SC*G%!4>D"?&*9SH>SER+#N9
MY"/QSM;K< C$LC*S&RCP@!>8G/C@S^U_.V+GV1;.MG LU Y[%4;P_^R#-_*%
MVL#7--1RU4:,-F>)*64MW/@PBOPMB[G38!M!*_5VEM<:5K[2@!%UH=0XT@"R
M$/L5UYG888^.M%KH.+K7;[YZ%<SF3H+6%@B9/N71]M)<='GR5:57C^U091E\
MC=BQV1%RNP9(>VJ .5523%3+-Y22=ZRU$0G16DFDYSY^S7 L=L0\I E(;'U-
MZ(H%Y%@%-I"5-_^T^.3YIP;_Y&1CY-]*K YE0"DB(1ZWY\_"JGOVS,4;PN53
M+I;EAIK#.G"\0>7LDQ>?AN?IZ.T()(.A)ISL+0W1DL!16'.T7:6/:TTKRK^=
M#C'A.>M25.ODL[SX/'V4I^7<SL#).P G_S@S7]X;)XDRZ\/:FV44YY<^ -9-
M+5@K"1)FV>JJ"VG*L]1 >0TK7J,X$@PV*6.U?5\S,#)L?I>\$32A@/GZ/7$+
MD%U'F[92[T_>!Z9<'=.=7C$#S.$&6V+.R(IU/M&"')!D(R2&[[DBM$H+?G!F
M3;!YX84.4_X3[P27&4D6:,X9D!1K*4B]!/?<!CC+@;R_F%%%2!T?]'A+=ZSY
MIJ_7:^D8!!-+DO7$F%QC.LFW'JLHYKS[>6GW6E3:TE$SD0/7XKIDD$;QD-3"
MN?4MX:L@=.R>VFO(0>(=>$NT3>1]FT;:T+W*3I3NM8<O\E!\G11&[)<R/QRS
M#3FVO_YQ\;>OWGPO=1?-^O[*,:!9=W@/_-GN8G\921\ 'W%*\X:OUSVZE4X(
M^:P=359G6K#NH?482=]1JM3JJT[9J.@."0.E_Z%??6&MB%(8=6XBZ[QNDUD:
M32'[2\"'K=>U=#S&B2M5CHOH8>C+R#HGF6C'()B]8YW>=*MQ*IW5(PB%T//W
MF/ IWCF^2&GH<:\\PR?($HK;*D\%1,XD\D%=OL+?,(PBA C;$5^666G"T%4[
M>!QH09N^*O1U:-I!AYVWZO)A"\09F&K:848C,0J2?] 7%@<>BXF2AF"Z'XII
M>H602*)BP*8PB2[I*E)0PPM76V9@C+I1M.P@::)M5MP,;)B#00K&JHZP9@HR
M= ^%=%-;L\Q=_O-VO0ZQ2M<7/NS+OR0I_B3;(Q 8)P/-1I WL]5L''IX(XW0
M!FC!*A%YI:7"TG7GBIEA71,!NH>S_L3+*L?M(6V\Z\7^DBZ+]U@N7[YXM@AF
M;D//\ GE43Y[^?R/IY_KWSX%TP=^\+__HX"174MXL.NVVZRN(57:--0^O=MW
M#?>)8\B4Y0,W!^K$G7MTC<21KYS&Y;1RPLCC]DKYS,FP,-/M4DG.*)70KL[%
MV8)6H"*?+RG4[+/F[X)9\G[>4SL>4@#4F:>Y-^FHP<I">X.!A+9@H^ :#.:4
MPM<(.-)]3D^9:4WLW'LG.;I^J%_8!7<V.$OHZ^$5+I;PB46PLW-Y^PDU]O64
MV0R]O+X)-[+:,*N)/\688P>' NF^1[ZSY(C?JZ:3> )(VI\=4@70=!31B\6Y
MPEQLU54-D2E-[)BC([7T&%CY2&FB_;H@-A2-AJ1%*^J\.8AP&<9?@V.+_1('
M1S=_\'3!*4W"9N_TE!5Z>3LVG0."C%755,00S@>[/4_OE(ZY::W/YH;Q+1F:
M&'$?< ':H9RZ9RG[,1LC\[9Q6=8Q<%UM.I\KB8G3PP0/'VSPNJZ(L)QP?'*B
MNU$Y]'9FM+2_S#FNCIJ#..(<Z8PO8WW&V=IG;LJ67*NF6X/WQ_O(HHQ!?7.R
MD/$..*8B[N9VE<A(Z.5/%W]OKRNF)L$R3\MHSXN186<$=9]0GF+5E=?EYE-S
MN7VI:Q4?X1->.9Q%&!\1<A3.LU94!1[3WCJ@RGCGGW(>'!^'%USDS(A)O,!'
MZ!W#!S3J$=)V.!6Y#T.2KMLJ415BRCTCR^,\NDG@\HN_Z8)^V*G81^0K#X=V
M(X0)V,6@-LI;3+"SUUV8/2+:UQ6$!_^>?_:7X+44&"5[^%%]G A7A;C_=/'/
MQ$F*(I!Q:E/1S6T;K "MJ^B8.3\J]YEH'[.S%%TDR9-GKA%Q'Y!G]"K$$U D
M\5$C1R2$J2$GB?UWM9#16/OI-\.]^/HUYK=IKYG=GH YJ[#X>GXKR_:\J?^C
MP0YOP=Y%2E%[/LZ^OZ4M/SDFUDGK13\,DX.U"H<UQW^QY];'P]: HA:00-__
M4*(\N661O27];I^'!G$D">%\^)V=+?02Z3BQ:1;TY:UF(RQI)"RE*SLY,K(G
MEP'H ?WU*ZV"T8V*>/&^7%?G>S1X* V*';V,1\U7K%DRL@-,##;21WBZ^(XJ
M:$VU^%]O%,,*D94!8%;8/#UG#;C+A$LM)$]/>*I-N=<P/YM?.;=CS3QF MK.
M)V,6GR1IRO&TRZ>.NF3D:N%MAQFO>^K<SO( P393VT6[F[IR+.P=?40A:=7:
MVO07Q2GIHH:OAV[YO9(;9F/E<W:Q[D?'_CKN[1M'3D8/4+R]3A$H%:^;A>L$
MBE?@7PW.&\6-?$,5(/-H\ @_Z!I_I:D%193(@8&JD=+=,9@W0FCX?'PA2 [:
M.+W?ILX^F$N!F?G!O@-&L\M]U^\C/U^OM5K"?M3]EN:ITN9[CL7YH"ZAX'YR
M=CBA_Z6T5<V)BP9%7@63R'H-+ZB^A!2]&EP#9.H$T975RR(?[HJJI'%&XB;$
M;6QS)]:")BNK=_8QL07 >83[,(ULI*,0U0QB/^3.O\[+8PA>T]ZW++ M<<S\
M%)G5_04C'#M.K#-*4,]Q"9!HIW.;D*Q^LTWFL:Q:Y'E:'H2B*STOL>M-HX+)
M7+%XOQ6+).;+_6/E<AV&E&PJU8FH3A3I$5E'/WGQ[-F+WW_^Q>^_?OVIX/]Y
M556,FP67_ZY\I]> "P=.^5A&L(9 6;',P+0YY(>C[& &-U-KUJAF1H%AJ#<,
M6T&'FL8Y*$$RR>IW;)$V+/O4--&JB+F7D-;&(#%,C^HFNBS[;&8KZS^QIT-U
M8$>/=M[R+'3F!\; SZEZR_P'=[\KUYF\0 4+\;-U4--%WE1$ETN;^ON*6$*X
M11AM@NUV2SUBYIJ\)E>\!JD_!W.Q_X55^[Y\*=57LB3+$$MV;!3HE28#D5<E
M,W4:#C\B*36NMT80RP?ZB_G>240S-E6?U&L&V],]ZYT@A?H(%?H4YY^9-'P7
MN,!65.(07K"YV0M!<L[>X(&#L>V2HP'_2\$:)NUS!C0,;T<86C,.B+..:7(5
MD(B3<BP0L<D0 CS,B4&B5F"47T_-E%&&L3[7D\H=SNB7.Z!?OIAIP^YGYH/O
M15::VC<8E:=2:S6[U0#FA:?F_Q9E;B..T'X2)!:%D,E1:PW2%WECR!W[^8O%
M,L2;[185KJ3@4DQ46R(!P.R9_>9"3B4@0^9F9U0?";Q!3\NLGLA461#'JUU'
M=<0$U5J-9_\ORYU(MET]/>9][Z492_/D0U0#^SG:#9<%*\C#T=)$<.URSRYR
M8RT0BS=B<#9U0/KB9MDGSAC5+2*OL^,P>SUUV-800*G/6W#.8&;#"SP!'+=W
MGA?/3\;4T,.?Y<#&W %D\V_M,Q1"Q,!^ V<OQ7/0!@H98O_N"#XL:@8X N?(
M4J U:4<(#?:G$8X9&F;,,#EF@)^JI,]1=;J\EP6EF42Q1RK9%8SA$68L<+6Y
MNA#'DC:.!*47Y<&H0%_#;6<Q,JZ!48\>78C70SG +0WQ >8YX0'B7"IZ2F:4
M65\$FJ)WD<1O>,D=U8C#'6^\'R/)G2BS,;FD8LRF+I,2=#4#I>4=LD+RCD57
M^9I,B):7;L7(6':[!OTQPG%FK:VBH7E1]37)]QPH>[0)=HJ1!ECOZWW/?.[V
M\,1+2=7R$\LF7;'"R%W'H[E!761[99!0&+V3,XV=G-@O8? M@_FCS)'1]#)G
M!A*(X+..RG"J>?WI$!+BEBB7^58"=M_2PVO5Y]B+1P=G\  NZ4UIDZT.!J6@
ME$";"T!HBOVU$V@O4S3$16BJX34';E#A/TFB$BA:<-FP%01K@?\^VW?AA">^
M8OXW"C1(?\H$%"DVM869HD5 >7,YO;AZ@.K$JD+($NY.0&%=Z[ +2K4D+RW\
MA -FWCY.='- 9@<$&$!(3&4?'HEI^AK)@$BW55@2K$+U1&7$GY#W_H%I!/]!
MR[I KS1O*.2PP^<MB0S[8R[8&#RJ)<6H1.Z%A'RY7&7$%N+MLRSXSCEI=9*$
M9XIP<LJ9=,UG3-ENA(-Q3?9X;Y1 8R0Z(^!DE+S0#I[B%<AX]@IJCAO*BIDC
MVZGX$/MIYI%\W&&.U;T  26S30]V%$>BL8Z4%&S9PG.B_F,"U5&9.[A JTJ2
MC+;V(AP61](/KR/17.G4FQC.$\58PH)?YB0_SYFI466>[ D&/_NVM)]PI2_<
M-=:1%(P,3,(UD_Z7?$PE%@,0(%?CU\ -^ISP@!4%Q0=B& \TTRX8&".A Q#\
M.VY9:=P!O5,N"J%APQAQ58C"1NX]T\&RA/6&_%P<]N^:]KH1(:P0W[V#(Q,^
M1D="HW*("G$9<M#*^ZP[-GBE"T+DC4]2USJ"9@'@*HVB*#4XI@YG[(H8P"')
M6Y",%G%H1[,N$<]!S1FCZ84SC_RC\I*LQM/R$68;=C<;YL]^<"!$6MD4:;4Y
MZD)D>SJN>Y9@%CG6F_T%;C'X;WT&YHZ)7OO B2 +F[48M+$).X$Q+]L39X,]
M9?\GF@S060@A1/D+N13]DJ9*9LP1H/I!?1IFXM#*.:#E$%$1GG?DQ[LC"5],
MC%+MI:K@'32WXI>^+&F79A%6:]N2YL]&JJ;>:PK(]Z,#+#O-,36EM'VB7R2_
M$W7X3?WO?;V*"=JMB&:[&Q%)BGP[H8L>9T@>C > 7I_1,%UG) *4V+,TE.TZ
M58+/F)U]VC@&-793Y!_*YEV4BT\Y6%N%U]BFUJRJ-1R2%#7A Z[*C9DDLU35
M+Y)#[4QY*ABV%:&Y@1UR*8XT+1JYLF0NK]"R ?[<V5Y\I/8B%;);2Y8W%P9F
MR!F7"Q@G7H0UWG5UU9VLPP%H/,K;-DK=+2 ZCJRX]&RM:L@K7K ^;45[O2E-
MOXXTA4](1UY,4A_/,W;'1?I<H@6 R"J!;*K;/N6QFVR$@%S<L4V83'CLB!+:
M]:<FTI;$'^R-S!OE8]TH2#J7;@<D>2SH^%P2^\L*Q3=1TM[Q!XP3TD6;][P-
M/>488248*"HZ;E0F#S B<,D4&H<5D5(&1VEY1A0\4>?HZQ\+=E+=96)2@2#Z
MGII'W$\?<M)A5357=<?RIP5O2PDZ4064U#WT*3CD=9FV3QQ'[Y!N6PN^BMOR
MK;K2],B5G?#*]@07"%?O>JT G547Y2;LW80@W%W<9_E&H'\4,2-WP")+^)H;
M.2%,"8UY\S/><'_)W/C*=7^KWSL;VG?[2YFEV=O_N(V2+TZB7.M@B"VTEQ6]
M%WS&S:8"$ZHH\\62:S,2"Z1)<H?2QY8G46RL9Q.DC^& Y![C =N$G45LY!&0
MR?E-WK((X4TU-J$%&:-YY:N+[Y$\B_'09!"$=.>I;X(.1&H;I)A@=[IX6S?2
M\>"F;]!FA1D 4SG=XM_[<H.".2$V)'ZIZ(J@1UXO)E3^BAS/4H@M1CZ!JZ/_
M$:2"8TJ+4F]>7_;(?>CL88:R%9]5I/"GN.01R2!QM0;51+'O,)-L[]P4<7?;
M@$T= 9PJF]^@.R?3VK3"8VE_\3S1)-((/9?SRAXF84K^*[1I>ZG#_XU2/>&)
M:D2$6+-T_::%EUG1>9$SSA/D,;BK89,*W=H*701TS!J7Q9,RM#.,] XPTB]G
M&.G]S'PPUB?H'G4V$FAT=0('5M,1*G[][:O%)[$5YY\MHK]F\4T7HE#TH[7A
MF8MD[T_8XGZ(\$+O$+>1JEB&7;^BYGMV1\OPA*0-OHOXN774,_U/U$!EH78O
M!>N[D\+U$ZNF E[23EHVV17MF#)[&FZ:VL6VV1P84K(*XV79,C5U+%Q.1Z_7
M(SOC.U,H[0X!M?2<Z/+@(CE3?-JZ$&G1RXXY6_;60*E''7?EWN+(D#2].]ZM
M2)6APEB@=A>Y.O%BEA=U=24*:?N>F?^]<"J@=*4A;H"UVG'#1;L,<8#3)>=>
MOU4B=\^,IR1[$'%^H%P9F;JQYPK/M!:UN.%$I')":9Z5-\@T'.AT\?55!2 A
MZ\=!Z%B(H\=8#J9J,]S2HPWL2DHM[YRJPUQQN250Q)(Y? $-H5G_@7B60) M
MB5NKQZB<D\"W0:E#U%K+*MT?AN_F++3<M.Z(D*"1F'1U7NTLHAR;<NJ^P0NC
M"-_/_U&EI@F,R"@^Q.7.AS6G"PO^C4U6B!>W$#QLE^^>5BSXA([)#PS7B1I1
MX\"!J/^9%DOC2HR9H2@E8BT0JF6D:NO0\:U(ZN/RPCA9.*;T5^2%/00L.-*7
M')X%0^T,>==>SQBJ1[/JWW_^@UD[P4Z7:S:3V>_K7Q;+VI*(* ]>.9USCY;?
M"Y=%*V*AG X _$\LK:0X_)). <H1<XV66@<J6+">+' Y5L+C(:TEQNWDD$DV
MY$7;HT:')H:D89=1\=5RS_$\G=Q=24I"R04(IQS^>T]B$ZNZ+_L=LBP#BL'"
MQ%KQ_+RM!VTGUKNE+.0)=Q/\#CIR@[D8SQ[WAW!_4@.2_IR) S#;\#'[Z;R:
M_'A\:K+TLQVX6QZ4^&)6U8KD4E+\KBE396TV)JX]>D"&Q8\6>J^W3'\T)DKJ
MB'<(!$V1OD4J"MO\==M1JC[$F=KK[ 4@_@I.\.!,7M1G-3;/@7_NFK9:UR6%
M5L4#QTJ7Y8%#-*(]8Z59B?W06UT>V!?O[ O"C$FE(/PW(0M /"Q$ DB>Z;\*
MC0G47L&\UBEXBTHS^)WYQR:7?;GO *(&."O8P.",<]A^6)0:%@D-4VQE8,/(
MSTAQ**!3X&/IZWXGL*[1B?%1*WL2^H]9*O5C-PQCK8Y_%>$4ZN;BMD9.JDLM
MH'!0(:;HBUQ9MO^7O+65',3G@<*.#E[$=H3Z]*\LW0P"BM[=Q1=G) UPFY:F
ML!R"S2-^2-(3 )$XT;0AF-<1%^0_H#C,Y#EBK"SI'9NAI?>RY3;LV/"GOU]4
M82;;0R4L/ J08E\DL1+48:HZBFR)8'K=0)J5)WD7.'C7CW5@YJV_<6"HRT1N
MNQ65FY2?)(055#/OD@'$9XU#%1S[%;DK^#'>T8C P&Q"/E83\J^RJ]5+&'+[
MFP/.)Y80!5DP2WN,>C2E;-=70#S5CL-=^QQ2PG8Y245(7K:";"IBMX:CH"X^
M?7^=\*);%GFYH?-S74O(8%&%N?]R5J<019-!M8IE9HSP3VS+2-9N[/-T].LO
M"<E(SA(+,N>QO3#]*!41F"(+:Z;.J+GNY-MQMI9?6<19P-$#56^PU]0K8\EG
M <S"E4I*"XR8"?.2R,/J])8LS93GJ(^_6Y\W9+@K0LL0YX2!QP"28T/78N]
MO5S8GVW2QVJ3*-1PX;I?^5CC4]F]$07<%&CA::"6P=G>"+X82,V-HWZ5F@D\
M*&[Z7U5GP3TQEEQWVBIRR[C_WW[].N)6^"I A(8+,"&GDFIJEX68*W#.-APE
M:0Z%BVE#^GDZR!-$';E$S#PEC6Y/;/_,N?)?FY85PIE1QNJWC/Y5'Y>VQDET
M_@O^ U$C$Q\'*LTX-(ALH=MIEHP00HWG,V</EK%,8]D'T$X0Y 6@+GH>\D"2
M.EBZZN>4^*-9W.];L100?%Y@P1OD;.]]K6-U=CAB9-4KU'TRQMT?<(5_P%W3
MC)A3:8K-L1:$AON?L\",18@46(-GM^W.P^_^HT/@1#39_^#'%7H4E(UQ>VWB
M/W!.M5WR>$8=@B/))=HPUFW=9ZDX(\TFX0:2EM^I'\GJH%#.F4B\R2O!GP<Q
M+  9DL.K-IQ@0R(/:<B.QV>TO99+ !GRDFFD660F'*?A(4\7_TI.S?@28'HF
MG )U!2(Q$/L)CFJ)1E[WBA'?H;6#Z5)YI= PZO!6*O0<B]> UL<%>;M./(B+
M$Z99K;P^ZZ[<KQ)&IP&;DW^!WF["LB+@E^9H]P)\Z[50KJ2)@I@"@8ZK.3BT
M%)=P3CKWYQ.3LU[%Y$=!&AT@H]Y%J1TFA/*K%L/4#'/5G',URD/BR?Z/)$=^
MSX@.4>]I*H(;,6E_%R(-\& M@\\&4; 2BE&$X S1:CG8UA, 'R8WLXK,1;5A
M6K5-3 "[5<R7"N$<5X,BH%U!H>!=:[ Q94.W<<L5T'4BV$4B?8)-M3$QH_]
M>A<OE2$MU(R_J5:B 8?&C<C=-3M]'RF&\X_/9@SG^W3ZIN;]>U30OX?4$ [\
M[\*^)VY]^ -4S7F#@VYW>%A.[$/?F(]J<=P^(O@.;-3< <<=G[TRTHW0_0FQ
M'/Y<^S5U*6OJ=/$-NO"LOK-02OW-X +TFZYFE1N1;[1L)Y*?=OQ%9NF%8D:B
MBD+=>964A[6HY\CLWLZ?[SSGJ6]HKALF$HIKW,K9C.2-&#OVV0IVI D+R@L4
M;G7PZCM 0YUHYV!9VUK6N&H*ZLKK6%IZ&#*UO6P;=M'Z0Q,^)TTXN,RD&\F_
MHA)$#/["3\ZTWD%^8'D)GW=;!;<M[.J]:*&YADYFC\13RY<0-53E3FJ4L4@1
M^:6AN+>N#$E,]0?,4Z1^AN]\PIB%6&T]Q5'DK$D?%BS!P-2O7.5.-T586X@U
MD'0SQWA<'(@1(,.\-QL)XD33=0K.KD8.4/A+:0<F6FS6=S&X"=Q;,4K<T1#\
M\9H9_J5>"4ND3RZ=<4)_126HZ'N7K"# G?#DRH=EQZ!\9%\9]O_SON$7#UW0
MPSA0C@5XDV6J<85;AZQX<+#GIS A%I2NC:\$OG_-^=M^2<K;DLP=7I)OO(JB
M04I_NSFP"'1AFO1AG:*FS2&+W$I.@=AR4*55'3<^)?6AL4&S&1$7^  U7DI7
M47I9_^#NQ<LAHL-18J,9U#:?%Z[(PPM?RA9,$I,#5T#1S1SUC 2;]%#6M3#.
M$ADLE:W!KN^2!*CB]'7G#(E2^DG%>P>L2]D+?2VS?G<L/DH#V1!13PCG1>EX
M=/@NSVX0/$;9&ALN$E!GQ(1+^*]]5W)SKF/:!K6-"0PD$#"U@&1U4O.)9R&Z
MD02:XR:+:4X*ZW,BWN9ILT9/#?6F375%C$J1;FAGDD&7;=_7K)#G1D^U.Z<!
M?Y"+,R5P)$ 4D"QG-0$A<"7@=K\C/4<11V&J"1 04X8OIH &PSY=?!M^P!K5
ME-PCTL5EW2WW6VZ>[9,9P;PQ#IJ$J:,T'=OECCO;,(^4[!*711>8-B@/EQ)#
M'!S2.)IY. [:NQ;-L$Z@)+#X+";N%ODWL <Y:01S\!,"S(('_KY01\N/GUI:
M:#:S=S.S?7 QFW/D>\U\W &)!V5A^L55N[E"CQH:9AP$OH=O MW;?^^)+-]:
MO=C065^<MYNI[=7UWUZS80J/(ZNW$+I^MBF.-8&U+?6!!$]7UMO$.YQP3$GR
MGC4>P8ID_8D>RR*FGW.\6EIRK15?2_+6[6W*XB:>.P999%N7GL?<=/P<SB[(
M%LS9%7JX3EQ%&>@X@01+=\@0F,B]*;NNO:[ =X^K(SU%B63*:.\;YU2?+D2"
M? N-URH^UD'\81NL^)T6?S2KT9>IYE653S>')!'A,PZQP60J5$-EAYMI69)&
M,4WH"B63C!W)J7E^_W7CAPG?'HL]G.TKV@9=NB7BF2=@30.0CIIV.F_;S6K
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M3!:Z04<M0PVR=(#$*4V:3J*&B;);;2KN=3& 5:.>AMS[HJ3D_ZK*?EV57?!
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M^,ZRJ\\JAI'RE<(+H;/$O67;^>[J[!Z'Z RD0-04 A(@.AEWZ RENH6L;VX
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MJ&J'7SXO1E;'KBL;3M?PK<L%MPTL7V+<)SP1;1?VZPD] '^Z>KGH#WVXM%6
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MA*CHJ6G-'TZ**-5;TY?=Q&CKZL9=.7T2<]+(U]%T&V3F1,&)6[/JY4X@-Z6
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M.3;-B8U,W[)_NS3A^6N=#=U[ +@HZE(VH/Z3C=%@(V9[D+_BC1OC/L-R[?;
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MNB7-W0$OH:M=X5K#\IHEKDDNHWS_)-LQFV4<1J*#?2KYOQZ4+AOJ_KBI_?@
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M&#;/@C0#R'4OVAX?(?KW T\0A\RA]V\KWQ%=V3*"U F= Q+_<&WX$&A6(*$
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M@MP<EFU#UTEKJ;U?+^NDM7\C-L*QK]KUER7H/Q9K)EM:]S$,A QJ57/2O"]
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MZ.C%_]V-4/BHG.]X'4:QW.5@UBAM]U/:1M][9]7;&,RZK04^_ O!K%&@[JE
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MJ:GA9<IHAV)H+DG":'7.?G!9L,T/L+2^>O-:F+$R6XC *)Z"&4J1B0A*(+5
MD;-]_H*BY!&><>$R_F<E!3T7.CR49$+[9C2_">LW6^B3E[53G4AEX&]&87SQ
MY'#_22=G^<7CP_UOW"=6>:QI.]210"\V\DC\._H'_:G(^HP69KT?;<T[:?TH
MB,"FTY:4$8<\4BZ-;"0]>OBTETS]XLF3(&5*.Q3%9+&4E"&[>$Z[:R"_4W\$
MOH=="(R/*O;Z$_H#'ZBEX"IXWW?J.&@OO3!Y<J&:SP&(R'4@:7/X.;T+FO;
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MQB L,\LX<PE5\79<8%8S[3C==K-&??1T/C/U\)WAVFW7E;-=FLK7:PG=BBW
M8A^^QT)H]U>?=86] Z62$OY_>L+U<:M6N)B<1CF+P-]6%J1_U@%#4Q6]*\H+
M&7LB-);*E,8!8;W.<BAZ6?11!:-.W3+)&/:C,W&]L9:A'K"=#U @VA9)KQ(X
MFW&U;!%K3]H+0(.TWM:R.*DR<!K ER=XMO.@,^@P71V3]%S"/0YU98M[8TLN
M*0I&&>:V):2&6.>N-T\AU3K;XZ@+-&+-2G^ ,.,\@I''),&8)-C=.?_;_P1&
M1S<XNTUU2,\">U5?D<#&M&;?7VDJH2:BFJ>;5XRI\]W91*/@[I3@LM@IAY%V
M?KE43,4[$TI^=M!B)WY#/QM%\AYLCU$D[T(D.57IFOLXX7'!8ZXA ,Y%Z(#
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MC>Y#G+T:^$TU1RD6<_VBP@RI!1S =A?<\Y9J>)L>$H4[S+XJQY$U)QSO!B?
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MR/TKQ31:[#Q!-< %8EFB9B#UOBP>%(I&BA;ZL'=080*/W'%BA\+#4>@9M#[
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M445JQLI^0:6V7%+SR%G^(F7YFG@QRQ@TA!NY?3N5$=A1 U^)-YJUTRH $"]
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M773@DJ),8!:F>?L"$1T0'%.G904DAO*B^]H38YOXIN[1I6>-PPW-W(5,2@X
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M4<&8,*QF_62>T41!X8.R;ZM7%&^U#Z!9/U:7Z0[]YRK$C*7MO\DB]Z\>]RG
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MD^G#^L(038YX$@<?)L!=1"B/YOI71^T/\O&FQY=!$L,N;@4P'[DCJRTAIK\
MM^3Q122.(K'@8)"+%!;* 2+7?K/J<+UV(U ;/3=>'J7?7^-V35_7&@UZOR#P
MUO%2]5"[-1Z/'WBF.VZUV]TM+&0-X:'10P^UNL,'%^JTAOWA-G;4AZ-U2@]5
MP\^M"#;%I8Q\87LL"CS7V:X'?%1AP38)/.?.4;;EWE)6W)--8[K/]??Y)4'W
MGGDNZH>HC=W9 ;[RW<M\VMM'DG6ZS7:$]5:Q@)D:J2"F:P*32%UGGT1DA^X"
M(QD&)/T]F3<8$-HRQ\;9!]0>I&8BW.T2[IEO!^$"@X_"89,E^R:F(A2^+=C?
MX%_79],PF*=(\6(9M<N3,-+XMAE?"D)V8<^$DWB".#EQ<N+DQE.MZX&:RSX!
M)Z\BP1KOX"<2)A+>,0E?G)XP(&/Q_INX:K'-CA?J;U9)U'F%M-].'=-^J7F'
M"21K@$:]N[1?J_YIOR]M<+8Y!3B=]&;U529/*0/X'I_!$Z]L5Q?##%"7B152
MDE$]M1)*5MY]LK)5L61EXF+$Q:I%;O5*5J9N;&;"A2AP!]W8>K5VB%'=084<
M652D90*I$;0JX^X@$)A@KA$4" IUAP+I7P07@@MQK1UU8^MT6VU3RM0H+^/U
M\S*ZE)=Q8&Y\X\S9"N1E#+OCT:"4E]&I?UY&(1?C^"H40OZTDHS18&>^W9)I
M&'\/?![/X#8^A^):I"D8?W"X9F99:Q(P*F#F$R,Q484FF4Y9#?O,:NA05@-Q
M,>)BE-5 60V5A@M1(,V8(^^ML;X%RFJH#*@HJ\%8&4E9#7L' 46F" H$!8("
M08&@0%!X<<9"O]86)CDE[D]8Z%'"PH%YZ(VS5"N0L'"WD42W_@D+QW/A.S)+
MH=Q)XL79"SW*7J@=5Z&H@X$"GK(7=I^]T*7L!>)BQ,4.+GN!Z,T$*!"]4:X"
MY2J80,IF>8 .R;EK+JD1M"A7X;!!0#$I@@)!@:! 4" H$!1>FJO0;;<ZU%WA
M,+T2Z&OO4[+"@3D(C3-5S4U6Z ]Z_7&[8[5[EM4;OK_RXJ I4Q4N.^U1_;,5
M3OTKSXUFS./^5<*O!(N2^1RG5013]KO@D=B<MW!G!,;)^<>S"W;\_B)-7#A>
MA*['U-@+:]/4BYU>Z*ZNK54A'P5Q2@JE5$MID0D85KOY/Y1_L:O\"TJ_(!Y&
M/&R'U':<7"51#,K/UJ:#O^:<+P+_"V^SI/$2<;\@<E_#R<%5@4P%Z0XL^F9W
M/.CW*0F'DG"JZ=D\I*B%N:1&T*J,@XM 0" @$! (" 0$ @(!@<",K)MZ6Y3D
M@[C']V>UK+^89^U0RLU!&::OD'*CDV4ZUJ55_TR9W]THQJR8BV02N8[+0Q?6
M@-_CF6#?Q!5\&G(_INX<-:)I @&!@$! (" 0$ @(!&0[4S2V<I8416,K RJ*
MQM9"A!$(" 0$ @(!@8! 0" @$)@1C>WV6GWJ@7"@\=@NQ6.K[BPREV(-C,=V
M#R$>>Q+X$78E"*;L]%_LM\#Y(7PG9M_$M1O!#F#+8>R+,!)>](-/&@S!LA 2
M-BR4\5H1"H<MDHGGVHS;-MQ,#-!E4S><4QBW1JR 0$ @(! 0" @$! (" 85Q
M*8Q;.0.,PKB5 16%<6LAP@@$! (" 8& 0$ @(! 0",P(XUH=:F5_L&'<'H5Q
MJ^XL,I=B#0KC_K0(;D1X&4PO.7PA],6RWI'<KWA<C.,>Z^.RMZYO>XDC'!;
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M#]TW*5Q!WH1L"?3;52'J:B)7-W8XM+I8@NN.X I[QD]^?=-Y0S"NI\+V&_=
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M;3#XQ4ELQ)\<8S?!'O#<=P#E,O@IH+#OLR J?JHQ#AX!1>0&- .PW20@045
M^:]P!%^%2!=,8@XO# 6/ E_B#(^B))2OYI,@@25F KX1KB@_*RQ@&@J!^\J4
M)L2@])%&MH:3"$GG80@B!?YO&L)&\ @%S(]0@R_1#5JJ#?AK",>!=\&9A'\%
MW$1^J$^%>I4^E5:H7/2'^[ 5O/$P\%@ I%LX@?*1 TVWV#$H@5R5@.9P:."+
M5DE87Q>\2T;LY:TC6\!W/O9]; *WBF=$N2IUMR1<( QA$<T!\:F[3%!,ITIC
M]I%)WF&Q3SFPQ"_X$?5=O$_->/V 10EJF>K%1/%;=L<5B=SV$M35-?XJ;3NP
MA9.$*D\#Z!!!(H6K&_V(-I)7B@GKB/,!TFL4&</J%I!_*#'M*/&$."JWTF(7
MB"6%A[/CB%NX)1^6:B#6<@9",4:Y[,)6Q+4+&&,C15UQB7Z*%\U1N"HAY+B1
M[0617G/CL90.H:^2>U%0V, U]Q(>9XNO,V98@GH"O@]$N>].05K"-<).7;Q@
M5%8<P2;+@M+20+/T1H!9"/^NO +)# U&;4?RHDVX?O/ ^2?"<\6UYM(%Y@]W
MBK<$-U=@R9-,#2^8MX=FD54F!/0*\YW6@?ZE[X.;<6]A\_Z79 Y_L&4@^?-E
M?R3&UF0T:$YZSKC9ZTTGS7&?.\WV2%@#,>WV)J/N&RERX*:_8<+=R>50#/N]
MZ6 $#SGM9F_<'37'(X<W>R,QZ%BC=KLO)F^8S^>P;4>X1[)%2Q!^@3]4'SZG
M_V*_!<X/4/*QB03V$P2=&]4+'_0%X44_^"0CB-*%_Y4(^B ).HW%P%/7*):B
M]18O5T0"(@M%*/Z1), 6$&9';)-W'-&9C@?-SM1V@&UV1L! 1]-F9\"M=H\/
M1-NQML0V?P]LJ7-4GQ).@H7P9Z!R^0WV2?@ S1_$*JF56W:;:V=;'08*4,)M
M=J&U2;CMK& &)=Q6,>&VXB$^&M[P8@R0*M^N6H 9<-\K3;YJD76UKE,98?T!
M\;VWTKT<)!'W'?1-WV+V"XMF,E:LG.+I;\H__>Z0T&0OJL)69Y*8/I+D*8-&
M!H/6:#A^8-2(U1I8O0>?>6A@"0!A-&@7_F>]?,GM;*S;:G>?NIFM3998F;3X
MXK&*IL\=,&."XNO#Q:PA'P9! >X</_GUS>#-ZT)DX^P.5I:ZIE-4U29Y%'.(
MS:#-!S"A^#J 2050P@SR)AE9:?"1C#0&"IF,[)",/ @9B:4U9M DR49BKL1<
MB;G6B[E:9M D,=?7-CR>V-JRTQXV.CULPMAY&<!IXN)6)BY&D7CN;,6M@?*)
M\M20$,ANLR6>*U&W#!,:<;D]]9- <RB@(4Y&G(S(A4!CL!J^+;N+U/"MI.TE
M88CEP?PEZOB>W%LDQ/829R-.:98WF$!C+&B(DQ$G(W(AT!BLCI<MJN(=ZY5V
M,_;)*MPW*>U/5=JQYV?6(A<[3UUS3_CD3C=>ZFT7#GY0'2@\@\Q>D:)^-H-R
MS!> +P5 !;FM;MWQ.>2V[-JE>G=TAW;;'CC=9J\_$,T>=O$8"VXW'3'M3:WA
MD \G]FKOCHD8]/K.=-1T^AVGV9OT>9.+L=6<6!-8KC,=VV.>]NY(HN85YXLC
MY/7'OH/_G.:,_C@^X6&(3?C_EWN)>,,2WU5O^?/RSXM/H%(#;L$JW3?,$;8+
MUQ/]^J8)OV$/-Q[_^L:]A7M+YDX0Z\_?_+7;:0Q'@[2)1GK<OQ(OVSH1&"$\
M2(B; 8<J(3X)<1+B=1+B?-2W^DZGT[1X=]3L#:QN<R0&XZ;H8/,M>S2>..-5
M(<[Y>&P-^:0Y'(PZS9[5MYK<ZK6;TPD?M_L3J]W-&W"]OA ?=!K]09>$N(E"
M?&=!5/+:5($%_<'#'T(W%\BZZIOA>#6,-*NC[#T5#L0@*>) NMJS=+61U>'M
MB>4T1]/.I-GCPVES,A[SIMUMCX>C]M0>C[?B<,G9=#[[1&?);$5#ZPP;O>YH
M6QH:,:!J,R##KIPDKPE0J,6%D^2MB^3E XOSH3UM6MT>2E%GV$2_25/8[<F4
MCP>6/1AMPTNR:\G;'38&'9*\1C(@RF@Y:-_(UU LN(N3H1;"CX2:\Q3(F53V
M-C+4*3AFAA*Q58?R8YLN& :M6@!F^_TP2 LTA1EO2'CI3D>]7L]NCJ:\W>SQ
M[J Y<BS1'+?;-I^,>J/!>+@-_XL6!:=*$AS[SCF* =4N8*O:8&-@:+;+DUN)
M$(,C#8 T -( 3"(0T@!JIP&,>YV>L'K=IK"FW6;/'@^;X[%E-:V1U;7LZ;1O
M.=-M^(%>2P,8-V#WI '4@L&]2FY-9Y?^HP[YCYZ/&-^#&&?:4S.#^BB*Y%\W
M_,(IP%<]/KE>L>MU)Y/Q>&@W1R,Q:?8FO7%STG>FS<%T#$I:>]"!_VW#M;-]
M%6[0!1VN32$]8CD&7CG)6A.@4(L+)UE;%UG;G3A3IR-Z39!;_6:OZ_2;XS;(
MS:XS;D\[8L)[]AU9^QPGRO9EK67!M;8[)&Q-Y#F4/W/0_H^UM44-!F3:U$X1
M,Z("AM%I=30TJL0T_,))0ZL>UUROH5GVJ-L9V:/F<#R:-'NV8S='[9[3' IK
M-!Z/VZ/1J+>K0J,O@6]O467K-^ H1D:XB 61["79NW\HU.+"2?;61?:.QM,>
M'PX&S>'0!CDZFK:;?,*'3<>>CD?VV.Z.>UOQCKR"[!TWVKVM%1L1"S+464*-
M6*K'>LX7(N2QZU\Q3_!(,,F2F\&TF< O,G?$#*^^871:'86-7,N&7S@I;-7C
MFNL5MF%GPD>BW6EV!E/LH-<;_O_LO6MS&T>R-OA7.GQF)NP(%*=N71?IO(Z@
M)7E6$1Y1:]FS>_:+HZYBCT" @P9D\?SZK>H&2/ JBFI0U6!Z8B2(!!K=F97Y
M/)69E8ET;1BRQE-5$X;KR(8(EIS[[%^RR_XU/_!1_+T-79KKWGSM1P7%(N!D
MBA0YH&L)6M@+@0.Z[@NZ6BXYQRH@Y[!$^1](2R40<T01%7D(V \1#AD*71D'
M="W1R4!UR),.>.2>TZ<GZ?6DFCTXN '9J#+8 (2""Q<XT*_Q><B;Z1<F,=$O
MB9&7V""N>*)21GA$G;<L"JTQOS8>X&$M3^:)@"W/WD[-;'DX\^?^^LT7L*\[
M>YW4$C)1X'X*%#G@;@E:V N! ^[N"^[6@>-T1P'1W&6,UT8@1:5'D;E(J26,
MA&NMQA[6:&0 W/V18IBW4Z2/@3*/)QWUZ+H&K7N!#'$4!O)/9?""04/#T$&N
MV#P5=)#;.V(7-;4V'ZC1FCG$#1'(8!N1Y0%+;12G;)!&(UL-XP:NZJ43*G61
M22[H&5>^2RM,Y(#Y@/EE&0A@_MYA/N5<4F48PCC]P4ET2-E($:D-#MH&RH<)
MYNP2\W&A8X, \XNLA($^L:6ZJ+Y/+(P2V@-*N,.&V_2 9D_JYZO<4*=H4O@
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MG&,Q#!6YR7BP50E_./-=0Y:M'PUSA'8B"^UE#[U8RG=QA8D<. !P@+(,!#C
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M$+]W$"\B]5I[AI10)J=3(M(J"N2#5QH;9J1@@XPK' [B.0>(WP\/!M4P3SH
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ML/IQ6WUA(@>X*T$+>R%P@+O/P!W!3OO@"8JD]H@S&9 *M40DF#R1V3OB .[
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M2] 6?DF ]B8LC^)OYM.7\^0?*>=%9H4_8_S;K#OINSP'/4+F#!0(*!!0(*!
M0(&  MUC&*"04O)0(V-JF2@0)<A$D2B0Y4*$6',9[2!E<3NG0(S>U*&M>+\,
M%*CHX.'MI7ATE\%#"L'#AZ^)W^9+,ZVZ;L+'\VDROK8_4:R?5^$_JV8)?8O&
M39L'3=4 ;2XV6;X_M!GHYIIN6LYUK1E%BM06<:$L4K6*B HJ!+::)BHZ1,3M
MW9;S?]7Y_$$.8 @RD?5@QQX?TX\53S.?@D,K3.2 ^(#X91D((/[>(7Z"=*UJ
M)I'@+"(>J,O#I2BJG>$R8!XBOC;"XR$!IATA/B%R0BE _GYXM$>I*H/ 4*D>
MJ@\,31MCFVFS;/)TBYG?0: (\JMEL),=QO'I <WNUL]7=AK*)HYE!_#_4H:-
MW5^[P#T+].PW<T_L=1UJZU%DBB".*4-:R40F&8].F[KVY-K1AX=$FWZY0)3#
MF=\1$Y5L0I0:08KS!N,!*EJ BRM,Y$ C@$8 C0 :43Z-D :+FB8:0;G*4_DP
M36P .R0=IY8)2YB^5B;^D!#6H] (0NF$DC)[B &/>'A(*_UMDIRZE[=)Y*_E
MH3S=J92^H3 NG/I(@F;]Y_-M/LL-"QMWJYC?A5 9EP]DFME9'ADWFR_3=9?S
M:GD<LA_L@M#=V<W8S,S,-5TY5OK!2;I >W!30>XXGKP:9&W=L.CW?7'=)M"?
MT9Z,7V175L;Q>7[AU+P//28B$Y/6GIGIG^:L??Y=]?>Q.>O=0MK8G'7W^>7"
MS-I,MYZM3D_#PIDV/&Q]VL3T=B;K?R2:Z);S2?5ZYFYTOR-ZEF%\\(Z6S&<L
M2.R[ 74[IFT&\,<%[O\Q3XO*Y,U&^T?7S>$1X&NG*_'%-M-Y=_Z<U3Q61^E1
M'PO9=OJ,O;ZZ/.FE(SO5+Y<[<!2P]D8NZ>^;6>+/\U6;9-U.JO#)A5S/D0<Z
M=^)/*VKSKY/T6,OVAS+$7^:NK]L,WU1 85;+^2;0D&\P[5^>X>?=V]'4G,U7
MRW3Y3\$_[[^*X$Z"ZP^D53,UIVUXUH93DWQ9V BG"Z#UU_[N:H')QZ9MNKC.
MV;/-YV\H,^F_3H@#)?5?LSQO"L*L[^E $/[9]^#/O8,>J#P]]_P_\O67'.;&
MV %F7WHS=U3VJ"\K[-E=Q[^-I=PK8*7*8"RJF"S,-ZK%'EX/#W"8CZF%)//\
MF__SG?BN^.+?(BWJ$9C'H.OA?X)95*^2S'SU,KAP8A/18&12AIE^<8UKZ:NC
M#$L'N!RU^@ NB]'".5Q2@,LG 9<44UJ&30(V@G,%YPK.=;^<*RG#)L&YCNL$
MWG#'[0HH(QMA <11G]R;O:_"I],P:P/T9R^OQ.*AZ/KDQB:7I"90#:@&/!EX
M,C 74$WAE!P&EX^/N/\:VF 6[K@K,O+A8YC.3W,=6QG;< "]$CH-%::%_3R*
M^N1&C7ZM D;H;&\9T>FX8UYK9)QUB#N=!XCGPZ+.D$ -K:7$5P^8RB!K'H5"
M6'F,N&8*:>4-XBH(2A3&]4TC.GM7?SCS+R\<_:L^7C/(Z5*N)A3#G/![^+"]
M  T [S+T,*:%#^ -X+U/X(T=ET[6 7FM(N(9QBT+ 3$NE(HZ9G"_!M["$$*Y
M1\0ZCK@@!FDB:X2Q-M0KP94CCP_>3$WX<!VF]MF'C3I( _.PQ^=Z_A%F86&F
M78S&^/2NIEWF=.O'4$:PM3#[' _3@Q&0A6Z%8 0D$+^[B5^,AGAC-7)4",2Y
MP4B94",KO+:)^D6L!XG:K'U_XGV'ESS_D-2/L G&9 1-P:#+?8G>K3"1 _P#
M_)=E( #_>P?_E!/!C8J(V9H@'K5.\&\%PIJJ2&7TL?9#Q'T>"?XETP#_>^'=
M8/KQDPX5]4-NYD.5XT-*L Q" B,0"V6*W_[D(3#%4GSO+8$BKI@3C"76QW@.
M]3!D<%"(!*("Q\)SQ8<(%)T?P5I3PW:HF<>)T169%01N"/[LR97K%V9DP!7
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MZ3/JG5#YM#KF/'$!Z3!2NM9(8&5JJ[$V=I#ATU_/'W[DL@9NL!>>"P8"[6G
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MX4P;'K8^[7SJ=R;K?R2^Z9;S2968Z8WN=T3/,HP/WM&2^8P%B7TWH&[7M<T
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M^K+"P-UUH=QXYGO%546N)RV!%]>%Y#V_T5F7X?7P@/W]8VK!;:8WBT>>WOR
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M('$43$>4 %PGCL$T4B101(-,+$1[2U48DCG<)\]/:C$A!"+ ^YFW!PX"'*0
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M,LX%+@US3EX?XOR ^O5=DXP[1S(0K8%;["3L\(CK]X=OEDB&J%.I/JUS%>O
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M7'!QG(K]ULXM^Y8J3N=_ME5<S$^J9O8QM,,$$B'Y_EB<S-U[1/&3:YE1DII
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M.#:S]^%7LPRO8@SN"YJSWN<<)4L:Y 1J8LH@9X]H,@]MU K\:IPP#ORJ4,4
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MBFL:KC).&P2O?53(US0Q3EL;9((FR!++I*-1.VW*8YR,3J0:C'!"9Y#2=]O
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MC)"6J2@HRQ%5,D$T$1();'[->!:GO$SR(MWHQGF ,,*#UC9BB"P\2HL E8V
MO0![ ?8:*/8"S-)AEEQD+%%QCDI9Q@9_,(,_BC1!A2QD3'F>IT0> K,<M*HQ
M/6$D 6 RJI@.E#2./[OF1QN(CYN@PP*6!YRY "TS H"6!QU. RTS!J:YMX-+
MS3D3L<&( B<449IQQ&.E$&8)3U46ER5-(*_F.!H38&8@FB^P;0>4 2@#4,8
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MHYR1%%%J.XEG"46I+&/-)<9$;A0U[@.R'+2HD9_$="@UC<,#)J-)KAEWBN$
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M@F*2I5FF<IE+?A=/I%E*E$@S5%"2(JJT^0[+-<I927)!*"DX@;)[P!,AVC#
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M)B+[D<SI YMORL%\!VV^[X9BCA%P"S#F,BRC/NXS_=!H<;1SB?#-=FBD O(
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M0H-Z:% ?%&V.UJ ^=#H-K?'\*EX :1RH- )MPJ4-:$K0E(^8RN%((W@"X F
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M]Q&'.BSNS$_R=*^5;3 I/ #L"7 "X 3 "8 3 "<& R<X*7'"58ERE7-$A3+
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M^?^W]Z[+;21)FNC_?8HT3==LE1D#'?>+5%-F*EUZ=;9&JE-2]9[^-197,K=
M@)L)4.(^_8G(!"B0 "\2DV0@&373% GDU3W<OR\\/-R[JW:.O6[L\KA=)#:<
M5'XZGY[V\4ROH]_MH-0NI[I9:>IS/9TF=^C\(C'MF4X@MY]NY\H5VF[]=M=:
M(O$88\\]@ IWZX(L5?(G@'G$A'*>2&6&6$O\NF#X(;S:Z,*R*B;<M5WZ>!1G
M-;_JUKO?]5D'F&5Q\5[&3+Q:]?'3AU?_$_SZ\N.;M++XG[^_>?_QY:=W'][G
M%8$H8/OPL9SS;DF)C48R=C+5L[Q&Q9[%I?YWG)M$(C\"7A;9T7]VO= QQ/ "
M)_OO;?7K7,>9:H3MUQ<F7Q'-[5]'4>W=Q.LD35Y\C]SI(M7']'7UX>0\)O6/
M)D6A?H^#KOJQ9S'V17=D^JC_P+WX:5+]C]4EXPV[6T1>T\W.OO*-ZORTJCW2
M/<@G=A)I53?%BC/:QM9MST).(ZV)'Y_,FW6X+'VZ>>7-983$%-;''*8'CF0I
M1'+V?^(T)@6\TG2Y7G3A.^<CM^KYQX5G.NA#7&TGQOCJ\?E6%UP)Z[_'-UD]
MU?K5^M<X[>)4Q\?>U1$[IT\J1'4O26-9RFH[;2\CB>VG[_H0O5):[QO.>[WI
M(?+=+*5@I^GH#K^U.N:2^WH[GT[GG]?^1+N5CUFY@,LGWD\)_CW4XNX$:Z*I
M)!@C "$F@)K4-2! #+B3P@=,C2;Z\BQ&$A>8%A P(QR@B/HXBS$60"QM\$01
MI,/E6<S7&<KF'.9E$Q'@L)NJ_WJV-8EY^3D.K#CIB@/O0^B^;5^>ZGJ:YL9O
MYTT'=Q?RL]ONF,W$['?OWU[(S$YM#E)V=LJ0;OWLV2^S^95YV7MNM558-GU(
M>06!:>%+K^674#R">MVVR_/EL0L@.UGQB_79'59O'[IA:=6AG_FF"V!T.!OM
MO8G ?D\=,'9-R2GW-#H/!EC:<DBYM, @Q #BP4&A.)-!7![,4,>)O(M3<N=U
MG)++8(!B:6P+YHGAEAHQW&#N?OPSA8%FA[_'!Y\[M#T\(UDZ'Y[[/@C#?-F
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M\> @!@C!2(LE94 9[8 TP3MFO S8#4:+[[SLOP;Z\S "NHCM'U^?HS??1&_
MKH5O/I&C1>]X@6E2=^&\-YD"4U8Y$CS02@I J8E6H#0'CFA-K1+!!CL8Y\W5
M%/"$C]T4+M'8ZM,\DI<HN\;;^>$LWO<BY^K*O,]:'\^:ZE6U]^5LA:R7P_=1
M'A%/=\9NVBLX774RC6(M2'63>;K G9+2 B51-#7'%3"&4*"Y(]Q%/*(27S9/
M"8EGR') 3 J>6RB397J@L",6J0A?>BM![<WQR71^YOU'WYS6UN^>H;Z?KT9
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M$$F!9FEO/\(@4.:0#DHBC+;:QRD9)#88" D]H(9CH)R@J;ZC(@)JC1U]5%+
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MIMDN\]_H3 I#+VF1A:,5CK8'ME8X6N%HA:/=(D1J@_)22> CM0+4$0\D,PI
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M.V5TUQ<Y]P'OE\?Q [MR 889AX,60'NC =4J(B_B$A"!&!(*$\74$"M+5[N
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M,R"L1U%3A.W&JE5P_QUB^8@[+!_>G>G/!S+'S&TPI)OI,<!?]KM'^)!M)T>
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M'/0;Z?_9!X_ 31#YJ@6:QR^$,/KN)D*/I)]"S7ZC:XBNAP?LQH'HKXZ?@&_
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M#=J[A;B:"KEG(Q9Z>WK)OJ5@/QFYTEH3UQ#;6_EV:KZ$9B9HTI:1#@I'R3K
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M7F5>B&UHAB(A-2QDK(--KO]C& 5BUYMXZS?\V\MM"?L#8'JF@"'EP<J&:B8
MBL7 5N.PM2CTE!64&)FM!:V/7"%GF[;\J'J_Y80GDY@)AN*EI=F>;RWK/=<3
M*1>!M:!T7B\*G@=K\S#T' G=/1G6YE-0;J.T.-U!3RR$WA1K4Q)T!$/6@6-M
MB@#E$Z7N";+V(/^  GS1C61-,/H=B"D2VYLZ=^<9QF$,/>@GE.E'X!(E+H8
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M.\Q*M:IO:4J]Q'\:LK*?O[W[EB02$+=R!_29LEBDFO?YH!97T#*E)LV]\IG
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M?>$_#7-X:PAZ_9,YZ%7F+GY'UB%C*.BZ+VQU\#0HA4J/ E8PAFAAN[!9+3G
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MXV) 9#[R0DW+0IL.,7[9Z&V_['&A.+M8T^016/D/2?R2/>%MZT5C>!HKN$0
M)A+R[$EA;JAH] \;(XWOTJ6#V\#+L^[H-DVVF:X@XXX8XQ]IBN'$4: B^>YC
M_$K&Y^(!'ZYO+\I6YG'"8EB12ZD8ZM<W3;F-K#L&NV\(MC:U>71F%O.O%T1#
M>&'=1I ?"<%8+%?7%!Z1T=W-"I^6X@R*$8^1M)P70WB+*DF+J1_@T@%ZZ#Y
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M6;Z+5-3H4/;/*7>?#%PCR1!ID9-%-+HLIP(NJG"&$;V"CX,8KJ( YT\(CW"
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M#"ZGF(6!BJ+2XYN6J\LP@I,0>HPG<1&9% =6!M/&QD@Y;725W+N(KP)V.\>
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MX 4-D,L0O(=IRJ;%P/7=,*;3D IR.@]QL\$L 97&>\7VH(XG%? .4_ZFX2L
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M=9FND;%+=N)Y.=SF=R@@US*008G<[BW1WF,V-Z1!M7$NS9#H="4+YNZM'C'
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ML*MCRD<75+T[]R9 VY$X)BUGE"AJ@U-[3Y6G5'B;JA__C+G)PL\V9UP7CQ)
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M,E& <80:;3-4HP#C")796HA(CL1/1ZBVMD>G%( <K;9*BX@I@#E:A946?5,
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M>F?2_4CJ]ST-X-'/T(+_SL$"M:'#(3."CF,7)%Q!7VUC& OO%4%<0@5Q5))
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M''VH!U&FG"SU?),]O7,3?RMZ3U,PL%8XBO3#CP!N??R J6T2LX"0@?YKOG@
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MK6+#\537\]B==&4V11SI0P(Q+GK\@4)\:].>),? _6$9;=^1A(IPEU&<_^-
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M59.R'=3A^%J-I];V!SY#,K6*Q;4=?[/DNI SWO977&8M"=>Y;_L;,;.6HVO
M@.U/TR:P2M1H ]O?OYFE8W&#%L9X5V?=<@P8")&OQ^?3>IBP'I38BL+^,:@-
MV*C7J/MJHR478CQS$W^+YCZQ5ZFG1Y-*SOO2E253FP>*)&Q^9X)@'=\3!U9N
MG+(0N7I%UV _IC_BDA]H@OR!CI@%\),4)PX2>+B@^$L3!$R;]/G^IRG"E5T
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M5T&;6#.XJFE]LMQ_P[->E2&BF(LL1ZC5WE2&I6'KL1P0"9-1ZP:K&V8LATO
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M!R2R^3Y)0XJ-?G@PL;GC@RAA5M0[IK!7G54]N!?VZC.N/P!02P,$%     @
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MH9U[D"A5YTB-$XB3*DJ6#BD,51'A:[+1S4O19&Q?I<Z?)./F%>R_4$L#!!0
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MD 9P2A,5"4NLRN16!&(><&.HGJ%(1*\YC+O4IX%S#)2!(27: L= @4#H((U
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M* &?$4$J*08E,"VGQ"(1@!996K&<#<$WGZ,@+"RTY^P)<4))-%M'-/X6$HW
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ML8;BWN-W<4)>3<SNH:P) "B#AH;/]__50*:H4H P@%]I("Z7:AC(,TP: 83
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M((HG4[U!R](*VDVNS)JV!>!W$/#-G0#\\ XZ/OUZ6Z_6CMLFPW26#.(NJ8)
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MP0;;XIY;Q 9L)]C@+(7;.FSQCD16-7!7[K'"3X07F*4HWT\TPG(E)=A4+@F
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M2^"%T/%>Z%R1F6@C-[SANETXACTQ%K ^0P$J.,=:S6LXL<(6S%B):YZPFRK
M/AMIH<+*")2V_!7F:6T !@7+!,PR'9+?BYQ-:<'-.V+\;6PTT#\6\/+.4EB/
M.!D[K'3N04"(]@B93$H !M +>]=T3*6$8CC5UFUES3&5'% 90^+B8;8EULI*
ME4"%LLRQ.18\G+A"8B5S8@04);/K]1-5*H#LONH9;K4+.E*2Z^ $VW%.N)5$
M%2]"N5(6:M &MJP-4),A8DZJ#A[K?'6N5Z>1CZ]!7-MZHI.CTTJA %T!.&CB
MND2-&B_!YR3@4!"R%P6X"+4LJ;;?UQI(:JEDPIP#<ZZJ6O"@S(&SY4BOL\#6
MY%95TBY'SKWL&*>KW_1]5/#ZF#Q+["M:*FF<JVB<QJ A.)\YN<$LCP5L>0,A
MSTEGI *(U5-5&7!4[;L"=!0X,B.>$_%"X60X%S[L+.#29=U[^,3N72M'"Q3P
M8W+'M96P7A %9ZK1]I 'E. %T9;#Q_F8.@@E57NP&C5PKB+NA7"^WY1ZFR6Z
M<S]&I.?-#KT'".;YZ>'I*2"D(T5 :F:@%Y]CLXJNF?Y7"9K;>.GFI+> T8(Z
M=D$H.(#%SO)S+$B/X7RL1%@-O0_#/>)U#9Q6"-4)8N2 \+IVWO:A6X-S'Y5G
M9T^?'S\_/GM\?/3D]/G3G^@\W&!Q>74BO*/0A.J[1_D/+P,U1F6XU7>']+*9
M\IC/J$\;K_B@343KY9DV6.FIU];08Z.G#L]V>+4M>%G-"6NZA6VR_Q[H=Z#?
MOPG]EJP>)N0I\;,+MTUG;(WU:"/I NW6JG;A&9=0>%V.;",.?M:(@_H=\0I?
M=6LN <U&],( (U(WS@;EXC3;OHE<4QS8;;58ZG0!&57=$Q;.W@;3'M7DQ30E
MUTFSIRRY+5)T%U"F+!4@@D*>+I7%HH!#E9!Y+/*4^&;5,2HH"Y&DO#)_L4W8
M'!S].+X !CJPNCVANX'5?0-6)SFIH.IR6_&)6Q277HUD(3WUI;^W,'& NM6\
M++B@*['>6:PUIE1-Q:G?+E7,=QI:RI; 0@RRZ;FJVC=73+-8I >4S%"Y^WO9
M!?-S, &1L6S .PY[&,>>V7S?X9GTW26<$Y3W6?EU<<1&IO=W5"_6Q?%6;VY9
MG731*_2>/1UDWCV2>4^>'C]]_NS)T9.CQV>G1Z=_.Z&7+$&RF DW6D5%/XU=
M.J).YFD\=\INVW>X1I6\JQXYD-1 4O>+I#BKUC7%&Y$*!@^R6$43128FA:%'
M&"HN)A@IK]H<(SY2;BC<HL ^XQC[4O]4]9NVRIV]QJ%K$@_4N2<G9:#.;T&=
M7@BSKN$9<?\&SQ]$H3WV:%69-G57<5.1MC.,&CXG>]-&GT_*1D\'X;G71V4@
MSSTFSW[5E C7W0519X"!:8QI/^X+RO Q^ %F.E57@U6.%4?#82QSR@BKK\UI
M3QBH! SSD-.A=N1H'6A\H/'[0^-<<1LJG17K2<61&Y-8X8@R3BD80FF%% .9
ME))*]?#/K&+GM3YM[^N0L1LFK_L^HU,6G;V /YNNZ%'VG;R:^UE/L54_V=Z7
M5 P570/2]H/NALJO/</8$(GZ4IKL2^*MHE*]J:08!06I35V\2-YR,D1'<4;=
M_/AQQY'5G]30U<7=U6>=N3 R&FNJ3.*Z$N,*4.+ZEC+Z:ZV^MP<94OYWFO*_
MW7NT!OK?P:587[(A=0V3-<KU;*8B),D8RY%T2O?$K"E$X"($U_]/>NWMO#($
MVR9ON?O"0L[22NI/78H7QM# N#!\P4E=.54HO@<;E^.9)V6BL<<N5EMZ982N
M_JA;D-631 +XYNQ8X,/4,P@O0DX.JH^CC:KZO.Z*@OP#7NN@X;*YK\0(_T6[
MBY3@PD!XU,::1=5<AFC.JHK#?2?K[ULME0=A>:2)R+=>'?([,QL_A1SX!M^5
MB=FHY&\W2K$W#T $B.:L1\C)A-IL>>4^5-XWLG D]B-[GY"*N3"8KEO%M_G&
MU,_@BYCQ:=T0EFLU;UNEQMHSRAQ+$^"0F(I*I8PN]I[P\S697ZW^8IC+9:N.
M@$=@$VN7#=;4MURS4)S"[[Q*PW)R&J'!\FBO*/?7TB 3PL'88\MG=>DN*^VR
M+;RRGDI711IB42=QY[H&5%8C<"2&<G*))R?.H5M=2XY'TRD.--&(\,A(4D0^
MM6JW,E&N<YM(O2.$#)W8'%WJI83]6FMT2@&'W92;-4@<^.,7\<<_4N&:YU+Y
M//?4]/,A[PUK_#SFTN0K= F;;X[9TO-VC_N BVWIFFS98"*-5--;TE-=&]).
M63O0(J6IN_M3ZSNYVYM)7195:6F2AT5=!7@Z-UFF=LLJF1!5$CE7UQM0SJZ_
M*IIOY?(!3+X]P#8'L",!LF?V2!$K8>65+LH&=BSCIMIELWK]"5Q+,?PK,S$O
M<W>XQ?7K\HK?&?7YWX]#V(-K>8%M H+"L"GGJ(,(77J;-Z1G\YBWY!\28$A\
MI4G\'31SFQB<E=LYS-#V,*B \8U94R>]@378]B7$<%HI[U8A<I85ZD1$R%B9
MC/5)R)-6Y<DWJ.U65-4=W*O\ZLJ<Y-FCDN9LL,">Z3C)PU\S&G7*H#9"T:9"
M>*61CLL-'&'G'.&2HX;NQ%E90?VO_S9, ?\:4#,:V<0&G-%01:51U=V[$^0%
M> F1)^%J]P3=#V0;^S 9SZIRW#&PB"3"7&+%3<<KJP'[F_K==A)87TURI(FT
M:,3G+YW+T&LWAH.]P?1JUK)Z#;,R+TCY 5P#=4[TG'F=NY?67M;N%"SJ6VI4
M@>V8*K>51\/(';A^AN_%</T</ WKT/77BI<C]YPF'SE@'4P4)9\SRT$@8,($
MKWF*L>-I6)+]PCPY;]EWSX]$))>U<4</CT_LTP;@W'C)[W :R5KY:[$YUQ,Z
M0]!(OV$S^$/-Q EXVQ2[:IJE$^Q5;=O8(Z<>ZUO:V_)9'5CB5V")E=)K&YW?
MP;_^G2"CGU=>YK6]8+T#KL/=LFL.W-T8(VI@$@."]LL!NPZ'50X2:B0W;L (
M^!?V.I[/<)(10.BG45SJN!:J=@#..H<Z?J$T:9I/]O[O3<;"VT/1G<9^ML[(
M!"D+#<GOC&QFH-?BS-^F5F,B7T1U[<"1C^KF%3JQ=EW17+7+MDY#"^/]CKDO
MQ7]GY#4%H)^[&ZQM6,7"JLH.+YMYVWQ70Y_)T;B+@7+ JKU:84TP-!>$ P2)
MO*T;PN65RVYE'VS(ND@GBB(TA#G,0XVM:WF0<+N7<-@K"]M4$H$"2!C^<UD*
M]T:2?:&S$#6[8UC,$?WC5Z37K*&%.E;[U U>5I*PCNU]AITIR@2+)M:-002J
M$KH1H,_[@/=M4O"TU5B3=5BO12N:Y1S=)+4]8!6T$;8-L-Y1<I*!M*6/HT9P
M=H0XN5G2=W2/JZG;<1[BA:^P8HEA:KHTUK*<J$1$8#_8G)%< $9U5(8:%.I5
M1VP?SY 8,NZ&C+NAU_H^D**]OXVK7WKXXD(9NIFM=4ND[":2N%X>3C]J] ^V
MC-%:%+YKI7=F;HO+\>A^SFXS?E@ N+!(0P<G+1C!2[B=I.7PF=%S__YJ+UVF
MVSV9&R9'.BY9/W4:5_6)O<VG-@VPGU/DM2O&NUSR$@1!T@0O;09V\ 1EE*Y
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M<.3/$3>1%XHPX,_>PWLC#9XEJIL#G>%/0&^E^&(7[2PCY;:"48 V$?(MI/M
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MSY$-;=^N@F#%VG$)?OSRI*[#/<1V199_N7A26S,CM,"L_%A57GPN1T<AUW5
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M\-MRJ7V&&L3>K/MI,R&RNVH:TJ28/WT=[#_OY.2W^&5,0LC'2H\NAEF'\HU
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M-UW_OP"P.PE+0Q\%9/RL4!J'/VC?G#=TS;+[M"OY@VW5L\Q5)<T+.SY-;RM
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M0*6(PHH1%KO5EQHB(PXP)TO <ZGJ@AP2*)[I"&QF"EH3)=#8/M!NCQXON[<
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M<=^06,-1IR&E8S</$;@IWT(-?>;<?,OZNGSZ][7M@I5VRR6\[XQ-]T[J@RH
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M@0NKFT;BYBXF8KB<B#D*0W6%2B-N7(S0;V]3U0K!G%S^CL+?H?;!WKQ<B&/
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M?9R+VGN =R2K#UG#E',JZ46[6F^AM7'':NZYML+W/N&$)1NAFKTA"_M$AL7
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MR:M818>YP'MK=ET2C&[R]%RL7'(PA'E9/2N4<SYPP0A$]VHC+V(N(]UE>"]
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MQYZ'?;8PP+H.4RX@GVZMJGD&+BG\Y%\>F?Y+/3(5_KL],HG^@GL[1WX&0Q$
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M2&<S&P%@??*1P>=W[\ _<@=Z=_[HZV[&#^3_D'6*#O?WKJ;@+\%KD%GP#V^
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MOB6C7?@</.I\YR+#V(Z]5SZ@J+2L_=8]8]6HFLY?BMOJ6IT:B&$FG]^ZGBL
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MW@^V6(<\^P;"$E>$KE5.YJLA-#S\M+G5X6]FMS5\FZCNW@;;='U7A(\>Z\B
M6O:5.-U2\]#2T:XL=CBCK "5\9.X-2-G$9?C*8;@^% ;[\+L K=7F:IH9E$3
MZO9$AH!J(EZ#\*M6@8PADE4G8 ,&(?J]+N6//51"KG:-"JV^W<U>B7^X@3OU
M'#^U*F R=^M&&_>+$OAQ0")QD"8)(X:#\U@Z!_O(NKMMRHJ!\@>JSSAEC;39
MI2&6\8B3\L=?FIP?A;%8YFFK\_%<S=ZX>$)X:-EFE1:;EV,FZ$IMIN3%J&:M
M-K*=E@@;7YCRD<"FEBSXRN8C[F=.-ZK75/C?\2Y2ZJA+1#B"6<,-5\9"":"P
MZ4=.8E)VH2*-IUX]ZA+,D!%ZF'+.?5]]]/C_; O3(CK UU4F>!G\P0UF<<%^
M;X+AIL/W^3TU]&1VSC,#[ O=V*!*<%Y9^:.E(?EP;R,3.]W6&3=VGLVS*(B_
MKY=PR 5H\+K$K'Z98@<])M0'_7C;)",*%6-RQU3 DSXJBS]@1KG@"EY8:S )
M+_8ZM9(7>MKH>LKOGN'O",3T/GT@27Y5.B]>+GU+CC7NW0VSV@:2T!T<Z:@"
MD<L/^?IW[)V8._,/Z%?!:7Y9\!##'BD!F(DM1(XK-N*!D,=7CIZDY8KV4.WN
MNL:!;PNF*Q]QCYQVH7<]+IX::24Y]>M<]GSFI!C*+4=F>7_&(SR:"Q6!"C*J
M)D3)OEQ8/)W'X,5#2[5H!@/CLA%6S'F$[&IY:6S6VU."(4I!\NP.[&?:;&X6
ME_9MZ)PA!:ZYT%L@I+?=<")YUODRIY*4YQ,^.GZN85#S8LG CJDY57%"Z%VD
MY$=I-_,O?)XX_!S_*K:4V P)KY7SW,X#O=0RUB*E):MESZU;?KBGT%(_R+'6
MB"BP>>>$.J[45S*J9O)Q:0'Z4,;ATJ=<ZA^(4#-@0F3N"#(A.K($[ZD@GB-D
MI$%(!;6[M011 .KT6IG;HQ_9W2UG=[;)9?++3"@/4ICXN-^-I9[/TK8"9M*]
M%UPC<"[SYG1!S$0=T@N_#'C\M@SZIEC#+<$E&IJU5F>)S?R09EA6F,/*9JIC
MI=:(NZ7H>NN9&*J]SW*GD@AF;_6[4L/]+O >1;"V2S""MVY?T0:ON_8.9<KH
MVO5-85&#4LZ5>V/3=KX&)1_Q>-HTZ2+1@*4X$?';G"QL2*XBNKC6 O7RJ#6_
MDRVV]PHMJOG40/E?LFA>>>7336CT2\V[++R$,(Y=+:M@/OZD0@/0OTH!:NMN
MS)<L.F]I4?OD2((^.911&7U<K36G>D\!DOHR'EPSE&&!^0Q^VQF95! \,1K]
MSLFH@:A77G/9S+?G1LNT$'^G1 ML4VP->3S2K;?E6TCHRX:A6%7/DY&WCZ^+
M-M 3R=08N<U@65UU0<&4Q1OYL_$/D=@":?'3>J;<OTG1_[-T_(SL&;GKA:H(
M.;N,89%Z>(H1GP^SA+'UK]EYN?"AFBC\%JY(^^SW\XLNTE2<=RS3$H"XSN9>
M[3+6+:/"816&:_>:F=PW3A>:#L/:)..V5J^MU^Z8GJ9>G//34J7%V[F_'H4_
MO<FQ]E$O,YINBOZ*[*SAQA@SG*,VQ<O&%AUK ;MLF@H$IG/QU%Q'3?A?>&OC
MX'2Z2!E)[]JQL"; 1S58&2,?:WA>039UUDO'W2;#=%A[],YC%J/=^HE,"UC;
M9I@D]A7GS/BI$A,%_JN=:,\\'QPORKYGR0SNR5]Y;A"4KCW+B9;P5]J=G1,_
M 5IF<$Q([!D9@TL;2Q1HG TPK6-6DW*>:.B<ZX.-P!K%R]\RR5&G<5_=RK2<
MNR_G&61E:0$]_-K_9OXG=D4P(3:31&Q,P*^9PA!BSD(4P"CF^NH.;BD.X&V(
M5%6]O:WSI@\?2=A,9[O$<]/].C=&4!<V4\KA&5%::9<G#1)XHE5M<T3(5L%3
M(*7?5RO-D5:J;SGMD0;D8Q.5@TNJO]:%R E%X::C@O#X,-EPZFMOC6]NO']R
M)%E2EE/G""FP156.8XAT?XXZ'W>WW/B*](2&O58Z*_'[QU^$0Y8VEJFXZ;3+
MHS2?$:17/[@^24\ZRN<0I4VGF)OV(]JJCL&Q".73V \SN,;DPFYD#5[WM"7%
M(*8R@C/\G\!@C0"V(TI J>KYIC"WEDGJD]8+>7B7-),E_$0B4]/C-R+6[!Z"
MBN_.?HC,F%09D.Z^^<O5&$$!6I'/:8HG3%+]^9(ZAZ8=SR9]%A4**+NVE/P,
MG+PE9:7?+5EC8^@I#AY:$!Y=3Z4WGM&Y40<%=$.N]> WB+TIO7C;-Y@ZZJ84
MSKG+'\#;&KT$$+2DIJBLO,S<*<JD46PRDVK66"3YF!'Z^LNLRIK$8$*5F+=-
M:JCH\5>348/3F:5O"&_")@AEC]E'P]\TIRC;]KWRDE(\307C!K__W+Z@.Z04
MEW[2QJ1>6UN'6[;M]1 FI,3IG/U+G9Z\13OG GHQ_$8K-^C&8R#@_&):=<RB
M^(39"P/0^].TUG+4/MV'$PDEQ9J'JUW;Y%VP3Y4N^.GDY,PD'PO/F)V'BR>_
M*?LNV0%3KRXBM,VIS[@;+NXKYR=OS)V>O/'+=<^#^74-BR*"HLKQ<B) WJAF
MXS?PF[EO<2_@'K,-)=VT?&C[DNQD^AU);@&S0X5^5SJ&^.F?[("*=++9O_3[
ML[,?6+QS,;YSV3DI5;>-IP ;MP>>HP1,>L>[(K%?H?8!U#G61\<KC;-V]]=M
M3VG,* !ZC )<%_<=#IBU(*'6;Y7A=G@>")@3+DZ1'5)\5>)D5EP"L4+7[8KX
M PN%[M4@K!ZO0\\_8%N;4AO.%)$WX?(HN%K/G5W/?=@Y9^BSL>R4T>QL31U-
M%4E9R-57E>#-K7>->:V%9JE7JHZK>FL QOHB?1!^_Y;%4H7TUV)MU6WALC/Y
M7/[H;M7,5Q7/Q?!J6%XEC8*1Z$@YOY"M%QS6O6LVS-$B1?K>"]I*>;BCL*9*
MIG)"78R7A?8M\8*M@D\3)1;$:7[ON_X,C'12$\_9FVE%ZA6#'18DW]CC3/H7
M>=;=O5 X9E_HWK,X-EUSV'#>"H$X.'7/8+>[58YI;$Y,\8H?IP;IJ8_SM]Z1
MD0\9>49KYJ.TCD)M'2HNYK:'ONXA&PHO1QPSI[?ETEN0)#3.<SOU;1;PFFLB
MOTCVNO"!;:J-@_,]H56O[KE=9Y/'\&PVDQ@;GJ**+:2WC>%.#M1APK?K)>@G
M$<2*S47S0L #T'_"J)?0<\DU,E8""Q45E40;-[4[.>4M:@X-#CJR'E)V<#K1
MT]JH0&O-J$\W;DX!&AW4R?PSRX*O19Y-/?_"^&Q !. &,N95@E/>,V00.]!C
M#YUM0R:%PX1/77_-_#4WCEWX7HOB"5V29^XH@J,@S-E3?D?X1<D+K.6$>5)%
M?=<:R[0)>[.H.EUV^JRP&]9^W^8%)#\>:ZSEJ@S1CYF[U#3BG9!3]K@KR?@]
M+R:VNPZO5QD'@$6"X_B$1'1I>64.O4(/1'SA2=8+F+F:LR57AIG;YBWK!F&,
M"DOTH,Y_"&GRE^L6#*;CY\6"S],ZOU9H #USWI%JBY4-EK%A9'2O9("YM ^Z
M3 'Z"U)WSR9#'NU":''BO2/JZ<4Q;J]U#*V43<E'5@SK@N_ZMMUOS^FHJWWF
M=A+CZE>C@YX'=1:8):[AHS4959^Z*S8\%LFWS?[]_W9&U9OA>_I^HL3_/#(=
M^/9'OYCI8"+<CC07#T2:*QP,0<]L"L?]_7?8.JJYLY%Q\>"S6A(JFB1M@AM,
M%55D4]Q[B-?9;[[WYRQ;Y'MY?%8!LH>?-C\_YMQWMMHB-S*@:Q1<GBF8N!*Q
M709A5M 2WWORIEQZ:SB%.>SRVY8.161<[X+S^5O&J\XOSB!'+YI5LC$5[):5
M"KE89<]!.#;:3U!K0MCFA@;+C31G4O==AL"7M+**ZUHK72%FRB$&4? >5Q\_
M\7YJ:Q',.+AD"<3. 9VJS5K5]QDVI1D><715CY /W-1NUC(>)SPLE7OT8B]M
M?.KIB)69=1M'4=NZ[N:<-UZ'81=" 1ZZ-Z$C]TJ3'[2YTJ@Z,70EC+".^FN\
M!8A<7AE5*\OAFYQ'/7+'3GXB1+3:QGD4@^13YL!;OZA/7DV6$D4R#\U3@).^
MH+L=Q;-:R+,;HKO,8/"M*!*[U)BF"WVSQ/G+%9%!_'9T2'2TJGD__DLN\H.\
M9KAV1:Q.38_!<<X,W7< >R/-=D#]![D6S=4[\7%KB(3-Y++@1DFC^U4W/RUT
M-'WQ.\S_PI(N\N*NSD2-T:R,94NV5*K$FFT8'8"F^391%5P6[ #O%VGJI"X)
MN#Y-DRQ<XS9 /MWG1)B/1#:B7QD9LUG[Y7^>N'CE3.C,IT,G'V!S4C\AC=:U
M7//FVKR%_,54#U%?36W)$HKQTT@)E';\W^3=_SX2HBLTP>ESP9=%R_?-O-(3
MUX,0SC17/85C%T -%&#< I5+#M"B !A;"C"1.UL6_2%F5O$^!1 +^0X9JA0=
MN&>DI@@[EE8%=H0P*A@P[@9:K3R%-,>2698?U\V<$M[;U5DMR(04[V63N[;P
M8(+@Q=?7=G '6]/^6]:T>7W&?W/^;$RG ,&8B9AWF#=6@MGKIW:1L[@%"H (
MNTLW?*Z>?)I<XH=0WE3'26,::E:-]ZCO4("Z,++D;TI2&RU;& +O(+GO+[P2
M%.#?S#^9&4/(^_YC>JV:U6=ATD ^ZG@][TKDX/'V4-]1;;N=5_2ASRC _G+\
MED43&O7]VJZ7U92Q4RH*;)GM@S;R!+U'-#\K7 VJ2-R"4P!B+-G +P&S\Y4"
M8)VZS8D:8?^U5HD=9X\C>T.FU :S]I=C.CM&HZ>I_E]\]D.^O*.0*:U'GVV/
M,9V:Y,%6'D3].F/U-Q;W?^13*L5!YG!K^$H1FH@5$[&$&<%#B/5 R.%4W#AC
MW03O=_H1S ^HR_/_I%"7/S%? B^2OI53 /]]<4F/COQ/ 7QBOX;$]6T>PJSN
MR'S/W7.D1O^)N>;_]3"OGW!PC_YHUXOZ($Z0 7Y;IR>5L#_KJ]?MCY;4GS@5
M7)B#H#P*?Q8<<>\!6WS3-[9'>1YE*\4W^U<7KHCO*LD(;>PBK;Z[-^$V1.K(
M] (I@6AN<98/&&=4+#F8C0*\?6APD#:YX%%B++57,:'S[;05!:!ETCM(6U?T
M=)L/;!'#(#-ZF%UVJ-I/$AI(U(2Z6PTG[0]P"I0"K-BP\!XLL!Y/_,<4^]<C
M#SLIP(&6@?YJ]>XW^V9+8#<0\I7_QWU^A<'!=JCA44\%#?<]'B@)P+2JB'G]
M"_3#O\7^#<2^[/XU-+?]7-$$-$%M7TDTR+Z8#A6>AG3RR*KPWK&+%"#H2':A
M^:QC/O+G=YGVDTQ]ZYZ16E&PV,6,^265 I N/8X^0(<?[HQ[/%U7IJ"Q;X3#
M*<"7!C'(P<)Y-CD8*.&@J'\,L8A?[6L_X\\NU<O?[Z7$,3*3\(X_[]K)<,+^
MT&G]*VG,]*[5ZCKD(P:K95Z)Y!$RO8,A7<--M^PV"6QD_<;B_/.]&E']@%MC
M0F>VRL_^PR3^$'KB"K=#T].&, IP)#PQ;7]@?^A/ZC^CVOZQ6+>L@S-S?,-]
MCL02CO2R+8A]S+Q>W/CM=>Q*'AM7E#R'B'4T9? _ %!+ P04    "  [,&E6
M-2$OV"TP 0!R8P$ $@   &EM9S$P.#8T,C$R,E\Q+FIP9^R[951<7=<E6D@@
M>' )%CQH<(< *32XNP4/$+S02B! **20 $$+=ZC@#L$EN >WX('""[\\[^C^
M^O:X7W_]OOUTWSM&W]XUYJ]SQJF]]EYGK3G77N=A[F$5\$Q97DD>@((* * \
M_@ /"P YP%,,#$R,)T\Q,3&QL)YBXY+@X>+@X%(2$1.0T%#1T=)045/3,W&S
MTC-P,E)3LPF_Y'S%*R @0,<J*BG")\'-+\#WUT-0L+"P<'%P*?#P*/A>4+_@
M^Y?'PP\ X5.TEQ@X:"@, %1"%#1"E(=N -WC/)^@_&, _M- 045#?X*!^10+
M&^?QAMIG %04-#14=+0G3]#1'Z\&/EX'H!,^(7K!*X-!K&F)R>!&PO<I+OLI
MHVQE!ZG6.(*)W\H]& N;C)R"DHJ9A97M);N H)"PB*B8W!N@O(*BDK*VCJZ>
MOH&AD?4[&UL[>P='#T\O;Q^0KU_(Y]"P\"\1D/B$KXE)R=]24G-R\_(+"HN*
M2ZJJ:VKKZAL:FSJ[NGMZ^_H'!B<FIZ9G9N=^S:^M;VS^WMK>V=T[/CD].[^X
M1%Y=_V47"@ -Y3^/?]<NPD>[4-'1T= Q_[(+!=7GKQL(T9^\X,4@DM'$M'0C
M9N#[])1$-BZ[L@.+D5\+06KE/HY-QB2PQGS\EVG_L.R?,RSX?\BR?S/LO]@U
M#\!%0WG</#1"@#3@\IHMYR/V_\'_P?\PX+3(<8%*1R/%&(6W72S>E30]IB(>
M@[V"^_Y4+MZ-!P+Z'QVD"0+4RW;UKJ/+%U&Q9MU=&RS<TMUY_^B#UW1!S?=!
M?\ (Y@< ,G7R%S P-\5JK]9+Z0%@SKA85&'=1\6=70'2F7/H"9K<8G2_D<<T
M<X1WM1/L9=*,'Y:?:Q48<@M7_!*^;7Z]?TX*8__=.@)WX'$8^%GH49G3@KJU
M[HHT8<_T3).NBW5>=(,*Z+=/IHMR;0&Q[V?35 SGV'(@0SO_M345'.O"X8*N
MA+L7&KO,;^*4AV[R?G50E$!4?\5IJ1&Z*V\[ 3W:GDZXUJCC&,\Y,CW_ZL,5
MOOC*(&YTHHE=U7#N0\)7;<<.((D6V^.S ?\:JB5DRF76_N#O:S<\3R*]TJ U
MA6)+$P$%*@Y"7[*55IWW#)'%IE38Q5 DE_:OZ02Q%'6M2V)O:9)0S61P1H\3
M[5+ ?E A(IW A $JQVB',%_SE)2Y+^53%VC7^.I;3JYZ2,D2@]U1#[M TH/*
MBJV/\II?:+Q/W ,;RN^^ZL4G%696)MJF%W<>2[9!CF&A9J]:3#4%<'8SC1V^
MWJ4W#D1\'%F\?D9 VW .MV5"2?A15HB):>LU!J<:VY8!:HHMQS.=C!2^H[MI
MMW][;UA:TO&5+U:&$MVGJ++$X8"+]+DZMM!L(FDK#L!1O'1?A1G/Q^M)@TN8
M(:K=:19W)(GVBU2.+TD&-DJ,+C%1%'3=VCL4FKHN@APX"E@>_LXXF:@#[,72
M*:6$_?&]3-'3XXVXA?3W M@[7B2Z+\H<PL#TCD*V[S=^$E<<7%N+YOR8-TZV
MS\EU6%.8F\BIS[; 0V/**54J^B7G7C>Q;)S?Y1F1K]&'&'$<1FVR!))HO,J!
ML '^_PKX<^3L ^ %%^M]P\!MCS\S:*6W_0K+0?J\5WV+PY&.2N3X ? #S#.D
MCG>K6SEV*VY3H%*PJ'RQ6]/4]-&7]7I6<^T! !$RHY]UKFFH6?B2Z?Y#O"GV
M57Y[OL(J'!/IKX'P3O'QR5L8EJ@D.GDE:MTPJVZ]1D>P6Q^W;+BKAUA4R(BG
M%Z6DD,X6V-I=VBW.>&KE:W656',3)0VI_NFZFL(4IA]]B^S=M"(PUS1\ &"Z
MV#4B_MRH"\1_;_[!QVN%T7->VD[6O@E,OF]CO/?*0)C? UOE[ML> !? ;/"3
MZ\]IUWMF"FG(F#TGNB^7ETE[5"!!8DZ+J.#!*VJ?37WUX@"IX_P_N?O"?I!A
M,%1@(<+8[X8;8RPPG#;Q4\E/$CHREE1W=,V]CO3,3V\^PB;:($P )1&T5@>M
MW.#HF #!IS,>6X'J3$C3#?^%UM?V8GE'4F<L,_JB%CKOBB5[41BEOI7 *.#<
MY2U B^\FPT1I;^.H0V7$%R8:CYX\ /("-*N=K$\$IRKRP!ZXX$3G /L'0%R"
M^@, KGZ74=*H55*F4//U>\R1G564'T&TA(,-;464:E.1BJ?#Q3N>GXF4%Z*L
ME*(5/_N"N!L107&6.0Z7N->1KYL/WXFG:. U-]ZST)^?"<XBI5Z0APCH:@"$
M-(5I]PC.X53(JGB>F"V>C')T&_[=*/ K1X:[O"NS_IDR,]IP">.MQ J50B1.
MSS)+I:F9<0^M_0IA<T/@"=I8##X*;<-M"1@'N6"(R&R]@\*5!)(B61/9WRZD
MHMW]ELHXGJ3AF/<<>)&F7!,_%X(F&\8GYORC!Z3>XVN9W.?Q19$SMK?*8GNK
M#TFH1GP1W:LBHY_S?4S7X:?YT!D\HHVE!7$4OD[E[^LC[.YKI2$*1&."!H4<
M"_[8H46?NC7/YRY;9I#C3Y(R;E;<<U<8\NB0N,=HY3='3,._2+QPMBP>O7"P
MBJ:T8PHZ?-T@.K#IU0]G;T0ZK >*ABXG'9OU3+-6I6,PSJ;3_10H%LA]=S#8
M(^M2*)#S^_G[S#Z5U4A7ZIT@>C+AI'I]*H/8GI=)KS4Q+S<X_7PVBD8I2]LI
MN>WJ)CR[T$_>O#W BA[<_GU1H=_5_DP"F.WDYC _E:".^:U2E73L[L#WD.(T
MTV/$XWI6Y;CT_O6U^5V \'T($%:K3Y1N1N;(M;N278_8.I]=FQ).)F JD!:=
MJR;JQK!>V36SL_$JNY4_IHXUV5>Q#36<$([]K!D7"D1_=R*)A+]%&F7?TQEQ
M '1:LD(6705[G&#83/'7WHC#QPE0B+<-,#7$O_*W2X=Z0'N_-!0/7O-.ARII
M%JQ7E)<< GU6X90@=8VZ0*+#]3_FN<9$J!O5Q2)]LY ++@;_A0R6&5/EV8/Z
MLI"1+Z]>&+>]4L>$FYVOPGTVP&A*=##F/V7 [Z6,OK&5-.&ZMXUP>X3=%RA$
M0A@_E\F)>B'*O>1NJ6MR+IA@0]M0G.7@]F>',K8+^^Z%[1V)ILEV'HDF$/#/
M@G0+1L5-(R%NB9K.F6R<MN((.X:K5."L+R<_,H.0GB%EP[("0P."PV<Z#X!7
M8#0C+>3T2("1R^<R?:2P,TD0<6.#+NW[^O>4E0/8I9^N84.S.;,) =3'3\J\
MZXUHNDNI_PAG *RCKP"DM!OV(I>"N_.9A0YY#I/F9H.5,D1)5NKFEGOJ^6+%
MIU4?$J#?(P^D9CI'NE_5U 0O"C,!*=[>RS:H1_BI0VH[\ J@*(&B^IZ#">P"
MT$,L2H#WN;1R_BH\0JS]2X ,;;);X4*34F-497P8$YJHI,R!N%=).U& 5XGA
MOFK6+E^:.2=/!A]=1LI'>K1;1G1WT9+/K)0+Q8E&9W8RS<W.V<HW:X#O8RRM
M:4; )@CC"_DO3T\PO ]'UV 3&0@[_:;[Z98)6ELG;1>[-]:Q490R?04^'F>E
M_+?<#??##5,MP'6LK20*(SU=YKK8O+L+5NE$ZP#JQZ R"+X^ =_A<>A=97,T
MI\>%5\-Q%)+N?=AO=3SHNK$R_,K<"&&70$\<1)_NL5#&777)/J>@2MZI'BO4
MO4BB)"%3ZJ/;D<E1#_B*CAN\'V5^C>?_I^ES783"ZX]!B?QI48S6R@*6>K5
M2?B]W>< [FFX0#ME7P&9*\-^@%:W.LI7HN>TC137Q*9'/71D)DBP<O!(ISSD
M! %;AAN,68N<L=+;[9MYK#X KMAG5LXOA4_\EI'3.-'F*NG;/^TI,0ODWCT
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M/*(/(J$9%&#IS12KL-5%T],1I;9YVY-&'R\B,BK*6JMZ7.#ZM*]DM\D\E.N
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M8%;.IT)KQ6==])M:TT_S[:'4,>L5N661B0+1Q U[;/^]P_1_#E2I06472$A
MBRG*8?N=XTK,FT2T7 SM,<@&^W3B69V6C9K&W:8DGDKTQ4OEA0Q34KS:(7U-
M+(;W,1L-UU/3*5G_8E4?93N(>\P+#\?H,2%T=46D?*6K-_K47;KT7>SFCG_?
M5#^L1;,0E*MF7/H2$(NR_;IO^\LUG:O<V,STAR &!/4 ^*YY3:FMHZ28<_PE
M#O5RBR?Z#<)_H]P^-;XFQE!6)V];U51R=B_F!+): XW08.Z[<(5P,4T(HJ]6
M%Y\LK$R#-8],AXB[/+"'T8LYW_+!GV-H27XI_FKB(U2H1TK>--2JTIF*4?XB
M_D:I-DE/U$'(V>/<,MA)BB=<BBCTDCN:4/I/_X$TP_24IFQZLH:G0[T/Z25I
M6<T^EQ =2^\$COT#H!G74N:V9)@D:A!B^$47C2GA([N*$O,[+LWIVD@\ G7_
M)=DURU#QS+) P&%@Z;?9(&8',4^8]427XWPD33%>_5!SZYS7->X]:48^2%CG
MF#NG:26:SGO98E+G-@YZ$0:Z]I(<=1R7G?_YQI+],J"F%AQ\SN&@1]Y.6#M7
MNV1$C!'BV'?@'?T X%+S@VGVL;;Q[IO!HG"Q'1GD(7$E)6R=)5$ R2=B!5I;
M9]R)W,"*\L-."%NQX/]KWWTY-?6&+JXI:"LQ11"1>X221OAX7_+LA.2,O<VW
MG$TN=_>NT.,=\[MSS"?1L%KZJSKR3Q^>_K>@().@J B(_X#I][.YA>\WHXC:
M]DRJ/LJL3T\UM0+.4JMC-(E>L4%L3EY]: 4W8ZC4Z7=-4]KLW+GRT(Y:*+%,
M<)^;9)4?3/GY]REC?5$(N[&_KTO!L\ZT/)<0>K!8-6UTD4JS375 7D@\)N.>
M;Z$;TR]YB#^00=GJG26]R+R":&GNFZDH__O!N=X@Q.CO]/$/U;:!I )"U:-N
M%Z -%C/YR8Z-?3W&\5HLG_=UKE]CW5]O!JH+F#Y)8QLWHO).X?I]F< @5D*W
M?()B/@(KV24R4!R!]"[0<U2C*O5=_5'>NZ#CJ!T:9/_3E@#VHHCG\&;S(Y+=
M/BTY71AVXDF6> _=<5C4>Z>C>S[N11XY1%9>3[GY$<RY5;XS:=+EY/W]5T28
ME#<WN2MFD:2#B:/8GM6XGK/G3>EB&LCPQYX[X':8;VO"7U2B^<N@$!_*ML A
MAV2_4\0Q>8S4@/BO74O:-\QFWI38@20^UV?E[62./ 5(OW6#&.8$PA=GK,6W
MU68R)A1#;[(/Y3SV&GS8\B/4"4U-6=^U#TTE=*=.5;DZJVW2MG.&*FR*E*OR
M](EE?(74.U\TB(>O_;B0WM!&RBE7MB..(!7<Y1.&SIR?8_F]HMM<%#8Y8N&2
M.L4X2BH>>YG$F%^V<]E5EJI^<4V?51Y2!66[%O]2\'&\67=#ABS2^37$"S@G
M"FZ!"6HQPW63?M0?%LK^\!-[ )Q77V&?E5Q\. \L(X&.\IL03+FIQ?L8P^5D
M1?5T^_<7M?<%#1X#X+ 91)/]N..00SM4//XQ<)'\S^BK4'7UX"K+44S#;#@(
MJIWX9:[@3ZO_V^TR]J)""T8RBIZC.%>*?Y;:,%GY2U/G0!"]%4K-F7O$<T[J
M7B78^J]6"[&I*B(+]KV7Y?-M2(<"ZV/T=_R@G0W%0>0_"X<FD4[=Y$U.Q G$
MO#;27QBA18([7W7EW6-Z==FTBXZ8B[=EZ2!BKCA2:<4E9TL?%6\3KL;O*H]5
M[D-;>>[O>1X M'!@3NF\+Z-TZ45ZVP, B9E!CLPOPO4U,DO+O-+KVSL;1VSH
M32\*1[1H>GG1:;MBR&XO2!#<;+720B1S=[,"]7@VG*^K&=\@VJ+7YNH<ZGB[
M-RWSI06BSZU'UR9J=W*RZ\[MWECEE)-:Y$!>XO[/*'+_4X7P*L5*>=,1$HW#
MRFQO$<T!P7!?[UD^/WFIG:P4Y4Y34\FA% GZFU+=G9P0LL/'[43]VP$1"T"D
M!CB2$:$43/3UV4J@HEN**?PK/O%P#_594<M+&Q4#2:OTF!XGA^Z,M)T=;O4/
MEC)(AA8_ %CJWG-RK[8T):VM@PY%V?,2_DSYZ8NZE@2FJ22-B 0Y>#2I+K?-
MG95X3];6#GG =2SFSB^*':IUF<J<'.JV)KN79>@\ZZ2^B117>.'T'#-T5[4G
M,>D0QGRF]LZK:C=5Z-90>W$2TYGG,@*2FA;<:N 2I-0\V(A7'"%ZN_H)FL_E
M(NCD.E4UUAN@4_9ZD7X)>7:OFS2?>'EQL2)XO/W^Y/1D0V3WK 13NU$,NE"/
MPATHTE<X4=.^QJBZ;#^9<R//NV4'^PV;B>3U8#%-U TPQM) L3]9,:$J]2@R
MXXD@8TZ\K63(BO*DWZC5F^!F:CY&5>6P6? .;!#T.S4A2XTJNG ;8++#8OGP
MNF\BTLER21#,IU+ "RI9E#_( 3[_(8(W"R_7F-Z,-_4_&.7XAI/UJ^'/CKB>
MOR-_6PZ/ 53@%;WW=2#[2&X9\ZT%SAN(2; -)J?;0KXXKRA+BG^W<+W>91P0
M%TYBB?(<G\]#?=J6566R8DMC$D-/=$/BW0/@A:YV]XMU8',59&TR-Q[S3&):
MI=7,_V=#H46VE84FILRHG](K=Z,]EY0$/3?FF%Q.XI('0(EUW^^5\Y)K=@GO
MZU2ERZG81V/A#P L$GLC1<\=ZW3H><H#8-_NO*3.J&L^?PS4,M.P67=@<?KG
M")@1/@1WWTHN,LH0/^!79ZX^[$_$YQ^%.Y:6&YLLM$@%CLXSL@?42[H=78W;
ME?:XVB>=SO5\>):17]D;E#4=J**=K!FG4I)#W\EP49#0R%6A'7E\@"<<%@E7
MM%5P+>1X %1CGPQ>&J>!*O[DUZ?X -F_6AXX]7L=$2S9^P"9M"X.P#ZOJ%^=
M287/MRP&L@[_(>N;_] F!JL"&8HK7YK9E2+5NXRD<M=:C0)1_^3631W,+-L7
M.@\[LV][!\KC@Z_[H!S';_V8Q#9C[3'TJR+>!+V/;AYVN_SF3U5L7>YH9)/_
MNSQQ,;8#E&G:R:-$/GDN*:FJ$[SL5)Q$P>C 9!VJ2\G2R*JIS/[2T?_;>^H=
MO0RC1![R^L7Z(R?#P&VY50-:<^(NAJ@RWN;*,W3G^]J]VE&D=M?*G#?GI,72
M< B+&-M!3A/V^?>O&6+>_M5K_(OO>4%]['X]'*S+*P@#K5(2B\$/0&;2"=!O
M9#Y1A7],3E[9M%44I;I@T$OTTKC9AJR:0RD(6Y[&OQ%8PTN_0ZCE!ZXC0>/G
M#E#%K88WUDCBU+:RBNROP7GOGH$8/I+]/T(Q1WK[<5UB(:AJLBNA?*"U":=V
M&B7:QPZ0OIWNC?%13.RO0, >>M&8M^M>9A16;./ B#=83XY%R3B%JD"J?T_T
M ,#]ZU0Y[P&P^AY\JPMX/_X68K =P1P&C!?6Z-]QIZ#]3+L.^T_MQ2'K[62[
M]P23:RU3#(WQHC8GB<[3AM7!_G%]I/CU&\[\KYLFG ]SFGRF^I]]BU,T2:03
M,K ^PD_)6;/.^TO(5!@;'!_&Y2N/O?!OG W^ON$(D^V[MBT*D#LF2?7*\[,I
M"V5M,)T0.S>XMCX6O8WVU?U@Y>9"M!FV/;7YBX178#I ?M1F93@SA;Q'W)J>
MV,$]QRX^/DSD^IETAM>\5'NATW=*3CO<GY<;+C1!N==G\.?3 =(^N;OSIG^Z
MNL?W7J7D/%5B1]D![?>7^'EG>^2O*/@ZO%"R%L6LI V?HNJDF(]++''T$XFA
M[=3/^QTZ?C9=6^@/DQG7J<F0YS)7KFN/#$WA4[A4EY5&B]-WFE85] R06&-3
MZE0>MA<3I7V)EDMJV<_0Y"RM83R'^%!5=)4\NZC/HP[1?UQ((?9!=SP\$Z6Y
M@Z(2;_)=?W*;N*"3!X"F/@>CQG\L_+9O[=9!+<QK [6LFDS=5Q_DP3&R^/P'
MKY0N2%"J??P=++%23_:>@\+U4U]'7J6.1/8$T60, N$.,5U52[WJIW#863EY
M=SOQ>6/%NP:^]XPCC=_6&#!SBNB@@$"G_"DI#$<-@YHZHQIR?>S&$R-&VB.+
M7Q)W;J]IMY[2/W,GD&5_GE;J+_)V5I]0YID(#T>H)C(5H1Y&^VK*4YU(+FM%
MB</01&F3(I\IS5<4C39$@A!Y 0<B.QX 3!?[]\W !T"V!J;V8QBB#7\ R&2(
M/P!0$VX=%6N7&'RP\$NM&6%K*I]9SP1/^S[=TZEL&#L-Y$YIC1F+9>,1!OY"
MOX8JS\]*X>P9Z26X@9V+.WPN/!UH>3AS2=%875E9%R" RT&.7BD<9,']^C68
M8$GYU+B,Q9YR@(7OZ1.9,]'=!=KSW..TGF0QF_**<&M^.>8)2A<:_.<_1U"W
MQV(][@_%4P%G(66[5ML'?5K5IZ?U@Z>SWH&\Z=-[5]-2)(ZNJW'KA#YTJ18W
MBM5S[M:]!X>CIBT;=-'>=!@!AAY%0(^LE;<3M4V^=2/;7-4B-J-93-9[_MB
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MU<89 \R:16:95IP]YQ/3>X3&H.^7\[Z@]4>R;J4IU:R;35.NI"\;^?.ETGP
M@(([,M]--L[:>GD%0Y#95\^X&RFCPAG1Z;D\K5?G89W'[=1+@B5J;EQ)@7ZO
M%G&WL^<\Q*@<H K24/L."B)O>BJ+M))V-[D9,IG!]6!I,<J6I&/FG],B6))%
MGLYZ2[%NIJU1;^C0Q&A94-U#,AXLKYXAF^DY!-><JNO./B#&MJJB_;6K1/DK
M3 P-)H;BS%\X<A[G4K!LD_4.2G"IB(7+S)2Y)*M_29<$'@ID]'T]:S^GWS*Q
M: GD;;!.Y.%'W_AAYFWV:6Q<4Z;O/3,40YI2JE7FJL0?X]DH/,/?]0X#XGL=
M;I_RW0?\)\!<J]' .)H<<5>L<J^ P\TNI++AIN#XF[DDU8Z8M(;<&*4,P-CG
M^:U U-LF?/UP?AJDD!=Z,H0+V0/6MZ;QYL;3[G$Z):QGAP18Y$7%C00]M1 *
M%-0W>.G/^)&-*POKV!QNPY2MFZJ],R1/W^PME Q.J.1 .GQ%[W(,C#H/Z)+S
ME<MY7^93G/ZY<3 (G_58VJFI6J9(6;X#NOB*6&/B])6(WI]]822L5\^6+'S'
M$'1^>DH^!M@_P43%^T/K^"]$4QVZ@+NS/B*RRB1(^Z^RY;J_LQ%54LP4I]&E
MZUE.8QM3=7ZB^0$#1-V(MJWG'Y'R?83Z7V!V4"O]_NU0TTW!@?>XD2BS$<^\
M3TF'$*NGOCZC1@1_>#'2TRY56V,JHDO47XD*W 6%G;,50!D4'E3QWS"/]MXM
M#\6L/SHC00I_23)^Y4#O)+RX>N\ \/VLF?;>X?@A]Z,G.^G P'W)P/TXVN1B
M90$JJ$#_D%?\+]'$+VKC86-OC'4+6._Z0[)&UNR-2D63Y!*S\7U,@Z&B>V\M
MA' ?I^IOJK?;MKE.GJ\951Y=O%]SU(5HI.'K\_ P5VI8:A!1\07;0-I&9I2'
MH-S!F1A5SH81\8$_:T-CTA>=&=8%U>\#Q,5;) R3K9B;*(6XD;KE0TA6IQJ!
MPN<$<]EP]"= O&'-$\#@V52-*SKZ\Y+"ROQQE>MEX"F! K@P0^^]QQ=79_"
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MJTT)H:G R^-^=R?A=R&\!!?5S2\0E20=32'WTWL8TRZ]=2=*G3ANJ8]RNTI
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MK?8T1"F]]M?^!D>K(:N+:NB<7^JFQY46&A!*02K6,G73I\Q*\(ONG X\VJ+
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M \J.W<ZNJ.K3);H]_W3 I:;>5V UTF@C#AU$8.?*H_NN.1=TVH*4'8Y";J
MN]TE#AM01/"MR[TW"G 89I#XEY3\-7[Z+RD9ZLP425?J#5A5<_GG_<W3UM7O
M+JY367\5B;Z/AI7$ENU[N]@*DX(Z%'CR-5142'D$L<9F<&BT8J$O;I"LIP(G
MFH%Z%MCSR-*".<L/VJ;!//VIKJ# A6K!U+K2K"GQ/'4 $SG D23%8>V(Z&IS
M<<G\UO,\)H:UNG<00L0MH8EQZ':9@'A):=OQ^+ETGF+:\C+72:V2J>:F[0WG
M][?VX5YU)6;O)E^.-3IE6R"?SG!4L7'M*[&SY83Y9L2<4S]#>V%: ^ ,OSQ6
MF9L?LKK2MDZ/7B$_2T'[Z&Z<+6&<N9>D;9R[-^V<C+R>6]6Z]K)[3/HTU?AO
M5\#6 _!E6\L%]D$RC&;%]_?B@3?U-"\>O2ZNEDZ60GJR<*B/W\C=[%6IHSRW
M8H22EQBK=?QE]TR=EII,1_A38\8T1 '6Z57(JYT%H/3$_(%0X\97O_.#!HHA
M$/Y.DFO)@?JT*.:\H:5R60,'=729?E;)6<&FAV\NK+ Z*3LW1)1(S[R>IU0T
MTR+G?8PX_2<))B 3PZ>8/^'<!BG_S&HOI<+E^M-+/QI<:)1M,:]2OS?O59Q4
M-Q#BJO&F9\6<(M=([V:EX]:EXR#L)97AU*4NFZP<:YE4HNK(8WLJYQ[5&=XY
M2])ZWIK6(;'*UXT>S"7H_HT+VT2OU,&.:!$)P9=/H03F"36OMP^D)W9^_TXT
MK98RAD<E58GXI4PE5M16^EJI -[TD9N\<+R1Z7I%>$Y-DHN(U$ !_JA!>V>
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M#E0=[/,,RIPOT:';1P9^WX;C*X2-N5@XE4//PT$Z+60<G[.;(I*1#*X^52@
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MS OW3W=*<6T---WIZS1DLEY)_H6FEBC 8OS#%(*&N!5A;_T*AC9G+:_XN%"
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MF$B3!B2H*+S/]%<80?"F,\OT)O[/U]"@3# =5YMJ,VNMG]87V44;2V$5SE<
M>R](+V4<CJ)CGBVY%B;#WP@H1*:*=GL)\,17WG5ZQF N>_XS?,=WOC[6EDWP
M&>E=YZU*(>!=/L9&?C.!^":VD]+ *U<_UX_K3DMUPT0%)QRAI__K8P\^WN4K
M2+I[4%80VG,,RA<O@GZ17E)YTT/^KRUQ&!+TJWO.>$H3Z_M]:C85MK>N1TP_
MA3\-><\_O*K0+;? /&M&RMW]73CA36IVZB_,S3IEH;?'MY7993EF'U:%@0(=
M-T_YLY1!4FE3S>WM.MKN!5^S:-<-4ISTPNZ70S)%CDW6&_\A,#',)IB<3&T.
M8Q[K$,7E7E;GYY%IP)FZ7W4V.WM$HF4%\'C+YPI!^;#):E666=2ZL'(]O\9'
M.@+FHT;8MH,W*R6R'6/<SP)TL3YOQQ#1-YQS? ?F@.UIXRG"!"RI%*FB:M]$
M_@9VU_/CKAP2B>_AQS9*M[JB>RFGN_W66]^V9-]KA\#\%P^;F-RI(OWJ]XVO
M:[&L86="7\>^^#G-7@<RZB2!.4;RB['070K'.YWV"W/19@(/2^8++WK.@7VU
M>W1B7;,)5>.5?UC._Y4Z^)^8XH+00!## =^?IZO3[S[K;G>%1N)?I761EH5)
MQ7+."R3+V[$+ND/W)R>\\0!(@!4$K=HPL!UGX]#(0FB:7. CP+@T_VF/[@'9
MK(JS/E ]B*@+L?P,/A5)% <VU9(;<.?EWTF<E>S^;C(N%<'PVQF1+!-HDL3;
M,CC?6ACS]>CK*%TK:#$<-LL,WA?@J+ORY(?F:48[W84C9_P&[ERKV4S5+0,@
M[!#MQ9\4TFVO!8^3GZ#16"/][X)CCKGVO/W8(;6VUKHTM0I2QM<"+'E4T/WJ
M236&E</EA;W76;&)6WY[O>!;D*.R_!HY\,KR9O</7_/G/VM25+E"HH!D0+#1
M/Z1)HWV[^0M>VE/TYH8OH=+$^DH0QYD( LAD 0I3CD6RF#T+BVQ;7\5NASQ?
MV(V:-RR'@L= _('EXX2;_&8/IUBG"P_/4C(AX.#S(-"BB%2E?Q]$>)'GP"NM
MX,:@X?9VSY.K3[,Q;Q;/D.I2J&.IZLI!,SGN8NFL*F)KLX]+Z/6HP_DS$I2$
MP.,^[MI--R_\K L9JR2A88)E63_\C8;A\'/^:PW&A=GYK0W4RYY+FZ-[2VS'
M9A6C4Z0\%Y+I89OCH@M%MQJ]XRH].,JVV\9E *>5B'Q*7COA(X#4T-#+$%AB
M'V,.6?YJ;Y^]('B0FL<.Z>U56(@X)KQ1 6*Y/+ALRGCJ!;VE?;;"3 1=0LR_
M]ZK>WFW[SAZI'.K+1QP_B$%4)1CK.(@!7#,U2US,;32^"%%]$X@CONR*E?$(
M(!XK!>I6QG005WE1C'\/<25E6D ;V6I=OR%UFS;_+VH>4DQ3W1.Y\U]2]V[J
MJ?$4%/\I;\#:#.U$;BE'XK0DL6]$C2":NVC]#+_H/_D"E*PJC)T )"G.ZA?[
M5B#_3JE^@8]9NR+IF$J_*LA,R&0Z3P%&$\Q$%+173.O\"A)KA,F.-!E7,H^
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M*@R.D)]T@#.LM09K*DPP?9Z2M/(E"8IC[:08XL9.!)R1?(W6-#<,T*57?5]
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M8#SKP456!4MS-#W,1&JW><^QAI(<H8[N$54?AY I] !@!,68F5JJQ:'$&Y.
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M *^M5/#ODZ&C+H!*.&/C:B913"[@G8X)%KN^$F"'''YH-!I.7S)2\QE?2T"
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MY"RU-Y)SE%K.+;13NTO-15NEU)\'I:K; C85(&0W_VE2_CO!JQGYAIW1C_U
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M76+CK/5-ZRDS\M$3SF=CA];)T09K*BOCE43+1D4AA)IFJ/C+Y&9P6X4/ 0
M$+ZA %%P8?]U\R7[[QR\\R\;\,.,%(*3,+S:X@BM>V'5HP0?WP-)(W$&/3[R
MCNM"SFD"\_8U@KY^+4I*C\3/O )H45?7TO9+9H^OL!4&\^?H;/$]./^F'J60
M*+8U1M].>G=N0!X9,1<#;J3AJ26C^SO]4[5(P?<_[WT\(^S'-LVW6QOC&<%"
MP03,15ED>&65RT)55$.,-13)"H:\.CKILWUUH)/B%#/!#F@W =&;>5X]-151
MHUJ/-QH7X*F5 <0U;\6RH]2@XN;LO[Z[^5I? 7RD\3OR**@A!:</7EBA$[RC
MO9$\+TO[E%.G'[YX44:L%%">&:"I8UE:!K1#;N12:8Q9L+WTN!>?^43![VD=
M*.>37'GLI=:&6([=%6 T[[XIIU# 2Z\$P\,\5:F]<FID-7><&X4F)4ICY50#
M!E,+P %*< 23_-WWAS$B9LM7 /C]ZAI]CD5MKNED3T[#Z<7+#WHWXQ(ACG=7
M55AY.P:!XDWY.Y,Z7R_S2-76PQ'"L<RJ(4(U_%.U.S#&_(N5.=@':@)"JB6N
MC03BWBJV7'LCMC1*KI?5E$@! ^\K0*+B_T=F]G\$J:-^N>-Y52\[U8'GI,D*
MU=:?8E<1;2E>3&=1WCBP3-+[7:&PP2T\B; #@?N:T\6:P9B[%M[(FQL#O90/
M]4N?8G*SR)ARF-;U!!ZLFE*4"\6#8"NI& V^_G[)8.WK4WR?EAVRY2U@3%R/
M(,"-2+HARC[/3I-A[8VT2+U^G1]S1S2NKS"ZV]&_\1XRVK$[:D3#NU#'405L
M')HQ2'MQJNZ%:_YF, 7HEMA(JX%A S(R*(!<,5*-*'!O]B^-R9;F5_#?^F)C
M8<R4CC#Z4#ZE-!_VSDRMSM&[V1>1$(TH<9\K0'[TV/I;[6&USV01/AC"A2T%
M&B][#KR!;7B&^0]ILB&H<EQ(-&W4N%ZVCAOX9M]>3CP5?%MZ 9WUF8-]/^3]
M?$Y1W<H6*K5 [EH O$F'BUAIJ#YHA(2':*"#"=AEH'!3K# VF$U=QL5-ZTE'
MX-9H@T(T$EK;7EC8<C'.#)82$#9S*1[$$LL@0)MF]HI))B@2;=9]'$/_^ EC
MZ@>O9+;/Y>LXJBX;+DD[NK.D><UM']KLY$.U="2/&9Y[V46I#<AO./_J@/@M
M2<UKW+B:^%]02P,$%     @ .S!I5ATG^\7J.P$ 77L! !,   !I;6<Q,#@V
M-#(Q,C)?,3 N:G!G[+MU7%3AMC^\D<X1I*44$)"2K@%$I 4$I$L$)8;N1D!
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M7F%=X\=E\^MO8@0FM[AKAEMU8P[;9=M[)-\7*QRH3L]%,*W;FIO.[GP/ZS[
M8\,%2%2 /65WN?!FZ0)X])M)[@.N)]&*/^9)2!TS-W^ :&<W;C$M55)21"J$
M$UX(61VFPV0<EHF.=;PE XY.W$RH$M(5*.-(>8Y\,.VUV$H1*C#,WZ+A<[I2
MIYA4[-1Q+SYF1M1A9Y@JJT\M[GQ.Y!H+C+#=K!1O#(,9/D$!FE#ZJ/6Q<NYT
M+RJF-S[=!T]O:= OY5DRLO:-IA3M-ZZ23?:+^G<_5%NP?@_[M?-WO?\&V+#<
MO6CXB).OLY7FQN=7;"C=Q6:G_@M<1NP8W?I^8(/ 9<CE7$Z_*;U+:I*;\]VI
M+>=A3B(K"F@=R/&'QVJPO'=]H[D8N\4B"U]G6O)#,"W1ARJ,_$945'N9][/<
M65=92)?><O2[Z4?C".W5>=< PX'&O#16G@#2C#1<)G/*$70F NVX':?2K9+3
M)<3S9+8:;E!X0PTNUT?R)'H+V9-)6TH&+L'SC?7 L(N1$.HA9-L*(8O&Y%53
M,B\M+)H/0@:*^@W0]U8KY/KM%]WB>*( (P5DOH8,Z9N(.^&!OP7[=@MV-X^[
M:6]2\J=1\&ZCQ<4CX&0)!2A>DS0KK>XQ99"4DTWIV&0$4R&?[F3;ZAJ<5O0W
M?OEBF/;31;_%>,VWQ:K6TTL*@C-+N9GX3/77KUGT.E6K'5_.^=R,$'Y]"^0&
M]V;Y* /ZE7:A,R79EA^5/[)O@DCX1MH)!:#EXZ5.A"GV$QN##G;>?$G;N#0W
M7"F_(JF.OK[0.Y6,4*"&)_=_06/4(UQ:]S*]GEI\N)8;%;TZR"GN/!^:7_=)
M5L%%D\GKQ$]Q>-S9QW2-(FQ&9]+FE];#A+2!F""*[T\\MV<6D@ND.FT=QZBT
M2_$F3673*R<V%&#O%.:V7RHX^9O7;]Q%54:W$[*=F8D]:K< SHRNVD('^YC.
M1Q%E4@8$J??$M.RZ,_!&UCCIV [B?0Z_<10NO93TD&L#HK/.RZ2[Z!\\@=X&
M[(KV?!H/MXNE\M4E]7,)]'2F%<Y) E-PJP0U/"7;/J3]DA@1M[XF%'Y6JHZO
MK-XY3NY88NK^F5FAU_>RHE0U8OD$9T)RO\EO1Z ;GFVL2NG>.+XW,&YV91ID
M:JO[^9V3__DM>RU\" 4P1/(AF^J0@=H#7U9SOT57.V5K.AFRZ_2,@8W7(9SD
MPW-=7:T^.6J88<85K^9G*GY:TW<V-94_E,JR\#2<^<RY%7!TP3M$P$.?$,P7
MT\=8L'*JW4R& AYKQ=YIR*!>4N/[X)S[QK/SAAC]4F#%&Z<9*AJM!U\,:N1<
MJ#5-56!I\TH^L8&9[I>RL"??K:V#!H9^M!V; O=YTJ4D:C;GLO<L81\.J]VG
ME9\;U,651CRH2\\A^E8.J1IS+I4P%4C\]MZ&[:%;U[ULTPD&YW+RR7.=:NYP
M-[V$;D>PO4$5[Q.A^QHTYOMZ:E7QFX8$/$56]R_*#VV#W>OA90J'7&!]<Z'9
M;.^G+WX6C[RF<@/D:4_'6_ U)JMOM5<%%GL3@\4T:TZF&:?%ZQ^JCC> *+Q?
MA/?H/1\[&Q+<]CYA>[="+BR"IND4G[Q8-UI631\XEU SEU"?*)2VCMQRZ-O
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MT.!LEH0Y5+?PW>!W-QI&I3;Z%/79.5'R/KJ?Z1V/3]],>2[NY9R/')8\414
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MO9=6<KA05P:1@(V^PECKB ]V_.;@16&&[6ZL*L$&'2Y-V('DJH(W& 5D>:$
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M;*-=0AP.Z4GN"[>VY:C>/U1Z19[R5E_,+>;%312T0\F[;U/L1\-#.3'<<J7
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MJ7H ]62$%^DU5S_2MU=S<O!B->6CNT6-X/;QVQW5T?F>O88PHQ1J,2I:37>
MB9\-1+E[6Z )1JBD3B%2GT4(/I'-AS!S"NR^O_U#_M=UDT3<]TOSV( O/4%S
M)1R^P0 ^!=ZG_#WG\#.#IQX)7; Z/ 60'%BA8POD*5!)0#X?AO7U2SO/[,?
MI=#U'D2'^N.(R$ 6G'W5"?2B.%7")&BJ8:["+]L.*HIFMTM=6F&>R<)-QJ'>
M4:/^2WT)M].9)8'5+XMM4(% 4&;/F+A&-A_*+,*3]2_?:P9(+0&9CB#=^=KO
M=1C1B%(1WD2'Y6'A+$V>I]\VGC[4Y$_47)$@J?UGF<(:E]1Q6_JEYX^MO5[$
M%^,>@3"+KWZWENC(:.D'=9=-X7B1N8CL7;%38"F9&/%8WE$G0L_A#-90)E%Q
M%^V'=053$S6%N)YY\_,D&O(D]8-#L>HO\=(0K%:S@2L.>B]V;/U8!4V;_YL5
M[]29Y.EW5I_]F%=-.##US]FA T2DFFC(@7>I.04N$<F/\RG0#CFW5HWL/V:3
M1L^!4S<J:$2_O;SA^HB?QSK8;3980>6/F9YJ(2>AW5Z9C0UASLJJ.+EK(3>O
MBFCR4\HP\V1WUD!_;6I4_^.3$ -ZS0D]*C547KU8.6_U-@(I6C"SW+'_),E[
M5,C/!G"E6!JW^J<U,AW,"F%FT_QX,T^!5Q)%6A^Q3<Q;UC'CG)>2^;DY0W%C
M8?_OD-LP%6^!LW);#%*Y"Q\FF\I+=A;E"/TRD1CX33S8FVY.8!FVAVJ\T]HY
M=W^XI%AH<1OM_-3(2KL=K0H(]"S-DXP%"_T%0$#R?>[R]Q&7*ETJ7_]ADVQ5
MV*A(WI,MJZ?%E!\%TLX&H5S)_&36S57=K#S "_6]?8]09!^&'8ZBC&97R?9>
M)KY+<KB> FI#W% G'VKL18F^QHLO9()T,]H-W,WKS812'J@P.<B/<$:8)D3;
M>&3A5F3*1)NP=FTEANU1968X4HM$?%TW8FF!+5SL6XAV08$;(G!0%V4.7SX%
MSE&;0,VA&,7%'P+8Y=+9-TQ]5B:^:JWCG;"F&['@I" ?E^HAM6]-#_1@9R_6
M(K[*C6W_ON.,1*57K2"850V.@=W!DI6Y?6P<*[3F1;ULC&Q=_QJ+5G<P))=W
MZP3='AX+I,H!/V>K&N2%!02 A</[T!8V*=]R21+J.4K!>>]C4]CV:OM]#5N,
M[5[&3(]5F)N;SXJ!,]8/&R:7NY1,2%_LEE+]W+/^-U X:)\!="0U^W,'D%^_
MB7KQ^W(N=X(@+FRA[%POA+H*NFQJ:IEWJ7-(L;5%*YZ<\I:N@G?U0/O3&'<J
MZ"L.ZC*K04G0])IWM'!I3OP[_B_E+=<T6<S<WC(RD=7 HT#G]T39P5)U3:F%
MQBKR!JN.8P?WON:KR$&HZV/=YYVGUCR0]0@J>ZGGYS!F'Q(A/LA5K%ROE^QY
M6:'-KB^E6NRZI(4*]J1?"72!/%B.,'EKD8KB/K8&QE6A2UW.'MF5*X X(/:4
M6XCD&NQ&(IG@C""-"C8N0E[+S0.2"V9,39JJ%TKH/ 6DORH)D2PG"9%ADV7G
MTS%QL8JTV.>%BP@T2]"MK8?#2S -],7?+EX/>QS8O6#(N?7,4L>=);0%(%V]
M+2C:]F#.Q-=0(_3Q+;8[<@(/?_3P[=]Z2;(]*1>[L9.4/O*/G=I!)D/PZEV_
MW2W8G)'?%'3(B6_[PWTQ2/)GM[>6Q_1*5_^6ABH^!0H/ND XF5-@0S!U ,_A
M5XC;ZO!GG97!)B)7.:R/Y3X4J\ R+GE/WYN?CQ4C7U1B'U1U=0T4,W+A2L8[
M+SX99!57Y?O<8DIZH#-*3EYPEN..8,,__24UI"M+,*(EBQH^9MII=W<2S+)X
MD"1]_F:\!N*;DBRR6/U>[9_EU1!X;0P-GK^.U1L[@V ;+5VICD K/J;AMB1+
M77+WCEX$V(UL7+H7\9?F+2+9SPR7.DGTSE'J@N6;W+2J,ZL5 1X&5?G@1H\#
MM9O]2K?C** ]YKBH4\ 5<<+O6(9-U<?R%H3-#S>(6GWJ"PH217@4M'%+-MBK
M<*2+)S^34UJCW"HEU<0<=&I9O*K E1U?[91;/P6FIYF_OVPN9WMWYN/Q_L?'
M(!&3I15OG2 .@L@I<*(Q=RBMQ*8>YF72!R$^5>['"5VK( D5-.-PZU.;>+:2
M,)[XO!!#>317]3]9_J>#'5.3U7'Q)\B3TC69S 78SMGGX.!['Q9;E^9M=OL
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MKNIL<2]3T]-N@)_BTD\J;*#]RNSVZ0?W.&;=<?>YXWV^25DSC2/#AX. E.2
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MU[2/C8_B6;HT H8FMVN0CDE)TX[YBR(0_6Y"T0WYO+-BY<U[+_0:%$RMU/(
M>_2WNH8!\7=8?K6_*;5+'SFS_))>[G75'L!(-;]0-+)802EP<+OM,^ =7AYO
M::G=WYK[1XQ>C\R3DF+C\\.)@+Q]H'O7 *?.B$ILC(EX]H 8_,U.N+ESN%*1
M\AC#^F:L;?311S&-#@Y<@EDCA@2QU:'0F,I5<]OP*%E,&3[".NLLX#(F353I
M 6<G3A[I8=)-I8,[.9S(Y"X43A4U@![7<'UAE/JQ%IJUB;?]4HZSB)T>5Z /
MQ[!N35?Y"P=0&T,DFL(V\.F$17GQ;]_BE,;/ 7-[7?K8MR%@8E2>IM!K 'D!
M]H*Q/1\7N#O@22>I(#W!AK"8<,30KE,YG*LM>SUZD5V(92$Y$LXBNZR$+F\X
MFMZ)ZQ&<_I"W2)0G[Z(_8>#R'SV,#1M<TBJN[8G[(_%=@RF5/^]$FSA@!Y^$
MO[+-_7 ;-)VIQ= E?=F5/).O/':UIV,.G  ,V0SAL_G&JW-*R1G%F,W9S=/.
M%*$/!SV3>DN6%S7="G=);J<M^GZ2E4*E',M1?JB:MT*0 B_MC&<JH&U0#-4U
MH/=*(5Y'$+<0><P3XOGX\6)?2S+ EM-NW:T^%B_80C !&?>B;UY^+$R! QSG
M+-9,\1-"*?5"YH3/-[RK6_[\2,2UC?FSF?>@VK0_YYILV'0!&KO#'5\.Y6'Y
MS!Q$)CJ$AV^#'42'6@Y%4](2:NC=$,B+,9X,\_(S+&A*I_$:4*W6?H<TKOR.
MW!"5BM-5:1'S3ZD!%9:L<VSY30#Z3V\%^)_9:US* !/1>^A:IL5409W)QXI7
MY;(*,LB75$HH7@9&VDUV"@]-P<WQ-ATYP_G37N2#4;''_6EQC;5.SJ#OMQPC
M +3=@"._\D-"51CJRX4.L$=S [QODU;WA$O).*4S9<M9:7?7$NID6^$OUXX>
MB"**$L!F*^JU2QAE*#4FV$=8_Q()3ILO;'1#!'FO<GO.^EW KP'ALWG+42?7
M@&#$V=26/S\2DDUO%7W8(^D)7R:8T2O,F03?-;[+:OW#+><]N[/O;7ERC8GZ
M?2*0-BG?#W[ME]SO]4A(4I(#MB;%H+)*"&M$?;G&/I1SV+B Y;:N)I:GVL"]
MEG?TG\)L$]_3R/H$$G#)\YGJ@KH&$AK9]33KN8?X-2> XTJMOQ+IG?YJ7'KO
M6?VL[ N-9$V%'Q,1)MH (LOWE%F_E5A ?:3VF_T*U/4S;>+<'7"D7;'AM(!U
M7)J) :LYMAM L.$L);WN_B[T,\'TGIP5>F!MSNXLIL(W)YU_+T[=%?!CT/R8
M571 N7L$0YH&1_]@7K)5Q\BG:+J4?RJ:X&R,,]3C).%@Z=AO]6:M52\](65^
M,EG_T-9""!0^ZOA6]'N-H*3T#NQLB<B>$RYRE9TZFW'53@/?@$W.C W'3QX#
M^9^>@T[>OJ?+M?\P*OGAX_)FJ2+RY@_D!_^;&,%0*+H-9(TDO6UAJZ>9,<_[
M]#7Q@=.GD+,$4T'\^7_MEBK> 9G1E7@%=HNQ55*MR4N)%HN%]PH.-:D<>40$
MS"RK02#KN;HU 4FF@X@\W&#/+EWE98KB M6<_X@+);L$D2?#]I1;O'<5WS7
M=!SJ>'P-B.P@Z@R9^>6#@D\=/T&:!FSB^UCCVKNZSWL371\V2](OKVP$;K<S
MN'&#!6>OVO9+BPJW3C*FVW-C%>COB+6_F85V?"[4\%1#!>DK+Q2[K3 BPWRQ
MX1$EQCOTIH4R'@T=!;[T^ZY](N;!N\%).!*L6*,,66J)O5%+:O;[QY96B;,B
M^<A"SF+8&&_*J!VB$WOI3F4UBYWZ7VV?2AU&Y?!VH$O>ZQQD;W#WS5(NW(M*
M=_=$_B")E0V^&%H]KK)49,3E=IE.%\'C'%>GZUF5@QIG@9^-^QQ\B0Q0#)O;
M0[SXY-HS8C&L?AK-D]B'^"=>CVJ?R@]^D8^4XCAYT!:_VQ6H\'5"2([6EB>S
M'.>X[6EF855#]9/']19>*>O7.T-$\1\*"F"S(R-3CJ,P*UCNYZV6PMF,F7(/
M9+-8ZUQ]3/GM02-XMA&)+K&0L\O*\:!8#C5:,&7UMQLP*]W+*-WX]Z%0\>]W
MB61!6;>"]Q0:&HJ,2874:Q%]<0\;@N]321K.Y]D>EZ?J#K=25<U\5OUO,OL+
M[H31,-3B2+O6@4J(Z"+;0*XJJ3F92L\U@$S,BG@'5*JL\#G W_HH&?6\Z;?I
MPVM 4Q: :/?0(H!&S_F?+OQ]R.8OJ2 SN\?3W$)A//_S>^1$,G>\)Y_>X!M"
MV9SE/VRAJOP$8_SH@R*W+XOF_A*XB)*8D6Y*.T$MNO@3RHE3LEC%]NZAO=Z<
ME)Y.D@OIU?/3#D1^4_+6YWAIP7<B#(E9J;I=@1W8V7W][L:XKE<LKD1_;J>5
M'0;F;YBY_Z?>M/UGK&UW4(%C]AJ %)VX>/1Y)^V,?T69ZR9%YQ"D?W\[1,GA
M*#H 8AV0)\^?%4+EXIMXKVAH^Q3YF>W:_G:H?G..UMR1L6$A27@]'@16B(64
MAJZNL.[DHI,T5U<8%P8AU0-%E0><#-%8(HQ0,R!':A5]I]]>$QGE;_O6 XQJ
M9QO0>-7N66-F%D5HO5711^&6,#9N!'R+M&+;S3B-&(Q&:%%L22KX[G@>/)LU
M9GG(&LQA>]^7?'!F)\.P]:KM4G/W[:53R6<S$*+B./..@_NY767E:XN:?JI]
M W:M.E4:.%OW?S.RA="Q-0^<PSU9B!#WTW.SO4\RD?YVF"4TE2/A1_K3<?=J
MTNW2$KL3/5/3TB&-W\-8KJ/!X&&N&PP-_#\5'([DW9"><-Y(\5QZ,%.R&2YT
M/R1 T9HU^0FG@; &.:,4)V*VFI4HPD.'?RTA_$"@3>5S6%MM^G!';7/DU:]7
MY ^7U ,C.*7.3C\$&VA3Y-%)2['JW%,=&6>[6-)BDH@HPOF!S$@?###+&D@?
MK9G;G*5,Y1#Q9HSG1S,W_9=JF/\=HQ77K*H\COE9D4]M,8A7+YP3C]34PV49
MA6_1*SQN1=<K2*(WHYT\VI_P..U;T.T=Z#:_C2-:XK &O$I"G)>L0$:QG>'S
M<2517!C>X ;O8^B3S2M%8%&"1_L ++**C/S%^.^A[A_Z$RMG-WDQ0!UQ=M5.
MJJ/8WY(;(R== %&@;JA+Y6U^.?6@[4.Y4FB$7O!I\.%V:&B.F'OU+6^KIS.;
M,^Z7; P-C)\^;0K\4'98KUI[LLDKU<\;XL_GS_U9/@L.<VAM:DK>V7$.QONV
MR4LLA5=".VD@R^MQZ>-+U6!Z#;!"_U\5N'A9UX#W]WHV^_;7)":0 28?I9L\
MW_T)?]RM.7^G:YUD5EV5QOVK1]/?H<&0*-;_<8[@!+5VVN9PQ/[C4=Z#WBA:
M%N$GY%7\@3<?P-L)C^JP#F[--D6P6RD.I)\E,.^NU):F+SRP?@VPO09,^3$=
MT'=UT%G SCW<^>^7.JYL_H$-9AT,ZOS<]!0]M""E 5(=T38$OOY[FL+_MO]M
M_W^T*I7^95:,8N3!6@.B3?LRJO#.8!8TG^>7T? 0:5*-2RR%6[(KJ0=6W2SD
M8%-Y"KK'=73(W9C$X8^"I-X';49_LJMZZ56SIHY,[Y6<=GR3.2@3LV/8&]#7
MZ1AS:NO\K,['!J\Y:'V3I_4:0.(MV6?),)WWV+L']7(\\X&VCK+D4 %X7O]9
M#@X%L!9'SK^#(^6I#<U(S7KAWPJ>7OV8$GAJG :YX;MOO/!^W"*29L!C(3[#
M0Z:&%Q1?2$] Q0V2!">IGKF&,(D+:-T?XPCCL&[D5VU 7 ,$.S=@GZB6Q\XF
M8+VL4!H]_7]]A=M"5M:\HAMD_U0>M[/]6"TV5DL<VJ-@L4%>#CIB/Q==O&R-
M,# CIP*_&8TA %.:D/ALF3#SLOVYV+5]8K<6KQ"SB[/S#:#MOU#"A!V&<7R%
MW %N^*7Y?^JEN!T\?ENQW7P>=PT8O.>0GH!LRID8U^#2-G%^&1N:W6?-NJWV
MH; JIC2VY&Z3[)(/6XVJ2PX5+NKUFDG:-[NXXCQE?D;9M&<P][-S]ID6H)M9
M+?HJG?OR(NR-Y>UJ@?V?+[W$R:A J94ZKRVSD&/TGPM4?>@O!')I=M,%,PBC
MB[FE_KP!FP1(2@("#5Q[U]BC!#RTS4 46X$OO:@J7O>!*!FEAGXHG[F8^MW-
MVF57[6@\A)+KY3>-12H\[D!GT1$.W/.QW,@2SA(&",H U$\[M7X]P)PFV(;Q
M1/3R<^D_M''_FE6.-\01OJX?]TC3O.7C-^?,T/;9I-V7AH%A7GX!G^<M["56
MWK4ERT_VUE<ACN42/E<2CY;+L@K[#XO]11"P*SAU.6F/4KX"K2 !C4O&X:XQ
M."ROBKE[A0H+M.IS!K<4&I;3#ABPB?&IH#A<040,%ZKFX&]ZKFJTPF+;4R_7
ML;:E$ZJN5[*8ISETXY._?K[Q:RZB[*N]K?XL68DSC_T3+65,2JUXJ;[8VB8P
M:4K/TF.5G7W%.\$P4W<*!=>4*^ "4J5RA0Y)\]:,K4(FP#_(R+YGB!>8RJ'_
MVLR=\OS_TVO8Q,[NO?L<W5@ MGT-A7)JTW\<E:GSX@#<8DN%=%E*9/9K>A'L
M4?3Z.(7WF1!_\][2Y"2JEN\'[Q6-C(YO&I<Y5M=VE(!5G\]@C>MUZ [U/[X%
MHH!PJ47?6[@L\H&V5FU<3>72KH0A8F[NGE_4!%F?\X))3:(VY9EG/LT&MSMM
MS<MM3360H1\!;6;5;J,EZ^3RU>50G(:! :.M]?BM7<MW"IPXN&E34KT\H^D2
M<[[24:(\8_#@UL,P:4T+ @<#&5":V8EZM9ZY48C_6UCUB@4XHS'[1'O7[F*@
MI];&AH3647G="$C?MT)KS_3AI,4RR=;Y>0UEA8AL&!&C%,QE/J. 9WY/96!2
M3W_6BG/V2[40(I#/TLP^QGK-XJ%)LI*MJHWP9K/:\"#JSVQ)R!U\EM#QZ$\]
MSQ=GXKP-=;KW@#1&F=[E:X4R_I,F=B[<WS')M2 .!=-$9R46NK/CL\GWW)(V
M,M-(-3F$;>&$^68P=J&3$N<H>SX=]4Y$AOV1!@/1>(H%ZR->^G<O>4IHN>MN
M('O2Z__!#/O_U\S @Q_GWBYX^+QI:=VTY[=FO<W^<\VN,^(&DQ:DC[N.VO*<
MV;#G2;*/\P^U 6X-YO#  ^^_7G+7Z-79;Z:;7>ACJDI9?,.ST9-K9B9&[M1B
M)0(1GXEL52S3D0':^M,7\M" <C"TV'*X]7N]=0H;0_ 8JQ(1IOK!Q%M<^V?P
M<W#C&'(;6#FN?B=C3>)A:/[ZXR&\>%?O74LX4AJ;F4LZ/[)VRUY<8F7SGB&A
M8IOG:HB?=3NX*#MR5COSI9ZJ1L^_&E=-C'M;:KQM*="6<[7#;Y<Q/2Y704/W
MFP)UK)C*3NDA"Z+VKIID9:;7K:E@1K'OLM1TL36-6?F6K"J2S>$R^^"&7K_T
M:#P/'QYE@A=9U4N>"5>_F9"CS]NB]CF14 +%WK5YLZ?P:1MG!-4<H/ZUXVUL
M+PX9/['_)ODGBW?@3BP3+ ();!K@U@]PIC#*][:Z4F6EOVKCN 9,0,R)!G*Q
M,D+G"-A>ZM26PJ-Q 7_N(N! W9L$V@]\F#\[%AK*2?4LFPNT'U+<"ZRKL@I8
M++1;[3JY? 83H/GHE3X-(8'9;V2<K?-9@(5(J;-47DSY-8#AL##%%'&,'AR)
M7QD=\%[\KGYD-5/;P!R!"\-0W;>EOOQ8.W"7I8(O\)U"-N@7@;LB0[W)LC;0
M7GR)BO?G!B?.AQLTOIXP,M-HJD5L-K>6X5ID^ASGV+F:79@N8Q4DQ^_ $S>S
M#*QA?W3+UE6:M\2<:02.RT56JAW< PGNB@R5W22O\3XTB+==5@D#B_#7^:Q,
M6 F,;%+5$V\_6*I8#=A8ZL:>5,MCU$^,<4EV+4KU=/G&A,#;[Y>:; \P&=]H
M$%!->T_#/BW*V%+QD?R:B0OP->!%_C6@7?)JV.A8,2J']>NXV(+T>C.UV7P_
M=?!=3M<\(BRM"@ITEDU_N=UYHK5](8L$D2_BK#5SH&S?-&WJPI;F*;2%E33%
M_#J^R?7-E_=/G4 =X,?JFI OIDMS9LN##RD6U6K5S/>Y*)-F=U\43FAHQ#]U
ME=E_!4G#* ;M^6L)O%S4!+-FO9.:I&5^@@F.G^L7[>FX58_.*1(_ED3H3CYY
MP_\@",#%@KG:M[8S/9W:WZP<^X8J\;N*$,8X/4\^N@9HHR_AHYQ?4S]XO9-]
M#MNR^EB1&VG*?O'@+"T*]DHB$JG1&WP- #X88#A/2AB:)H&P"6.P)Y_S:7\C
MW01$I $/'A%'Y(C&LO^H;]-&'K)9V$V.5"RJNH'M2394>-1N#3, CGE:UII]
M#,8>%&9;@<7I#HX#Q.1A.ATQ+Q! I\_7 ",7JJ&.GXS]/D;QZT[4%ZJ(-D5J
M:AH":W]/X&_I"QKR;PU7]+AH;K3'GB0HN.@@\1HP^^ >[/%*D0L;2^T-,!,?
MV7=2=8_?MP%R572]ZO!F)&J$R#BO?\BU+J&TFI\LH:D>;;$TRPCD2[BB6(F:
MF<^Z6SNOIAU4)C4?:$(#0ZUD^YG*#$5O=:>&*[/>J;Z'"0]%">U-3_DKBWE1
MF&81&NJ_<,'[RF)+NZU(Y@';=R*<=W(8A62"%5<5O:X!K/Q:%4X$_,OSM*&Y
M0)^>4=ZR9[LW^?&7O-+_(]B3ON^* B,9[>'#":,=+MS2KE>'EMPW*?H3^.;(
MQOK7&!XG TI\R8@?PP/56D'.- LFFEL":_@F-IW-X]:MFRRF13R-_@_BWC(@
MRF_M%[X1%)1.05(!05+I'A$ID1+I4D IZ<XA)"4$!*1!2B1&I+M#NKL&D(X9
M<F"&F7?<SXZSS[//_SWO?O:[]X?U:>Z<M:Y?7.M:Z^:2:/ 0LP4',I$A+;+,
MX7P_^%?%W&..>+=Z,A\_CPEKL=E#L4.S*!#V:"7^1JW[57E"BOTJM>52ZG&Q
M61R.W2Y9[V[!V.MAO(E9D79[;CZ]]VY:NN0IWW022E:F7$^(D?$0W[KAN6^J
MBO [S(,M?;[\W(4T>&JO\ @YF.NQFSHVI8NN,IU>D9N$[-9<H-\F_J'6Q+K<
M[F9^#- [6H#MY>\88&0N% 0+]7W%<:"_I#S\^H?I%C,&D,W]_97PZ#L.5SZD
M5\3%YFLD<1O;4P:-ML>/-^@(T+O.I"N*:&GC<O\]L\L%.%?7\601X^HXY>I9
M"09X^WVD]*>U/?-@G&X1 %5<=<$ OM.\9=:V7Q";'9?.:^<W;4H4W9>30!%L
MD[$$5=/1,G<-=VYW.%9&L(/5/P(M:;[+&0;P952BG^C5KL,52;HNM\;1O>*S
MHNF#,9/PY#7>O>@BZVKQ>T(A!3U%YK%7R:<095AS&DD"M%1F#.\6'M?08^20
M@EY6=R,&6.-+XP:_W;%ZWYF3'1> +/RVB0&8RA+:ED1&#U$@:^K)JZ;2=7(>
MYQZI0(&7YH[#&H^'&;D?W-]6Z#%^H"#6EXYLT-N3^HI:%C6[2',_[!$[&<[W
M].C(>-:O L]?/S_7-'SZ*DZNKTU6<CIV9+K,&LTY>FJG8RRIWJB2\B5VP/W#
M)UP6QT52S;%&TS83IA]P_@]\>Y"!+]21RHJ?YM7DOIZ<"[W0B?H4$I6Q\\)U
M;W%YRP@1]VW6,Z'SS,EJ<U\M+MRC6W!#W#R$J<D;.5UEL/>CO+HFU8*4X=G[
M"IQTHK<_7$VO6TG@80"K'^7,5OL\)<9AX]*@6T-P]8YY=:J=(K#P"4RB\]Y<
M)$$KVV96Z?/\FP:2;+9JB39JV@9J+[9_2)PDB>,\JF^6V!>'R"!"OFS7*P;R
M7P])UZ#CB,[XY#N@8AGO)5P'9;X^[_ET\3/?1JVHI. &)^U\EOIY,>NJ>^%K
M4'"9';2Y.MY) /?.L_Q0^DR<04YK3<XFPDX1V%&BO.5;=5@A^FDX!MAMS!IJ
M\#[& "'UT9],*$*G5/I=:VW#""F?Y0PI==]P,0G4TEU[ [WCRKI%I2G_UO7_
MN*+P_\_FI=YIY_%DQ%=G'_S%5G=:=TY27RKI,1699+6B-#W+\0'WY+>R?#!)
M8K[QSFVZ([O77NMS N[?XIT0M[ .M"_ZT,*W:MU7' /D*':#SN>F1TR);ZN:
M ML=2A6-E>4#S4:BA0*00WK)%H:X_<B5$P@CZNEDE7X2-^-#9;?<:"W5[XRW
MZ!(5SME\NT0]<./&\[T=@E&*S!^DN%^7]MP,WN?TZ%1SERC7H3L0(!7^TL*-
MQMK9.%*W*U<,$&2O*4_-^G]*WHO'DB H56!#A<)7GZ8=>,H_AZ=,?+T>N'9+
M^KKKB:;:"V</BR?IUF5ZQ:SXG6CR\49=ZD:/(R/%,W>S:%S JUNV5R:H;@M-
MYNG&(&AD(T!Z4%D4.WK=XT2;*_[9SY1AXF?.&Y_L!YIN=]3KAF5;5?8_#?-8
M]DWRN"S?@"P8RGDXL#<-*/,($)?%"-#Z1"9%)LU[O/WV*/*7BEQ@$T(1BDP9
M2#HV,2C" $E6T$]^HM? !N5Y*-X1H8;:LI2RLOR(X,+T%4Z6=09.YE+W"6VD
M_MST([UG-X\Y<W&QN#V.TDOJ!_,.@"UY-%K[!!OHAF1/J"'FEDQ9A?/Z3_2Z
M'"@Z0V+4)@$B)%R'\^N&G=ZD5F1"JL'WK_;[4T=#/I8>\JDB43\8!((>??2S
ML7E ,SD$[F B&??EY/-O/:<0[EX\E.0FN^%X UA+,/S1F= .5\K)=>/J\PEN
MH[I\4"=RT/N>E>"H2Y]!.ZN#\4[WTB4!OS!+\L<+@;<OH1XWUM9WC];28:KV
M")<.'9G;XYE]K7V]1W1T&Z_TXH$]_/QWFB\W.7(MGH2(27;I%15MC]C,O>G.
M<KT9"KTE,AXDN. 34Y4,C268\=3D>]'M4Z2S4O1:LJB-;CN$J26[])++*Z-T
MI$:-[YF=35 D9Y[>OZ(200<4V2CG %4G,MWU>"15/M?3T*]&6'[WI66U,L-9
M:>0O%-C:J=B357?<=;TB\T@OZ1'U0*#&M0ZV]"@&B^"=Z\\A=K<BU9YM)AOL
M>L^9%!1;PA2FN$-EWKD0/*GE^#A[U(:_'&PRG[>PL+1UIJN;5#"V8T6A;/?S
M9T0O'F3%$\)<.8$6F)OKP56&SO9QF@KHKRW,G';@7.I"MHY,^K_,_"SR,K6W
M(EOPXGBP84=?C;04*Q6J#O5>?K'_MVUJ_O&>XX.>L:V7EA&'^X?\!?7*+*J1
M=]V J,WTHM/2:--GU5,GQ=$2>Z)Q$OMVA7@N'Q5K6>XTR.L*CO<.S\KIVIV+
M_\X:@51A7Q8(\3,5:KF;-E_UX(KA DX_OU8YX&ZG]H3;G19'E"5M7 MY(:H1
M]KJWETM]UYB7RJ7OO/G+&=7%2]XO=^NK:IJKXN=VJ%)OWF 2-0KB#JE'R&6K
M/_#DX[=K$Y\I*\G=CLN::KH6R2JN^)::4ZL87OR9B1[FG@!]S:K'%BT4;#LH
M:&\F+=:*N\75'+BBRM^1VCB7F#[M(/2U5T?W13;%S6XJIHXF;#@/\[HM4-^R
MF3)\A\51Y:^ZUYU@"8_KZI+<&R82\YW7>8H"E(>9V3TJM16<8P:&\N^X^0N[
MA)0CM'*L+T.JUCT,/B@[</5].[H_]G+=DD!LM>$;YQ>M3S6OU:(>%,O^KEA(
M^)>(KO^O[>L![VI#==*<*RG15\V1DS>L>/[:[&\]8PB+LXAL1O0V]YUG!SZ^
M6CGD?(*N+4JKU-?4C5>,M &3E%0^2:TTI<K[/FJL^I["TJ?$\.=#GDA4@.P0
MT$VB:' &)MJN?QL!]9/I44JT&,\)]$T)#CVF.FYQ7-D4[UU+O4"V#Q<BXC>?
M5]>/'H2%-;+FJ?/E.#@QR2V2=:L)3F0^%@,]V#;I@97U'<Q#[:,=?"$,T83?
M%9']]))4#!C@A[QA_8>:?OCO+X/T+F+E5FD++_G&YFI9<9F-P**^Y[CB2,\\
MD8B!\:\4S\UHI8N--.M'ZY3;XS4&![ZZJ\QDBYXM"C#[8+!=@:FQ0=6OQ?-X
MCJ./%G;R]B1*TC[F^5[R=96PY8!&31C6(8T?T'?6Z-95A/"F#([T[;F^>A18
MF=43<SIK\VAX!73'4ZXS%?%Y&VY57+"T^(4.3_"Z5/6(VDW04'Q5LCT&X+B<
M0[?<;5B<]P,+7YIT1\=V9F@IP2 ?0FOM#H5CB0=8CG.-(UP:]Z,C8])/<:L$
M^CO]!6!3%5!K*>62N9TDIGNO*9\D%=^LB O@HDX^C/U,E*7>73>#D@1C5>1-
ME,)4Y:Y*++=!78RQ.)LJ1.+I?,UU*50K?,>FW]9]F>P4#&RG2HFJ.N4.,@X5
M-M-H5QZU_]+[B,-6A$L%=9\\/W?8GK[<>F P-.^S# .5%=9KFH(0\ZU+#V$>
M[_FK, !"?^[7YJQORX)#JO1\WDODDE.WJ&6AS9GZ]6'AZ4!?:2<GG@1UOI1W
M1\JL-);F%/'*4O'JXGF"SO^*.=%_>BY5O:=^,Q1+W62(-.46V'DXW_)+P]=>
MP@4B#Z.U$U[OSPOO)WY8/23K@:K?LKFS$$<G7^*3]-"IZ>>M7.E -I<7R$3Z
MI=Z+XEX$5EP_B8T"'U9!\E$/I^(\)95M]0J"!M^9/5($778^#L9I:MTU,;9;
M:PFO+EY]P/].J+^XE&%N84&_ZXC'_9 A9N61. ^@;A)6ZOUQ8E_8@8!8PU!=
M.F,Q-FM= >0)_V%I1<<L0B(Q^;,*_\J5G?LGV#A6"-;3R4^':'Z9H-H(>TX^
M*!A>4K:18C\G;"98KK<9.%U(/6J+YH>S#T<5PEJ"2UQG[?=*0P;7+Q/$HNR1
M7W,()&-D?ZYE+MH.2FGR=\POAUVZ>-[K(_3S.S2G>?@$-!ZOBCI<;Y988XOY
M7/:CYT4%++E[F5Q]E;"WY,N$ZQ9[D-?,/>7REP_Q8&JR:W.)U28M0;72?-C0
MVK,!M\^8(G0Z.LU507-O=Y%2>H=K^_K=HF /9M'M0YT3TMN(^.5N#81A-XW$
M.UV/I.Z-H355RT?5RXU1# FUK])/UN"0^W?<^E LQCX_/\UB@';-J_R,,) E
M,@V^'6><U"!<$RO#9_T VF2L9VAU+F-WE>9 4WI/@O6-TD6@H]-'EVTUB2K_
MA@N?&E07+V5-__!2S2^'YLV*45,Q7T78=)0,,\)[60>K@./*3"^F;>U^>57(
M1^56[UV47@V8,^YN7?X3"]K_0VUXNNK&F)1TD8U2SM+8E/ZD^A-M%?.3TEL6
MY8I2_$1?F41?E)0(T#(1" NH%GQ<';.NV!R\AURM"7=@JZF!VZ5[4%B/[&@J
MLI&_CW\@V"JCWX8?/+_49 G-N.HNA"%5FNLGWDSP6>IZ628^J=[?3VQE>ZW>
M]VC&E9%[2'B?%$K<H6_5 OM4G24=$4_E8QL5$+/7+>*<[T@HJA67J0PQA2U%
M%VPQ,9:/"\6\NQOEI=KB#O-:C)MF2XCK$?Y2E=%2B@%4*,;KA:V^1,;]MAE,
M8'@-6ID$JZ:Q0'BIR>C*A#54\5Y0"/*Z 0;8RB\#KSF@XAD]T(L8X.2+Q);4
M30S =MQA>G8+BSVC*H\9_^0=+'=3![/"*B473:[.#.:>CC437"\?U66[UKF"
MDZE\K5%P;3H29?H%D336WHT^5!NSJ-%_[:-,1S1VK>T(*HMG#V2;/2J/Y< =
M.Y&DCPUG)M@K;31E/JR2E+=.O4&@M%C_0$$ EXP</LYQ_?&%%0!3[#(E19QK
MUGT?O]<<M$/0N)KLQ'7X/$"):T",W7OMD,@RW8/Z%P8@01/-(BB-DG737J+'
MZX^B="ZJR E<SC^_^7S &B!+>SU,?&WBWT_F)?M@E>]3)X3[HB][9LKNODFI
ML9MK\K"L?I2.U(EVP@!4^_P.S72[29>^SLJ.([@_0(U]="H!DJB<VJ*L]H.7
MPO%2]>?07S');O2[IM090H,6"J22)F?LM!H62[(:><2=U.M.)N?6=M<3TVFJ
M>RD(S/76-$<X:7&/(&E/ZQT^O)-27=4=XU,+SM^"6QM(4=[?4#:T*3)1'Z ]
MQ1=[;2KK:;)T,-[N+5V%]I^F_O1 1%VR'7!!3&4PGRXMAVU8^E1B@+(LV/(]
M)2GI+X8VJD6&6Y>^N@?*ME_WX]Z8>?]J'089)+P8K2Q]*Q3[<OS=8;S@)\.O
M-!J%$S?PJ;TCX\/1PZ2SZ.'UGG6[V5]V].YKM#W/S:NTQUWM^!6BU\9.YB6I
M/AZX506:$?DI:0CJ?LV6BF6^RFU9S[3& &?4L1A 7L6DS02$5 3_E!K' 'O<
MS.C(I*:@_PI+KB8,, ^J* -7-,;6>*F?@2LM^X\?NA_V2+I$K:7K#C 38@"H
M%!:!(*0I5\6;7D57D*N<S?TC5/7\)KBJ0L8$+6JW_YA9Z__R4S[_L:9+#,?M
M:6:"[5<-A17M".HO+<V*AXSA^^4$<[X+\"8#<QW89"PE%"SWL3>.[_.QX5I9
MY^BR>%O$) H8]75\J*@[G@I>=7A/DWDM=%IKU#Q-2\4Y 3)+J,KS^5>2U@AE
M[[KYB%F3+910P9]F*].XK5:3/KJ3/'9)M+\7_]<V0E=AB6E$4T4DMN KXV"E
M^:4VTL>*ET6/-SN&5E?2//K:U\-6ZD+APPW5ZB/VOZP ]\( W<L7;!*'5UB4
MV7[J-N))B5;>#&W9H[;% %^2ZC! =,N1DMLRT@,#C(7O9L,X4 G#Q. 9KFEL
MA_,"KO^J@MA_IE$'KCF0BX9(,1;9.K57J-C1/NI>#[%\>ZNNYUV<X6GRJBI3
MARGL%SJYJ+I?,CP\L>,Z)_[=0*EK!/A9SU[,?)U/,8(G(0+A;TJ%([ICOWP:
ML^#VOD8Q\EK.OB?EF,@E+O4LXYKMARR2[8K%!7D7%]X2!QY8%%O42XK^UI5,
MQ6N-_"_&?1\5[[3W/T.4V+$W5(<.:^(]4NFX\WZQQ?&%'I$YA[C4<>1Y*;]:
ML.(8S\F\W;)E92!+K-?/N6R<A-TNW5ET,WAZ2:'F=\UCC;QG3-5:AJ$1(@,*
MV4LK#I<2$ :5E\0I]=:,79/JZ%F2_9A;8]IA^=)/JQL+0L*FQ%VKQ"J*XY4^
M3Q/0[#\N7J@(!C@/+BIX^_@+)1498FGDNE,3O7KASIYW*374?%6DV9_RVU4E
MV"[#'$FU_&Z3T7? =;$F=KK4]8[6CO]-1'Z!YUM3,AN#[HSBV<9@Y#-3$:6"
MQVK:#0\(QY="BE'-N^@GWKS@4KN+3QC ZO""(Q5\%6*.99@7T]]U8]&CRT?J
M0A@ >:L'.V+R(:^R_R/S@_],,^H)1\F66=V&#Y.&O9UT-:<]SOOA./VP64W]
MD__EFH.:HO#X=")*':Y3] 41JUJ. =X'HH1S5=Z-B>35@^=0/VO,^[I)'C;"
M=Y6;-,::!L T:>#PU,'0XMQM.*)&N:;:JF"T^\N[_.KTFLLIK>#Q7RCN6H1Y
M]@X6'RJKZ_-,WQ[SK2?-]>PS@6>@8O,T:$0;:C<9%A:VC[[KZ73J9_6\/D_4
M6=%\E5"LN<O%B0S@:>&?B")3I-[RIQ\_C>97CY_6G^PNOM?G^R&!('K DY8$
M_WK@L#3BFTJB\)4MY!3\Q'B^Y;0@:S(Z]<]UEJ18<X)5"&'&&* &?,494T]Z
M#0O6L.FKH%+PR8MIT!^KC6R2H/^H+\E:78Z5DF0*+O-\9OS,T$X_6[/R\2\U
M]]H7K>2A#/["N]0*:_)C$ [K ]?^!QOO[./UJ#^?K<<I%V^]-,X8SG)KH42Q
M9+4*S%E?WKM?<#9_5]-*QRJ_AVCL'#A24U,T'VN*'W^>8(+0M2R8W1E[.NUM
MI,F.B$IJ>TQHQ\:DX!,\^ XKN\5SP".WU3! ZTL,<&LTDA,:<2^"1FSD^DO-
M@&Q7P)U:;5#H$@.TW346FI9K.QT.\W\TYD9Z8_O,GS7U;&YL]TWCB-77XD*<
MFO/8RH]8&?_N.'C05?3[K@P>(N&KYP?D;<WI=U6VM*L>X]G+]X9I-8]90%P9
M=<-JGMN1IZD/C ]W$<4D_9=''NB6E<S;V"?8-&6^&4QX]ZI6.'8?\OWPY\G1
M\;C[DA/"K50NW]17#3Y@D(@.^;95+U^0+/TIVH<Y02C^>51TN9HGSD\B609_
MZCTJC4IP\J)#+U.QZ:XAVG(@B\:?TDH&%U9:5I2_N*.ESKMC^&-1*2KGF236
MVXOWD:"K3A8],< ^XV^=J8X!OI> +[D,SF[]4\M>_Q.-.P;N@SCHN^0^O-53
ML$-CQE*Q72-G7G&#[8?,XY]X1)2!,6'",Z/*44<BB-(UJWRD5-8MM[>?'?79
M/Q;XA;^/\A<>0=B<K]ZO*)'S*-V>LX_(+=BPU5BR&YA] ?#&4UD$S\"C7(RK
M)B>;$BN315VZ\,BCAWG*J%]ZQWM2JTWKU4Q6Z@LSTNA!1DJ";BA<L+NQO1)]
M;D\[_,SC1VUJ<Q@IG'_5!2%RKCYV4LM2-V'/II#^O.0GWM,5RLK8SYGI9S*3
M^:L8X+8MC0G;N!0_-$WEP6G:S!PTK^4MF1S%9A+A,842:ZS:Z9K,@Q]P^T2H
M-3L<_SVJ&'EEPIU6JEE%:S2P4MT;Q/?L*P.)$L/EM$>1S8MM4UJ4\"HSQ7Q!
M-/%! GM%A*5NS,U \ZI\6I,0K_,<7FID2]^V'P:8REXJ6TS>?(O>!T-3&@I\
M53T;N5>YE\GT%&\40;>)1!T-F\T38PDT,A^;]XAWZ8PU>JTV\%K*?NA*-4DF
M#@N7,13G,1[X* Y\ZZ-=2?@HA@%V=?$]"OM7022^VE-"WZ=I/'0=T[S(E2G"
MC2H23P&&J:'RDNU,_A;$F]=?3.0]7(@'= 6[R(E&[G'1+.$O@AZL7&J%EIHB
M6R*G+X^H*M66EU B&(!?L/P/X2W*]RG":545OS4UJ1 ,)]6>+'U]5#.KQC;+
M]T:>;J!$C(TI+-\'% A:S_2T1;?IM%P^L";:^H\.UH3)1I_7T'VW/>%YR4&9
MP13YY@+X0=6G1/SK/0OOUE]=6@I/Z7[R[.\Q:/>$O(#M1P^'G" -):WF=.!X
M45\.O=??XX8"CO+W]T:PY#1,;[23[,^;NFJ->B,2S$8NDLC_?D'HW<S%P'LW
MR7H?W3Q/2J0+FBQ#$$VAB@'FFO6/&P<<NM=JW$$?[!>0R&E"*#/Q8#%"IZ>+
MB;PIN>/V^>M,6]ICWJ@!AB(9+;\1=Y@N[8TF?CD_$]5[N&4=MC1Y O<-%7C)
M63[>VDPG#PX>%];YI<:V= :>/KTR&OW+GF9P[)TDT<H;61C@M1[6P[ZLVOO]
ML>M*#U3"( C=CF7<K2+;F7^_#_QG&X0-40X7U8/%U)GG;)MU3RP]9K=[ C>>
MXJG@OY5]TBK>X;9M4J,-J43ROAC=%R94XBM=/I27>CUQ);N:H'O'<B"3=?3^
MA*\L]*9P+%UAI);.!)[H30>^UP'V40)E]%%ATM>NN+>-Z17&4:!\V?QMG?:Y
M/N"ITPW>J'AUMG@OMB/;05]5F&*[GIVA:DM:A]9\EI!1C^B!^2N7QE"6,DF[
M-]<:U(&?3OS![YK'2[M*^Z*Y&)_<>S9 HP"LQS@"=)MB.]Z3_$']=?RNLS5^
M!3,['WGNA"0V+3R#3DF&)\D329 12,4:\)_,$^M,S.V(Z$PGK8<^,GKZX[ZB
M[\-[I9I*%B+525,BY7-SAET.#K1S<4\"R16S<0.UW[GRLJK4)JVICY78<:1=
MO4LZVZ8'@3\'W$39/HF4ZN@]_F./X8(!Z,'K'W=;S@XQ0#[YM.R*^@5'YATL
M^6A#T)$&P'\V1 =\7?(\\W8'BPP1MAU+#\8"-!GS]^O]"A;L+H(D'5]^7UPX
MCM(MU%3.*?#"8Z;RM<CAV6^FM(FCPB%S<(UV:NTY>(P++X-TD*Y=/5M=/>R,
M*-@6*<5E;\KX?OQ&E^WUX@]%@ EG4RHP<I^+L'<SM<^SU!(IW='=3S4OYV47
M0X\?'#R7-K>G,P%3->UP1'!WH>F#IHZU5.UM3WV6*4SH*):@M%D+"4DO9@#S
M8RGXZ/*V")@,_= VE:_9,DUE="\7*?SM>>\712!%YH7 0MS%2^^R$/CM;F_5
MK!!?Q?Q9.0?JL9\>I>QCY!(/Q&8I K3#I5L97*DA)58F'+#E3L)A*D]SY6"]
M#UJ5>GR\3+]>6:T_OM:\L1*%T[H)F0H90X.3,K/&2<KFMR]V=PLO&&CA)F7+
M!+>?H4?KCM5:KJ+LS]'GO<AEGS*GGO'(;;L2U^504YK*4G[E5!5I2JWQC?@C
MN@/"I]%W*KSRZB[4*!/&Z?;50;?<U!':N:J4\Z1DT8I(4]8KW:RLNBS51LOI
M.8@^PM 47ABE90A/BKB1_,:VL-\L2=G]OM? -^V9'\R)[A4D=<RE8DL[R%.L
MA+.[P "?\^UU[>K!*Z:_''HW_640R;)3OH3F#OF[WG8GNT7=^XRE8\_:?(L4
ME%ZH"3P>KH6X0C)EA%&2,,A[7WI+<,ZVJ45]@H:2/GJ4)T6.X7V4)/FDXB]3
MN;%_R=KK?TNZ(MY7#Y%6XJEH5#YR4FYNX\!"49WC6;9+HY\<HN']B@%:?P(Q
M_#8]YY=49'66&I)W6^?WOBH/=_RSX<K%T8(;ZN1;"38R++#WJ3U1XUT/BFVN
MT;^O27[8*JI ITO<+9<9Z)]X4A:=:XUF'LL>.RE^;?<&N"<63-.MS/%[JL-+
M&-K,AP!#71%9>9XN<D'G\A.0UZ).)G,+-#'WZ>=E]"]^2#6+U =FINM6>FJI
M3U9"B.=F=KW#)QR@2TR[64O$/?8N0^XK_HRJ+PW6QUM0I*TIO@9G(E9_7D$H
MA0'^,#UJ],>ICP")6YS?SL^G+M]FN("].))M;2D'!?<Y;#C98_ Y *9/.&:1
M6.1"&+>0@K9>8X"?W+%H4444WW)8ULE##+">B'7#]-FDC[\T8@#T;8>.X4M:
M\-$S++E%3SN]]G,HVIZ:/G/V2JK19!MI'A-E!5ZN' D0[#ZF^;<C6)<_/T*Q
M\^972(2KGZ&!CSA;C&0__0-#7Y6 AE4-K^W>4_$AP=C?.[<5".UYGM:T-?07
MZY6Q(H)76>*SW8@&"O$L/QH&[YL4Y\U4I^3.ZDEW)O/:77MJF7RH]!*G%IG^
MMM:/2YTB*T9BSHA8'4T.-2M8Z(6<.0B26UJ#^ Y;QI>:*+ZA=_Q^5F7^96TC
MSG]7 -P]_RWQ\&<7KS4)N3]>:;L[[Z/,SU%3$Z^WGSNTG?+R8S"0'O]HY'3+
MME6&'F4"#POW9]/?GHL:79Q9EHJT,PL2.KHQ!HVK%3-N/'C+[M(APHF[5?^?
MGKOX?VOK5<P,BH4HQ;%&IG=TRQHUUEV]R3@/&=;LQ9&93;NE$"9$6!ZBFCGR
M3SLUYC"JOBMY;B'XK6S5 H_AH[>8D.F2[CP:]TK1P>U<(N/^;KL_/_ST]$3D
M-KX);)=>H38Q15M6@(_JQES'X9&"5]EJLP^L#Z4!ZVZ"[$RA;RKG35E2]L4_
MSU;P>-0.Q0#STG[<\U+\/L4[,DS5]=.NO\9/.18WYKGM;X:RN"1,O$(+C9WK
MGD),.U61P[ 3$>Q(>_RO2C=2;V* 8\>6<R[P_J)73T\+!:)"$6X7W924ZU>P
M'3KN2FSI"(_(<EK2^VKZV3?7WA#7>LV+>AS!M&O<C,C-7T D+?=.KL/\[<FR
MY3  <YCU&V:WR'TVIR"EUBU ^C^2XFA4[ZI Y':;TAQ*L><B8G:?5HV_D^_>
M??M&X)$V2&3JA;.QHA&1Z^E9WQ&$PI=GNHJ9<1F1]12N>_:\QBE/WOQ]TBUJ
M6;P#.KROPKRVYU=7M]05K]PP *O*RG2D&S\5@F&P^-G;QHHZ'YW/IQ^!/,K#
MT&Z?U2:21G4EA/ :X[4Y%3N.GD-+HG@ZQKLUKPC)<$ ^$-PCB'[U.!\(2O=!
MI;DYR3;V!Z%7V9JD\;S]E%/Z2L*@4<;DZ$W]^6SY56D2O^?;'W<E7)-WGJ6]
MK)?C9/TZ0^)Y^;(^J2K?:K3G?G'1[$Q>F(WPQ"Z9^18A>2JLA1[AT6&@-"I%
M#*5_!(J47U4YF]"P9S%*6N2)Q#E,=R?,%!M6M2[00T#6PB+LJN;%W B$]F5H
M[59K-;;2@I)8F'!^2IW2Y55588'U^M7=)M$CE''+2F;Y6;C_\%FL!(C5'@.(
M.L[7T UYFS/NE*656AL,.-Q/+II=OL=8-E51DJ.>PZ7&O2D_468(O;5E\JX%
M"RCO<Y&B]$/^P^=GEN/W&W@]MTU)T'S;HM[&0;,S*KF+TOM-J=<I\I2.+!V
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M"1>$;K:FJJ0D!C T/!K1J:\Y;<( @O]=-/^#V;J\AU_JP!3@=J^K7&;4/0P
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M]/FD/X\GM]PDG]"@NF[\W-'BF0KEK-$;]2MX$$$;GJ,LGL6=/984>[O5#+Q
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MQF>ZR'E&XQ^=T?B=,^ZUJ\:-?4,\ UA9XF<TO_4,Q7]F)-MD_&OEK;.71Q3
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MA#X6[<Q0C+$@NE!GL(R61UR;GS%$)KS<+ EE4XXXL8N+$6C.Q$@%W CD;9P
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M8EWO35S/KM^0^*=S,''JRF0T(T [IX8+))L,4@[BOZFYNI**9UM<^7P =*<
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M?.Z,CF/7M"^+ZELF\X':!1(WYIL-.L0VZ.%F_2"/^;&9QVJ"V&^OKZE1W[M
M_EIJJTPDYU>C^_1PV#.'T3\UN;_R_AS8;BF74+GT64)@HGJAQDZ<JJ*RU]SI
MTK'JP!! M>_\3?LC.C,A<+>_&)@6;&4.RY]=;VC>WZDR@CQGUOO^[BVV6!%Q
MA/]>]149L0-!<P=6%Y4J:.7.?H*N(>F_"QM2*_5PBC]_XQSH%WNGX@ !Q<ZK
MSDQD/L5)[D01M?)@9MQCY3PXZ3!V5=</Z]P-"88O .*\BFV8#\JB,C)L:T39
M@@W_&X00RFB\Z?E54>.O:88?4K7'A[[H:)%%"WX&T&>N03KTCPIBF\SS"*2?
M6F'J-;75"?,RGE7@5UUOM*R>G6>S1^ )^(<E+GD_B4Z'.S^OKR\,$$\!%&<.
MGO??IB,8O/<U:L!1:RT-0*E-M2@*G LS;PN9\\]P2*$VU2LQJ/Q[CFU0W'9C
MN?&Z,5T84?F6T3SLJES:(>]/_3EZ%1FSD%@?'+$WH[V<X-EU[.84;EQ!!$N<
MZ&A!0!8]TD'P\ZX_;FV:O(]3B<9-'($#%-R=T,=&#ML?I.3P$;L[]ORL-E]?
M&:DL%RFGJ'Y]?\;UE81P2;,M+.Q,(2EAQFL"<EGIQMH?0BTJ8U43( EBGX=-
MQA^.:>)/ 0'(@1VF[8J:UL7M2&_/@!I/G&.<8RJUL7Y$%E3+(S4X)=LG"CTW
M)'LA_ +2CU+'SR7^V:T0(* ;!+P-=#S;/?GO*K!$]"G?2&Y(#EHZXW#]R9ZI
M74/Y) W?2>3]QSHL69891(1H)G-YC1"47&9,N*"F-6-W_J)52#AOZEU1C>6S
M &C@'=66(9>IUY32:7;CM2$AO\M"XRT >4OY>ZY?K#H_72'F0XKT ([BT!\1
MIAI5B],)0/M)(2[[JD^8U[4B)Y9K:R:>AV0;6/%0,MS:?)J@GD^IE+]=@-UY
MEGRH()]OTR@1VA*XC^EB0:)A$9=I[T*;.-AT>\3P9=!_X:!0!<4ACW,^L&;+
MWW0_!0C!#B*U]!M@N\VG !6;[$B*OX5X5)?0Y^I30%@#?K)ZK%/!PX5U.7@I
MJ?*U"E .O_50YW-EMVFN'B$*#0)W3M,4CF)4"^U8XHU4)<*->$0RWP>@6(DG
MW@8 $J@*68>C#/(76/]H-Q6OR=#KPY0F<+OQX[SQTF5B$_ZS0L9,QCE<3YZM
MC\,2-Z= ?"GKY*83][89+Z<+(@[9RO-SZA00MTF$E$8-TZ[.<X_GCN$%[X&+
M3$P$=V>QA@7S_( Z'LXK-S]#ADX!J(&7CU[D?7?:6,GZL@&E$U[\F*:&S8^6
MU%(T&Y/)G<*#-#3WX9V.>O<WJJE%I^7B44R;[.X?QO<&M'CY-$!+&DBD_O2'
M%R0]VHC\&U%9MD<F+A(1UDZ<ES=%#6^%?"86GTCGC3%,_3X _<-_MKM0N6>O
M]]Q*F )=B=VTKX56B8WG ]87-_EINKRI5[#ED97$IUG<5^&./]59JHS\\NZ]
M6SKN)S_GW+=.H12:;U ;\F"V?R5I@0!#/PC* J/S"2'[45$V-+.U<=Q'\@#I
M.[$>&+;>?O&MJ6;/^RUI3T?<-H[#?2/*'7+>H4F8.X'J2ZF[H81S7)]OI_6D
M5AG?D&HS$*Q;-O=\;F"T.!SFJ<0PQ=^:UBV77UQ!%J[BUE6<H#)[IS=#C# 5
M.9VCZ"9?? 8Y_MCXN6;\,KM[2/?6P)UV)PXM7KW;]PH_+[K @261382*'.!5
MG991D$A-8XPJ(M'*BGDMY3G'04!ZHR<U?ETL?M".D-/;(!(B?*VZZ5AO<+/P
M!41+\-&G\%X#'C>HZ\Z:F:6K)6V$MY(@43)6Z$1.S6VB>O))G4G@&=.KXV$0
MZSU_KH Q<0?Y_<2?'+EP> 8W(ZC@1VPDWG8,O#K]WG;'].?JXV-E(6FY%VD1
M"U7'!?F;<6C*\\_QK;2E7#][YOEPILE)KGDVTY$/WJB^RH#H8))3K)_K.&_4
M99H88X7C"M>YA%IQWT]^D[-8KW56OQ!M;[2/]>Q_&/=VT0VH#%4K1H(:-PAG
MCYV,\)Z?L24@H),=_QCU^Y,[0DD2111"E]%+^""0QB<9L+3CZW>-T$\^?%1\
M0 'F"I-E+"]/I$T!P0<@.,GA: =?T-(,P2UHGZ4U4S=C]J'HI<>O16]1J/.?
M AYQ4:I,[ VSKGOK?YB_63^B '.G@LQJP>SG]7:+>/VQEPV+BUAEA@!L;5PS
M2PM7ULZP6-9D==$4S.N!(AN=N_G7N(>+.Q)T3'!DM_%][_(P\YS5!N I8/I#
MQLTI30$]Y6NWXAID3-L"QF/?YN?8NK1N'($=:Z\F.#>06@M064F+(G3]\\J?
M)JIW:->GE3(+;'>-YV;M(CY!#MGJ^!'TI&MSOTI]7V9'>HZ*;-1!]$\!Y>U_
M0"Z#=,+_?GML2C<)*5#L5DO8*> BNA2%DIZA*;K;L\3$%NFZ!Y1=BYS#.D6[
M#;.O=I"Z#ET+/KO:GP(V>/S7Y^=>^9#<R@9]W,Z(.H%G0:AJ@X3 *I=P/<V'
M&:MWB2]]$VE2%8["%.JA _>G*)ZEJXKV\@@Y<BY>N=/E.:._MT!MJHTC?Z %
MXC""I-\BP6*TNMA_NR<&+YL0.$B* ] UT-67S0R2=YN!</KQ7"597VV.A,,0
M^X4"D>X)FI/@OLB<[5B65SQNF'RA";O$:2B*2"=Y$%&&.7$_WEO_4PAEPZF;
M3"HH+[YSDC!*!JF5/P]EZ.=PMB9W&NSE4[25?G[M?QL_T[FOV/K?K#&EZFGA
M/98.=YO3UY"8<QRB4+M]D0QYX>(=N$)< QT0G ^_VJM/$JE)GE\GMZPPS!3>
M[U )C0F[\!O7P\1#-\6(-EQY$+J5S71@R3G+T CN7I[@6LPVF3M]\:40Z[+L
M]7H^SO?X08DR_DPH@;W@.R'RP&!Z >NI+E8.5W]<C[(818_CFPU,22/(AL0N
MU*N+BY$2Y+P7,0 $G>NP#-/V7F36,\%5BILV:TX;1R,*IX"*C5_31?];6BCI
M@5["2OQH23Y,-)[ ZCB 8TA'0FOYK2V]B5+>28G&9J45SWAWJLX;XT$U 924
M*(I\S;KJ,.9$[8RKN01*+90OB#NR!ASN'>S=].9=7KVT78G##?&:@,/0\78V
MH$RW=V9GNL7/9UBI>*E*EP0[ERZM[>? -@$8_?HS<I-AHOA!H')CX2E@$7P*
M,*Y1D,7Z=+2PH,IJTF6=U.9:MC)>'*?\>%+ QQ4\%5%F<,\8(=[Z1\]FI@!T
M)LM:"T--H-9D75U]O4ORE$>\5Z).9P*37V,JF D^\! ;4GH'>O@3_*H;M 6R
M_'GC;6RC06SZ9QX#RK)U:2514\I>TOF90E-;&G[7M2K?3XROR&^R+;7M;;P/
M= Y$[FTLRT/V0/"%3N_A6#<_D2X2.ZQ9P##RTA6(:>8-(][$P.AGZ05U*ZV6
M^DU42Z860 ^0D_[85K7,[4WEJLWJ-%OB8B3$55Z4_\4;.1>?75DH54%XDR9F
MF/ 0KWAM0[42^5'JU;3)D-%WC^=?9F2F*2C-WY,/.ZD7F^W@:T\!!3^T4$=[
MI!:5?Q PKY28)O,SSWH;24 LE>2-X^63YMP+AW</Z3$>UR@OS,9B"BJ>%$!X
M#ZN>HH>JBE;]*9)W'F5H.:#HU5S=&;YO+;WLE(LS"\*5WUT_.NCT*JT)G7(D
M/EWT08>4EW,.*&8YDF^O&^QMO79^WRS24TDP_MEUI%1T XFAH^Y:NVI6K6RC
MX4G]L()7ID>#=55#IM<ORBG4NRGUT107(\Y%(,@]G-CIY$KW'O< (Q.=:7)4
M!-Q]8!/GCCJJ.F'-M#[QJE!:W=Y1X,C>\+\^U@0YG]#I!Z 5J$ZT:8BN(#L%
M-,ERAP&%BHJG_:+E7J;!S)T:/]=&\,8Y_^H3G=E?.NYA# HNQ_O\ @Z_7UR8
M2'>G6S\=(=* YM\I),^47XO\L7Y]8*9C,-2=JYD2H]?"!U_?N-\X3A3/OCAN
M-MFG(2SLKP&:2&\<X&*K&GW@U[XH?5FRI.("H>+9J%,-C5//D>VX:_'=:]+G
MYI_XVR^_B:KFC/T&V.M+J< WUR"$0QQ./"5I*RI\99*'#1Q>[G0K4;8*FJTO
M?:F:9N[A]GS2K%C50]:N> H(;^+()@Q6-^MH7H_\,3GF ]F0_G;CR_9,8T/F
MN"SPYPJ[0( DC65G@MKB O.A&=647M2W^?8? _:7.K.M%5;X"HE@@6][QZQN
M@U)3'0N>B0X,JER8Q)J[Y,I)-GMXL,XI8$Q\8;0,4:&4E_H/*/%S(7Q>KF%4
M>.\40+T:*(&J<6&@BLI,H'(7<-SM#;7?T\U\!:=V_S07P_<!MYU79$.Z,.5.
MP^OJYV0_S-;C@?"J7+#Y3!0:<*AHTEY*/]?;DRH0+M)D]$'[BH/.$'[@,\O!
M-_'T+!T7><OTSC<#8/IU;CHB#%&@5;S1<J<J#LQ@)];+EKDYOI*@R7]MBY*O
M]JYL+[NQ>I#C#FBH&3O<99N_VM"?Z%PPU_Z#__ZRF-HR!5#JV+T'H'68<^)$
M4%K<RH7BD>C8!8,1HB).O4,J4=8#^4ZM.WW6T.BYTV,?+E%UY,?R_&DR&(RF
M+D'SO,95W[+Z&7(VR]GC*>L07T7*$%\Q\VQ(_UA>KL^C:%'3B.NQ\B\2>^V^
M%GMH%VX^;-1L_A.R^&M6.;1;27Y<0<CYPOM:U%%HEMP[A@%PT%#: .6%OKZ.
MX\03.V46HNJH BNNTQOI:>#$EK)9JWN)W[#7B)7A7&'O$T1\N;I!P\1PA+T2
M/_S6!1Q%NNN+VSNW,3(I-O;??0+ISEORQ+Y?!ITH5Z!4IN=;4:OZA( <0C;0
M3T$WRWB=SK+HFQJLV'BZ^*26M=/QFE*=A<RA:U"FA1PX],BCB+HAAKC/PJX4
M<TN5]EVNSH)DDPWMBA6)^27_>V+7BD">?%NRW/>%\)H%Q@VII[811;?%(+8_
M'[UPTV@_3/NT7'D([P%S-6\].3# YYU%H:1O(@8GL!-_J<T_Q>1$V/S-"05;
MC'PFI8UQB8V'G-T[=].[K4GR%Q1R[RZ^EF_%C'.DO-F:&",@2^?7WMA(#12;
MK+%KXP\2"^VD"ACNU?6_7NC,<%'7;CYD"K,NLEN@;3(W=T#[Q&V5T1Z+VD[O
M];/[^"US"ZNOJ_"X*U*HWZ-@CL+$2/I*^YUQ21;54E@+,.6Q#\3/!>9BL;M[
M[BJO[.Q% ;XW8G$JHYW8G"X:!Y:P?)S%'%Q10!,3JJ%JXJ _RT?WU2=H[[%,
M<>#4"??RV/CD58&\AHJAS?7JS# <W*?G@'T^RG_?VWW9>LO;F$=,H3D=T3B[
M2%= R?1MA(+B F,#OQ)R^^^__:QP,^/3YN[04'QSUTKGTVQIV76G>3"!UC!@
M>\Q!<!W26$.V7LO"(:,E@:K=R6?TERCIUN!?X-)87L-&@EY3<.RZN]@8/^N&
M7S<(B^J:\E8F7E?B0G&8X.)"$C1&%@Y?FCMV^1[G"02R1KM.O+!LVCEQLB[<
M)S5NNND?)9<MTC&NI2*BA)61OHJNTL2'^,80.E!I],7.^N''&D/>+K1DY!\;
M"(C+\%U4M['D\5IB)9]N*/\%D:NS;C3O7Y 4O10\TK#C1A/548JWE%FO'P3R
MP\NW, G4LZSMU)6AO>2LR]R$BVMF?6?;MMFK6F\MTU@8/8O-_OXJ?U3>,>J:
M66&<6.WDPJ) )&Z"W9K;B<YW3U,[<6++??A<>$"[)U_=VL9$T52?O_T$H:IT
MW9L[(*]Q7"!AQKU+UV3N?KT/W.CC4 [J Q$6V=@XZ7O1WEUK\($3*YQA5R-/
MFB6S-75P]_+G.CQ;._"76Y5P:V7O78(-7UT]RDU=B%80OYJK[3URDL4[*W:K
M*1C#QF.9Q8,![H-:V-9W;<4-X4^[^S)HIOA^TC1_47+MYHA&W_%S7<_U_,R6
MK?REJ74I\\?;W^/1)- SO(D&AM:&:N$>1!5)O2NYUX<^FE.E"@=C/ZXNB-SS
M>>4BYS$) 5>&/1IWL <=>$F-\HMMR\H_ X@?ZJ4Z#JA]3)JO>/5'$]__]HZ%
M*;B6*.Z(O: <E3*EM*)M2)1^I%]9L^R39YR?5G;;%$L\]1)(H%MK>W7FJ2<6
MEN==ZY]9]P+B9XC+[A49/#78L' )&N_C;I:M'/@V541!@E942JS&+,-HJ0V$
M^@.@CMR3TT,2M$ZL.06$WA3I!1-<S3:ZC,MZ]]^T5M>'H:62"B33FW3I/_VX
M\=P8GL(M'O*Y;:\/>/<; ;;D5H<3(J2IU4XJ*.;DTD.HY(/)*KX]V_%\^H;"
M@]B9H,IU2;)U:8&N$U-!23" X-1*,V>DBJOR.L0B50,]EF-?M0E93N B]^3&
M9F/*6U&'S<IYJ0<I*?A#([M?$_-4_I:'H$PT@\)ST,*-I=.K_KQ<P!$)KYBJ
M.77F->MW_KBA!Y/<NC,5CDZF4[XW<>R["QWCLT.IT1=YQYHT;X5 &D.64EXK
M/7&.>P)O[]F.>CSNJX==Z3[*J%_:$M9V[3RJ;O&;SZ0_V;N34?KZ'%A @;SW
M/#5%D03HJCXN)5+"#_84B\5N!V6'^=!(MAGQOXM;> %P /R,)L\T&0M)3YRI
MJ( 2F#G3M&MV2:WB:2.;OI"R52ULWVKE:O*4]O?UZ6C8[@"SBY1WXX&L[$;O
MPP.@N$[MF$2CJ=S@98AQU\>NW.40W8!A_R2[R)+$YW_HE] 7HFHQ(:Y[7J()
M&Q8JJ3:Z5;VJBP?>5V_1'KI3&,2'E.U3],)0C@L-$(VRX&F=9E((#L+#"3M-
M=X;N8ENKCV,A  JP+]DX/_UHP+7D%),9A#Y7K<?L=_RO$6=/2/,S;?[7)QQK
MK(+?0KLVL_3G-PCJ_F+MLHJRP_PJ'XSAXYU3!ZTT>R=<%W<<<VUU6CYLPJS[
M;%D/'#O?Q[[M^SS/S([J:CR^*.Q[4R"T2=;!9W^CN]XTT>R1O/TT+9T'7Z9)
MM,''2;>#AIT3;Q*WE_1J@\/W$Y&N7BPR[#918*E1D:&K2M4^UPG1M*EC%#>1
MX#Q=*Y@=.N/Y/*GZ#P1,MM(B@<+/+# 9$@0Z#L2^06?;',MWEK5/ =:O.7US
M&J]FCA?HMA-:3@$J8]4U6&B4I,\I@&&VM$<KQLB"K+ILEI=T3<<Y"31R<L%3
M^8J"2,4IP&EM_@XV(E;;HD/\_)3+>] 7_D1DX4IBSP,7415R!?Q>BP AQ4DX
MBCM( #M9LQP/A#YNY#"[KYI>E/1D)9J\;ZO'5OW30L5"0?]<#8>'Y]H)].AK
M![8#WOAPO%R!+&<M.1^VZ\C2I?NB^WII^DL!0MIYLF%?2SZ!:2)H:4#Y$L%Q
M^'[E[9&9FQP+._)7DRWQ_.\]RH2T#.WM/U0CM=^TL_>RQ_;G /SOY9<XN)$:
M&5(0&W7_JS&R_ZFUK(!8BC$P^UC3-.*N6>H>(Z6J^(&!GK$LFLE]U>4.F5*N
MVXT:7X,R4[A/IZ=W7OX[J;S;5(U]P:^=YUI>N[8)',8Q:L'ZFLBYN\HX>I#C
M&Z(AJ22JM-?//>9^JE:1.XIWO%^)MN0)<:]X,[:V@.,N)$3;'3F6^4O,/5"F
M'[S>G!*^M^J5('1?)C[+K!&2)2LS-\R9,;Z$"+W^J66"J H#[L?DKHN+0VP2
M>1X7 LX]H+Q^23Z6;%6=WZ)!"TIKR\4S(:',-FO87%N>/, C5G_/\\,AE-N'
MC<?Z%%!FJF=:+]RP<8* F,;CKL\<D9HV R,%BP1_&=/-2Y<O"0!<M$&2HR\>
M/&#3/T^_I3D_?4ZA7)D1OM*#2ER J^V5B7<FIU"(>16>&W1C)&Y2T+*0#D\!
M/N5B"D\ME\#1+M"*T)UX!7!^D=J;.)"3)3DE)W$@X:[C'(%G0M\[S1?T:<(7
MB%&\AC[HJ&K*M&P-5.SO6[G.'1^$:E%9BP^44J#YH%Y!6*=C,5X%9:_*N;^I
M'EM*YN5,.1]('4SK',K#H.-"ZST>DYZB]:O=FR+H1SN2^6Q7(B3CA;[A,?LS
MOQR1+,7%-5&M\NN"W9:ZJ%"-/4E:_ $\5HPH-))1-_RTV\>N4.URSF4* # $
MQ#C3BI_0O/ '?S+3]O)#QX4W;%?!L@C!<,^[HS^DAMTY(7D95L>]LAS/_-0=
MFYM?-B7^:ZXQ#P5=V^/65LYU/1.X! Y')9.8,WZX33Q7H4U":SZ[-3<K0MU$
MMIL8[9W80RLMKUJ)<T1FB73R9?=F0XRD4TKLQ"H&;AOU?5O?F5U>J0 *Y8Y4
M:T-ZS 1'\67@SL[.!MI(X*8$BNQ%PDMEOS=DU>1#HK1^KF85>N-FC:< :)8T
M2B<3M=??\#+=(=?6H\$]E;&V)L(\0O/SY1SRC)-;DXR/Y^:^CM4&G#D2P.\_
M@"GHHEOI%^#9X$OP&QSBA2H74X](V,Q;$])SCP&RENVKWGOKZ@+H]BQXYK%\
M^_RMJ=+>6+[HMW@AC?U.QEQBI;CS01V&///>7;F6Z^S#G</AGAEB5>,O)_:
M^OS:#X7<O]1N!I&U[;4-@3G?.+>7>VU6*T>@IKP]@WVEK^>_F0Z;P3L\\7D5
MD-9DH\F?F/'ZM:)8ZN.#TC/'U8K51PW_D%727Y@[0&0$9'TE("$C*4OQHY:C
MH-*T@<D:5M3WY-O+]GC/;1=75&S2MMS_9,M]  "EBM:S;S?__L'_KPP68HEK
MX4)TJ#H[5=BX]%JB80SL5*'0A.?*@2I!\3M!:V.-TS<E_>Z&CIA$R5Q8"I_S
M@JVPJER$<DO-_HQ>82LJS$[[&^5"DWB(:F.^5_,'&9'.,1803Q]YE^B9M/,W
M[6E9/#DQ"L=CCIT/OP^'FPFEM+=<J9]<#)0M)\_5O9T;3-T+J)5MVSAR-D,4
MKK?<($#*U-$@ZZ=Q1B.212E;MI<_G:0^:6(-$O=M-(CU(F?E?&:<D5-FP_S9
M 3/3UZ2]..<B05?8"0!_TNCD64*$95%^I0\4U:H@7U=B;AQ;T(PSQ,6\-6#W
MRYL< ^5]>"%4OZNSS;IH_N#2CXQ*SXT3VU, )>YZS76GC4E$RJ+/C<Q"8[L&
M7Y9]\=Q]Y$7^R/NK_7:#KO[GL(UPY?8I8XG$TG&U^N_NQXW?HJ[4;XH'F%Z7
M-3XZUUQS^6\-/<Y]\M4MBZ,A0)],/;J!J&P;"V_O0<M1[[/MZ/D:8;3IVCW$
M9C>D [EEDD)%2P=Y@:\ "M31&>^/42D5X41HP:J4/VC*T8&HN:1MS$UX^[7=
M,6=3<-8<T<2R_?Z@3WF^R--VYLC26.(KU"[CSLCMS1:!E@+;0MN#-ZHG67DS
M81HY$2W;'5]F ^<>R H$7JHPP1Z$2^PPVB0?U:8HI\%$,0IW,M8[*YF6G\*Y
M0'S:XS4(*G Y(4XE>4FXS$W&,? NAWQ2>IR\"E J,?[SCED =J,#I<0^)F+5
M$LLJXB[?VYPZM7"B5VEO(7E$-E4]KG<"JB9^.58Z!<1EIH#7@#&,ND_^-D+;
M"A[5E0H.<4N>P*?5U-;H7V0MLOCB+4B> %=.HOG*T-)]W!A2797Q?>)3)X?&
MO5@-<@6#2,UB. HZ FH16$M-^@WV(O%JSGUN2T@)<.EKY05LO8S>JBC\7$%<
MMYED:V5:K[=PEE.)C?.<-F<#PUVFA&^&KV<JZUIFQ?;ZUF6*$PCBFI.^DLYH
M*(79QJ=5U,J7>BP^.%ORW<_0Z&5BD )]**: -:\8Y32.FB2O.D 4K!Y)>*<$
M$JWSX1@5;;".1:F2YM97XDB+TAJ>*ZS9S;V=J(2=Q"?GE1)2GGX,TVJ8_&+N
M]M5$!GF?E>/MJZ$Y35)NP+Q>?U?/_N4_)8_^NED=7#AP1V4!H6>\FXMC]+8[
MZ_);JJUK:P8##KWOKGI>]CEV;V=CVI1X@FS*1:J,EB_*G7V#MG_C(/7*[/"A
MA<YDB[%^=(^I_W=,Y%"_5V"R]:N M];R#UP)[("T'C/0*2#8F$9.YG;+3*&=
M@9:MK:,5?9'KW-N@UTIA-<[3 C&2.Y3P)%]YW&7#A]!&S8+U^!;+Y9\<P)(V
M?H &*Z;RO-5ZBH&_8,.9& XT($H#E:SKFK,^)1]\1V8-*5!A[YSQ7I2M'R<<
M4Z[E[P9FDER(Q'O9YP8]C!T;& B<K===&;A)%<JA_@A#*9"JI>YW"EBJQ;?B
MGWMX.SAU#H\M3 Y_$"QMI5E#R:F'N@W*[2[/SLY U!FK&'3V+Y/)2A8]FTQ_
MD]C0^'<3_*A@A7ZK %PJPGLM^@1&5W:?$WW*5]D1G1$T<739*8H(S8>K/JAK
M:FI 0N*IFFM*$\_[A.J^*:93?"6^8^94"DM-&LN\3'Q2]:EVW/TW_4^3$N@.
M0:MUIBCK\YPN<'R?+)4!$O]]79&YXN@4\-K,B0U>TD:ZSL(E'7EUZ<1,=WG0
M22!5XJ"7/K'&15064\F3X;IQ91#8=5/BSNUXC:SXD651Q8N*W7#]^AR8'-6:
MMU.T)-4.LZUN,FEXO-1M=UA^\U:^+=W=K+K#=XW[%3H$YP]V7&S8&^EYZRZ.
M#1%&[Z2WZ2DL[I$OV,B0]!X.>CN<>)(R<NTR\0<5(FM O7\D;8>FW.=$.O>A
ML$FGLBW>H4G;W$O-S13>J=K?3&.$0IM+9^ ^*BV3VYVL(%Y;TZ<[4O)T+O *
M4".N-7I/*$V9W6[:5[U#+ECL=O)CG1L)@Y#M/IWNY96,YE<:Z.P&W%2#VXQ/
M*\?JOO9BZQ75CUH6IAFC)KXMMGB>GW&=\;55>#"MG3_S2*F#2).F>QD!6!"S
M6%E5R<+"<IE53JV1P^.5[&VR54H[[P+/[Z> "\KCV*M5^J2F5%(SV'&\AD,1
MJA/T>'R; 3WE1L=9Z,**R)BTJP.'F'$WC?@JPE%28X:=?C[7Y\K?;QM.W_LZ
M'3:"29#W<S6=D[K^JX0P]/_FH,<_KU>I*]VM-*MRLPU6'797J;P8A!H;??RP
MQHUN1AQ\F<_I_#%,?791 H%$<S_E:)9CSXX6'KW7=D][V,H>&"5QDX<,<+U=
MO;@6N8'/)%N5RF#$,37W%+A;%JP;6#]N?=M S'GU4J]O$5BW[=\LE(J]JNJ.
M(S<><QNT6.E28F1V_K+EQUNG4>X96,S6@+V$&?%DS"X?\\$?UYS8=Q@+.+0N
MKIX"!H$&@40FY5#S"0G4!&:B25J\--4O%W<8<U%9C"/N@FLTM0_6-6,Z\F8$
MSQ]Y+@,6=&O$-$MP#;FY*T66CRNGF7N'X5W^8P7K' U-,O53 &3"P-:D;"?0
M;3^S"X6;-S&>A25G4[U3/5=Y*\NT_R(FMO[DIGQ6":= A&/YGO)58\*1/H(>
MKG3TM9??B:'*L%<0^LZ _+N\.O0)G8! +A8:E#V*UTH[(=>+1%#:C7@-%,BQ
M/-Z:N[2:ZTZYJ@Z(5>TX!7S;7Z#?2^?N,.-M0DE<VCMD>5I3_W:86K D>/U<
M='H.P'D\J]O'S3E7M]0Y.YOG<G$.@&R$[%F"IN2*DU8SMY_[_?6YS)2%@KT.
MF3'!*9E1W2L7]'1? U8!!?^X367"B(0?(0+=3]@[GR*=;0O#%CPXPCV2 $GK
MZH/#!<W )]M #FYT142J0' -]T<3B)TT4I,N4\X0<IAI'5?5IPF@^SEKP(>>
MV1A\X"> %@C=45[B&2F%^/7\=O=DGBDI5S<ZE&S(M6]Q5X;9UR(U,]A7O_7*
MGHQR]1YLX$6406T8M;&HDE'*Q(5>Q<KA\_'QBSY;]$I"/;Y4'KNK#35ILW;Z
MUVX\JW(_SCT',$F,IL8(5+)>2\.CL*U+SQ/U_:J)#LCTH; .?^"G>AQ-1321
MOOAZ>5@1KUSH>\M#8*C_^LKR<]=,'><WK_QN4,$=S T=EF)94[9S[9C4_0&Y
MR-K L3F>VE 9<Y606/[+)7OD 4]&/WWZ:N;TZK\^^<DGZ'YK[F)[5D ;LKN5
M#EQ>'@/;'WGY_EM[44WYAKCSB/!6&U*&TWDG%A98.VHO&4>_H<1,"',"MD:*
M?#>J/GDI5OV(Z1Q/]!ZWI[PW9WS[N493Z[8,]E$%^H*UE.GO/])RUE =JU^L
M+V[Q,4]+8X1"[:.]_?DXEEK>V:*!JL:ANUX*JA_6C(-=;%"HKK[^8\U7I5X\
MOIF;&;0WU6Z< I0[MSTO226A\*WS9?43!%BG<?IVQ(64.)"]I'SZG0WWF%'Y
M:35HP^;%Q5. @HOXYZW5[*+:KJ3 /W(=Y5=-",BE9DI(BG:ZY*60I@BFN;GF
M%@+(M.%V3/SP1\I6Y\CMC> I7\H/T_"G7?H'[.F3L9E%INGW2!8;NS'M[PSX
M7GM@ZH_V\JI03ANDBP<C2WB8SU,<Q6XOVJJF9C*_XG)[KAVN((7Q(=M;05EY
MCA7.E8^?>7XT<E,1Q/7"M%JQR"CF<2/L26/6>/[;'T^"WI3*.RR29^KVK0W
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MSSY#2I[VB.#-G)P$*$(CG,;7S\2WYCLIKQ%W/&JC__E*NH]EB]TIIX*.5@A
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M:R0Q^%034RTF5%"*S]J0AW,219QR]3<E1N*9MI]48?WA]Q!ONA)/<;7<(MM
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M0!5)^J&25>BHHDOU.W_([QJ%"=GDF4;\RJ]/=K&A^P1.%]82O]=ZU:SF,**
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M%!<$!.?$$0#?"/SHQV$["4]'NYPE^].YD,H\_/B C'5O:MQP!(#.5@?=Z1Z
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M)[3VC^><IV_-J33+^6##+FJ&UVM^[@D)V]UHL8R8A4PI=6$$<&&^!@% +B.
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M^I)0^>.R"@J.U)W:__8K8IL\L8='P:<SZH???3?8Y:I^*2LER.99F@QM4NZ
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M3%("+"2L99,8!QLJ$SA6X>RQJ,W$&/(JC9?/D;Q^H;*+#S-J=R94%3?D%;9
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MQC-7'C$H6(IGG-8Q]JD0T(YYQ+U++-.I'*DLX<<^IB)94B3NT HM3N1+*FS
M93JS;3T9Q+40P)7& <$='SS<;A3P?Q#CH+3VT9]2'UV/W.1LWI&0W0Q_B$QM
M]878NU4E!FN[-\1EZ<)N*H64!?N<^?@(Z?T"B9&"?*?IPI9Z>([! 5Y+?U?1
M%<%G60)"==BR_M/'6^)WE^_P.B43]7FJ3! )E9U<7R85.;D=QC52<7NEP<S?
MOG> ]ZY!7/+;Z!L1#F';:VN3DNKRR-0$Y,]X@NA#O=_9!WT@]3MVR]W'4$
MQI+738O((FU]HM8:)-2+<V?(T,BPH7H=5X<(IQN$++VV*2A9W?'IWED,$I](
MQ1GJ+(\S<;M5N_$'L^_7[[U=S9D*O&/%Q9.HV;2[""7L"6XL?V#OJO(FIZU
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MDOPH91TL^BQB//\7*.4W_0<<#3'T_P!02P,$%     @ .S!I5O6RSBA^T@
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M,"FW1[?Q$2#)V.FQ;53VK; ];U<[W>WW8? T11@_9B 0]Z3T_3OJ_^F)H?\
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MEU=LS]E(UH;DD0$NXHW+%#L-_F_@GV5[$6\\H!.B:-O,1E3R@V->U8G-;R/
M@#LFA!63XMV[>A1K'U9W6I9Q6PMO3>@]+8N;4/W]RZ@F-:$-O)L.J$U>YDQM
M-BHCB>W8I)*33\?H>>%H".P.* Z<>[78$=&J?=7Z/(DD/$W'Y6&UGUZ>_ZK
MQAW0EH'FK*J?$KR1O"VXAC-+2&:#!H42(>NQ]Y:9C&EUW:.$P67\UY,-[].0
M; ':UO1R3W9?49V9%.V#[EMIZX+-R.LPSX;1& :PTF(4QVH,J_I/*_'G,5B&
M*B-=@ZPC<U57FW= 60SYU2<8*J!;O*"RA$O#^BFGG,;;-I'!H%[VD%TM_"K-
MS?"5F+U5I$9TIE&:N]NDNJSK]R?_V9S3?P/*Z#4H^9RGO*R]-H8SDHDLS\!^
M2MDB#A<G*+XG4+@HFS[0*AM?ORRQT#:5Q*Q$[[6'#;I*D\DTJ\L;Y#P$2??H
M&+EOK9-H!-]1I_TA%C,BF(PC_<,H G>'\]>_QDYE[)WIF,)R]&LDG3SD;T!*
MQ&U6&<<7'<GCW3=?T<AYZ?S=132;&!XU/..6$4!BI=/0#%>ZN$BD-=<-Y)$Y
MPPF"]A1.\*Y-N9:JO+KO%K9'\8VRC9 RD$5T1'+T?@E'R8QW;&Q0H+&QP?SC
M2!R^R/SWI_1G6OV;\=E;@5QCLA2 ^G\#%_WM*-ZJD0A_&@2:WZ"ZH"2-2**A
M(M&W:J%1093^O$\0:WI,U]W_^<2QKT' :E'2AHEN1Z72$!7+\]F>Q_7;5]?:
MFP"%QHO[&G]DW@DH[CPG>'PCI3K&<\"STEB3+/$T^"6S,#$QC9,7SKO[4?]L
M/:<6ZL>/69O*77=A>$%M@(.S5$NBE0.A?.$?%]S]'@[LZISZ>"+4J3R2^ZS!
ME7]I=B^A\!M;V ^[T3^EO:*2I'T[*JYG@/I[M](YP46"=RVAZODU-4GFQ )Y
M)4DOXA:T X*K&Z&D*!&E:5XRUKK&0$7F#CP9%^][BK=6V-[_G&ZJSLHU*XJ,
MC=UL[@M[35CP4.M"= \6TDGR>@C0R_EU@-8J7$+5W &=ZFQ]+16AGU+2N>2T
M*F)$(".G9["!?\X(E;%HH: %N[5IVA=P]@@WK2KWN#4_"34!6?+R)8V-H!ZQ
M7LHQ3TB7MV74F:Z;/?/Z<'4:2V)U8KC6!V_2.V"&%H<.F/IOD^6YL)<0MQ\V
M5!>.O_<,K,FH1A9=\IZAD3*,RNO:*,XB6\V6:A\<[]2UIZE=;Q7M3AL'-?*;
M%;=@GB!#E-2/O5]PE,WN@WS/?1P794>G<0E^@,/2D$=5_(,.)0+:+HT[5;4H
M!Z9BHAN"3<BRP:8F7FX68>,  VH20?V'$S,39^7A8$*[:EOE9N'QD</1M[_G
M4R;-71A4WX<*//)B_(*U\^5?Y WEH.=^KW= X-E71]XGJ5MZ"WG"B'6?%8N,
MK$#BP@4=M7];OH 4,PN@M\8(( _A(A=^+2E>%C]ZUE$XJHQVWA5]:(4##NRI
M)NXU/%^MU0P&AZ6'3%&'!%PNC_2<NKUZQ^O]U-8RF[RGEI*SK<0+(WCL(@P*
M*V)H<B31^?]THE/4X[T&"M=Q+$3C5S3'K!X>\+!IQIS GH &<E&4%@RMG03*
M;2^$SD[57F0I\R44*%XS91/'M[>(34A:VSK9LV1-7XRA&TLY4^:YN/LV_G&*
MXV1;6,Y697(P C<^$956..=F57P>%].)#39)/I>NWG\/Z,2C?#"JX=W0"_SX
MOTJINOS#OTE[RC"V_SM.Y1X9P)H [*EX]4:X-<93V(!GKPV"S,-=)\A#/XA7
M2'WQ;TU16VLE52E9S,25MV^/U-O4#%S*E?KB 9XH(^3K]Q[,MGKM73\T-:(F
M&+<]AFNZO&<;W.Q@V<_0"F:9;5_U2[^H7,Z_YCD^P\#X2$J:_.D1U]"*D :O
MOO:O<65+41(D^0[+>^[&!!-AR7E!PGFH4]8>!;.%FVM>QVW]2XT:! QZ\?2S
MY*W26ZY+_/HGS;BMV8?G/ZUY[-$LWRP)?-:>>>GV+]1T73KJ7-P!;!J%8LJI
M(&J=,2^FKK5G&H6'MM;$T3^A[OKOJQ%=9KHS_0U3!;>;S1G"NJ#CUL*SZS.W
MEE(DM6ZHP\\?)RO)6Z]8(N6D:D^C&E>A.(8F1G> />IKU42?!ZPITR_Z#D""
MH?G>''_9NXVA=/SSL[%X+JT1:*E&B[#_>*FS$=GH*>^!8\0,>%^(EQ,S7_)7
MAS/'HU[ZFOQUHR!CYI5SD'7*'?"5<K=*RT=GC/2<0VH^X,6?\([2XCX1[R,U
MS9NDO]1FJIV#4OD GM[SX,6L/;\#8CVHK_/CTD@R?"#TG//.&[>XFB@=\E)?
MA9NQ7>VE)=<[8$S^'!QJH4E[@'G&0"$0,>V_P;M=+(:R7FWDB)D1$3'6/QGB
MVLOV?R(+@4<@5,+,*B986[\$/!YAS@9#P:G/\ZC@E]'' L8&,8SF"6NB=T#V
M-?[Q&0C'^EIUK@QH;*0_=CXIO@,L HIO.;]]M)W&,$;7[TC68H=B!#32S)VN
M'8,=SV>H06;!'5,MNQ8L\1<O-VX5T;9UX[X/<ZP#)>9A"YVHK7?R*\U@R1DU
M65M\[6F5VBU3C=^I"5%1)PKFSO+XAW%"LF?J06HY"0E8K"O$>=,%S-.J]6N<
M1 ^(9G@;/M$J:!Z+H$@@AL<1:!_*LALCII^5KK9Q1:U'UU!_J/XJ%55KG6VF
MW*WIDLN)DG*C'X5+ #V)]SHL6GFQL%3JK;#A1OV^5:.;12RD*^T:?95Y(4/2
M?P_T)2#R$J9"W:Y?5DB6$6SWL[]_2=KR#@B\ S05S6#6=*]+=J[?IJ5!.YW=
M9L '1</@U_H9OI!RMZ<]5'= S=]IFMM/(HW)W/0"\YY*X2=_81E4X9!OO*6^
MRF3+REB] _#?T/<3:JQ_*W0R=RQ$8:G^1KK'%^_9%LXKLB8I$$_S)\ "%>E/
M1QFGPBT12V08A\(B98DLO8\T_9=F20%*8^0HM8XDRM<X'OA\[EN*TI]/Y'>-
M*KZLV^;39)FO*GE4?MF^]1U6L&PS>:0@9L1S.9$M![YY=BM=O;=HV]]DNV9
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MPM,9E4!SATK#&ALY3GG4$#]/>-YC4E9QNJ?)_K(>)S@.@Y7J V>)$Q!;)2@
MA(QR;[8_,J ;] 25]."ZVD &.<,$X"/4 K']_E ^=<C$YQR^G-NPEGA+@G+&
M%W:V,;3F+1-#].K.YC 5;@/;O4E_0CQJJM_F/2"=7G=V!NXH@<4?FH,WTRE7
MN"Z"M;>:31XW-CG[?@6P!^OEK0IOYQ-92[01VNWN2J9[^A4RS#NX_3 ]9&;E
M/R3L<F8A<M^\3RDWF6[V87U&N:I7:2(Q:%M"MZ0XX1K(!]7T5>?\'K:#H.%4
M6_QJH2S[D1^G1#%G'!:]UY$6?HK[!.Z/F#=$%64X, :IZ-V;X6^@SI.O-DOI
M+L'V">VR^% -'9%TF;C"\L6Q_^19T#]L5^@HR?2:ELX:;WE$=D&=/E14N1*Q
MA:I^]&=DE$B,--3Z7^2@_;/F'I9V)CHY;ZVK"T5&J"9[#SR>+_&O=.!@G!TP
M.-[**)@7BDNSIM](F$-,*48Y)+5I)4)^7%H\ 956A%MV5TH]?1*]^")ZHQK[
M?MM4^CS%5@!\TVKJ%XKFD(DK=N\JU)RT+N/:%?&J31/#/'>E=6V,!6^KK:9^
M]!9^:]OR\[<%CP *5?<5:F"!3#</IQZ[V7@3PKQ%5\(W)SGP?:O $17SQ8PU
MR(NR8^J39,1_T1/,-9S^TA<TDQHG-=SGX?G4T02X#II3:(#B^)**/(?%3GC%
M7;K9EIPS>D9RP,A>.W9$'ZW+-Z/DQE_\FW7]%P !2)9;ET0E._<\W<GHRR'#
M.<V-(,SEZ0ZWW'E:F',E/W7_CB?%2G++*"*T#2TDY&@5;Q1"%81]O[G<>\S2
M#,E!YPGK(B>G)),2PF]!X2D,5K!4M*GT?"Z:3D)PT6:>]B7+B:&5Y;Q T@R6
M-_=D ZS401KH(KF>OD4 9/'FD]'O;Y-KAJRE*.!+#G8:LR@BLTW=HQ<VL08,
M!4T@RRJ'46CY.0U$DD_231IY'A3T0;8^WKLC[KY]_=T+]_8*7.+-E9%'^1@Q
M_/23>#'^@XK'^)<Z*[<"^\KR6=NW[IR4 W<(@.4%?,..VWZ0%7NZ$C8+X[KQ
MJ3#XY[:66^1L0[+")DYV^2?W5P,K0[O'-8QBZ2#[?=#(J6Z*0*58Z*F'1,_T
MI-J5_7?GQ*:IRZ?:H?S/JT?O"E-L6KRN4W1YVGQ.? +[5>CEHR,NA^]')OV(
M,.H4JE\)KKF D,[0ZU@"<+3=E[BN/6?7@YT$R:@F28@Y9!9A&P]])*G8Q6@#
MOWWU6?H:.G*3S/5I8C&Z7]SKH^295C8!,$$YG+'&V'$[MYVJ#D0]0_/,;X Y
MI=,V:\1]:MN$VY=V&Z E;/OFX%W6'#3K6@'OMR/#5;J::]_8@B':4P''L)9+
MT-ME/WS&<R)FL;&5C\Y01@.UPUQ#D!R9-'=AU:&*W@6CV3#O26(2Z"1+0[WU
M+@$(1ML*W_/"?(4M?-NW[W3&V41<)%AF;0;K8A49*R]FS7A3< X04T19(8X\
MU<KR_J@=6=66^7>YE#](2+'=5@:)W'7]G-\S5_L,<OAW&@?>%LZW.K"=BNDD
ML0^STO3,XR]7<QSFX77#!/<;=LU(70>B8#WKA0,8Q3J>]':SL@@J?%^!_L#2
M-<IUHS4XBF0/&2L0:S!K"'L:N$DYZ PJ?"]Z'Z<XW\4TG/.  #@IS3G2+3=[
M2H5<8-O\NHC*WKN?WR0<=H%-N'C**47?&1._#&F> C<ZXSJ)ZT)/(/XI+Q&T
M4[,%:\I-#^/P;\W[UT[6XS<$H&0VK/?\A*+-_=J@8V5QTP0 D,9ABMYS</2H
M"N'PA]5MFC!)J_F#T_O5_37!CX6"_2,@5LP+MV8.!XZ.BU+D1R4$4VV3HFV5
M,(XL9M.W0<=NK_$BN/PT_\6U< O&>/R!%>TUO6BJU LKP&X+G1@BBT)CT4F<
M3%T=BNQ,WT'Y[U):#O-#&35.,H=Q+U># ]EFLC//!4R%%#E@1S:#\Y/QSWYO
MM0K$LM:])EFWKS.$S_!SQW]M!]=>(B%>:EQ6C=AN9>6.Z0Y]%WT'.O9"Z$6*
MR7R2 4QVL R68C#:UMN"-^8.V_]=20#R?N1HY$RY[I=PTOQ4'VHR+1E+Q#V9
MVZHTO*>XEV/_LAAG4SC2 "IY\=BEIW/W+G,)%QDLGY5X^X7)HX9HH3)D?UCT
MK["BW"J8HR=EAV 0I%W?N\],QRLW"%?L6]?K97>63P N#0Q'A(ILG>\WT3[2
M2:FI;SMI/) W\%9<A%+<A2F6T=^Z%(H*:]25P.O3!N6Z]Q@WF$:_&%FP2Q!Y
M*^ET ANS+DK(W(I/ TV*659^)@ ]K4F0V@'HR;,B^$N,FPW3C7+#F)H?B3^>
M:SOM7:0LY293>67.IHZBJT<&%$>",<EP7/CZX/2,M; XSU+RP6*U!#44A.IS
M$8.V[!KH5<X8=Y@;8FCVP&$BYS9#NQ]V"][<G&IB?@I;#'V6NVWY.KT\H;K'
M4#"7YU$^;]WA*N:=WEZ,+GMRE3]V+W=D,2FU_5S.=3VIV!<O.*MN<*X#,TM:
M8X@Y;KSJ7AF">PH**/=2;%$12A(]_7)'Y ZN)]%,9 5ZE%]3C@0%%?$L5P47
MW0_1I@A=.[KZCI7H@WN,K KT>56Q;?ISX><=&"-G\,B&BN,\N6".Y6,!TM["
MMK0'3V9=U\D:?2_PY@CGDUR:J3&K XENO?@)ZWZJ2/7D1JGL+?=;+3V(KH1M
M_HOD7S/''P=F?9K=[M#1VPN-*^SFNB\7?\:U)V[RH'3.?M]<P]WF!8S).5\&
MMO^"\C#_1L:FP[)Y@GF5*--K]7/.75HE*D,V81U[#SZ:L@K8GF%KXXO+V>DA
M^=337@$7H?3/-YSY+KEZD]".L=4ZJ6$%&KQ<L5V=6^KT.YZ>_I8R]<@_GBJE
M:]\%!<<W!RCBGG[8?%A$LKRD4;I3/+P2#I-A6\ _ ZV_^H,?,J\)VHCWJ-0<
M_.**+V'6,37(.;8[IQHLP4[W#QU9I(T9%JHV]^"EX#R+4A$*EW#Y@1>>R+ M
M/D886QD=E,<82P"6\]L,RC%6YK'";H?=7E]&[YP[*4^-Q;10UD%U6SJ6<T^X
M\ ^RQL/03!\"JCW^"H:P" D"0.W?T,/R6)$!S2=%N7()[U)OLU!_;?RJ'G?A
M-A?].24HZT.3C;UUK>WN4H /V[,,=$9T766$B>_ND^^8UZM;NZ?,],?CH4=J
MF*.1OI+DSS*51]^'",!U>,C18Q=RPQZ9,;+>><S&4CU%B%1!2L>#ENU^<(N?
M*8\JZ_AB5L3KV?F!1^C0YY3C@N4V"WW71H@^T,D=Q7W%!\&&*W_FAY(X3#W0
M;-=-/H"&T]!5'.>6S%U/,U48?'C.:?"PL$)TVEZ'1EWV\K^]UL'?MG?%\A*\
M9#]916GR'VU(+X3XF&,"#7]*".;U7<#2#@M^Z;#:9NK&HH=76B3DD>)M.KEN
M.1@+?44T4[#W_"\U\0?M XP,G K+:PN)SH7PJ]Y<B%74!U9V5'0M79;3Z]]-
M5YW*VHP<:V.7+34[U>>/EG?Q]Z8W", 5MN$=0?TLU/WSUF"'&#-V3KU57TF^
MD$^OC\PV54N1R5G(_-:Y:Z,C&N%%1\$(INEG55.,W_E<3JL@YPQ7GH%>_I4T
M>8E\=E1(QVEV1JKS3FAF^"_5,?4(]V/:-2=O2_4K6W3)Y"C:]F^)%6G'/C]U
MSUHJ)+M8,7#U][H:!6D_OMV4DZ:-6V(QZ6C!LS2,'EU.'YZB[L_)</B4,9-X
MZ2CU2DO#W9$Z]73#+:Q1NZ%^4[L<HX((9TOQM6I)S:6L,H-91'CJQE\H</W3
M?Z' 28Z[G012,FP]32X/1Z;WG[2 B8KLUW5"]#667P4S^(Q-'J#V;@HOZT*(
M]-E!9#R\0._X^*T!_F3E7W_EP44VX46'<1;VCA\BEJ;V_L*#RYP4^!\\N&SX
M@[_PX S^(QZ<P/\C'IQ^S5JY;9K5KLM'QXXO?SSA5</7J^1NN4[)?HZ)4:L0
MV"#6D?QT K^-.,I/<GMED^_O.RS2M$@_" UU>ON4)*)D9O_WPJR'B2D)OD#V
MIS6]07_&_;&>O:B!H5>>E,\X"_NV#)^]_HR<]T;S0?W.(%*Q<,'^^=D7PN+,
MKYWZW"#T2 &A)Z$VK5DT#^<J#I+I!QL;S\#XO!;RSVOGN[:-8,RUR4"K3GSA
M9]V([6'P&N[;Q?;$T/F\SQAU^3@T<;ZQM'&1O_GA<XZ*1HQ0)DF+G411B0Y=
M3K=W]=@6[Q$ +Q:I)$A4OSNLHV36OFR85(98!BQO?P*M 9MF.5)-![+:MC9H
M620N<\]+SV]]E-PJ9I@^^]&X<,NWFP;L83Q;?]9H>L ].[=E<G=4.]OJL873
MYU!Y$DE@A[-;)L>*PP71<S8T/"?4JP"=?G,"*T'MR]:H2>9?%[+".GF7J+$Y
M<11+&A& D@S6V:VVJ&'#GA5WSZ[UV@[AR#O<DF.>=TY$P4I+RH;U!* HJ)CC
M?0_MNQH>J9.1U5QK&Z;\L;"SUO'Y-V573H06WG1CV<WV8(Z<AK8F!RLL_,T&
M-H8OW#T^]1;N];J;'OKK1SQ(L>4WLCZQSYUC??E$,6K@S/&$ 'Q:WS9 5)BP
MH6AKFNQ)K&KT-[XT&% 1@#3P0:&9ZTXE#H(/O*4H=U!>AX9UV1& ?-J&MK2-
M \;RA);<>8L'4[,EJ02@XIP #%PK2T<EPYVHF](V%)F5FS^'9I*> D0?]-V5
MGR'1]];5HT4S00?#*Y_BCDU1?9IC$M[9TA:ITX*M.:OZ),S0W[JYYU)1<*[L
M^O6>E7(+_G@XK^-CB/V+!M,1_GWB;P\J^;<,0JP0>#AG&^:-E!EZVRC!L,?'
M9V6J[F1$&'55%)PB<B)2U#_05%-4_9'76\;CGO_P$VEO3\^'6%TU[AJ0/QKW
M.8R([;-TW'UP+UZ").7U^K[BI,>>05M[3+7*(^4R[9C3TJ@A/.M-OW6#1-G;
MH>T,$Q_!4W;^2-SF^-S]BG*'+'>E+@G$J01FN0N\=P+6) #C><)3V3E+"/,(
MK9$RYP_\G1-JK02 R8L27\\.N3^,D[PBG6K@,?*K96Z&PG!#;/D >]MH,*1,
MP!C;*'V@G5!OZFG<T'TDY PC-ISPS\-$+++'B(<HG<J"=V^=P#:/<JP) !4/
MCV^04M NA0BU"*?_AEC*<!6YC';#F/FAO=V[N-K+[J:I&YS',8M)9IHMAOHE
M[=#5L@SKY=%;X\A<[?DF66A<YJ_PQK(V);PA.]_9JS'!CENFL[M!HJ9/*]K!
ML^KCR*LCMM.JE>$:I/HN7)$G,G[%ZY/RO?/!(*7IR!># JZ\A=:%'HZB0HBZ
MPPU#G(-:.4*0JP_10#<4T<];\_X%&0% <DA0=AS^7'$[26[T$CC.;1\=K[VP
M*OCA6:":6=&LP:,Q^)MA9YSWKV*J;Y[7QR,QA_K;C[]:W&O+F53)F[T5$+%
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MBM/'.Z_Q+\P%?WO[C#0Q2(2H_>F/'<JW;KL&9%KNLVW&:X=&*N.+"PN'^0B
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M1%\QS]I.K.M231:Z_-QETJM72N@N9RED0+KA1B7F5P[CDJ>XLWB;[IB[F?M
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M18&DF!CT1.U1T<Z$)L-47J:AU[EU>B9*\5</7WZC0/YX^RTV#9/;H/7+JF)
M'Z513+N*=^'>R3JH6!#:3?#-P -;4MZ;IY<2@AX.G^-'S(<M %DF+94=A<%'
M);9=:E4>?'9*!8VJ!,PM.B:[L"9Z.EAK63VJP@1-^RO<E_T7-%#="JMH8^43
MX?#@ ROU]"WS!R"&E, /B]0W>*4C4H94)7)4E26@1II"1%TIZ%[A'\B8E)P_
M3E1Z.M,^)#IFZMC( B>WC[8N&E0YA.-HM8YR*EY; +:Z85.?"<[U1!']$7$=
M=VQ@57F02RO7\Q/$/.J[Z7*L0/P4A]WI]NTW?C8*<JW-^H(I_K1$E47\56GZ
MU1%,P6MY5NJ+(]=],0>*51UWKI;!""_'3'XLXIK-$"<]HA6E2WVU.N7[;_X$
M\^8129/AN-(\:*@$CG\4G0NC<]N"_?+B9%H,:"9?Z8N<,E/=/NOZ_M]A<$$8
M])V4V/ %9X$\"F3@?CO9#$#RI85DXNQ[.D-F;>X;\1<*/$*&%MKX6ODDK@N:
M)OF:O1HEYC;;)GAS%(BN-81>R_P_"H!SI;JVK1(NI/B%U*[;I<?KLDYJ*[<N
MZ^9\:.; U A_\5AXG)^50OWF&M5"DE:#KE1AHZ0?MW5"9X7NGJ[!O2L65)W7
MG)Q;+[ZGACROU9T+;U7#!V 6-<JB8K$;/L':9G'A-0HL..E1/[FA;H^ 67CH
MI="5U@;"I+L<M#*NZX*(H;#=,X_YF.>W][_Q<O)_P3@TJ)^EOZ"/CVL9_U[W
MK>12P1>&TO2;!^E%WS6RWI_P)-V13?[W>JEOH,L3[PW(' <]\Y6:N[.+07M%
M 'MY=H=DSYW;%(@D,G=EY0R[)'(CXVG!K,*5#Q+W-825B?P-9>S*1*W9318?
MA<%4\P/M-/WELZBG=MI%U9QA'.3:"(BW<6!>8Z&EN%3IN1I'XSLEEY4CVEDL
MJ)F:C8B&);Z/-CKN8,@EA0*):]\JOP:XJ'@'VF[!CGQVC%),S%9-)_=\G?G^
MDR= ?NI\9"Y9MQTFHUT8X'9VU(>_[]X#IBRE9$6JV)?.;<2;<J\U3HR\E;%(
MQX^H>D_=2M<)(5:N+VH4-TR''Y'UAJ[0NH@MU#&:K,V,L[>P^4"OE@V%NX<'
MI,"F%DC.W&37U?_Y_8W_P44M, <]-K;2C+03'Y_>F:3^L3CI)C>_@_2[[N-Z
M.NDJ]\>8V\S'Y?=]TV5@^K@$_E.F<U-SZTMN6BW=MWXF/%:UP=WF%PHN,>S8
M37+0\$RWUS-[KDRHA@7/&[DEI2Z//YYK[[\=>=.0IHA0]*NP3_OTS: ?W4B^
M J,KN/7>H+GAZ2U \-?T]7GR6C:+GV)E-042G,Q9UV:@6.9,U-G0Q4E",UR?
MZ+2KV3H]^LB+Y4^VD&CDO-NB(!Y2(.HP*K<T02:88#)]J^>X LAUDS,-M;NG
MG.3RMOU<EW':!SID@4>PG'H;M6\$D>Y\,E]3X4_K!,/>;^AP 031M0C>7?9S
M1(9SKMJA9,IPXA;W:4'JV"78F%FD7U"5:I=XJX9:7.PK0R&26+@X(/7+@<R&
M]]OF8?E5ZCS-*@SP]"R'6M7O,Z#?J8P\-O;B4'I'AAI;O1M),&-?A=9^_-GK
M[3_H#?^AHQAFY^J3.=RH%2GYB0)I36JTTU/_TJT-+VIV$\)L&O<;MJ6L^AVH
MBMX[<'P/X]#E1UK*75%.\%52?=_VN133=-+!20O>M&W0HJM3^6LH=7:_DHU8
MMX7,2UG99;4A77YP:_CIP (0^A-V0\L%=7Y52OQX##&'A0*)?>C.2]KR@ :Z
M<+'APWS38\H&&Z?UZ835-\T(YT>68%)K%1[LS9#SNQ?B23!G0=A=F/Y5GM(/
MG%*W$+6*;K[)X8W]=?R(&#$;^OQR,"^; _-&F8ES=N<-U06'":RL+33"/OF^
MY<EE#:L4",VOLA.;=Z.RY-O*XXZCJ/KJ@G>0+[M'[M=]'+>F%83[9#E\DK<,
MP9D#PM!6J$KP265CGM5S(6F"*@D$"@2QGQQ=0)3L*U/K'\_Y^DUFXZW/VX,L
M]0ZF[N94XMW>$IO,R?W=QHVO'\0U9"'143C&$(OY0MK+;>:.I(P7)YYP>[;K
MEC,2&\E4N@)R?.G69D.B.69)'G+*F^359_#.?L/=@2=/DJCYVVX#WX+)@O#]
M S$HU@76,Y9+@1 %(GC)/D(P; \VC7RA)9H"D6-&X1?Q?9L4"-^97G!L_8?+
M7(QR75AQ]?BL<74[#/QG,]0,'T>! , ^ Q\*A"!FRN#OSLP0G0]W;PHL2J=
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MU]2S"8L!+HOR+=LOBLZ#[/;TX:9,HA0((YYA\XQCFOX8BB16K&C2)4^ZD]+
M_R4M)(?70A214.3\ES6MWXQOJGB@YGIVY@$_)Q?:>U^C990PZZCSFTCNHT>7
M-9O*7,7^=W3,/[ F]_])>W/^_<[=T%"IE.$:-(>"^@S\8E97"3"]6@T-+O/2
M_7/K?/;-H 3:GYT#6>,"XW<<.1X>LVS]QD(2"<UN1SPQUXD5R+ 2^K&:DB#]
M[K'E"SWN5ZQ&CQ2H)ME\/>7B<U<0]*X.:[7:^G;""A]=%XZ0%LAY9/6<"<-Z
M3SO.KM*\&\*""ZZ2QYX\XJ@+5CN]DEO25] GP*BI8?^?>?ZH;N77DEJC"K?W
MCV2OADMLY_.C('C[S2O+'>=A7LPO2"+P_BK]ZSEB)9>?I  A/)[K,PW>U&TE
M@TA36:6$5'G"\UQ8 _N\ '^2A.'V.2_>9)"717XN7#5.O&]2%J>5-)N]R>2@
MZ!FWV],$<EFYTLVRW!VY!WYR10D?H*$?[LP)J-[WF'2]M@ ]^!F\4ZB<_:LB
MZ*>X.HU3"IE9HW'GCQJ^H976V6RR5TQITB-:"]4 C7*Z2Y\84EI.UE\,P ?H
M6F6'L!V+T#ZG>#3[.^-*5Y+*[L@K,-^Q_$?5[/_1I>V]^J.4)/=KU^F>.%:T
M^-F+=0UETO&GN?I=P;O(X&RKYG(2<OR!A)?]XTJ2)=5B(@42/G-.$'<0 5/O
M7U\7O1+7KJ=6MT-]&U(DDZPD'SK2ZP/#2JFS+WF)5SC86##ALA?4C[;^:C@Y
M4U3R9L+9?R2K0+^WAGN.5FE6K@C-W\7CK:8R[";>P1=X'MV$N+[DY"[HY229
M?X:? F'WN8-U>&LK5,IJRWSWF_++RIM29E9W.YN_49]JB$PGWX$^Z/OW*OWD
M&1^]8JFR[D0TB5X'2U->4.YI>VF*02)S\_MN_9J:G8_BT-6^.L[5BMY;RA^&
MHCA<=6#OSVV<>5FS^MT8Z)>Y-2LKW*.&&7GGRI+Z5MG;W?R9_BU^I_WGB@]D
MO$R51(^L)+.,3#1Y:1DK9UBSO0CAO[>[U^=I?Q*RX%4HZU?6-DTT*).J[8KT
M1Y-,3%05)QR=32\LQ52_AKW;P?78#DW,<"Z/SS1,V33ITPY >;J?50>-!&E\
M/L'Y[@I47>$A7L*4*;BAED717]_%<^'VS_C/6S :^B^,1\K0]*S+<F+]TWL/
MK9A288+>GH,WOE:D0=2-6PD!1K2>0H',!Q*[0=@@!'6;G:L9Y_S%)9,]3\#P
M!P62Y#7T'YY5V$J4I4!X%>9Z#HXK@4EYO)?ZZ_^LG?SO7+]M/(#_\\8#DCO[
MCHB6BNS,1(/SUQ2M^W5E?NVAGUB2[6-R5<\4\O&PMA)/.<+;<_>!<S+ WA6[
MN\=QEVW),%FO0":_H9W!7QY25M.TS?LB705^UU7MA*+SE[;N7SQHN?P$CJ>"
M1;@08)$^LMFS/%_>5Y+/^/^,PB<#^A-5Q65U\([J\B"7/XJ<RCJMH70R@'=L
M**L=QYX_GABI]#/4/7-/AUF0AUU9=40A7YGA"3U[7LI2NQ.M5$TSF7.U2C7>
M1<"2L'ZC[_QZBSS14>WPH+!6*6JVY,_V*<;%HGK?*1#?V\2E72OB#;DR$+!?
MH/6[MG.:_\T F<]*"^U08"_ LG-8$-I!C4,6JF-/1.7.ZEF+;Q4M^6-F]MH6
M<=FO/DRQ:S4]SL'\Z$\-Y5,[A*8T)#/%XA&7O9):N!.7=O"TP@J]F;&-C7N>
MC\2P7)L;VZ)R?'&&USG23YSII#LQPFM(:Q#7H6;<H"H]^O;]M^5)KB:N%N3Y
M<KA90BV=>P^UE2#JE[*9KUV.7JN[E7#'L0"^5;*'V/.:.#+/#*T8?*ZJ7Y!]
MB9T""7$D4"!"Z@-BTF!?TAW7[[U'^<WN'7,3?71AR%:*B915?=5*H,\^]%JV
MU+\$GO^SKR\UU4$-+7-;Z/)&!W95;B^^\.C]T\DU"D9X4HKD8*E-Q GR4_5$
MFTL,7R9K<@B.=UB#YQ$1KAUM/8$UE^/$B\IO[5HA#>DFPE] ;+1 PL(@=]T$
M'Z96,NC#M.O-NI$6.>>PUO&)^*T#TE692$7%BU"9DV/W>5:&X8GV3._)5'-_
MN2<@6_-N!7D$<K8Q!2U/).7UN0#C5,K#.^N BAK#+F_MM\BI%\+73QN]>:.4
MJ0;Q_N/YCK,<'T80/L\J8/+$YKM=P+$#V49%.5N+BZ[+1F*,1Q:E]AH[9/G1
ML'<XNY-&/_8TXM^HW8J*'Z"!]" GM>K8\"/RB>C,CWML!4DEH_H%M0UJPFF*
M9NQ.\K+?C_G:]/%_K,%;S%:3E'?.(.C&9#O*%Y]E:,-S--RB\1K4R3ZR?1E8
MWD#RY<FQ>Z9%(TA[9G4Z\<A[GV[C.K*))]<-$-0U!NF%C1-&PF3R.$@\5(45
M'&D[W_SY68=K;8UX+'9B0H'C9DO*X]N#?-F<$*HO2.>G>/?#$]8V_SAA+4O2
M\\ZU;M^G.:Q$2ZI(O >(Z*-]M+ .X7;%+@TAIE;7'Q]+N;O!YPNXT1-/ZN9K
M>[.?41-LX><_8UE08&I4U,P0J,WU73L4\C\$L9&O?WT \H7^V7_!*VI4(AJ8
M#7CNPO3R\%;1RH$;BH2["=/_*48?J&^X;\->N?X4I],4"D21;.I2<QZIOC33
MHE?):CX/ @8T%W;:OSLQ._&;;NJ-ZF\4B"N>F(,E*@[C<H[I;[R37_[&?T\=
M)4F-:?:R$W_0_[33Z7*5Q/&G+Z -A>.\6&YH;CO0D&@2*FD$S$D$%WXM5K^:
MAD GW01N1>V/J-EYVGDS)]HX,F(I$"]>&N#64_U@?Q_I[(7RY*^29&GGG_,8
M#K^8SDFBX+>R]SVIJPQ@ $TUS(%BQ Y7W]36UCCPGWPT'^-Z<0G\'>0!+#WH
M%:O/P4B\HRD.8]JG0*0JS+$Z3#!^[?Y?_JTTO4FCP,;G<_L)QFVX01O61[M)
M<\2^Z9FG$]8Z3OI&#<7U%QOY8<GTM9YV79D%F(FG!T8I-DD\;HU4?<%[!GW!
M9C/;3#-6Y%N]8C(GQ:YI]V!4?,I[LKK"R4P%C@['=_(F)A6CY?G0,94TU\(_
MB]K(#V:=7E:AURZY;P?5*QX1Q=44Q_G8-5X_^#%5SQEA4L@[B"O00F\4D'(R
M1-0R'WR7DKA(OX'".6SYGI<?R:]1R"J82MRZ_8%[+\U!@2R[]%D@=]3%IA*P
MT-17)?0.IH;RBZ3_EY^^_*-,P+I[<_X*%]V C- 7-39_P317UY?Y1.3NN*)D
MO?$C3['5LNV9R(W".C8?6W@+](4$V\O4US>UPB-"(RO7&H\$%R[>X1H#R0<B
M&%@RZ4=AZ !,H<RP6+7#*1^COE)E'[$OF3'9:P<"D^*FO)%WW>")6?21KU\U
M)O/A3+B(9ZY^C=G8O.PD\E,V[P+7Y N_LD6U.58_(9^7O2\&;#/"'O9/\9!^
M29SL:RPI%S[Q0!OB[=5+W?_D/]IW]O\Y@.1O ;'JE'"CIEI<^2M#NND7ID4X
MV=PIQE/I0_$MUE":4O::L@K$RT6R9]U/8B*0PA3D0SN7=#:V3PQ^BYI80F?&
M2S[JE(456\;IA.9'==W@Y-F(0<0&QW;,]3 MWZQA(X=6Z'16O["Z/,[BSA['
M3]#E=4 BX0412G<9)E(.AK>2.B*7$7,F2/KM0K]\.X6&A LYT:Z9WPUW/%I:
MB".L_ZV]*P]J(L_"K8@HPZ$" @()"HYR"LB-$%!)0(=+E$M0$! 18P3E3" @
M2C1RR*V H! .Y1(-J(A$;C!*"/=](Q ))(@AD) LLUNSY>Q5.U4S.S.U_O%5
M]>O^]5==7=7OO>_UJ_<KC'$H)M]TEK'WDAP>.(NN0F!05F[C!GM3AKI4@;6I
MUSKO,:MQ(0.ELO3 <$^R" MF[NV)M_0XX4='3OJ?G3IUR+"066WFB"_LJ=H>
MR@J6-GN+KAR<6.N7D>\:K]5MJ3W36N2_2$&>$OMX%V5!*$LR*;E0++6L<&^
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MI+,7Z4,\X[5,X3I,K5-WTH1+>U/?0X?<(P*#[-PL7<L<2-93@"$L$)3^ ST
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M_$H9NN2W-M\:/WO&/63+B6'<(.!Z=K'9V;[2N22]Y-2+"*$I+CM5>*R]P'7
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MP$;D:3D3 T8N#%8-C7?I#<Y2;3?T \V?>3+?-$==;2&_E"63035>7(<%I%-
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MW,$;X4H4(S,/<9507MF12#>;M,^Y7*4;6M]"G7A?>63QTVA)"Y:3J<F4KQK
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M[9[U_%G6&@PX0\Z(*.OQK^J:9\9X$=:8H4\84,C7>NSACB;+"8LKGE1,IVK
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M#*B6('*:-1S@BY <K6=*B[RJ4M1(@4ME__9QN\;19@PZWYZV\=WK0M1*\4>
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M]JS+O2Y^^*D7\UJ5.F7E,0_BJW:AN)!5/3MAI1&W!R-UF5B9"7L/UODZ_FH
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M-J%<SS5('5L1.\FY5WVA]X!58@GV9ZZ=R^90V6\7/F+A9SSFHA>GZ?%&+P.
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M['].L,#_)<G^1;!_E6L&@(6,A)@\9#P $/#]"'P+T1NY"QB" S*3NTK+2>"
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M,,9ZL>) L@@>\ZR&6VWLRK/'.I=V2C<!7ZIJR#N](J4ITE/QQ=CT*OU4EYO
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MH2Z[.6\SB*US;R!8B^TX+=^9@<()B>ISK%?TX#'1N/D-@UH'135?IJ[?C]R
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MP%31F)>=FD/X'S^*U63Q\\5[!!&4&T,/\XKF\:EOKNY!<,!AB.VQ<.%CNMC
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MKBW_Q% A,,8#E^EW,GZW#F7@S0W'F\O%5=64XHRKJPP83!!Q*P1D#':P"@<
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MU1-EKZ<+QQ"PJ"EU$8W73-'>)QYEL=#BN'L \.\X^!HN/O>P9/W.9^X!NI&
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M%/99+MHZW<=+S965_%R0I1$6S _1*V2,O%MK"D/SP0:.,1WUD,=N1CZ."+8
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MY+-WV=QH#O7N R[4R%<7GE.K3@)3BQ.]E86I5C+<KS_M?ON,P8LB/E)*&7?
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M*M&=<TL,N$U!Y@CA]J1^(CSD*9']S4JW] NIT+3:"-BV?TQNKIT$'56\5<
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M^/GB3;8^U?7N8Z$3=*H56K[V=K#)Q+9[*IX>#) BZN)W=/GT+>G]!P(/IN/
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MM:?Z9K@^UI>FT)IUY*O+;(D$:W)]@2E%@MH;?'/<JD<R>4<J/EDPV4OBP/\
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M'96SQ!KPNYSL^!#K^\J#2W','0THSC%_I ]0@']+V%/,QQMS^!X YC#'%$K
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MR[U*1PB<[]&= F^4W7O=BYS^+,\2G7&_/*:Q;V8S$]W4/[NE9^/V(#:KXLW
MW+:@@KZM^\.X[,KFP?D=,@ ;&Q,M[G%,^'BG^(]#N,)#CHN)P)7AW"G>.Q$4
M1Q&\U.I>XV.R_ "[&RFC36D%O['.C'<4 /Y5_E<]F"#2SUO+Z0H@P%,_0_CG
M"%A^#^%P!#B#<XQ)!D@ 6SJ1JHK8:K=A6EJ+ EUU 0O"25(VOATB9AUZ-#BF
M>[&3RTV9AT!+S39K?W!]\3GD_;Y-&8:$!!6Z6)*4NK>0P<';JVL4@KO&$BK^
M"ZN;5$TW>N5 60\$\N(%2BN @7+23D>:90=AXH%A$3N1YX? Z&=KZ_VGNW.K
MZDLN;H= H_/HYB'P0="_UXBN<OTZ3Q]K;;8CUE=V[%R)'4B<^8/)Y1FV29OF
MK3I_I93*75"Z^]=));).DE.%P%WZ@!SZO+$*ZJGIZ2>M3;KY-5 )_?-Y_AF=
M"98^HHP/&F+L]_)P;^+?:!&^>_.*\)M:PH/0W4'%@@&+"C5U%9MT>Y%4=S7H
M%YKAS?J6M_T;_N]+)131KAO7V]*>)[D'7Z]^MO7<Q>A#=:&>HB7^LW<92DSA
MRI%*3-$9D4K,UYDBE925F"*UC@2'P.&[+=W.?9L%_9 ELX?;QES-"YH+XE&[
M"CR/]QUIK$)5G=WX>L [7@<=WH5ZT-W17GMT/]6067/=8SL<]U)<=&W#*[$E
ML%]V]B%P)^,0R!^_:=:SX+0KWGZEMB).J&)/<!?-DVHSZ<VQ67  W33+H^\N
M5R1G_32"*>RS>+=Q%U+.:U"[SVJ7V0XGO>AE@2=L"[S;&9CCZ]X1ZM]5WV?Y
MV-](?ART1E:0EPH?U/=EO%Q7VY!4D#6T;62Y:]RTXN&,T_"WY5C4XML2\<+!
M@8-*I$C!<_. X(A=3WBE@0G)F%YS-XKVC9>:^[?S'QO>CY\E'GZ*0ZMT86VM
M^5'+VJKNU,HF7>&7R^8<0]#<(;>JU#*B2P3%?BL1I8? %[IO9(A; =PV-]A:
MA+MLI=N1"AFW&DX7C"^<KW</6S-/GW0TF#L$#!'^4RUZ7 LL?<%$#OL4&U<G
M>U(G=KPIHAIQ/>Z'+<2>$6V-E0K2Y2LJE.!:]2GRBGQ=2;.H<IJ](W/9]U[X
M<@&'Q1B-K@1JGP6Z+;ZJ#X[I_W8(?$*54M^<-%*INPKFYIV:>ZART8"@I'__
MXL4=+W^I@[CZR7>&NY7I$8NO1MU[3+8V]Z&.^ZQ%!9VN+N"GW*^-)N>YQE4D
M0-"/^P*Z2^"#HL_QDVE%MBQL2]%$3N X*6*&A/9QEL]UK#LB#LI.3&6?%NLX
M1Q,?+X:>K\=A;;5:GYCR%Z@ \Z;J'U24DZ>=)1"AT<+4BPZF7K(/N[<(UUU1
M5'AZ[SCAJ9!4I;>[$/]5R'VML=V2W3>":OSH=%Y4OG-R^R*_7YB3GZ^;H>V^
MO1V[>-E]&W/=YL*X7?T0XX(WQ8'$-8G%J2K)AP#^RN;*_BY[1;G\;IKLG>R
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MR+6MW+,@13Q*O;R+[,DB:KFMK:B/_,C";)W;:596+K%&#9>'SU\CZ9C^VFW
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MN2RS;*5Y$ &6;V(?J!4>V#)6[=9F-MA?8D6CK;;\BJS<VNY3)BWS&[CI)E
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M%.=&SK^Y:+8+>MGJO)I.F"9+N=Z'\R>;?DKN^^_8QH.1  ^]*@4!M.RGU<)
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ML\^K*9T/=)C@QX8$GQI=>4YI"CE=RZS182B15B[!N%E6\:$I3G]\_(S6 BZ
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M,,^/X6S'WS'Y6N>X5]%,X'\/UKI+'1UR'4:*-X]R%8M[$8;=ZBO:5$MC=JT
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M\9U'9 8?*DAR'%5./9;4HVHW;2AIN@A6["JDB59:VU:(=07W1]RU:ADM8#O
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ML]9)++P A'2!Q('K8\G,B/9^F&N!,](RT',.U;HGX)>'+7!"XN<L6_)@-PE
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M^ 709.'@QA]+ ;#$5B(5TJU([::X%F\$YYAL(IH]]?)PTKW$ND9V*UP-TO\
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MN2NKBH\$P9>.(W&H:$[35![CH3@B,#-EC*KDDPPS+#5A387J)NLZ;?INZ4"
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MM1TQ>V=5S9Q.T4D[U"Z(KA9T6=L5.&1'+F3FW3Z#AX-E:D<^W\8'Q(RE<MG
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MM_(;!RPQ_]7X5/_$C,JR%.[_F*O=;]* >MPT&D2=:ERJ9@@2B_Q4ZD;6]V+
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MK1&/MA(CNDLU3C+*_@<(BQF/(&T:6"O#_K&*,YB(DV[Z!>?Y]5[AC3K%9/]
M%6^<#V+? G',VW -51DR ]4RHXVNP&""<!7YQ369LO\6@CADEN;A96S\0C T
MI[NTKRY&36(3XQHZTF>MK[V/G&/-EY@2V.2K?/*QOO,E8QH_%0*G*80GO?39
M#>:6$)7E,L2)^3J,E;.G]$X,GNR($VLRHY4A$^$H:5CYY;AV0;$\4]E.UA)L
M4FP7(QCO_8G:$;M!))=MJ(CI"OD+ZAHV*I*K_\'S$OF5@][FF&_*JO08/3S@
M4<2$'7+URX:>?!S0&U->NKYQ,FPT2J%Y_BJ'6/;!@;F*W@]MR\VJM1SE5PA5
MI/O<1%=5U)^;Y_VZ;E\@'K._S@0D[\ QKG&N U^'>KJ9VWE-FF_P)$SL#*S<
ML<0%\<^" U<]_&9G0^>L^WH9EKX/-C8/\==,F.&+H4_X"$ >O^KTF4URXSWN
MJPZUDT/_WD\G'?VVQ:)09X6Q,_3O\SLEU:2)N;;<4#-L+_E%A[1^]+>#OR##
M:FR\FH2#9N%FGTH3[(KN1K/T99J ],1![T(_W6E;@[B6G)R@\[<,^T$\E7M\
M-3+\#K1/!+\\^Q50_?>P0U@L\U4K3V2^P:Q K07]GG4<OUU<TA#M1[ZEQ4/9
MJ.]'@RR4/E=D><?EC01G3/" CC5=HX8G<(>U?>-0?5HT3' H\WV+AKH)BPKS
MUMO\!M +$QE7H\SI?.+;81\@+8#[<Q4AV;>=VFM5/YK2.KR.X:'K+V[-8@Q/
M&*CY:\QGPNTPAVW]/@^HZ^M.^@G(I9'#\+O?GS)"'5'!M:!#<9RI(V'D_IO]
MQ=3?VC67)V.QR-M$U[NZE?[32?#/SPN2?29F]][%YJMYWW?-Y7CHK?L6@["Y
MSE*FQL@;!L.1;A79#3RMUV>L*;EO8/M[$JK;F[0ZFZO,I753\!\EU7#7=.WL
MT8&.E?BHS%1]KL6L<F$4DK52FID(_Z-L8:+?#./&?E]M5^\ XK'$[-V9 :1X
MHXYOS"<YKO_.N629T6:M-'VD?5"F5OI0P:5YZZZ M&H#C;U#FFW]%A1 +DY)
MD]?L'!QD"EV*DD\ID5^#QT?'V?C(FTDL,D785$ZJT)W:83C N(\%.>I5<KYU
MNQ4(.*<T6-_\?Q'VE4%Q=5V7C1,2(&AP=PTN08.[=N,0W-W=DN#N[M8TTK@3
MW"U XQ#<">XRSWQ34U,S]3WOG'_WW]VWSEE[[7WN7@MI&P4/@1EDM,H^0I'8
MGZOX;>^$G"[.;M'V,7)Y=ZA DY,8=VGC!": Z+JJG9<TDGLG9!_X@4.P1KN7
MM\5K[SNT9>'ZMPK4;3^WH!B62[3S38&6_6''"KH[17D7NF-(8,AP=8H4;A[T
M, _M/?8<'866']DRZ4=-V'TR-XE\&630:&Y!.MUNB"-Q[MF.N*+*&:F#\9S(
MOR>IV*8,,MQ>EB$YY[^G_H7M>YA#.*;:A'B[P<51J)DYEM+#8IJ_6T#-4]HC
M9Q'5)'F[7"4,9*AW@8YET$-3W8KT5@@@L^=J.:B6B3,N6,\G+XTI+V3SEPXV
M][=O *^2N)2X'L1(APY_*:N^%!_?"=8IYYI53?=?;2>E1K8TB[N!:1L?[&JF
M1$U%U_.?\?9KKZ8<*653,LK3_SM]:L:A<>3Z!GZ(JXK<48AT3;MWFN\"RPU!
MFDO"!88]GO?^3/C*\2G,ISUP6$Q?4LMHE$XC^V.0/6]Y*84I7%N]O])!H.+-
M%_V_JIZ+;:S(8QBK:O9C[@^$A(VPOU+:! 2-:QDYB7@GIY5$483O]%A/*@Q@
M[V"YN>Z!^F9N@Y[B1ZPK-S(*?YVY+BZ.F[+-[ .4&F9K:ZBYZ$:=H="-E8(S
MWRHQ&_" V-E7PL\KP[GQ.K\9V-_7$E&4P= ZU,DH-?4B(N&=!:U4P >[LKVT
MGXN#Q[\QI'_GJX6[I'AI$J82Z%9T\ADV]>W,ZU N0CA\$MA>OY5>W7OR\U_K
M5K0_?0/4G3U9EJ,4=)I?;VT').NK<@P\CH=:F0CP/.7)7.\&/\GAW[H(<1BU
M*0K2]9:>#..RS'G?@E#=HQD)/7X*@&QV2A@G)YYXPI.:,'$8ATV;/"*9@C](
M 0HSAEU]3(L%9TL>KU24GXKO"+)RS(=JUZ+'FTQ7<;E,+4QU&W<V=RG,V>.2
M@* ?Y@&_HR$V+Y-QMK,/-36KQ@:AR:$MM/EXT'<4>DKENI5')JCXFF?9(1UW
M\,B6B1'@?[G5,KUM2KF[R=@#U=<I-QS17N)$#D.2+&0'&59W/>K#F DB>*D8
MWZ6@( N(A'X$)^]R 'KF WICE'A/.>L.>@87BBR,LI+LW4RWYF/14XW\874+
M!D!P*G0M! FEY6+\J%V_W0<RW\6UQ]9#_&$+%F.>]B+&\^1>B.P!C0K$K/V$
MN:QU!@_R )_$>)>:[//TKV2A[Q&UFB4Z*M6!,AH-VMN6*TDEP\OENR-5\R/?
M ";#D9) :KRE1,D-"3?ELLS'C=O?UQHH]J>V+$=L!4Z1&4L^2DK4^IP:I[7;
M.W97C3!S"NHXGTBRJ*]13$W3JR.>9>3U=Q5>1'XQ ?MW( Q>-OLW0*NR0\\&
M[YI]M&%!@C29B+KI9Q,#F[H9$]^?S=50W3ME4H49P3(W^'#U$U'&9"R\-=#N
M-+?9)6K8JP)68:F@BJK*HG_E8*M/I"A5R)"BLBHQPFR<GK_@C:*P 7/;OJ52
MP)ETG+G<PAE3>2!/990IC[<[)86.!]*#NZ9\E,%[!N$UI>E.N=_F1O:A@\S-
MYM[WU9R?<Z9ZB3612U:>*^)3N,Y]$0!>ZX1VP]__K<L9/V8KY;Y74ZNP+K!]
M;_%8JE#=T+ 7O (*NZ[4U"\<Y%BK*+NC))@<&AH0%>BFL<K"[Z;]1'("5&YV
MA/1$Z3XIK1,?UE4J^J=UU[0"Y&_YW=FDE(O^6/Q)K<J8\WJ,M@4N.I_-V.?
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MG?^3Q9IHIUO2EP$X<W6NFORM< ,#N"?N1\<#&&P\ATW$XF^@/!.]FCM2^H/
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MC471,[(;$(;P%O36C,DK.2M!>=/8$U.C-7LA/L3U@7,I-?/^HL)38-L6NC>
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MO'!QS<U]YL^?AKJ:MB]&*[51;L]$5\<E?K>2O+2Z)3PFNXM>(W6_['5UO0'
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M DFWR7-IQI&\ Q?IG 5F7*>/B;?R>\4@D[RZ7:?26S*H--KR3,,D0\@+S>8
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M>G&!RP??#4@/#=*T[\O)<-H,T*L[YLB-\"L5(HI%#<L)JUDF8@*9OA655<.
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MW I^^(FE^V_7^,^3"W(NLB::S[HM)1<=UD5-ES:E@IN/#$F0U!.*'>$S>4G
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M<&[?OGV'Y X=*2G=$U9&UB?_\,"V .1$N/,$DG@X;  N.0X>.0ZV P#=S),
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M7(%,JRS-12%,#@_BJ1$BG>58(!^F_I4),<I7>0&:VL#;47ST=GW?5YIZ8#-
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MVX%!A_&#+\:V8Y%1TSPVC?&$KZY@/_:5EK$ H8J9.]=GD8N J162DJ2%Z.<
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M%=W4_S?E*<(-VJ:"-,'XGSJBJ4JPP/VLK^+1B)6A8#\Y!!/%D/((1^4+/X3
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MVKK%?#_K%8L%[\<#4>5D"8L0^-/3#=C0+T01DO8S?X-05M_/)3"YUXO6B^R
M/])8(%<%PO%(5 ,9&F$OQ96=$N8L,-\L4/E;JF=I63)]VY:L-8"BP?<<J1LV
ME%IHZ#?R'!%AL==M%KT0VF23'B0%\5X1T,50JE+D;F6WCNVE['>D:I>BFP^*
MLQE.\D6'Q<;_L3CR3P8"PX,%>L4FFO=@F.B7NWPP5!X6X/C+%:L@E^(\11UG
M@DVWL4!/DC<6,"7$ B/.4]E3*7Z46"#FR3&FC0P+9")*E#(-/D[_EZJQ+*5R
MN,T77U,W0D&WJ-GD#U:_B@C:AFS<E.@5@BCS*:C\[6D5PXOARO4XUR9(9:=
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M[RPQ#YT3 01N8?O#BRJYJB\;I&%=,T"O,AN>8[RD+197ZU"[<85]-E"!*;A
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M!_>)Z $B1-KH!R9I)[LV-08A$3EU*WC06RK=T0C145!Y()+,UJ8<<N?=D30
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M.GL69Y5I]7#ZW2=S*0.S&QTY8==E\XI>H.D#G$QHI_ASR]^PC%H[A#O &?#
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M3)9)#[HT/2Y1V:=0/5,'7/17@W)5%Y)WF*=;DCRF:OCDE4:)GETY9/.5/V*
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MZ3)?X"6/.I)O?8RI?GK='EM[8 0/QXHTTOFP;B2<V1MX#H<YO[_+!1;&#I6
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M[V$J0K3MI#N0%!7IP^MVS5,MG4;^\MB7@3)2E9^S#K69X'N=')!BWCQ,!%H
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MC%G*WS_\T>5<_CCA0&4C.Z;GZ!<)V@9LS7=7G2=A!N(YH*?8OW]7Z:U;?P
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MYQ?^A&T0!HYD56T#T=1,N-3N+:[:=M: /.GP5"3O MAAL;Z6M5ZPL&8P2J'
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MBOJMMKE_-9/*)@/O?%R)M>#P^OQ^U\@?3EWIH[Y\#>@LXQRL^*-ZH#?PL&2
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MZKR/GM29_[%A2]'H'"!A?E+*V$P&06I%,Y,[=S]YEG*/O.S\2,U/FMJ/$;]
M&$]Q15\%1 FYD(5^FJKX?@UHY)T#9^E/7Z69J>\V>:I%M R%N9NEV=D+&<<1
M!?RH' Z9SJ 9^]K%<NK\XE'R;\XU3=)JB4-HGAF6&T5XYE=YI4"ZT^ 54I_(
MZAWU2R,S^A-1"< C.<S/9/;3M'6WP\=>Q)5S='-02T7$Z_']CP4$74[W7F)V
M@AG 0XUS.C=69!M,SXM]SWKU?08A?+>2AWG@:K;POE.TV\49_'6.4_[J?DQ2
M51/3@<QDP3B<ZD>9*!&+Q.G[W0\;G[U?2/&M2OIHE42U=Y;F\U\JS^>ZMIW
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M>J]C9?+G3J-';@RKCSCPDM?K^3=@8IY>-SB8P*17'N+>E2S*)E87!5U/_R*
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MT[D^YXF"0490%\@$@P<O=-G9K)(6G+K _VK_4$_CDK^G@.-Q^>0_@5&\Y6L
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MZM*NLL6E9D Z'65VM01(QI/B9BKTRPR&JXR<:6:A8>(44PKG9)L9'5!KK&^
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M;P"@73#P=(E_?K*3GJ1R9Y0?#J\[ZEVV;Y*Y"&5WWI^M!)R"H][)"W?.)M)
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M/'<H@L0].Q,=Y%36&!,TH*LLU%8!<. D>VN<L(4-EW^=G#O6US=((7J2[<N
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MD+M<7/7]X(1CVXN!I2@].ER. N.9*D^F,D_I*8X&I%1\D5*<TKHBUP3%3'%
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MU3/;F8]=9\K7T5&Z9D9BXS><*"R-C[Q4&WOLAG(-)4[COB?C<2<O=&'$:V%
M8\)AHI*20]Z7<DOWZZ,5_/8#IYP0&/ NIL::8([(WQYJ7Z6XWAR5.G!&O::X
MO6F\D8?ZQ 4/ _K^7'4!QP2.=>Z5=/3="9X95;M2OJ7Z87Z[JRR]=%W.:TKM
MOEK&K=PG(KG<P*'>A3/OSOW-'K O?W19%I-1SVH.N_GE\;MH+2<B0.^3NRB%
M@\]'N*+(HM"Y)853X'1W[.]5.OYV,:C8,OU(]^J/ ^N7T&E+6A>DK&@*_3.]
MZTP?:GFE%<2@KVYA16T-Y9-,DB/!QBEG2$N$\/7+;MM);;%7)A(.W7_AWX_^
MLG/4'.2GKR<F42*UB\]37M?OE9N)5F'[;HFNP9HW62I4D:N[W<R<&IMXK(Q#
MD\_'<$T$-PIYZO,_@P'Y6^N]7);?NQUUE^D2)Y7#6JI.;GOJ9T[8Z</ &'IL
M"M]&?^N#":-=MYS4DG8^]S;HT&!:@ #7<OX5GJ))#,O0XN2!ID]&"_HY[@6_
M,0&2<V!-;7H%;YI_MGV>>)J4CT#MK(-/(N,FO]JA[NB(,1B@V_E&6O;/%6*U
MR"6:+AQASQQAX)/S2,#O+X/E^+'+<GQ4M$Y_5=W5X\PG__M?</W?1RH/E,\U
MB03&J-?M><)90>#UH@XTOE2(2U*5>=_V(I/V K6"6>?7NN]5/FDBR2_9^$>;
M)/[<:/I*&^@AJ+CFNWX,!IC]9"YH5)4_BV^O$)O)RBLC\>YT']W"KZ._%3CN
MSK"'%(FZ<KFE@<VM\+TQ-U9F,B7I.Z'03G3;'*&GL*,)Q5>8@$N?UWM:)1J9
M]/3XSL64)Y:4CGO#P[GR+N0#4AOQFEU93'-^L:-G1CY84VZ#QU*"R\&'- S%
MJZM=H++PVJ32V(."S-9SF3#09N1O2O6 5).X8H0I#R94>G3<VW5'6CW:(@W1
ML7O0D\Z;PX2<\JOS)3KJU:_B$-"?>?[O#,+XAHQY:MD_$Z;[H=(18U**GMMZ
M&9VQ$XT)Q\[C<^515/.DHNVGC<3QHVJ@-]\;J*/O\@+JX67JVH*6[ZG;O25M
M_.9??V_P&A8ZCL?RY;W$Z\SYSV>?CC:Y24ZNB=?,7GS=;4--XU-^[,)7FWU9
M<1'57\6;I^F[:%U6'71YPB4T6IDUTS?8-!D& C=81*W+NQ^6]:[79FCT]7YY
M!P.FOQ9J!W\HV+\-6@;9/IDT^H+$EM&0#_U"LC(W8,#C<NNHA1^2"EWQX-A)
MVDK9E]@MB[M6\610/?9TW+NSB8.X]S!P!)UMGV(D42/^DRW7R]W3TNJ;<\G,
M>B,J41["!Q9FHSCMRDCA[F)[U)?(,(!.O-'FSNN[1'Q"8[/Y26EKK(KDGNQS
M[#:=:'SD]X9A?8@B9<=SG%/@8N\02F9*%:=3SL=;<.B7DPJX^*81U5_J4&-/
M')Y=C=<+/= Z%K1X7@V5/= ZK^X[T8%:.,+R\O[K+>:7KE8MS-3EF];D=NM1
MRO7;-GZYTBME2LSL]IPO1QDW')@@MQ*!'-.8/W(%9 U4CK/F"/;D?<<]+550
MB&PD4F+TY=O3[+J-\3M$R*(?5[[HX^%IX97>KB*Y.2HC^K.5=D@1C.-D24E2
M]G[OM7CK^5.YE=!?0J4CLIS1X$JJZKSQZS&IOE/<6I(:GQ42VXS#R_T9&6AS
M'\SX2SF^%T44]3X$#]I-^-3=2PBX-P\2+X: _7/F@KB1^1]UX/CE]'K7K/3*
MM*G/K&"!W%/5KO5Y&$C7@8$#6Z$JGG;G$B!Z21ZM/_)\E9RQ:)(%FJ(3C2D7
MN[I^WV [(L%KH&&IQZ*'P!N"WN60S<W7F4*Q":0(=L, ;PFZ/T7>@-@R7S2O
M.N^-IG1_6+;O,K)LJF)QZU_O6:_&DG.B0!6GQ,^!5-,<2B=3%,<->V,]M][?
MN&YW&.#QZG.;ZH9Z86#X ?(+*%<VX-I4S1IAAH90Y'='O*PNJ>L01N_:[-'X
M'\>C_P,DRF5"-H]*92LOMW-"'7!D'Q?%*V7@._94L!3Q4>*;)3_'A_ZV"I3C
MQ*$$T4N7MX56%FPS3__8:1(0[:ZYS"X;RUGALE-M&#IO197(J9RLZ9[5)6.:
M\EZ7?WAJ,F_WTYWUQG6HZA(,&(*#YG+ZRV&DCWO''<D<Q.HW/V;+HZ);,$N5
MV_AROH.C S3K-"_%GM\N(NHN1XCG"I1XF7<,B<P#JSES8ELH%$55F?0@:4Q+
M1*$A9\79Z7RU:GKTL]J&2M1AFM)G\K[.+IHD'W2[U2;F%'VCM; N8-*G$@K-
MNYI-*9IT[!XQ0WVR50IZOM# (9 ;]H:7GM%JO&'!1L%JD#Z_BV[@^PX#BTY6
MVYDO=O!8IU>.%<X?V[W0Q!H>P4B=OO[+I:>.1Y^:$77.R?/YN/O5,K5+6=.3
M1Q^Q7N _/G[PSW31,"/E=(1-M]K/>R];KE*#L0A0]\6'45F^]?Q4=<D<*3<J
M^?J<&=I&GZ4I/[3PDC5[Z<&/O=E_CW&/V/UZ=<:A&_4;LQRC7=J3'W^)$9,U
MM82_D?J64IEGXJ_V[]>?+=&UW-;3SLNSW6;+]PIMOWK)S.#&T2+Z%CMT8R!?
M1[FA]77]5%OW(VD\BRG'PJG7)BJ8X""& E^0TV[MKG#81)5BF7'^1488\'>4
M'AHQ&C8K'$[R>LA_X203Y(YSF<"SC!YY0(+>JB_HC][&-S$H=QJ].>*5KH(5
M7VOPF=#[NF?LL@$,\+O2\B[ZPL!^;*P_\4K"UX6>.6?\]Q.%@;4"7I:0D:&Z
MDZ]_RH(AF2+*H(YPB:6S7B^P)T772Y_=CPY^&,6H%W./]/UC>]'@&T*UHRL#
MK>Z8-P'%1=?_[.[@2I.+:H !F<(/E(ON,VB.Q05P*%$6G>\6UC#TDU>O17;8
M_X_B<I >D]QLF:@N?W)\P<\[5T7AT*>?,- :_J[7AK#:.JG5J1BF6P[.E!:.
ML0_P7B;?<(8!,ZD$[&JSTMC^?M[+_24Y, !>V[UO8YU!U>'0><(164;Z;*DS
M_772YC&G%(4R!QCP&6LOAH'HOIX)L]L;A$X3^M(!D%(557/@/1\-XG;>*KD*
M \V=^RQ^QTSA>&Q7H(V0=]!MPL\CZCW-<M=Q_N(C,&"<0&'167$D,L. KS(B
M;#ZLSCB>SEC#'5"EAYM>9T#33G9_A0%)I@A$/P&D4XH1C[G?894!!HXZ[H.J
M^(0Q%/I9$E.ZS[PB&T;S.-?N-W 8()J/K\L)!W=T'P\!=NW+W[9>35K'6Z":
M$8UZL$_$86#!R.G*G 8FME>+M$R9A<ZN[,=3CDU1]4"D;!&6C7(7I[8BS@X#
M<U+[PE%/BE0UL0<(.T.:$JL^X31&GU$W_/[R[FXK2-L6)![L%8*!-_KUA,7H
MZD?X[ECHL*,.$U?#E@L,#*"/:B)*WW^"<#QEVL!^3?>R BL5OH/?<)1KI=RK
MX >W%A@HE.L; C5>S,DMD*HDPMG!'O21LS#0F:#K'VP<R?N;YHBF/^Z]F[0=
MJ\2*5&-O$/ZH:N\$M7'2*'Z[ #TH< +'*S5^N*C$_*0JFD*_TM%_=R=>0#82
MO3:@'032]_)@ESZ;HS=2!/OOU<- /('M FTS4&F_)9D5W3CUQP9]XRTE"^HE
MLYHY^]UZ(A S=ZL-"4QSB*"65=;99A][!"_C"W@FT0LBAGXN_L(C WYHB9VU
M-F8H)!$(@X[XZX\$;#5=/-&J26#[@7^?^-AK=5UF?&F<I;+%Y:*I"9KF*YV'
MBG2/K].ZHESSM<71_15TD]!?@#YL5\"]8Q%<E"+4L2P<] AD:W@B22079M/^
M,.?_C%E?+,BE'[>CF9_M^^GD?'#D"WZL]'.0,SWACOJ&V!%G"IVDG;$R8[,H
MCEE)[DN6I$G[)16(BTH.;"7Z?; D']P'N*%)":]@P()(8%>.KOBTQ@Q=:HF'
MCHZC5"HK*RM*A'(KBU_+!YQR,2SK#V!XN]Q32K0_,;O%T_2R?-J"JI]%"+N9
M1] B1W\8>U,9352EK^=@DL48]52&FR&^ZM;8POG?6%)2B-[VT<3>H.6A>4^3
M$>6+U!9BV+QI5NO3TG>?K ;.2?@DEU?)8_'O= G?/LV0%+;OMZ=1-!S<SK>*
MY8%3E3.1)T93(I6]4TF;63874*$;HI:CZQWLY;-EUS B;"T%MM_,*#]ZM]9^
MWZO1H>0*'S,4]S'CF,F;8KO62ZS!9F/*LK*P=@%OF-%1ML9>;;=?A:C1%')C
M Z&0O!#,5EN1A4/7W<H1'=-OE)Q;X5=K2-F%3YYXFG 7,D-RV_0S2.^N*4="
M&(-;'YPUJP_$;@RI+BH'S6HIWQ^B$!KC4[UY?@4?[;JY4+!]A,W^NKSL@=KC
MNLH;*GL#7H6J_S??M_=?2]8+<INQF3A*@IU^6>O.)PU&=.J"?5PO=':>TRZ@
MS='='5\M%+C7<5TB" 1L?QJHNM\:&1TV4NH9-57>*]KWZ]%[S%%S:P2T"4?3
M;LC,&X.#)YST;8@B^Y%)'#.U?AU;2K%\9V>P9[')N$T^N,3A(;BS?#4$!I[D
MIH\VT*/\329?AUF%_1853Z4]F7\V^67I,PE%3)Q%WR+/1@68')/A1+W\+'GP
M\,_MY[+EM+T,9L@XK#E+5&N>_FA<MP@#$@8Q3F#]6S)%7[N(C-4H,:MR.#)6
MS7>N:"<7UUDN!@,,3(FK1]>.9]!$>AQQ27FF"K^?>TJI)TP*CR=WP, >3(C]
M0H H:?;I!.>M;4<1QK*69H9[T96,(=2W!B<%R2M1"4PHR[M-1U_T=QV&@0RK
MO6"5:'8G='0N\7'&@G+IV<"O!K=>!$,3BQOW;3;V33\NF$1Q4Q8\R[KNRGA8
MQ5F'U.I -$H]51!C/%\C2<)K=K\U6U@%;<<XQTM;E^]\]L#7^ ]C-%:(H:)>
MNMR6:I-70V[<VH-38M;P%]WDKWX&W#F8"EP"/++^W?<:_B<HU/>*"7YCLQ/Q
M<F;LLFOO<E-9O6G"Q#;\QM"AA-G>H=.@_!UFBB=1]GY;AO)AA9M'Y"VH+ ?G
MY]*)EJ^1:<.L@03%]#%[SN!N-HV[&'VIL/JM1Q.#E"*3\##:IE<V.E9XH_!]
MA"='],FI^J'IU#?2!1=I6R9+_+R>O7FH7T:2%)2.6"WV$$7%[['BCU.ES@YW
M^= MGV4BQ#GE\Z##!;I]'YE#-J[<HR_)-MV +CTFQ)UP-.YX54'^G+8R:]3L
MDP%ML[IL%.FG1X;@S@A(5)?<+9ALE_\(L6'5$W]"=P.-/<;$^_^ @=ORTN^L
M4XO[RF3+67/P=NLR=]Q%ZCCDV56-VZI(+8'^^%*;*K^F+5\KX;46FRH624;$
MD^MR8)Q(T;GO54VL0R?07YL?CMI!;%4=F[7!IZK=VI>C)V!@_.HAQ<J"38H_
M\67LON"A<DM[UW.7,,IWSX;5BZ%E DX-3 BEEW:^49U8P"ZJ!+YK'Q[RDZET
M&+0P&E+#"BBO#9<%)(4AH_ J,7?F&M4Z4OI%1O9P7[(J?9-WNZ>PYD31-T5G
M=B,+W+(=STUG?+,:= >!7%=6AZ=)XR&%C[QVA-H>CH<R,*YE"UU;;$@<&;RX
M*.>1BKK=*_5LV+/W'?K;IQR2U@P,7*B1)5;B7*VE^ATICLSH9.'-TWD/DJNX
MPL]-K="3"_(G_#E59@=>WI1[_<YZP(BL$ 'V:MXX&KAA,X"OZ]P#/ECH%_K5
M[:=ISXV$/C9;\6/^G->7YM6&?A0]?#34^BR_$^Q4O684#U&?N6XG)J)XS/.X
MXYMJCU?<&UJ^[,A+_BH8<*? <3+YL;E0USEI!OH21C]JC7(>_>/)13&:2P"?
MX$#-A<LM+H]/%SNW>BC1\LS'FQ._UWG[<"3/\CNXVV1V3-3;><O?M-)*Q#W=
M>,&LLWD[&63+Q\X;<7G"P*%9&'@1';^O."5[2C/FB&+!!U .&++@PJ*YS+D'
M[BE\,\EOA &^^Z &"E>C@.8RX)*)&C$=;!? '*F@V_,,M=;)[@4?VJ=W[; X
MFJMUT%>1:)=OSO^FQ^/-%+]AX&A6!!&\L[F1E6IG8TRI;HQ/8+=/]#W:I=7P
MCA;>_C>A(.ZK*<7 .$Z;;G'S<P=IW/9P64 6TF&QLH%%FLX@BF+\^!#8];P_
MBN+X@XWS>K6"0,3:'1)4X'#A4."[X<"AQB;'8(KB6>;-OMQIKR'.!>^R*AVZ
MS0?3]2K1=K#</<_I8?^&EXK/&,7AA7^QP!F!R[61 "6R<?8MF&4X4@?JT<\@
MO.]%.R;)S=O3%A05E[FJC!O8B3:#=')HWHF#53+XRYBUE?RF05H=DGI_2J\,
M(8L7E[M2-"@X0Z?4V&V%*]"1P7BZ<\C&.M4D T=S;^=D21;C: <;K($=*OH9
MUV*V&OA""LUG:P]]ZM''T>DR]W:/\-[=3= 3=P-HX^+6;,WU.:I_'0P,[H;4
MG4:SE6FTB5$8]%4YP8P?J0P&&OR)T=14M*$5>D?L!"60>.NB^S/5/C3M3#%+
MQNYZ )FY(0RRO 6.BT''""0\Q0 *UH>!6#"$\YZ;VRL#:1A@86RH;-WL99[+
M![/0"(?))9X:ZWE>//WU/RT6[.H" XU[R>\9UX.N(RIV_T5JX5 D.JN$0-/Z
MUXH.;(627_J?%>AW!<G'0(3EN_62)YK"B(&!P_^L+TJ XO8\,BD#!A[MX':W
M"&#]%+7W#H3-YXP@98Q"NKJ[3 =HPCXHVGHM#-2[MR)%56G"QL+T&QB2V5]5
M!#:X9QQ]DOB2:ML# V2D96\11+G6IH<40C('FO(_*27EYYJ)VK9\A]\)P\)
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M3\0=U>R9:FGC?="Z=4^'+M*@S <^EK+8NGW0_S_^4LB_DQC@P?\#4$L#!!0
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M9CNKJ@C6#!]3"]W$-'Q_G+F_$I:9%6)V>CKX:$BWLRX-T T_D:B% _2GV7#
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MT#T& K<U&H_VZ&X.6:Y(BJ^O.N& 5W!R,)#/'_LEX.&R[)GR_GB5&T*W[C#
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M(>^.>;D%K6WUQ0?J"J%^Q@2@=WCN:>E7RM=1I/&$EJ?KAQ&E/(S?6UW:0'#
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ME50\2)9T4R"3DG.6\&0I%UVI5M=8F[ZYJJL8,-AE<[]M!Y(DEP9 9RW:_7!
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MT33W%ZO"7L(<G7H9>N\&"IVW<B>7S5M=PF&I,4L3338+03K^+_HRJ10QO#@
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MS(2/%NL$9JD$-0.,$6-%#!8FG"[<"D2-@55NK?8>?6-KG&^"T*R9^ND' :R
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M%#"_Z)GY5;8BH)2UQWQ! #',KJ@JUT*32KB*3TUA>H\]HO&BSK?I8FR;9H!
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MLZV^T7_,H+&6CK':>%:[3I%)6D @P-E$XH0C!+X,PI1<N=F?.SB NE^K'/)
M<^KK8RP?A@E$Y%7>DR#7^=;=S)[N]3-%2BP+Y'ZY(D)1'#>WGX+)'B2Q0NV%
MG-]GZ9JW+2O830N.4/4LWB/-5;:'3CA6,]B$OL51Z)0%N75,HVFKQY>_=<_7
MU1=JWRS /QVE>+,E7[7$Y-\,QT_,5RY[*7<;Q2ZF>BXS()PJ;"2]BVIBEQK[
M>0PX@O5APT0JXT_?/4>4O[G;*(1O[!X=(&5G3[UG?^?7WZI_3W[7,^74=!1$
M%UP4]"A!(,"TF[GH_S(G6.GI#[9Z*"[D;>6@3X7BX/,A?)QL]<_?3_:/ %=A
M3LG<KOZ^[,$ZU><N;*;,%R\DKFCJ">59<O[M8\1YYS6$J&Z!J_L*EEH!:O8(
M]KAUW.W(!F7F<*7SNS8T0.)?.<]*&-#_,T!L2NL\99D:9RVY(J3J7$-81ZI'
MJC")K?B+HD4RGR?X]8CRTG%:/)J;Z"KX%MAT!'8X*P+_;,FM5]T"Q8QHI6S"
MD*CM6^!/9M[_45[1F63O(C5K3IRB'ERJ<A)!(X36UA\QW,X41+L:_#OI/WS&
M7WKGO66QQ@?/\A-=HU&;MT";&UIT<N9A,<K3>&8P5M\7=YIJY2L%_-(MAF)I
M(6[*6SF&7)[CZ9O[-I=-(AACXR:WP(T^XQ_Z90.3@;V6_U.N+%:>'HM\]!;X
MDZG\YQ(88]K_(OR+\'<CQ-X"$>?^0/QA!(_-JSPW?*/4OO-^ OB,*(2VCS!J
MP?W9P,CTZ5O96,!=Q$#N%B /_R5_"_P093PQ#/Q#28]%"T?AF=LM\"=3^]^+
M .YD_V+\B_'W9]CY*;'!0(;ANI*!G=KM?<UPU;O3+L^E9!Q7/E7X:) :3!TS
M^SNI$=_5?EZ:DOY#K6(Q8SDD!3'36R_F,M]W)=Q_[ZY^TO"B_*H=&<:$MDGO
M<MDZ 34+?,IZ@N';T,N/"][IDZ2Q*^)T.J\<&3BFP"07"%YV;N^WUJHWPVMN
MP5]<Y6G:6 +YNWV2&"Z.VC_UGY><10P9\8;:E1KWM2=&=;=-M&B6&=4E;S:K
M>R"226 ,MK^R0UPSI0U>E)(K%G=@ EIWQO\32V*#>V)K:!8'H03$W"T@OW*C
M!]%[82J&!S$4I>#?5J!5RF9,Q9FN^+N+5?TUP.'>\'65,5)AD6Q3N06._[A+
M":*GJ35A,?F^ZDLCQ2FTZXW$-S[7+"?'K?_2@UN6J"XY\2[//5_FALV.6^!Y
M:V[?PS$8JN.Z?CS^QOUEPX6VHQCIJR%#9:%#J_"[_ESV5H9,<60CLY.<H]E4
MV3A_2RL9/*SP>SKA#K8R95]1GX9$H\B-UNG9!T8L[@O!1^2I*]H:<0^<MV9$
MAS4[:;82!W^:F>58%L_!E2\^:N6'89D&F+:*8TYJX6BNK9 Z+'-6^4)E"W3)
MPAZM9@K354GL511]\(9&_5BX!2CV*&@HH[1A"P3"O6+Q(/+AJ6*29_Q?%)7%
MUC&D%9QH"W&T0(7([5!11L(]I;46X[*]E!I%?9"_:L]<$@L1K8L6Y-)[?R8*
MV.>L)*MMG1$)#*,,$)8Z@OJ6#%4Z.#NS]JE8$KANE97;'0](;6:B=C60WZ%0
M!S0;8CB?D;@B\?N:5;NISS=(H])J,W$2!4+AK!^G / %DZ_.IT9 P,X]4CVG
MXCUDQFISX/*D[I0<J):2Q];H#8PUYH._JRE6[W&DC#)ET&'1I*CLO1^WP*%J
MX%:?17((!X?U_3NN'U2D/6T\LHDTIB!$!ZUBH)4:TZ5+PU^]^0$VE8DX@TW4
M^UG9HBYON?N.*R!9A*C ?BF!F7/NW@D:A)KTM\BOC<\^A@S:4'&TKQDU2(F5
MK6<Q>J7UHTF@=NI5L+#QW+"N#<M3&B&W1#S\?BY!N,Q9-I%F;LL[S:GS8W+[
M9:(QV^FC-Z\GF9L3K]"3H9G:F(?W8N,_?@EY(1Q\/C(:^@;"B[_^HB1W$16M
M,U6>I![EA776NRR+$&#*#$4&O,$,P7$$SAS_V1G[/PK])W(1ARW<N:JE2PM+
M)CV)K%;<3XE8:JOT[N%1;\:=5YO(]<;# KN(T9%;_D6'%P$&Z1GI-V=]!VXQ
M&Q+9=_K7-1?J\$&:*,66U\[;@]67,S3Z QM?^[Z#%SGW- L\R0?L Y'5[76Y
M?]S1B"9V/E@4_WQ!!/.>Z^P3OVEU_7)1$3"J/.7G60SRB5GFG7:'U4[:UM3"
M)NR(61598@8$3Q.].P_\4< Q?]TWL-PKQ%F3CFV6CE#$*X"KS>A(NFE@HQ"C
M8$P4[DR\,^:8XL"E(.A2)H 1-LWE%J*L)[L_\CMJ3TTFVQB7]DA8&QSX\IQY
M!@1JJ::2O&X!7Z= FIP<C>(5%*ASF;IFR@Z1.YG?EO)];_;]IWP=P3E:XDZV
MVLP\,HR#,X./B[OS1]$ECFTD-2=\)0$-S2(-];K+)A1-=9EB0 #2(ME*>2O>
MI%Z.:GGO,?<8)**209:"UM?>.9<DX.";&VT5#PZ$^\%V(7IQ#*=<VPR<AQHY
M544N91;YYZ"2#))>I?G.SFC6BS//LP<NY7PCR+,TP>@WFD4N%[CZ;E22/6.=
MN4.U5I/([? )O>WW1F7ARR.."NDHX,"^DJJV;4;4GZC#XP+]L*4N71O>&N>;
M\\C#_8XZ1,(*N%0=(224J,CJKG)DH#PY02ZF'>64._ST\35["J%^6MNQLU?$
M'YP,7O2- L[^0Q_9%!T-ES*K+?M:9KQ'TQ9;K)[CQ(%P&B*0H!='*O17<%?F
M!DEF2'=(86=EF^]\7U9KA-Q/GW/:$M)XVX_*N-KTZ!/PIIMD8$3Y%]G39$^^
M*"AW3-7NLVKP?X$<O;"1?6H-W%\EW+Z3?Z(<O3T.P=?@4!TOFJY++YZW@47I
M1>JP,5%ZT[ZGEF H+$)F11GWN"P_\RP<+=A+(8FHY"FT^"ZD]#*,3BAA0 2#
MK2A4)-T93SSL=9P:5'1J:MH#ZY,TA4PQ5:<,<8@ -X<JRJ'0(:V@]>RJ#5[J
MGW#S3<U?Z6:8 &X1I.TB":S:250@HH -4?.P9MN",A-'L?GZIOS6">?F:/4V
M 667V3Y3%V\FBPWJJ^ER!B($E&TL;9RM(?[9*XII5N>/X:90.%.B[[:LS_>&
MXFQ"D"Y2*;TTPV54=OX6>%..[UH]"?[1=C14TM_FAM)/3GD/LH;N&97KJ-M-
M/E7CJJ8U^*93!K-F>3>B6MRB6W$+= FOP8?-#U8<KB5TMYSGX#R4%8125_J-
MDL#5&,YGK_9NBC3^]V>Q4BM*,Q!N8\G-!'[WDJ#V6ENV!N;WM,$\"KM!&-M0
MX;7X\*+Z$\*RBE_AQG5U30UQ6/X>&C.I?%0IGHQ=P'RV9Q]HTOZ_@8K3/PBU
MHDN$"SU2;^=,OPH]K>V5$'Q N+,H%:>PP25LY*Z%86)6C1Q]/@4!92C1ZQHC
MEI'OO"G2?2SC-C>H(9VC=*YQA?4MVNL2+<(%;.-U:3_6O1/GIZ?IG#-MKTOQ
M5MU9D\8P#:^(8D6Y6WUD27L"J+,4VQHC"V##")-^"1,GC#& RH;.1PO[RV]?
M ?_A*ZQ_^ K)--7"5G?%!)PI:?_+^7Y:CEQW!L5&M[X1BX9?M#7WL(,W&=JT
MAW"HIZ8Y2"[BHE_S^?YO;W+N?HPWT2+HYN9-/YU7[$C)Q9)RK=,D/#0@Q><%
M$%F^C._6P$$3QQK(&\#5-)[O+*GL,U\FM+T,"G<":.4Q<:(.[+-QH= -6%W8
M//D"&6=U;MP@-E!A9XP*S-]O1DVS-4\>VMF'4@K.+<$$E_JD6+/?=B=*,#>W
M3<6N@7W1).:$"XXKMM?B7Q!$W $W8 ^S1GJ/[2(?8/V\$ICO%0\YPS=TWD0<
M\CE]WHZ-\!)7.H"V K-/$F G YAI>W["JU#I;M+%I7Y(L2/-^\'0WU5O%!X9
MD&(_ ,A\,,Y'L-P__K_3T$^@--D^Z(G'^@ JY%0Y:E\YHG(VPSK3/U$U69GI
ML$^!Z:T75!-86E: HJ*[DT#"(+%FXRZ+UHQW@^(E2Z15:U')^S.9H-P3RO<B
M_!1&;!5-1<^\R<!-XA3Z3U;NYQ-GHF0FYRG#85GW=\N*=J8%7\V_@UO9I#CK
M<[#%8R:JKFKAX&T8-[4(KYN^^#Y7S=Z:[Y^)U?G]D$XI0SKY4^ *>?H:BA6-
M&)>AH'K11M?:W)SE\O41XXTO.L G"X7E$U"2XY V62_D*!8M/;O(.UQMI9S*
M?.9$)/>DEV*>(MT.:K;_P"ATDC^99!T\I!9*98;7T7%&AG$ZE9Q2"[5/0F5J
MXFE"2I-8\WHX>DXZP)\$^UBL0_5VZ^"VS<Z4P^5>Z3T^[*F^V?0>V.-Y+4D:
MT09J$IN?XX>N@WMR7 1AJW:2G96*K2CS5:BR$=ALO_L"829\[+&X1@]/D?<0
ME/TA">4G]I+K1G/712T8(];@<8SGKWAB,B3T=7#I"#$.Y1E45N;KS0ED[ H6
M=[/F+NKCG< B%U/6K;[@H::8FL1!B;O8C#T^,VIK-3_CUR_/X9_.;@'*3M).
MMLF:=^09\$>"(JP;;YX<DTY6L5Y[Z"_C(I=2P]F0O^J3R:1L>J@ME2Q,0G!Y
M+A<U,1-]]79;Y H609CZ*6.BQW.Q.4F^ENL<;-1N=6'^"ME$9,CE3WZ4E?8-
MS47A'#6G1R1$A\/\AL+= :,_XH4X6#]:>9((*%"3']=]=3"_[T>=Z[BA-W%&
MZU5)WL"2ZHGKK_<JJN2L@^K0%/Q/UYWX1\(.E+85'PXK@=!>4ELIDFM3N@UN
MOW]J5MZ#Q'*[8D@M SUFBNZ5NKDST$W:6[@+;Q!M;A.7*9<0$L ,[HJ3E(3&
MDWCI/CN!Q.@;;7V&-T1IBI*.>"%G6225[B(U;.RS\/VHUY;," R>C[>-^F(?
M\YG7J5^_O9=)/2!#.A]$V1_!<PM4M<A3<5R8%5!_CMB]W]Z<]+C;2PY)<QI<
M;/X,#"5+_<71-XY3K30Z:.2&0[T=81/;3CAUF!:7X5"VVR#E?\,,4OLT]+9/
ME?;C.35=?%<)(_X.E"_^8;7&O%!RU<-9;Z#8A-![%6/$1PLGWNN=6O.TGV>)
M/72-\H0A*U_!&2OCT_3[*..B%,)?G[$B.6B;7:,@Z))US@"J^5U$-[O-S.,.
M2PTKCJ0#%,]#4 ';R^U-MBK7/LE*W1..H!O!]=W<=!.$57/:P[K7A"=MLO@/
M[\9IXL0YKB+K0]L8T!TT>I47+Y;:7\_]@(P$-&W+N@T#WO$A[H>:W9F25; &
M9-8-BY'_IE!TM,',!IST0],K"J&%&EP@>13G"Z24 ?"$3\E(OEY7<2VT6C<E
MOOLY2NWCYY^PLF5Y0BUW3(G-DST&.B31^QLVF:2=M*?ZM0-P(YUCEHTQX43Y
M51>N3F1 J'N9K/ !J]$K$_STUZ_R"<ARHIWNTWKJRUYO%/RQ;S_23]+=3P&Z
M7[N+O\X-:4J8,)@0K24822N[!7@N*+B;!%S$,K_,U-L;A=+4!Q?M48QR=[HY
M)>:I V_OO3NUCKE:KSHW#S,CF*Y+F:HCN(=7:1CFN;Q'%W=0VFGX2V$8(OB,
M[D&^0%]U+\W[IPKOM20 C#$MS)W_!HIX_\+_G[B=^Q]02P,$%     @ .S!I
M5GC"[0AHK@  GM0  !(   !I;6<Q,#@V-#(Q,C)?-RYJ<&?4NG5<G-NR-MBX
M0W!W#Q9<@H9@(6AP)V@#C;M+@CL!@DMP#>[N%KQQ:QR"-&Z!8>^[YYSO[#G?
MW>?<N7-GYNU?_;/6>E?54U6K9+W]-/^T#GCQ3EI.&@ #"P# //\ 3TL 20 R
M(B(2(@(R$A(2"@HR*CH>!CH:&CHQ#BX6'CD))04Y"1D9%1T[(Q4-*RT9&1,_
M,^LK3AX>'DI&01$!+F%V;AZNWS:!04%!04=#)\+ (.*B)J/F^K>?ITX -C*,
M-9P]' P- !8;!@X;YJD70/DL)P+,[P_@CP<&%@X> 1$)&045[7E!W0L + P<
M'"P\' ("//SSK,_S/  >&P&'FE,"$5?%&(G& 8\K("X'F?9-51>^ZN0I'?='
MQT 45 )"(F(2>@9&)N:7/+Q\_ *"0I)OI:1E9.7>?5!3U]#4TM8Q,34SM[ $
M6CDYN[BZN7MX!GWZ'!P2&A8>G_ E,2GY:TIJ[K>\_(+"HN*2ZIK:NOJ&QJ;F
M[I[>OOZ!P:'AJ>F96?#<_,+B!F1S:WMG=V__ 'IV?G%Y=7US>_<;+A@ ',S_
M^?Q37-C/N&#AX>'@D7[#!0/K]ML";'@$:DY$' D5)&,'7!JN &2\-W$Y55TH
MM-RJI_@?'2=1">AX-NBAOT'['=F_!BSPOX3L;\#^CFL1@ X'\VP\.&R &.#Z
MCBG7'_5_FHJ+#Y*$^#+X<HKU!D! 3.&A/ 'U(8 %E,J7U[:1,DI0#(5WU.4)
M(/,$F(1.(*GGWL1(0\EP%+Y9N<X5$\-*H@4S*;V/SJT<<K%#/^UBA=)-Q]-$
MI2/&!B34N@B000VT*X":JX33K5*0,<_-T?89WS';R;TID9*WX9VFPXZ=9 ]C
MD0&=AP.9"_ILXU'.0Y<@QUN>- 552]JFD ^9:I\-EKG@4_P_$C?^0)0A"P?<
M<;\'L_)^:O)">=BN;_32CN[7KRY$;PU(]XQ^>>END%]I';:Q-.5"^KE&E*.Y
MOKDQZ5BV5V/]H<A,>8S,HW,X6L@AU3?E5VFIM2C1Y"[4K/?.9VLQR6RJCMCP
M54G_$.G[8;1$0=*J=#*+<H"7:;+&Z3@ZSCB.@B -TT(G$)GXM<R'@'%\-N]C
M<WY//W]>'R^]F9SHUQ'W@G:/TU3,WP=IZ*+=R! 82V&"] >Z0:KR$6V:2JEW
M"AJ6.(P^BFQOY-,\1@CZ\9\ LZ)"19L!^^(4.5+N/,W'V7=ET<VK1<(&PA)7
M#ODH6<,$ 7<>AFXC"^=V#TX:PEA.I5)B/2NJ("^-E@3M>SW^.'U]GCBN7+Y1
MYCWI":>9\S& 5Y1*+9B5HX[EE^BBS[4&>H0313^%MLMR:UQ0W'[JN1W)@$_1
MS;5FE8*U>G5=W>E0>S0+2T$H<9(<;-7 K0#QOMX7 \:YXU8,2"D8S)&T3SM)
MPJQACL@71\.N^7U9C@X34]$2;FVWN:$..RT,\DD6PL,EH/_#DVE<U0LUJ=T5
M^CDRB8*F;;KB<LP*Q/A^EJ<EB/6Z8@QVF'0LP<T&'YYR@S'2O/+@KKV<(\+N
M:!W*ZNGAO^AG*N=5/$Z4A%/BQFH567.RQ6F2GF4%N&JST*HZ?8QS*#GX0&1S
M-,-3#<_F+TL.H#N3,M! SPD8I*5I][Y)*?+)W>T'IU94%4MX8<4VFV>015,G
MH;-PX\%98[7*4WQR@50LW&1"#$.%C+^WMH7XEO)FS-;U%])5C-15-2\7R2;3
M;G<QQA1G8[F:H^:'=<(Q?+_P([+4^;7EVFRVGZD-$IT/&G9!9-L167M%V9MG
M4NZA%'A<9ZF[\5C,UU:J/U(6,5A)T]0,I#5["_KZ82(P>[=X-W7;^9<J2E1T
M#@0+VPKL*/9YOGR9'P>%_JO>6)5VO]Q]*ZS'(A/<_B(+6I?3 ;\!RJ3%[/43
MP%+.@E11SS@"=- S<REZV2*.@*?R=]*8L5N?NAAI>[,?OK38?3XL/H1<H@5=
M\[<:^^@^C%+Q;# T+_=,[>UI6U6!3=71GQ^- '#Q<D?B> \BFRNXO0VE9I:V
MZ\U>#BYXFJ[C*$FXD]/V/1RT<;I"P36%0*#M=8,<SO(R?9E,0K.F@/IF$^_.
MHF80Q\43 %&FXH#2&NQBZ2W,>N3<1/,"6;F?7^IS#\$CCMQ*%[FGQ^SXI^,*
M%_H..S0]OC2R>NXQA(H8WN:?F-UFLE]K./MAA$W1-\DFD";!J5];9BI_/O9Y
M8,TO(&7QZ'Y,<]SEK/<U$J*4U%1/_,+UG>J"ZK(2%\PC8F7-08%!*M\>N+I_
MT0,O9F$&!$W1X]!P((22X2,)XQ^J)70K>9!_TKBZ^W0'&@]EHX!,\GB440=R
MXH71OB2@8X9'M$7TK84Y2@VN*MQ769+S<HZCG^W6?=.+0R$CH$YT^5"R9\:J
M]HI5*/*B$F'F@61BS^U[0T@EX_3%&D%8=KV\F^L]&ORY</[!H,-2-%:;W8/P
MM&+R9FGM]TE;L9J"<&V,HZNO5PT$O<UQ,*X0]743<@ >S&K7)AN!'['>C8JM
MEA48&D;"\ 8.-J==8T^1B,POH&SN)FWCY/O^-<&:;6NRLDS\ZM34Y'9&'%$I
MI\0$;&&"GF_'!LA@MV^5#8J98B%TD J:3=Q)H8[\W(1F2Z#UY0GPPO@L]K4_
M"VVGZV)#H.U%AK7ZZ6,E?3DX]BJ2[8A$KMR4D/W>X!4_0 ))X, 2;M+L)FMC
M:V).*XJ7-$+\3$8P<%B:;_3K,CW1KP5B<FNGGE6:.BA;D(&.KJ$$,A5S2[VE
M?" ,>DMS)$5NZ\Z:U&R%, (4225!OKD^6=]CI_:[Y7A&C3G>%[)@DZSD<E?"
M),\:;P8^':L1@O)?T56]'0Y@)29TI\GF&!-Q<B,7FXV KJZN/4MT4@&J]<WP
MVQZMTY79G:]^&X2G/VH*.U-!K4*1=M9T()'.QM!(YNT%<7-V(<S+ P.TT]/3
MM1AA=6L38]Z"*#H-1]W \FV>-")!5<_,E*Z+,8!;Y$';F;TL7/% _H<I%]Y9
MYR*.L?R5V$1Y#\*J6\<"%$JNW>B4.VP#+F]J-U+Y<ID\0PQ];\LQLFY!?C1)
M9KJ Z9'788Q$@H=*IT^ H&->4H[@.]^Z;P:\Z03-_NWA6GE2D4D(!(I?AP#^
MGA!_D=B#*S@=?;+ERJN@I;3$$"0&JB4WB\(/X8W$<E0O9 ^XI]I]3_T^LSN/
M8^]I>H:$V#6DL41X>6S5NIZQ:VS=<C#(#,,;&65RAD_>>&T<*2YI564Z^)B5
M==DY)EO="<>5'7>NCSGJE77P$<OBP1P*)8<>\8PYR4R916MFJ<5K04P!)433
M'BL_9"A2RLU<C!.-I!UBO>;&KIKQMUMUT,'MJ&#ZV2.:=GW]PF I^6(=8@!"
MUVW-^*A8*T"0)B]! FPV^2!''AWB@="V79&YCY&9R)M+K+'A9B/-*L_T0S<H
M(-TD'N;DKKZH62.-?J^FI0UYN%WABX'-IR2T[MUZ1Q\ KZXXE+PP5/57^;<D
ML:HUA8\0/=AQ8ICP]4S!RN<:Z9-M[:"P0_Z>)^_!_C0YNZZ6<;B,-IFL<'>&
MHSBQC:>3&F[/G.'2'"P6Q@'4^LR]0KX4]+[S$%7G-J]J;8*=WR$FC;8<X ,G
MA:<,\_\B <2I KDP&&9IX=%]F"VSX:E>2)"1_%Y/.L.&N$01KP261,9[PNB9
M)T(YY&==T(@(E6:.CNH(XFPX+#YKD,;[)S2@:UD@D?J/ 5S-)(BH*"X0U(F4
MD7P1'!;%>GW$=$Y_?(,P.;=ID',-SR_?UG27[GY&US:Y_2Z[*+''O5JS<Y-F
MXE-PX-!C5[+_H2*!/1_HX& 9,A:F>=*?_[W7WK6>^R(;2V*1W[9S)=*BC9UE
M+ T2SI[F8FV2?TB2E&-2."!\+6<5@9/<@%/:,?X923A@SR$NLF\CAF)9VUU>
M*D%305<-S&L&W P9#N1GPI?GVDA\Z_V0ES$@,)"-5*@2L&_@Q]^W0C@<]K-V
MS%#YG.<)<(3#!IKY^8F;)6D$'9])XH$SU>RDU^>U$ECG3OYPR'E@DJHC>/CU
M6_K1ZJ,WE2T.3K%\V %S/#![;V&1J5YX[@26R-+!RDA&)^X(N?6&4<^UZKJ4
M]13I !>=-7P5LT2:PZ;DX&!+"$\(0(U;,86\W\3ZHMA_&%:O6=[-UN>R?VRX
MAQ./XN1BX<*'&31RQ>X:I#-UR\:\MOQASQUI'@F0ZQPZL Z/@=A^N>-LXQ,*
MU'_.F.3\]X*;4EE' --*MEITI\9Z3MU54BAY5MC%/@<;;2HM^@E(F-N?@EGY
M8=A>]E@0/MH2S@3OLUKD"^1KO-J_< \NH"HR7:K&$IF5=DPV'$,C.2U$8>5R
M-8IMQQ_$4P[:DD>KK$-R5,-I_P@B=0,X!#J(4P1)V>L0]I++:)RRYT-&8K#0
MY$F]^)OJ/KB35Z BK0H8QIK9HY#M"I2U=(3.-0B9Y]@56R:3&#5/%,S\-*_O
M0-24>A_7R'&\!O_"?CX;2R6W-5<L5.<(G%RL;;F(-LK3QL5LWM$T([U]SO8V
M?&!KI%UNO(*[WY[94E0HJSL3X_0G85Q><U(EF@%QG8A^:UN V@D75WQ^V :
MBNQ<G&)(RL/Q0:]UACKJPA"];D%(;M8,9[7,0(<U.KK#>2LP'7M.!$'2#\J
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M?&)YKS(;7N@Q3&#NC=@[-L%3B!Q61^A/%8)W)S]V!-2]=L:1MR+=E7INTYX
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MD2C+;\]YB<&.)HF>!']ZUH*IBT2WA7X_5ZN9A7#32O2= F'HP,%MC./O(HK
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M,BS.EANIT\6^]\DZ;Y5E6BR!=CLJ6>]3F ]/K3?.B\PF))F)X0U^2%!>KTA
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M7'E'B*K82)*-=UYSJ8N')*L=Q3<OSZY[<71D.>R.WD,$[-&M[ <"/W]]T39
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M%#0?,,&]<->4)I&;"HXKC!+(Z)_[>;AM,6?+F>49\_CB"([)[_M%:QX#PA-
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MR[3#6EUJY9,OLE(R;2%%XN<<ZW:>V0]=)XSAKG[=;Y.9&5@__AJ(1T%O=1P
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M=WJS>JO*8.IL=[>DP1R7Y)ZX[QK2[7HHQ;G^D\[&MIFO]TL<+V+9&^O@;7+
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M_ ).^EP:B3D\*< 4+TS%$-:/5G32UDEZH"QU:F"_PT-4#)>U=O(@W>$S[<<
M[%# H1'3/;3(QW*G;_/15<8(T[T /7E;L"HM,HU==\30#;\.7WAN\I^X+9[]
M?9G'MU]S  B33Y[ZU#GB8::/4/K\,#WEN-O3L %9%+S2+]HDNK>#<5;XS51A
MPCC>VP\YU%T;GD=N/-DGG7'"L<?D?-$UCDWI,%$ZISV?,4=!B2N[\+>0KJ#U
MY)D8P/Y_,),\K:VU\A 3EJ+ &O3K[*6#_FC[Z)?8>P;G*"NZ>K.YZD*F11%!
M5%C*1H9(^)I1C?$<I/MF)#RWG1-#9=M:#VUOAL5N UA=Y5HUVK<T)SW-BU:^
M?\HF;5SI!UC+7Z7@3LQPO/OVOM+78+XFD'S9G$>(+!-O5S[4J/0X5/DIX*R&
M\(9[]KR3T"]/9?81;^_>A9MI/[!-T-EA8U'-3IG^DV2 WD1HNVF9U.=OA:V\
MNJ)1VU//U>Q3Z;/IS=]81.>LNP^:G'_ZDR;_-'LM*A?XR0AH/UO%V12Z)(1[
M7*(?^?PV(\Y]'X8T-O&=$G7T'$:M=_7!R4"1KTVG>K9<^D4@--LKS[$O\_X=
ME(O"2RI-95?-N#T1E+8IMB]-NT-<#^EC5RX20LA^'#KK7XP*9Y;W;J31(@6/
M8@[.*^(YKR7[B"G&V&=4V-],DK[%U;W-KBP5Y5<R=G)LP,0XRRL]46R^; 8V
ME(@C%UZ>%&Y^V?SE2PN)9)S5MX6/Q[\E Q7OE9:="*U<4-3Q9._DMHFWL+HA
MG]QS!669''\"[J &[NX&="0)2PF<$GN(X7[].IPZ_F;N5HM.G+1[-YOG/$RK
M=S1:BPX!G7V(U^+JBEL9FNYUNGYZBL+N!-U+WC7W^D>>CK_5_";Q4_8ZB4#&
M2*6H8-U])5@Z0DV-BWQN"VXB;I.LQG +&_)\D&= T"1#A@1*?WP;[$-H5[RX
M1_=VOG+B^T=/+S:C0N*S]OSD+A: =,=J_._QB=D^DI1T='&Q-[**)!QF;:*D
M($K1LL(%>(1PGB34E6-Z>O6G.P:M)AOEOM(<V:E^?KKDE\72QJ:'8+-N&RD@
M'EF68SCYS!:C2)(0GS2B)(??7/:OIH+*Q9KU7&2@GPLJ)= #9ZHPM-$V+K[+
M0T"<MNSRGS<E%&NX-9T,"\W<1L:KM358<3&D:#V7I2ZMC&6T'M0C<A8F#*PJ
MCUM5[[Z(HG^;PR0@SO2A^M][??2W9R&'U56')6T)XD=JMUG] ;\O/].!#]+&
M>_\O]J-_X [Z?^=-_[6$'[3#2(>O@6.21NVPV4>'J-!NMG)@IO8FWA4AUNQ)
M0-;1[]4,_9U9X*%M@F3L4($_"9GMVX>>!P3;H;R[3?'/BTW@4GTP4B(UVBQ=
MPA9L6C: ($:__)]WF>Q/M$,V$BG](OJR@BZBE9NG>$,SG1\5I^%D '(D7RDT
MDSP6C-L11OPMY4[?95G:T:P[MHK]A&Y)E!6<O=;&<X:@R*CRIY4+&CN>,5O'
MJ7)9"CJ<M0_ -5>6$&$Y-F*5QU&K3 M!/!MI4]#4$@'9@TE5>YX6R-$X L:-
MP@VE&?.J$>FS]Q<ICTL'AN(J0P*)-Q^ 30MS'[@Q/<3F"_D0*N3P3[MD *TY
MOH*.OCIP90A[;]\HG?DM:VMEY4%)K0!4.^OZ=S4-M$\!4NHI,7=W-41WCM>K
M:M4"VT5 G+O%99DD;2&3YI9:$KZNA@+DI6M W 7,7;/<I^X/+]+_3\\3@<MA
MRNE(H+%@O0-<9-",+.)F?[S]T;K6W26G$ :ZN?&<>2;Z&*\&L.ZV6@0+G# *
MP$==RYEU3OQ[;8_,B>IL615'U%U5R'*?517+]ENH!Q?VT_^&BV@_"[T0S1>D
MLU%<7Y_+]<@ZER?;_AUYKJTS#=Z@&"A!"@S^_;"%;&O!]FQ])36JKENAXC\!
M!'Z!^G7ST+&79F#^TKVJ.^]XE[+$;-[<*27J(M=4!1F:&L\OU*[*<T!;59&<
M6,@D@9T][G_*#/COWM1#&T2!U#8@6DH"5TJG>/&VK/=-ZUAGQ*H]>SJH%S;0
M N!5UE0M:BJXB6,ZVJBAOCYJ>9K?ZK$J=AB\]?OO :*"1WY:]P3[4FR0+)P6
M$C=^8V#Z1_$I4K;>/V/J:,3:ZJ18O]9* -%3)Q=-M!W^!+3-O40M_SB4_@G
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MHB?W$\06#G'(TFB8NKA0\#(_7R/T8,RAMR,D2&ER]'D)?(R(QYY,< Q8WD'
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MT,:OBL40[]93NV?7,6=9G>&=9 X<_D;:Z?U.Z;4_>H).@/DR595J2;7, H.
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MZ6*=\T+.AN2XQS!AHQOE26%&44,(]3-88!L]=3O>-D&Z5 SI1,_6)!/)YRQ
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MLX)?4%9[PZ[RE6 B \*^Y&DGIA2)!7S0]%G@Q!\_M6M,J_A&X:2I^C+6KIR
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M_R/%X-0IHR)N<_;4\,B#*4(F/R5JVLH4= 8R78)@> J&S8"#*(;!^TP)0'
MA/Q_V'0X.!/%9@9"4]9>4^=,].^S;%F=68PEUJKS_YH]=6V_NMWNC"XRP[1K
M($P0Q A,(##=EYCN] U7[$TWG-V&(%_@Q!1'LC7+U4QCRLC?8M7LN+.G3ITX
M99UK;;]:UI>*UCN WU$I2;5JWU^Q!FJM&OAEPT;:YM>;&;45T55B_F=.  I
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MHGO-LN<OOP:2\;I&B$K7C*B=4_L:3 XXU,1=3%>5LMT;)'*C@!@F5]QJCL)
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M:V8_[D@5J5<5FKV"010B)5QA0TH,;+2&9@.C5B^)68E,I5Q3@0P+MBVBF^2
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MA>HU#R61CN'WWVXA;B71;-8Z*&]$?0$R X8+%57+I[AVMB^J(C)(0$Z/UFQ
MKKI 0":;79),#@W;)@*Y4! 453A?S/01)O?E9M#([BM/#.)E6TNES!8 DY19
M8?"NV(BD*<H,.2:CQY$XY+N,?L+,,"UFZ+Y  1)9.$\S5JO&J*I"!LT8D:XT
MC%*WTY-4*127[8J6[DLY5H5Z/35$8YY;-E !RN-(B!'<0M/+%HMVN#[,]<1L
M.P(X9I<H)%1$BCO%1K6!6(S+9*JQQD K>B%&Q01)#'%RB^GVXF7%$P$_QN8
MEJG23!XHQW.HX](>%ZH/QU!3 E4LQV:"()EIDIE<6?,CO]6)%?N@UB^"@W(?
M1""^@=;Q02&$D+H6E-5 0T2R=EKM-)6P$:\X!D\&:M;0#E/!E.IG1V X!55B
MH7K* 62*ZO$8U/#=K>K& ZP_X TV -KE!DO@E5B0 IM= Y-::0%0(F"GDT#
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M9,G(%$MIE/=*7KS58DO#62X.8CFHV%S/F[,?NI6+0,5K#08)5&%*+4A)#T,
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M+,[Q?4IH^"91<*)A#$)I5AY^;96-<V0GPRF,J)HDVNQA'EI6@@:<#M9<ND^
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M*X*SZ;C]R7NON^O1E9<_V/A\S$X[TV]_G+SY]B,ZP*=:\OW.E<N>W@*W?W(
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M)<4[=CNB*<*P$Q4M!U)RN-Q^4 JY?8*CP92DF+7"!LH>TZ9HR'ZC8/F)0 &
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M4O(8-94KO#/KNBV-+0*17L7';Z'-$6%?2Y/##F]%?H3^K?\D PY:I'?PU)7
M*6*U#=(:Y54+5[(/]-:0L[-E7?"VO9B(X7_9B\7;G&]YE ]H:GQ[@HO(RB*)
M=UJ*N@%]#3N?;H1M,-?0K9K//\1I(>5%0E$CMN0UMKI 6NQ5G6HZ/BTQ0S]E
MCI5CPPKED&16Y8[JIL>;#M&G(KZN_]CD"2J*PTH;UD\90\7PE[NE9?+BU]U+
M[BC3;T2DQ83.EFI/,*R0>,'C"C"HN^<NT--R&A>LQ?V"7-K!EN)WF7SV2RJ+
M2E*3M3]N77]37.Y$>G>L\3"&T5"T'0Q)'4;&9MQE](#N369?RH O<;P(>'SK
M)86K.G@Z_LY(A<A<I8)6: EO9 +[)3Q4;B3/6X_:SA863B]Z8EI/4WU8C*GZ
M3KSS%>LSP9_JJ6$LA@S&W>$?HYHO1&6USNN"1KJ];_X!XOLO461_7FJ3%IZ
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MK[\]HKK%TR)DTU@IJJ%$3O5#>UY\B=;TH*[9K_2KY898A4O;W ?!<1_;O_\
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M=B=;YETW(3;:"),.5]A'K#F3EB6+6]0A^.('&A,21MQJMQ=:H:HH39E1GS3
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MHH2P'FJKB!\6PBV^/I6WHL*R9@\N>LOEY75N=1HSBZKFY";+5HF#'OK2.3_
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M*>392N Q_U99O.*@;/V'%=&*"8S0.*'/?V[%:*^;%/U6%U_;_')5;_9T;UF
M&N#S3WYX2X>!D?8=4'PB+_%T)G@9^XS<G]YMKG'XGX<'^1!^Z&[W1OPN?])@
MFON[7W%9KQ"#HZSN]XSBJS:""2W<]I.2G8+$27_H,TRA]#^91+*+6B0X+U[U
MSJJ6"1-[R'].'U_A,@%;5.E970XF7,Q>G-J^Q<-1T(VS3H+U/$^N#C&CS2^"
MV 9@I1GB6+QVG[)>:2R?LD$6N_U&Z7F)D8*E2X(1?I=>?;Q5?R6K=_,^(US%
M'0PHW?E)E3G#_0XX%C,P*S[*7O8Y270[3%X6/384R((LKNK6@#J>)I.4$ND\
M:P4IY@F0FMQ5\A&>NRRN13^]YE $Z%SWR[S>I(U&4JL5&\ ]A](I,8] _A&R
M?;N"IH(N0L+%C5[K@A%73#FN5?7=:BW>0"[<Q <?MDSLF0O2YVY*_X:W3$F2
M24^6WG@M CW]W@$-L]E/L:610]6?A^IX7KDL+B?@(S!KB408#KX):U L::I[
M3BQ)BENIN?I+#;=(P+UM5Q)W8K=2-LN"@"<;\[9=;V&JC6Z2<XN=NF7;BR?H
MXQCUU@FQDP?YKG4E@)U)\501@MUWP*-P"T,+?OM9N,3P.Z":3!?M'L4_'\BG
MUU/!JY-DP8#H8J4FIU+<0==-N:&PU17:'&2B2EM$L2QYZPQ:GS.Z>4;K/RJ]
M#.27/S$/#OU9=T.Q:B1N?CZT%P(N_]LII:N>5/$]P/HA9<FB?JK/;T)\HG3&
M2M.K#,KAS =:&R#_U32CF5Y4LVS;87I3Y%>8%!"^?&SU3[RH?I0-^]DTR&7A
MUB+^=A;TX[-$.W@5]GS'I:0#VP]$?=W!'P'<@MRFH1=SQM^8YF_> ;- UW>
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M)!MJ#<5M(6J(^D-WQ(G1G77$\43ME&&&IOS"'%SYP47.@7NM+ "M__O&E30
MQ0@<T*L7QO604*]08W[/\4)A91J]/G->8[1?8^=PD*.]+17TXFFF_N\.9?YT
MW-:9R,5F2Q2+M/' 07EI.Y6#66-\@]7'O+7.A2%\-AN*I*GP[4VV)5MR&)@
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M(%+_2U].*S43/D&!VH N5G*_V8U3+)*S@NZM JB[$'=#/O<V(#%_@1+%ZCI
M!*"4A4)LHI2/&#D/8@5R77Q;U-DK?HRU;\YL9#NWCY3$3EE2.#_ C'K_1;&2
M?M^VQD(M<\L:F: L3H9+BJ:-(*GGA([H^YPHTT.5U_/(,- 7\F]::Y"Y&0P)
MUYD1);0WQGJ @+67NMR[+OUMP=HOE]XO8$V)TI*K%G;:TQ#"=\X4L2/HN]03
MD*J# F$W?2RB90J,-!0!PH_]I.1PV05H1FU9RLS-.PC^"9(7Q@7W6@[<%/?I
MR](&I7:,I3B[]3P=X,LYSEP.,"! /^?7+&Q^G AVR5VWPJ7.[59-:0D&D\5_
M<<(4GZ5BGG*;"8ZUOO0ME%@V9#* 4GVM2[C872V^"QG5TX+55:I[8EM1Y4H2
MRZQ%&E8V&AWQ9MR@DI[Q&&"+T-B"HX-0>NX0;./;.7F.%==TE5NMT J5JU8Q
MK1:/R>8$!%VLW;+ZV44+?'N?5#//N+O=NK:7JVOSO7__EW3*RQR[!-.RZY>8
M"2X1XI\D;E Z+.CAA?P_=1 >UW1,D=#,"_WJ4HPMFNN;_XZM.X#06$7SZ@=R
M37"E$,G\! =)XD4(OLV:8Q*@M1>!:>=BJB=)F[&!(L:8-J0).K^S===V_DIB
M/5:YU@$7QY2<'+43RB%D)HOTS(L5L?06U#A3.(/U:#(4=U14.Z#B4+A_YY&Z
M:2'OA:8'_:?HG5B%8^Z'PPL[L1'?+\XD5=G9^CH%P''+PTFQL)V]E.S!1KO8
M*^X*XZR?2-_Z0$/&*0C?D(06:5<&'=L0G0-[D:$$+SR(M+BG^PGA5(6.GB8H
MT6IP4QIL(MZ60&NZ*\L0/4 B?Y7 J#/$%K:)(J9VVVI0> )O@!ZRMFY;NLJ"
M&E'\$\'8%BL;S@Q0(/(C-X#"!(<;]UV(PXT;]"]RRZ8Y;O>C9@GT-\35J^[.
MLN=FC_Q\+;Q_:*5&44H19$J2+\'#G28+L_YP+<<BVGXO( N$0V(!$I; HZ>7
MF_K^' 0BI83JP((;I@&[4/S;CXZYC0S@OQEJ)LJK7>?#L&UX9?O@E^P#C+[,
M+!>&! NMNR\YHX;]6T6N4:^NJXO:%8I3.PL3SC\5%<"PHFP!1_%7\< ^77QM
M>(-$O)V=\Y[ A"#.W(B;&SVH/_]ZR%%BBOB88L'>GB!@RZFTTZ[UAD)T[O!W
M^\EW/O*X%B#Z(/(RF]0P56ZM':U+^=M3EMQ\SH3F=^ET-'HS$T=\W ND;1!K
M&Q&K!\P*!9$3]]]#8C>-\?,QQ:IS)K;CMJ2*#"'NFSNK'=G^+A*'P[0?YD>[
M#"W?NZ7T1NCWQ%N8A*$H_D'J@&RRNNC>YH@4\@@O^KUBO,^?=7"=%>'\X*Z&
MUN-2G:^>&);_,ADKGC.AZ5HPU!-D$YGAA4V1=4=VEBE#1FV<NEMLJ!&I!^'5
M$ >ICLI,K0)9J+)8HF_W,-S"2'"^V13(PW00LKT3,PUGM&31_EN-"<JU$E!(
M)\O;A3Q.O\47MAY;7_/^4\V"?"(?9OPX^C"=3.H'@&R4,+? J?A+OSX&+:E.
MFV/W^)P(C8T]ND],9RTU@XPT-T^/$,%;)VH9= ;RP(D0-!%%6?LJE^K4LHQM
M.Z,82[4=G2VF"'JNAL,A/L?H/6OQ7K%P>@>EDP\O?<)^08N=1XYMC%ADZ\DG
MGN_RS"D382/73CS^Y&6CY'_N'RM1_[HU5_YHO+=@&^)1[-RG"\YX_H0A^FA8
M:H-[EP*<-B T"7HMYPWM7F%$**:.U!P;R4=KQGRF$24#<M6H8YSJ@1J;,)E&
M2?9:O_4*>%"1O"+[;LH^U/[;+0]-A?5YB/=I= :NKXF'[H?A53F-B:3I&S9R
M:ZM9IZTJEO?5IJ^JE>5%)-8D+"Y3(\OMU/PQ7%P5H-J&2/:@"3AI;I)=;@'X
MW8@^(KR2N&ORWYM,=!U2V8^$F<,91&[FN0)T:8.IKL6_^8#<8T]S=[>2HIU.
MDHTJLAM+H-6<&0X^O-YV.,N5^>\.#DEH,QKMJ1Q[V'93O.?$*R,WN]%7<?Z<
MZ/VW329#.:H>;@W[S8'BX*F4*\%83Y]:MJY.[KJI_81A=CN5\53A4._(O3"Y
M; + ]UII6 ;!$+'" I 7-7(U*0C4FL9^B O^BZ((RP/P1(2*BSRI@9_[5V:(
MN^)"M&+YX0/ ,^#CPZ?M;B_A] $PDH9T4PK*%BDR'I'5.%K\2'-'@$HGRD5P
M6U?WY4ENXJ8**8\2RU@HC4G>Y&"T#G$:[4O%WKWZQ\O1&UUU=X#]%'.U"TW<
MD*BT-!WW21)C'TN)_ Y%X&Y+P]&?57MR [QWKXH:<'L.GF_ W5_YUE*#X&1/
M7U%\,$@R-5;V@"/O,B"+RF0JV78O#4QU=S;]++R=WQ8CHNC^&6H:D6B*FQN*
M/RG'*Q9&V6?9-EW]WWG>+DKF!6'XD-,=JW)_&4S12]]>(2C)>S]4505G9F0T
MF" ?3V7]DR4_19P@,Y6@E\Y6]B?ZFNC?2NF\1-=Z89%@]GYXL2CG.**\ *G?
M'KM7"^4G(?D5?L:EV\D<A*@2T!6GYK[UXL9'($9-;>B2*M!!FV@I# >='B$A
M879:C8>GF[,F9'!QQ6OYRY@BJ&@>6E2&(D=FK]P;_E_4@6N 3MF$*VJ\8R9Y
M9-_'22T$&F0SH3?O[[ 3!DM8&J)5"-('S%@&)^/J5NA(AXEO%1G&95<BDJOL
MM+6;!T\3:&B@@Q,NB6""%U ]Z%#V](D.?Y''*N <_7X-:=%AE84+S394,@?*
MX4W4[47,1<!CTT3O:&_O71]@-8IQ\*EZ(,LO;34IPB?F,WA75C05,3*>_IGY
M% #3BHRU823Z;PRDABKA"4L_':M38_&5Q)2K'*RGKBH78^6!#F+VV"*UCZ!0
M6?1RC6[CX V S9XI ;+W:!6-]>F/J*L,()J%%Z'-QSOV$I/E30U=M8P+3)PC
M)>E='6=H%>$F2J"99:MSTO^J22L+&N\#C%4^+*=[9SHFPJH^-'AK#OW5[I->
M_8'2'_9#<6I5%[B,=3N$$HB+2\0M2 <^T2[H+*CD9N!1'9P1/;5>95U$#1W,
M%"]:B)Z@'PU(0=.CT?4J_3+&";#9KU:47>)I@W"(!2<.@I/+E(U$*+)R9(!$
M&/]V__'"%%F_H=B^ X^L2*OD]]G2W]$QGZQ!!2Q@Q 2(*EN[,+VX%0(:DIS7
M(G2HK-@H4/A'H31[@_"GD"B90R)6[@O_\10-XBZ-.!F:$YK!A/L4?(QGNTG#
MQ43+E6K)NC&C9FVIF4E4H1;;C1& =OZ&(49BF3B$4D4B^?-8W@Z<(!7/"#1!
M5E9LI/K>+[8\CQSH)X.9!'?.D,0G<-:[-W6*S!YZ^=T/'L]/7WAD#VZT@ ]<
MR\MFT"4D>:\5<N+)G]@L9TOQ4L3X\Z<8>00U"0P!O "8H%6??W,]\Z>"\L&"
M>26'R80C,]L? $TM6PJ6B9]X>TRS:K$0BC92UU74;DD";8-OJ/ER7DY+7Q""
M_*LDFF Q7LL6J2GZXJ5)8@L3'NDD: P0]06.*-'RA:VUK,Z3K-LUY&7);G2J
M#VN-IA:K%C^;EV.8CF1-N=WW987:CL))_C1FIUG'AT.^_0W!::DSDO&.4YTY
M) $X'\9_ C(1/_[:4R3Z*?0[V4?=TN;X F-#DSQ5B]-T<\8K?!$)&;J]22W>
ME8WKAX*$8;BN*H6Z#ILAPK>#?)&[BI1/\,*)4MP=P=&N/0#3V]%AU5@AI]HL
MVO^,!$Q[(@\A(IN#$%@^Y/MO-F3+'3K+91(U"B':=W<S35WV.K>;OY[[:(,J
M7C$>-XLM:D]I6RO/EN! :#[]YK6$[R;/<-X&A]*[U[CDS@T-4*&)Q0DODGPM
M%,I[,<>?]^SV ZRR1D#I\[*XZOH[S-+'<16;V;R[=#S5/EQ_)=1\ZFX1.>N2
MR/W"%3<ATDA>[=.UA.6T)[/QX?V$9]0,XGOO)?A$B5F.0]3B[.<[MB:J19&:
M^-JQ8$N\ST$/WZ*O_N*2C^04^?&G%!H!_Z<G0/^#TZF)2[&UK9ZE4VFI#6!!
MJ6X^ !IU&F&A#E&Q&JO-V&LR!@:N%J,2M'1JB;RLQ>XR->7W6; YDBBF*)^!
MPZ692PO+\+C4\FF.;XV#@-"@=>G7)YS6I\)LK\G5VG+TSCLF,\_Z3.<[!@V]
M.&0:$[6L]V5P) 0-+'U/:5K-T8[<N6-B=TZ/'%/(L6((*M4%0LLVLY9/0+<D
M--4%25\->2'S"-Z9.,?1"_P9.?76R.%][SK A5%4?K6QL)RY1V+-&4.B-.N5
M3F\1T=V=YV[,$ ZRCMBOEFPSHB1:OQZ0O:V*#7R$GU6X4#)3'(J?V_C-^-LY
M.LC+A4C_,F/5]5W>KJAY.L3RF\-8JX*@/,VQP ]76GS3!COF83=9VL9&8%%E
M-&(/32:^O$\&#RE_F[&65SY[B:B*=:0FU%(9K5LT_^%)0IR?#()8!0H;D=PA
M =?,+Q$B3XUL(AI:;39#\<()![,ESV;VYWWK5J/:^_*X_9KA/3/FV:8S/,G[
M*[- U83$4@M-[\(HN2QKSD*+%DR)F'7\UKV$K%M ]/;+Z! __]+>8^ZUK<?]
M?CE'L":Z'V[K'Z04-KW8<>-KT]B^4-E"("43)(:1XRUP>GGW:ID:O91A8/'+
M;\C5+?- :;&=);!<KN/)E N3R6X+!@61VW<[5M# JZJ&<^ &7/I34-SX]+?K
MJ,D,K4>]8H483!%LO>[W6)0!)=M\R>4BFTI";3.I[\)'T,.M63^559.C(>=N
M8>ED7S%MIH8- ]R1]:)]7ZD?XKQV;J_V1>^AZQ.*:HJ3_<7<SA$FWVFL+H9X
MP<3,/YLR-HSA38_.Y&/Z@0--D<:X)I%PJ]B@_<X."LIL^5"*D%&Q/J[=_JW'
M%X&C@R!A[A$KYW'AQT?'+,=E7'7=I-%+C^N8#:?K;E=5#-M^%Y)=.:A:GLGE
MV'X3,J.&#T#_0"(YT0G7 >[FYEY$+G0%Z[.3QD'8-F*JF^%9,\PR3+(7Y2-\
M=@RYL^+7\U(W5K9H(NYAW5=^D%"/OI&W6#,E#<G53^(8K=?4@8)29RSJ 4$E
M5U##R=<ULUB\ZU'X5O"XRIO/R4H4I;ZF2?VHE-#PEDIC!5[$-^0P*;128&NL
MH3VW&^M715CR@2 8(AR8<QVQ9VXW*FGM'':Z<L@'@$W$J*5=CKZ^4BNSL=F3
MO7E3:ZWJJ=\EG+-_8F'0-,;$)I0V;,1('EEN+@5!>@'XY[NNYERRC# *":++
M+@ YN$0(5ZUMD(CE26>$2\DS+ME%3B^VW>+3-8M/7^63#>MJK1$R:O-@O0Q"
MOC5>QF^#>4EU1GMGKM,$G,>A,^&O6J9X(N4<?VV*6AO9<)[SL@*<1Z_(!1$P
MM^WI]>IK$EMSXZS^]E1/C71X4167X;V?'V/+@*,_U6<<?K5<F+5YMC&U<O*T
M&9REL--WQG 9F(K$R A"S+/K]75AX4%F&MXMW>V52U]O&R;-8X]?MUC]2_@5
M:WVJ<^$>A4=57YBNXR2@W"R[H\])5@4],T56+[(EFV(1<BM+>155?ES4OTZO
M'K['DV",C9LDHTB#R:A&8B@:__MHZ/Q1!H@#9P5][G;1.K+*%IM'\$@D<$H<
MYGG6]*>S^S<AC$7ECEVF69&Q:U*,$,V>U< F!ISIU'0RAQCJ@"V>Y+Z[:^<V
MK)8>4?-9@>XNL:69&SA&B(/#YK P_E1"8%-W*>!/UJ'#$4P"%,PK\B=@6BPQ
M>VJ+A)N-3IR]Q11S4\H:)M1DML%*EO2+&22VS_0J1%:_J(DP;\6BQEF]^ T=
MW[M^[UKZI  W9HYS;A[M^+&O4%.68.+SGU:C-8<_<2B07/+]A^HD!\B__XJ=
M_]L&"#)R=TI'_%.)+NDV,AO1,U/TB9"OPHR* M_8@07T;0^.<U-&.@*D/$$1
M'Z&X -'(SZR#S4M$.L*C';W'X6_QW0?AKGMK2WN8C*F%Z ;UQO[.>MJ[V#NK
M<//&];&T2>JM3K=;:9QJ@J@D[,O(&\U@91<C@;_1*)/+23;^@+Y@.%+_'MQ#
M-8*IOIOJ@%*[%._U[;[&9$""52I9W_S";^0\$[ZOI1W^IM2<P.>*Y<E(!:0<
M:557QY\5PE&E305G$36DCY1(:ND'JA.3JX?:P!,N4]!&[\Q4JH_CDQ,3!A@]
M'B9Z'N8B!Z_G*1%<>:8D+>@S?'=+V;#5XCT8Y_T '&;(,E"I )0P@]3NW@B1
M94>68BB,NV/;VWFI)5^UJ3P17OHKQR-Q;O50ES[1\9AF '<#_@)P5Q79EAUO
M*%#BU>6&;GE!?@CVL.R,2YW6*75/_B(KWU[("NNQ-3BC*(*8.%18%,5\FEEC
ML'HFCO);;&H@%J3\:=3/=T=#9(LQK+?%8G'-BI^&OL*./.?Y";QA=?O%=7BW
M*-PUO:T^F,8[92Y] S;/GE='*T<FUL6U#YDF0KK;A<9^6UL?P,O7>UB7/<'Y
M<W9G=7G&5,@+%]'"V1O.LZA1(8&E /N; E)$0O8#E0)ME<U2*/R=_N8$Y3-,
M5?Q&%E*S1=2W@98L:,/>TOT*0.&9&,-%&+#"K F-)R58A&E=NB7?QDQ:L/]'
MF+9ZSY/7H2:Q^-^N"M"H37[,1?PG0D*0O)'B *L<R?VB=.CL$A6%F2-H\RB]
MD%UV6-VLE^-3243Y'_\9HLW#(D;+2!QIA^$XF$T4Y3*H?FA)B[T+FN7LP67L
MQ3]4)UC:,?/)E1WZ7RAC04K);V[E; /)2J[*=-(A9O1 'QB7,&J,:(HJ4DT]
MXDA'L+;.3:LZYBBLW5( H,?S:O2P6F;D@9Z\[\8FJ=HG;IA^,Z*6@E/^, J,
M_RVG-*4B5LUQQ2:^')U&#3CXP+]#K"=5JD&WZM&P^J? )U=FDQ#>BT-U="Q.
M\^R9"RCT#ZC#F)!G(:+/6,2*-AO,7ENX5EDQQA\LJ.(29%0=^@4F])^HKXA:
MIFZ01]M7,\VE[2AYQ SN@HFFW!/:&-V5O7]G?4W>_RR]_.AM"2>J!;S)KA:0
M/MSJ>75H>V];M[,>;G[Y55[:;OU<LDU(_CM-]E0KLMDGE!7OK$).R-_<4:#I
M3A=I2GK$03LY/9!F<AHZ2P5O:< HS'OBFSJ M,V2&X!XN+LM?'6MOKA/%69U
M ;CJGGR0HFB?JL /'J;K:[GPK]?6+;0#4E&!PP<&5F7/T8C)8N71XQ4Q$W6B
MYM"U\'5<C\!XT)8%M&K#*+1X.[K.0<1W@0].O-_F":B)$ZV6Q^4&I$!/N+Y'
MR!&FYW8)[I9M59GO,(9Y-?LE;<ICT6;!(KASXB8*+'MJPJNZ!/@&E?ORXRL;
M.M.2/V9YI5]UPUC+LH3L/H&= .3D"8E^%#<I<(^+NQGCHY-*>_H/IU14+2^L
MO66[*>B5D^Z$Y33WMPP)+0>GGA6Z:_@0.M@%AW%H-NT2HF*;[./R/<68B-0&
MGD+U]<YK3BFT/B@? NDI)9%HU^,X0)54SWGE[)N,8"N$*/(D\WJ%-<+,NM30
M 2;M,=FIAB5?.XW8IMT *4"T *Y4710TJ2,NOJI=O#$Q1X"9U7&*76JIN0R5
MV_@V$"KVEQE*^&J7Y^J*XF^[XRCH_PUP,GVL_&]02P,$%     @ .S!I5K9K
M8V1//   =%4  !(   !I;6<Q,#@V-#(Q,C)?.2YJ<&?MO&=85%NV+KS(&21)
M#@H*"H@DR12(9 %!)0<5D"0YQR)GB0(*DD$RB))3D8/DG&.!)($J8@$%=6MW
M.+=[[^Z]NT_O[G._[SFKGE%_:K'F2'.,]YUS+E#3J&7@FK*\DCR @0D &.@/
M@)H#9 %\7%P\7!Q\/#P\ @)\0F(J$F(B(F(Z"DHR*B9Z%F8F>D9&5O9['*PW
MN=D8&3F%[W#?YQ,4%&3A$)44X9>X)R#(_]-#, @("(B)B&E)2&CY;S#>X/^G
M+U0+0(Z/T8GY% OC)H!)CH%%CH'J %C0>N)@_.$"_G1A8&)AX^#BX1,0$J%O
MJ+H&8&)@86%B8^'@8&.C?_5!_PY@D^-0W."3P:74>(EWTX&*WS\N"Y_M844K
MM>8(C%W@E6,  >%U&EHZ^ENW.3COW!44>B L(BHF^TA.7D%12?GIL^=:VCJZ
M>B:F9J_-+2RMG)Q=7-W</3P#@X)#0L/"(^(3WB4F);__D)*=DYOW*;^@L.C+
MU\JJZIK:NOJV]H[.KNZ>WF^C8^,3DU/3,[,KJ]"U]>\;FUO;\(/#H^.34\39
M^4]V80!8&'^^_J9=Y&B[,+&QL;#Q?K(+ ]/MIQO(L7%N\.%2R&C@O72@O,GO
MCT_U,"ZKHI6 34 31OW*<83P.KO@RBWX3Z;]P;)_S+" _Y9E_V78_[5K%B#&
MPD '#XL<  &GYYS9?H2_JQ351^=9YDZK^G@))]I@[L6=),V*F0.4TM<+<HES
M3<FCC[5XU 9]Y+^WB?K753^S3+!DD-VP$VD=)%,&:N2HGF#\OR0&>!U@TJ7M
MZD.CZ;E,"QM".AMD5WTRSU7!S=@\K\.&:=*JI9&'KKAECHLLL./)Q,QM5^T'
MD\*4!@(9 MX96QX&KVTNPCBR6ME&:R^Y6LX;I6X["6H=ZL^F:E\(=BWKQ30Z
M$%T7C_*IP92RC6PIU\U.ZWR1'7&'F#,[ OB]!8X"9L6OE+YGH("7.BC@Z%G5
ML#<%"HB7S0+/=5^]4S)  ;M,*(#]4!T%?"X!G]_5VY0B /?>&(;L0E& ,GLF
MF71V!"?PDY1<.NE6PJXBG8H6DR\DZT->!'([2@.DHNS^>M1=WJKB2&%+*P\:
MO<1*=B^:H:-/01TH(#@\XRRAT1 %! Q=?8M!Z&0<<[@WH "<C,M$UW<:F58.
M8%@%:%L-[G9%!+JX"UIY!1Y/6]U'7@>?/)_5D/<O[$0!;>C'%(IW+B&X4<"/
M@I\>B0(TW2(A,%T4,*-M*4>/FT^# H@HKW+W:<#+7U' EYRKZQR72HOW4$"K
M.0HP,\RCLJ#_:(SD5C__7U7^5Y7_A"J]6\V2E9!)&^?>(QL[U90=>_]C(O4[
MC 6]P)[$:OTWJ(3+1:EQ&PU6"'V;7(:Y)OXEU]>L '05C6V+X,S$_ >$C.4R
M![*6;HD"3JAC4("<BB%>*^\9NQC-92-XZU'BT-7(TH&Z( JX(.Q& =EY98'+
MR<AX)J*K1=!1MC)P]%]%>TV*55_=R2:3^UKOO0';B?F;2;.9U4K=TI+6Y=E^
M+_]-U17O!G3.<H\LA/B:$F]B^6S/E=[UZ4!7'6CF:5GSGTK-/RA8:.LL]L\X
M4L"7P28H8$1S2@:F<J5$&HP"[%C.-6XYH8!*-V3" .BJK0(%;!9:9R)NH6M=
MZ$,44!-SR1GO)_E?3JT#AQFALR:(J]5MMM\2.UFI6MSBM4^V$JV?Y!P6]S/'
MA^D*&N/:PM A0EDH",]X<Y"-LMZN*@Y^49?\3K25U7R=G7CW-58IX#UC!Q_J
MOF\=;Z4*QA[I;:V(QUC#.:OVPZ4U 1O.14_,ZQ">9\A.OD'*9LU8G9 U3^[=
M2N27X4HOFF;'Q6.-@LE0'\IE_#B#TKFTFSE//CCAJJS._&HGSVAZTW[=CR.$
MD'1LZ*%OZJCSM+,-?;=*C24]$9?[+M02G_LY%2<'0+SL20C4_<<[)K7LLRG!
M- K!A.<3W#\T!J_-#U;L204ZT&42'3UWMRN]QUJ3PO#>-&(-UW^BE2) F"0?
MP@B?+=&PQJ">F&A*+*G1?JJ TZALI&3ZHBC3A3T]<0@AW"VF'6W#>Z_R79V.
MC?D!7;YTPZ! 8JO$B]/6DP*D\7(DB&X@_UZ^FR,W]\RB"N?'(H.*N1H/O,S6
MTXV",JP3QR?-=%-4]KA9_BC FY"MV&WW/*A2J7P'?""V1(_4&98@*);]M.TZ
M&S36A__>)TGP19$2EGB:Q_+$/I[WHY%&FT_&5@_X%O3F=*IO6W<^:IEK ''=
M;V&N:G6/;(60\UYQ63'?'"8)#N"I;[7T<-Y$ ;>'26E(93C<GF]:W]U8Q?U:
M[GT#GI1:6M1=NB4O;AW.]B1;SA*3T;_+_85#*S0BM5G^'%UPKLJ>EPO6&[)]
M^8HX7"X><'">2#H1="//6_N,$QR^[-1@S[RNT,PU9MW2J/Y)E^,')$^Q>J2X
M(^DP!X>.=#_DS7E:5T(GB-9;87E'G7AF1L_RD&<RV,:-R[#CQ\6</<AEW&2=
MJ<E:Q5OE:T7:B<_$P/ZOX@!C*?>IU<$FZ  ]$^^SRK&7 5S!M5I5;R<B<<Q:
MYW_PA4HV<6V" HP/%)UY+]Q1P&CX767)?Z12_3L%^(AIO;:KHIC<=74=;M<A
M^?1)6AF/[221_@MY<K?,UIZ++&. V)&@O,1Z QUU)OCSM,EB%(#O,I21LUW&
M#%45X#93VVWQ[K@#'(EBDXINO]R_!.O3L$SX=#1+UC>,-E-ZBT]R[R$+N=\6
M<\L&[*ZM,9X#N>1++EZS#]:TCNG* 1BDS9ANQS/DW95P(Y^EF-8(CG^:Z:VG
MM$^N)3Z1!JK=7IC,^V#I*RWN-]@=\!O2F+TDN^N;^!V,T\A1BE!Y-%%ZW,?[
MI4]R(Y7^K. BV8+NC*#3TX::2'[),7U2PLT0EA\CP0O=5>AH)@B9TPQ\9J!N
MZ<+*_-2%X[M+SZ B*PH@I]W7:N2 %1WPXKG'DY$;WIB4D"<RD#!Q;)G_<M3"
M+D#AT/URQZA"CKUIT3BYQVT2!0AL=,%8.IFT9;[ [N50!XGAE+2DR9AIF4<Q
M^K^="Z-;MC$*Y*#>=WU@OS7K4Y58>Y/!/8FS]4?1?9",%F=1<]",T4;,K[:6
MC5^OQS?2_?^'D3V@AFO]W4N_/(*%JLI016.XRCJ5Y %#2/3]Y+<V]":Q&1S<
M]O+JDKZ)1W7+E,:<""<HR5!@E8_Q!:]"V);VE*H]]Z>/%<%#>-;!C%[4FWB2
M_<5.UM.E'L[[5^9J$))F?EPZN$N7  J0^;"S:8I],V0;3^CPV]7H5*<?NK6\
M7DI  2 ;%- Q-=PS%Z<__KIRZMW;>V(1G(6T&G)4 %HPH+_1L>I^ \Y+,_]?
M#U/W(N7A*0B:UBGZ^F[&FC<[.+F:MK,'U0X?2?UEA372:GO8G^#IRGF'OX1#
MNI,\\^<^39@TX6 *-776X[\GF5[!C'7L6%?D("25QFPN'CY.!5W;=-5K"MRO
M:@@W>QRKO%%438#AW\,F<4T.L/B3_O\IP>C7<Y_]MM]]>G5-17=R[]NT@40W
MLS[FM66GCTAHC8F1+]J-H:$:,VJ1169JH'6TMZBU&Y_#]=O2B>"=QY57C/&J
MNN04UILWPB0B>DHP'&7)WS:R**^1=<8$=\3[,LW%>Z$ \SE-M2W^E)KC-6>L
MDSC8%BOXU?9'%# %NKK;E*;OB(LN .DTJS5MJRUDH:YG0Y=8N\6;IJS9L??Q
MEY_/+=0Q*6C(4;/]&6E)@$^BT6'RR$<!TUJ@2VH>9Q9LR%KLIO$)FJ#E46B#
M+A3 O1)C:-C*Q7(5D51/]I>EEA-K^,]TCBL#GA_T VF]XE5Z'8XL%R8C7L&J
MY+_S[3,>'(_VE@IQU/=Z0DZL]4C0S&$7_T[(MZT2FQ_:EC8RKQ>C1'H>K?0!
MZL143/GI09?"N5N?-V>%HI-M1P6O:\'GND:OZ11Q/E$#Z%J.J!U_A5.6V74U
M"XUYX^7(%EG%&@Y@UQ#9%EM%]-,6/U#[KA%U8W_+@ 4IZ!:(3EZ&,O!2&!BQ
M"WCA4*LKC6=-.ELS:2Z8ZO#:0&O?F@+WM9^T,%((!&Y;K0-4&G*_JY@LN:NW
MIZ3-+6PSLXR6[1DS?*_]&JWPAIBX CL=H(8V/X#OMY<3[5!LZ;GY'=EH;>/>
M$8]4?/66H3ZP(O*:)PROR6MDTV&R6;UJ_*A4?&4HVEGU<:X49]*Q&YWVQ@>M
M9]\"?[3V,I^=JWC.G<_GED.<8XQ2-EKH?6-6#&4U8+[A>"=GX<^UNJX?J'SZ
MD1%KBOG,?$EH6QJX+T)]*/P6J9!CC0)(D>0K:;=U]EVF.[_$76-O\_X<+&Q2
M^*H1"REQ4IXW3$X?.(Z1,JGB9>-V3E>6'EB0'1$0\#N#_VB/E:J:I-55G94
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MW:& EK!40+X%W")-?><B>7L"!3!034'Z9J:/&4 Q4H2-4S2JNG8F"@[T1BJ
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M0QR2<AX&H$J:@%L3)#EIRK187RZK=OW#_#\^H(Y<AL8D2T3Y#TIJ_LYKR?^
MP$I-EHVRA,/*-,<Z(BU7(G<R*M4M3%U>.'W$OG@;W>_IR7RUK88A=/"XF7I2
MBG6SF1.^/OA)9T;U]C23BD"17Z=,#R&US@OB(R'ARO(9@]Q4K3T4T']BQX@@
M[#.<1(IZ2)5;FZWL,H%&69-L"H.Y*CDY+'H8E"3]=HS2^?RCTRJ,;]2T%]L(
MR,(@X2XDRDI'AGJF$= ?\*"D^6I/<_LW-K;N6V,IYW#I9X S%F9E58Z=\.F'
M!4/]FI7A?X0$</V1!#@9P9*C&]$D0+VC&;?Z*R14Z[&!OMIVL_[I&P%.B:@
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M:5WVZR#_"5[F'\&!=C/DZQCW6B.D(6!T4L(NQ0/;HHZ5N&+9-!9$#U3(:5=
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M6Y/KS01GKI J+;;28^H\NO#N!5=7V\YF*1!Q8OGA*:/O#+X%.[P*WD>FU:(
MZ#MP6SS" P4\/+U2FP?#OP'YF3K>;+#J@OJDR!*+R>27A':&]I_-)&6YE&5)
M0[&9I26E/WFK(K)RMGQQFZY:I[CMA,3+CW1\.UWC)<3]%SAZ5I()&8C%^/0@
M*(!0967CDFCI3-P!W3 X?SXPQD%WL+>LPXHQE>7Y>M%^_.B3=7Z\]T$OQ]@9
M;37;1:"BC%/3KBC@FC>#DQW5UFHI+7L8TZ/DBAQ WD.+M?"$E7SQ,QJT*7E+
MH( L+Q3 80M"K+/ <IN9P<--*""AA@7IZ"=&AE!#LJ!1G1$:U072@A%%H!5Q
M&/B2Q)/EBO@E"E@MSO@M?VS^_"^>JJ(I]^N%,L&FAZ/G.(YO;Y7TW0UI$;FE
M1->*Q[Q:"T%H&I.!-HU00.]<S)6HH4((DB?'74$MOEWVZ\6MDO@/'R2F$NY)
M8Z_W2E+Y/L.H^%</4?U+&_& YS]5QW]-W/'"K^ZA '-OAZJ9>X*JO+ZI+@?'
MB^V#X+J&=1<U7*<UF/WW)HB!JJ8JZ8DD^;*JZJII=;SK;%S=LNB9OK@GU'*0
MK\O)6 3<+H)HOPK08[E$ :DHX.T3O+$C;>%E22Z]X486DUSKT5E5-]/TARI6
MZXFKQG4?LY>#VTX'AYWB'49_GS-I_R%W,MO!RSO%AH*\&<S!68L^\=NJ,C?,
M#^(?9T4_E&<DGU!8-R)' 40UJRR7Q*"S6W8HH&MG]DK*4BSIZ[(^EP^O>D-S
MFHO(0DY5<-Z+YF<Y[)P<=*SF\]J#&;  ]_:K8%4T7L89 \,%,4Y 0?ME0B#<
M3;?3>(]D;3UORL<7TO.[]$DBC,3QGEJ=+Q'W"$J]B59VO,)R0]PK^TSC1:F*
MV?#?79-9N^;>:?NW?20,':)N7Q["6]KAI^V'?^K366)I_% K$Q4@[\'*N*O%
MEN<!^7$)M:RR)D(!I%;"%*H>;_8]L.,I!MAMSQ(X&./8;/LHU#]L5DUZ*R,<
M/.!D/^Z#VV0NTTRLZY#!5?QG\<S"?(=4]B*,IF9U&UC)L/(6ZQA"]QSU*1YO
M_7H5)=EW5X-8_0_O;R7<Z%KG%H@6B!L O.3^EI^IDPO=DV5&RJXO/9L\FJ.;
MP2IQTU:BI.ZEPP@3Z6&3ZD(SQ#:WGY@E_1$(2=N. CJ?X(5XVR1W&E'  Q8L
MK]@F7XP>"_*W,WH&%54HUE*P,O1V*==(XR(Q#B910$ND,;6UMK 4VY3+V]=0
MU;?$6@X+AM]&AFZ(F /-^$\(#_!O19-JUF>$34F1P*<"]P2#X>#0U09MW=U;
M"1HQ5LIU7?8+A$E&B(6/%#@VFT8W81RASEP\-]L[Z>GG]!Y5W+9;QJF82,7&
M[%A+B%:Z[4<6EB[8"+L=?+V<-/(RW_I[6!F?_:O[&WL5;?=GU;'C[RM'.W5_
M:+U0&G!QH&Z"!*RE>!BP.W077#=_90]@<L>KTY8_GI*06U:_MNE6+X<"(@2%
MJQK"L[V-6Y0W<NXI8?BWXC%>(W'G:.-AD:E !+MYE>^D"-I;E#TBN36+O_>Z
M][E[7Y080.=/RWKVVD\JY\!W)M]#++B29$/NRRKQ6<7'*/XU_SH/MEA^<=)$
MN'F,Q!WA0 D3<$YM;$M,\Z3"T/X-VR<; &7,NUB^.AW2Q.,E)(?O3YNTY3]M
MTD:!D,\=?/FK$3Y0$G#[>=Y2.%)*+<U>M2WU KS4'M#*(#HOT=)(@3N94$>%
MP=$"P4?'37399;R,AF9V<"YI8Z\-XR YA!6FL@$@$2#7IH=U*. WZGX!5F9V
M\?32S+:KPZ*.8:N;]6U75>R 1V\H2&GM[658@G7^8T=O_PTB"J;P%H>51U;1
M[A\/\.ZZ:73<T+YX5+&"P4[,AC$1LX$&<'_=)YLP(X!#M,_^JG,I(._PAF8<
M\8+7=M$6,)9+E[,B%E9!=.ZR%\):PT)V7RT37L]:- \0_4A-TNH+Z'9<>T'\
MTT(6L/2SEIJ84>;- I-/S5I<TG&7W3W5@@L66@D1O1,PB2^2Y9N7M[_O:"\R
MJ$ #2^V"7/-V@%(%'!K$5:8^.MPGG&EK")6+L8\,&)ACW=5NQ=8>1L,&/.0M
M"%K/]^!U7S2V#"^W&VZ^YL[V=+BDO!S)<D)4'):D7246W/?>J4>+O7 >EY^O
MM6>#3N(1&BS%\\943T)>+:ULG5KY/W\F7Y#_/2P@2SE<^8X<'OY.>AV+[# >
M&A#\-0( _0QCH&L\1D:V18I;J&"88.GMI1\G]VT/5A>':IRN2U2P'RCMZ/T&
M%:H>$[R(O.A]I#4)K_Q2MUF$JU1,W88TL:1<D:HW8>>+ON^P:28-?CP^,,N3
MG5G.'JVW!#UN6&B57 JN8E#%7+6[S:,Q=U?]HL$5/BC]2EY\ZG-.25A9%!VM
MF0YC %<;\BF5[(G!F)0<MJQ57Y?4*RC'3B]RX#E<..SJ]M8),TU,V^=M3=W>
MS-E><7W+['5O:.T#@QPGOT;SL3_M42^BR>M@X*\?4PIRC]]8G8JLW/PA-,!A
MT% 5K<&??\(70XH!K+/AY; ,EEBD0+IX22U@EF)JJ67ZTZT-?9$7-+X+_3H'
M(Q0>[ =6RE+EV<TO4$!0'S0#>;Z3@;AI?"6@@+QMS(@"-J;0;*(5S2[@*<"Y
M;\19X!4E;S3X<*<,O!P.1@RPP#YXH_M;AB'Z"UL%W1DML+;.N;Z3(1XWBZ*
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M=YIYQLN$5 K>=G[Y=F5Z#:^5J/)P$-<U%B^?L;BF:,96\GI,X3[YSU5J=D2
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M$$-.KRBUH3:[I H]AW/_\DP'4'X?$0=_94Q@%6?A>3OY,K^XTM>YR(TZ7.R
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MU)^<EO8WG<8B,>)BX[K1B::1B%C2'!MW906NE[DACVV5V&*)8WW.S6M83U$
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M65>ZBRG<3\-Q*[4<<!A;X,PNSDOJF-/__._Z[X+_7Q;4S/\!4$L! A0#%
M  @ .S!I5@S%"87R(00 SP<R !$              ( !     &=L=&\M,C R
M,C$R,S$N:'1M4$L! A0#%     @ .S!I5E"5@;CK#@  QZ@  !$
M     ( !(2($ &=L=&\M,C R,C$R,S$N>'-D4$L! A0#%     @ .S!I5H+%
MM,BT#@  1\T  !4              ( !.S$$ &=L=&\M,C R,C$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( #LP:5842'/JRAP  +C9 0 5              "
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M;RUE>#(S7S$N:'1M4$L! A0#%     @ .S!I5H+C/^Y#"0  15<   \
M         ( !2R(% &=L=&\M97@S,5\Q+FAT;5!+ 0(4 Q0    ( #LP:5;*
M4@'^* D  /%6   /              "  ;LK!0!G;'1O+65X,S%?,BYH=&U0
M2P$"% ,4    "  [,&E6FJ &G2<&  ">3P  #P              @ $0-04
M9VQT;RUE>#,R7S$N:'1M4$L! A0#%     @ .S!I5L0#0#XI&P  ^+X   X
M             ( !9#L% &=L=&\M97@T7S,N:'1M4$L! A0#%     @ .S!I
M5M'DL*];G   I_0  !(              ( !N58% &EM9S$P.#8T,C$R,E\P
M+FIP9U!+ 0(4 Q0    ( #LP:58U(2_8+3 ! ')C 0 2              "
M 43S!0!I;6<Q,#@V-#(Q,C)?,2YJ<&=02P$"% ,4    "  [,&E6'2?[Q>H[
M 0!=>P$ $P              @ &A(P< :6UG,3 X-C0R,3(R7S$P+FIP9U!+
M 0(4 Q0    ( #LP:5;QR<PJL"H  'HS   3              "  ;Q?" !I
M;6<Q,#@V-#(Q,C)?,3$N:G!G4$L! A0#%     @ .S!I5B<S-'36.0  MVP
M !,              ( !G8H( &EM9S$P.#8T,C$R,E\Q,BYJ<&=02P$"% ,4
M    "  [,&E6];+.*'[2   J#0$ $P              @ &DQ @ :6UG,3 X
M-C0R,3(R7S$S+FIP9U!+ 0(4 Q0    ( #LP:597]6^P9<4  "_^   3
M          "  5.7"0!I;6<Q,#@V-#(Q,C)?,30N:G!G4$L! A0#%     @
M.S!I5FE;L8OE?   ?(X  !,              ( !Z5P* &EM9S$P.#8T,C$R
M,E\Q-2YJ<&=02P$"% ,4    "  [,&E6'&I^YL@2 0 X; $ $@
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M.#8T,C$R,E\V+FIP9U!+ 0(4 Q0    ( #LP:59XPNT(:*X  )[4   2
M          "  6_?#0!I;6<Q,#@V-#(Q,C)?-RYJ<&=02P$"% ,4    "  [
M,&E6SIXAGNT  0!M-0$ $@              @ $'C@X :6UG,3 X-C0R,3(R
M7S@N:G!G4$L! A0#%     @ .S!I5K9K8V1//   =%4  !(
M ( !)(\/ &EM9S$P.#8T,C$R,E\Y+FIP9U!+!08     '  < /T&  "CRP\
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
